
<html lang="en"     class="pb-page"  data-request-id="4de36e0b-35ac-452d-923c-0a35e0c23b73"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b01092;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-4;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application" /></meta><meta name="dc.Creator" content="Wei  Yan" /></meta><meta name="dc.Creator" content="Naga Rajiv  Lakkaniga" /></meta><meta name="dc.Creator" content="Francesca  Carlomagno" /></meta><meta name="dc.Creator" content="Massimo  Santoro" /></meta><meta name="dc.Creator" content="Neil Q.  McDonald" /></meta><meta name="dc.Creator" content="Fengping  Lv" /></meta><meta name="dc.Creator" content="Naresh  Gunaganti" /></meta><meta name="dc.Creator" content="Brendan  Frett" /></meta><meta name="dc.Creator" content="Hong-yu  Li" /></meta><meta name="dc.Description" content="The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin recept..." /></meta><meta name="Description" content="The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin recept..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 6, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01092" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01092" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01092" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01092" /></link>
        
    
    

<title>Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01092" /></meta><meta property="og:title" content="Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0031.jpeg" /></meta><meta property="og:description" content="The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01092"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01092">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01092&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01092&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01092&amp;href=/doi/10.1021/acs.jmedchem.8b01092" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1731-1760</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00990" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01679" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.0c01351"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wei Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Yan">Wei Yan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naga Rajiv Lakkaniga</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naga Rajiv Lakkaniga</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naga+Rajiv++Lakkaniga">Naga Rajiv Lakkaniga</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francesca Carlomagno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Carlomagno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Via S Pansini 5, 80131 Naples, Italy</div><div class="loa-info-affiliations-info">Istituto di Endocrinologia e Oncologia Sperimentale del CNR, Via S Pansini 5, 80131 Naples, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Carlomagno">Francesca Carlomagno</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Massimo Santoro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Massimo Santoro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Via S Pansini 5, 80131 Naples, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Massimo++Santoro">Massimo Santoro</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Q. McDonald</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Q. McDonald</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Signaling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, U.K.</div><div class="loa-info-affiliations-info">Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, Malet Street, London WC1E 7HX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+Q.++McDonald">Neil Q. McDonald</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fengping Lv</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fengping Lv</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fengping++Lv">Fengping Lv</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naresh Gunaganti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naresh Gunaganti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naresh++Gunaganti">Naresh Gunaganti</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8149-9795" title="Orcid link">http://orcid.org/0000-0001-8149-9795</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brendan Frett</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brendan Frett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.F. E-mail: <a href="/cdn-cgi/l/email-protection#d6949790a4b3a2a296a3b7bba5f8b3b2a3"><span class="__cf_email__" data-cfemail="d89a999eaabdacac98adb9b5abf6bdbcad">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brendan++Frett">Brendan Frett</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hong-yu Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong-yu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><span class="conrtib-corresp"><strong>*</strong>H.L. E-mail: <a href="/cdn-cgi/l/email-protection#125a5e7b205267737f613c777667"><span class="__cf_email__" data-cfemail="2a626643186a5f4b4759044f4e5f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong-yu++Li">Hong-yu Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9212-2010" title="Orcid link">http://orcid.org/0000-0001-9212-2010</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01092&amp;href=/doi/10.1021%2Facs.jmedchem.8b01092" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1731–1760</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 6, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 July 2018</li><li><span class="item_label"><b>Published</b> online</span>6 September 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 February 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01092" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01092</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1731%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei%2BYan%252C%2BNaga%2BRajiv%2BLakkaniga%252C%2BFrancesca%2BCarlomagno%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D4%26contentID%3Dacs.jmedchem.8b01092%26title%3DInsights%2Binto%2BCurrent%2BTropomyosin%2BReceptor%2BKinase%2B%2528TRK%2529%2BInhibitors%253A%2BDevelopment%2Band%2BClinical%2BApplication%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1760%26publicationDate%3DFebruary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01092"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4357</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01092" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Naga&quot;,&quot;last_name&quot;:&quot;Rajiv Lakkaniga&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Carlomagno&quot;},{&quot;first_name&quot;:&quot;Massimo&quot;,&quot;last_name&quot;:&quot;Santoro&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Q. McDonald&quot;},{&quot;first_name&quot;:&quot;Fengping&quot;,&quot;last_name&quot;:&quot;Lv&quot;},{&quot;first_name&quot;:&quot;Naresh&quot;,&quot;last_name&quot;:&quot;Gunaganti&quot;},{&quot;first_name&quot;:&quot;Brendan&quot;,&quot;last_name&quot;:&quot;Frett&quot;},{&quot;first_name&quot;:&quot;Hong-yu&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;1731-1760&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01092&quot;},&quot;abstract&quot;:&quot;The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01092&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01092" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01092&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01092" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01092&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01092" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01092&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01092&amp;href=/doi/10.1021/acs.jmedchem.8b01092" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01092" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01092" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26pmid%3D30188734%26genre%3Darticle%26aulast%3DYan%26date%3D2019%26atitle%3DInsights%2Binto%2BCurrent%2BTropomyosin%2BReceptor%2BKinase%2B%2528TRK%2529%2BInhibitors%253A%2BDevelopment%2Band%2BClinical%2BApplication%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D4%26spage%3D1731%26epage%3D1760%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/jmcmar.2019.62.issue-4/20190228/jmcmar.2019.62.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0031.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The tropomyosin receptor kinase (TRK) family of enzymes are transmembrane receptor tyrosine kinases (RTKs) that regulate synaptic strength and plasticity in the mammalian nervous system.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6 ref7 ref8">(1−8)</a> In this role, the TRK family regulates cell differentiation, proliferation, survival, and pain.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(9−23)</a> There are three members of the TRK family: TRKA (encoded by <i>NTRK1</i> gene), TRKB (<i>NTRK2</i>), and TRKC (<i>NTRK3</i>), which have all been implicated in the initiation and progression of malignancies.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41">(24−41)</a> Similar to the BCR-ABL gene fusion product that drives chronic myelogenous leukemia (CML),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><i>NTRK</i> rearrangements and fusion gene products have been observed in numerous tumor types, which has been comprehensively reviewed by Vaishnavi et al. and Amatu et al.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Unlike CML, however, the incidence of <i>NTRK</i> fusion genes in each specific tumor type overall is rare. This generates profound difficulties for patient identification and adequate recruitment for clinical trials. For instance, <i>NTRK2</i> gene fusions have been identified in 0.2% of lung adenocarcinoma,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> which represents approximately 184 patients of 92 138 diagnosed in 2010 in the USA.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> On the other end of the spectrum, <i>NTRK3</i> fusion genes have been identified in virtually all secretory breast carcinomas and of mammary analogue secretory carcinomas (MASC), an extremely rare tumor of the salivary (in general, of the parotid) gland.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In fact, the defining characteristic of MASC, when compared to other salivary carcinomas, is an <i>NTRK</i> gene fusion.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In addition, <i>NTRK</i> fusions are found in about 50% of pediatric diffuse intrinsic pontine glioma and non-brainstem glioblastoma.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In major cancer subgroups, <i>NTRK</i> fusions occur in 3.3% of lung cancers,<a onclick="showRef(event, 'ref45 ref49'); return false;" href="javascript:void(0);" class="ref ref45 ref49">(45,49)</a> 2.2% of colorectal cancers,<a onclick="showRef(event, 'ref45 ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref45 ref49 ref50 ref51 ref52">(45,49−52)</a> 16.7% of thyroid cancers,<a onclick="showRef(event, 'ref45 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref45 ref53 ref54">(45,53,54)</a> 2.5% of glioblastomas, and 7.1% of pediatric gliomas.<a onclick="showRef(event, 'ref43 ref55'); return false;" href="javascript:void(0);" class="ref ref43 ref55">(43,55)</a> Finally, similar to the receptor tyrosine kinase RET (rearranged during transfection), <i>NTRK</i> fusions (particularly ETV6-NTRK3) are common in post-Chernobyl radiation-induced papillary thyroid carcinomas.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> Thus, targeting TRK oncogenes is an attractive therapeutic approach for a diverse, frequently rare set of cancers.</div><div class="NLM_p">The primary method to target TRK oncogenes is the use of small molecule kinase inhibitors. Because gene fusion products are the major oncogenes observed, other targeting strategies, such as antibody therapy, will not be effective since transmembrane tyrosine kinase fusions frequently lack an extracellular domain.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In this case, the fusion proteins are only susceptible to small molecule inhibition.<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59−61)</a> In general, small molecules are designed to target the adenosine triphosphate (ATP) binding site of TRK to block catalytic activity. This is based on the principle that protein kinases catalyze a phosphoryl transfer to a downstream substrate and only have micromolar affinity for ATP.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Since turnover is rapid and kinase affinity for ATP is weak, small molecules can effectively bind and inhibit TRK despite a high endogenous concentration of ATP. Because of the druggability of the TRK enzyme class, a number of attempts to target TRKs have been completed. In this Perspective, we discuss current development and clinical application of TRK-targeted cancer therapy.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> TRK Biology and Signaling</h3><div class="NLM_p">The TRK oncogene was initially discovered in colon cancer in which the cytoskeletal protein tropomyosin was fused to an unknown catalytically active kinase domain.<a onclick="showRef(event, 'ref50 ref63'); return false;" href="javascript:void(0);" class="ref ref50 ref63">(50,63)</a> Further studies identified the kinase as a single-pass receptor tyrosine kinase expressed in the developing central nervous system and was given the name tropomyosin receptor kinase. In the extracellular region of TRK, there is a leucine-rich motif, two cysteine-rich domains, and two immunoglobulin-like domains and all are essential for ligand recognition and binding.<a onclick="showRef(event, 'ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66">(64−66)</a> Unlike typical RTKs, the TRK intracellular region is small and comprised of roughly 70 amino acids before and 15 amino acids after the kinase domain.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> In comparison to other RTKs, TRK is most similar to the insulin receptor and has been implicated in insulin signaling.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">The TRK family is comprised of three distinct isoforms: TRKA, TRKB, and TRKC. A major difference among all three isoforms is the ligand that activates the receptor. TRKA is activated by nerve growth factor (NGF),<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a> TRKB is activated by brain-derived neurotrophic factor (BDNF),<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> while TRKC is primarily activated by neurotrophin 3 (NT3) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> The kinase domains of TRKA, TRKB, and TRKC share between 72% and 78% sequence identity.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> When looking at the residues that interact directly with ATP in the active site,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> TRKA and TRKB share 95% sequence identity, while TRKB and TRKC are completely identical.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In the TRK domain, the TRKA hinge is more structurally constrained compared to TRKB and TRKC, suggesting that the hinge environment differs between TRK isoforms.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Further, the kinase insert domain of the TRK family is not structurally conserved, which is another key difference within the family.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic view of TRK receptor tyrosine kinases and major signal transduction pathways involved in cell differentiation, proliferation, and survival. TRKA is activated by nerve growth factor (NGF), TRKB is activated by brain-derived neurotrophic factor (BDNF), and TRKC is activated by neurotrophin-3 (NT3). RAS, rat sarcoma oncogene; RAF, rapidly accelerated fibrosarcoma oncogene; MEK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase; GRB2, growth factor receptor-bound protein 2; SHC, SRC homology 2 domain containing; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT, v-AKT murine thymoma viral oncogene homologue; PLCγ, phospholipase C-γ; DAG, diacyl-glycerol; PKC, protein kinase C; IP3, inositol trisphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similar to the RTK superfamily, TRKs dimerize in response to ligand binding (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> After ligand binding, TRKs autophosphorylate each monomer followed by rapid phosphorylation of the kinase activation loop.<a onclick="showRef(event, 'ref76 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref76 ref77 ref78">(76−78)</a> These phosphorylation events enhance catalytic activity of the kinase. To generate attachment sites for adapter proteins, the NPXY motif (Y490 in TRKA) in the juxtamembrane domain and the YLDIG motif (Y785 in TRKA) in the carboxy terminus are phosphorylated.<a onclick="showRef(event, 'ref79 ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81 ref82">(79−82)</a> These phosphorylation events create docking sites for SRC homology domain 2 (SH2) and phosphotyrosine binding domain (PTB) containing proteins, such as SHC and phospholipase C-γ (PLC-γ). After binding, SHC and PLC are activated through TRK-catalyzed phosphorylation.<a onclick="showRef(event, 'ref44 ref83'); return false;" href="javascript:void(0);" class="ref ref44 ref83">(44,83)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ligand-independent signaling leading to constitutive TRK activation can occur through three distinct mechanisms: a genomic rearrangement event, extracellular point mutations, or truncations of the extracellular domain. (1) In a genomic rearrangement event, the kinase domain of TRK is fused to an unrelated protein, typically called the fusion partner. In this example, a cytoplasmic chimeric TRK fusion is shown without the transmembrane (TM) domain. Of note, TRK fusions can occur with or without the TM domain.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> (2) Point mutations can occur in the extracellular domain of TRK, generating a TRK oncogene with transforming abilities. Point mutations that are transformative under laboratory conditions have been identified at P203A and C345S.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> (3) Through in-frame deletions and alternative splicing events, the TRK kinase can present with a truncated extracellular domain. These aberrant gene products have been identified in AML and neuroblastoma.<a onclick="showRef(event, 'ref105 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref105 ref106 ref107">(105−107)</a> FP, fusion partner; KD, kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SHC was the first adaptor protein identified to bind to the phosphorylated NPXY motif of TRK, which results in the activation of the AKT and RAS canonical pathways.<a onclick="showRef(event, 'ref80 ref81 ref82 ref84'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82 ref84">(80−82,84)</a> After SHC is activated, a secondary adaptor protein, growth factor receptor-bound protein 2 (GRB2),<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> is recruited and facilitates GTP-loading of RAS via the guanine nucleotide exchange factor, SOS.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The activated GTP-bound form of RAS activates the MAP kinase cascade, which includes activation of RAF, MEK, and ERK.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The ERK kinase translocates into the nuclear membrane activating transcription of target genes involved in cell growth, survival, and proliferation.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p last">Activation of the AKT pathway occurs via recruitment of SHC and GRB2 to the NPXY motif of TRK, which signals through the intermediary molecule GRB2-associated-binding protein 1 (GAB1). This simulates activity of phosphoinositide 3-kinase (PI3K) leading to phosphorylation of PI4,5 lipids at the 3′-position.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> On AKT, there is a conserved pleckstrin homology (PH) domain, which interacts with the 3′-phosphorylated lipids leading to AKT activation.<a onclick="showRef(event, 'ref90 ref91 ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref90 ref91 ref92 ref93">(90−93)</a> AKT activation leads to increased expression of cell survival and proliferation genes that enhance prosurvival phenotypes mediated through TRK receptors.<a onclick="showRef(event, 'ref94 ref95 ref96 ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref94 ref95 ref96 ref97 ref98">(94−98)</a></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> TRK Implication in Cancer</h3><div class="NLM_p">Genetic mutations in the TRK family have been reported in many cancers, namely, carcinomas of the colon, thyroid, lung, ovary, breast (secretory breast carcinoma), salivary gland (mammary analogue secretory carcinoma), and pancreas, melanoma, spitzoid neoplasms, cholangiocarcinoma, stromal tumors (congenital fibrosarcoma, congenital mesoblastic nephroma, soft tissue sarcoma, gastrointestinal stromal tumor, inflammatory myofibroblastic tumor), brain tumors (pediatric glioma, astrocytoma, and glioblastoma), and leukemia (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref43 ref99 ref100 ref49 ref51 ref53 ref57 ref101'); return false;" href="javascript:void(0);" class="ref ref43 ref99 ref100 ref49 ref51 ref53 ref57 ref101">(43,99,100,49,51,53,57,101)</a> Within the TRK family, TRKA is the most commonly identified oncoprotein, which is found at a rate of approximately 7.4% across multiple tumor types.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Following is TRKC and then TRKB, which are found at rates of 3.4% and 0.4%, respectively. The majority of TRKB mutations have a frequency of less than 0.5% and many TRKC mutations have a frequency of less than 1.0%.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Oncogenic TRK Fusions Found across Multiple Tumor Types<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cancer site</th><th class="colsep0 rowsep0" align="center">estimated US cases per year</th><th class="colsep0 rowsep0" align="center">TRKA %</th><th class="colsep0 rowsep0" align="center">TRKB %</th><th class="colsep0 rowsep0" align="center">TRKC %</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lung adenocarcinoma (NSCLC)</td><td class="colsep0 rowsep0" align="left">92 138<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></td><td class="colsep0 rowsep0" align="left">3.3<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td><td class="colsep0 rowsep0" align="left">0.2<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colorectal</td><td class="colsep0 rowsep0" align="left">135 430<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></td><td class="colsep0 rowsep0" align="left">1.5<a onclick="showRef(event, 'ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52">(49−52)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.7<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">intrahepatic cholangiocarcinoma</td><td class="colsep0 rowsep0" align="left">2 970<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a></td><td class="colsep0 rowsep0" align="left">3.6<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">papillary thyroid cancer</td><td class="colsep0 rowsep0" align="left">45 496<a onclick="showRef(event, 'ref108 ref112'); return false;" href="javascript:void(0);" class="ref ref108 ref112">(108,112)</a></td><td class="colsep0 rowsep0" align="left">12.3<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14.5<a onclick="showRef(event, 'ref54 ref113'); return false;" href="javascript:void(0);" class="ref ref54 ref113">(54,113)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="left">11 376<a onclick="showRef(event, 'ref108 ref114'); return false;" href="javascript:void(0);" class="ref ref108 ref114">(108,114)</a></td><td class="colsep0 rowsep0" align="left">1.25<a onclick="showRef(event, 'ref55 ref115'); return false;" href="javascript:void(0);" class="ref ref55 ref115">(55,115)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">head and neck squamous cell carcinoma</td><td class="colsep0 rowsep0" align="left">63 030<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.2<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td><td class="colsep0 rowsep0" align="left">0.2<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mammary analogue secretory carcinoma</td><td class="colsep0 rowsep0" align="left">151<a onclick="showRef(event, 'ref108 ref118'); return false;" href="javascript:void(0);" class="ref ref108 ref118">(108,118)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ph-like acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">1 192<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.7<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">15 976<a onclick="showRef(event, 'ref121 ref123'); return false;" href="javascript:void(0);" class="ref ref121 ref123">(121,123)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.0125<a onclick="showRef(event, 'ref57 ref124'); return false;" href="javascript:void(0);" class="ref ref57 ref124">(57,124)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">skin cutaneous melanoma</td><td class="colsep0 rowsep0" align="left">87 110<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.3<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">secretory breast carcinoma</td><td class="colsep0 rowsep0" align="left">252<a onclick="showRef(event, 'ref121 ref125'); return false;" href="javascript:void(0);" class="ref ref121 ref125">(121,125)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">92<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">estimated total cases per year</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 917</td><td class="colsep0 rowsep0" align="left">310</td><td class="colsep0 rowsep0" align="left">8 325</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">estimated percent of cases per year</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">55.8%</td><td class="colsep0 rowsep0" align="left">1.6%</td><td class="colsep0 rowsep0" align="left">42.6%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Only positive studies are listed, and thus the actual prevalence may be lower than reported.</p></div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Estimated contribution of TRKA/B/C mutations to all TRK-driven malignancies. Data is based on estimated incidence of cancers at major sites and contribution of TRK mutations at each site. It is estimated that a total of 19 552 cancers are diagnosed each year that have a TRK oncogene. Of the new cases, 55.8% (10 917) are TRKA, 42.6% are TRKC (8325), and 1.6% (310) are TRKB. Because of the limited sequencing data, the actual amount of TRK-driven tumors could be significantly greater or lower depending on robustness of sample size, sample selection, and data analysis. Also, tumors with a TRK mutation could be dependent on a separate pathway. (B) Estimated number of cancers positive for TRKA. Lung (lung adenocarcinoma), IC (intrahepatic cholangiocarcinoma), PTC (papillary thyroid cancer), and Glio (glioblastoma).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When an <i>NTRK</i> gene fusion occurs, the translocation event generates a hybrid oncogene composed of the active TRK kinase domain linked to an unrelated gene or fusion partner, triggering constitutive activation or overexpression of the TRK protein (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref44 ref53'); return false;" href="javascript:void(0);" class="ref ref44 ref53">(44,53)</a> The resulting aberrantly expressed novel oncogene can occur with or without the transmembrane domain.<a onclick="showRef(event, 'ref43 ref102'); return false;" href="javascript:void(0);" class="ref ref43 ref102">(43,102)</a> Certain mutations in the extracellular domain of TRKA, namely, P203A and C345S, have been identified as transforming under laboratory conditions but have yet to be identified in human tumor samples.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> On the other hand, in-frame deletions (ΔTRKA) and splice variants (TRKAIII) of <i>NTRK1</i> have been functionally identified and characterized in human tumor samples.<a onclick="showRef(event, 'ref52 ref105 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref52 ref105 ref106 ref107">(52,105−107)</a> The ΔTRKA in-frame deletion, identified in acute myeloid leukemia (AML), contains a truncated extracellular domain that can transform both epithelial and fibroblast cells.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The TRKAIII splice variant, identified in neuroblastoma, has deletions in exons 6, 7, and 9, which results in the loss of Ig-like C2-type I (IG-C2) and glycosylation sites in the extracellular domain (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref52 ref106'); return false;" href="javascript:void(0);" class="ref ref52 ref106">(52,106)</a> TRKA activating mutations from genomic rearrangements, point mutations, deletions, or splice variants compromise the ability to regulate the kinase domain. This suggests that a key attribute to the oncogenic potential of TRK is the loss of form or function of the extracellular domain.</div><div class="NLM_p last">In the tumor environment, TRK oncogenes stimulate uninhibited signaling through the RAS/RAF and PI3K/AKT pathways.<a onclick="showRef(event, 'ref49 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref49 ref127 ref128 ref129">(49,127−129)</a> The preferred signaling cascade is cell-specific, with dominance from the RAS/RAF pathway observed in both colorectal (KM-12) and lung (CUTO-3) cancers. In certain cell types, TRK oncogenic signaling also occurs through the PI3K/AKT and STAT3 signal transduction pathways,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and in other cases the RAS/RAF and PI3K/AKT cascades are activated in concert.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Because of multifaceted pathway activation, TRK oncogenes are potent and highly oncogenic by stimulating both antiapoptotic and pro-proliferative pathways.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Further, TRK fusion oncogenes have been identified as important mediators to stimulate early tumor progression.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Taken together, inhibition of TRK oncogenes can have chemotherapeutic and chemopreventive effects and, subsequently, has become a hotbed for therapeutic discovery efforts. In this Perspective, we summarize TRK inhibitors from peer-reviewed literature; compounds from patents have been previously reviewed by McCarthy and Bailey et al.<a onclick="showRef(event, 'ref133 ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref133 ref134 ref135">(133−135)</a></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">TRK Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The following section represents a comprehensive overview of known TRK inhibitors and their corresponding discovery and development efforts. Because most TRK-activating mutations alter or eliminate the extracellular domain,<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59−61)</a> antibodies directed at TRK or its ligands will not be effective as anticancer agents. Thus, all inhibitors reviewed are small-molecule kinase inhibitors that primarily target the TRK kinase domain. The inhibitors are at various stages of development from exploratory research and preclinical research to clinical trials. Inhibitors have been classified based on their interactions with TRK<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> and are presented according to their binding modes. TRK inhibitors can be broken down into four, distinct subtypes based on ligand binding interactions. The classifications are (A) type I, (B) type II, (C) type III, and (D) type IV.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> (A) Type I TRK inhibitors are ATP competitive and bind to the ATP-binding site. The majority of TRK inhibitors under clinical investigation are type I. (B) Type II TRK inhibitors are ATP noncompetitive and exhibit noncompetitive or pseudocompetitive binding kinetics. Type II inhibitors bind at the ATP-binding site and also to an adjacent allosteric pocket. Only a subset of kinases permit such binding, including TRK, a binding mode that can be incorporated into compound design to increase selectivity. (C) Type III TRK inhibitors bind to the kinase domain outside of the ATP-binding site. Unlike type II inhibitors, type III inhibitors are true allosteric inhibitors and can exploit unique, kinase-specific functionality to help achieve selectivity among TRK isoforms. (D) Type IV TRK inhibitors bind to a region other than the kinase domain. The majority of kinases are expressed as multidomain proteins with a catalytic domain and a regulatory domain. Type IV inhibitors can interrupt key protein–protein interactions or ligand interactions that limit activity of the kinase domain.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Because TRK genomic rearrangements often pair the TRK kinase domain to an unrelated gene, it is unclear how effective the anticancer properties will be for type IV TRK inhibitors. Type IV TRK inhibitors are not reviewed in this Perspective.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Type I TRK Inhibitors</h3><div class="NLM_p">Type I TRK inhibitors exhibit vast diversity in compound architecture, which will alter activity and selectivity profiles of the compounds. This helps to better define chemical space that is relevant to TRK inhibition and suggests points of refinement for future drug discovery efforts. Wang et al. reported 4-aminopyrimidines with TRK inhibitory activity from a high throughput screening effort against TRKB (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The group discovered compound <b>1</b> with activity on TRKA and B (IC<sub>50</sub> = 0.27 μM and 1.1 μM, respectively). To complete SAR studies on <b>1</b>, the isoxazole was replaced with a phenyl group, and halogen substitution at the 4-position of phenyl was found to improve potency (<b>1-1a</b> and <b>1-1b</b>, TRKA IC<sub>50</sub> values were 0.10 μM and 0.36 μM, respectively).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> SAR studies at R<sup>2</sup> indicated that the (<i>S</i>)-enantiomer is preferred over the (<i>R</i>)-enantiomer (<b>1-1c</b> vs <b>1-1d</b> and <b>1-1e</b>, TRKA IC<sub>50</sub> values were 0.65 μM vs 0.10 μM and 0.006 μM, respectively). On the pyrimidine ring system, substituting bromine to fluorine or chlorine had little effect on TRKA activity (<b>1-2a</b> and <b>1-2b</b>, TRKA IC<sub>50</sub> values were 0.017 μM vs 0.004 μM, respectively).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Replacement of cyclopropyl at R<sup>4</sup> with isopropoxy is tolerated (<b>1-2c</b>, TRKA IC<sub>50</sub> = 0.006 μM), but altering aliphatic length or bulk decreases potency likely from geometric constraints at the TRKA hinge region (<b>1-2d</b> and <b>1-2e</b>, TRKA IC<sub>50</sub> values were 0.081 μM and 3 μM, respectively). Further optimization and refinement strategies furnished orally bioavailable compound <b>1-3</b> (AZ23).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Compound <b>1-3</b> was active against TRKA and B (IC<sub>50</sub> = 0.002 μM and 0.008 μM, respectively) and exhibited anticancer activity by oral dosing in a TRKA-driven allograft model and TRK-expressing xenograft model of neuroblastoma.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> In 2012, a ring fusion study of this scaffold was reported by the same research group.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Two different ring fusion strategies were employed to generate imidazo[4,5-<i>b</i>]pyridine and purine derivatives. Representative compounds of the two scaffolds, <b>1-4</b> and <b>1-5</b>, exhibited potent TRK inhibition. Both compounds displayed IC<sub>50</sub> values of 0.0005 μM against TRKA-dependent MCF10A cells (MCF10A-TRKA-Δ) and were also active in mice bearing 3T3-TRKA-Δ tumors.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Identification of compounds <b>1-3</b>, <b>1-4</b>, and <b>1-5</b> and (B) cocrystal structure of compound <b>1-3</b> in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AOJ">4AOJ</a>, 2.75 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the cocrystal structure of compound <b>1-3</b> with TRKA (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), TRKA is found in an inactive conformation with the C-helix pushed into a non-catalytically active orientation.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Compound <b>1-3</b> forms two hydrogen bonds at the hinge region with the pyrazole moiety and interacts with the amide backbone of Glu590 and Met592. The isopropoxy group is oriented toward Phe589, which is the gatekeeper amino acid. The fluoropyridine ring engages in an interaction with Leu657, and the fluorine atom is in close proximity to Gly667.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Numerous TRK kinase inhibitors exploit this region to increase selectivity and potency.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Based on the crystal structure, compound <b>1-3</b> is a type I kinase inhibitor.</div><div class="NLM_p">Further exploration of type I TRK inhibitors was reported by Brasca et al.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The group initially identified compound <b>2</b> as a potent CDK-2 (cyclin dependent kinase) inhibitor (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Enhancement in selectivity, antiproliferative activity, and optimization of the physiochemical and pharmacokinetic properties led to the identification of compound <b>2-1</b> (milciclib, PHA-848125) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) with high potency (CDK-2 IC<sub>50</sub> = 0.045 μM) and high bioavailability (<i>F</i> = 85%). Serendipitously, this compound exhibited near equal potency against TRKA (IC<sub>50</sub> = 0.053 μM) with selectivity in the greater kinome (IC<sub>50</sub> values >0.15 μM).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Identification of <b>2-1</b> and (B) cocrystal structure of compound <b>2-1</b> in CDK-2/cyclin A (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WIH">2WIH</a>, 2.5 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B illustrates the crystal structure of compound <b>2-1</b> in complex with CDK2/cyclin A.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The compound binds in the ATP pocket of the kinase with the pyrazoloquinazoline ring system occupying the adenine region, while the phenyl moiety points toward the solvent accessible region. Compound <b>2-1</b> creates two hydrogen bonds with the protein backbone of the hinge with residue Leu83. The amide carbonyl group of <b>2-1</b> is within hydrogen bonding distance of the conserved lysine (Lys33).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><div class="NLM_p">Albanese et al. further evaluated the dual inhibitory activity of compound <b>2-1</b> against CDK-2 and TRKA.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a><i>In vitro</i>, <b>2-1</b> was able to inhibit NGF-induced phosphorylation of TRKA as well as downstream signaling in the DU-145 human prostate carcinoma line. <i>In vivo</i>, <b>2-1</b> inhibited tumor growth in a human prostate DU-145 xenograft model in a dose dependent manner. Because of the dual inhibitory properties of <b>2-1</b>, the compound shifts the paradigm for precision medicine. Instead of generating a “magic-bullet” with high TRK kinase selectivity, Albanese et al. focused on validating and developing a “smart-bomb” with activity on the oncogene lesion (TRK) paired with cell cycle inhibition (CDK).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p">In line with developing TRK inhibitors with dual activity, Fancelli et al. identified a series of 5-phenylacetyl 1,4,5,6-tetrahydropyrrolo[3,4-<i>c</i>]pyrazole as Aurora kinase inhibitors (compound <b>3</b>, Aurora-A IC<sub>50</sub> = 0.027 μM) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Further medicinal chemistry efforts lead to the discovery of compound <b>3-1b</b>. Compound <b>3-1b</b> was found to have dual activity on TRKA (IC<sub>50</sub> = 0.03 μM) and Aurora A (IC<sub>50</sub> = 0.013 μM)<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> with weak ALK (anaplastic lymphoma kinase) inhibitory activity (IC<sub>50</sub> = 0.091 μM).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Akin to <b>2-1</b>, compound <b>3-1b</b> obtained dual activity on the oncogene lesion (TRKA) as well as cell cycle inhibition (Aurora A).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Identification of compound <b>3-1b</b>; (B) cocrystal structure of compound <b>3-1b</b> with ALK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA">2XBA</a>, 1.95 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, Menichincheri et al. disclosed research efforts to generate compound <b>4-3</b> (entrectinib, RXDX-101) for ALK (IC<sub>50</sub> = 0.012 μM) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> To develop ALK inhibitors from compound <b>4</b> (ALK IC<sub>50</sub> = 0.073 μM), the cocrystal complex of ALK with compound <b>3-1b</b> was studied (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Analysis of the complex suggested that a mono-substitution at the 2′-position would generate derivatives that occupy the ATP sugar pocket region while simultaneously displacing a water molecule. In addition, NH-R substituents at this position were able to stabilize the bioactive conformation through intramolecular hydrogen bonding. Based on this concept, different amines were attached to the 2′-position of the central phenyl ring.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structural optimization from compound <b>4</b> to <b>4-3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The introduction of a primary amine at 2′ led to compound <b>4-1a</b> with similar ALK potency (IC<sub>50</sub> = 0.067 μM).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> This was consistent with modeling analysis as compound <b>4-1a</b> lacked the substituent necessary to fill the sugar pocket. At R<sup>1</sup>, a methoxyethyl or methoxy propyl group generally led to a moderate loss in activity (<b>4-1b</b> and <b>4-1c</b>, ALK IC<sub>50</sub> = 0.21 μM and 0.135 μM, respectively) while a fluorine or a hydroxyl group increased activity (<b>4-1d</b> and <b>4-1e</b>, ALK IC<sub>50</sub> = 0.014 μM and 0.026 μM, respectively).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> In contrast, phenyl or cyclohexyl significantly decreased affinity because of size constraints of the sugar pocket (<b>4-1f</b> and <b>4-1g</b>, ALK IC<sub>50</sub> = 0.684 μM and 0.56 μM, respectively).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Interestingly, introduction of a hydroxyl group furnished <b>4-1h</b> of which the <i>trans</i>-isomer displayed 10-fold higher activity (ALK IC<sub>50</sub>= 0.01 μM) than the <i>cis</i>. When R<sup>1</sup> is 4-amino-<i>N</i>-methylpiperidinyl (<b>4-1i</b>) or 4-aminotetrahydropyranyl (<b>4-3</b>), the resulting compounds exhibit excellent potency on ALK (IC<sub>50</sub> = 0.015 and 0.012 μM, respectively). The latter of the two had better cellular activity (Cell IC<sub>50</sub> = 0.438 μM vs 0.031 μM), which might be due to a difference in cell permeability.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Introduction of a methyl group to R<sup>2</sup> generated two enantiomers (<b>4-2a</b>), with one enantiomer being 3-fold more active than the other (ALK IC<sub>50</sub>= 0.059 μM and 0.019 μM, respectively, absolute configuration not determined).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Due to labor-intensive chiral separation and stability of the benzhydryl stereogenic center further development of these compounds was terminated. Strong electron withdrawing groups on the phenyl ring are crucial for ALK activity. Removing the 3,5-difluoro substitution, changing the position of the fluorine, or replacing with methyl all decreased activity (compounds <b>4-2b</b> to <b>4-2e</b>, ALK IC<sub>50</sub> = 0.106 μM, 0.03 μM, 0.038 μM, 0.181 μM, respectively).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><div class="NLM_p">After initial development for ALK, compound <b>4-3</b> was subsequently found active on ROS1 (IC<sub>50</sub> = 0.007 μM) and TRK (IC<sub>50</sub> values for TRKA/B/C were 0.001 μM, 0.003 μM, and 0.005 μM, respectively).<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a> In antiproliferative studies, compound <b>4-3</b> was active against the colorectal cancer cell line KM-12 (IC<sub>50</sub> = 0.0017 μM) and also induced tumor stabilization (>90% TGI) when administered po to mice bearing KM-12 xenografts.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Compound <b>4-3</b> is currently in clinical trials for the treatment of patients with ALK-, ROS1-, and TRK-dependent tumors and is exhibiting remarkable signs of efficacy.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a> In a Phase 2 clinical trial, <b>4-3</b> is being investigated for advanced or metastatic solid tumors that harbor TRKA/B/C, ROS1, or ALK gene rearrangements (NCT02568267).</div><div class="NLM_p">The cocrystal structure of ALK with compound <b>4-3</b> was consistent with the above expectations (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> A similar binding mode is observed in the cocrystal structure of <b>4-3</b> with TRKA (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The compound is anchored to the hinge through three hydrogen bonds between the aminoindazole moiety and the backbone of residues Glu590 and Met592 (Glu1197 and Met1199 in ALK). The difluorobenzyl-indazole core creates favorable contacts with Ala542 and Leu657 (Leu1256 and Val1130 in ALK) and the gatekeeper Phe589 (Leu1196 in ALK).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Moreover, the 3,5-difluorobenzyl moiety is involved in multiple interactions with the backbone carbonyls of Asp668 from the DFG motif (Asn1254 and Gly1269 in ALK). The central phenyl ring makes a hydrophobic contact with Leu516 (Leu1122 in ALK), while the methylpiperazine is oriented toward the solvent front. In order to optimally fill the sugar pocket, the partially solvent-exposed tetrahydropyranyl moiety adopts a roughly orthogonal orientation with respect to the scaffold.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cocrystal structure of compound <b>4-3</b> with (A) ALK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a>, 2.22 Å) and (B) TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KVT">5KVT</a>, 2.45 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another drug discovery campaign centered on ALK serendipitously uncovered <b>5-3</b> (belizatinib, TSR-011), a novel, potent TRK inhibitor (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Through HTS (high-throughput screening), Lewis et al. identified the ALK inhibitor <b>5</b> (ALK kinase IC<sub>50</sub> = 0.003 μM, pALK cell IC<sub>50</sub> = 0.054 μM; 64-fold, 103-fold, and 15-fold selectivity over JAK2, SRC, and IGF1R, respectively),<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> which was cocrystallized with ALK (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Through the benzoyl carbonyl oxygen and the benzimidazole NH, <b>5</b> was shown to bind to the hinge of ALK at Met1199, and the benzoyl ring was adjacent to the gatekeeper residue Leu1196. The <i>cis</i>-1,4 geometry of the cyclohexyl group pushes the methyl ester moiety into a hydrophobic pocket surrounded by Leu1256 and Gly1269. The piperidine moiety engages in van der Waals interactions with two backbone carbonyls on the N-terminal lobe (Gly1121 and Leu1122) in a shallow pocket on the surface of the protein at the entrance to the ATP binding pocket.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structural optimization from compound <b>5</b> to <b>5-3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Co-crystal structure of (A) compound <b>5</b> in ALK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOC">4FOC</a>, 1.7 Å) and (B) compound <b>5-3</b> in ALK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOD">4FOD</a>, 2 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To improve cell potency, selectivity, and metabolic stability, SAR optimization was completed. First, the methyl ester was replaced with different esters and amides (compounds <b>5-1a</b> to <b>5-1e</b>). The isopropyl amide compound <b>5-1e</b> displayed the best combination of activity and selectivity (ALK kinase IC<sub>50</sub> = 0.002 μM, pALK cell IC<sub>50</sub> = 0.054 μM; 813-fold, 429-fold, and 36-fold selectivity over JAK2, SRC, and IGF1R, respectively).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> To improve metabolic stability, a wide variety of modifications were investigated at the R<sup>2</sup> position. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> depicts some of these modifications, and the tertiary alcohol analogue <b>5-3</b> appeared optimal. Finally, different substitutions were introduced to the 4-fluoro phenyl ring; however, these derivatives either decreased selectivity or suffered from compromised cellular activity against ALK.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> When <b>5-3</b> was screened against a kinase panel, <b>5-3</b> was found to have potent pan-TRK activity (IC<sub>50</sub> for TRKA/B/C < 0.003 μM).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Currently, <b>5-3</b> is under a Phase 1/2 study in patients with advanced solid tumors and lymphomas (NCT02048488).</div><div class="NLM_p">The cocrystal structure of <b>5-3</b> with ALK (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) shows that <b>5-3</b> binds similarly to <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Compound <b>5-3</b> pushes into the active site of the kinase in a pocket formed by Val1180 and Leu1256 and is in close proximity to the gatekeeper residue Leu1196. The iminobenzamide moiety adopts the exocyclic acylimine tautomer permitting key hydrogen bonding interactions with the hinge region residue Met1199. This tautomer is favored by extended π-delocalization into the pendant aryl ring, achieved by retaining a coplanar arrangement between benzamide and benzimidazole moieties.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><div class="NLM_p">Isothiazole derivatives have been identified as TRK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). From a HTS campaign directed at TRKA, Lippa et al. identified compound <b>6</b> (TRKA IC<sub>50</sub> = 0.007 μM).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Initial SAR studies at R<sup>1</sup> determined that substitution at the benzylic α-position remarkably influenced TRKA activity and VEGFR2 selectivity. Small aliphatic chains were well tolerated (<b>6-1a</b> and <b>6-1b</b>, TRKA IC<sub>50</sub> values were 0.003 μM and 0.004 μM, respectively), while larger substitutions significantly diminished activity (<b>6-1d</b> and <b>6-1e</b>, TRKA IC<sub>50</sub> values were 0.035 μM and 2.6 μM, respectively).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The orientation of the R<sup>1</sup> substitution also played a key role: the (<i>R</i>)-ethyl enantiomer <b>6-1b</b> was >10-fold more active (TRKA IC<sub>50</sub>, 0.004 μM vs 0.052 μM) and was >100-fold more selective (VEGFR2 selectivity, 1300× vs 10×) than the (<i>S</i>)-enantiomer. SAR at R<sup>2</sup> and R<sup>3</sup> showed that substitution at these two positions is not necessary to maintain TRK activity (<b>6-2a</b> to <b>6-2d</b>, TRKA IC<sub>50</sub> values were 0.01 μM, 0.008 μM, 0.105 μM, and 0.111 μM, respectively).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Further optimization identified that bicyclic moieties were important for TRK activity, especially the 7-membered ring system (compound <b>6-2e</b>, TRKA IC<sub>50</sub> < 0.001 μM), and consistent with previous data, the (<i>R</i>)-enantiomer was more active (<b>6-3</b> vs <b>6-2f</b> , TRKA IC<sub>50</sub> values were <0.001 μM vs 0.091 μM). Compound <b>6-3</b> (Cpd5n) had picomolar kinase potency and single-digit nanomolar activity against TRK-driven cell growth.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structural optimization from compound <b>6</b> to <b>6-3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal complex of <b>6-3</b> in TRKB was obtained and is shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The aliphatic portion of <b>6-3</b> is oriented toward the glycine-rich loop and exhibits clear type I binding.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The glycine-rich loop forms a cage around the inhibitor and engages in strong hydrophobic interactions through Phe565. The urea and amide groups on the thiazole bind to the hinge of TRKB, forming three hydrogen bonds. The benzo-cycloheptene group is sandwiched between the gatekeeper Phe633 and glycine-rich loop Phe565 side chains, likely contributing to the stabilization of the TRKB DFG-in conformation.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> This also explains the potency differences between the two enantiomers as the <i>S</i>-enantiomer could still bind the hinge but would clash with Phe565 due to difference in stereochemistry of the benzo-cycloheptene. The affinity of <b>6-3</b> for TRKB is also enhanced by several water-bridged hydrogen bonds between the inhibitor and the kinase.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Co-crystal structure of compound <b>6-3</b> in TRKB (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AT3">4AT3</a>, 1.77 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; sulfur, yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In another campaign to uncover novel TRK inhibitors, Choi et al. developed a series of substituted imidazopyridazine derivatives from compound <b>7</b> (TRKB IC<sub>50</sub> = 0.083 μM) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The crystal complex of <b>7</b> with TRKC (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A) shows that the ligand binds to the inactivated (DFG-out) form of the kinase and the imidazopyridazine warhead engages in a hydrogen bond at the hinge with Met620. The benzonitrile ring is wedged between Phe617 and Phe698, and the phenyl ring sits under the glycine-rich loop and faces the solvent front of the active site.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structural optimization from compound <b>7</b> to <b>7-3b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Co-crystal structure of (A) compound <b>7</b> in TRKC (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YMJ">4YMJ</a>, 2 Å) and (B) compound <b>7-3a</b> in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE">4YNE</a>, 2.02 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preliminary medicinal chemistry efforts focused SAR studies at R<sup>1</sup> to R<sup>4</sup>, with the goal of identifying compounds with improved potency and pharmacokinetic properties suitable for <i>in vivo</i> profiling. Nitrile substitutions in the phenyl group (R<sup>3</sup>) at the 3- or 4-position were equally tolerated (<b>7</b> vs <b>7-1a</b>, TRKA cell IC<sub>50</sub> values = 0.85 μM and 0.74 μM). It was also observed that 3-substitution at the benzylamine phenyl ring (R<sup>1</sup>) led to a 10-fold increase in potency (<b>7-1b</b>, TRKA cell IC<sub>50</sub> = 0.076 μM).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Modifying the phenyl ring (R<sup>3</sup>) with 3-F substitution at R<sup>1</sup> furnished many tolerated functional groups that could either increase solubility or further drive potency (i.e., compound <b>7-1c</b>, TRKA cell IC<sub>50</sub> = 0.006 μM). Methylation of the benzylic amine (R<sup>3</sup>) led to no significant change in potency indicating that the acidic proton on the benzylic amine does not hydrogen bond with TRK.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Cyclizing the benzyl amine moiety with the adjacent phenyl ring was performed to rigidify the structure and reduce conformational entropy. The fused five-membered ring system was optimal for TRK inhibition and exhibited a preference for the <i>R</i>-enantiomer (<b>7-2a</b> to <b>7-2e</b>, TRKA cell IC<sub>50</sub> values = 0.17 μM, 0.075 μM, 0.068 μM, 3.13 μM, and 0.021 μM, respectively). Derivatization at R<sup>5</sup> led to the discovery of the optimized compound <b>7-3b</b> (GNF-8625).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Compound <b>7-3b</b> demonstrated potent antiproliferative activity against TRK transfected Ba/F3 and KM-12 cell lines (IC<sub>50</sub> = 0.001 μM and 0.01 μM, respectively). In a KM-12-derived tumor xenograft, compound <b>7-3b</b> demonstrated antitumor efficacy in a dose dependent manner, inducing 20% tumor regression at a dose of 50 mg/kg BID.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><div class="NLM_p">Imidazopyridazines are frequently incorporated into kinase inhibitors as they readily form a hydrogen bond at the hinge with the C-6 carbon oriented toward the solvent.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> The warhead of <b>7-3a</b> is based on imidazopyridazine and was expected to bind TRKA akin to <b>7</b>. Surprisingly, the cocrystal structure of <b>7-3a</b> with TRKA revealed an unexpected 180° rotation of the imidazopyridazine core at the hinge (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Only the (<i>R</i>)-enantiomer of <b>7-3a</b> is active because the 3-F-phenyl is optimally positioned downward in the hydrophobic pocket. The moiety fills a pocket endogenously occupied by Phe669 and provides excellent shape complementary, likely contributing to increased affinity. Molecular modeling and crystallography studies indicated that two distinct binding modes exist (i.e., core flipping) with scaffold <b>7</b>.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Based on the different TRK cocrystal structures obtained with <b>7</b> and <b>7-3a</b>, it was concluded that the preferred binding mode depends on C-6 substitution. If the C-6 substitution is modified to (<i>R</i>)-phenylpyrrolidine, the “flipped” orientation is preferred as the pyrrolidine anchors the phenyl group in the hydrophobic pocket.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The phenomenon of “core flipping” could be employed to generate compounds with activity in multiple kinase families. Based on the crystal structure, compound <b>7-3a</b> is a type I kinase inhibitor.</div><div class="NLM_p">Compound <b>8</b> (larotrectinib, LOXO-101) is another selective pan-TRK inhibitor exhibiting low nanomolar cellular potency against the TRK family (IC<sub>50</sub> ranging from 0.002 μM to 0.02 μM) with 100-fold selectivity over other kinases (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref49 ref157'); return false;" href="javascript:void(0);" class="ref ref49 ref157">(49,157)</a> The compound can induce cell-cycle arrest in the G1 phase and apoptosis in KM-12 cells.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Compound <b>8</b> is currently in a Phase 2, open-label study for patients with advanced solid tumors harboring a fusion of TRKA, TRKB, or TRKC (NCT02576431).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The medicinal chemistry effort leading to the discovery of this compound and its cocrystal complex with TRK have not been reported. However, because of the structure similarities between compounds <b>8</b> and <b>7-3b</b>, it can be inferred that <b>8</b> exhibits similar SAR properties to that of <b>7-3b</b>.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of compound <b>8</b> and second generation TRK inhibitors <b>9</b> and <b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Second Generation Type I TRK Inhibitors</h3><div class="NLM_p">All first generation TRK inhibitors exhibit profound, upfront efficacy but eventually lose effectiveness due to the development of secondary mutations in the TRK kinase domain. After treatment with <b>8</b> or <b>4-3</b>, mutations in the TRK kinase domain have been reported<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> that render further treatment ineffective.<a onclick="showRef(event, 'ref47 ref159'); return false;" href="javascript:void(0);" class="ref ref47 ref159">(47,159)</a> These mutations include TRKA<sup>G595R</sup> (and its paralogue TRKC<sup>G623R</sup>) in the solvent front of the active site, TRKA<sup>G667C</sup> (and its paralogue TRKC<sup>G696A</sup>) adjacent to the DFG motif, and TRKA<sup>F589L</sup> at the gatekeeper region.<a onclick="showRef(event, 'ref47 ref99 ref159 ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref47 ref99 ref159 ref160 ref161">(47,99,159−161)</a> TRKA<sup>G595R</sup> and TRKA<sup>G667C</sup> are analogous to ALK<sup>G1202R</sup> and ALK<sup>G1269A</sup>, respectively.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> In TRKA, the native residues are important to accommodate <b>8</b> and <b>4-3</b>, while the mutations create steric clashes with the inhibitors. In addition, TRKA<sup>G595R</sup> increases ATP affinity to the kinase.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Structural modeling suggests that each mutation directly interferes with binding of <b>8</b>, <b>4-3</b>, and all other TRK tyrosine kinase inhibitors.<a onclick="showRef(event, 'ref47 ref160'); return false;" href="javascript:void(0);" class="ref ref47 ref160">(47,160)</a> Functional studies have subsequently confirmed that cancer cells harboring these mutations are cross-resistant to all TKIs with anti-TRK activity.<a onclick="showRef(event, 'ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref162 ref163">(162,163)</a></div><div class="NLM_p">To generate inhibitors that could overcome point mutations in TRK, compounds <b>9</b> (LOXO-195) and <b>24</b> (TPX-0005) were designed to limit the compound surface area in the active site (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). Both compounds were designed as fused macrocycles to reduce unnecessary interactions at either end of the binding pocket. Modeling suggested that TRKA<sup>G595R</sup> would introduce steric clashes between the arginine side chain and the hydroxypyrrolidine group of <b>8</b>, and TRKA<sup>G667C</sup> would create steric clashes between the cysteine or alanine side chain and the difluorophenyl group of <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> To determine the impact of TRK kinase mutations on inhibitor activity, <b>8</b> and <b>9</b> were tested against TRKA<sup>G595R</sup>, TRKA<sup>G667C</sup>, and TRKC<sup>G623R</sup>. Compound <b>9</b> achieved low nanomolar inhibitory activity against all mutated kinase (IC<sub>50</sub> values = 0.002 μM, 0.00098 μM, and 0.0023 μM); while compound <b>8</b> displayed significantly reduced inhibitory activity (IC<sub>50</sub> values = 0.069 μM, 0.045 μM, and 0.048 μM).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> An innovative first-in-human clinical trial has demonstrated efficacy of compound <b>9</b> in 2 patients who had developed acquired resistance to <b>8</b> mediated by secondary TRKA<sup>G595R</sup> or TRKA<sup>G623R</sup> mutations.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Compound <b>10</b>, an analogue to <b>9</b>, potently inhibited ROS1<sup>G2032R</sup> (IC<sub>50</sub> = 0.0084 μM), TRKA<sup>G595R</sup> (IC<sub>50</sub> = 0.0004 μM), TRKB<sup>G639R</sup> (IC<sub>50</sub> = 0.0019 μM), and TRKC<sup>G623R</sup> (IC<sub>50</sub> = 0.0004 μM).<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Compound <b>10</b> also exhibited activity in xenograft tumor models bearing WT and kinase domain mutations of ALK, ROS1, and TRKA.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Proposed binding and steric interactions of <b>8</b> with the TRKA double mutant G595R and G667C and (B) proposed binding of <b>9</b> to the TRKA double mutant for which steric interactions are not predicted between G595R and G667C. The kinase is depicted in yellow ribbons.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Other Type I TRK Inhibitors</h3><div class="NLM_p">Several other TRK scaffolds have been reported that exhibit type I characteristics and are summarized in the following section (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Aza-oxindole and oxindoles were reported as potent TRK inhibitors by Wood et al.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The representative compound <b>11</b> exhibited pan-TRKA inhibitory activity (TRKA/B/C IC<sub>50</sub> values = 0.030 μM, 0.007 μM, 0.005 μM, respectively) with selectivity in the greater kinome but also inhibited VEGFR2 (vascular endothelial growth factor receptor 2).<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(168,169)</a> Compound <b>11</b> shares similarities in structure to other known VEGFR2 inhibitors, such as sunitinib, which likely accounts for its VEGFR2 profile.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Choe et al. reported a series of pyrrole[3,4-<i>c</i>]pyrazole TRKA inhibitors (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). The representative compound <b>12</b> inhibits TRKA with an IC<sub>50</sub> of 0.019 μM. SAR studies indicated that the cyclopropyl and benzyl carbamate groups are essential for potency and removal of either resulted in a loss of activity.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Carboni et al. developed compound <b>13</b> as a dual IGF-1R/IR inhibitor (IC<sub>50</sub> = 0.0018 μM and 0.0017 μM, respectively). Kinase profiling showed that compound <b>13</b> was active on several other kinases, including TRKA/B (IC<sub>50</sub> values = 0.007 μM and 0.004 μM, respectively).<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Cho et al. developed compound <b>14</b> as a c-MET inhibitor based on an aminopyridine core substituted with benzoxazole (IC<sub>50</sub> = 0.08 μM).<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Compound <b>14</b> was later identified to have activity against the mutant c-MET<sup>Y1230D</sup> kinase (IC<sub>50</sub> = 0.003 μM) and TRKA (IC<sub>50</sub> = 0.039 μM).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Stachel et al. reported a series of pyrido[3,2-<i>d</i>]pyrimidines as TRKA inhibitors; the representative compound <b>15</b> had a TRKA IC<sub>50</sub> of 0.011 μM and moderate cell activity (IC<sub>50</sub> = 1.688 μM).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of other type I TRK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Radiolabeled Type I TRK Inhibitors</h3><div class="NLM_p">Positron emission tomography (PET) is a noninvasive <i>in vivo</i> imaging technique that enables the visualization and quantification of the distribution of molecules labeled with positron-emitting isotopes. This method enables the evaluation of biochemical and physiological processes by monitoring the distribution and kinetics of a labeled molecule <i>in vivo</i> and has found broad application in clinical practice (personalized treatments), research, and pharmaceutical development.<a onclick="showRef(event, 'ref175 ref176 ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref175 ref176 ref177 ref178">(175−178)</a></div><div class="NLM_p">Because of the clinical importance of TRK in cancer as well as the central nervous system, Bernard-Gauthier et al. generated radiolabeled TRK ligands to assess and monitor TRKA/B/C levels in the brain. The TRK ligands were synthesized from known inhibitors using <sup>11</sup>C- or <sup>18</sup>F-labeled PET radiotracers suitable for <i>in vivo</i> imaging (compounds <b>16</b>–<b>20</b>) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).<a onclick="showRef(event, 'ref169 ref179 ref180 ref181 ref182 ref183'); return false;" href="javascript:void(0);" class="ref ref169 ref179 ref180 ref181 ref182 ref183">(169,179−183)</a> These compounds demonstrated comparable activity and selectivity profiles to the unlabeled precursor.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Compound <b>16</b> displayed excellent TRK selectivity in a panel of brain and cancer relevant kinases and TRK-specific binding <i>in vitro</i> in rat brain and human neuroblastoma cryosections. The radiocompound also exhibited uniform regional brain distribution but was highly susceptible to CYP450 metabolism.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Nevertheless, TRK radiocompounds can prove instrumental in studying TRK biology, diagnosing TRK-positive disease, and determining drug disposition of TRK inhibitors in real time.<a onclick="showRef(event, 'ref176 ref178'); return false;" href="javascript:void(0);" class="ref ref176 ref178">(176,178)</a> It is worth noting that compound <b>19</b> was the first TRK radiotracer clinical lead involved in a nonhuman primate imaging study;<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> compound <b>20</b> was the first reported radiotracer used as an <i>in vivo</i> probe to explore endogenous kinase densities using PET neuroimaging in humans.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of representative radiolabeled type I TRK Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Type II TRK Inhibitors</h3><div class="NLM_p">Type I TRK inhibitors are ATP competitive and typically possess pan-kinase activity. A method to increase kinase selectivity and potency is to generate inhibitors that bind in a type II fashion.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Type II inhibitors are generally more active against tyrosine kinases, which can be exploited to increase selectivity and potency profiles.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> TRK inhibitors that display type II binding kinetics can be preferred depending on the biology being studied or the disease being treated. It is important to note that the most advanced TRK inhibitors in clinical trials are type I (<b>8</b> and <b>4-3</b>). These inhibitors are being evaluated for anticancer properties and may have inhibition characteristics optimal for a tumor environment. In other therapeutic areas, such as the central nervous system (CNS) or pain management, TRK inhibitors with a type II profile maybe preferred because, as a class, they are more selective than type I inhibitors.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> However, the typically larger molecular architecture of type II compounds can cause less favorable drug-like properties, leading to development challenges. In the following section, the development of type II TRK inhibitors is disclosed, and developmental efforts were primarily focused on optimizing for anticancer properties.</div><div class="NLM_p">Albaugh et al. identified type II TRK inhibitors based on an oxindole-core (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Oxindole <b>21</b> inhibited Ba/F3-Tel-TRKA/B/C with IC<sub>50</sub> values less than 0.06 μM. SAR studies at the R<sup>1</sup> position showed that the phenyl ring is critical for TRK specific inhibitory activity (<b>21-1a</b> vs <b>21-1b</b>, TRKA cell IC<sub>50</sub> 2.3 μM vs 0.91 μM).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> To improve drug properties, several basic groups were introduced at the terminal phenyl ring and were well tolerated and increased potency but did not improve solubility. Substituting the aryl ring with 3-CF<sub>3</sub> at R<sup>1</sup> is crucial for TRK activity (<b>21-1c</b> and <b>21-1d</b>, TRKA cell IC<sub>50</sub> 0.39 μM and 0.013 μM, respectively). Truncating the amide group to aniline resulted in a total loss of activity, indicating the amide is necessary for TRK activity (<b>21-1e</b>, TRKA cell IC<sub>50</sub> > 10 μM).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Replacement of the pyrrole with other groups or methylation of the pyrrole nitrogen yielded significantly less potent compounds suggesting that the acidic proton on pyrrole is involved in a key hydrogen bond at the hinge region. Substitution on the pyrrole showed that carbolic acid at position 4 is preferred for potency and selectivity, with or without methyl substitution (<b>21-2a</b> to <b>21-2c</b>, TRKA cell IC<sub>50</sub> 0.014 μM, 0.01 μM, and 0.012 μM; selectivity 43-fold, 150-fold, and 108-fold, respectively).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Replacement of the amide with urea generated compounds with increased potency and selectivity over VEGFR2 (<b>21-3a</b>, TRKA cell IC<sub>50</sub>= 0.004 μM, selectivity 130-fold).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Introduction of a methyl substitution at R<sup>3</sup> and a fluorine at R<sup>4</sup> generated compound <b>21-3b</b> (GNF-5837), which exhibits pan-TRK inhibition (TRKA/B/C IC<sub>50</sub> values = 0.011 μM, 0.009 μM, and 0.007 μM, respectively) and about 300-fold selectivity over VEGFR2 (IC<sub>50</sub> = 3.0 μM). In BALB/c mice and Sprague–Dawley rats, compound <b>21-3b</b> demonstrated low drug clearance and moderate bioavailability. In mice bearing RIE xenografts expressing TRKA and NGF, compound <b>21-3b</b> (100 mg/kg/day po) significantly inhibited tumor growth.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structural optimization from compound <b>21</b> to <b>21-3b</b> (GNF-5837).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the cocrystal structure of <b>21-3a</b> with TRKC (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), <b>21-3a</b> is found to bind to the kinase in a type II manner.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> The oxindole core and pyrrole nitrogen form key hydrogen bonds with hinge residues Glu618, Tyr619, and Met620. The urea functionality interacts with Glu588 from the α-C-helix and Asp697 from the DFG motif. In addition, interactions occur at the phenyl bridge with Phe617 (gatekeeper) and a face to edge interaction with Phe698 from the DFG motif.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Co-crystal structure of compound <b>21-3a</b> in TRKC (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V5Q">3V5Q</a>, 2.2 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Skerratt et al. reported a series of pyrrolopyrimidine derivatives as pan-TRK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>A).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> By employing a high-throughput TRKA/B cell screening assay, compound <b>22</b> was identified as a pan-TRK inhibitor (TRKA/B/C IC<sub>50</sub> values = 0.002 μM, 0.005 μM, and 0.004 μM, respectively) with strong kinome selectivity but poor water solubility (<0.3 μM).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> To improve solubility, the urea group was replaced with an amide and the 4-NH<sub>2</sub> was removed to generate compound <b>22-1</b> (TRKA/B/C IC<sub>50</sub> values = 0.012 μM, 0.004 μM, and 0.003 μM, respectively) with improved water solubility (∼13.2 μM).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> It was determined that the scaffold was likely metabolized by aldehyde oxidase and inhibited hERG (human ether-à-go-go-related gene) potassium heart channels.<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188,189)</a> In order to reduce metabolic liabilities and off target toxicities, an amino group was added at the 2-position furnishing compound <b>22-2</b> (TRKA/B/C IC<sub>50</sub> values = 0.008 μM, 0.005 μM, and 0.004 μM, respectively; solubility = 30 μM).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> To further improve physical–chemical properties and aqueous solubility, a hydrophilic hydroxymethylene group was added to the N-<i><sup>i</sup></i>Pr motif and the terminal ring was replaced with pyridine to obtain compound <b>22-3</b> (PF-06273340). Compound <b>22-3</b> was a potent pan-TRK inhibitor (TRKA/B/C IC<sub>50</sub> values = 0.006 μM, 0.004 μM, and 0.003 μM, respectively; solubility = 131 μM) and exhibited selectivity over a large kinase panel.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Currently, Phase 1 clinical trials are ongoing to examine the activity of different doses of <b>22-3</b> on a panel of evoked pain tests in healthy male subjects (NCT02260947).</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. (A) Structural optimization from compound <b>22</b> to <b>22-3</b> and (B) cocrystal structure of compound <b>22-3</b> with TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JFX">5JFX</a>, 1.63 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; chlorine, green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>B shows the cocrystal structure of <b>22-3</b> bound to TRKA and highlights key protein–ligand interactions.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Compound <b>22-3</b> binds to the DFG-out form of TRK, with the 2-aminopyrrolopyrimidine forming hydrogen bonds at the hinge and the ketone binding to Glu590 through a water contact.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Most kinase inhibitors engage in one or two interactions at the hinge, while <b>22-3</b> is found to engage in three. The central pyridine group of <b>22-3</b> engages in a double π–π stacking interaction with Phe589 (gatekeeper residue) and Phe669 (DFG motif). The carbonyl oxygen forms a hydrogen bond with the amide backbone of Asp668 (DFG motif) and the amide engages TRKA through a water contact between Lys544 and Glu560 from the c-helix. The lipophilic back pocket accommodates the chloropyridine group.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Based on the binding characteristics of <b>22-3</b>, the inhibitor can be considered type II.</div><div class="NLM_p">Compound <b>23</b> (cabozantinib, XL184) is a multiple kinase inhibitor with activity against c-MET/VEGFR2 and was found to have a potent TRKB inhibitory activity (IC<sub>50</sub> < 0.02 μM, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>A).<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Compound <b>23</b> is currently under Phase 2 clinical trials in patients with RET fusion-gene non-small-cell lung cancer and those with other activating genes, such as ROS1, NTRK, MET, or AXL (NCT01639508). Compound <b>24</b> (sitravatinib, MGCD516) was developed by Patwardhan et al. as a potent multikinase inhibitor (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>A) active against several kinases (IC<sub>50</sub> values for AXL 0.0015 μM, VEGFR2 0.005 μM, FLT3 0.008 μM, c-KIT 0.006 μM, TRKA 0.005 μM, and TRKB 0.009 μM). Compound <b>24</b> blocked phosphorylation of several RTKs and induced potent anticancer effects <i>in vitro</i>; the compound was also active <i>in vivo</i> in MPNST (neurosarcoma) and LS141 (hybridoma) mouse xenograft models.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Compound <b>24</b> is currently under Phase 1 clinical development for patients with advanced solid tumor malignancies (NCT02219711). Compound <b>25</b> (altiratinib, DCC2701) was reported by Smith et al. as a multitargeted kinase inhibitor with preferential activity on MET, TIE-2, and VEGFR2 (IC<sub>50</sub> values = 0.0027 μM, 0.008 μM, and 0.0092 μM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>A). Subsequently, <b>25</b> was identified to exhibit activity as a pan-TRK inhibitor (TRKA/B/C IC<sub>50</sub> values = 0.00085 μM, 0.0046 μM, and 0.0083 μM, respectively) and FLT3 inhibitor (IC<sub>50</sub> 0.0093 μM).<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> In cell antiproliferative assays, compound <b>25</b> exhibited IC<sub>50</sub> values of 0.00069 μM in K562 cells, 0.0012 μM in SK-N-SH cells, and 0.0014 μM in KM-12 cells. Compound <b>25</b> inhibited tumor growth in the MET-amplified MKN-45 xenograft model in a dose-dependent manner. Further, compound <b>25</b> can actively penetrate the blood–brain barrier, indicating its potential for the treatment of brain cancers, brain metastases, and cancer pain. Compound <b>25</b> is currently under Phase 1 clinical development for patients with advanced solid tumors with NTRK or MET genomic alterations (NCT02228811).</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. (A) Chemical structures of representative dicarboxamide TRKA inhibitors and (B) cocrystal structure of compound <b>26</b> in c-MET (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DG5">5DG5</a>, 2.6 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>B illustrates the general type II binding mode of the dicarboxamide kinase inhibitor class.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> The pyridine of <b>26</b> (DP4157) binds to the hinge region and forms a hydrogen bond with Met1160. The central difluoro phenyl ring is in a hydrophobic pocket formed by Lys1110, Leu1157, and Phe1223 and engages in a π–π stacking interaction with Phe1223. The terminal <i>para</i>-fluoro phenyl ring binds in the allosteric pocket between the DFG motif and α-C-helix.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Other Type II TRK Inhibitors</h3><div class="NLM_p">El Zein et al. reported benzothiazole derivative <b>27</b> as multitargeted kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Compound <b>27</b> was active on several kinases with IC<sub>50</sub> values below 0.1 μM (including VEGFR2, ABL, TRKA, TRKB, and TIE2). Specifically, the IC<sub>50</sub> values for TRKA and TRKB were 0.0038 μM and 0.0044 μM, respectively. In antiproliferative studies, compound <b>27</b> was active against the KM-12 cell line with an IC<sub>50</sub> of 0.019 μM. Arcari et al. reported a series of 4-aminopyrrolopyrimidine derivatives as TIE-2 inhibitors.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Compound <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) was identified as a potent pan kinase inhibitor with activity against c-MET (IC<sub>50</sub> = 0.0047 μM) and RON (IC<sub>50</sub> = 0.0012 μM) and exhibited antitumor activities in multiple mouse xenograft models.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Medicinal chemistry efforts led to the identification of compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), which was found to be a TIE-2/TRKA dual inhibitor (IC<sub>50</sub> for TIE-2 and TRKA were 0.0037 μM and 0.004 μM, respectively).<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> A close analogue of <b>29</b>, compound <b>30</b>, progressed to clinical trials, but the Phase I multiple dose trials were terminated due to the development of significant CNS adverse events, including cognitive deficits, personality changes, and sleep disturbances.<a onclick="showRef(event, 'ref28 ref187'); return false;" href="javascript:void(0);" class="ref ref28 ref187">(28,187)</a> Compound <b>31</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) is another compound reported by Stachel et al.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> with good TRK inhibitory activity (TRKA IC<sub>50</sub> = 0.009 μM, cell IC<sub>50</sub> = 0.007 μM). This compound was found to bind to the TRK kinase in the DFG-out conformation.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> On compound <b>31</b>, the imidazole warhead binds to the hinge region, the central triazole ring forms an interaction with the gatekeeper residue, and the pyrazole occupies a selectivity pocket normally occupied by Phe669. This inhibitor is very unique because of the innovative triazole linker and imidazole warhead. Frett et al. described pyrazine-based derivatives as TRKA inhibitors (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Compound <b>32</b> had a TRKA IC<sub>50</sub> of 0.005 μM (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), and modeling studies determined the compound binds in a typical type II conformation. Compound <b>33</b> was initially reported by Conway et al. as a selective CSF-1R (colony stimulating factor 1 receptor) inhibitor (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) that completely inhibited CSF-1R <i>in vitro</i> at an IC<sub>50</sub> of 0.06 μM but was inactive against 26 other kinases.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Later, the same authors found compound <b>33</b> also inhibited TRKA with an IC<sub>50</sub> of 0.88 μM.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> The radiolabeled analogue of <b>33</b> was reported by Bernard-Gauthier et al.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Bertrand et al. reported that compound <b>33</b> bound to TRKB in a DFG-out conformation.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Hong et al. reported a series of 3,5-disubstituted-7-azaindoles as TRK Inhibitors.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Further modification uncovered compound <b>34</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), which is a pan-TRK inhibitor with selectivity over 30 kinases. The activity of compound <b>34</b> against TRK isoforms was equal (pan-TRK IC<sub>50</sub> = ∼0.001 μM), but it was 100-fold more selective against other kinases.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Amino pyrimidine derivatives were developed as TIE-2 (tunica interna endothelial-2) inhibitors with compound <b>35</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) exhibiting TIE-2 inhibition (IC<sub>50</sub> = 0.005 μM) with almost equal TRKA inhibitory activity (IC<sub>50</sub> = 0.008 μM).<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Through screening of an in-house kinase library, Kim et al. found 2-amino-5-(thioaryl)thiazole to be a promising scaffold for TRK inhibition.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Further SAR investigation led to the identification of compound <b>36</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) (TRKA IC<sub>50</sub> = 0.0006 μM), which was selective over CDK, MET, and IGF-1R (IC<sub>50</sub> values = 0.54 μM, >1 μM, and 0.43 μM, respectively).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structures of other Type II TRK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Pseudo-Type II TRK Inhibitors</h3><div class="NLM_p">A quintessential property of type II inhibitors is the formation of a strong hydrogen bond at the hinge region.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> In certain inhibitors of TRK, however, the hydrogen bond at the hinge is abnormally weak with the majority of important interactions occurring in an adjacent allosteric pocket. This was first reported by Stachel et al. with the development of urea based compound <b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>A) (TRKA kinase IC<sub>50</sub> = 4.233 μM, cell IC<sub>50</sub> = 0.549 μM).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Structure optimization resulted in the identification of compound <b>37-1</b> (TRKA kinase IC<sub>50</sub> = 0.011 μM, cell IC<sub>50</sub> = 0.003 μM). <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>B illustrates the binding mode of <b>37</b> with TRKA.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> It is clear from this study that the compound bound to TRKA in a DFG-out conformation, which is a typical feature for amide- and urea-linked type II kinase inhibitors. However, <b>37</b> is structurally unlike any known type II TRK inhibitor because of its low molecular weight and simple architecture.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> At the ATP-binding site, the thiazole heterocycle forms a very weak hydrogen bond (3.45 Å) with the amide backbone of Met592. The benzylic ring is involved in hydrophobic interactions with the gatekeeper residue, Phe589. The <i>para</i>-trifluoromethoxyphenyl group occupies the hydrophobic pocket normally occupied by Phe669 in the DFG-in conformation. The amide carbonyl forms a hydrogen bond with Asp668 as is typical with most type II kinase inhibitors.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> A highly unique attribute to <b>37</b> is the cyclopropyl group, which occupies a hydrophobic cleft and is tucked against Val524. This is an uncommon trait, as most kinase inhibitors are unsubstituted at this position and hydrogen bond to a glutamic acid on the α-C-helix.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> One interpretation of the cyclopropyl SAR is that a critical hydrophobic mass is required to fill a small pocket near Val524 and Phe589. The placement of a hydrophobic group at this region is hypothesized to displace water, which would otherwise occupy the area.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> These interactions suggest the compound exhibits binding properties more typical of a type III inhibitor.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (A) Identification of compound <b>37-1</b> and (B) cocrystal structure of compound <b>37</b> and its binding mode in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMP">4PMP</a>, 1.8 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan; sulfur, yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the same manuscript by Stachel et al., the author discussed the development of compound <b>38</b> (TRKA kinase IC<sub>50</sub> = 17.13 μM, cell IC<sub>50</sub> = 1.162 μM) to compound <b>38-1</b> (TRKA kinase IC<sub>50</sub> = 0.051 μM, cell IC<sub>50</sub> = 0.029 μM) (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>A).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Compound <b>38</b> was shown to bind to the DFG-out conformation of TRKA (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>B).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The cocrystal structure revealed several unusual binding features. First, no direct interaction between the hinge backbone and the inhibitor was identified. Instead, the N5 nitrogen from the azaindole was shown to participate in a water-mediated hydrogen bond to the hinge region.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The naphthalene moiety was buried in the hydrophobic cleft at the front of the hinge flanked by the activation loop residue Met671. One of the more unusual binding features is that the indole carboxylic acid interacts with two backbone amides in the activation loop. The unique interactions at the hinge and the activation loop regions anchor <b>38</b> to the ATP binding site. A third interaction was also evident between the carboxylic acid and Lys544 on the roof of the ATP binding pocket.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Compound <b>38</b> exhibited phosphorylation-dependent binding, which was due to the unusual conformation between the indole carboxylic acid and the activation loop. In the cocrystal structure, Tyr676 was involved in a hydrogen-bond interaction with Asp596. Since Tyr676 is a known phosphorylation site on TRKA, phospho-Tyr676 would disrupt this interaction with Asp596, forcing the activation loop away from the active site and stabilizing the active conformation. As such, the phosphorylated form of the enzyme is not able to bind compound <b>38</b>.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Because of the highly unique binding of <b>38</b> to TRKA, the compound exhibits a profile more typical of type III.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. (A) Identification of compound <b>38-1</b> and (B) cocrystal structure of compound <b>38</b> and its binding mode in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMS">4PMS</a>, 2.8 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Type III-JM TRK Inhibitors</h3><div class="NLM_p">TRKA activation triggers intracellular signaling cascades that increase the sensitivity of nociceptors, thus leading to chronic sensitization and pain.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> However, TRKA/B/C share significant sequence homology at the kinase domain, which will make it extremely difficult to develop inhibitors selective for a single isoform. A method to circumvent selectivity issues is to develop allosteric inhibitors that do not bind to the highly conserved ATP active site. In an effort to identify TRKA specific inhibitors, Su et al. discovered compounds with novel scaffolds that bound to the juxtamembrane (JM) domain of TRKA.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The JM domain is located between the kinase domain and the transmembrane domain, and there is only 36% identity between TRKA and TRKB and 40% identity between TRKA and TRKC.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> These findings provide the research community with a novel exploitable region to generate TRK selective small molecule inhibitors.</div><div class="NLM_p">Compound <b>39</b> is a selective TRKA inhibitor (IC<sub>50</sub> values for TRKA/B/C were 0.099 μM, >81 μM and 25 μM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>A).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> In the cocrystal structure of <b>39</b> and TRKA (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>B,C), compound <b>36</b> bound behind the DFG motif opposite of the kinase active site.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The DFG motif was found in a DFG-out, inactive conformation, with Phe669 pointed toward the active site. Asp668, which coordinates to the phosphate groups on ATP, is away from the active site in the structure. The central urea of compound <b>39</b> makes two hydrogen bonds with Asp668. Asp668 is part of the DFG motif, and binding to compound <b>39</b> requires the DFG motif to be in the “out” conformation.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The fluorine moiety of compound <b>39</b> occupies a relatively hydrophobic pocket formed primarily by aliphatic amino acids. The structure clearly reveals interactions at the JM region. Ile490, within the JM, sits on top of the fluorine moiety, aiding the formation of the hydrophobic pocket<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Similar to other TRKA cocrystal kinase structures, there is a shift in Phe646, which creates a pocket to accommodate the fluorine. The oxygen of the central urea in compound <b>39</b> forms a hydrogen bond with the amide nitrogen of Ile490. The phenyl moiety occupies a position between Lys544 of the β3 strand and Glu560 of the α-C-Helix.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (A) Chemical structure of compound <b>39</b>, (B) cocrystal structure of compound <b>39</b> in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMI">5KMI</a>, 1.87 Å), and (C) interactions of compound <b>39</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>40</b> is another selective TRKA inhibitor with interesting binding features (IC<sub>50</sub> values for TRKA/B/C were 3.3 μM, >81.0 μM, and 27 μM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>A).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The cocrystal structure of compound <b>40</b> revealed the compound bound to the same pocket as <b>39</b>, behind the DFG motif (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>B,C). The trifluorophenyl moiety of <b>40</b> sits in the pocket occupied by the fluorine of compound <b>39</b>. The central amide nitrogen is positioned close to the carboxylic acid of Asp668. The binding site is quite similar between the two structures except for the following differences: (1) for compound <b>39</b>, Ile490 packs above the phenyl ring, but Leu486 packs above the phenyl ring for <b>40</b>; (2) for <b>39</b>, Phe646 was displaced by the bulky moiety in the hydrophobic pocket, but for <b>40</b>, the smaller moiety accommodates Phe646 in a position closer to the active conformation.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. (A) Chemical structure of compound <b>40</b>, (B) cocrystal structure of compound <b>40</b> in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMK">5KMK</a>, 2.24 Å), and (C) interactions of compound <b>40</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A similar finding was also disclosed by Furuya et al.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Compound <b>41</b> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>A) showed potent inhibitory activity against TRKA (IC<sub>50</sub> = 0.0027 μM) but was selective against TRKB and TRKC (IC<sub>50</sub> values were 1.3 μM and 2.5 μM, respectively). <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>B,C illustrates that compound <b>41</b> bound to the JM region of TRKA. The configuration of the kinase domain and A loop is very similar to that observed for Apo TRKA.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Compound <b>41</b> binds to the deep pocket formed by the DFG region of the A loop, glycine-rich loop (G loop), C-helix, and JM region. This pocket is completely separate from the ATP site. There are four key interactions that <b>41</b> creates at the binding region: (1) Asp668 of the DFG motif forms two hydrogen bonds with the urea moiety; (2) His489 interacts with the pyrazole ring via π–π interactions and with the ethoxy group via CH−π interactions; (3) Ile490 forms a hydrogen bond with the urea moiety and interacts with the difluorobenzene group of <b>41</b> via CH−π interactions; (4) His648 interacts with the difluorobenzene moiety through a π–π stacking interaction.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> In addition to these, Leu486 is also involved in weak van der Waals interactions with the methyl and ethoxyl groups of <b>41</b>. Interestingly, these amino acid residues are not conserved in TRKB nor TRKC but are integral for high binding affinity in TRKA.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Further exploitation of these TRKA specific amino acids could furnish numerous allosteric scaffolds with high TRKA selectivity.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. (A) Chemical structure of compound <b>41</b>, (B) cocrystal structure of <b>41</b> bound in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5H3Q">5H3Q</a>, 2.1 Å), and (C) interactions of compound <b>41</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, Bagal et al. reported the discovery of a series of <i>N</i>-phenyl-pyrazole based compounds as selective TRKA inhibitors (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>A).<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> The original hit <b>42</b> showed moderate TRKA inhibitory activity (TRKA cell IC<sub>50</sub> = 3.3 μM) and >10-fold selectivity over TRKB/C (TRKB/C cell IC<sub>50</sub> values >50 μM). By introducing an amino-pyridine ring to the dichloro-phenyl ring and switching the methyl to an amide group, the resultant compound <b>43</b> demonstrated 66-fold improvement in TRKA potency (cell IC<sub>50</sub> = 0.05 μM) and was >80-fold selective over TRKB/C (cell IC<sub>50</sub> values were 14 μM and 4.1 μM, respectively) with improved drug-like properties.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> A variety of functional groups were evaluated on the pyridine and central phenyl ring, which led to the identification of <b>44</b> (TRKA/B/C IC<sub>50</sub> values = 0.01 μM, 1.8 μM, and 0.7 μM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>A). Compound <b>44</b> showed <15% inhibition against a panel of over 390 kinases at a concentration of 10 μM and was 72% orally bioavailable.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a><a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>B,C illustrate the binding mode of <b>44</b> in the allosteric pocket of TRKA. The pyridyl nitrogen forms a hydrogen bond with the backbone of Asp668. The dichloro central phenyl ring occupies the lipophilic pocket surrounded by Leu486, Ile572, Phe646, and Ile666. The terminal carbonyl group interacts with the side chain of Arg673, and the tertiary alcohol is exposed to the solvent front.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. (A) Chemical structures of compounds <b>42</b>, <b>43</b>, and <b>44</b>, (B) cocrystal structure of compound <b>44</b> bound to the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20">6D20</a>, 1.94 Å), and (C) interactions of compound <b>44</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; chlorine, green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, it is worth noting that two analogues of <b>39</b>, compounds <b>45</b> and <b>46</b> (by switching the fluorine moiety to naphthalene or pyridine), were also reported by Su et al. (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>A).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> These two compounds were active against TRKA and TRKC (<b>45</b>, TRKA/C IC<sub>50</sub> values = 4.1 μM and 7.1 μM, respectively; <b>46</b>, TRKA/C IC<sub>50</sub> values = 4.0 μM and 2.3 μM, respectively). Interactions of compound <b>45</b> with the kinase domain are similar to <b>39</b>, but the JM interactions are altered as His489 is shifted away from the compound (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>B,C). Instead of binding to the allosteric pocket, <b>46</b> binds to the active site in an atypical type I conformation (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>D). The urea carbonyl group forms a hydrogen bond with the hinge residue Met592, and the pyridine fragment has a weak π–π interaction with the DFG motif residue Phe669.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> In this case, it is still uncertain whether compounds with such scaffolds will exhibit TRKA selectivity. It could be expected that only a subset of type III inhibitors could be TRKA-selective because specific JM domain interactions are required for inhibition.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. (A) Chemical structures of compounds <b>45</b> and <b>46</b>, (B) cocrystal structure of compound <b>45</b> binding in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMM">5KMM</a>, 2.1 Å), (C) interactions of compound <b>45</b> with surrounding residues, and (D) cocrystal structure of compound <b>46</b> in the active site of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMO">5KMO</a>, 2.7 Å). The kinase is depicted in yellow ribbons and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Beyond compounds described above, there are three additional TRK inhibitors under clinical development with structures that have not been disclosed. These compounds include PLX7486 (NCT01804530), DS-6051B (NCT02279433), and F17752 (2013-003009-24).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Clinical Evaluation of TRK Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All TRK-directed compounds under clinical investigation are pan-TRK inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This is likely due to the conservation of amino acids at the ATP binding domain of TRK isoforms. Pivotal TRK structural analysis completed by Bertrand et al. only identified a two amino acid difference between the ATP binding site of TRKA and that of TRKB.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> When they analyzed TRKB and TRKC, all ATP binding site residues were identical.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Because all TRK inhibitors in clinical trials elicit activity by binding at the ATP binding site, they all possess pan-TRK activity. This activity profile is possibly beneficial because the inhibitors, in theory, can be utilized against a broad spectrum of tumors. However, this must be vetted cautiously, as dose-limiting toxicity can also increase based on inhibition profiles. An extensive clinical overview for the development of TRK inhibitors has been reviewed by Lange et al.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Reported Drugs under Clinical Trials with Known Inhibitory Activity of TRK Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">NCT identifier</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">therapeutic agent</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">patient selection</th><th class="colsep0 rowsep0" align="center">estimated completion</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT03213704</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">larotrectinib (<b>8</b>)</td><td class="colsep0 rowsep0" align="left">pediatric cancers</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">NTRK gene fusions</td><td class="colsep0 rowsep0" align="left">09/2024</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02637687</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">larotrectinib (<b>8</b>)</td><td class="colsep0 rowsep0" align="left">CNS cancers</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">06/2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02576431</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">larotrectinib (<b>8</b>)</td><td class="colsep0 rowsep0" align="left">NTRK+ solid tumors</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">NTRK gene fusions</td><td class="colsep0 rowsep0" align="left">04/2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02122913</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">larotrectinib (<b>8</b>)</td><td class="colsep0 rowsep0" align="left">solid tumors</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">NTRK gene fusions</td><td class="colsep0 rowsep0" align="left">02/2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT03215511</td><td class="colsep0 rowsep0" align="left">I/II</td><td class="colsep0 rowsep0" align="left">LOXO-195 (<b>9</b>)</td><td class="colsep0 rowsep0" align="left">TRK resistant tumors</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">TRK-resistant lesions</td><td class="colsep0 rowsep0" align="left">08/2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02568267</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">entrectinib (<b>4-3</b>)</td><td class="colsep0 rowsep0" align="left">solid tumors</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">NTRK, ROS1, or ALK gene rearrangements</td><td class="colsep0 rowsep0" align="left">10/2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02097810</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">entrectinib (<b>4-3</b>)</td><td class="colsep0 rowsep0" align="left">advanced/metastatic cancer</td><td class="colsep0 rowsep0" align="left">active</td><td class="colsep0 rowsep0" align="left">NTRK, ROS1, or ALK molecular alterations</td><td class="colsep0 rowsep0" align="left">06/2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02650401</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">entrectinib (<b>4-3</b>)</td><td class="colsep0 rowsep0" align="left">pediatric and CNS cancers</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">with or without NTRK, ROS1, or ALK gene fusions</td><td class="colsep0 rowsep0" align="left">08/2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT01639508</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">cabozantinib (<b>23</b>)</td><td class="colsep0 rowsep0" align="left">advanced NSCLC</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">RET, ROS1, or NTRK fusions or increased MET or AXL activity</td><td class="colsep0 rowsep0" align="left">07/2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02048488</td><td class="colsep0 rowsep0" align="left">I/IIa</td><td class="colsep0 rowsep0" align="left">belizatinib (<b>5-3</b>)</td><td class="colsep0 rowsep0" align="left">solid tumors and lymphomas</td><td class="colsep0 rowsep0" align="left">unknown</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">09/2016<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02279433</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">DS-6051b</td><td class="colsep0 rowsep0" align="left">advanced solid tumors</td><td class="colsep0 rowsep0" align="left">active</td><td class="colsep0 rowsep0" align="left">NTRK or ROS1 gene rearrangements</td><td class="colsep0 rowsep0" align="left">11/2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02675491</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">DS-6051b</td><td class="colsep0 rowsep0" align="left">advanced solid tumors</td><td class="colsep0 rowsep0" align="left">active</td><td class="colsep0 rowsep0" align="left">NTRK or ROS1 gene rearrangements</td><td class="colsep0 rowsep0" align="left">09/2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02219711</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">sitravatinib (<b>24</b>)</td><td class="colsep0 rowsep0" align="left">advanced cancers</td><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">MET, NTRK, or DDR2 mutations, MET or KIT/PDGFRA/VEGFR2 gene amplification, MET, RET, AXL, NTRK1, or NTRK3 gene rearrangements, or CBL gene function loss mutations</td><td class="colsep0 rowsep0" align="left">12/2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT01804530</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">PLX7486</td><td class="colsep0 rowsep0" align="left">advanced solid tumors</td><td class="colsep0 rowsep0" align="left">terminated</td><td class="colsep0 rowsep0" align="left">NTRK point or fusion mutations</td><td class="colsep0 rowsep0" align="left">01/2018<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02228811</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">altiratinib (<b>25</b>)</td><td class="colsep0 rowsep0" align="left">advanced solid tumors</td><td class="colsep0 rowsep0" align="left">terminated</td><td class="colsep0 rowsep0" align="left">NTRK or MET gene alterations</td><td class="colsep0 rowsep0" align="left">11/2017<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Study has passed its completion date and status has not been verified in more than two years.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Actual primary completion date.</p></div></div></div><div class="NLM_p">Larotrectinib (<b>8</b>, LOXO-101) is under clinical investigation to treat melanoma, glioblastoma, NSCLC, pancreatic and ovarian cancers, and pediatric cancers. Following a single oral dose, the unbound plasma concentration of larotrectinib is sufficient to inhibit TRKA/B/C signaling without substantial inhibition of other kinases.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> In a phase I study with larotrectinib, six patients with <i>NTRK</i> fusions with heavily pretreated advanced disease were enrolled (NCT02122913).<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Of the six patients, three had partial responses within 3–4 months and one patient had a near-complete response after 8 months.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> The drug was well tolerated, and the main side effects were fatigue, dizziness, and anemia. Larotrectinib was even well tolerated and efficacious in pediatric carcinomas harboring a TRK oncogene.<a onclick="showRef(event, 'ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref206 ref207">(206,207)</a> Due to the overall positive results of the phase I study, Bayer and Loxo Oncology initiated a multicenter phase II basket trial to evaluate larotrectinib in patients with an <i>NTRK</i> fusion oncogene (NCT02637687 and NCT02576431). The overall response rate to treatment was 75%, with 13% exhibiting a complete response.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> At 1 year, 55% of the treated patients remained progression free. Based on the phase II results, larotrectinib has marked and durable antitumor efficacy in patients with <i>NTRK</i> fusions, regardless of age or tumor origin.<a onclick="showRef(event, 'ref99 ref208'); return false;" href="javascript:void(0);" class="ref ref99 ref208">(99,208)</a> Meeting future end points of clinical trials, such as median duration of response, progression-free survival, and overall survival, will further confirm the clinical utility of larotrectinib.</div><div class="NLM_p">Entrectinib (<b>4-3</b>, RXDX-101) is a pan-kinase inhibitor under clinical development by Ignyta with activity against TRKA/B/C, ROS1, and ALK fusion oncogenes.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> In a phase 1 clinical trial, 119 patients were treated with entrectinib split between two subgroups: ALKA-372-001, 54 patients, and STARTRK-1, 65 patients (NCT02097810).<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Entrectinib was shown to be well tolerated and efficacious against <i>NTRK1/2/3</i> and <i>ALK</i> gene fusions, including patients with primary or secondary CNS disease.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> The majority of treatment related toxicities were grades 1–2 and reversible with cessation or modification of treatment.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> In particular, responses were achieved regardless of histology, with responses observed in NSCLC, MASC, melanoma, glioneuronal tumor, colorectal cancer, and RCC.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Response rates were highest in <i>NTRK</i>-rearranged tumors, which provided first-time, clinical “proof-of-concept” that <i>NTRK</i>-rearrangements are actionable drivers of tumor growth.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Because of the success of phase 1 studies, a global, multicenter phase II basket study (STARTRK-2) is currently recruiting patients with <i>NTRK-</i>, <i>ROS1-</i>, and <i>ALK</i>-rearranged tumors (NCT02568267).<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> These studies are being performed to confirm the results of the phase 1 study and to further establish the safety profile of entrectinib in a larger patient population. The clinical success of the phase 2 studies relies on the successful enrichment of patients with targetable gene fusions. Because of the rarity of <i>NTRK</i>-rearranged tumors and the success of the phase 1 trial, patients are being enrolled based on molecular, rather than histological, criteria.</div><div class="NLM_p">Sitravatinib (<b>24</b>, MGCD516) is a multikinase inhibitor under clinical development by Mirati Therapeutics Inc. with activity against RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK, and Eph families.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> A phase 1/1b study is currently recruiting to evaluate dose and preliminary efficacy in patients harboring gene rearrangements involving <i>MET</i>, <i>RET</i>, <i>AXL</i>, or <i>NTRK1/2/3</i> (NCT02219711).<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> Based on preclinical data, sitravatinib is likely to be effective for metastatic soft-tissue sarcomas. Similar to entrectinib, the clinical success of sitravatinib will rest on the ability to appropriately enrich patients for targetable molecular lesions. Although blockade of multiple driver signaling pathways can be achieved with sitravatinib,<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> clinical investigation must identify a therapeutic window to safely target <i>NTRK</i> rearrangements without breaching dose-limiting toxicity on other kinase pathways.</div><div class="NLM_p">DS-6051b is under clinical development by Daiichi Sankyo, Inc., for advanced solid tumors harboring <i>ROS1</i> or <i>NTRK1/2/3</i> rearrangements. A phase 1, two-part clinical trial is underway to determine dose-limiting toxicities and tumor response for up to 2 years (NCT02279433). Results from a phase 1 trial in Japanese subjects have already been published with dose-limiting toxicities experienced at the highest dose of 800 mg QD (NCT02675491).<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Tolerability in American subjects was similar, with dose-limiting toxicities experienced at 800 and 1200 mg QD.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> Partial responses, based on tumor regression, were observed at or above the maximum tolerated dose warranting additional safety studies and better patient enrichment for a more durable, clinical response.</div><div class="NLM_p">Cabozantinib (<b>23</b>, COMETRIQ) is a pan-kinase inhibitor developed by Exelixis with FDA approval to treat metastatic medullary thyroid cancer (mMTC) and renal cell carcinoma (RCC). Cabozantinib was first approved to treat mMTC in 2012, and later, in 2016, it was approved for RCC. Because of its pan-kinase profile demonstrating activity against c-Met, RET, ROS1, ALK, VEGFR2, and TRK receptors, cabozantinib is under phase II clinical investigation for patients harboring <i>NTRK1</i> gene fusions in NSCLC (NCT01639508). In the same trial, the drug is being evaluated against patients with RET, ROS1, MET, and AXL oncogenes. Cabozantinib has been found to increase the risk of gastrointestinal perforations, fistulas, and hemorrhage and carries a black box warning for these side effects. In head-to-head studies, entrectinib exhibits stronger inhibition of <i>NTRK</i> fusion genes compared to cabozantinib, which suggests the clinical utility of entrectinib might be greater.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Further, cabozantinib inhibits VEGFR2 at an IC<sub>50</sub> of 0.000035 μM<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> and other tyrosine kinases >0.001 μM, which positions cabozantinib as a highly potent, selective, and unique VEGFR2 inhibitor. The clinical utility of an inhibitor with strong VEGFR2 selectivity must be further evaluated for usefulness against TRK-driven disease. Because of the pan-kinase profile of cabozantinib, clinical response against TRK cancers can be robust, but this also must be weighed against the high propensity for DLTs. Phase II clinical investigation will further evaluate the usefulness of cabozantinib in safely treating TRK-driven cancers.</div><div class="NLM_p last">A major clinical consideration for TRK inhibitors is the propensity to select for drug resistant TRK mutations. For example, a metastatic colorectal cancer patient harboring a <i>NTRK1</i> gene fusion displayed a marked response to entrectinib.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> However, after 4 months of treatment, entrectinib lost effectiveness in controlling tumor growth. By monitoring circulating tumor DNA (ctDNA), it was identified that the TRKA kinase domain underwent two different point mutations at G595R and G667C. These point mutations were also shown to limit the TRKA inhibitory activity of larotrectinib and belizatinib.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> To overcome TRK resistant mutations, LOXO-195 (<b>9</b>) was developed, which is a constrained analogue of larotrectinib. Due to conformational limitations, steric interactions with TRKA G667C and TRKC G623R (homologous to TRKA G595R) are limited and kinase inhibitory activity is maintained. These results have been translated into clinical trials where patients have responded to LOXO-195 after failing treatment with larotrectinib.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Clinical trials for LOXO-195 are ongoing and are displaying the potential to extend durable remissions in patients with TRK-resistant lesions (NCT03215511).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion and Future Perspective for TRK Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Kinases have since emerged as one of the most intensely pursued drug targets in oncology research due to highly druggable active sites and their critical roles in cellular signaling. However, there has yet to be a clinically approved inhibitor for the TRK-receptor tyrosine kinase despite its intimate involvement in tumor pathology and disease. The vast majority of kinase inhibitors developed for TRK exhibit limited selectivity against any of the three isoforms (TRKA/B/C) and are active in the greater kinome. These types of inhibitors will have limited utility as tools to further study TRK biology but have exhibited excellent therapeutic potential in clinical trials, especially when patients treated with TRK inhibitors are selected based on their molecular pathology. To further study TRK biology, it will be beneficial to utilize highly selective inhibitors with activity specific for a single TRK isoform, such as <b>41</b> for TRKA. This will permit the inhibition of a single enzyme in the TRK family, which can help identify isoform importance and interplay in a variety of preclinical TRK models. It is important to note that TRK singaling, specifically via their corresponding growth factors,<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> has been implicated in mediating and modulating the pain response. As such, beyond cancer, TRK inhibitors are being evaluated in clinical trials as agents to reduce neuropathic pain (NCT03346330).</div><div class="NLM_p">The most clinically advanced TRK inhibitors include entrectinib, a pan-TRK, ALK, and ROS inhibitor, and larotrectinib, a specific pan-TRK inhibitor. Both larotrectinib and entrectinib have achieved orphan designation from regulatory authorities.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A recent report of the clinical activity of entrectinib in 55 TRK mutant patients displayed an 80% overall response rate with long-lasting responses in 71% of patients (>12-months).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> An aspect that needs to be considered in the development of TRK inhibitors is, given their role in the nervous system, the possibility of adverse neuropsychiatric effects. One parameter that may influence this property is activity in the greater kinome, and another is the ability to cross the blood–brain barrier. Noteworthy, the most advanced TRK inhibitors under clinical development, such as larotrectinib and entrectinib, exhibited neurotoxicity. This is likely due to target specificity, although they are able to penetrate the blood–brain barrier and exert therapeutic effects against brain metastases.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The identification of the clinical candidate PF-06273340 (<b>22-3</b>) provides a strategy to deliver peripherally restricted and orally bioavailable compounds, which was to design compounds in physicochemical space appropriate for absorption across the gastrointestinal epithelium while, simultaneously, engineering the compounds as substrates for blood–brain barrier efflux transporters.<a onclick="showRef(event, 'ref187 ref202'); return false;" href="javascript:void(0);" class="ref ref187 ref202">(187,202)</a></div><div class="NLM_p last">As observed with all kinase inhibitors, TRK resistance to precision medicine is a major therapeutic limitation for durable efficacy. To overcome resistance, LOXO-195 was developed and is exhibiting effectiveness to induce remissions in patients that have failed larotrectinib treatment. The exact duration of remission is being investigated in clinical trials, and the development of LOXO-195 is a hopeful addition for treating TRK-driven disease. Clinical studies have confirmed the importance of selecting patients based on molecular criteria, and this enrichment will become even more important when transitioning from first to second generation TRK inhibitors. Although all evaluation of TRK precision medicine is in the early stages of clinical development, significant breakthroughs have been uncovered for the treatment and management of TRK-driven tumors. With the completion of clinical studies incorporating larger patient populations, it is expected that TRK precision medicine will continue to exhibit efficacy. Larger clinical studies will also illuminate if selective (larotrectinib) or pan-kinase inhibitors (entrectinib) are more appropriate for treating TRK malignancies. With the advent of routine molecular profiling of tumors, patients will be treated with TRK precision medicine to induce a tailored response. This will translate to customized treatment profiles that will better target the unique pathology of a patient’s tumor.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01092" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brendan Frett</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1a585b5c687f6e6e5a6f7b7769347f7e6f"><span class="__cf_email__" data-cfemail="21636067534455556154404c520f444554">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong-yu Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9212-2010" title="Orcid link">http://orcid.org/0000-0001-9212-2010</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b737752097b4e5a5648155e5f4e"><span class="__cf_email__" data-cfemail="96dedaffa4d6e3f7fbe5b8f3f2e3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Yan</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naga Rajiv Lakkaniga</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Carlomagno</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Via S Pansini 5, 80131 Naples, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Istituto
di Endocrinologia e Oncologia Sperimentale del CNR, Via S Pansini 5, 80131 Naples, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Massimo Santoro</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Via S Pansini 5, 80131 Naples, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Q. McDonald</span> - <span class="hlFld-Affiliation affiliation">Signaling
and Structural Biology Laboratory, The Francis
Crick Institute, London NW1 1AT, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Institute
of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, Malet Street, London WC1E
7HX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengping Lv</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naresh Gunaganti</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8149-9795" title="Orcid link">http://orcid.org/0000-0001-8149-9795</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Wei Yan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4022-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei Yan</b> received his Ph.D. from East China University of Science and Technology, Shanghai, China, and worked jointly at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Following, he worked at WuXi AppTec as a process chemistry scientist. He is currently a postdoctoral researcher at the University of Arkansas for Medical Sciences. His expertise is in medicinal chemistry and process chemistry for pilot plant manufacture of APIs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Naga Rajiv Lakkaniga</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4027-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Naga Rajiv Lakkaniga</b> is currently a Ph.D. candidate in the Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences. He received a Bachelors in Pharmacy and Master of Pharmacy in Pharmaceutical Chemistry from Birla Institute of Technology and Science, Pilani, India. His current research is focused on discovering novel small molecule kinase inhibitors for anticancer therapy using synthetic medicinal chemistry and employing computational methods for lead optimization and conformational study of protein kinases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Francesca Carlomagno</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4032-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Francesca Carlomagno</b> is Professor of General Pathology at the University of Naples Federico II, Dept. Molecular Medicine and Medical Biotechnology. She is also associated with the Institute of Experimental Endocrinology and Oncology of the National Research Council (IEOS, CNR). She received her MD degree and Ph.D. from the University of Naples Federico II. She was a visiting fellow at NCI, NIH, and completed her postdoctoral training at Cambridge University and Federico II University. Her research is on the molecular biology of cancer with a specific interest in antineoplastic targeted therapy using small molecule kinase inhibitors. More recently in her lab, new projects related to alteration of DNA replication and iron metabolism are being conducted with the aim to identify new pathways relevant for cancer.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Massimo Santoro</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4037-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Massimo Santoro</b> is Professor of General Pathology at the University of Naples Federico II, Dept. of Molecular Medicine and Medical Biotechnology. He graduated in Medicine and Surgery at the University of Naples Federico II and then pursued a Ph.D. degree in Molecular Pathology. He has been a fellow at NCI, NIH. His main interest has been molecular genetics of thyroid cancer. He participated in the identification of RET gene fusions in papillary thyroid cancer and activating point mutations in medullary thyroid cancer.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Neil Q. McDonald</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4042-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Neil Q. McDonald</b> is currently a Senior Group Leader at the Francis Crick Institute. He is also Professor in Structural Biology at Birkbeck College, London. He received his Ph.D. degree from the University of London and did his postdoctoral training at Columbia University, NY. He previously worked at Cancer Research UK Laboratories in London where he focused on the structural biology of oncology targets. His current research interests are neurotrophic factor receptors and their downstream signaling pathways, in particular Rho-GTPase activated protein kinases.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Fengping Lv</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4047-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Fengping Lv</b> received his Ph.D. in Organic Chemistry from East China Normal University under the supervision of Professor Wenhao Hu. He completed his postdoctoral trainings at University of Arkansas for Medical Sciences in the field of drug discovery research of kinase inhibitors for cancer. He is currently a faulty member of Shaoxing University, Yuanpei College, and focused on translational targeted cancer drug development.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Naresh Gunaganti</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4052-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Naresh Gunaganti</b> received his Ph.D. in Organic and Medicinal Chemistry from CSIR-Central Drug Research Institute, Jawaharlal Nehru University, New Delhi, India. Later, he joined the University of Arizona as a postdoctoral research associate under Dr. Hong-yu Li. He is currently working as a postdoctoral research associate at University of Arkansas for Medical Sciences in the area of kinase drug discovery. He is interested in developing irreversible inhibitors for various kinases using synthetic and medicinal chemistry tools.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Brendan Frett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4057-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Brendan Frett</b> is an Assistant Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Arkansas for Medical Sciences. He received his Ph.D. degree from the University of Arizona, where he codiscovered a clinical candidate in IND studies. He has successfully transferred academic-based discoveries to pharmaceutical companies for clinical development. He is interested in pursuing translational research projects, where research completed in his laboratory can directly help patients.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Hong-yu Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=BIO-d7e4062-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong-yu Li</b> is a Professor of Medicinal Chemistry at the University of Arkansas for Medical Sciences (UAMS). He is also an Arkansas Research Alliance (ARA) Scholar, the Helen Adams & ARA endowed chair in drug discovery, and codirector for the Therapeutics Science Program, Winthrop P Rockefeller Cancer Institute. He received his Ph.D. degree from the University of Tokyo and did postdoctoral training at Columbia University and Harvard University. He previously worked at Eli Lilly and the University of Arizona where he focused on oncology drug discovery. His current research interests are in chemical biology and drug discovery, especially for oncology related targets and phenotypes. In his lab at UAMS, a robust oncology pipeline is under development exploiting single agent polypharmacology and synergistic medicinal chemistry approaches.</p></figure></div><div class="ack" id="ACK-d7e4015-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">H.L. was supported by the grants (NIH 1R01CA194094-010 and 1R01CA197178-01A1).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">v-AKT murine thymoma viral oncogene homologue</p></td></tr><tr><td class="NLM_term">ALIS</td><td class="NLM_def"><p class="first last">automated ligand identification system</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BDNF</td><td class="NLM_def"><p class="first last">brain-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">diacyl-glycerol</p></td></tr><tr><td class="NLM_term">DDR2</td><td class="NLM_def"><p class="first last">discoidin domain-containing receptor 2</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular-signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">food and drug administration</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">Glio</td><td class="NLM_def"><p class="first last">glioblastoma</p></td></tr><tr><td class="NLM_term">GRB2</td><td class="NLM_def"><p class="first last">growth factor receptor-bound protein 2</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">intrahepatic cholangiocarcinoma</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">IP3</td><td class="NLM_def"><p class="first last">inositol trisphosphate</p></td></tr><tr><td class="NLM_term">MASC</td><td class="NLM_def"><p class="first last">mammary analogue secretory carcinoma</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">NGF</td><td class="NLM_def"><p class="first last">nerve growth factor</p></td></tr><tr><td class="NLM_term">NT3</td><td class="NLM_def"><p class="first last">neurotrophin-3</p></td></tr><tr><td class="NLM_term">PH</td><td class="NLM_def"><p class="first last">pleckstrin homology</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-4,5-bisphosphate 3-kinase</p></td></tr><tr><td class="NLM_term">PLCγ</td><td class="NLM_def"><p class="first last">phospholipase C-γ</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">PTC</td><td class="NLM_def"><p class="first last">papillary thyroid cancer</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma oncogene</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">rat sarcoma oncogene</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">RIE</td><td class="NLM_def"><p class="first last">rat intestinal epithelial</p></td></tr><tr><td class="NLM_term">RON</td><td class="NLM_def"><p class="first last">recepteur d’origine nantais</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">SHC</td><td class="NLM_def"><p class="first last">Src homology 2 domain containing</p></td></tr><tr><td class="NLM_term">TIE-2</td><td class="NLM_def"><p class="first last">tunica interna endothelial-2</p></td></tr><tr><td class="NLM_term">TRK</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 215 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.22-04-01316.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.22-04-01316.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11850459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFeksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=1316-1327&author=A.+R.+Carterauthor=C.+Chenauthor=P.+M.+Schwartzauthor=R.+A.+Segal&title=Brain-derived+neurotrophic+factor+modulates+cerebellar+plasticity+and+synaptic+ultrastructure&doi=10.1523%2FJNEUROSCI.22-04-01316.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure</span></div><div class="casAuthors">Carter, Alexandre R.; Chen, Chinfei; Schwartz, Phillip M.; Segal, Rosalind A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1316-1327</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The effect of brain-derived neurotrophic factor (BDNF) deficiency at the parallel fiber to Purkinje cell (PF/PC) synapses in the cerebellum was studied using a mouse with a targeted deletion of BDNF.  It was shown that TrkB, the receptor for BDNF, was located at parallel fiber to PF/PC synapses of the cerebellum.  Although Purkinje cell dendrites were abnormal in BDNF -/- mice, PF/PC synapses were still able to form.  Immunohistochem. anal. of mutant animals showed the formation of several PF/PC synapses with the appropriate apposition of presynaptic and postsynaptic proteins.  These synapses were functional, and no differences were detected in the waveform of evoked EPSCs, the amplitude of spontaneous mini-EPSCs, or the response to prolonged 10 Hz stimulus trains.  However, paired-pulse facilitation, a form of short-term plasticity, was considerably reduced in BDNF -/- mice.  Detailed ultrastructural anal. of the presynaptic terminals showed that this change in synaptic function was accompanied by an increase in the total no. of synaptic vesicles in mutant mice and a decrease in the proportion of vesicles that are docked.  These data indicated that BDNF regulates both the mechanisms that underlie short-term synaptic plasticity and the steady-state relationship between different vesicle pools within the terminal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-tCNU8Ekjd7Vg90H21EOLACvtfcHk0lju_mqN6u6UdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFeksbY%253D&md5=89624d26614a23cf85ba6c54a2f5707e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.22-04-01316.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.22-04-01316.2002%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DA.%2BR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DP.%2BM.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DBrain-derived%2520neurotrophic%2520factor%2520modulates%2520cerebellar%2520plasticity%2520and%2520synaptic%2520ultrastructure%26jtitle%3DJ.%2520Neurosci.%26date%3D2002%26volume%3D22%26spage%3D1316%26epage%3D1327%26doi%3D10.1523%2FJNEUROSCI.22-04-01316.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palko, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N. Y.</span></span> <span> </span><span class="NLM_article-title">TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1506</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1038/nn.3237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnn.3237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=23064382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=1506-1515&author=K.+O.+Laiauthor=A.+S.+Wongauthor=M.+C.+Cheungauthor=P.+Xuauthor=Z.+Liangauthor=K.+C.+Lokauthor=H.+Xieauthor=M.+E.+Palkoauthor=W.+H.+Yungauthor=L.+Tessarolloauthor=Z.+H.+Cheungauthor=N.+Y.+Ip&title=TrkB+phosphorylation+by+Cdk5+is+required+for+activity-dependent+structural+plasticity+and+spatial+memory&doi=10.1038%2Fnn.3237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory</span></div><div class="casAuthors">Lai, Kwok-On; Wong, Alan S. L.; Cheung, Man-Chun; Xu, Pei; Liang, Zhuoyi; Lok, Ka-Chun; Xie, Hui; Palko, Mary E.; Yung, Wing-Ho; Tessarollo, Lino; Cheung, Zelda H.; Ip, Nancy Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1506-1515</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The neurotrophin brain-derived neurotrophic factor (BDNF) and its receptor TrkB participate in diverse neuronal functions, including activity-dependent synaptic plasticity that is crucial for learning and memory.  On binding to BDNF, TrkB is not only autophosphorylated at tyrosine residues but also undergoes serine phosphorylation at S478 by the serine/threonine kinase cyclin-dependent kinase 5 (Cdk5).  However, the in vivo function of this serine phosphorylation remains unknown.  We generated knock-in mice lacking this serine phosphorylation (TrkbS478A/S478A mice) and found that the TrkB phosphorylation-deficient mice displayed impaired spatial memory and compromised hippocampal long-term potentiation (LTP).  S478 phosphorylation of TrkB regulates its interaction with the Rac1-specific guanine nucleotide exchange factor TIAM1, leading to activation of Rac1 and phosphorylation of S6 ribosomal protein during activity-dependent dendritic spine remodeling.  These findings reveal the importance of Cdk5-mediated S478 phosphorylation of TrkB in activity-dependent structural plasticity, which is crucial for LTP and spatial memory formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk9Ot31Ld6FLVg90H21EOLACvtfcHk0lgQ1n0WKITNOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsbbO&md5=3028d87d6d76fd70470936f4e8370a15</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnn.3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.3237%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DK.%2BO.%26aulast%3DWong%26aufirst%3DA.%2BS.%26aulast%3DCheung%26aufirst%3DM.%2BC.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DLok%26aufirst%3DK.%2BC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DPalko%26aufirst%3DM.%2BE.%26aulast%3DYung%26aufirst%3DW.%2BH.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DZ.%2BH.%26aulast%3DIp%26aufirst%3DN.%2BY.%26atitle%3DTrkB%2520phosphorylation%2520by%2520Cdk5%2520is%2520required%2520for%2520activity-dependent%2520structural%2520plasticity%2520and%2520spatial%2520memory%26jtitle%3DNat.%2520Neurosci.%26date%3D2012%26volume%3D15%26spage%3D1506%26epage%3D1515%26doi%3D10.1038%2Fnn.3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubner, R.</span></span> <span> </span><span class="NLM_article-title">Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: role of BDNF-TrkB signaling and NMDA receptors</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1007/s12035-007-0028-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2Fs12035-007-0028-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=17917111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1aisbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=224-235&author=K.+Renauthor=R.+Dubner&title=Pain+facilitation+and+activity-dependent+plasticity+in+pain+modulatory+circuitry%3A+role+of+BDNF-TrkB+signaling+and+NMDA+receptors&doi=10.1007%2Fs12035-007-0028-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: role of BDNF-TrkB signaling and NMDA receptors</span></div><div class="casAuthors">Ren, Ke; Dubner, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-235</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Pain modulatory circuitry in the brainstem exhibits considerable synaptic plasticity.  The increased peripheral neuronal barrage after injury activates spinal projection neurons that then activate multiple chem. mediators including glutamatergic neurons at the brainstem level, leading to an increased synaptic strength and facilitatory output.  It is not surprising that a well-established regulator of synaptic plasticity, brain-derived neurotrophic factor (BDNF), contributes to the mechanisms of descending pain facilitation.  After tissue injury, BDNF and TrkB signaling in the brainstem circuitry is rapidly activated.  Through the intracellular signaling cascade that involves phospholipase C, inositol trisphosphate, protein kinase C, and nonreceptor protein tyrosine kinases; NMDA receptors are phosphorylated, descending facilitatory drive is initiated, and behavioral hyperalgesia follows.  The synaptic plasticity obsd. in the pain pathways shares much similarity with more extensively studied forms of synaptic plasticity such as long-term potentiation (LTP) and long-term depression (LTD), which typically express NMDA receptor dependency and regulation by trophic factors.  However, LTP and LTD are exptl. phenomena whose relationship to functional states of learning and memory has been difficult to prove.  Although mechanisms of synaptic plasticity in pain pathways have typically not been related to LTP and LTD, pain pathways have an advantage as a model system for synaptic modifications as there are many well-established models of persistent pain with clear measures of the behavioral phenotype.  Further studies will elucidate cellular and mol. mechanisms of pain sensitization and further our understanding of principles of central nervous system plasticity and responsiveness to environmental challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjbE4QewGSQrVg90H21EOLACvtfcHk0lgQ1n0WKITNOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1aisbvM&md5=8ead666a6776789ec641cd802cc639c1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12035-007-0028-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-007-0028-8%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DK.%26aulast%3DDubner%26aufirst%3DR.%26atitle%3DPain%2520facilitation%2520and%2520activity-dependent%2520plasticity%2520in%2520pain%2520modulatory%2520circuitry%253A%2520role%2520of%2520BDNF-TrkB%2520signaling%2520and%2520NMDA%2520receptors%26jtitle%3DMol.%2520Neurobiol.%26date%3D2007%26volume%3D35%26spage%3D224%26epage%3D235%26doi%3D10.1007%2Fs12035-007-0028-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuman, E. M.</span></span> <span> </span><span class="NLM_article-title">Neurotrophin regulation of synaptic transmission</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/S0959-4388(99)80013-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-4388%2899%2980013-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=105-109&author=E.+M.+Schuman&title=Neurotrophin+regulation+of+synaptic+transmission&doi=10.1016%2FS0959-4388%2899%2980013-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2899%2980013-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252899%252980013-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchuman%26aufirst%3DE.%2BM.%26atitle%3DNeurotrophin%2520regulation%2520of%2520synaptic%2520transmission%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1999%26volume%3D9%26spage%3D105%26epage%3D109%26doi%3D10.1016%2FS0959-4388%2899%2980013-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuman, E. M.</span></span> <span> </span><span class="NLM_article-title">Determinants of BDNF-induced hippocampal synaptic plasticity: role of the Trk B receptor and the kinetics of neurotrophin delivery</span>. <i>Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1101/lm.3.2-3.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1101%2Flm.3.2-3.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10456089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADyaK1MzosFSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1996&pages=188-196&author=H.+Kangauthor=L.+Z.+Jiaauthor=K.+Y.+Suhauthor=L.+Tangauthor=E.+M.+Schuman&title=Determinants+of+BDNF-induced+hippocampal+synaptic+plasticity%3A+role+of+the+Trk+B+receptor+and+the+kinetics+of+neurotrophin+delivery&doi=10.1101%2Flm.3.2-3.188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of BDNF-induced hippocampal synaptic plasticity: role of the Trk B receptor and the kinetics of neurotrophin delivery</span></div><div class="casAuthors">Kang H; Jia L Z; Suh K Y; Tang L; Schuman E M</div><div class="citationInfo"><span class="NLM_cas:title">Learning & memory (Cold Spring Harbor, N.Y.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">188-96</span>
        ISSN:<span class="NLM_cas:issn">1072-0502</span>.
    </div><div class="casAbstract">The neurotrophins are a class of signaling molecules known for their growth and survival-promoting activities during neuronal development.  Recent studies suggest that the neurotrophins, including brain-derived neurotrophic factor (BDNF), can also dramatically influence synaptic transmission in the adult hippocampus.  The experiments described in this paper indicate that ability of BDNF to potentiate synaptic transmission in the hippocampus relies on functional Trk B receptors.  Moreover, the rate at which BDNF is applied to hippocampal synapses is also a potent determinant of whether synaptic potentiation will result.  Hippocampal slices perfused with BDNF at a very slow flow rate (e.g., < or = 25 ml/hr) did not show synaptic potentiation.  Increasing the rate of BDNF application resulted in synaptic potentiation in which the magnitude and onset kinetics of the potentiation were determined by the rate of BDNF delivery.  Immunocytochemical analysis of BDNF detected with confocal microscopy confirmed these electrophysiological observations, indicating that the penetration of BDNF into hippocampal slices is influenced dramatically by the perfusion rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6RwrXwXIsY6x48Rj5GnGofW6udTcc2eZSNF4XChJVJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MzosFSgsw%253D%253D&md5=1a5f796a1559289d5c82ceba1797dcda</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1101%2Flm.3.2-3.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Flm.3.2-3.188%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%2BZ.%26aulast%3DSuh%26aufirst%3DK.%2BY.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DSchuman%26aufirst%3DE.%2BM.%26atitle%3DDeterminants%2520of%2520BDNF-induced%2520hippocampal%2520synaptic%2520plasticity%253A%2520role%2520of%2520the%2520Trk%2520B%2520receptor%2520and%2520the%2520kinetics%2520of%2520neurotrophin%2520delivery%26jtitle%3DLearn.%2520Mem.%26date%3D1996%26volume%3D3%26spage%3D188%26epage%3D196%26doi%3D10.1101%2Flm.3.2-3.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, D. C.</span></span> <span> </span><span class="NLM_article-title">Neurotrophins and synaptic plasticity</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.22.1.295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.neuro.22.1.295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10202541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=295-318&author=A.+K.+McAllisterauthor=L.+C.+Katzauthor=D.+C.+Lo&title=Neurotrophins+and+synaptic+plasticity&doi=10.1146%2Fannurev.neuro.22.1.295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotrophins and synaptic plasticity</span></div><div class="casAuthors">McAllister, A. Kimberley; Katz, Lawrence C.; Lo, Donald C.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295-318</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with ∼220 refs.  Despite considerable evidence that neuronal activity influences the organization and function of circuits in the developing and adult brain, the mol. signals that translate activity into structural and functional changes in connections remain largely obscure.  This review discusses the evidence implicating neurotrophins as mol. mediators of synaptic and morphol. plasticity.  Neurotrophins are attractive candidates for these roles because they and their receptors are expressed in areas of the brain that undergo plasticity, activity can regulate their levels and secretion, and they regulate both synaptic transmission and neuronal growth.  Although numerous expts. show demonstrable effects of neurotrophins on synaptic plasticity, the rules and mechanisms by which they exert their effects remain intriguingly elusive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvlEInDNTlWrVg90H21EOLACvtfcHk0ljmu52Zeov4_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFems78%253D&md5=89366179460c0f90c5a6b50983440ae3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.22.1.295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.22.1.295%26sid%3Dliteratum%253Aachs%26aulast%3DMcAllister%26aufirst%3DA.%2BK.%26aulast%3DKatz%26aufirst%3DL.%2BC.%26aulast%3DLo%26aufirst%3DD.%2BC.%26atitle%3DNeurotrophins%2520and%2520synaptic%2520plasticity%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D1999%26volume%3D22%26spage%3D295%26epage%3D318%26doi%3D10.1146%2Fannurev.neuro.22.1.295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schinder, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poo, M.</span></span> <span> </span><span class="NLM_article-title">The neurotrophin hypothesis for synaptic plasticity</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1016/S0166-2236(00)01672-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0166-2236%2800%2901672-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=639-645&author=A.+F.+Schinderauthor=M.+Poo&title=The+neurotrophin+hypothesis+for+synaptic+plasticity&doi=10.1016%2FS0166-2236%2800%2901672-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0166-2236%2800%2901672-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-2236%252800%252901672-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchinder%26aufirst%3DA.%2BF.%26aulast%3DPoo%26aufirst%3DM.%26atitle%3DThe%2520neurotrophin%2520hypothesis%2520for%2520synaptic%2520plasticity%26jtitle%3DTrends%2520Neurosci.%26date%3D2000%26volume%3D23%26spage%3D639%26epage%3D645%26doi%3D10.1016%2FS0166-2236%2800%2901672-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span> <span> </span><span class="NLM_article-title">Trk receptors: roles in neuronal signal transduction</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.72.121801.161629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.biochem.72.121801.161629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12676795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=609-642&author=E.+J.+Huangauthor=L.+F.+Reichardt&title=Trk+receptors%3A+roles+in+neuronal+signal+transduction&doi=10.1146%2Fannurev.biochem.72.121801.161629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptors: roles in neuronal signal transduction</span></div><div class="casAuthors">Huang, Eric J.; Reichardt, Louis F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">609-642</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Trk receptors are a family of 3 receptor tyrosine kinases, each of which can be activated by ≥1 of 4 neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).  Neurotrophin signaling through these receptors regulates cell survival, proliferation, the fate of neural precursors, axon and dendrite growth and patterning, and the expression and activity of functionally important proteins, such as ion channels and neurotransmitter receptors.  In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity.  The cytoplasmic domains of Trk receptors contain several sites of tyrosine phosphorylation that recruit intermediates in intracellular signaling cascades.  As a result, Trk receptor signaling activates several small G proteins, including Ras, Rap-1, and the Cdc-42-Rac-Rho family, as well as pathways regulated by MAP kinase, PI 3-kinase and phospholipase-C-γ (PLC-γ).  Trk receptor activation has different consequences in different cells, and the specificity of downstream Trk receptor-mediated signaling is controlled through expression of intermediates in these signaling pathways and membrane trafficking that regulates localization of different signaling constituents.  Perhaps the most fascinating aspect of Trk receptor-mediated signaling is its interplay with signaling promoted by the pan-neurotrophin receptor p75NTR.  P75NTR activates a distinct set of signaling pathways within cells that are in some instances synergistic and in other instances antagonistic to those activated by Trk receptors.  Several of these are proapoptotic but are suppressed by Trk receptor-initiated signaling.  P75NTR also influences the conformations of Trk receptors; this modifies ligand-binding specificity and affinity with important developmental consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH3Pdvfi72LVg90H21EOLACvtfcHk0ljmu52Zeov4_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D&md5=939bf60802da0a203c2e0d8585e28dd9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.72.121801.161629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.72.121801.161629%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DE.%2BJ.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26atitle%3DTrk%2520receptors%253A%2520roles%2520in%2520neuronal%2520signal%2520transduction%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2003%26volume%3D72%26spage%3D609%26epage%3D642%26doi%3D10.1146%2Fannurev.biochem.72.121801.161629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, F. D.</span></span> <span> </span><span class="NLM_article-title">Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development</span>. <i>Development</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">4369</span>– <span class="NLM_lpage">4380</span>, <span class="refDoi"> DOI: 10.1242/dev.008227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1242%2Fdev.008227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=18003743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFSktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2007&pages=4369-4380&author=K.+Bartkowskaauthor=A.+Paquinauthor=A.+S.+Gauthierauthor=D.+R.+Kaplanauthor=F.+D.+Miller&title=Trk+signaling+regulates+neural+precursor+cell+proliferation+and+differentiation+during+cortical+development&doi=10.1242%2Fdev.008227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development</span></div><div class="casAuthors">Bartkowska, Katarzyna; Paquin, Annie; Gauthier, Andree S.; Kaplan, David R.; Miller, Freda D.</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4369-4380</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Increasing evidence indicates that development of embryonic central nervous system precursors is tightly regulated by extrinsic cues located in the local environment.  Here, we asked whether neurotrophin-mediated signaling through Trk tyrosine kinase receptors is important for embryonic cortical precursor cell development.  These studies demonstrate that inhibition of TrkB (Ntrk2) and/or TrkC (Ntrk3) signaling using dominant-neg. Trk receptors, or genetic knockdown of TrkB using shRNA, caused a decrease in embryonic precursor cell proliferation both in culture and in vivo.  Inhibition of TrkB/C also caused a delay in the generation of neurons, but not astrocytes, and ultimately perturbed the postnatal localization of cortical neurons in vivo.  Conversely, overexpression of BDNF in cortical precursors in vivo promoted proliferation and enhanced neurogenesis.  Together, these results indicate that neurotrophin-mediated Trk signaling plays an essential, cell-autonomous role in regulating the proliferation and differentiation of embryonic cortical precursors and thus controls cortical development at earlier stages than previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeFolN0ielRrVg90H21EOLACvtfcHk0ljjZ_JYnOxMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFSktg%253D%253D&md5=c5c0983e47b863c644a777af76c42eb3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1242%2Fdev.008227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.008227%26sid%3Dliteratum%253Aachs%26aulast%3DBartkowska%26aufirst%3DK.%26aulast%3DPaquin%26aufirst%3DA.%26aulast%3DGauthier%26aufirst%3DA.%2BS.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DF.%2BD.%26atitle%3DTrk%2520signaling%2520regulates%2520neural%2520precursor%2520cell%2520proliferation%2520and%2520differentiation%2520during%2520cortical%2520development%26jtitle%3DDevelopment%26date%3D2007%26volume%3D134%26spage%3D4369%26epage%3D4380%26doi%3D10.1242%2Fdev.008227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Islam, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heese, K.</span></span> <span> </span><span class="NLM_article-title">Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways</span>. <i>Curr. Neurovascular Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.2174/156720209787466028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2174%2F156720209787466028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19355925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislyjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=42-53&author=O.+Islamauthor=T.+X.+Looauthor=K.+Heese&title=Brain-derived+neurotrophic+factor+%28BDNF%29+has+proliferative+effects+on+neural+stem+cells+through+the+truncated+TRK-B+receptor%2C+MAP+kinase%2C+AKT%2C+and+STAT-3+signaling+pathways&doi=10.2174%2F156720209787466028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways</span></div><div class="casAuthors">Islam, Omedul; Loo, Tze X.; Heese, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Current Neurovascular Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-53</span>CODEN:
                <span class="NLM_cas:coden">CNRUAM</span>;
        ISSN:<span class="NLM_cas:issn">1875-5739</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Neurospheres can be generated from the mouse fetal forebrain by exposing multipotent neural stem cells (NSCs) to epidermal growth factor (EGF).  In the presence of EGF, NSCs can proliferate continuously while retaining the potential to differentiate into neurons, astrocytes and oligodendrocytes.  We examd. the expression pattern of the neurotrophin (NT) receptors tropomyosin-related kinase (TRK)-A, TRK-B, TRK-C and p75 neurotrophin receptor (p75NTR) in NSCs and the corresponding lineage cells.  Furthermore, we analyzed the action of the NT Brain-Derived Neurotrophic Factor (BDNF) on NSCs' behavior.  The effects of BDNF on NSC proliferation and differentiation were examd. together with the signaling pathways by which BDNF receptors transduce signaling effects.  We found that all the known NT receptors, including the truncated isoforms of TRK-B (t-TRK-B) and TRK-C (t-TRK-C), were expressed by Nestin-pos. cells within the neurosphere.  Proliferation was enhanced in Nestin-pos. and BrdU-pos. cells in the presence of BDNF.  In particular, we show that t-TRK-B was abundantly expressed in NSCs and the corresponding differentiated glia cells while full length TRK-B (fl-TRK-B) was expressed in fully differentiated post-mitotic neurons such as the neuronal cells of the newborn mouse cortex, suggesting that BDNF may exert its proliferative effects on NSCs through the t-TRK-B receptor.  Finally, we analyzed the cell fates of NSCs differentiated with BDNF in the absence of EGF and we demonstrate that BDNF stimulated the formation of differentiated cell types in different proportions through the MAP kinase, AKT and STAT-3 signaling pathways.  Thus, the in-vivo regulation of neurogenesis may be mediated by the summation of signals from the BDNF receptors, in particular the t-TRK-B receptor, regulating physiol. fates as diverse as normal neural replacement, excessive neural loss, or tumor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvh-yjUGScLVg90H21EOLACvtfcHk0ljjZ_JYnOxMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislyjtr0%253D&md5=4486c380d58707ce1f2c639d2f29e6af</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F156720209787466028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720209787466028%26sid%3Dliteratum%253Aachs%26aulast%3DIslam%26aufirst%3DO.%26aulast%3DLoo%26aufirst%3DT.%2BX.%26aulast%3DHeese%26aufirst%3DK.%26atitle%3DBrain-derived%2520neurotrophic%2520factor%2520%2528BDNF%2529%2520has%2520proliferative%2520effects%2520on%2520neural%2520stem%2520cells%2520through%2520the%2520truncated%2520TRK-B%2520receptor%252C%2520MAP%2520kinase%252C%2520AKT%252C%2520and%2520STAT-3%2520signaling%2520pathways%26jtitle%3DCurr.%2520Neurovascular%2520Res.%26date%3D2009%26volume%3D6%26spage%3D42%26epage%3D53%26doi%3D10.2174%2F156720209787466028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdi, J. M.</span></span> <span> </span><span class="NLM_article-title">The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">9861</span>– <span class="NLM_lpage">9870</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.14.9861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.274.14.9861" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=9861-9870&author=S.+O.+Meakinauthor=J.+I.+MacDonaldauthor=E.+A.+Gryzauthor=C.+J.+Kubuauthor=J.+M.+Verdi&title=The+signaling+adapter+FRS-2+competes+with+Shc+for+binding+to+the+nerve+growth+factor+receptor+TrkA.+A+model+for+discriminating+proliferation+and+differentiation&doi=10.1074%2Fjbc.274.14.9861"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.14.9861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.14.9861%26sid%3Dliteratum%253Aachs%26aulast%3DMeakin%26aufirst%3DS.%2BO.%26aulast%3DMacDonald%26aufirst%3DJ.%2BI.%26aulast%3DGryz%26aufirst%3DE.%2BA.%26aulast%3DKubu%26aufirst%3DC.%2BJ.%26aulast%3DVerdi%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520signaling%2520adapter%2520FRS-2%2520competes%2520with%2520Shc%2520for%2520binding%2520to%2520the%2520nerve%2520growth%2520factor%2520receptor%2520TrkA.%2520A%2520model%2520for%2520discriminating%2520proliferation%2520and%2520differentiation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D9861%26epage%3D9870%26doi%3D10.1074%2Fjbc.274.14.9861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vellis, J.</span></span> <span> </span><span class="NLM_article-title">NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-4547(19981215)54:6<754::AID-JNR3>3.0.CO;2-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9856859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFajtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=754-765&author=S.+Kumarauthor=M.+A.+Kahnauthor=L.+Dinhauthor=J.+de+Vellis&title=NT-3-mediated+TrkC+receptor+activation+promotes+proliferation+and+cell+survival+of+rodent+progenitor+oligodendrocyte+cells+in+vitro+and+in+vivo&doi=10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo</span></div><div class="casAuthors">Kumar, Shalini; Kahn, Michelle A.; Dinh, Lan; De Vellis, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">754-765</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We have previously described the expression of a functional full-length TrkC transcript for neurotrophin-3 (NT-3) receptor in oligodendroglia (OL) cells (S. Kumar and J. de Vellis, 1996).  To date, the role of NT-3 and its signal transduction cascade in OL remains poorly defined.  We report that the NT-3 responsive population of cells in the OL lineage are the progenitor cells and that the addn. of NT-3 results in the autophosphorylation of p145TrkC.  Furthermore, NT-3-mediated activation of p21ras and mitogen-activated protein kinase (MAPK), extracellular signal-regulated protein kinase2 (ERK2), were also obsd. in the progenitor OL cells.  These protein tyrosine kinase (PTK)-induced responses were sensitive to the presence of K252a, an inhibitor for tyrosine kinase.  We have detd. that NT-3 promotes progenitor OL cell commitment to enter into S-phase of cell cycle to initiate DNA synthesis, in a manner similar to platelet-derived growth factor-AA (PDGF-AA).  NT-3 thus plays a role in cell proliferation when present alone, while augmenting the proliferation capacity of PDGF-AA as indicated by the nuclear binding activity of the transcription factor, E2F-1.  Both the initiation and progression of mitotic events were confirmed by the expression of c-myc and cdc2 in the presence of NT-3, PDGF-AA or NT-3 plus PDGF-AA.  A cell survival assay examg. interleukin 1β-converting enzyme (ICE)-like protease-mediated cleavage of poly (ADP-ribose) polymerase (PARP) revealed an increase in OL progenitor cell death in the absence of NT-3 or PDGF-AA.  In corroboration with our in vitro studies, in vivo results show an increased expression of the progenitor OL cell marker, glycerol phosphate dehydrogenase (GPDH) within 48 h following an intracranial injection of NT-3, PDGF-AA, or NT-3 plus PDGF-AA in PN4-5 rats.  These novel findings suggest that PDGF-AA potentiates the OL progenitor cell's ability to enter into the S-phase of the cell cycle and that NT-3 can augment this activity.  Furthermore, PDGF-AA and NT-3 can block ICE-like protease-mediated PARP fragmentation in progenitor OL cells.  These results provide important information which further delineates the signal transduction cascades and the role of NT-3 and PDGF-AA on OL progenitor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8DITf886ZbbVg90H21EOLACvtfcHk0liEUqbMp84QUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFajtLo%253D&md5=43ff80a18e3010a043e0abd0e8ffa522</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4547%252819981215%252954%253A6%253C754%253A%253AAID-JNR3%253E3.0.CO%253B2-K%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DKahn%26aufirst%3DM.%2BA.%26aulast%3DDinh%26aufirst%3DL.%26aulast%3Dde%2BVellis%26aufirst%3DJ.%26atitle%3DNT-3-mediated%2520TrkC%2520receptor%2520activation%2520promotes%2520proliferation%2520and%2520cell%2520survival%2520of%2520rodent%2520progenitor%2520oligodendrocyte%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D1998%26volume%3D54%26spage%3D754%26epage%3D765%26doi%3D10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashiro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, C. J.</span></span> <span> </span><span class="NLM_article-title">Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1806</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=1798-1806&author=K.+Matsumotoauthor=R.+K.+Wadaauthor=J.+M.+Yamashiroauthor=D.+R.+Kaplanauthor=C.+J.+Thiele&title=Expression+of+brain-derived+neurotrophic+factor+and+p145TrkB+affects+survival%2C+differentiation%2C+and+invasiveness+of+human+neuroblastoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DR.%2BK.%26aulast%3DYamashiro%26aufirst%3DJ.%2BM.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DThiele%26aufirst%3DC.%2BJ.%26atitle%3DExpression%2520of%2520brain-derived%2520neurotrophic%2520factor%2520and%2520p145TrkB%2520affects%2520survival%252C%2520differentiation%252C%2520and%2520invasiveness%2520of%2520human%2520neuroblastoma%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D1798%26epage%3D1806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moheban, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5671</span>– <span class="NLM_lpage">5678</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.20-15-05671.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.20-15-05671.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10908605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=5671-5678&author=Y.+Z.+Zhangauthor=D.+B.+Mohebanauthor=B.+R.+Conwayauthor=A.+Bhattacharyyaauthor=R.+A.+Segal&title=Cell+surface+Trk+receptors+mediate+NGF-induced+survival+while+internalized+receptors+regulate+NGF-induced+differentiation&doi=10.1523%2FJNEUROSCI.20-15-05671.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation</span></div><div class="casAuthors">Zhang, Yan-Zhen; Moheban, Daniel B.; Conway, Bevil R.; Bhattacharyya, Anita; Segal, Rosalind A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5671-5678</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Internalization and transport of a ligand-receptor complex are required to initiate cell body responses to target-derived neurotrophin.  However, it is not known whether internalized receptors and cell surface receptors initiate the same signaling pathways and biol. responses.  Here the authors use a temp.-sensitive mutant of dynamin (G273D) to control the subcellular localization of activated NGF receptors (Trks).  The authors show that dynamin function is required for ligand-dependent endocytosis of Trk receptors.  In PC12 cells, nerve growth factor (NGF) stimulation promotes both survival and neuronal differentiation.  These distinct biol. responses to NGF are controlled by receptors signaling from different locations within the cell.  Neuronal differentiation is promoted by catalytically active Trks within endosomes in the cell interior.  In contrast, survival responses are initiated by activated receptors at the cell surface where they orchestrate prolonged activation of the kinase Akt.  Thus, interactions between Trk receptor tyrosine kinases and intracellular signaling mols. are dictated both by phosphotyrosine motifs within the receptors and by the intracellular location of phosphorylated receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXnkF0vu4BU7Vg90H21EOLACvtfcHk0lgKTDFC0Kq56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbw%253D&md5=0e3daad42223adfe91d8927b32c8d64d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.20-15-05671.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.20-15-05671.2000%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DMoheban%26aufirst%3DD.%2BB.%26aulast%3DConway%26aufirst%3DB.%2BR.%26aulast%3DBhattacharyya%26aufirst%3DA.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DCell%2520surface%2520Trk%2520receptors%2520mediate%2520NGF-induced%2520survival%2520while%2520internalized%2520receptors%2520regulate%2520NGF-induced%2520differentiation%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26spage%3D5671%26epage%3D5678%26doi%3D10.1523%2FJNEUROSCI.20-15-05671.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnabe-Heider, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, F. D.</span></span> <span> </span><span class="NLM_article-title">Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5149</span>– <span class="NLM_lpage">5160</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.23-12-05149.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.23-12-05149.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12832539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltlentLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=5149-5160&author=F.+Barnabe-Heiderauthor=F.+D.+Miller&title=Endogenously+produced+neurotrophins+regulate+survival+and+differentiation+of+cortical+progenitors+via+distinct+signaling+pathways&doi=10.1523%2FJNEUROSCI.23-12-05149.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways</span></div><div class="casAuthors">Barnabe-Heider, Fanie; Miller, Freda D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5149-5160</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Cultured embryonic cortical progenitor cells will mimic the temporal differentiation pattern obsd. in vivo, producing neurons first and then glia.  Here, we investigated the role of two endogenously produced growth factors, the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 (NT-3), in the early progenitor-to-neuron transition.  Cultured cortical progenitors express BDNF and NT-3, as well as their receptors TrkB (tyrosine kinase receptor B) and TrkC.  Inhibition of these endogenously expressed neurotrophins using function-blocking antibodies resulted in a marked decrease in the survival of cortical progenitors, accompanied by decreased proliferation and inhibition of neurogenesis.  Inhibition of neurotrophin function also suppressed the downstream Trk receptor signaling pathways, PI3-kinase (phosphatidyl inositol-3-kinase) and MEK-ERK (MAP kinase kinase-extracellular signal-regulated kinase), indicating the presence of autocrine-paracrine neurotrophin:Trk receptor signaling in these cells.  Moreover, specific inhibition of these two Trk signaling pathways led to distinct biol. effects; inhibition of PI3-kinase decreased progenitor cell survival, whereas inhibition of MEK selectively blocked the generation of neurons, with no effects on survival or proliferation.  Thus, neurotrophins made by cortical progenitor cells themselves signal through the TrkB and TrkC receptors to mediate cortical progenitor cell survival and neurogenesis via two distinct downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMFVyGXurVMbVg90H21EOLACvtfcHk0lgKTDFC0Kq56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltlentLw%253D&md5=328361111454b5d369dcfcf3443ab6f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.23-12-05149.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.23-12-05149.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBarnabe-Heider%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DF.%2BD.%26atitle%3DEndogenously%2520produced%2520neurotrophins%2520regulate%2520survival%2520and%2520differentiation%2520of%2520cortical%2520progenitors%2520via%2520distinct%2520signaling%2520pathways%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26spage%3D5149%26epage%3D5160%26doi%3D10.1523%2FJNEUROSCI.23-12-05149.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eggert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikegaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span> <span> </span><span class="NLM_article-title">Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2043</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1203518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10803465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtF2jsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2043-2051&author=A.+Eggertauthor=N.+Ikegakiauthor=X.+Liuauthor=T.+T.+Chouauthor=V.+M.+Leeauthor=J.+Q.+Trojanowskiauthor=G.+M.+Brodeur&title=Molecular+dissection+of+TrkA+signal+transduction+pathways+mediating+differentiation+in+human+neuroblastoma+cells&doi=10.1038%2Fsj.onc.1203518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells</span></div><div class="casAuthors">Eggert, Angelika; Ikegaki, Naohiko; Liu, Xing-Ge; Chou, Thomas T.; Lee, Virginia M.; Trojanowski, John Q.; Brodeur, Garrett M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2043-2051</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the neurotrophin receptor TrkA by its ligand nerve growth factor (NGF) initiates a cascade of signaling events leading to neuronal differentiation in vitro and might play an important role in the differentiation of favorable neuroblastomas (NB) in vivo.  To study TrkA signal transduction pathways and their effects on differentiation in NB, we stably expressed wild-type TrkA and five different TrkA mutants in the NGF unresponsive human NB cell line SH-SY5Y.  Resulting clones were characterized by TrkA mRNA and protein expression, and by autophosphorylation of the receptor.  Introduction of wild-type TrkA restored NGF responsiveness of SH-SY5Y cells, as demonstrated by morphol. differentiation, activation of mitogen-activated protein kinases (MAPK) and induction of immediate-early genes.  Expression of TrkA in the absence of NGF resulted in growth inhibition of transfectants compared to parental cells, whereas NGF-treatment increased their proliferation rate.  Anal. of downstream signal transduction pathways indicated that NGF-induced differentiation was dependent on TrkA kinase activity.  Our data suggest that several redundant pathways are present further downstream, but activation of the RAS/MAPK signaling pathway seems to be of major importance for NGF mediated differentiation of NB cells.  Our results also show that the signaling effector SH2-B is a substrate of NGF-mediated Trk signaling in NB, whereas it is not activated by NGF in rat pheochromocytoma PC12 cells.  This might explain the differences we obsd. in TrkA signaling between neuroblastoma and PC12 cells.  Further insight into TrkA signaling may suggest new options for the treatment of NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMcffQwGzqfrVg90H21EOLACvtfcHk0lgKTDFC0Kq56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtF2jsbk%253D&md5=11c2bc9243954f97c9a8dab11d9103fd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203518%26sid%3Dliteratum%253Aachs%26aulast%3DEggert%26aufirst%3DA.%26aulast%3DIkegaki%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChou%26aufirst%3DT.%2BT.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26atitle%3DMolecular%2520dissection%2520of%2520TrkA%2520signal%2520transduction%2520pathways%2520mediating%2520differentiation%2520in%2520human%2520neuroblastoma%2520cells%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2043%26epage%3D2051%26doi%3D10.1038%2Fsj.onc.1203518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiCicco-Bloom, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, I. B.</span></span> <span> </span><span class="NLM_article-title">NT-3 stimulates sympathetic neuroblast proliferation by promoting precursor survival</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(93)90223-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0896-6273%2893%2990223-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7903858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1993&pages=1101-1011&author=E.+DiCicco-Bloomauthor=W.+J.+Friedmanauthor=I.+B.+Black&title=NT-3+stimulates+sympathetic+neuroblast+proliferation+by+promoting+precursor+survival&doi=10.1016%2F0896-6273%2893%2990223-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">NT-3 stimulates sympathetic neuroblast proliferation by promoting precursor survival</span></div><div class="casAuthors">DiCicco-Bloom, Emanuel; Friedman, Wilma J.; Black, Ira B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1101-11</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">Although proliferation is fundamental to the generation of neuronal populations, little is known about the function of trophic mechanisms during neurogenesis.  The authors now describe a novel role for neurotrophin-3 (NT-3): the neurotrophin stimulates proliferation of sympathetic neuroblasts through trophic mechanisms.  NT-3 promotes survival of the dividing precursors, but does not directly stimulate mitosis.  NT-3 trophic effects differ markedly from those of the sympathetic mitogen, insulin.  Furthermore, whereas NT-3 exhibits trophic activity for dividing neuroblasts, NGF characteristically promotes survival of postnatal sympathetic neurons.  The stage-specific activity of NT-3 and NGF in culture parallels the sequence of trkC and trkA receptor gene expression detected in vivo.  Thus, neurotrophins apparently serve as trophic factors during ontogeny, acting sequentially during establishment of individual populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz0VvHzDYw0rVg90H21EOLACvtfcHk0liuqcK-jrVOEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFCnsbs%253D&md5=ac26a42025cd5874fbd32042b524ab06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2893%2990223-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252893%252990223-E%26sid%3Dliteratum%253Aachs%26aulast%3DDiCicco-Bloom%26aufirst%3DE.%26aulast%3DFriedman%26aufirst%3DW.%2BJ.%26aulast%3DBlack%26aufirst%3DI.%2BB.%26atitle%3DNT-3%2520stimulates%2520sympathetic%2520neuroblast%2520proliferation%2520by%2520promoting%2520precursor%2520survival%26jtitle%3DNeuron%26date%3D1993%26volume%3D11%26spage%3D1101%26epage%3D1011%26doi%3D10.1016%2F0896-6273%2893%2990223-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glass, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nye, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantzopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squinto, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">Trkl3 mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90629-D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990629-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1649703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXltVOjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1991&pages=405-413&author=D.+J.+Glassauthor=S.+H.+Nyeauthor=P.+Hantzopoulosauthor=M.+J.+Macchiauthor=S.+P.+Squintoauthor=M.+Goldfarbauthor=G.+D.+Yancopoulos&title=Trkl3+mediates+BDNF%2FNT-3-dependent+survival+and+proliferation+in+fibroblasts+lacking+the+low+affinity+NGF+receptor&doi=10.1016%2F0092-8674%2891%2990629-D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor</span></div><div class="casAuthors">Glass, David J.; Nye, Steven H.; Hantzopoulos, Petros; Macchi, Mary J.; Squinto, Stephen P.; Goldfarb, Mitchell; Yancopoulos, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The neurotrophins nerve growth factor (NGF), brain-derived neurotropic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) have been defined by their ability to support neuronal survival.  These factors utilize the trk family of receptor tyrosine kinases, perhaps in conjunction with a second component known as the low-affinity NGF receptor (LNGFR).  The trkB mediateds survival and proliferation in response to both BDNF and NT-3 when expressed in a particular strain of NIH 3T3 fibroblasts, with BDNF being the more potent ligand.  The BDNF dose-dependency displayed by these trkB-expressing fibroblasts is similar to that required to support the survival of primary neurons.  The LNGFR is not expressed in this fibroblast system, implying that this receptor is not essential for responses to physiol. concns. of the neurotrophins.  The data are discussed in the context of neurotrophin signaling pathways and mechanisms of neuronal cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC8ylYZ45m57Vg90H21EOLACvtfcHk0liuqcK-jrVOEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXltVOjtLY%253D&md5=c34a721159f4a54521e99505a5db90d0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990629-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990629-D%26sid%3Dliteratum%253Aachs%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DNye%26aufirst%3DS.%2BH.%26aulast%3DHantzopoulos%26aufirst%3DP.%26aulast%3DMacchi%26aufirst%3DM.%2BJ.%26aulast%3DSquinto%26aufirst%3DS.%2BP.%26aulast%3DGoldfarb%26aufirst%3DM.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DTrkl3%2520mediates%2520BDNF%252FNT-3-dependent%2520survival%2520and%2520proliferation%2520in%2520fibroblasts%2520lacking%2520the%2520low%2520affinity%2520NGF%2520receptor%26jtitle%3DCell%26date%3D1991%26volume%3D66%26spage%3D405%26epage%3D413%26doi%3D10.1016%2F0092-8674%2891%2990629-D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehler, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, J. A.</span></span> <span> </span><span class="NLM_article-title">Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6433</span>– <span class="NLM_lpage">6442</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.16-20-06433.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.16-20-06433.1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8815922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1Orurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=6433-6442&author=R.+I.+Cohenauthor=R.+Marmurauthor=W.+T.+Nortonauthor=M.+F.+Mehlerauthor=J.+A.+Kessler&title=Nerve+growth+factor+and+neurotrophin-3+differentially+regulate+the+proliferation+and+survival+of+developing+rat+brain+oligodendrocytes&doi=10.1523%2FJNEUROSCI.16-20-06433.1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes</span></div><div class="casAuthors">Cohen, Rick I.; Marmur, Ronen; Norton, William T.; Mehler, Mark F.; Kessler, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6433-6442</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">There is increasing evidence that the neurotrophins, particularly nerve growth factor (NGF) and neurotrophin-3 (NT-3), play a role in the regulation of glial development in the CNS.  Recent studies have shown that the proliferation of optic nerve-derived O2A progenitors (OLPs) is potentiated by NT-3 in combination with platelet-derived growth factor, whereas NT-3 alone supports the survival of their differentiated progeny (Barres et al., 1994).  In this study, we have examd. the expression of the high-affinity neurotrophin receptors (trks) and the low-affinity nerve growth factor receptor p75 in developing oligodendrocytes (OLs).  In addn., we have examd. the effects of NGF and NT-3 on proliferation and survival of OLPs and OLs, resp.  TrkC, the high-affinity NT-3 receptor, and trkA, the high-affinity NGF receptor, are both expressed from the early OLP through the mature OL stage.  The truncated form of trkB, lacking the tyrosine kinase domain, and the low-affinity neurotrophin receptor p75 are expressed at low levels in OLPs and are upregulated in mature OLs.  NGF and NT-3 both induced the phosphorylation of mitogen-activated protein kinase (MAPK) in OLPs and in OLs.  In both OLPs and OLs, NT-3 sustained the activation of MAPK more than NGF.  NT-3 enhanced the proliferation of OLPs and supported the survival of OLs.  By contrast, unless coadministered with FGF-2, NGF did not exhibit mitogenic effects on OLPs but did enhance the survival or differentiated OLs.  Our data demonstrate the presence of functional trkA and trkC in developing OLs and indicate that both NGF and NT-3 have a broad spectrum of developmental actions on cells of the OL lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOnumLvXiccLVg90H21EOLACvtfcHk0lihADTlefMAkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1Orurw%253D&md5=1d2424f7bd37bcb9d8e6cf2049157b69</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.16-20-06433.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.16-20-06433.1996%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BI.%26aulast%3DMarmur%26aufirst%3DR.%26aulast%3DNorton%26aufirst%3DW.%2BT.%26aulast%3DMehler%26aufirst%3DM.%2BF.%26aulast%3DKessler%26aufirst%3DJ.%2BA.%26atitle%3DNerve%2520growth%2520factor%2520and%2520neurotrophin-3%2520differentially%2520regulate%2520the%2520proliferation%2520and%2520survival%2520of%2520developing%2520rat%2520brain%2520oligodendrocytes%26jtitle%3DJ.%2520Neurosci.%26date%3D1996%26volume%3D16%26spage%3D6433%26epage%3D6442%26doi%3D10.1523%2FJNEUROSCI.16-20-06433.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebendal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbany, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, H.</span></span> <span> </span><span class="NLM_article-title">Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(92)90413-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2892%2990413-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1314703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK38XisVyltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1992&pages=329-341&author=C.+F.+Ibanezauthor=T.+Ebendalauthor=G.+Barbanyauthor=J.+Murray-Rustauthor=T.+L.+Blundellauthor=H.+Persson&title=Disruption+of+the+low+affinity+receptor-binding+site+in+NGF+allows+neuronal+survival+and+differentiation+by+binding+to+the+trk+gene+product&doi=10.1016%2F0092-8674%2892%2990413-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product</span></div><div class="casAuthors">Ibanez, Carlos F.; Ebendal, Ted; Barbany, Gisela; Murray-Rust, Judith; Blundell, Tom L.; Persson, Haakan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-41</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Nerve growth factor (NGF), like many other growth factors and hormones, binds to two different receptor mols. on responsive cells.  The product of the proto-oncogene trk, p140trk, is a tyrosine kinase receptor that has been identified as a single-transducing receptor for NGF, while the role of the low affinity NGF receptor, p75NGFR, in signal transduction is less clear.  The crystal structure NGF has recently been detd., although structures involved in receptor binding and biol. activity are unknown.  Here it is shown that Lys-32, Lys-34, and Lys-95 form a pos. charged interface involved in binding to p75NGFR.  Simultaneous modification of Lys-32 with either of the two other lysines resulted in loss of binding to p75NGFR.  Despite the lack of binding to p75NGFR, these mutants retained binding to p140trk and biol. activity, demonstrating a functional dissocn. between the two NGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwSfq0fFSwybVg90H21EOLACvtfcHk0lihADTlefMAkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVyltbc%253D&md5=f93630f51f55697033df8f5f94772884</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2892%2990413-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252892%252990413-7%26sid%3Dliteratum%253Aachs%26aulast%3DIbanez%26aufirst%3DC.%2BF.%26aulast%3DEbendal%26aufirst%3DT.%26aulast%3DBarbany%26aufirst%3DG.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DPersson%26aufirst%3DH.%26atitle%3DDisruption%2520of%2520the%2520low%2520affinity%2520receptor-binding%2520site%2520in%2520NGF%2520allows%2520neuronal%2520survival%2520and%2520differentiation%2520by%2520binding%2520to%2520the%2520trk%2520gene%2520product%26jtitle%3DCell%26date%3D1992%26volume%3D69%26spage%3D329%26epage%3D341%26doi%3D10.1016%2F0092-8674%2892%2990413-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavenius, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gestblom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahlman, S.</span></span> <span> </span><span class="NLM_article-title">Transfection of Trk-a into human neuroblastoma-cells restores their ability to differentiate in response to nerve growth-factor</span>. <i>Cell Growth Differ.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7669728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1amsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1995&pages=727-736&author=E.+Laveniusauthor=C.+Gestblomauthor=I.+Johanssonauthor=E.+Nanbergauthor=S.+Pahlman&title=Transfection+of+Trk-a+into+human+neuroblastoma-cells+restores+their+ability+to+differentiate+in+response+to+nerve+growth-factor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor</span></div><div class="casAuthors">Lavenius, Erik; Gestblom, Carolina; Johansson, Irja; Naanberg, Eewa; Paahlman, Sven</div><div class="citationInfo"><span class="NLM_cas:title">Cell Growth & Differentiation</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-36</span>CODEN:
                <span class="NLM_cas:coden">CGDIE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-9523</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Human neuroblastoma cell lines frequently express the TRK-A proto-oncogene and bind nerve growth factor (NGF) but do not differentiate when exposed to NGF.  Transient transfection of an exogenous TRK-A gene into SH-SY5Y and LA-N-5 neuroblastoma cells restored the ability of these tumor cells to differentiate with NGF.  Stable TRK-A-transfected SH-SY5Y cell clones were isolated, and they responded to NGF by autophosphorylation of p140trk-A, c-fos induction, morphol. differentiation, and increased expression of two neuronal marker genes, neuropeptide tyrosine and GAP-43.  In phorbol ester-induced differentiated wild-type cells, TRK-A expression was increased with no change in NGF responsiveness.  Thus, the restoration of the NGF-induced differentiation pathway by exogenous TRK-A presents a system of NGF-responsive human cultured cells and focuses attention on the trk-A protein and its function or malfunction in neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp88QfC8g6tO7Vg90H21EOLACvtfcHk0liT6BokzI8YEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1amsrY%253D&md5=86376b5d0d2690ca256d2a937653c3b8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLavenius%26aufirst%3DE.%26aulast%3DGestblom%26aufirst%3DC.%26aulast%3DJohansson%26aufirst%3DI.%26aulast%3DNanberg%26aufirst%3DE.%26aulast%3DPahlman%26aufirst%3DS.%26atitle%3DTransfection%2520of%2520Trk-a%2520into%2520human%2520neuroblastoma-cells%2520restores%2520their%2520ability%2520to%2520differentiate%2520in%2520response%2520to%2520nerve%2520growth-factor%26jtitle%3DCell%2520Growth%2520Differ.%26date%3D1995%26volume%3D6%26spage%3D727%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. V.</span></span> <span> </span><span class="NLM_article-title">Neurotrophins and their receptors: a convergence point for many signalling pathways</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1038/nrn1078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrn1078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12671646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFWqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=299-309&author=M.+V.+Chao&title=Neurotrophins+and+their+receptors%3A+a+convergence+point+for+many+signalling+pathways&doi=10.1038%2Fnrn1078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotrophins and their receptors: A convergence point for many signalling pathways</span></div><div class="casAuthors">Chao, Moses V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The neurotrophins are a family of proteins that are essential for the development of the vertebrate nervous system.  Each neurotrophin can signal through two different types of cell surface receptor - the Trk receptor tyrosine kinases and the p75 neurotrophin receptor.  Given the wide range of activities that are now assocd. with neurotrophins, it is probable that addnl. regulatory events and signaling systems are involved.  Here, the author reviews recent findings that neurotrophins, in addn. to promoting survival and differentiation, exert various effects through surprising interactions with other receptors and ion channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzyi5WZRP_drVg90H21EOLACvtfcHk0liT6BokzI8YEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFWqtLw%253D&md5=8aefc951eb990e6923ac657dba2e725d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrn1078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1078%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DM.%2BV.%26atitle%3DNeurotrophins%2520and%2520their%2520receptors%253A%2520a%2520convergence%2520point%2520for%2520many%2520signalling%2520pathways%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D4%26spage%3D299%26epage%3D309%26doi%3D10.1038%2Fnrn1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bapat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostetter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span> <span> </span><span class="NLM_article-title">Perineural invasion and associated pain in pancreatic cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1038/nrc3131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrc3131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21941281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=695-707&author=A.+A.+Bapatauthor=G.+Hostetterauthor=D.+D.+Von+Hoffauthor=H.+Han&title=Perineural+invasion+and+associated+pain+in+pancreatic+cancer&doi=10.1038%2Fnrc3131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Perineural invasion and associated pain in pancreatic cancer</span></div><div class="casAuthors">Bapat, Aditi A.; Hostetter, Galen; Von Hoff, Daniel D.; Han, Hai-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">695-707</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Perineural invasion (PNI) is a prominent characteristic of pancreatic cancer.  PNI is a process whereby cancer cells invade the surrounding nerves, thus providing an alternative route for metastatic spread and pain generation.  PNI is thought to be an indicator of aggressive tumor behavior and has been shown to correlate with poor prognosis of patients with pancreatic cancer.  Recent studies demonstrated that some signalling mols. and pathways that are involved in PNI are also involved in pain generation.  Targeting these signalling pathways has shown some promise in alleviating pain and reducing PNI, which could potentially improve treatment outcomes for patients with pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfmb_ZatxfE7Vg90H21EOLACvtfcHk0liyHtvP80IK5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajurjM&md5=b66fe422a5c7a543bbc14524f5d35a89</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc3131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3131%26sid%3Dliteratum%253Aachs%26aulast%3DBapat%26aufirst%3DA.%2BA.%26aulast%3DHostetter%26aufirst%3DG.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DHan%26aufirst%3DH.%26atitle%3DPerineural%2520invasion%2520and%2520associated%2520pain%2520in%2520pancreatic%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D695%26epage%3D707%26doi%3D10.1038%2Fnrc3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miknyoczki, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchkovich, K.</span></span> <span> </span><span class="NLM_article-title">The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1924</span>– <span class="NLM_lpage">1931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12060637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Crurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1924-1931&author=S.+J.+Miknyoczkiauthor=W.+Wanauthor=H.+Changauthor=P.+Dobrzanskiauthor=B.+A.+Ruggeriauthor=C.+A.+Dionneauthor=K.+Buchkovich&title=The+neurotrophin-trk+receptor+axes+are+critical+for+the+growth+and+progression+of+human+prostatic+carcinoma+and+pancreatic+ductal+adenocarcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophin-Trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice</span></div><div class="casAuthors">Miknyoczki, Sheila J.; Wan, Weihua; Chang, Hong; Dobrazanski, Pawel; Ruggeri, Bruce A.; Dionne, Craig A.; Buchkovich, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1924-1931</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant expression of trk receptor kinases and enhanced expression of various neurotrophins (NTs) have been implicated in the development and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma.  We examd. the antitumor efficacy of administration of NT neutralizing antibodies on the growth of established human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.  In initial studies, tumor-bearing nude mice were treated with a mixt. of NT antibodies [100 μg each of anti-nerve growth factor (NGF), anti-brain-derived neurotrophic factor, anti-NT-3, and anti-NT-4/5] or normal rabbit IgG (400 μg) intratumorally and peritumorally three times/wk over a 15-day dosing period.  In subsequent studies, tumor-bearing nude mice were treated with individual NT antibodies (100 μg), affinity-purified antiNGF (0.1, 1.0, or 10.0 μg), or normal rabbit IgG (100 μg) using the same dosing schedule.  Treatment with the antibody mixt. inhibited significantly the growth of TSU-Pr1 and AsPC-1 xenografts as compared with IgG-treated controls (maximal inhibition of 53 and 53%, resp.), whereas this treatment caused significant regression in PC-3 xenografts.  Treatment of TSU-Pr1 xenografts with either anti-NGF or anti-NT-3 resulted in maximal tumor growth inhibition of 67 and 64%, resp., whereas anti-brain-derived neurotrophic factor and anti-NT-4/5 did not inhibit tumor growth in this tumor model.  Administration of various concns. (0.1, 1.0, or 10.0 μg) of affinity-purified anti-NGF resulted in maximal TSU-Pr1 tumor growth inhibition of 49, 62, and 66%, resp.  These data add further support for the therapeutic potential of disrupting trk-signaling; events in select types of nonneuronal human cancers, specifically prostatic and pancreatic carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-AePr6eQAhrVg90H21EOLACvtfcHk0liyHtvP80IK5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Crurk%253D&md5=3032fa3c58ef1986ecbd548b165a5111</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DBuchkovich%26aufirst%3DK.%26atitle%3DThe%2520neurotrophin-trk%2520receptor%2520axes%2520are%2520critical%2520for%2520the%2520growth%2520and%2520progression%2520of%2520human%2520prostatic%2520carcinoma%2520and%2520pancreatic%2520ductal%2520adenocarcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D1924%26epage%3D1931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeper, D. S.</span></span> <span> </span><span class="NLM_article-title">The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1007/s00018-005-5490-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2Fs00018-005-5490-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16568244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFWisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=755-759&author=C.+J.+Desmetauthor=D.+S.+Peeper&title=The+neurotrophic+receptor+TrkB%3A+a+drug+target+in+anti-cancer+therapy%3F&doi=10.1007%2Fs00018-005-5490-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?</span></div><div class="casAuthors">Desmet, C. J.; Peeper, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">755-759</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Increasing evidence implies altered signaling through the neurotrophic receptor tyrosine kinase TrkB in promoting tumor formation and metastasis.  TrkB, sometimes in conjunction with its primary ligand BDNF, is often overexpressed in a variety of human cancers, ranging from neuroblastomas to pancreatic ductal adenocarcinomas, in which it may allow tumor expansion and contribute to resistance to anti-tumor agents.  In vitro, TrkB acts as a potent suppressor of anoikis (detachment-induced apoptosis), which is assocd. with the acquisition of an aggressive tumorigenic and metastatic phenotype in vivo.  In view of its predicted contribution to tumorigenicity and metastasis in humans, TrkB corresponds to a potential drug target, and preclin. models have already been established.  The encouraging results of pharmacol. Trk inhibitors in tumor xenograft models suggest that TrkB inhibition may represent a promising novel anti-tumor therapeutic strategy.  This hypothesis is currently being evaluated in clin. trials.  Here, we will discuss the latest developments on TrkB in these contexts as well as highlight some crit. questions that remain to be addressed for evaluating TrkB as a therapeutic target in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjYylyi1Y6rVg90H21EOLACvtfcHk0ljuM4qtzGbeyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFWisLc%253D&md5=02d9f1889ee960621d97eb6f35ddac97</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00018-005-5490-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-005-5490-8%26sid%3Dliteratum%253Aachs%26aulast%3DDesmet%26aufirst%3DC.%2BJ.%26aulast%3DPeeper%26aufirst%3DD.%2BS.%26atitle%3DThe%2520neurotrophic%2520receptor%2520TrkB%253A%2520a%2520drug%2520target%2520in%2520anti-cancer%2520therapy%253F%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2006%26volume%3D63%26spage%3D755%26epage%3D759%26doi%3D10.1007%2Fs00018-005-5490-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Growth, survival and migration: the Trk to cancer</span>. <i>Cancer Treat Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1007/0-306-48158-8_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2F0-306-48158-8_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2004&pages=1-18&author=J.+B.+Rubinauthor=R.+A.+Segal&title=Growth%2C+survival+and+migration%3A+the+Trk+to+cancer&doi=10.1007%2F0-306-48158-8_1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F0-306-48158-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-306-48158-8_1%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DJ.%2BB.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DGrowth%252C%2520survival%2520and%2520migration%253A%2520the%2520Trk%2520to%2520cancer%26jtitle%3DCancer%2520Treat%2520Res.%26date%3D2004%26volume%3D115%26spage%3D1%26epage%3D18%26doi%3D10.1007%2F0-306-48158-8_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minturn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A. E.</span></span> <span> </span><span class="NLM_article-title">Trk receptor expression and inhibition in neuroblastomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-1815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1078-0432.CCR-08-1815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19417027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3244-3250&author=G.+M.+Brodeurauthor=J.+E.+Minturnauthor=R.+Hoauthor=A.+M.+Simpsonauthor=R.+Iyerauthor=C.+R.+Varelaauthor=J.+E.+Lightauthor=V.+Kollaauthor=A.+E.+Evans&title=Trk+receptor+expression+and+inhibition+in+neuroblastomas&doi=10.1158%2F1078-0432.CCR-08-1815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Trk Receptor Expression and Inhibition in Neuroblastomas</span></div><div class="casAuthors">Brodeur, Garrett M.; Minturn, Jane E.; Ho, Ruth; Simpson, Anisha M.; Iyer, Radhika; Varela, Carly R.; Light, Jennifer E.; Kolla, Venkatadri; Evans, Audrey E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3244-3250</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Neuroblastoma, the most common and deadly solid tumor in children, exhibits heterogeneous clin. behavior, from spontaneous regression to relentless progression.  Current evidence suggests that the TRK family of neurotrophin receptors plays a crit. role in these diverse behaviors.  Neuroblastomas expressing TrkA are biol. favorable and prone to spontaneous regression or differentiation, depending on the absence or presence of its ligand (NGF) in the microenvironment.  In contrast, TrkB-expressing tumors frequently have MYCN amplification and are very aggressive and often fatal tumors.  These tumors also express the TrkB ligand (BDNF), resulting in an autocrine or paracrine survival pathway.  Exposure to BDNF promotes survival, drug resistance, and angiogenesis of TrkB-expressing tumors.  Here we review the role of Trks in normal development, the different functions of Trk isoforms, and the major Trk signaling pathways.  We also review the roles these receptors play in the heterogeneous biol. and clin. behavior of neuroblastomas, and the activation of Trk receptors in other cancers.  Finally we address the progress that has been made in developing targeted therapy with Trk-selective inhibitors to treat neuroblastomas and other tumors with activated Trk expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XUqj0KJ-GLVg90H21EOLACvtfcHk0lhvADQSVHkd8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D&md5=cb21a6625f5d8464325522fb5b87c710</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1815%26sid%3Dliteratum%253Aachs%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DMinturn%26aufirst%3DJ.%2BE.%26aulast%3DHo%26aufirst%3DR.%26aulast%3DSimpson%26aufirst%3DA.%2BM.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DVarela%26aufirst%3DC.%2BR.%26aulast%3DLight%26aufirst%3DJ.%2BE.%26aulast%3DKolla%26aufirst%3DV.%26aulast%3DEvans%26aufirst%3DA.%2BE.%26atitle%3DTrk%2520receptor%2520expression%2520and%2520inhibition%2520in%2520neuroblastomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3244%26epage%3D3250%26doi%3D10.1158%2F1078-0432.CCR-08-1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Trk kinase inhibitors as new treatments for cancer and pain</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1517/13543770902721261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1517%2F13543770902721261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19441906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=305-319&author=T.+Wangauthor=D.+Yuauthor=M.+L.+Lamb&title=Trk+kinase+inhibitors+as+new+treatments+for+cancer+and+pain&doi=10.1517%2F13543770902721261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Trk kinase inhibitors as new treatments for cancer and pain</span></div><div class="casAuthors">Wang, Tao; Yu, Dingwei; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-319</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins.  Trks play important roles in pain sensation as well as tumor cell growth and survival signaling.  Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.  Objective: This paper reviews those patent applications since 2002 claiming small-mol. inhibitors of Trk receptor kinases.  Methods: Primary literature and patents were searched with SciFinder and Google Scholar.  Patents were selected based on their relevance to Trks and were evaluated and representative compds. were listed as examples.  Results/conclusion: Several series of Trk inhibitors with excellent in vitro potencies have been reported and a no. of compds. have gone into the clinic.  It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvknvXUUz2DbVg90H21EOLACvtfcHk0lhvADQSVHkd8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D&md5=ffc2d3e33102631cac7b89dce7f96a5a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F13543770902721261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770902721261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTrk%2520kinase%2520inhibitors%2520as%2520new%2520treatments%2520for%2520cancer%2520and%2520pain%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D305%26epage%3D319%26doi%3D10.1517%2F13543770902721261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weeraratna, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miknyoczki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span> <span> </span><span class="NLM_article-title">Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11489797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsVOmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2237-2245&author=A.+T.+Weeraratnaauthor=S.+L.+Dalrympleauthor=J.+C.+Lambauthor=S.+R.+Denmeadeauthor=S.+Miknyoczkiauthor=C.+A.+Dionneauthor=J.+T.+Isaacs&title=Pan-trk+inhibition+decreases+metastasis+and+enhances+host+survival+in+experimental+models+as+a+result+of+its+selective+induction+of+apoptosis+of+prostate+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells</span></div><div class="casAuthors">Weeraratna, Ashani T.; Dalrymple, Susan L.; Lamb, John C.; Denmeade, Samuel R.; Miknyoczki, Sheila; Dionne, Craig A.; Isaacs, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2237-2245</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">During the progression of prostate cancer, mol. changes occur resulting in the autocrine prodn. of a series of neurotrophins by the malignant cells.  This is coupled with expression of high-affinity cognate receptors for these ligands, termed trk receptors, by these cancer cells.  The binding of the neurotrophins to their trk receptors activates the receptor latent tyrosine kinase activity inducing a series of signal transduction pathways within these prostate cancer cells.  These mol. changes result in the acquisition by prostate cancer cells of a restricted requirement for these trk signaling pathways for optimal survival.  CEP-701 is an indolocarbazole compd. specifically designed as a potent inhibitor (IC50, 4 nM) of the tyrosine kinase activity of the trk receptors required for initiation of these survival pathways.  In the present studies, the consequences of CEP-701 inhibition of these trk signaling survival pathways were tested in vivo using both rat (R3327 AT 6.3 and H) and human (TSU-pr1 and CWR-22Rv1) prostatic cancer models.  These in vivo studies demonstrated that treatment with CEP-701 inhibits the growth of both rodent and human prostate cancers, without being toxic to the normal tissue including the host prostate.  Because of this selective effect, CEP-701 inhibits metastasis and growth of both primary and metastatic sites of prostate cancer.  Based upon this profile, long-term survival studies were performed using the slow-growing Dunning H rat prostate cancer model.  For these latter studies, the dosing regimen was 10 mg CEP-701/kg/dose twice a day via gavage 5 days a week.  This regimen maintains CEP-701 tumor tissue concns. of 25-50 nM.  Such chronic dosing increased (P < 0.001) the median survival of rats bearing the slow growing H prostate cancers from 408 days (395-432 days, 95% confidence interval) for the vehicle group (n = 18) to 566 days (497-598 days, 95% confidence interval) for the CEP-701-treated group (n = 24).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0P697XWQs_bVg90H21EOLACvtfcHk0lhvADQSVHkd8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsVOmtrw%253D&md5=4458b949ee63142d57c0c72632915a7d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeeraratna%26aufirst%3DA.%2BT.%26aulast%3DDalrymple%26aufirst%3DS.%2BL.%26aulast%3DLamb%26aufirst%3DJ.%2BC.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26atitle%3DPan-trk%2520inhibition%2520decreases%2520metastasis%2520and%2520enhances%2520host%2520survival%2520in%2520experimental%2520models%2520as%2520a%2520result%2520of%2520its%2520selective%2520induction%2520of%2520apoptosis%2520of%2520prostate%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2237%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weeraratna, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span> <span> </span><span class="NLM_article-title">Rational basis for Trk inhibition therapy for prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11027413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsFGisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2000&pages=140-148&author=A.+T.+Weeraratnaauthor=J.+T.+Arnoldauthor=D.+J.+Georgeauthor=A.+DeMarzoauthor=J.+T.+Isaacs&title=Rational+basis+for+Trk+inhibition+therapy+for+prostate+cancer&doi=10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rational basis for trk inhibition therapy for prostate cancer</span></div><div class="casAuthors">Weeraratna, Ashani T.; Arnold, Julia T.; George, Dan J.; DeMarzo, Angelo; Isaacs, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-148</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Prostatic cancer cells are lethal because they acquire the ability to activate survival pathways that do not require androgenic stimulation.  As a rational approach to developing effective therapy for these devastating cells, specific signal transduction pathways uniquely required for the survival of these nonandrogen-dependent prostate cancer cells must be identified.  Previous studies suggested that the neurotrophin/trk signal transduction axis may regulate such unique survival pathways.  In the present study, the changes in expression of the neurotrophins (NGF, BDNF, and NT-3) and their cognate receptors (i.e., trk and p75NTR) during the progression of normal prostatic epithelial cells to malignancy were documented.  Addnl., the consequences of inhibiting these trk signaling pathways on the in vitro survival of prostate cancer cells was tested.  Immunocytochem., RT-PCR, and ELISA assays were used to characterize the changes in the neurotrophin ligands (i.e., NGF, BDNF, and NT-3) and their cognate high-affinity (i.e., trk A, B, and C) and low-affinity neurotrophin (i.e., p75 NTR) receptors in normal vs. malignant human prostatic tissues.  CEP-751 is an indolocarbazole compd. specifically designed to inhibit the initiation of these neurotrophin/trk signal transductions.  The consequence of CEP-751 inhibition of trk signaling for in vitro clonogenic survival of a series of human prostatic cancer lines was also tested.  These studies demonstrated that normal prostatic tissue from patients without prostate cancer contains substantial levels of nerve growth factor (NGF), which is produced in a paracrine manner by stromal cells.  These stromal cells lack both trk and p75NTR receptors.  In contrast, normal prostatic epithelial cells from patients without prostate cancer do not secrete detectable levels of neurotrophins, but do express trk A and p75 NTR.  While the NGF/trkA/p75 NTR axis is present in the normal prostate, normal prostatic epithelial cells do not depend on this axis for their survival.  In contrast, malignant prostate epithelial cells directly secrete a series of neurotrophins (i.e., NGF, BDNF, and/or NT-3) and express at least one if not more of the trk receptor proteins (i.e., trk A, B, and/or C), while no longer expressing the p75NTR receptors.  In addn., inhibition of autocrine trk signaling via CEP-751 treatment induces the apoptotic death of these malignant cells.  Prostate carcinogenesis involves mol. changes leading to the paracrine and/or autocrine prodn. of a series of neurotrophins.  This is coupled to the ectopic expression of trk B and trk C, as well as to the continued expression of trk A, and the loss of expression of p75NTR receptors.  These changes result in the acquisition by malignant prostate cells of a unique requirement for trk signaling pathways for survival.  Based on these findings, trk inhibition is a novel, rational approach for prostate cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UOauVsgym7Vg90H21EOLACvtfcHk0lgIm1aCZTBAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsFGisrk%253D&md5=8d63f443c04004fb615dce89f1c3d91a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0045%252820001001%252945%253A2%253C140%253A%253AAID-PROS8%253E3.0.CO%253B2-%2523%26sid%3Dliteratum%253Aachs%26aulast%3DWeeraratna%26aufirst%3DA.%2BT.%26aulast%3DArnold%26aufirst%3DJ.%2BT.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26aulast%3DDeMarzo%26aufirst%3DA.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26atitle%3DRational%2520basis%2520for%2520Trk%2520inhibition%2520therapy%2520for%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2000%26volume%3D45%26spage%3D140%26epage%3D148%26doi%3D10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, A. E.</span></span> <span> </span><span class="NLM_article-title">On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5962</span>– <span class="NLM_lpage">5967</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1078-0432.CCR-08-0651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19755385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5962-5967&author=C.+J.+Thieleauthor=Z.+Liauthor=A.+E.+McKee&title=On+Trk%2D%2Dthe+TrkB+signal+transduction+pathway+is+an+increasingly+important+target+in+cancer+biology&doi=10.1158%2F1078-0432.CCR-08-0651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">On Trk-The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology</span></div><div class="casAuthors">Thiele, Carol J.; Li, Zhijie; McKee, Amy E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5962-5967</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  In the beginning, Trk was an oncogene.  Yet Neurotrophin-Trk signaling came to preeminence in the field of neurobiol.  Now it is appreciated that Trks regulate important processes in nonneuronal cells and, in addn. to their impact on tumors of neural origin, may contribute to the pathogenesis of carcinomas, myelomas, and prostate and lymphoid tumors.  Although mutations and rearrangements of Trk are seen only sporadically in human cancers, such as medullary thyroid carcinoma, a no. of recent studies indicate that expression of TrkB contributes to tumor pathol.  In neuroblastoma, TrkA expression marks good prognosis which TrkB and Brain-derived neurotrophic factor (BDNF) expression marks poor prognosis.  Activation of the BDNF/TrkB signal transduction pathway also stimulates tumor cell survival and angiogenesis and contributes to resistance to cytotoxic drugs and anoikis, enabling cells to acquire many of the characteristic features required for tumorigenesis.  Small mol. inhibitors, such as Cephalon's CEP-701, are in phase 1 and 2 clin. trials, and a series of AstraZeneca Trk inhibitors are poised to enter the clinic.  As monotherapy, inhibitors may be effective only in tumors with activating Trk mutations.  Important clin. follow-up will be the assessment of Trk inhibitors in combination with std. chemo- or radiotherapy or other signal transduction pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8u_7H2PK8S7Vg90H21EOLACvtfcHk0lgIm1aCZTBAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltbnI&md5=7e3f0c917b803215734a3231ee5271a9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0651%26sid%3Dliteratum%253Aachs%26aulast%3DThiele%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMcKee%26aufirst%3DA.%2BE.%26atitle%3DOn%2520Trk--the%2520TrkB%2520signal%2520transduction%2520pathway%2520is%2520an%2520increasingly%2520important%2520target%2520in%2520cancer%2520biology%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5962%26epage%3D5967%26doi%3D10.1158%2F1078-0432.CCR-08-0651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petrocellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span> <span> </span><span class="NLM_article-title">Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1210/endo.141.1.7239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1210%2Fendo.141.1.7239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10614630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslCj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2000&pages=118-126&author=D.+Melckauthor=L.+De+Petrocellisauthor=P.+Orlandoauthor=T.+Bisognoauthor=C.+Laezzaauthor=M.+Bifulcoauthor=V.+Di+Marzo&title=Suppression+of+nerve+growth+factor+Trk+receptors+and+prolactin+receptors+by+endocannabinoids+leads+to+inhibition+of+human+breast+and+prostate+cancer+cell+proliferation&doi=10.1210%2Fendo.141.1.7239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation</span></div><div class="casAuthors">Melck, Dominique; De Petrocellis, Luciano; Orlando, Pierangelo; Bisogno, Tiziana; Laezza, Chiara; Bifulco, Maurizio; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-126</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr).  Here the authors report that (1) anandamide and 2-AG inhibit the nerve growth factor (NGF)-induced proliferation of HBCCs through suppression of the levels of NGF Trk receptors; (2) inhibition of PRLr levels results in inhibition of the proliferation of other PRL-responsive cells, the prostate cancer DU-145 cell line; and (3) CB1-like cannabinoid receptors are expressed in HBCCs and DU-145 cells and mediate the inhibition of cell proliferation and Trk/PRLr expression.  β-NGF-induced HBCC proliferation was potently inhibited (IC50 = 50-600 nM) by the synthetic cannabinoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but not by the anandamide congener, palmitoylethanolamide, or the selective agonist of CB2 cannabinoid receptors, BML-190.  The effect of anandamide was blocked by the CB1 receptor antagonist, SR141716A, but not by the CB2 receptor antagonist, SR144528.  Anandamide and HU-210 exerted a strong inhibition of the levels of NGF Trk receptors as detected by Western immunoblotting; this effect was reversed by SR141716A.  When induced by exogenous PRL, the proliferation of prostate DU-145 cells was potently inhibited (IC50 = 100-300 nM) by anandamide, 2-AG, and HU-210.  Anandamide also down-regulated the levels of PRLr in DU-145 cells.  SR141716A attenuated these two effects of anandamide.  HBCCs and DU-145 cells were shown to contain (1) transcripts for CB1 and, to a lesser extent, CB2 cannabinoid receptors, (2) specific binding sites for [3H]SR141716A that could be displaced by anandamide, and (3) a CB1 receptor-immunoreactive protein.  These findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential neg. effectors of PRL- and NGF-induced biol. responses, at least in some cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNwzwH2Pc55bVg90H21EOLACvtfcHk0lgIm1aCZTBAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslCj&md5=14d3446530519dbddaee9e1071b7a76f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1210%2Fendo.141.1.7239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.141.1.7239%26sid%3Dliteratum%253Aachs%26aulast%3DMelck%26aufirst%3DD.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26aulast%3DOrlando%26aufirst%3DP.%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DSuppression%2520of%2520nerve%2520growth%2520factor%2520Trk%2520receptors%2520and%2520prolactin%2520receptors%2520by%2520endocannabinoids%2520leads%2520to%2520inhibition%2520of%2520human%2520breast%2520and%2520prostate%2520cancer%2520cell%2520proliferation%26jtitle%3DEndocrinology%26date%3D2000%26volume%3D141%26spage%3D118%26epage%3D126%26doi%3D10.1210%2Fendo.141.1.7239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawara, A.</span></span> <span> </span><span class="NLM_article-title">Trk receptor tyrosine kinases: A bridge between cancer and neural development</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/S0304-3835(01)00530-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0304-3835%2801%2900530-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11431098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Onu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2001&pages=107-114&author=A.+Nakagawara&title=Trk+receptor+tyrosine+kinases%3A+A+bridge+between+cancer+and+neural+development&doi=10.1016%2FS0304-3835%2801%2900530-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptor tyrosine kinases: A bridge between cancer and neural development</span></div><div class="casAuthors">Nakagawara, A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 40 refs.  The proto-oncogene Trks encode the high-affinity receptor tyrosine kinases for neurotrophins of a nerve growth factor (NGF) family.  The Trk signals spatiotemporally regulate neural development and maintenance of neural network.  However, Trk was originally cloned as an oncogene fused with the tropomyosin gene in the extracellular domain.  Accumulating evidence has demonstrated that the rearranged Trk oncogene is often obsd. in non-neuronal neoplasms such as colon and papillary thyroid cancers, while the signals through the receptors encoded by the proto-oncogene Trks regulate growth, differentiation and apoptosis of the tumors with neuronal origin such as neuroblastoma and medulloblastoma.  The intracellular Trk signaling pathway is also different depending on the Trk family receptors, cell types and the grade of transformation.  Furthermore, developmentally programmed cell death of neuron, which is largely regulated by neurotrophin signaling, is at least in part controlled by tumor suppressors p53 and p73 as well as their antagonist ΔNp73.  Thus, the Trks and their downstream signaling function in both ontogenesis and oncogenesis.  In this short review, the dynamic role of the Trk family receptors signaling in neural development, neurogenic tumors and other cancers will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHWRClrjDaErVg90H21EOLACvtfcHk0lgIm1aCZTBAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Onu7Y%253D&md5=c02ab60eb9ff9c18d0708ee5b064d45e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0304-3835%2801%2900530-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3835%252801%252900530-4%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawara%26aufirst%3DA.%26atitle%3DTrk%2520receptor%2520tyrosine%2520kinases%253A%2520A%2520bridge%2520between%2520cancer%2520and%2520neural%2520development%26jtitle%3DCancer%2520Lett.%26date%3D2001%26volume%3D169%26spage%3D107%26epage%3D114%26doi%3D10.1016%2FS0304-3835%2801%2900530-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edakuni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasatomi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, K.</span></span> <span> </span><span class="NLM_article-title">Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.3892/or.8.3.477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3892%2For.8.3.477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11295066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=477-484&author=Y.+Sakamotoauthor=Y.+Kitajimaauthor=G.+Edakuniauthor=E.+Sasatomiauthor=M.+Moriauthor=K.+Kitaharaauthor=K.+Miyazaki&title=Expression+of+Trk+tyrosine+kinase+receptor+is+a+biologic+marker+for+cell+proliferation+and+perineural+invasion+of+human+pancreatic+ductal+adenocarcinoma&doi=10.3892%2For.8.3.477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Sakamoto, Yuichiro; Kitajima, Yoshihiko; Edakuni, Genichiro; Sasatomi, Eizaburo; Mori, Michito; Kitahara, Kenji; Miyazaki, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-484</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is a widely known severe malignancy with a poor prognosis.  Perineural invasion extending to the extra-pancreatic nerve plexus, a significant concern in the treatment is frequently present in this cancer.  We analyzed immunohistochem. expression of neurotrophins (NGF, BDNF, NT-3) and the cognate receptors, Trk tyrosine kinase receptor family (TrkA, B, C) and p75NGFR in 28 surgically resected PDAC specimens.  A comparative study between several clinico-pathol. factors and Trk receptors revealed a significant correlation between increased expression of TrkA and cancer proliferation, as well as TrkC and cancer invasion, including venous and perineural invasion.  The present findings revealed a novel mechanism in PDAC progression that is mediated via a NTs-Trk interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbjgctwxB0yrVg90H21EOLACvtfcHk0lgy0XBEkfL70g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVSitrs%253D&md5=6c76c1e851cc29c1ad50c7c89ade6955</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3892%2For.8.3.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.8.3.477%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DY.%26aulast%3DKitajima%26aufirst%3DY.%26aulast%3DEdakuni%26aufirst%3DG.%26aulast%3DSasatomi%26aufirst%3DE.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKitahara%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DK.%26atitle%3DExpression%2520of%2520Trk%2520tyrosine%2520kinase%2520receptor%2520is%2520a%2520biologic%2520marker%2520for%2520cell%2520proliferation%2520and%2520perineural%2520invasion%2520of%2520human%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2001%26volume%3D8%26spage%3D477%26epage%3D484%26doi%3D10.3892%2For.8.3.477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Standop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friess, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andren-Sandberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pour, P. M.</span></span> <span> </span><span class="NLM_article-title">Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1210</span>, <span class="refDoi"> DOI: 10.1177/002215540104901002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1177%2F002215540104901002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11561004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFSqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=1205-1210&author=M.+B.+Schneiderauthor=J.+Standopauthor=A.+Ulrichauthor=U.+Wittelauthor=H.+Friessauthor=A.+Andren-Sandbergauthor=P.+M.+Pour&title=Expression+of+nerve+growth+factors+in+pancreatic+neural+tissue+and+pancreatic+cancer&doi=10.1177%2F002215540104901002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer</span></div><div class="casAuthors">Schneider, Matthias B.; Standop, Jens; Ulrich, Alexis; Wittel, Uwe; Friess, Helmut; Andren-Sandberg, Ake; Pour, Parviz M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1205-1210</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">One of the characteristics of pancreatic cancer is its tendency to invade neural tissue.  We hypothesized that the affinity of cancer cells for nerve tissue is related to the presence of growth factors in neural tissue and their receptors in cancer cells.  Sections of pancreatic cancer and normal pancreatic tissue were examd. by immunohistochem. for the expression of the neurotrophins NGF, BDNF, NT-3, NT-4, and their receptors TrkA, TrkB, and TrkC, as well as the low-affinity receptor, p75NTR.  TrkA expression was found in duct, islet, and cancer cells; TrkB was found in the α-cells of the islet only.  The anti-pan-Trk antibody (TrkB3), which is presumed to recognize all three receptors, immunoreacted with duct and acinar cells in normal tissue and with cancer cells.  The staining with TrkC was similar to that of TrkA.  The low-affinity receptor p75NTR was expressed in the neural tissue and in scattered duct cells of the normal tissue only.  Duct and acinar cells, as well as neural tissue and cancer cells, showed weak to strong immunoreactivity with NGF.  NT-3 expression was noted in capillary endothelia and erythrocytes.  NT-4 showed specific staining for ductule cells.  The expression and distribution of neurotrophins and their receptors suggest their role in the potential of pancreatic cancer cells for neural invasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPSyuQpq0sW7Vg90H21EOLACvtfcHk0lh4O0YeG8aOkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFSqtrk%253D&md5=5f600dbef4456c54ccdfe021fdc129af</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1177%2F002215540104901002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F002215540104901002%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DM.%2BB.%26aulast%3DStandop%26aufirst%3DJ.%26aulast%3DUlrich%26aufirst%3DA.%26aulast%3DWittel%26aufirst%3DU.%26aulast%3DFriess%26aufirst%3DH.%26aulast%3DAndren-Sandberg%26aufirst%3DA.%26aulast%3DPour%26aufirst%3DP.%2BM.%26atitle%3DExpression%2520of%2520nerve%2520growth%2520factors%2520in%2520pancreatic%2520neural%2520tissue%2520and%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2001%26volume%3D49%26spage%3D1205%26epage%3D1210%26doi%3D10.1177%2F002215540104901002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCune, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romans, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkin, B. D.</span></span> <span> </span><span class="NLM_article-title">Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4545</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.8.4540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.96.8.4540" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=4540-4545&author=L.+M.+McGregorauthor=B.+K.+McCuneauthor=J.+R.+Graffauthor=P.+R.+McDowellauthor=K.+E.+Romansauthor=G.+D.+Yancopoulosauthor=D.+W.+Ballauthor=S.+B.+Baylinauthor=B.+D.+Nelkin&title=Roles+of+trk+family+neurotrophin+receptors+in+medullary+thyroid+carcinoma+development+and+progression&doi=10.1073%2Fpnas.96.8.4540"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.8.4540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.8.4540%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DMcCune%26aufirst%3DB.%2BK.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DMcDowell%26aufirst%3DP.%2BR.%26aulast%3DRomans%26aufirst%3DK.%2BE.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DBall%26aufirst%3DD.%2BW.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DNelkin%26aufirst%3DB.%2BD.%26atitle%3DRoles%2520of%2520trk%2520family%2520neurotrophin%2520receptors%2520in%2520medullary%2520thyroid%2520carcinoma%2520development%2520and%2520progression%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D4540%26epage%3D4545%26doi%3D10.1073%2Fpnas.96.8.4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sclabas, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, P. J.</span></span> <span> </span><span class="NLM_article-title">Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15701826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=440-449&author=G.+M.+Sclabasauthor=S.+Fujiokaauthor=C.+Schmidtauthor=Z.+Liauthor=W.+A.+Frederickauthor=W.+Yangauthor=K.+Yokoiauthor=D.+B.+Evansauthor=J.+L.+Abbruzzeseauthor=K.+R.+Hessauthor=W.+Zhangauthor=I.+J.+Fidlerauthor=P.+J.+Chiao&title=Overexpression+of+tropomysin-related+kinase+B+in+metastatic+human+pancreatic+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells</span></div><div class="casAuthors">Sclabas, Guido M.; Fujioka, Shuichi; Schmidt, Christian; Li, Zhongkui; Frederick, Wayne A. I.; Yang, Wentao; Yokoi, Kenji; Evans, Douglas B.; Abbruzzese, James L.; Hess, Kenneth R.; Zhang, Wei; Fidler, Isaiah J.; Chiao, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">440-449</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pancreatic adenocarcinoma is currently the fourth leading cause of cancer death in the United States, and most pancreatic cancers develop locally advanced disease or metastasis at the time of diagnosis.  The mechanisms by which it invades and metastasizes are not known.  To identify the genes involved in pancreatic cancer metastasis, we analyzed the gene expression profiles between highly metastatic Colo357L3.6pl and parental Colo357FG pancreatic cancer cell lines using cDNA microarrays and confirmed differential gene expression by reverse transcription-PCR, Western blotting, and immunol. anal. of 54 samples from pancreatic cancer patients.  The correlation with clin. outcome was also examd.  The possible signaling pathways involved with tropomyosin-related kinase B (TrkB) were analyzed.  Our findings showed that TrkB was overexpressed in the highly metastatic Colo357L3.6pl cells, which correlated with perineural invasion (P = 0.026), pos. retroperitoneal margin (P = 0.0005), and shorter latency to development of liver metastasis (Cox proportional hazard ratio, 0.3; 95% confidence interval, 0.1-0.8; P = 0.01) in patient samples.  Extracellular signal-regulated kinases 1 and 2 were activated and Elk-1 and AP-1 DNA binding activity was induced in Colo357L3.6pl cells.  Furthermore, interleukin 8 and vascular endothelial growth factor were more strongly expressed in Colo357L3.6pl than Colo357FG cells, and these findings were confirmed in Colo357L3.6pl and Colo357FG orthotopic tumors.  These results suggest that overexpression of TrkB and activation of mitogen-activated protein kinase and AP-1, which may in turn induce the expression of vascular endothelial growth factor and interleukin 8, may mediate the cardinal clin. features of locally aggressive growth and metastasis of pancreatic cancer.  Our results also imply that TrkB receptor may be a novel therapeutic target for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw13VKIBfliLVg90H21EOLACvtfcHk0lh4O0YeG8aOkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWgtrg%253D&md5=5412f2a642835410bee82aecf302ba21</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSclabas%26aufirst%3DG.%2BM.%26aulast%3DFujioka%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFrederick%26aufirst%3DW.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DEvans%26aufirst%3DD.%2BB.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHess%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26aulast%3DChiao%26aufirst%3DP.%2BJ.%26atitle%3DOverexpression%2520of%2520tropomysin-related%2520kinase%2520B%2520in%2520metastatic%2520human%2520pancreatic%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D440%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, S.</span></span> <span> </span><span class="NLM_article-title">Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2001.tb01077.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1111%2Fj.1349-7006.2001.tb01077.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11223544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis1KgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2001&pages=152-160&author=T.+Sugimotoauthor=H.+Kurodaauthor=Y.+Horiiauthor=H.+Moritakeauthor=T.+Tanakaauthor=S.+Hattori&title=Signal+transduction+pathways+through+TRK-A+and+TRK-B+receptors+in+human+neuroblastoma+cells&doi=10.1111%2Fj.1349-7006.2001.tb01077.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells</span></div><div class="casAuthors">Sugimoto, Tohru; Kuroda, Hiroshi; Horii, Yoshihiro; Moritake, Hiroshi; Tanaka, Takeo; Hattori, Seisuke</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-160</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Little is known about the signal transduction pathways of TRK family receptors in neuroblastoma (NB) cells.  In this study, an NB cell line, designated MP-N-TS, was established from an adrenal tumor taken from a 2-yr-old boy.  This cell line expressed both TRK-A and TRK-B receptors, which is rare in a single NB cell line.  Therefore, the MP-N-TS cell line was used to det. whether the signal transduction through these constitutive receptors is functional.  Three neurotrophins, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), induced tyrosine phosphorylation of panTRK, and BDNF and NT-4/5 induced tyrosine phosphorylation of TRK-B.  Tyrosine phosphorylation of pan TRK and/or TRK-B by the neurotrophins was inhibited in the presence of a tyrosine kinase inhibitor K252a.  Tyrosine phosphorylation of Src homologous and collagen (Shc), extracellular signal-regulated kinase (ERK)-1 and ERK-2, and phospholipase C-γ1 (PLC-γ1) was increased by the three neurotrophins and the increase was inhibited in the presence of K252a.  Activation of Ras, detected as the GTP-bound form of Ras, was induced by the three neurotrophins.  The neurotrophins did not modulate the expressions of TRK-A or TRK-B mRNA, but they did induce the expression of c-fos mRNA.  Exogenous NGF induced weak neurite outgrowth, whereas exogenous BDNF and NT-4/5 induced distinct neurite outgrowth.  Exogenous BDNF and NT-4/5 increased the no. of viable cells, while NGF did not.  Our results demonstrate that the signal transduction pathways through TRK-A and TRK-B in MP-N-TS cells are functional and similar, and the main downstream signaling pathways from the three neurotrophins are mitogen-activated protein kinase (MAPK) cascades through Shc, activated Ras, ERK-1 and ERK-2, and the transduction pathway through PLC-γ1.  Further, BDNF and NT-4/5 increased cell viability.  The MP-N-TS cell line should be useful for clarifying the TRK-A and TRK-B signaling pathways responsible for the different prognoses in patients with NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAYVFkXAMrWLVg90H21EOLACvtfcHk0liKyFrERSAezw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis1KgtLw%253D&md5=f01b9d02f6f598fe55ef304b5069be8d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2001.tb01077.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2001.tb01077.x%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DH.%26aulast%3DHorii%26aufirst%3DY.%26aulast%3DMoritake%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DS.%26atitle%3DSignal%2520transduction%2520pathways%2520through%2520TRK-A%2520and%2520TRK-B%2520receptors%2520in%2520human%2520neuroblastoma%2520cells%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D2001%26volume%3D92%26spage%3D152%26epage%3D160%26doi%3D10.1111%2Fj.1349-7006.2001.tb01077.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borrello, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongarzone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plerotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luksch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pllotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rlzzetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondellini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bernardi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Martino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garaventa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisigotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span> <span> </span><span class="NLM_article-title">Trk and ret proto-oncogene expression in human neuroblastoma specimens: High frequency oftrk expression in non-advanced stages</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1002/ijc.2910540404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fijc.2910540404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8514446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXmt1ejsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1993&pages=540-545&author=M.+G.+Borrelloauthor=I.+Bongarzoneauthor=M.+A.+Plerottiauthor=R.+Lukschauthor=M.+Gaspariniauthor=P.+Colliniauthor=S.+Pllottiauthor=M.+G.+Rlzzettiauthor=P.+Mondelliniauthor=B.+De+Bernardiauthor=D.+Di+Martinoauthor=A.+Garaventaauthor=M.+Brisigottiauthor=G.+P.+Tonini&title=Trk+and+ret+proto-oncogene+expression+in+human+neuroblastoma+specimens%3A+High+frequency+oftrk+expression+in+non-advanced+stages&doi=10.1002%2Fijc.2910540404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages</span></div><div class="casAuthors">Borrello, M. G.; Bongarzone, I.; Pierotti, M. A.; Luksch, R.; Gasparini, M.; Collini, P.; Pilotti, S.; Rizzetti, M. G.; Mondellini, P.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">540-5</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Forty-three fresh tumor specimens of human neuroblastoma belonging to different clin. stages were analyzed for the expression of 2 proto-oncogenes: trk, which encodes a tyrosine-kinase receptor for nerve growth factor (NGF) and ret, another receptor-type tyrosine kinase whose ligand is unknown.  The cases, with increased frequency in I, II and IVs Evans' stages and in patients with favorable prognosis according to the Shimada classification.  Moreover, trk expression inversely correlated with Nmyc-gene amplification.  Ret mRNA was found in 36.8% of cases and equally distributed in the different stages.  In addn., ngfR (low-affinity NGF receptor)-gene expression was present in 9 out of 25 cases.  The simultaneous presence of mRNA related to both forms of the NGF receptor, while not proving the presence of a functional receptor, indicates the existence of a sub-set of neuroblastoma cells potentially responsive to NGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh8NpsOzKBJbVg90H21EOLACvtfcHk0liKyFrERSAezw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmt1ejsLY%253D&md5=3df319674e53149df74c242ffb379b0b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910540404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910540404%26sid%3Dliteratum%253Aachs%26aulast%3DBorrello%26aufirst%3DM.%2BG.%26aulast%3DBongarzone%26aufirst%3DI.%26aulast%3DPlerotti%26aufirst%3DM.%2BA.%26aulast%3DLuksch%26aufirst%3DR.%26aulast%3DGasparini%26aufirst%3DM.%26aulast%3DCollini%26aufirst%3DP.%26aulast%3DPllotti%26aufirst%3DS.%26aulast%3DRlzzetti%26aufirst%3DM.%2BG.%26aulast%3DMondellini%26aufirst%3DP.%26aulast%3DDe%2BBernardi%26aufirst%3DB.%26aulast%3DDi%2BMartino%26aufirst%3DD.%26aulast%3DGaraventa%26aufirst%3DA.%26aulast%3DBrisigotti%26aufirst%3DM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26atitle%3DTrk%2520and%2520ret%2520proto-oncogene%2520expression%2520in%2520human%2520neuroblastoma%2520specimens%253A%2520High%2520frequency%2520oftrk%2520expression%2520in%2520non-advanced%2520stages%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1993%26volume%3D54%26spage%3D540%26epage%3D545%26doi%3D10.1002%2Fijc.2910540404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eibl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reber, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, O. J.</span></span> <span> </span><span class="NLM_article-title">Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells</span>. <i>Clin. Exp. Metastasis</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1023/B:CLIN.0000046131.24625.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1023%2FB%3ACLIN.0000046131.24625.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15554384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFOgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=285-292&author=Y.+Okadaauthor=G.+Eiblauthor=S.+Guhaauthor=J.+P.+Duffyauthor=H.+A.+Reberauthor=O.+J.+Hines&title=Nerve+growth+factor+stimulates+MMP-2+expression+and+activity+and+increases+invasion+by+human+pancreatic+cancer+cells&doi=10.1023%2FB%3ACLIN.0000046131.24625.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells</span></div><div class="casAuthors">Okada, Yuji; Eibl, Guido; Guha, Sushovan; Duffy, John P.; Reber, Howard A.; Hines, Oscar J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Metastasis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-292</span>CODEN:
                <span class="NLM_cas:coden">CEXMD2</span>;
        ISSN:<span class="NLM_cas:issn">0262-0898</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Pancreatic cancer frequently invades and migrates along neural tissue.  Although the exact mechanisms are unknown, perineural invasion neg. impacts prognosis for pancreatic cancer patients.  Matrix metalloproteinases (MMPs) are overexpressed in pancreatic cancer and are assocd. with poor prognosis.  We hypothesized that nerve growth factor (NGF) released from neural tissue increases the invasive properties of pancreatic cancer cells.  In the present study we investigated the effect of NGF on the expression and activity of MMP-2 in human pancreatic cancer cells.  NGF dose dependently increased MMP-2 protein in the culture medium and stimulated MMP-2 gelatinolytic activity.  This effect was mediated by specific binding of NGF to its receptor trk A, which was detected on all pancreatic cancer cells, with subsequent activation of the p44/42 MAPK signaling pathway.  The NGF-induced increase in MMP-2 expression and activity lead to an enhanced invasion in vitro.  These findings support the hypothesis that neurotrophic factors, e.g., NGF, are critically involved in mediating perineural invasion of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNTV-xLbJq7Vg90H21EOLACvtfcHk0lhh2P1e2LlrzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFOgsbs%253D&md5=5096ebb4253a5c9c0dcebbfc10fca5c3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1023%2FB%3ACLIN.0000046131.24625.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ACLIN.0000046131.24625.54%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DEibl%26aufirst%3DG.%26aulast%3DGuha%26aufirst%3DS.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DReber%26aufirst%3DH.%2BA.%26aulast%3DHines%26aufirst%3DO.%2BJ.%26atitle%3DNerve%2520growth%2520factor%2520stimulates%2520MMP-2%2520expression%2520and%2520activity%2520and%2520increases%2520invasion%2520by%2520human%2520pancreatic%2520cancer%2520cells%26jtitle%3DClin.%2520Exp.%2520Metastasis%26date%3D2004%26volume%3D21%26spage%3D285%26epage%3D292%26doi%3D10.1023%2FB%3ACLIN.0000046131.24625.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sapio, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raggioli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deandrea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limone, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caleo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, M.</span></span> <span> </span><span class="NLM_article-title">Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings</span>. <i>Clin. Endocrinol. (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2265.2007.02800.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1111%2Fj.1365-2265.2007.02800.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=17381488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvFKlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2007&pages=678-683&author=M.+R.+Sapioauthor=D.+Poscaauthor=A.+Raggioliauthor=A.+Guerraauthor=V.+Marottaauthor=M.+Deandreaauthor=M.+Mottaauthor=P.+P.+Limoneauthor=G.+Tronconeauthor=A.+Caleoauthor=G.+Rossiauthor=G.+Fenziauthor=M.+Vitale&title=Detection+of+RET%2FPTC%2C+TRK+and+BRAF+mutations+in+preoperative+diagnosis+of+thyroid+nodules+with+indeterminate+cytological+findings&doi=10.1111%2Fj.1365-2265.2007.02800.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings</span></div><div class="casAuthors">Sapio, Maria Rosaria; Posca, Daniela; Raggioli, Angelo; Guerra, Anna; Marotta, Vincenzo; Deandreat, Maurilio; Motta, Manuela; Limonet, Paolo Piero; Troncone, Giancarlo; Caleo, Alessia; Rossi, Guido; Fenzi, Gianfranco; Vitale, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Endocrinology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">678-683</span>CODEN:
                <span class="NLM_cas:coden">CLECAP</span>;
        ISSN:<span class="NLM_cas:issn">0300-0664</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Fine-needle aspiration biopsy (FNAB) is the primary means to distinguish benign from malignant nodules and select patients for surgery.  However, adjunctive diagnostic tests are needed because in 20-40% of cases the FNAB result is uncertain.  We investigated whether a search for the oncogenes RET/PTC, TRK,and BRAFV600E in thyroid aspirates could refine an uncertain diagnosis.  A total of 132 thyroid aspirates, including colloid nodules, inadequate samplings, indeterminate and suspicious for malignancy were analyzed by reverse transcription polymerase chain reaction (RT-PCR) and mutant allele-specific amplification techniques for the presence of oncogenes.  No oncogenes were detected in 48 colloid nodules, 46 inadequate and 19 indeterminate FNABs, then confirmed to be benign at histol.  No oncogenes were detected in one follicular thyroid cancer (FTC) with indeterminate cytol.  Five out of six papillary thyroid cancers (83%) with FNAB suspicious for malignancy were correctly diagnosed by the presence of oncogenes.  Among these, four (67%) contained the BRAF mutation and one (17%) contained RET/PTC-3.  On final anal., no false-pos. results were reported in 131 samples and five out of seven carcinomas (71%) were correctly diagnosed.  The finding of oncogenes in FNAB specimens suspicious for malignancy guided the extent of surgical resection, changing the surgery from diagnostic to therapeutic in five cases.  Detection of RET/PTC, TRK and BRAFV600E in FNAB specimens is proposed as a diagnostic adjunctive tool in the evaluation of thyroid nodules with suspicious cytol. findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYfEq1ByeMabVg90H21EOLACvtfcHk0lhh2P1e2LlrzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvFKlu78%253D&md5=1d3d7c671e9964057261c2f5e3fb0ccd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2265.2007.02800.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2265.2007.02800.x%26sid%3Dliteratum%253Aachs%26aulast%3DSapio%26aufirst%3DM.%2BR.%26aulast%3DPosca%26aufirst%3DD.%26aulast%3DRaggioli%26aufirst%3DA.%26aulast%3DGuerra%26aufirst%3DA.%26aulast%3DMarotta%26aufirst%3DV.%26aulast%3DDeandrea%26aufirst%3DM.%26aulast%3DMotta%26aufirst%3DM.%26aulast%3DLimone%26aufirst%3DP.%2BP.%26aulast%3DTroncone%26aufirst%3DG.%26aulast%3DCaleo%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DG.%26aulast%3DFenzi%26aufirst%3DG.%26aulast%3DVitale%26aufirst%3DM.%26atitle%3DDetection%2520of%2520RET%252FPTC%252C%2520TRK%2520and%2520BRAF%2520mutations%2520in%2520preoperative%2520diagnosis%2520of%2520thyroid%2520nodules%2520with%2520indeterminate%2520cytological%2520findings%26jtitle%3DClin.%2520Endocrinol.%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2007%26volume%3D66%26spage%3D678%26epage%3D683%26doi%3D10.1111%2Fj.1365-2265.2007.02800.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span> <span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nm0596-561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells&doi=10.1038%2Fnm0596-561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0lirwr1TuGn29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnm0596-561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">TRKing down an old oncogene in a new era of targeted therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-14-0765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25527197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=25-34&author=A.+Vaishnaviauthor=A.+T.+Leauthor=R.+C.+Doebele&title=TRKing+down+an+old+oncogene+in+a+new+era+of+targeted+therapy&doi=10.1158%2F2159-8290.CD-14-0765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span></div><div class="casAuthors">Vaishnavi, Aria; Le, Anh T.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date.  These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago.  However, no drug has yet been approved by the FDA for cancers harboring this oncogene.  This review will discuss the biol. of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.  Significance: Precision oncol. approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples.  Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types.  The scientific rationale for the targeting of the TRK oncogene family will be discussed here.  Cancer Discov; 5(1); 25-34. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUH4ooHY0TbVg90H21EOLACvtfcHk0lirwr1TuGn29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D&md5=02103d46d85b6dc948dba58d32ffba9f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0765%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTRKing%2520down%2520an%2520old%2520oncogene%2520in%2520a%2520new%2520era%2520of%2520targeted%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D25%26epage%3D34%26doi%3D10.1158%2F2159-8290.CD-14-0765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span> <span> </span><span class="NLM_article-title">NTRK gene fusions as novel targets of cancer therapy across multiple tumour types</span>. <i>ESMO Open</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e000023</span>, <span class="refDoi"> DOI: 10.1136/esmoopen-2015-000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1136%2Fesmoopen-2015-000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=27843590" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e000023&author=A.+Amatuauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=NTRK+gene+fusions+as+novel+targets+of+cancer+therapy+across+multiple+tumour+types&doi=10.1136%2Fesmoopen-2015-000023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fesmoopen-2015-000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fesmoopen-2015-000023%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNTRK%2520gene%2520fusions%2520as%2520novel%2520targets%2520of%2520cancer%2520therapy%2520across%2520multiple%2520tumour%2520types%26jtitle%3DESMO%2520Open%26date%3D2016%26volume%3D1%26spage%3De000023%26doi%3D10.1136%2Fesmoopen-2015-000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span> <span> </span><span class="NLM_article-title">The landscape of kinase fusions in cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">4846</span>, <span class="refDoi"> DOI: 10.1038/ncomms5846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fncomms5846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25204415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVShsbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4846&author=N.+Stranskyauthor=E.+Ceramiauthor=S.+Schalmauthor=J.+L.+Kimauthor=C.+Lengauer&title=The+landscape+of+kinase+fusions+in+cancer&doi=10.1038%2Fncomms5846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The landscape of kinase fusions in cancer</span></div><div class="casAuthors">Stransky, Nicolas; Cerami, Ethan; Schalm, Stefanie; Kim, Joseph L.; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4846</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genomes harbor a variety of alterations leading to the deregulation of key pathways in tumor cells.  The genomic characterization of tumors has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as extensively.  Here we develop heuristics for reliably detecting gene fusion events in RNA-seq data and apply them to nearly 7,000 samples from The Cancer Genome Atlas.  We thereby are able to discover several novel and recurrent fusions involving kinases.  These findings have immediate clin. implications and expand the therapeutic options for cancer patients, as approved or exploratory drugs exist for many of these kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtVLhAUa2IjLVg90H21EOLACvtfcHk0liqOMTJ0jTmXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVShsbvP&md5=f71bed662172018e65e53ec086e113e3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fncomms5846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5846%26sid%3Dliteratum%253Aachs%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DCerami%26aufirst%3DE.%26aulast%3DSchalm%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DThe%2520landscape%2520of%2520kinase%2520fusions%2520in%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4846%26doi%3D10.1038%2Fncomms5846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dela
Cruz, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanoue, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthay, R. A.</span></span> <span> </span><span class="NLM_article-title">Lung cancer: epidemiology, etiology, and prevention</span>. <i>Clin. Chest Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/j.ccm.2011.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.ccm.2011.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22054876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC3MbmvVOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=605-644&author=C.+S.+Dela%0ACruzauthor=L.+T.+Tanoueauthor=R.+A.+Matthay&title=Lung+cancer%3A+epidemiology%2C+etiology%2C+and+prevention&doi=10.1016%2Fj.ccm.2011.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Lung cancer: epidemiology, etiology, and prevention</span></div><div class="casAuthors">Dela Cruz Charles S; Tanoue Lynn T; Matthay Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer death in the United States and around the world.  A vast majority of lung cancer deaths are attributable to cigarette smoking, and curbing the rates of cigarette smoking is imperative.  Understanding the epidemiology and causal factors of lung cancer can provide additional foundation for disease prevention.  This article focuses on modifiable risk factors, including tobacco smoking, occupational carcinogens, diet, and ionizing radiation.  It also discusses briefly the molecular and genetic aspects of lung carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvaMTw8VxvNHRxY89Cm6SyfW6udTcc2eYwbG0otGaatbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbmvVOgsg%253D%253D&md5=e5901b74d858bf24d8ed740c1ed4d929</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ccm.2011.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccm.2011.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DDela%2BCruz%26aufirst%3DC.%2BS.%26aulast%3DTanoue%26aufirst%3DL.%2BT.%26aulast%3DMatthay%26aufirst%3DR.%2BA.%26atitle%3DLung%2520cancer%253A%2520epidemiology%252C%2520etiology%252C%2520and%2520prevention%26jtitle%3DClin.%2520Chest%2520Med.%26date%3D2011%26volume%3D32%26spage%3D605%26epage%3D644%26doi%3D10.1016%2Fj.ccm.2011.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneval, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katabi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A. L.</span></span> <span> </span><span class="NLM_article-title">What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1093%2Fannonc%2Fmdw042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26884591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC28jhsVWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=920-926&author=A.+Drilonauthor=G.+Liauthor=S.+Doganauthor=M.+Gounderauthor=R.+Shenauthor=M.+Arcilaauthor=L.+Wangauthor=D.+M.+Hymanauthor=J.+Hechtmanauthor=G.+Weiauthor=N.+R.+Camauthor=J.+Christiansenauthor=D.+Luoauthor=E.+C.+Manevalauthor=T.+Bauerauthor=M.+Patelauthor=S.+V.+Liuauthor=S.+H.+Ouauthor=A.+Faragoauthor=A.+Shawauthor=R.+F.+Shoemakerauthor=J.+Limauthor=Z.+Hornbyauthor=P.+Multaniauthor=M.+Ladanyiauthor=M.+Bergerauthor=N.+Katabiauthor=R.+Ghosseinauthor=A.+L.+Ho&title=What+hides+behind+the+MASC%3A+clinical+response+and+acquired+resistance+to+entrectinib+after+ETV6-NTRK3+identification+in+a+mammary+analogue+secretory+carcinoma+%28MASC%29&doi=10.1093%2Fannonc%2Fmdw042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)</span></div><div class="casAuthors">Drilon A; Gounder M; Hyman D M; Ho A L; Li G; Wei G; Cam N R; Christiansen J; Luo D; Maneval E C; Shoemaker R F; Lim J; Hornby Z; Multani P; Dogan S; Arcila M; Wang L; Hechtman J; Ladanyi M; Berger M; Katabi N; Ghossein R; Shen R; Bauer T; Patel M; Liu S V; Ou S H I; Farago A; Shaw A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">920-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity.  We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion.  PATIENTS AND METHODS:  This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro activity against cell lines containing various NTRK1/2/3 fusions.  RESULTS:  A dramatic and durable response was achieved with entrectinib in this patient, followed by acquired resistance that correlated with the appearance of a novel NTRK3 G623R mutation.  Structural modeling predicts that this alteration sterically interferes with drug binding, correlating to decreased sensitivity to drug inhibition observed in cell-based assays.  CONCLUSIONS:  This first report of clinical activity with TrkC inhibition and the development of acquired resistance in an NTRK3-rearranged cancer emphasize the utility of comprehensive molecular profiling and targeted therapy for rare malignancies (NCT02097810).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9gxQ1W-lQaLt7lRqEFUJVfW6udTcc2ebv2r-hUNvhH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhsVWhsQ%253D%253D&md5=2fb8579504f22f5fbfc90f086dd0c743</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw042%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDogan%26aufirst%3DS.%26aulast%3DGounder%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DHechtman%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DCam%26aufirst%3DN.%2BR.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DManeval%26aufirst%3DE.%2BC.%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DFarago%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DShoemaker%26aufirst%3DR.%2BF.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DKatabi%26aufirst%3DN.%26aulast%3DGhossein%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DA.%2BL.%26atitle%3DWhat%2520hides%2520behind%2520the%2520MASC%253A%2520clinical%2520response%2520and%2520acquired%2520resistance%2520to%2520entrectinib%2520after%2520ETV6-NTRK3%2520identification%2520in%2520a%2520mammary%2520analogue%2520secretory%2520carcinoma%2520%2528MASC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D920%26epage%3D926%26doi%3D10.1093%2Fannonc%2Fmdw042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khotskaya, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills Shaw, K. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span> <span> </span><span class="NLM_article-title">Targeting TRK family proteins in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.pharmthera.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28174090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=58-66&author=Y.+B.+Khotskayaauthor=V.+R.+Hollaauthor=A.+F.+Faragoauthor=K.+R.+M.+Mills+Shawauthor=F.+Meric-Bernstamauthor=D.+S.+Hong&title=Targeting+TRK+family+proteins+in+cancer&doi=10.1016%2Fj.pharmthera.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting TRK family proteins in cancer</span></div><div class="casAuthors">Khotskaya, Yekaterina B.; Holla, Vijaykumar R.; Farago, Anna F.; Mills Shaw, Kenna R.; Meric-Bernstam, Funda; Hong, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3 genes, resp.  Binding of neurotrophins to TRK proteins induces receptor dimerization, phosphorylation, and activation of the downstream signaling cascades via PI3K, RAS/MAPK/ERK, and PLC-gamma.  TRK pathway aberrations, including gene fusions, protein overexpression, and single nucleotide alterations, have been implicated in the pathogenesis of many cancer types, with NTRK gene fusions being the most well validated oncogenic events to date.  Although the NTRK gene fusions are infrequent in most cancer types, certain rare tumor types are predominately driven by these events.  Conversely, in more common histologies, such as lung and colorectal cancers, prevalence of the NTRK fusions is well below 5%.  Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations.  Currently, several TRK-targeting compds. are in clin. development.  The ongoing Phase 2 trials with entrectinib and LOXO-101, two of the leading TRK inhibitors, are designed as 'basket trials', inclusive of patients whose tumors harbor NTRK gene fusions, independent of histol.  Addnl. Phase 1 studies of other TRK inhibitors, including MGCD516, PLX7486, DS-6051b, and TSR-011, are underway.  Interim data examg. NTRK-rearranged tumors treated with entrectinib or LOXO-101 demonstrate encouraging activity, with patients achieving rapid and durable responses.  Consequently, both drugs have achieved orphan designation from regulatory agencies, and efforts are underway to further expedite their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozoy77YmUc_LVg90H21EOLACvtfcHk0lhUyXUW74_w-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D&md5=f18f232e6d3c4c9a5d2e398fe60ae7e4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKhotskaya%26aufirst%3DY.%2BB.%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DMills%2BShaw%26aufirst%3DK.%2BR.%2BM.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DD.%2BS.%26atitle%3DTargeting%2520TRK%2520family%2520proteins%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.pharmthera.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kako, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1472</span>, <span class="refDoi"> DOI: 10.1038/nm.3352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnm.3352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24162815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1469-1472&author=A.+Vaishnaviauthor=M.+Capellettiauthor=A.+T.+Leauthor=S.+Kakoauthor=M.+Butaneyauthor=D.+Ercanauthor=S.+Mahaleauthor=K.+D.+Daviesauthor=D.+L.+Aisnerauthor=A.+B.+Pillingauthor=E.+M.+Bergeauthor=J.+Kimauthor=H.+Sasakiauthor=S.+Parkauthor=G.+Kryukovauthor=L.+A.+Garrawayauthor=P.+S.+Hammermanauthor=J.+Haasauthor=S.+W.+Andrewsauthor=D.+Lipsonauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=M.+Varella-Garciaauthor=P.+A.+Janneauthor=R.+C.+Doebele&title=Oncogenic+and+drug-sensitive+NTRK1+rearrangements+in+lung+cancer&doi=10.1038%2Fnm.3352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span></div><div class="casAuthors">Vaishnavi, Aria; Capelletti, Marzia; Le, Anh T.; Kako, Severine; Butaney, Mohit; Ercan, Dalia; Mahale, Sakshi; Davies, Kurtis D.; Aisner, Dara L.; Pilling, Amanda B.; Berge, Eamon M.; Kim, Jhingook; Sasaki, Hidefumi; Park, Seung-il; Kryukov, Gregory; Garraway, Levi A.; Hammerman, Peter S.; Haas, Julia; Andrews, Steven W.; Lipson, Doron; Stephens, Philip J.; Miller, Vince A.; Varella-Garcia, Marileila; Jaenne, Pasi A.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1472</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein).  Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic.  Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth.  Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHNoZGMQLMrVg90H21EOLACvtfcHk0liNqMOUXFDmHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI&md5=23b413826ea700bd831eadbfde270615</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnm.3352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3352%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DKako%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMahale%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKryukov%26aufirst%3DG.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DOncogenic%2520and%2520drug-sensitive%2520NTRK1%2520rearrangements%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1469%26epage%3D1472%26doi%3D10.1038%2Fnm.3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1038/319743a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2F319743a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=2869410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaL28XhvVSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=1986&pages=743-748&author=D.+Martin-Zancaauthor=S.+H.+Hughesauthor=M.+Barbacid&title=A+human+oncogene+formed+by+the+fusion+of+truncated+tropomyosin+and+protein+tyrosine+kinase+sequences&doi=10.1038%2F319743a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences</span></div><div class="casAuthors">Martin-Zanca, Dionisio; Hughes, Stephen H.; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">6056</span>),
    <span class="NLM_cas:pages">743-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A biol. active cDNA clone of a transforming gene present in a human colon carcinoma contains gene sequences of both tropomyosin and a previously unknown tyrosine kinase  [80449-02-1].  The predicted protein (641 amino acids) encoded by this oncogene seems to have been formed by a somatic rearrangement that replaced the extracellular domain of a putative transmembrane receptor by the 1st 221 amino acids of a non-muscle tropomyosin mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0AjUZGDew7Vg90H21EOLACvtfcHk0liBhuoRpE9kaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhvVSqt7g%253D&md5=da5002349ed602cac199727be7149d40</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2F319743a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F319743a0%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DA%2520human%2520oncogene%2520formed%2520by%2520the%2520fusion%2520of%2520truncated%2520tropomyosin%2520and%2520protein%2520tyrosine%2520kinase%2520sequences%26jtitle%3DNature%26date%3D1986%26volume%3D319%26spage%3D743%26epage%3D748%26doi%3D10.1038%2F319743a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaschini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raddrizzani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span> <span> </span><span class="NLM_article-title">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.molonc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24962792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1495-1507&author=E.+Ardiniauthor=R.+Bosottiauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=A.+Somaschiniauthor=R.+Cammarotaauthor=N.+Amboldiauthor=L.+Raddrizzaniauthor=A.+Milaniauthor=P.+Magnaghiauthor=D.+Ballinariauthor=D.+Caseroauthor=F.+Gasparriauthor=P.+Banfiauthor=N.+Avanziauthor=M.+B.+Saccardoauthor=R.+Alzaniauthor=T.+Bandieraauthor=E.+Felderauthor=D.+Donatiauthor=E.+Pesentiauthor=A.+Sartore-Bianchiauthor=M.+Gambacortaauthor=M.+A.+Pierottiauthor=S.+Sienaauthor=S.+Veroneseauthor=A.+Galvaniauthor=A.+Isacchi&title=The+TPM3-NTRK1+rearrangement+is+a+recurring+event+in+colorectal+carcinoma+and+is+associated+with+tumor+sensitivity+to+TRKA+kinase+inhibition&doi=10.1016%2Fj.molonc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span></div><div class="casAuthors">Ardini, Elena; Bosotti, Roberta; Borgia, Andrea Lombardi; De Ponti, Cristina; Somaschini, Alessio; Cammarota, Rosaria; Amboldi, Nadia; Raddrizzani, Laura; Milani, Andrea; Magnaghi, Paola; Ballinari, Dario; Casero, Daniele; Gasparri, Fabio; Banfi, Patrizia; Avanzi, Nilla; Saccardo, Maria B.; Alzani, Rachele; Bandiera, Tiziano; Felder, Eduard; Donati, Daniele; Pesenti, Enrico; Sartore-Bianchi, Andrea; Gambacorta, Marcello; Pierotti, Marco A.; Siena, Salvatore; Veronese, Silvio; Galvani, Arturo; Isacchi, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NTRK1 gene encodes Tropomyosin-related kinase A (TRKA), the high-affinity Nerve Growth Factor Receptor.  NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3-NTRK1) resulting in expression of the oncogenic chimeric protein TPM3-TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC.  The KM12 human CRC cell line expresses the chimeric TPM3-TRKA protein and is hypersensitive to TRKA kinase inhibition.  We report the detailed characterization of the TPM3-NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS-P626, a novel highly potent and selective TRKA inhibitor.  NMS-P626 suppressed TPM3-TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors.  Finally, using quant. reverse transcriptase PCR and immunohistochem. (IHC) we identified the TPM3-NTRK1 rearrangement in a CRC clin. sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-EhukkQ24OrVg90H21EOLACvtfcHk0liBhuoRpE9kaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI&md5=2a9de2410f69e2eb8ff84c9516828984</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DMilani%26aufirst%3DA.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26atitle%3DThe%2520TPM3-NTRK1%2520rearrangement%2520is%2520a%2520recurring%2520event%2520in%2520colorectal%2520carcinoma%2520and%2520is%2520associated%2520with%2520tumor%2520sensitivity%2520to%2520TRKA%2520kinase%2520inhibition%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1495%26epage%3D1507%26doi%3D10.1016%2Fj.molonc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappabianca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A. R.</span></span> <span> </span><span class="NLM_article-title">Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.2217/14796694.1.5.689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2217%2F14796694.1.5.689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16556046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyiu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=689-698&author=A.+Tacconelliauthor=A.+R.+Farinaauthor=L.+Cappabiancaauthor=A.+Gulinoauthor=A.+R.+Mackay&title=Alternative+TrkAIII+splicing%3A+a+potential+regulated+tumor-promoting+switch+and+therapeutic+target+in+neuroblastoma&doi=10.2217%2F14796694.1.5.689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma</span></div><div class="casAuthors">Tacconelli, Antonella; Farina, Antonietta R.; Cappabianca, Lucia; Gulino, Alberto; Mackay, Andrew R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  An assocn. between elevated tyrosine kinase receptor (Trk)-A expression and better prognosis; the absence of mutation-activated TrkA oncogenes; the induction of apoptosis, growth arrest, morphol. differentiation and inhibition of xenograft growth; and angiogenesis by TrkA gene transduction, provide the basis for the current concept of an exclusively tumor-suppressor role for TrkA in the aggressive pediatric tumor, neuroblastoma.  This concept, however, has recently been challenged by the discovery of a novel hypoxia-regulated alternative TrkAIII splice variant, initial data for which suggest predominant expression in advanced-stage neuroblastoma.  TrkAIII exhibits neuroblastoma xenograft tumor-promoting activity assocd. with the induction of a more angiogenic and stress-resistant neuroblastoma phenotype and antagonizes nerve growth factor/TrkAI antioncogenic signaling.  In this short review, the authors integrate this novel information into a modified concept that places alternative TrkA splicing as a potential pivotal regulator of neuroblastoma behavior and identifies the TrkAIII alternative splice variant as a potential biomarker of patient prognosis and novel therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH2ePUWUJFSbVg90H21EOLACvtfcHk0lhFKWKYAqcfBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyiu7fO&md5=54842fe723412f666aec829930979c76</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2217%2F14796694.1.5.689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14796694.1.5.689%26sid%3Dliteratum%253Aachs%26aulast%3DTacconelli%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DA.%2BR.%26aulast%3DCappabianca%26aufirst%3DL.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DMackay%26aufirst%3DA.%2BR.%26atitle%3DAlternative%2520TrkAIII%2520splicing%253A%2520a%2520potential%2520regulated%2520tumor-promoting%2520switch%2520and%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DFuture%2520Oncol.%26date%3D2005%26volume%3D1%26spage%3D689%26epage%3D698%26doi%3D10.2217%2F14796694.1.5.689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.mce.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19883730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2010&pages=44-49&author=A.+Grecoauthor=C.+Mirandaauthor=M.+A.+Pierotti&title=Rearrangements+of+NTRK1+gene+in+papillary+thyroid+carcinoma&doi=10.1016%2Fj.mce.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span></div><div class="casAuthors">Greco, A.; Miranda, C.; Pierotti, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  TRK oncogenes are obsd. in a consistent fraction of papillary thyroid carcinoma (PTC); they arise from the fusion of the 3' terminal sequences of the NTRK1/NGF receptor gene with 5' terminal sequences of various activating genes, such as TPM3, TPR and TFG.  TRK oncoproteins display constitutive tyrosine-kinase activity, leading to in vitro and in vivo transformation.  In this review studies performed during the last 20 years will be summarized.  The following topics will be illustrated: (a) frequency of TRK oncogenes and correlation with radiation and tumor histopathol. features; (b) mol. mechanisms underlying NTRK1 oncogenic rearrangements; (c) mol. and biochem. characterization of TRK oncoproteins, and their mechanism of action; (d) role of activating sequences in the activation of TRK oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGkkW9wYpTLVg90H21EOLACvtfcHk0lhFKWKYAqcfBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D&md5=ea9abddd4191599672958ac3875bf9ae</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRearrangements%2520of%2520NTRK1%2520gene%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2010%26volume%3D321%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.mce.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kralik, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranewitter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesmueller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschurtschenthaler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpold, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webersinke, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia</span>. <i>Diagn. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/1746-1596-6-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1186%2F1746-1596-6-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21401966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=19&author=J.+M.+Kralikauthor=W.+Kranewitterauthor=H.+Boesmuellerauthor=R.+Marschonauthor=G.+Tschurtschenthalerauthor=H.+Rumpoldauthor=K.+Wiesingerauthor=M.+Erdelauthor=A.+L.+Petzerauthor=G.+Webersinke&title=Characterization+of+a+newly+identified+ETV6-NTRK3+fusion+transcript+in+acute+myeloid+leukemia&doi=10.1186%2F1746-1596-6-19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia</span></div><div class="casAuthors">Kralik, Johanna M.; Kranewitter, Wolfgang; Boesmueller, Hans; Marschon, Renate; Tschurtschenthaler, Gertraud; Rumpold, Holger; Wiesinger, Kurt; Erdel, Martin; Petzer, Andreas L.; Webersinke, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>CODEN:
                <span class="NLM_cas:coden">DPIAAA</span>;
        ISSN:<span class="NLM_cas:issn">1746-1596</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Characterization of novel fusion genes in acute leukemia is important for gaining information about leukemia genesis.  We describe the characterization of a new ETV6 fusion gene in acute myeloid leukemia (AML) FAB M0 as a result of an uncommon translocation involving chromosomes 12 and 15.  Methods: The ETV6 locus at 12p13 was shown to be translocated and to constitute the 5' end of the fusion product by ETV6 break apart fluorescence in situ hybridization (FISH).  To identify a fusion partner 3' rapid amplification of cDNA-ends with polymerase chain reaction (RACE PCR) was performed followed by cloning and sequencing.  Results: The NTRK3 gene on chromosome 15 was found to constitute the 3' end of the fusion gene and the underlying ETV6-NTRK3 rearrangement was verified by reverse transcriptase PCR.  No RNA of the reciprocal NTRK3-ETV6 fusion gene could be detected.  Conclusion: We have characterized a novel ETV6-NTRK3 fusion transcript which has not been previously described in AML FAB M0 by FISH and RACE PCR.  ETV6-NTRK3 rearrangements have been described in secretory breast carcinoma and congenital fibrosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5P9PTYZD7rVg90H21EOLACvtfcHk0lgUiZVSJzQRSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCjt7s%253D&md5=4e65d970d478898268f34cfb7a4cc5ac</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1746-1596-6-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1746-1596-6-19%26sid%3Dliteratum%253Aachs%26aulast%3DKralik%26aufirst%3DJ.%2BM.%26aulast%3DKranewitter%26aufirst%3DW.%26aulast%3DBoesmueller%26aufirst%3DH.%26aulast%3DMarschon%26aufirst%3DR.%26aulast%3DTschurtschenthaler%26aufirst%3DG.%26aulast%3DRumpold%26aufirst%3DH.%26aulast%3DWiesinger%26aufirst%3DK.%26aulast%3DErdel%26aufirst%3DM.%26aulast%3DPetzer%26aufirst%3DA.%2BL.%26aulast%3DWebersinke%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520a%2520newly%2520identified%2520ETV6-NTRK3%2520fusion%2520transcript%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DDiagn.%2520Pathol.%26date%3D2011%26volume%3D6%26spage%3D19%26doi%3D10.1186%2F1746-1596-6-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifonov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoppoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danussi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgalev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porrati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegatta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heguy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisapia, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canoll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldape, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finocchiaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prive, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasorella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabadan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, A.</span></span> <span> </span><span class="NLM_article-title">The integrated landscape of driver genomic alterations in glioblastoma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1038/ng.2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fng.2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=23917401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wrt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1141-1149&author=V.+Frattiniauthor=V.+Trifonovauthor=J.+M.+Chanauthor=A.+Castanoauthor=M.+Liaauthor=F.+Abateauthor=S.+T.+Keirauthor=A.+X.+Jiauthor=P.+Zoppoliauthor=F.+Niolaauthor=C.+Danussiauthor=I.+Dolgalevauthor=P.+Porratiauthor=S.+Pellegattaauthor=A.+Heguyauthor=G.+Guptaauthor=D.+J.+Pisapiaauthor=P.+Canollauthor=J.+N.+Bruceauthor=R.+E.+McLendonauthor=H.+Yanauthor=K.+Aldapeauthor=G.+Finocchiaroauthor=T.+Mikkelsenauthor=G.+G.+Priveauthor=D.+D.+Bignerauthor=A.+Lasorellaauthor=R.+Rabadanauthor=A.+Iavarone&title=The+integrated+landscape+of+driver+genomic+alterations+in+glioblastoma&doi=10.1038%2Fng.2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The integrated landscape of driver genomic alterations in glioblastoma</span></div><div class="casAuthors">Frattini, Veronique; Trifonov, Vladimir; Chan, Joseph Minhow; Castano, Angelica; Lia, Marie; Abate, Francesco; Keir, Stephen T.; Ji, Alan X.; Zoppoli, Pietro; Niola, Francesco; Danussi, Carla; Dolgalev, Igor; Porrati, Paola; Pellegatta, Serena; Heguy, Adriana; Gupta, Gaurav; Pisapia, David J.; Canoll, Peter; Bruce, Jeffrey N.; McLendon, Roger E.; Yan, Hai; Aldape, Ken; Finocchiaro, Gaetano; Mikkelsen, Tom; Prive, Gilbert G.; Bigner, Darell D.; Lasorella, Anna; Rabadan, Raul; Iavarone, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1141-1149</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma is one of the most challenging forms of cancer to treat.  Here we describe a computational platform that integrates the anal. of copy no. variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma.  We found mutations with loss of heterozygosity in LZTR1, encoding an adaptor of CUL3-contg. E3 ligase complexes.  Mutations and deletions disrupt LZTR1 function, which restrains the self renewal and growth of glioma spheres that retain stem cell features.  Loss-of-function mutations in CTNND2 target a neural-specific gene and are assocd. with the transformation of glioma cells along the very aggressive mesenchymal phenotype.  We also report recurrent translocations that fuse the coding sequence of EGFR to several partners, with EGFR-SEPT14 being the most frequent functional gene fusion in human glioblastoma.  EGFR-SEPT14 fusions activate STAT3 signaling and confer mitogen independence and sensitivity to EGFR inhibition.  These results provide insights into the pathogenesis of glioblastoma and highlight new targets for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjNGcPWRhHtLVg90H21EOLACvtfcHk0lgIvSa88MonDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wrt7zF&md5=bd2514caccf8b5fd46ef070fe951f7b0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fng.2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2734%26sid%3Dliteratum%253Aachs%26aulast%3DFrattini%26aufirst%3DV.%26aulast%3DTrifonov%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DCastano%26aufirst%3DA.%26aulast%3DLia%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DF.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DJi%26aufirst%3DA.%2BX.%26aulast%3DZoppoli%26aufirst%3DP.%26aulast%3DNiola%26aufirst%3DF.%26aulast%3DDanussi%26aufirst%3DC.%26aulast%3DDolgalev%26aufirst%3DI.%26aulast%3DPorrati%26aufirst%3DP.%26aulast%3DPellegatta%26aufirst%3DS.%26aulast%3DHeguy%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DG.%26aulast%3DPisapia%26aufirst%3DD.%2BJ.%26aulast%3DCanoll%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DJ.%2BN.%26aulast%3DMcLendon%26aufirst%3DR.%2BE.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DAldape%26aufirst%3DK.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DMikkelsen%26aufirst%3DT.%26aulast%3DPrive%26aufirst%3DG.%2BG.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DLasorella%26aufirst%3DA.%26aulast%3DRabadan%26aufirst%3DR.%26aulast%3DIavarone%26aufirst%3DA.%26atitle%3DThe%2520integrated%2520landscape%2520of%2520driver%2520genomic%2520alterations%2520in%2520glioblastoma%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26spage%3D1141%26epage%3D1149%26doi%3D10.1038%2Fng.2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricarte-Filho, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Rendueles, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero-Conde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heguy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">4935</span>– <span class="NLM_lpage">4944</span>, <span class="refDoi"> DOI: 10.1172/JCI69766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1172%2FJCI69766" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=4935-4944&author=J.+C.+Ricarte-Filhoauthor=S.+Liauthor=M.+E.+Garcia-Renduelesauthor=C.+Montero-Condeauthor=F.+Vozaauthor=J.+A.+Knaufauthor=A.+Heguyauthor=A.+Vialeauthor=T.+Bogdanovaauthor=G.+A.+Thomasauthor=C.+E.+Masonauthor=J.+A.+Fagin&title=Identification+of+kinase+fusion+oncogenes+in+post-Chernobyl+radiation-induced+thyroid+cancers&doi=10.1172%2FJCI69766"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1172%2FJCI69766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69766%26sid%3Dliteratum%253Aachs%26aulast%3DRicarte-Filho%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGarcia-Rendueles%26aufirst%3DM.%2BE.%26aulast%3DMontero-Conde%26aufirst%3DC.%26aulast%3DVoza%26aufirst%3DF.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DHeguy%26aufirst%3DA.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DBogdanova%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DG.%2BA.%26aulast%3DMason%26aufirst%3DC.%2BE.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520kinase%2520fusion%2520oncogenes%2520in%2520post-Chernobyl%2520radiation-induced%2520thyroid%2520cancers%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D4935%26epage%3D4944%26doi%3D10.1172%2FJCI69766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeman-Neill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanova, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdokimova, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurnadzy, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tronko, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforov, Y. E.</span></span> <span> </span><span class="NLM_article-title">ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1002/cncr.28484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fcncr.28484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24327398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=799-807&author=R.+J.+Leeman-Neillauthor=L.+M.+Kellyauthor=P.+Liuauthor=A.+V.+Brennerauthor=M.+P.+Littleauthor=T.+I.+Bogdanovaauthor=V.+N.+Evdokimovaauthor=M.+Hatchauthor=L.+Y.+Zurnadzyauthor=M.+N.+Nikiforovaauthor=N.+J.+Yueauthor=M.+Zhangauthor=K.+Mabuchiauthor=M.+D.+Tronkoauthor=Y.+E.+Nikiforov&title=ETV6-NTRK3+is+a+common+chromosomal+rearrangement+in+radiation-associated+thyroid+cancer&doi=10.1002%2Fcncr.28484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer</span></div><div class="casAuthors">Leeman-Neill, Rebecca J.; Kelly, Lindsey M.; Liu, Pengyuan; Brenner, Alina V.; Little, Mark P.; Bogdanova, Tetiana I.; Evdokimova, Viktoria N.; Hatch, Maureen; Zurnadzy, Liudmyla Y.; Nikiforova, Marina N.; Yue, Ning J.; Zhang, Miao; Mabuchi, Kiyohiko; Tronko, Mykola D.; Nikiforov, Yuri E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">799-807</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: In their previous anal. of papillary thyroid carcinomas (PTCs) from an Ukrainian-American cohort that was exposed to iodine-131 (131I) from the Chernobyl accident, the authors identified RET/PTC rearrangements and other driver mutations in 60% of tumors.  Methods: In this study, the remaining mutation-neg. tumors from that cohort were analyzed using RNA sequencing (RNA-Seq) and reverse transcriptase-polymerase chain reaction to identify novel chromosomal rearrangements and to characterize their relation with radiation dose.  Results: The ETS variant gene 6 (ETV6)-neurotrophin receptor 3 (NTRK3) rearrangement (ETV6-NTRK3) was identified by RNA-Seq in a tumor from a patient who received a high 131I dose.  Overall, the rearrangement was detected in 9 of 62 (14.5%) post-Chernobyl PTCs and in 3 of 151 (2%) sporadic PTCs (P = .019).  The most common fusion type was between exon 4 of ETV6 and exon 14 of NTRK3.  The prevalence of ETV6-NTRK3 rearrangement in post-Chernobyl PTCs was assocd. with increasing 131I dose, albeit at borderline significance (P = .126).  The group of rearrangement-pos. PTCs (ETV6-NTRK3, RET/PTC, PAX8-PPARγ) was assocd. with significantly higher dose response compared with the group of PTCs with point mutations (BRAF, RAS; P < .001).  In vitro exposure of human thyroid cells to 1 Gy of 131I and γ-radiation resulted in the formation of ETV6-NTRK3 rearrangement at a rate of 7.9 × 10-6 cells and 3.0 × 10-6 cells, resp.  Conclusions: The authors report the occurrence of ETV6-NTRK3 rearrangements in thyroid cancer and demonstrate that this rearrangement is significantly more common in tumors assocd. with exposure to 131I and has a borderline significant dose response.  Moreover, ETV6-NTRK3 rearrangement can be directly induced in thyroid cells by ionizing radiation in vitro and, thus, may represent a novel mechanism of radiation-induced carcinogenesis.  Cancer 2014;120:799-807. © 2013 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWJqPd2X_b1LVg90H21EOLACvtfcHk0lgIvSa88MonDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVymtbY%253D&md5=848873fbbaa919533fee2208bfad31f7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28484%26sid%3Dliteratum%253Aachs%26aulast%3DLeeman-Neill%26aufirst%3DR.%2BJ.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBrenner%26aufirst%3DA.%2BV.%26aulast%3DLittle%26aufirst%3DM.%2BP.%26aulast%3DBogdanova%26aufirst%3DT.%2BI.%26aulast%3DEvdokimova%26aufirst%3DV.%2BN.%26aulast%3DHatch%26aufirst%3DM.%26aulast%3DZurnadzy%26aufirst%3DL.%2BY.%26aulast%3DNikiforova%26aufirst%3DM.%2BN.%26aulast%3DYue%26aufirst%3DN.%2BJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DMabuchi%26aufirst%3DK.%26aulast%3DTronko%26aufirst%3DM.%2BD.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26atitle%3DETV6-NTRK3%2520is%2520a%2520common%2520chromosomal%2520rearrangement%2520in%2520radiation-associated%2520thyroid%2520cancer%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26spage%3D799%26epage%3D807%26doi%3D10.1002%2Fcncr.28484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Selectivity in neurotrophin signaling: theme and variations</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.26.041002.131421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.neuro.26.041002.131421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12598680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=299-330&author=R.+A.+Segal&title=Selectivity+in+neurotrophin+signaling%3A+theme+and+variations&doi=10.1146%2Fannurev.neuro.26.041002.131421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity in neurotrophin signaling: theme and variations</span></div><div class="casAuthors">Segal, Rosalind A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">299-330</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Neurotrophins are a family of growth factors crit. for the development and functioning of the nervous system.  Although originally identified as neuronal survival factors, neurotrophins elicit many biol. effects, ranging from proliferation to synaptic modulation to axonal pathfinding.  Recent data indicate that the nature of the signaling cascades activated by neurotrophins, and the biol. responses that ensue, are specified not only by the ligand itself but also by the temporal pattern and spatial location of stimulation.  Studies on neurotrophin signaling have revealed variations in the Ras/MAP kinase, phosphatidylinositol 3-kinase, and phospholipase C pathways, which transmit spatial and temporal information.  The anatomy of neurons makes them particularly appropriate for studying how the location and tempo of stimulation det. the signal cascades that are activated by receptor tyrosine kinases such as the Trk receptors.  These signaling variations may represent a general mechanism eliciting specificity in growth factor responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZGcPFtywOLVg90H21EOLACvtfcHk0lhCgHHpsAQgUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSisLo%253D&md5=f585bf86e97bbcf7467d21533b62cda2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.26.041002.131421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.26.041002.131421%26sid%3Dliteratum%253Aachs%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DSelectivity%2520in%2520neurotrophin%2520signaling%253A%2520theme%2520and%2520variations%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D26%26spage%3D299%26epage%3D330%26doi%3D10.1146%2Fannurev.neuro.26.041002.131421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliardini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">The DNA rearrangement that generates the Trk-T3 oncogene involves a nnovel gene on chromosome-3 whose product has a potential coiled-coil domain</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6118</span>– <span class="NLM_lpage">6127</span>, <span class="refDoi"> DOI: 10.1128/MCB.15.11.6118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.15.11.6118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7565764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXovVylu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=6118-6127&author=A.+Grecoauthor=C.+Marianiauthor=C.+Mirandaauthor=A.+Lupasauthor=S.+Pagliardiniauthor=M.+Pomatiauthor=M.+A.+Pierotti&title=The+DNA+rearrangement+that+generates+the+Trk-T3+oncogene+involves+a+nnovel+gene+on+chromosome-3+whose+product+has+a+potential+coiled-coil+domain&doi=10.1128%2FMCB.15.11.6118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain</span></div><div class="casAuthors">Greco, Angela; Mariani, Cristina; Miranda, Claudia; Lupas, Andrei; Pagliardini, Sonia; Pomati, Mauro; Pierotti, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6118-27</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Oncogenic rearrangements of the NTRK1 gene (also designated TRKA), encoding one of the receptors for nerve growth factor, are frequently detected in thyroid carcinomas.  Such rearrangements fuse the NTRK1 tyrosine kinase domain to 5'-end sequences belonging to different genes.  In previously reported studies the authors have demonstrated that NTRK1 oncogenic activation involves two genes, TPM3 and TPR, both localized similarly to the receptor tyrosine kinase, on the q arm of chromosome 1.  Here the authors report the characterization of a novel NTRK1-derived thyroid oncogene, named TRK-T3.  A cDNA clone, capable of transforming activity, was isolated from a transformant cell line.  Sequence anal. revealed that TRK-T3 contains 1412 nucleotides of NTRK1 preceded by 598 nucleotides belonging to a novel gene that the authors have named TFG (TRK-fused gene).  The TRK-T3 amino acid sequence displays, within the TFG region, a coiled-coil motif that could endow the oncoprotein with the capability to form complexes.  The TRK-T3 oncogene encodes a 68-kDa cytoplasmic protein reacting with NTRK1-specific antibodies.  By sedimentation gradient expts. the TRK-T3 oncoprotein was shown to form, in vivo, multimeric complexes, most likely trimers or tetramers.  The TFG gene is ubiquitously expressed and is located on chromosome 3.  The breakpoint producing the TRK-T3 oncogene occurs within exons of both the TFG gene and the NTRK1 gene and produces a chimeric exon that undergoes alternative splicing.  Mol. anal. of the NTRK1 rearranged fragments indicated that the chromosomal rearrangement is reciprocal and balanced and involves loss of a few nucleotides of germ line sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpcwCHCIAp7Vg90H21EOLACvtfcHk0lgsjOVulZa9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVylu7s%253D&md5=e2a680bfd17f90e40faf4ed23baf4c98</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.11.6118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.11.6118%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DC.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DLupas%26aufirst%3DA.%26aulast%3DPagliardini%26aufirst%3DS.%26aulast%3DPomati%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DThe%2520DNA%2520rearrangement%2520that%2520generates%2520the%2520Trk-T3%2520oncogene%2520involves%2520a%2520nnovel%2520gene%2520on%2520chromosome-3%2520whose%2520product%2520has%2520a%2520potential%2520coiled-coil%2520domain%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26spage%3D6118%26epage%3D6127%26doi%3D10.1128%2FMCB.15.11.6118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Identification and biochemical characterization of p70TRK, product of the human TRK oncogene</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">6707</span>– <span class="NLM_lpage">6711</span>, <span class="refDoi"> DOI: 10.1073/pnas.84.19.6707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.84.19.6707" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=6707-6711&author=G.+Mitraauthor=D.+Martin-Zancaauthor=M.+Barbacid&title=Identification+and+biochemical+characterization+of+p70TRK%2C+product+of+the+human+TRK+oncogene&doi=10.1073%2Fpnas.84.19.6707"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.84.19.6707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.84.19.6707%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DG.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DIdentification%2520and%2520biochemical%2520characterization%2520of%2520p70TRK%252C%2520product%2520of%2520the%2520human%2520TRK%2520oncogene%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1987%26volume%3D84%26spage%3D6707%26epage%3D6711%26doi%3D10.1073%2Fpnas.84.19.6707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliardini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1201596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9488046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlGgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=809-816&author=A.+Grecoauthor=L.+Fusettiauthor=C.+Mirandaauthor=R.+Villaauthor=S.+Zanottiauthor=S.+Pagliardiniauthor=M.+A.+Pierotti&title=Role+of+the+TFG+N-terminus+and+coiled-coil+domain+in+the+transforming+activity+of+the+thyroid+TRK-T3+oncogene&doi=10.1038%2Fsj.onc.1201596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene</span></div><div class="casAuthors">Greco, Angela; Fusetti, Lisa; Miranda, Claudia; Villa, Riccardo; Zanotti, Simona; Pagliardini, Sonia; Pierotti, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-816</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The thyroid TRK-T3 oncogene results from the fusion of the tyrosine kinase (TK) domain of NTRK1 (one of the receptors for the Nerve Growth Factor) on chromosome 1 to sequences of a novel gene, TFG, on chromosome 3.  The 68 kDa TRK-T3 fusion oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform mouse NIH3T3 cells.  The TFG portion of TRK-T3 contains a coiled-coil domain most likely responsible for the constitutive, ligand-independent activation of the receptor tyrosine kinase activity.  It has been previously shown that TRK-T3 oncoprotein forms, in vivo, complexes of three or four mols.  By mean of different exptl. approaches, it is shown here that TRK-T3 activity depends on oligomers formation.  In addn., the anal. of different TRK-T3 mutants indicates that the TFG coiled-coil domain and its N-terminal region are both required for the activation and the fully transforming activity of the TRK-T3 oncoprotein, although, most likely, they play a role in different steps of the transforming process.  The deletion of the coiled-coil domain abrogates the oligomers formation leading to a constitutive activation; the deletion of the N-terminal region, although not affecting phosphorylation and complexes formation, abrogates transformation, thus suggesting a role in cellular localization and/or interaction with substrata.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVVcHfyYqbtbVg90H21EOLACvtfcHk0lgodTVOSVbksA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlGgtL4%253D&md5=916a02812313984aa591f5b164fd67a5</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201596%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DFusetti%26aufirst%3DL.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DVilla%26aufirst%3DR.%26aulast%3DZanotti%26aufirst%3DS.%26aulast%3DPagliardini%26aufirst%3DS.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520the%2520TFG%2520N-terminus%2520and%2520coiled-coil%2520domain%2520in%2520the%2520transforming%2520activity%2520of%2520the%2520thyroid%2520TRK-T3%2520oncogene%26jtitle%3DOncogene%26date%3D1998%26volume%3D16%26spage%3D809%26epage%3D816%26doi%3D10.1038%2Fsj.onc.1201596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gysin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies for targeting ras proteins</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1177/1947601911412376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1177%2F1947601911412376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21779505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=359-372&author=S.+Gysinauthor=M.+Saltauthor=A.+Youngauthor=F.+McCormick&title=Therapeutic+strategies+for+targeting+ras+proteins&doi=10.1177%2F1947601911412376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies for targeting Ras proteins</span></div><div class="casAuthors">Gysin, Stephan; Salt, Megan; Young, Amy; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-372</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ras genes are frequently activated in cancer.  Attempts to develop drugs that target mutant Ras proteins have, so far, been unsuccessful.  Tumors bearing these mutations, therefore, remain among the most difficult to treat.  Most efforts to block activated Ras have focused on pathways downstream.  Drugs that inhibit Raf kinase have shown clin. benefit in the treatment of malignant melanoma.  However, these drugs have failed to show clin. benefit in Ras mutant tumors.  It remains unclear to what extent Ras depends on Raf kinase for transforming activity, even though Raf proteins bind directly to Ras and are certainly major effectors of Ras action in normal cells and in development.  Furthermore, Raf kinase inhibitors can lead to paradoxical activation of the MAPK pathway.  MEK inhibitors block the Ras-MAPK pathway, but often activate the PI3'-kinase, and have shown little clin. benefit as single agents.  This activation is mediated by EGF-R and other receptor tyrosine kinases through relief of a neg. feedback loop from ERK.  Drug combinations that target multiple points within the Ras signaling network are likely to be necessary to achieve substantial clin. benefit.  Other effectors may also contribute to Ras signaling and provide a source of targets.  In addn., unbiased screens for genes necessary for Ras transformation have revealed new potential targets and have added to our understanding of Ras cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTnzEvjaufXrVg90H21EOLACvtfcHk0li4BojQH5lHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D&md5=f680dda525256c8388e417d45ebe4299</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1177%2F1947601911412376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601911412376%26sid%3Dliteratum%253Aachs%26aulast%3DGysin%26aufirst%3DS.%26aulast%3DSalt%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DTherapeutic%2520strategies%2520for%2520targeting%2520ras%2520proteins%26jtitle%3DGenes%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D359%26epage%3D372%26doi%3D10.1177%2F1947601911412376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oskam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Molecular and biochemical characterization of the human trk proto-oncogene</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1128/MCB.9.1.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.9.1.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=2927393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaL1MXmtV2ru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1989&pages=24-33&author=D.+Martin-Zancaauthor=R.+Oskamauthor=G.+Mitraauthor=T.+Copelandauthor=M.+Barbacid&title=Molecular+and+biochemical+characterization+of+the+human+trk+proto-oncogene&doi=10.1128%2FMCB.9.1.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and biochemical characterization of the human trk proto-oncogene</span></div><div class="casAuthors">Martin-Zanca, Dionisio; Oskam, Ralph; Mitra, Gopa; Copeland, Terry; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">Mol. anal. of the human trk oncogene, a transforming gene isolated from a colon biopsy, revealed the existence of a novel member of the tyrosine kinase gene family.  This locus codes for a protein of 790 amino acid residues that has several features characteristic of cell surface receptors.  They include (i) a 32-amino-acid-long putative signal peptide, (ii) an amino-terminal moiety (residues 33 to 407) rich in consensus sites for N-glycosylation, (iii) a transmembrane domain, (iv) a kinase catalytic region highly related to that of other tyrosine kinases, and (v) a very short (15 residue) carboxy-terminal tail.  Residues 1 to 392 were absent in the trk oncogene, as they were replaced by tropomyosin sequences.  However, no other differences were found between the transforming and nontransforming trk alleles (residues 392 to 790), suggesting that no addnl. mutations are required to activate the transforming potential of this gene.  The human trk proto-oncogene codes for a 140,000-dalton glycoprotein, designated gp140proto-trk.  However, its primary translational product is a 110,000-dalton glycoprotein which becomes immediately glycosylated, presumably during its translocation into the endoplasmic reticulum.  This mol., designated gp110proto-trk, is further glycosylated to yield the mature form, gp140proto-trk.  Both gp110proto-trk and gp140proto-trk proteins possess in vitro kinase activity specific for tyrosine residues.  Finally, iodination of intact NIH 3T3 cells expressing trk proto-oncogene products indicated that only the mature form, gp140proto-trk, cross the plasma membrane, becoming exposed to the outside of the cell.  These results indicate that the product of the human trk locus is a novel tyrosine kinase cell surface receptor for an as yet unknown ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru0x_s3mmlXrVg90H21EOLACvtfcHk0li4BojQH5lHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtV2ru78%253D&md5=6b98f810db97ba934de4c5e6a848abd9</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FMCB.9.1.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.9.1.24%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DOskam%26aufirst%3DR.%26aulast%3DMitra%26aufirst%3DG.%26aulast%3DCopeland%26aufirst%3DT.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMolecular%2520and%2520biochemical%2520characterization%2520of%2520the%2520human%2520trk%2520proto-oncogene%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1989%26volume%3D9%26spage%3D24%26epage%3D33%26doi%3D10.1128%2FMCB.9.1.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1999.2816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1006%2Fjmbi.1999.2816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1999&pages=149-159&author=M.+H.+Ultschauthor=C.+Wiesmannauthor=L.+C.+Simmonsauthor=J.+Henrichauthor=M.+Yangauthor=D.+Reillyauthor=S.+H.+Bassauthor=A.+M.+de+Vos&title=Crystal+structures+of+the+neurotrophin-binding+domain+of+TrkA%2C+TrkB+and+TrkC&doi=10.1006%2Fjmbi.1999.2816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.2816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.2816%26sid%3Dliteratum%253Aachs%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DSimmons%26aufirst%3DL.%2BC.%26aulast%3DHenrich%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DReilly%26aufirst%3DD.%26aulast%3DBass%26aufirst%3DS.%2BH.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structures%2520of%2520the%2520neurotrophin-binding%2520domain%2520of%2520TrkA%252C%2520TrkB%2520and%2520TrkC%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D290%26spage%3D149%26epage%3D159%26doi%3D10.1006%2Fjmbi.1999.2816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>401</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/43705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2F43705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10490030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=184-188&author=C.+Wiesmannauthor=M.+H.+Ultschauthor=S.+H.+Bassauthor=A.+M.+de+Vos&title=Crystal+structure+of+nerve+growth+factor+in+complex+with+the+ligand-binding+domain+of+the+TrkA+receptor&doi=10.1038%2F43705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor</span></div><div class="casAuthors">Wiesmann, Christian; Ultsch, Mark H.; Bass, Steven H.; De Vos, Abraham M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">184-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Nerve growth factor (NGF) is involved in a variety of processes involving signaling, such as cell differentiation and survival, growth cessation and apoptosis of neurons.  These events are mediated by NGF as a result of binding to its two cell-surface receptors, TrkA and p75.  TrkA is a receptor with tyrosine kinase activity that forms a high-affinity binding site for NGF.  Of the five domains comprising its extracellular portion, the Ig-like domain proximal to the membrane (TrkA-d5 domain) is necessary and sufficient for NGF binding.  Here we present the crystal structure of human NGF in complex with human TrkA-d5 at 2.2 Å resoln.  The ligand-receptor interface consists of two patches of similar size.  One patch involves the central β-sheet that forms the core of the homodimeric NGF mol. and the loops at the carboxy-terminal pole of TrkA-d5.  The second patch comprises the amino-terminal residues of NGF, which adopt a helical conformation upon complex formation, packing against the 'ABED' sheet of TrkA-d5.  The structure is consistent with results from mutagenesis expts. for all neurotrophins, and indicates that the first patch may constitute a conserved binding motif for all family members, whereas the second patch is specific for the interaction between NGF and TrkA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLzeWkHXAgWrVg90H21EOLACvtfcHk0lhQkYvZAKPLrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrs%253D&md5=3562e557288cf0c986b7bcb42258b59c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2F43705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43705%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DBass%26aufirst%3DS.%2BH.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520nerve%2520growth%2520factor%2520in%2520complex%2520with%2520the%2520ligand-binding%2520domain%2520of%2520the%2520TrkA%2520receptor%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D184%26epage%3D188%26doi%3D10.1038%2F43705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweiger, M.</span></span> <span> </span><span class="NLM_article-title">A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1811</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1656363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK38XisVKh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=1807-1811&author=R.+Schneiderauthor=M.+Schweiger&title=A+novel+modular+mosaic+of+cell+adhesion+motifs+in+the+extracellular+domains+of+the+neurogenic+trk+and+trkB+tyrosine+kinase+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors</span></div><div class="casAuthors">Schneider, R.; Schweiger, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1807-11</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The extracellular domains of the human trk protooncogene and the closely homologous murine trkB share 2 highly conserved regions as well as several invariant cysteines which are supposed to be important for ligand recognition.  Detailed comparative sequence analyses have now revealed the presence of a novel combination of distinct cell adhesion motifs corresponding precisely with these conserved regions.  The N-terminal part consists of an array of 3 tandem leucine-rich motifs of 24 amino acids which is flanked by 2 distinct cysteine clusters.  Significantly homologous structural features are found in the toll gene product of Drosophila, a transmembrane protein mediating specific cell adhesion events involved in the dorsoventral embryonic pattern formation.  Directly adjacent to these structures two repeats of the Ig-like C2 type were identified, which are significantly similar to repeats found in the neural cell adhesion mols. (N-CAMs) and in the platelet-derived growth factor receptor (PDGFR)-like tyrosine kinase receptor family.  The findings indicate that the trk/trkB protein tyrosine kinase receptors are involved in the transmembrane signalling of growth factor binding as well as of specific cell adhesion events during neuronal development.  Addnl., it is proposed that the specifically expressed truncated forms of the trkB receptor, lacking the tyrosine kinase domain, are functioning as neural cell adhesion mols.  The knowledge of this domain structure will facilitate the elucidation of the mol. reasons why alterations in the extracellular region lead to oncogenic activation of the human trk protooncogene, which is a major cause of papillary thyroid carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKoCn1JzNpG7Vg90H21EOLACvtfcHk0ljCCIxHCLJtkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVKh&md5=87ec0daabaccbe4541b69616771bec48</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DSchweiger%26aufirst%3DM.%26atitle%3DA%2520novel%2520modular%2520mosaic%2520of%2520cell%2520adhesion%2520motifs%2520in%2520the%2520extracellular%2520domains%2520of%2520the%2520neurogenic%2520trk%2520and%2520trkB%2520tyrosine%2520kinase%2520receptors%26jtitle%3DOncogene%26date%3D1991%26volume%3D6%26spage%3D1807%26epage%3D1811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geetha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rege, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, J. R.</span></span> <span> </span><span class="NLM_article-title">Nerve growth factor receptor TrkA, a new receptor in insulin signaling pathway in PC12 cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">23807</span>– <span class="NLM_lpage">23813</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.436279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.M112.436279" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=23807-23813&author=T.+Geethaauthor=S.+D.+Regeauthor=S.+E.+Mathewsauthor=S.+O.+Meakinauthor=M.+F.+Whiteauthor=J.+R.+Babu&title=Nerve+growth+factor+receptor+TrkA%2C+a+new+receptor+in+insulin+signaling+pathway+in+PC12+cells&doi=10.1074%2Fjbc.M112.436279"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.436279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.436279%26sid%3Dliteratum%253Aachs%26aulast%3DGeetha%26aufirst%3DT.%26aulast%3DRege%26aufirst%3DS.%2BD.%26aulast%3DMathews%26aufirst%3DS.%2BE.%26aulast%3DMeakin%26aufirst%3DS.%2BO.%26aulast%3DWhite%26aufirst%3DM.%2BF.%26aulast%3DBabu%26aufirst%3DJ.%2BR.%26atitle%3DNerve%2520growth%2520factor%2520receptor%2520TrkA%252C%2520a%2520new%2520receptor%2520in%2520insulin%2520signaling%2520pathway%2520in%2520PC12%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D23807%26epage%3D23813%26doi%3D10.1074%2Fjbc.M112.436279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hempstead, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">The trk proto-oncogene product: a signal transducing receptor for nerve growth factor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>252</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1126/science.1850549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.1850549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1850549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXisVWgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1991&pages=554-558&author=D.+R.+Kaplanauthor=B.+L.+Hempsteadauthor=D.+Martin-Zancaauthor=M.+V.+Chaoauthor=L.+F.+Parada&title=The+trk+proto-oncogene+product%3A+a+signal+transducing+receptor+for+nerve+growth+factor&doi=10.1126%2Fscience.1850549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The trk proto-oncogene product:  a signal transducing receptor for nerve growth factor</span></div><div class="casAuthors">Kaplan, David R.; Hempstead, Barbara L.; Martin-Zanca, Dionisio; Chao, Moses V.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">252</span>
        (<span class="NLM_cas:issue">5005</span>),
    <span class="NLM_cas:pages">554-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The trk proto-oncogene encodes a 140-kilodalton, membrane-spanning protein tyrosine kinase (p140prototrk) that is expressed only in neural tissues.  Nerve growth factor (NGF) stimulates phosphorylation of p140prototrk in neural cell lines and in embσyonic dorsal root ganglia.  Affinity crosslinking and equil. binding expts. with 125I-labeled NGF indicate that p140prototrk binds NGF specifically in cultured cells with a dissocn. const. of 10-9 M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOsZ0C6-OsXrVg90H21EOLACvtfcHk0lhlZQUlyIXnNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVWgtrg%253D&md5=5daf16d6938c40bbeb4c44fc58a5df87</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1126%2Fscience.1850549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1850549%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DHempstead%26aufirst%3DB.%2BL.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DChao%26aufirst%3DM.%2BV.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DThe%2520trk%2520proto-oncogene%2520product%253A%2520a%2520signal%2520transducing%2520receptor%2520for%2520nerve%2520growth%2520factor%26jtitle%3DScience%26date%3D1991%26volume%3D252%26spage%3D554%26epage%3D558%26doi%3D10.1126%2Fscience.1850549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Squinto, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stitt, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RadzieJewski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masiakowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furth, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distefano, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">TrkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90395-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990395-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1710174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXks1Gnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=885-893&author=S.+P.+Squintoauthor=T.+N.+Stittauthor=T.+H.+Aldrichauthor=S.+Davisauthor=S.+M.+Blancoauthor=C.+RadzieJewskiauthor=D.+J.+Glassauthor=P.+Masiakowskiauthor=M.+E.+Furthauthor=D.+M.+Valenzuelaauthor=P.+S.+Distefanoauthor=G.+D.+Yancopoulos&title=TrkB+encodes+a+functional+receptor+for+brain-derived+neurotrophic+factor+and+neurotrophin-3+but+not+nerve+growth+factor&doi=10.1016%2F0092-8674%2891%2990395-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB encodes a functional receptor for brain-derived neurotropic factor and neurotrophin-3 but not nerve growth factor</span></div><div class="casAuthors">Squinto, Stephen P.; Stitt, Trevor N.; Aldrich, Thomas H.; Davis, Samuel; Bianco, Stella M.; Radziejewski, Czeslaw; Glass, David J.; Masiakowski, Piotr; Furth, Mark E.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">885-93</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A variety of findings seem to functionally link brain-derived neurotropic factor (BDNF) and neurotrophin-3 (NT-3), while distinguishing both of these factors from the third member of the neurotrophin family, nerve growth factor (NGF).  It is demonstrated that all 3 of these neuronal survival mols. bind similarly to the low affinity NGF receptor, but that BDNF and NT-3, unlike NGF, do not act via the high affinity NGF receptor.  However, both BDNF and NT-3, but not NGF, bind to full-length and truncated forms of a receptor-like tyrosine kinase, trkB, for which no ligand had previously been identified.  In addn. to binding BDNF and NT-3, trkB can mediate functional responses to both of these neurotrophins when it is expressed in PC12 cells, although BDNF appears to be the more effective ligand.  Thus trkB encodes an essential component of a functional receptor for BDNF and NT-3, but not for NGF.  Further evidence predicts the existence of addnl. functional receptors for the neurotrophins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqElX9eizlBwLVg90H21EOLACvtfcHk0li49bmCQDbUPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXks1Gnur4%253D&md5=f00debdf449455a7105f172e3c088cdd</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990395-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990395-F%26sid%3Dliteratum%253Aachs%26aulast%3DSquinto%26aufirst%3DS.%2BP.%26aulast%3DStitt%26aufirst%3DT.%2BN.%26aulast%3DAldrich%26aufirst%3DT.%2BH.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DBlanco%26aufirst%3DS.%2BM.%26aulast%3DRadzieJewski%26aufirst%3DC.%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DMasiakowski%26aufirst%3DP.%26aulast%3DFurth%26aufirst%3DM.%2BE.%26aulast%3DValenzuela%26aufirst%3DD.%2BM.%26aulast%3DDistefano%26aufirst%3DP.%2BS.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DTrkB%2520encodes%2520a%2520functional%2520receptor%2520for%2520brain-derived%2520neurotrophic%2520factor%2520and%2520neurotrophin-3%2520but%2520not%2520nerve%2520growth%2520factor%26jtitle%3DCell%26date%3D1991%26volume%3D65%26spage%3D885%26epage%3D893%26doi%3D10.1016%2F0092-8674%2891%2990395-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanduri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">The trk proto-oncogene encodes a receptor for nerve growth factor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90419-Y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990419-Y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1849459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXisVWgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=189-197&author=R.+Kleinauthor=S.+Q.+Jingauthor=V.+Nanduriauthor=E.+O%E2%80%99Rourkeauthor=M.+Barbacid&title=The+trk+proto-oncogene+encodes+a+receptor+for+nerve+growth+factor&doi=10.1016%2F0092-8674%2891%2990419-Y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The trk proto-oncogene encodes a receptor for nerve growth factor</span></div><div class="casAuthors">Klein, Ruediger; Jing, Shuqian; Nanduri, Venkata; O'Rourke, Edward; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-97</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Two classes of receptors with distinct affinities for nerve growth factor (NGF) have been identified.  The low affinity receptor (Kd ≈ 10-9-10-8M) is a cysteine-rich glycoprotein encoded by the previously characterized LNGFR gene.  The structural nature of the high affinity receptor (Kd ≈ 10-10M) has yet to be established.  The product of the human trk proto-oncogene (gp140trk) bound NGF with high affinity.  Moreover, NGF could be chem. cross-linked to the endogenous gp140trk present in rat PC12 pheochromocytoma cells, as well as to gp140trk ectopically expressed in mouse fibroblasts and in insect Sf9 cells.  High affinity binding of NGF to gp140trk could occur in the absence of low affinity LNGFR receptors, at least in nonneural cells.  Addn. of NGF to PC12 cells elicited rapid phosphorylation of gp140trk on tyrosine residues and stimulated its tyrosine kinase activity.  Apparently, gp14-trk is a functional NGF receptor that mediates at least some of the signal transduction processes initiated by this neurotropic factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlUBY2nUNMtLVg90H21EOLACvtfcHk0lhDTzx1P7nNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVWgs7Y%253D&md5=362cd01ed7fdf258cfe7f59169b6b5ee</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990419-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990419-Y%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DS.%2BQ.%26aulast%3DNanduri%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DE.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DThe%2520trk%2520proto-oncogene%2520encodes%2520a%2520receptor%2520for%2520nerve%2520growth%2520factor%26jtitle%3DCell%26date%3D1991%26volume%3D65%26spage%3D189%26epage%3D197%26doi%3D10.1016%2F0092-8674%2891%2990419-Y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamballe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90442-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990442-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1653651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK38Xmt12jsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1991&pages=967-979&author=F.+Lamballeauthor=R.+Kleinauthor=M.+Barbacid&title=TrkC%2C+a+new+member+of+the+trk+family+of+tyrosine+protein+kinases%2C+is+a+receptor+for+neurotrophin-3&doi=10.1016%2F0092-8674%2891%2990442-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3</span></div><div class="casAuthors">Lamballe, Fabienne; Klein, Rudiger; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">967-79</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The isolation and mol. characterization of trkC, a new member of the trk family of tyrosine protein kinase genes is reported.  Gene trkC is preferentially expressed in the brain.  In situ hybridization studies revealed trkC transcripts in the hippocampus, cerebral cortex, and the granular cell layer of the cerebellum.  The product of the trkC gene was identified as a glycoprotein of 145,000 daltons, gp145trkC, which is equally related to the previously characterized gp140trk and gp145trkB tyrosine kinases.  Glycoprotein gp145trkC is a functional receptor for neurotrophin-3 (NT-3).  However, gp145trkC does not bind the highly related neurotrophic factors, NGF or BDNF.  In proliferating cells, the interaction between gp145trkC and NT-3 elicits a more efficient biol. response than when NT-3 binds to its other receptors, gp140trk and gp145trkB.  These results indicate that gp145trkC may play an important role in mediating the neurotrophic effects of NT-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp1C6bvPklNLVg90H21EOLACvtfcHk0lhDTzx1P7nNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xmt12jsro%253D&md5=8aa49b5b94d3f1f337ae097d246e8e9e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990442-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990442-2%26sid%3Dliteratum%253Aachs%26aulast%3DLamballe%26aufirst%3DF.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DTrkC%252C%2520a%2520new%2520member%2520of%2520the%2520trk%2520family%2520of%2520tyrosine%2520protein%2520kinases%252C%2520is%2520a%2520receptor%2520for%2520neurotrophin-3%26jtitle%3DCell%26date%3D1991%26volume%3D66%26spage%3D967%26epage%3D979%26doi%3D10.1016%2F0092-8674%2891%2990442-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobley, W. C.</span></span> <span> </span><span class="NLM_article-title">Early BDNF, NT-3, and NT-4 signaling events</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1006/exnr.1999.7148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1006%2Fexnr.1999.7148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10486198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVWqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=1999&pages=297-308&author=E.+C.+Yuenauthor=W.+C.+Mobley&title=Early+BDNF%2C+NT-3%2C+and+NT-4+signaling+events&doi=10.1006%2Fexnr.1999.7148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Early BDNF, NT-3, and NT-4 Signaling Events</span></div><div class="casAuthors">Yuen, Eric C.; Mobley, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Much more is known about nerve growth factor (NGF) signaling than that initiated by brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), or NT-4.  The authors sought to study early BDNF, NT-3, and NT-4 signaling events.  Using TrkB-expressing cells, the authors found that BDNF and NT-4 individually induced tyrosine phosphorylation of TrkB in a dose-dependent fashion.  At maximally effective concns., BDNF or NT-4 induced robust TrkB tyrosine phosphorylation at 5 min; this progressively declined at 15, 30, and 60 min.  Using immunopptn., PI3-kinase and tyrosine phosphorylated PLC-γ1 and SHC were shown to be assocd. with tyrosine phosphorylated TrkB in response to both BDNF and NT-4.  BDNF and NT-4 induced similar intensities of phosphorylation of TrkB and signaling intermediates at equiv. doses.  NT-3 treatment of TrkC-expressing cells induced very similar patterns for induction of TrkC tyrosine phosphorylation and recruitment of signaling intermediates.  BDNF, NT-3, and NT-4 caused rapid tyrosine phosphorylation of ERK and SNT.  These data suggest that the earliest signaling events for BDNF, NT-3, and NT-4 are very similar to those for NGF.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHikLwhhyc7Vg90H21EOLACvtfcHk0lj0dewZre33Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVWqsL4%253D&md5=f48a52261fc456fa4572a57fcfb524f2</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1006%2Fexnr.1999.7148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.1999.7148%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DE.%2BC.%26aulast%3DMobley%26aufirst%3DW.%2BC.%26atitle%3DEarly%2520BDNF%252C%2520NT-3%252C%2520and%2520NT-4%2520signaling%2520events%26jtitle%3DExp.%2520Neurol.%26date%3D1999%26volume%3D159%26spage%3D297%26epage%3D308%26doi%3D10.1006%2Fexnr.1999.7148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crenne, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span> <span> </span><span class="NLM_article-title">The crystal structures of trkA and trkB suggest key regions for achieving selective inhibition</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2012.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.jmb.2012.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22902478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=439-453&author=T.+Bertrandauthor=M.+Kotheauthor=J.+Liuauthor=A.+Dupuyauthor=A.+Rakauthor=P.+F.+Berneauthor=S.+Davisauthor=T.+Gladyshevaauthor=C.+Valtreauthor=J.+Y.+Crenneauthor=M.+Mathieu&title=The+crystal+structures+of+trkA+and+trkB+suggest+key+regions+for+achieving+selective+inhibition&doi=10.1016%2Fj.jmb.2012.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition</span></div><div class="casAuthors">Bertrand, T.; Kothe, M.; Liu, J.; Dupuy, A.; Rak, A.; Berne, P. F.; Davis, S.; Gladysheva, T.; Valtre, C.; Crenne, J. Y.; Mathieu, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-453</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Trk family of neurotrophin receptors, which includes the three highly homologous proteins TrkA, TrkB and TrkC, is strongly assocd. with central and peripheral nervous system processes.  Trk proteins are also of interest in oncol., since Trk activation has been obsd. in several cancer types.  While Trk kinases are attractive oncol. targets, selectivity might be more of an issue than for other kinases due to potential CNS side effects if several Trk kinases are simultaneously targeted.  In order to address this issue, we present here the first structures of human TrkA and TrkB kinase domains and three complexes between TrkB and Trk inhibitors.  These structures reveal different conformations of the kinase domain and suggest new regions of selectivity among the Trk family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryh_7mc93WjLVg90H21EOLACvtfcHk0lj0dewZre33Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN&md5=39409144c4655d93164a881cc28a6115</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDupuy%26aufirst%3DA.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DBerne%26aufirst%3DP.%2BF.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DGladysheva%26aufirst%3DT.%26aulast%3DValtre%26aufirst%3DC.%26aulast%3DCrenne%26aufirst%3DJ.%2BY.%26aulast%3DMathieu%26aufirst%3DM.%26atitle%3DThe%2520crystal%2520structures%2520of%2520trkA%2520and%2520trkB%2520suggest%2520key%2520regions%2520for%2520achieving%2520selective%2520inhibition%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D423%26spage%3D439%26epage%3D453%26doi%3D10.1016%2Fj.jmb.2012.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. H.</span></span> <span> </span><span class="NLM_article-title">Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.2174/0929867043455792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2174%2F0929867043455792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15032722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFWgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=663-673&author=M.+Cherryauthor=D.+H.+Williams&title=Recent+kinase+and+kinase+inhibitor+X-ray+structures%3A+mechanisms+of+inhibition+and+selectivity+insights&doi=10.2174%2F0929867043455792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Recent kinase and kinase inhibitor x-ray structures: mechanisms of inhibition and selectivity insights</span></div><div class="casAuthors">Cherry, M.; Williams, D. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">663-673</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent years have seen an explosion in the no. of publicly available x-ray crystal structures of protein kinases.  These structures have provided a wealth of information on the regulatory mechanisms, conformational plasticity and drugability of this important family of enzymes.  Drawing upon structural information, new insights into the development of protein kinase inhibitors are discussed including de-novo design, mol. templates for ATP competitive inhibitors and alternative mechanisms of inhibition.  The highly conserved nature of the ATP binding site is of central concern to drug development and the concept of a selectivity profile has arisen with structure-based design emerging as a key tool for addressing the challenges of specificity.  In addn., protein-ligand complexes, where the enzyme is in an inactive conformation, signify an alternate approach to protein kinase inhibition.  The belief that an inactive kinase presents a less conserved target is reviewed using observations on the structural changes occurring during protein kinase regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB19ovXBL1mrVg90H21EOLACvtfcHk0li0gUnakBbSuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFWgs7w%253D&md5=63c621c012a6e1cc9f795565580d7492</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2174%2F0929867043455792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043455792%26sid%3Dliteratum%253Aachs%26aulast%3DCherry%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26atitle%3DRecent%2520kinase%2520and%2520kinase%2520inhibitor%2520X-ray%2520structures%253A%2520mechanisms%2520of%2520inhibition%2520and%2520selectivity%2520insights%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D663%26epage%3D673%26doi%3D10.2174%2F0929867043455792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Nerve growth-factor mediates signal transduction through Trk homodimer receptors</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1079</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(92)90066-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0896-6273%2892%2990066-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1281417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVCht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1992&pages=1067-1079&author=S.+Q.+Jingauthor=P.+Tapleyauthor=M.+Barbacid&title=Nerve+growth-factor+mediates+signal+transduction+through+Trk+homodimer+receptors&doi=10.1016%2F0896-6273%2892%2990066-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Nerve growth factor mediates signal transduction through trk homodimer receptors</span></div><div class="casAuthors">Jing, Shuqian; Tapley, Peter; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1067-79</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">The mol. nature of the high affinity nerve growth factor (NGF) receptors was investigated by using cell lines expressing gp75LNGFR and gp140trk.  Gp75LNGFR and gp140trk. interact with NGF independently and that only gp140trk mediates NGF signaling.  NGF binds to gp140trk with picomolar affinity and induces its phosphorylation on tyrosine residues regardless of the presence of gp75LNGFR.  NGF-gp140trk complexes display the slow dissocn. rate and rapid internalization characteristics of high affinity NGF receptors.  Crosslinking studies reveal the existence of gp75LNGFR and gp140trk homodimers.  However, gp75LNGFR-pg 140trk heterodimers were not detected.  Coexpression in COS cells of wild-type and kinase deficient mutants reveals that gp140trk receptors can undergo intermol. phosphorylation, indicating the formation of functional homodimers.  Moreover, these kinase deficient mutants inhibit NGF-induced signaling through wild-type gp140trk receptors.  These results indicate that the functional high affinity NGF receptors consist of gp140trk homodimeric (or oligomeric) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSQLmINGdcU7Vg90H21EOLACvtfcHk0li0gUnakBbSuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVCht7g%253D&md5=f861b0c299299b4f409ae8fe37a4d72d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2892%2990066-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252892%252990066-M%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DS.%2BQ.%26aulast%3DTapley%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DNerve%2520growth-factor%2520mediates%2520signal%2520transduction%2520through%2520Trk%2520homodimer%2520receptors%26jtitle%3DNeuron%26date%3D1992%26volume%3D9%26spage%3D1067%26epage%3D1079%26doi%3D10.1016%2F0896-6273%2892%2990066-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span> <span> </span><span class="NLM_article-title">Autophosphorylation of activation loop tyrosines regulates signaling by the TRK nerve growth factor receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">10957</span>– <span class="NLM_lpage">10967</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.16.10957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.272.16.10957" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=10957-10967&author=M.+E.+Cunninghamauthor=R.+M.+Stephensauthor=D.+R.+Kaplanauthor=L.+A.+Greene&title=Autophosphorylation+of+activation+loop+tyrosines+regulates+signaling+by+the+TRK+nerve+growth+factor+receptor&doi=10.1074%2Fjbc.272.16.10957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.16.10957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.16.10957%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DM.%2BE.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26atitle%3DAutophosphorylation%2520of%2520activation%2520loop%2520tyrosines%2520regulates%2520signaling%2520by%2520the%2520TRK%2520nerve%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D10957%26epage%3D10967%26doi%3D10.1074%2Fjbc.272.16.10957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span> <span> </span><span class="NLM_article-title">A function-structure model for NGF-activated TRK</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7282</span>– <span class="NLM_lpage">7293</span>, <span class="refDoi"> DOI: 10.1093/emboj/17.24.7282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1093%2Femboj%2F17.24.7282" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=7282-7293&author=M.+E.+Cunninghamauthor=L.+A.+Greene&title=A+function-structure+model+for+NGF-activated+TRK&doi=10.1093%2Femboj%2F17.24.7282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.24.7282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.24.7282%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DM.%2BE.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26atitle%3DA%2520function-structure%2520model%2520for%2520NGF-activated%2520TRK%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D7282%26epage%3D7293%26doi%3D10.1093%2Femboj%2F17.24.7282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Middlemas, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenhelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">Identification of Trkb autophosphorylation sites and evidence that phospholipase C-gamma-1 is a substrate of the Trkb receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">5458</span>– <span class="NLM_lpage">5466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=5458-5466&author=D.+S.+Middlemasauthor=J.+Meisenhelderauthor=T.+Hunter&title=Identification+of+Trkb+autophosphorylation+sites+and+evidence+that+phospholipase+C-gamma-1+is+a+substrate+of+the+Trkb+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiddlemas%26aufirst%3DD.%2BS.%26aulast%3DMeisenhelder%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DIdentification%2520of%2520Trkb%2520autophosphorylation%2520sites%2520and%2520evidence%2520that%2520phospholipase%2520C-gamma-1%2520is%2520a%2520substrate%2520of%2520the%2520Trkb%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D5458%26epage%3D5466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span> <span> </span><span class="NLM_article-title">A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">8901</span>– <span class="NLM_lpage">8910</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=8901-8910&author=D.+M.+Loebauthor=R.+M.+Stephensauthor=T.+Copelandauthor=D.+R.+Kaplanauthor=L.+A.+Greene&title=A+Trk+nerve+growth+factor+%28NGF%29+receptor+point+mutation+affecting+interaction+with+phospholipase+C-gamma+1+abolishes+NGF-promoted+peripherin+induction+but+not+neurite+outgrowth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoeb%26aufirst%3DD.%2BM.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DCopeland%26aufirst%3DT.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26atitle%3DA%2520Trk%2520nerve%2520growth%2520factor%2520%2528NGF%2529%2520receptor%2520point%2520mutation%2520affecting%2520interaction%2520with%2520phospholipase%2520C-gamma%25201%2520abolishes%2520NGF-promoted%2520peripherin%2520induction%2520but%2520not%2520neurite%2520outgrowth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D8901%26epage%3D8910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmuller, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Identification of Trk binding sites for SHC and phosphatidylinositol 3′-kinase and formation of a multimeric signaling complex</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">22963</span>– <span class="NLM_lpage">22966</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=22963-22966&author=A.+Obermeierauthor=R.+Lammersauthor=K.+H.+Wiesmullerauthor=G.+Jungauthor=J.+Schlessingerauthor=A.+Ullrich&title=Identification+of+Trk+binding+sites+for+SHC+and+phosphatidylinositol+3%E2%80%B2-kinase+and+formation+of+a+multimeric+signaling+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObermeier%26aufirst%3DA.%26aulast%3DLammers%26aufirst%3DR.%26aulast%3DWiesmuller%26aufirst%3DK.%2BH.%26aulast%3DJung%26aufirst%3DG.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520Trk%2520binding%2520sites%2520for%2520SHC%2520and%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%2520and%2520formation%2520of%2520a%2520multimeric%2520signaling%2520complex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D22963%26epage%3D22966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedorf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1585</span>– <span class="NLM_lpage">1590</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1994.tb06421.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fj.1460-2075.1994.tb06421.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1994&pages=1585-1590&author=A.+Obermeierauthor=R.+A.+Bradshawauthor=K.+Seedorfauthor=A.+Choidasauthor=J.+Schlessingerauthor=A.+Ullrich&title=Neuronal+differentiation+signals+are+controlled+by+nerve+growth+factor+receptor%2FTrk+binding+sites+for+SHC+and+PLC+gamma&doi=10.1002%2Fj.1460-2075.1994.tb06421.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1994.tb06421.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1994.tb06421.x%26sid%3Dliteratum%253Aachs%26aulast%3DObermeier%26aufirst%3DA.%26aulast%3DBradshaw%26aufirst%3DR.%2BA.%26aulast%3DSeedorf%26aufirst%3DK.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DNeuronal%2520differentiation%2520signals%2520are%2520controlled%2520by%2520nerve%2520growth%2520factor%2520receptor%252FTrk%2520binding%2520sites%2520for%2520SHC%2520and%2520PLC%2520gamma%26jtitle%3DEMBO%2520J.%26date%3D1994%26volume%3D13%26spage%3D1585%26epage%3D1590%26doi%3D10.1002%2Fj.1460-2075.1994.tb06421.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span> <span> </span><span class="NLM_article-title">Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(94)90223-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0896-6273%2894%2990223-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8155326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2cXitlKqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=691-705&author=R.+M.+Stephensauthor=D.+M.+Loebauthor=T.+D.+Copelandauthor=T.+Pawsonauthor=L.+A.+Greeneauthor=D.+R.+Kaplan&title=Trk+receptors+use+redundant+signal+transduction+pathways+involving+SHC+and+PLC-%CE%B31+to+mediate+NGF+responses&doi=10.1016%2F0896-6273%2894%2990223-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses</span></div><div class="casAuthors">Stephens, Robert M.; Loeb, David M.; Copeland, Terry D.; Pawson, Tony; Greene, Lloyd A.; Kaplan, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">ISS/REP#/MLT:  3</span>),
    <span class="NLM_cas:pages">691-705</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">In response to NGF, the Trk receptor tyrosine kinase forms a complex with SHC, a protein that couples receptor tyrosine kinases to p21ras.  Complex formation between Trk and SHC, SHC tyrosine phosphorylation, and assocn. of SHC with Grb2 were mediated by autophosphorylation at Y490 in trk (NPQYFSD).  To det. the role of SHC and other Trk substrates in NGF signaling, Trk receptors with mutations in Y490 and Y785 (the PLC-γ1 assocn. site) were introduced into PC12nnr5 cells.  NGF treatment of PC12nnr5 cells expressing Trk with mutations in either substrate-binding site resulted in normal neurite outgrowth and Erk1 activity and tyrosine phosphorylation.  However, PC12nnr5 cells expressing Trk with mutations at both sites failed to stably extend neurites and efficiently induce Erk1 activity and tyrosine phosphorylation in response to NGF.  The authors postulate that Trk receptors can activate Erk1 by either SHC- or PLC-γ1-dependent signaling pathways.  These results suggest a model whereby Trk receptors utilize at least partially redundant signal transduction pathways to mediate NGF responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlp14Enz7B17Vg90H21EOLACvtfcHk0lgPSkmcWSG-FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlKqur0%253D&md5=f23ea0ae13424a0ebc5cb237d7b181e4</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2894%2990223-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252894%252990223-2%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DLoeb%26aufirst%3DD.%2BM.%26aulast%3DCopeland%26aufirst%3DT.%2BD.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26atitle%3DTrk%2520receptors%2520use%2520redundant%2520signal%2520transduction%2520pathways%2520involving%2520SHC%2520and%2520PLC-%25CE%25B31%2520to%2520mediate%2520NGF%2520responses%26jtitle%3DNeuron%26date%3D1994%26volume%3D12%26spage%3D691%26epage%3D705%26doi%3D10.1016%2F0896-6273%2894%2990223-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patapoutian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span> <span> </span><span class="NLM_article-title">Trk receptors: mediators of neurotrophin action</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1016/S0959-4388(00)00208-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-4388%2800%2900208-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=272-280&author=A.+Patapoutianauthor=L.+F.+Reichardt&title=Trk+receptors%3A+mediators+of+neurotrophin+action&doi=10.1016%2FS0959-4388%2800%2900208-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2800%2900208-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252800%252900208-7%26sid%3Dliteratum%253Aachs%26aulast%3DPatapoutian%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26atitle%3DTrk%2520receptors%253A%2520mediators%2520of%2520neurotrophin%2520action%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D2001%26volume%3D11%26spage%3D272%26epage%3D280%26doi%3D10.1016%2FS0959-4388%2800%2900208-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">14863</span>– <span class="NLM_lpage">14866</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.25.14863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.270.25.14863" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=14863-14866&author=Z.+Songyangauthor=B.+Margolisauthor=M.+Chaudhuriauthor=S.+E.+Shoelsonauthor=L.+C.+Cantley&title=The+phosphotyrosine+interaction+domain+of+SHC+recognizes+tyrosine-phosphorylated+NPXY+motif&doi=10.1074%2Fjbc.270.25.14863"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.25.14863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.25.14863%26sid%3Dliteratum%253Aachs%26aulast%3DSongyang%26aufirst%3DZ.%26aulast%3DMargolis%26aufirst%3DB.%26aulast%3DChaudhuri%26aufirst%3DM.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520phosphotyrosine%2520interaction%2520domain%2520of%2520SHC%2520recognizes%2520tyrosine-phosphorylated%2520NPXY%2520motif%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D14863%26epage%3D14866%26doi%3D10.1074%2Fjbc.270.25.14863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batzer, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(92)90167-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2892%2990167-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1322798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXkt1ajtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1992&pages=431-442&author=E.+J.+Lowensteinauthor=R.+J.+Dalyauthor=A.+G.+Batzerauthor=W.+Liauthor=B.+Margolisauthor=R.+Lammersauthor=A.+Ullrichauthor=E.+Y.+Skolnikauthor=D.+Bar-Sagiauthor=J.+Schlessinger&title=The+SH2+and+SH3+domain-containing+protein+GRB2+links+receptor+tyrosine+kinases+to+ras+signaling&doi=10.1016%2F0092-8674%2892%2990167-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling</span></div><div class="casAuthors">Lowenstein, E. J.; Daly, R. J.; Batzer, A. G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E. Y.; Bar-Sagi, D.; Schlessinger, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-42</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) contg. one src homol. 2 (SH2) domain and two SH3 domains was isolated.  Immunoblotting expts. indicate that GRB2 assocs. with tyrosine-phosphorylated epidermal growth factor receptors (EGFRs) and platelet-derived growth factor receptors (PDGFRs) via its SH2 domain.  Interestingly, GRB2 exhibits striking structural and functional homol. to the Caenorhabditis elegans protein sem-5.  To examine whether GRB2 is also a component of ras signaling in mammalian cells, microinjection studies were performed.  While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.  These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo0LYdxA1IuLVg90H21EOLACvtfcHk0ljy6m1yw6Ab4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkt1ajtbg%253D&md5=86885e1cbee3f637ae9470aa9f8c264e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2892%2990167-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252892%252990167-B%26sid%3Dliteratum%253Aachs%26aulast%3DLowenstein%26aufirst%3DE.%2BJ.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DBatzer%26aufirst%3DA.%2BG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMargolis%26aufirst%3DB.%26aulast%3DLammers%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSkolnik%26aufirst%3DE.%2BY.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DThe%2520SH2%2520and%2520SH3%2520domain-containing%2520protein%2520GRB2%2520links%2520receptor%2520tyrosine%2520kinases%2520to%2520ras%2520signaling%26jtitle%3DCell%26date%3D1992%26volume%3D70%26spage%3D431%26epage%3D442%26doi%3D10.1016%2F0092-8674%2892%2990167-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonfini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, U.</span></span> <span> </span><span class="NLM_article-title">The Son of sevenless gene product: a putative activator of Ras</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1126/science.1736363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.1736363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1736363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXisVyks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1992&pages=603-606&author=L.+Bonfiniauthor=C.+A.+Karlovichauthor=C.+Dasguptaauthor=U.+Banerjee&title=The+Son+of+sevenless+gene+product%3A+a+putative+activator+of+Ras&doi=10.1126%2Fscience.1736363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The Son of sevenless gene product:  a putative activator of Ras</span></div><div class="casAuthors">Bonfini, Laura; Karlovich, Chris A.; Dasgupta, Chiranjib; Banerjee, Utpal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">5044</span>),
    <span class="NLM_cas:pages">603-6</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The Son of sevenless (Sos) gene functions in signaling pathways initiated by the sevenless and epidermal growth factor receptor tyrosine kinases.  The Sos gene has now been isolated and sequenced.  Its product is a 1595-amino acid protein similar to the CDC25 protein in Saccharomyces cerevisiae, a guanine nucleotide exchange factor that activates Ras.  These results imply a role for the ras pathway in Drosophila melanogaster neuronal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_g7EQIixe0bVg90H21EOLACvtfcHk0ljy6m1yw6Ab4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVyks74%253D&md5=e36b8121233e5a78da0f5786c579b514</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1126%2Fscience.1736363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1736363%26sid%3Dliteratum%253Aachs%26aulast%3DBonfini%26aufirst%3DL.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DDasgupta%26aufirst%3DC.%26aulast%3DBanerjee%26aufirst%3DU.%26atitle%3DThe%2520Son%2520of%2520sevenless%2520gene%2520product%253A%2520a%2520putative%2520activator%2520of%2520Ras%26jtitle%3DScience%26date%3D1992%26volume%3D255%26spage%3D603%26epage%3D606%26doi%3D10.1126%2Fscience.1736363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, Y.</span></span> <span> </span><span class="NLM_article-title">The map kinase sascade is essential for diverse signal transduction pathways</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/0968-0004(93)90019-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0968-0004%2893%2990019-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1993&pages=128-131&author=E.+Nishidaauthor=Y.+Gotoh&title=The+map+kinase+sascade+is+essential+for+diverse+signal+transduction+pathways&doi=10.1016%2F0968-0004%2893%2990019-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0968-0004%2893%2990019-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0968-0004%252893%252990019-J%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DE.%26aulast%3DGotoh%26aufirst%3DY.%26atitle%3DThe%2520map%2520kinase%2520sascade%2520is%2520essential%2520for%2520diverse%2520signal%2520transduction%2520pathways%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1993%26volume%3D18%26spage%3D128%26epage%3D131%26doi%3D10.1016%2F0968-0004%2893%2990019-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span> <span> </span><span class="NLM_article-title">The TrkB-Shc site signals neuronal survival and local axon growth via MEK and PI3-kinase</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(00)00035-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0896-6273%2800%2900035-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10985347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVWmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=265-277&author=J.+K.+Atwalauthor=B.+Massieauthor=F.+D.+Millerauthor=D.+R.+Kaplan&title=The+TrkB-Shc+site+signals+neuronal+survival+and+local+axon+growth+via+MEK+and+PI3-kinase&doi=10.1016%2FS0896-6273%2800%2900035-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The TrkB-Shc site signals neuronal survival and local axon growth via MEK and PI3-kinase</span></div><div class="casAuthors">Atwal, Jasvinder K.; Massie, Bernard; Miller, Freda D.; Kaplan, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-277</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To det. how signals emanating from Trk transmit neurotrophin actions in primary neurons, the authors tested the ability of TrkB mutated at defined effector binding sites to promote sympathetic neuron survival or local axon growth.  TrkB stimulated signaling proteins and induced survival and growth in a manner similar to TrkA.  TrkB mutated at the Shc binding site supported survival and growth poorly relative to wild-type TrkB, whereas TrkB mutated at the PLC-γ1 binding site supported growth and survival well.  TrkB-mediated neuronal survival was dependent on PI3-kinase and to a lesser extent MEK activity, while growth depended upon both MEK and PI3-kinase activities.  These results indicate that the TrkB-Shc site mediates both neuronal survival and axonal outgrowth by activating the PI3-kinase and MEK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhOunf-Qm0DbVg90H21EOLACvtfcHk0lgqW74kcjFKbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVWmt7w%253D&md5=6203e8a8f3d7945c949b83e111ae0e97</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2800%2900035-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252800%252900035-0%26sid%3Dliteratum%253Aachs%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DMassie%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DF.%2BD.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26atitle%3DThe%2520TrkB-Shc%2520site%2520signals%2520neuronal%2520survival%2520and%2520local%2520axon%2520growth%2520via%2520MEK%2520and%2520PI3-kinase%26jtitle%3DNeuron%26date%3D2000%26volume%3D27%26spage%3D265%26epage%3D277%26doi%3D10.1016%2FS0896-6273%2800%2900035-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazeski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godement, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. A.</span></span> <span> </span><span class="NLM_article-title">Optical microscopy. 3. Tracking fluorescently labeled neurons in developing brain</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1096/fasebj.9.5.7896001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1096%2Ffasebj.9.5.7896001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=324-334&author=G.+Fishellauthor=R.+Blazeskiauthor=P.+Godementauthor=R.+Rivasauthor=L.+C.+Wangauthor=C.+A.+Mason&title=Optical+microscopy.+3.+Tracking+fluorescently+labeled+neurons+in+developing+brain&doi=10.1096%2Ffasebj.9.5.7896001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1096%2Ffasebj.9.5.7896001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffasebj.9.5.7896001%26sid%3Dliteratum%253Aachs%26aulast%3DFishell%26aufirst%3DG.%26aulast%3DBlazeski%26aufirst%3DR.%26aulast%3DGodement%26aufirst%3DP.%26aulast%3DRivas%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%2BC.%26aulast%3DMason%26aufirst%3DC.%2BA.%26atitle%3DOptical%2520microscopy.%25203.%2520Tracking%2520fluorescently%2520labeled%2520neurons%2520in%2520developing%2520brain%26jtitle%3DFASEB%2520J.%26date%3D1995%26volume%3D9%26spage%3D324%26epage%3D334%26doi%3D10.1096%2Ffasebj.9.5.7896001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellacosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsichlis, P. N.</span></span> <span> </span><span class="NLM_article-title">Akt is a direct target of the phosphatidylinositol 3-kinase - Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">30835</span>– <span class="NLM_lpage">30839</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.48.30835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.271.48.30835" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=30835-30839&author=K.+Dattaauthor=A.+Bellacosaauthor=T.+O.+Chanauthor=P.+N.+Tsichlis&title=Akt+is+a+direct+target+of+the+phosphatidylinositol+3-kinase+-+Activation+by+growth+factors%2C+v-src+and+v-Ha-ras%2C+in+Sf9+and+mammalian+cells&doi=10.1074%2Fjbc.271.48.30835"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.48.30835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.48.30835%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DK.%26aulast%3DBellacosa%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DT.%2BO.%26aulast%3DTsichlis%26aufirst%3DP.%2BN.%26atitle%3DAkt%2520is%2520a%2520direct%2520target%2520of%2520the%2520phosphatidylinositol%25203-kinase%2520-%2520Activation%2520by%2520growth%2520factors%252C%2520v-src%2520and%2520v-Ha-ras%252C%2520in%2520Sf9%2520and%2520mammalian%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D30835%26epage%3D30839%26doi%3D10.1074%2Fjbc.271.48.30835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Update: Signal transduction - PH domains - A universal membrane adapter</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1899</span>– <span class="NLM_lpage">1899</span>, <span class="refDoi"> DOI: 10.1126/science.275.5308.1899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.275.5308.1899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9122692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXit1Sktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=1899-1899&author=B.+A.+Hemmings&title=Update%3A+Signal+transduction+-+PH+domains+-+A+universal+membrane+adapter&doi=10.1126%2Fscience.275.5308.1899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">PH domains-a universal membrane adapter</span></div><div class="casAuthors">Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">5308</span>),
    <span class="NLM_cas:pages">1899</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs. on pleckstrin homol. domain in as signal dependent membrane adapter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_lyNIvJitkrVg90H21EOLACvtfcHk0lgqW74kcjFKbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1Sktbk%253D&md5=de871d2b24f7e92404f1c461173ad7fc</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscience.275.5308.1899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.275.5308.1899%26sid%3Dliteratum%253Aachs%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DUpdate%253A%2520Signal%2520transduction%2520-%2520PH%2520domains%2520-%2520A%2520universal%2520membrane%2520adapter%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D1899%26epage%3D1899%26doi%3D10.1126%2Fscience.275.5308.1899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffney, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(06)00122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0960-9822%2806%2900122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9094314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=261-269&author=D.+R.+Alessiauthor=S.+R.+Jamesauthor=C.+P.+Downesauthor=A.+B.+Holmesauthor=P.+R.+J.+Gaffneyauthor=C.+B.+Reeseauthor=P.+Cohen&title=Characterization+of+a+3-phosphoinositide-dependent+protein+kinase+which+phosphorylates+and+activates+protein+kinase+B%CE%B1&doi=10.1016%2FS0960-9822%2806%2900122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα</span></div><div class="casAuthors">Alessi, Dario R.; James, Stephen R.; Downes, C. Peter; Holmes, Andrew B.; Gaffney, Piers R. J.; Reese, Colin B.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-269</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Protein kinase B (PKB), also known as c-Akt, is activated rapidly when mammalian cells are stimulated with insulin and growth factors, and much of the current interest in this enzyme stems from the observation that it lies 'downstream' of phosphoinositide 3-kinase on intracellular signaling pathways.  We recently showed that insulin or insulin-like growth factor 1 induce the phosphorylation of PKB at two residues, Thr308 and Ser473.  The phosphorylation of both residues is required for maximal activation of PKB. The kinases that phosphorylate PKB are, however, unknown.  We have purified 500,000-fold from rabbit skeletal muscle exts. a protein kinase which phosphorylates PKBα at Thr308 and increases its activity over 30-fold.  We tested the kinase in the presence of several inositol phospholipids and found that only low micromolar concns. of the D enantiomers of either phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) or PtdIns(3,4)P2 were effective in potently activating the kinase, which has been named PtdIns(3,4,5)P3-dependent protein kinase-1 (PDK1).  None of the inositol phospholipids tested activated or inhibited PKBα or induced its phosphorylation under the conditions used.  PDK1 activity was not affected by wortmannin, indicating that it is not likely to be a member of the phosphoinositide 3-kinase family.  PDK1 is likely to be one of the protein kinases that mediate the activation of PKB by insulin and growth factors.  PDK1 may, therefore, play a key role in mediating many of the actions of the second messenger(s) PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2sSM5v7MnWrVg90H21EOLACvtfcHk0liWgaAc5hVVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D&md5=7f3794216810a4273d091b8d4590aaa9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2806%2900122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252806%252900122-9%26sid%3Dliteratum%253Aachs%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DJames%26aufirst%3DS.%2BR.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BB.%26aulast%3DGaffney%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DReese%26aufirst%3DC.%2BB.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DCharacterization%2520of%2520a%25203-phosphoinositide-dependent%2520protein%2520kinase%2520which%2520phosphorylates%2520and%2520activates%2520protein%2520kinase%2520B%25CE%25B1%26jtitle%3DCurr.%2520Biol.%26date%3D1997%26volume%3D7%26spage%3D261%26epage%3D269%26doi%3D10.1016%2FS0960-9822%2806%2900122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andjelkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frech, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucocq, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Role of translocation in the activation and function of protein kinase B</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">31515</span>– <span class="NLM_lpage">31524</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.50.31515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.272.50.31515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9395488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXotVSktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=31515-31524&author=M.+Andjelkovicauthor=D.+R.+Alessiauthor=R.+Meierauthor=A.+Fernandezauthor=N.+J.+Lambauthor=M.+Frechauthor=P.+Cronauthor=P.+Cohenauthor=J.+M.+Lucocqauthor=B.+A.+Hemmings&title=Role+of+translocation+in+the+activation+and+function+of+protein+kinase+B&doi=10.1074%2Fjbc.272.50.31515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Role of translocation in the activation and function of protein kinase B</span></div><div class="casAuthors">Andjelkovic, Mirjana; Alessi, Dario R.; Meier, Roger; Fernandez, Anne; Lamb, Ned J. C.; Frech, Matthias; Cron, Peter; Cohen, Philip; Lucocq, John M.; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">31515-31524</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The role of subcellular localization in the regulation of protein kinase B (PKB) activation was investigated.  The myristoylation/palmitylation motif from Lck tyrosine kinase was attached to the N-terminus of protein kinase B to alter its subcellular location.  Myristoylated/palmitylated (m/p)-PKBα was assocd. with the plasma membrane of transfected cells, whereas the wild-type kinase was mostly cytosolic.  The activity of m/p-PKBα was 60-fold higher compared with the unstimulated wild-type enzyme, and could not be stimulated further by growth factors or phosphatase inhibitors.  In vivo 32P labeling and mutagenesis demonstrated that m/p-PKBα activity was due to phosphorylation on Thr-308 and Ser-473, that are normally induced on PKB following stimulation of the cells with insulin or insulin-like growth factor-1 (IGF-1).  A dominant neg. form of phosphoinositide 3-kinase (PI3-K) did not affect m/p-PKBα activity.  The pleckstrin homol. (PH) domain of m/p-PKBα was not required for its activation or phosphorylation on Thr-308 and Ser-473, suggesting that this domain may serve as a membrane-targeting module.  Consistent with this view, PKBα was translocated to the plasma membrane within minutes after stimulation with IGF-1.  This translocation required the PH domain and was sensitive to wortmannin.  The results indicate that PI3-K activity is required for translocation of PKB to the plasma membrane, where its activation occurs through phosphorylation of the same sites that are induced by insulin or IGF-1.  Following activation, the kinase detached from the membrane and translocated to the nucleus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_oKYG4NVOQrVg90H21EOLACvtfcHk0liWgaAc5hVVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVSktr8%253D&md5=76c4e60f70dc603f066d3fafc67aaa51</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.50.31515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.50.31515%26sid%3Dliteratum%253Aachs%26aulast%3DAndjelkovic%26aufirst%3DM.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DMeier%26aufirst%3DR.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DLamb%26aufirst%3DN.%2BJ.%26aulast%3DFrech%26aufirst%3DM.%26aulast%3DCron%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DLucocq%26aufirst%3DJ.%2BM.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DRole%2520of%2520translocation%2520in%2520the%2520activation%2520and%2520function%2520of%2520protein%2520kinase%2520B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D31515%26epage%3D31524%26doi%3D10.1074%2Fjbc.272.50.31515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgering, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffer, P. J.</span></span> <span> </span><span class="NLM_article-title">Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/376599a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2F376599a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7637810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXns1SjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=599-602&author=B.+M.+Burgeringauthor=P.+J.+Coffer&title=Protein+kinase+B+%28c-Akt%29+in+phosphatidylinositol-3-OH+kinase+signal+transduction&doi=10.1038%2F376599a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction</span></div><div class="casAuthors">Burgering, Boudewijn M. Th.; Coffer, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6541</span>),
    <span class="NLM_cas:pages">599-602</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A serine/threonine kinase, named protein kinase B (PKB) for its sequence homol. to both protein kinase A and C, has previously been isolated.  PKB, which is identical to the kinase Rac, was later the cellular homolog of the transforming v-Akt.  Here, the authors show that PKB is activated by stimuli such as insulin, platelet-derived growth factor (PDGF), EGF and basic FGF (bFGF).  Activation of PKB was inhibited by the phosphatidylinositol-3-OH kinase [PI(3)K] inhibitor wortmannin and by coexpression of a dominant-neg. mutant of PI(3)K.  PDGF receptor mutants that lack detectable assocd. PI(3)K activity also fail to induce PKB activation.  PKB kinase activity is correlated with phosphorylation of PKB on serine.  Finally, the authors show that a constructed Gag-PKB fusion protein, homologous to the v-akt oncogene, displays significantly increased ligand-independent kinase activity.  This activity is sufficient to activate the p70 S6-kinase (p70S6k).  These results suggest a role for PKB in PI(3)K-mediated signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVbJ5pW1rL97Vg90H21EOLACvtfcHk0liWgaAc5hVVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXns1SjtLw%253D&md5=487e94d078aad3fcfb4ef6a4810c0332</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2F376599a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376599a0%26sid%3Dliteratum%253Aachs%26aulast%3DBurgering%26aufirst%3DB.%2BM.%26aulast%3DCoffer%26aufirst%3DP.%2BJ.%26atitle%3DProtein%2520kinase%2520B%2520%2528c-Akt%2529%2520in%2520phosphatidylinositol-3-OH%2520kinase%2520signal%2520transduction%26jtitle%3DNature%26date%3D1995%26volume%3D376%26spage%3D599%26epage%3D602%26doi%3D10.1038%2F376599a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, M. E.</span></span> <span> </span><span class="NLM_article-title">Regulation of neuronal survival by the serine-threonine protein kinase Akt</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1126/science.275.5300.661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.275.5300.661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9005851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXptV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=661-665&author=H.+Dudekauthor=S.+R.+Dattaauthor=T.+F.+Frankeauthor=M.+J.+Birnbaumauthor=R.+Yaoauthor=G.+M.+Cooperauthor=R.+A.+Segalauthor=D.+R.+Kaplanauthor=M.+E.+Greenberg&title=Regulation+of+neuronal+survival+by+the+serine-threonine+protein+kinase+Akt&doi=10.1126%2Fscience.275.5300.661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of neuronal survival by the serine-threonine protein kinase Akt</span></div><div class="casAuthors">Dudek, Henryk; Datta, Sandeep Robert; Franke, Thomas F.; Birnbaum, Morris J.; Yao, Ryoji; Cooper, Geoffrey M.; Segal, Rosalind A.; Kaplan, David R.; Greenberg, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">5300</span>),
    <span class="NLM_cas:pages">661-665</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A signaling pathway was delineated by which insulin-like growth factor 1 (IGF-1) promotes the survival of cerebellar neurons.  IGF-1 activation of phosphoinositide 3-kinase (P13-K) triggered the activation of two protein kinases, the serine-threonine kinase Akt and the p70 ribosomal protein S6 kinase (p70s6k).  Expts. with pharmacol. inhibitors, as well as expression of wild-type and dominant-inhibitory forms of Akt, demonstrated that Akt but not p70s6k mediates P13-K-dependent survival.  These findings suggest that in the developing nervous system, Akt is a crit. mediator of growth factor-induced neuronal survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhXSq1is28BbVg90H21EOLACvtfcHk0likhpSMMnBkgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXptV2msA%253D%253D&md5=46584bdcfb3f885781ba13d5f60c3266</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1126%2Fscience.275.5300.661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.275.5300.661%26sid%3Dliteratum%253Aachs%26aulast%3DDudek%26aufirst%3DH.%26aulast%3DDatta%26aufirst%3DS.%2BR.%26aulast%3DFranke%26aufirst%3DT.%2BF.%26aulast%3DBirnbaum%26aufirst%3DM.%2BJ.%26aulast%3DYao%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DG.%2BM.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGreenberg%26aufirst%3DM.%2BE.%26atitle%3DRegulation%2520of%2520neuronal%2520survival%2520by%2520the%2520serine-threonine%2520protein%2520kinase%2520Akt%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D661%26epage%3D665%26doi%3D10.1126%2Fscience.275.5300.661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R. S.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2933</span>– <span class="NLM_lpage">2943</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.18-08-02933.1998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.18-08-02933.1998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9526010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXis1ejtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=2933-2943&author=R.+J.+Crowderauthor=R.+S.+Freeman&title=Phosphatidylinositol+3-kinase+and+Akt+protein+kinase+are+necessary+and+sufficient+for+the+survival+of+nerve+growth+factor-dependent+sympathetic+neurons&doi=10.1523%2FJNEUROSCI.18-08-02933.1998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons</span></div><div class="casAuthors">Crowder, Robert J.; Freeman, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2933-2943</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Recent studies have suggested a role for phosphatidylinositol (PI) 3-kinase in cell survival, including the survival of neurons.  We used rat sympathetic neurons maintained in vitro to characterize the potential survival signals mediated by PI 3-kinase and to test whether the Akt protein kinase, a putative effector of PI 3-kinase, functions during nerve growth factor (NGF)-mediated survival.  Two PI 3-kinase inhibitors, LY294002 and wortmannin, block NGF-mediated survival of sympathetic neurons.  Cell death caused by LY294002 resembles death caused by NGF deprivation in that it is blocked by a caspase inhibitor or a cAMP analog and that it is accompanied by the induction of c-jun, c-fos, and cyclin D1 mRNAs.  Treatment of neurons with NGF activates endogenous Akt protein kinase, and LY294002 or wortmannin blocks this activation.  Expression of constitutively active Akt or PI 3-kinase in neurons efficiently prevents death after NGF withdrawal.  Conversely, expression of dominant neg. forms of PI 3-kinase or Akt induces apoptosis in the presence of NGF.  These results demonstrate that PI 3-kinase and Akt are both necessary and sufficient for the survival of NGF-dependent sympathetic neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocAiecC5-6hbVg90H21EOLACvtfcHk0likhpSMMnBkgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1ejtLg%253D&md5=72a9a6bafc78f567d8c1b38934bab7e0</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.18-08-02933.1998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.18-08-02933.1998%26sid%3Dliteratum%253Aachs%26aulast%3DCrowder%26aufirst%3DR.%2BJ.%26aulast%3DFreeman%26aufirst%3DR.%2BS.%26atitle%3DPhosphatidylinositol%25203-kinase%2520and%2520Akt%2520protein%2520kinase%2520are%2520necessary%2520and%2520sufficient%2520for%2520the%2520survival%2520of%2520nerve%2520growth%2520factor-dependent%2520sympathetic%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D1998%26volume%3D18%26spage%3D2933%26epage%3D2943%26doi%3D10.1523%2FJNEUROSCI.18-08-02933.1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, G. M.</span></span> <span> </span><span class="NLM_article-title">Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2006</span>, <span class="refDoi"> DOI: 10.1126/science.7701324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.7701324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7701324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXkslOkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1995&pages=2003-2006&author=R.+Yaoauthor=G.+M.+Cooper&title=Requirement+for+phosphatidylinositol-3+kinase+in+the+prevention+of+apoptosis+by+nerve+growth+factor&doi=10.1126%2Fscience.7701324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor</span></div><div class="casAuthors">Yao, Ryoji; Cooper, Geoffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">5206</span>),
    <span class="NLM_cas:pages">2003-6</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nerve growth factor (NGF) induces both differentiation and survival of neurons by binding to the Trk receptor protein tyrosine kinase.  Although Ras is required for differentiation, it was not required for NGF-mediated survival of rat pheochromocytoma PC-12 cells in serum-free medium.  However, the ability of NGF to prevent apoptosis (programmed cell death) was inhibited by wortmannin or LY 294002, two specific inhibitors of phosphatidylinositol (PI)-3 kinase.  Moreover, platelet-derived growth factor (PDGF) prevented apoptosis of PC-12 cells expressing the wild-type PDGF receptor, but not of cells expressing a mutant receptor that failed to activate PI-3 kinase.  Cell survival thus appears to be mediated by a PI-3 kinase signaling pathway distinct from the pathway that mediates differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ITwHLlYZv7Vg90H21EOLACvtfcHk0likhpSMMnBkgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkslOkur0%253D&md5=e6e47faef5b39f2bcb851b06e26ca064</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1126%2Fscience.7701324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7701324%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DG.%2BM.%26atitle%3DRequirement%2520for%2520phosphatidylinositol-3%2520kinase%2520in%2520the%2520prevention%2520of%2520apoptosis%2520by%2520nerve%2520growth%2520factor%26jtitle%3DScience%26date%3D1995%26volume%3D267%26spage%3D2003%26epage%3D2006%26doi%3D10.1126%2Fscience.7701324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zirrgiebel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span> <span> </span><span class="NLM_article-title">Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2241</span>– <span class="NLM_lpage">2250</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1995.65052241.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1046%2Fj.1471-4159.1995.65052241.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7595513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXovFGmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1995&pages=2241-2250&author=U.+Zirrgiebelauthor=Y.+Ohgaauthor=B.+Carterauthor=B.+Berningerauthor=N.+Inagakiauthor=H.+Thoenenauthor=D.+Lindholm&title=Characterization+of+TrkB+receptor-mediated+signaling+pathways+in+rat+cerebellar+granule+neurons%3A+involvement+of+protein+kinase+C+in+neuronal+survival&doi=10.1046%2Fj.1471-4159.1995.65052241.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival</span></div><div class="casAuthors">Zirrgiebel, Ute; Ohga, Yoko; Carter, Bruce; Berninger, Benedikt; Inagaki, Naoyuki; Thoenen, Hans; Lindolm, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2241-50</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">TrkB belongs to the Trk family of tyrosine kinase receptors and mediates the response to brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-45).  Here, the authors report that both truncated and full-length forms of TrkB receptors are expressed in developing cerebellar granule neurons.  BDNF and NZT-4/5 increased the survival of cultured cerebellar granule neurons.  BDNF and NT-4/5 also induced an autophosphorylation of TrkB receptors and subsequently resulted in a phosphorylation and binding of phospholipase C-γ (PLC-γ) and SH2-contg. sequence to the autophosphorylated TrkB receptors.  Both contain src homol. 2 (SH2) regions.  In keeping with a signaling function of PLC-γ, BDNF increased the phosphatidylinositol (PI) turnover and elevated intracellular calcium levels.  To investigate the involvement of protein kinase C (PKC) in the survival of granular neurons, the authors show here activation of PKC after BDNF or TPA treatment and blocking of the obsd. survival-promoting effects of BDNF and TPA with calphostin C, a specific PKC inhibitor.  In addn., BDNF activated c-ras in a concn.-dependent manner.  These results suggest that two different pathways, the c-ras and the PLC-γ pathway, are activated by TrkB receptors in primary neurons and that PKC activation is involved in the survival promoting effect of BDNF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomW6Wv5ZWfybVg90H21EOLACvtfcHk0ljgkKbljGN1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovFGmur4%253D&md5=056848ace12631e665b9116ea8dda4d2</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1995.65052241.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1995.65052241.x%26sid%3Dliteratum%253Aachs%26aulast%3DZirrgiebel%26aufirst%3DU.%26aulast%3DOhga%26aufirst%3DY.%26aulast%3DCarter%26aufirst%3DB.%26aulast%3DBerninger%26aufirst%3DB.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DThoenen%26aufirst%3DH.%26aulast%3DLindholm%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520TrkB%2520receptor-mediated%2520signaling%2520pathways%2520in%2520rat%2520cerebellar%2520granule%2520neurons%253A%2520involvement%2520of%2520protein%2520kinase%2520C%2520in%2520neuronal%2520survival%26jtitle%3DJ.%2520Neurochem.%26date%3D1995%26volume%3D65%26spage%3D2241%26epage%3D2250%26doi%3D10.1046%2Fj.1471-4159.1995.65052241.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, D. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1714448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1056%2FNEJMoa1714448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=29466156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=731-739&author=A.+Drilonauthor=T.+W.+Laetschauthor=S.+Kummarauthor=S.+G.+DuBoisauthor=U.+N.+Lassenauthor=G.+D.+Demetriauthor=M.+Nathensonauthor=R.+C.+Doebeleauthor=A.+F.+Faragoauthor=A.+S.+Pappoauthor=B.+Turpinauthor=A.+Dowlatiauthor=M.+S.+Broseauthor=L.+Mascarenhasauthor=N.+Federmanauthor=J.+Berlinauthor=W.+S.+El-Deiryauthor=C.+Baikauthor=J.+Deekenauthor=V.+Boniauthor=R.+Nagasubramanianauthor=M.+Taylorauthor=E.+R.+Rudzinskiauthor=F.+Meric-Bernstamauthor=D.+P.+S.+Sohalauthor=P.+C.+Maauthor=L.+E.+Raezauthor=J.+F.+Hechtmanauthor=R.+Benayedauthor=M.+Ladanyiauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Cruickshankauthor=N.+C.+Kuauthor=M.+C.+Coxauthor=D.+S.+Hawkinsauthor=D.+S.+Hongauthor=D.+M.+Hyman&title=Efficacy+of+larotrectinib+in+TRK+fusion-positive+cancers+in+adults+and+children&doi=10.1056%2FNEJMoa1714448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</span></div><div class="casAuthors">Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; Pappo, A. S.; Turpin, B.; Dowlati, A.; Brose, M. S.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W. S.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; Taylor, M.; Rudzinski, E. R.; Meric-Bernstam, F.; Sohal, D. P. S.; Ma, P. C.; Raez, L. E.; Hechtman, J. F.; Benayed, R.; Ladanyi, M.; Tuch, B. B.; Ebata, K.; Cruickshank, S.; Ku, N. C.; Cox, M. C.; Hawkins, D. S.; Hong, D. S.; Hyman, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">731-739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults.  We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.  METHODS We enrolled patients with consecutively and prospectively identified TRK fusion-pos. cancers, detected by mol. profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults.  The primary end point for the combined anal. was the overall response rate according to independent review.  Secondary end points included duration of response, progressionfree survival, and safety.  RESULTS A total of 55 patients, ranging in age from 4 mo to 76 years, were enrolled and treated.  Patients had 17 unique TRK fusion-pos. tumor types.  The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment.  At 1 yr, 71% of the responses were ongoing and 55% of the patients remained progression-free.  The median duration of response and progression-free survival had not been reached.  At a median follow-up of 9.4 mo, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative.  Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients.  No patient discontinued larotrectinib owing to drug-related adverse events.  CONCLUSIONS Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-pos. cancer, regardless of the age of the patient or of the tumor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwp_pcLYdv5bVg90H21EOLACvtfcHk0ljgkKbljGN1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D&md5=b636d83c2cd61b4b35c36e36c950196c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1714448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1714448%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DLassen%26aufirst%3DU.%2BN.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DNathenson%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DBaik%26aufirst%3DC.%26aulast%3DDeeken%26aufirst%3DJ.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DRudzinski%26aufirst%3DE.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSohal%26aufirst%3DD.%2BP.%2BS.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DKu%26aufirst%3DN.%2BC.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DEfficacy%2520of%2520larotrectinib%2520in%2520TRK%2520fusion-positive%2520cancers%2520in%2520adults%2520and%2520children%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D731%26epage%3D739%26doi%3D10.1056%2FNEJMoa1714448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span> <span> </span><span class="NLM_article-title">Developing anticancer drugs in orphan molecular entities - a paradigm under construction</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1056/NEJMe1716821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1056%2FNEJMe1716821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=29466154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1MrjvVygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=763-765&author=F.+Andre&title=Developing+anticancer+drugs+in+orphan+molecular+entities+-+a+paradigm+under+construction&doi=10.1056%2FNEJMe1716821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Drugs in Orphan Molecular Entities - A Paradigm under Construction</span></div><div class="casAuthors">Andre Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">763-765</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9RoVGgdaKyTMsgLhIoICsfW6udTcc2eZZInSgjJcVArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrjvVygug%253D%253D&md5=856d8e03d468f9b64a87f04026f265de</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1716821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1716821%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26atitle%3DDeveloping%2520anticancer%2520drugs%2520in%2520orphan%2520molecular%2520entities%2520-%2520a%2520paradigm%2520under%2520construction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D763%26epage%3D765%26doi%3D10.1056%2FNEJMe1716821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">Role and relevance of TrkB mutations and expression in non-small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1078-0432.CCR-10-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21242122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVGhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2638-2645&author=T.+Haradaauthor=Y.+Yatabeauthor=M.+Takeshitaauthor=T.+Kogaauthor=T.+Yanoauthor=Y.+Wangauthor=G.+Giaccone&title=Role+and+relevance+of+TrkB+mutations+and+expression+in+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-10-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Harada, Taishi; Yatabe, Yasushi; Takeshita, Masafumi; Koga, Takaomi; Yano, Tokujiro; Wang, Yisong; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: TrkB has been involved in poor cancer outcome.  TrkB mutations have been reported in non-small cell lung cancer.  In this study, we aimed at characterizing the role of three potentially sensitizing TrkB mutations previously reported in lung cancer.  Exptl. Design: We characterized three activation loop mutants of TrkB (M713I, R715G, and R734C) in terms of pathway activation/phosphorylation, migration, anchorage-independent growth, and sensitivity to a Trk inhibitor, using NIH3T3 cells and Baf3 cells.  We also sequenced the tyrosine kinase domain of TrkB in a large no. of lung cancer samples of East-Asian origin and cell lines.  RESULTS: None of the mutants were constitutively active in NIH3T3 transformation and migration assays.  M713I and R734C mutants showed low levels of autophosphorylation in comparison with wild-type TrkB.  Although R715G showed similar level of autophosphorylation to wild-type TrkB on brain-derived neurotrophic factor stimulation, the mutant was not as competent as wild-type TrkB in supporting interleukin-3-independent growth of Baf3 cells.  In addn., the Trk inhibitor AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth, whereas the mutants were relatively resistant to the Trk inhibitor compared with wild-type TrkB.  We could not confirm the presence of nonsynonymous mutation in 78 lung cancer samples and 29 cell lines.  CONCLUSIONS: Wild-type, but not mutant, TrkB enhances cell migration and transformation.  Our study suggests that TrkB mutations should not be used for selection of patients with lung cancer treated with Trk inhibitors.  High expression of wild-type TrkB might be beneficial for studies of Trk inhibitors.  Clin Cancer Res; 17(9); 2638-45.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1K7iKVaqCbVg90H21EOLACvtfcHk0lhMGnWLl92K0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVGhu74%253D&md5=4560249cbf46b90fda1f79c9ba6c6922</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3034%26sid%3Dliteratum%253Aachs%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeshita%26aufirst%3DM.%26aulast%3DKoga%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DRole%2520and%2520relevance%2520of%2520TrkB%2520mutations%2520and%2520expression%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2638%26epage%3D2645%26doi%3D10.1158%2F1078-0432.CCR-10-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1674</span>, <span class="refDoi"> DOI: 10.1097/01.JTO.0000473485.38553.f0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1097%2F01.JTO.0000473485.38553.f0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26565381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1670-1674&author=A.+F.+Faragoauthor=L.+P.+Leauthor=Z.+Zhengauthor=A.+Muzikanskyauthor=A.+Drilonauthor=M.+Patelauthor=T.+M.+Bauerauthor=S.+V.+Liuauthor=S.+H.+Ouauthor=D.+Jackmanauthor=D.+B.+Costaauthor=P.+S.+Multaniauthor=G.+G.+Liauthor=Z.+Hornbyauthor=E.+Chow-Manevalauthor=D.+Luoauthor=J.+E.+Limauthor=A.+J.+Iafrateauthor=A.+T.+Shaw&title=Durable+clinical+response+to+entrectinib+in+NTRK1-rearranged+non-small+cell+lung+cancer&doi=10.1097%2F01.JTO.0000473485.38553.f0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Farago, Anna F.; Le, Long P.; Zheng, Zongli; Muzikansky, Alona; Drilon, Alexander; Patel, Manish; Bauer, Todd M.; Liu, Stephen V.; Ou, Sai-Hong I.; Jackman, David; Costa, Daniel B.; Multani, Pratik S.; Li, Gary G.; Hornby, Zachary; Chow-Maneval, Edna; Luo, David; Lim, Jonathan E.; Iafrate, Anthony J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1670-1674</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor malignancies, leading to expression of an oncogenic TrkA fusion protein.  Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor, including TrkA.  We sought to det. the frequency of NTRK1 rearrangements in NSCLC and to assess the clin. activity of entrectinib.  Methods: We screened 1378 cases of NSCLC using anchored multiplex polymerase chain reaction (AMP).  A patient with an NTRK1 gene rearrangement was enrolled onto a Phase 1 dose escalation study of entrectinib in adult patients with locally advanced or metastatic tumors (NCT02097810).  We assessed safety and response to treatment.  Results: We identified NTRK1 gene rearrangements at a frequency of 0.1% in this cohort.  A patient with stage IV lung adenocrcinoma with an SQSTM1-NTRK1 fusion transcript expression was treated with entrectinib.  Entrectinib was well tolerated, with no grade 3-4 adverse events.  Within three weeks of starting on treatment, the patient reported resoln. of prior dyspnea and pain.  Restaging CT scans demonstrated a RECIST partial response (PR) and complete resoln. of all brain metastases.  This patient has continued on treatment for over 6 mo with an ongoing PR.  Conclusions: Entrectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrangements, including those with central nervous system metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9e_5UdIxTprVg90H21EOLACvtfcHk0lhMGnWLl92K0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rN&md5=1d0160c35a3bdbdcb2ebd01313cc18ba</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1097%2F01.JTO.0000473485.38553.f0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.JTO.0000473485.38553.f0%26sid%3Dliteratum%253Aachs%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DLe%26aufirst%3DL.%2BP.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DJackman%26aufirst%3DD.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DLi%26aufirst%3DG.%2BG.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DJ.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DDurable%2520clinical%2520response%2520to%2520entrectinib%2520in%2520NTRK1-rearranged%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D1670%26epage%3D1674%26doi%3D10.1097%2F01.JTO.0000473485.38553.f0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coulier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4202</span>– <span class="NLM_lpage">4210</span>, <span class="refDoi"> DOI: 10.1128/MCB.10.8.4202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.10.8.4202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1695324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3cXltFSgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=4202-4210&author=F.+Coulierauthor=R.+Kumarauthor=M.+Ernstauthor=R.+Kleinauthor=D.+Martin-Zancaauthor=M.+Barbacid&title=Human+trk+oncogenes+activated+by+point+mutation%2C+in-frame+deletion%2C+and+duplication+of+the+tyrosine+kinase+domain&doi=10.1128%2FMCB.10.8.4202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain</span></div><div class="casAuthors">Coulier, Francois; Kumar, Ramesh; Ernst, Mary; Klein, Rudiger; Martin-Zanca, Dionisio; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4202-10</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">Malignant activation of the human trk proto-oncogene, a member of the tyrosine protein kinase receptor family, has been implicated in the development of certain human cancers, including colon and thyroid papillary carcinomas.  trk Oncogenes have also been identified in cultured cells transfected with various DNAs.  Three in vitro-generated trk oncogenes, trk2, trk4, and trk5, were studied in an effort to understand the spectrum of mutational events that can activate the human trk gene.  Nucleotide sequence anal. of cDNA clones of trk2 and trk4 revealed that these oncogenes were generated by a head-to-tail arrangement of two trk tyrosine protein kinase domains connected by a purine-rich region.  These oncogenes code for cytoplasmic mols. of 67,000 (p67trk2) and 69,000 (p69trk4) daltons.  In contrast, the product of the trk5 oncogene, gp95trk5, is a cell surface glycoprotein of 95,000 daltons.  This oncogene was generated by a 153-bp in-frame deletion within sequences coding for the extracellular domain of the trk receptor.  This activating deletion encompasses a triplet coding for one of the nine cysteine residues that the trk receptor shares with the product of the highly related trkB tyrosine protein kinase gene.  Introduction of a single point mutation (TGT → AGT) in this codon resulted in a novel trk oncogene whose product, gp140S345, differs from the nontransforming trk proto-oncogene receptor in a single amino acid residue, Ser-345 instead of Cys-345.  These results illustrate that multipole mol. mechanisms, including point mutation, internal deletion, and kinase domain duplication, can result in the malignant activation of the human trk proto-oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBfzY9l-Be7Vg90H21EOLACvtfcHk0lhMGnWLl92K0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltFSgtro%253D&md5=5d0bdb195835480233dec86b99e587fc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1128%2FMCB.10.8.4202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.10.8.4202%26sid%3Dliteratum%253Aachs%26aulast%3DCoulier%26aufirst%3DF.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DErnst%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DHuman%2520trk%2520oncogenes%2520activated%2520by%2520point%2520mutation%252C%2520in-frame%2520deletion%252C%2520and%2520duplication%2520of%2520the%2520tyrosine%2520kinase%2520domain%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1990%26volume%3D10%26spage%3D4202%26epage%3D4210%26doi%3D10.1128%2FMCB.10.8.4202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arevalo, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hempstead, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, P.</span></span> <span> </span><span class="NLM_article-title">A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1204215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11313867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Oitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=1229-1234&author=J.+C.+Arevaloauthor=B.+Condeauthor=B.+I.+Hempsteadauthor=M.+V.+Chaoauthor=D.+Martin-Zancaauthor=P.+Perez&title=A+novel+mutation+within+the+extracellular+domain+of+TrkA+causes+constitutive+receptor+activation&doi=10.1038%2Fsj.onc.1204215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation</span></div><div class="casAuthors">Arevalo, Juan C.; Conde, Blanca; Hempstead, Barbara I.; Chao, Moses V.; Martin-Zanca, Dionisio; Perez, Pilar</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1229-1234</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The TrkA NGF receptor extracellular region contains three leucine repeats flanked by cysteine clusters and two Ig-like domains that are required for specific ligand binding.  Deletion of the Ig-like domains abolishes NGF binding and causes ligand independent activation of the receptor.  Here the authors report a specific mutation that increases the binding affinity of the TrkA receptor for NGF.  A change of proline 203 to alanine (P203A) in the linker region between the leucine repeats and the first Ig-like domain increased NGF binding by decreasing the ligand rate of dissocn.  This mutated receptor was appropriately expressed on the cell surface and promoted ligand-independent neurite outgrowth in PC12nnr5 cells.  The mutant receptor was capable of spontaneous dimerization and was constitutively phosphorylated in the absence of ligand.  Moreover, expression of TrkA-P203A receptor in fibroblasts induced DNA synthesis and transformation and generated tumors in nude mice.  These data suggest that domains outside of the Ig-like structure contribute to ligand binding and constitutive activation of Trk receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdInzQUFxLlLVg90H21EOLACvtfcHk0lgpyTh19Y3OEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Oitb8%253D&md5=ab124796f01721d55a355b5bb501dc5d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204215%26sid%3Dliteratum%253Aachs%26aulast%3DArevalo%26aufirst%3DJ.%2BC.%26aulast%3DConde%26aufirst%3DB.%26aulast%3DHempstead%26aufirst%3DB.%2BI.%26aulast%3DChao%26aufirst%3DM.%2BV.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DPerez%26aufirst%3DP.%26atitle%3DA%2520novel%2520mutation%2520within%2520the%2520extracellular%2520domain%2520of%2520TrkA%2520causes%2520constitutive%2520receptor%2520activation%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D1229%26epage%3D1234%26doi%3D10.1038%2Fsj.onc.1204215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomasson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremont, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westervelt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPersio, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, T. J.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4797</span>– <span class="NLM_lpage">4808</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-09-113027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1182%2Fblood-2007-09-113027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=18270328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVSrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=4797-4808&author=M.+H.+Tomassonauthor=Z.+Xiangauthor=R.+Walgrenauthor=Y.+Zhaoauthor=Y.+Kasaiauthor=T.+Minerauthor=R.+E.+Riesauthor=O.+Lubmanauthor=D.+H.+Fremontauthor=M.+D.+McLellanauthor=J.+E.+Paytonauthor=P.+Westerveltauthor=J.+F.+DiPersioauthor=D.+C.+Linkauthor=M.+J.+Walterauthor=T.+A.+Graubertauthor=M.+Watsonauthor=J.+Batyauthor=S.+Heathauthor=W.+D.+Shannonauthor=R.+Nagarajanauthor=C.+D.+Bloomfieldauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=T.+J.+Ley&title=Somatic+mutations+and+germline+sequence+variants+in+the+expressed+tyrosine+kinase+genes+of+patients+with+de+novo+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-09-113027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia</span></div><div class="casAuthors">Tomasson, Michael H.; Xiang, Zhifu; Walgren, Richard; Zhao, Yu; Kasai, Yumi; Miner, Tracie; Ries, Rhonda E.; Lubman, Olga; Fremont, Daved H.; McLellan, Michael D.; Payton, Jacqueline E.; Westervelt, Peter; DiPersio, John F.; Link, Daniel C.; Walter, Matthew J.; Graubert, Timothy A.; Watson, Mark; Baty, Jack; Heath, Sharon; Shannon, William D.; Nagarajan, Rakesh; Bloomfield, Clara D.; Mardis, Elaine R.; Wilson, Richard K.; Ley, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4797-4808</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in tyrosine kinase (TK) genes (eg, FLT3 and KIT) are found in more than 30% of patients with de novo acute myeloid leukemia (AML); many groups have speculated that mutations in other TK genes may be present in the remaining 70%.  We performed high-throughput resequencing of the kinase domains of 26 TK genes (11 receptor TK; 15 cytoplasmic TK) expressed in most AML patients using genomic DNA from the bone marrow (tumor) and matched skin biopsy samples ("germline") from 94 patients with de novo AML; sequence variants were validated in an addnl. 94 AML tumor samples (14.3 million base pairs of sequence were obtained and analyzed).  We identified known somatic mutations in FLT3, KIT, and JAK2 TK genes at the expected frequencies and found 4 novel somatic mutations, JAK1V623A, JAK1T478S, DDR1A803V, and NTRK1S677N, once each in 4 resp. patients of 188 tested.  We also identified novel germline sequence changes encoding amino acid substitutions (ie, nonsynonymous changes) in 14 TK genes, including TYK2, which had the largest no. of nonsynonymous sequence variants (11 total detected).  Addnl. studies will be required to define the roles that these somatic and germline TK gene variants play in AML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJsCqunCvQLVg90H21EOLACvtfcHk0lgpyTh19Y3OEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVSrsb4%253D&md5=b28273dc598f04d1de0633703a68299a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-09-113027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-09-113027%26sid%3Dliteratum%253Aachs%26aulast%3DTomasson%26aufirst%3DM.%2BH.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DWalgren%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKasai%26aufirst%3DY.%26aulast%3DMiner%26aufirst%3DT.%26aulast%3DRies%26aufirst%3DR.%2BE.%26aulast%3DLubman%26aufirst%3DO.%26aulast%3DFremont%26aufirst%3DD.%2BH.%26aulast%3DMcLellan%26aufirst%3DM.%2BD.%26aulast%3DPayton%26aufirst%3DJ.%2BE.%26aulast%3DWestervelt%26aufirst%3DP.%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26aulast%3DLink%26aufirst%3DD.%2BC.%26aulast%3DWalter%26aufirst%3DM.%2BJ.%26aulast%3DGraubert%26aufirst%3DT.%2BA.%26aulast%3DWatson%26aufirst%3DM.%26aulast%3DBaty%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DW.%2BD.%26aulast%3DNagarajan%26aufirst%3DR.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DLey%26aufirst%3DT.%2BJ.%26atitle%3DSomatic%2520mutations%2520and%2520germline%2520sequence%2520variants%2520in%2520the%2520expressed%2520tyrosine%2520kinase%2520genes%2520of%2520patients%2520with%2520de%2520novo%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D4797%26epage%3D4808%26doi%3D10.1182%2Fblood-2007-09-113027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappabianca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessitore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetuschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argenti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Screpanti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A. R.</span></span> <span> </span><span class="NLM_article-title">TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.ccr.2004.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15488758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsF2rt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=347-360&author=A.+Tacconelliauthor=A.+R.+Farinaauthor=L.+Cappabiancaauthor=G.+Desantisauthor=A.+Tessitoreauthor=A.+Vetuschiauthor=R.+Sferraauthor=N.+Rucciauthor=B.+Argentiauthor=I.+Screpantiauthor=A.+Gulinoauthor=A.+R.+Mackay&title=TrkA+alternative+splicing%3A+a+regulated+tumor-promoting+switch+in+human+neuroblastoma&doi=10.1016%2Fj.ccr.2004.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma</span></div><div class="casAuthors">Tacconelli, Antonella; Farina, Antonietta R.; Cappabianca, Lucia; DeSantis, Giuseppina; Tessitore, Alessandra; Vetuschi, Antonella; Sferra, Roberta; Rucci, Nadia; Argenti, Beatrice; Screpanti, Isabella; Gulino, Alberto; Mackay, Andrew R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-360</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We identify a novel alternative TrkA splice variant, TrkAIII, with deletion of exons 6, 7, and 9 and functional extracellular IG-C1 and N-glycosylation domains, that exhibits expression restricted to undifferentiated early neural progenitors, human neuroblastomas (NBs), and a subset of other neural crest-derived tumors.  This NGF-unresponsive isoform is oncogenic in NIH3T3 cells and promotes tumorigenic NB cell behavior in vitro and in vivo (cell survival, xenograft growth, angiogenesis) resulting from spontaneous tyrosine kinase activity and IP3K/Akt/NF-κB but not Ras/MAPK signaling.  TrkAIII antagonizes NGF/TrkAI signaling, which is responsible for NB growth arrest and differentiation through Ras/MAPK, and its expression is promoted by hypoxia at the expense of NGF-responsive receptors, providing a mechanism for converting NGF/TrkA/Ras/MAPK antioncogenic signals to TrkAIII/IP3K/Akt/NF-κB tumor-promoting signals during tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5rPRmGuddPbVg90H21EOLACvtfcHk0lgpyTh19Y3OEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsF2rt7c%253D&md5=ced7070be1a53d286839a908d65d03aa</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DTacconelli%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DA.%2BR.%26aulast%3DCappabianca%26aufirst%3DL.%26aulast%3DDesantis%26aufirst%3DG.%26aulast%3DTessitore%26aufirst%3DA.%26aulast%3DVetuschi%26aufirst%3DA.%26aulast%3DSferra%26aufirst%3DR.%26aulast%3DRucci%26aufirst%3DN.%26aulast%3DArgenti%26aufirst%3DB.%26aulast%3DScrepanti%26aufirst%3DI.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DMackay%26aufirst%3DA.%2BR.%26atitle%3DTrkA%2520alternative%2520splicing%253A%2520a%2520regulated%2520tumor-promoting%2520switch%2520in%2520human%2520neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D347%26epage%3D360%26doi%3D10.1016%2Fj.ccr.2004.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">8655</span>– <span class="NLM_lpage">8666</span>, <span class="refDoi"> DOI: 10.1128/MCB.20.23.8655-8666.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.20.23.8655-8666.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11073967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFGkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=8655-8666&author=G.+W.+Reutherauthor=Q.+T.+Lambertauthor=M.+A.+Caligiuriauthor=C.+J.+Der&title=Identification+and+characterization+of+an+activating+TrkA+deletion+mutation+in+acute+myeloid+leukemia&doi=10.1128%2FMCB.20.23.8655-8666.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia</span></div><div class="casAuthors">Reuther, Gary W.; Lambert, Que T.; Caligiuri, Michael A.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8655-8666</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, the authors utilized retroviral transfer of cDNA libraries to identify oncogenes that are expressed in acute myeloid leukemia (AML).  From screens using two different cell types as targets for cellular transformation, a single cDNA encoding a variant of the TrkA protooncogene was isolated.  The protein product of this protooncogene, TrkA, is a receptor tyrosine kinase for nerve growth factor.  The isolated transforming cDNA encoded a TrkA protein that contains a 75-amino-acid deletion in the extracellular domain of the receptor and was named ΔTrkA.  ΔTrkA readily transformed fibroblast and epithelial cell lines.  The deletion resulted in activation of the tyrosine kinase domain leading to constitutive tyrosine phosphorylation of the protein.  Expression of ΔTrkA in cells led to the constitutive activation of intracellular signaling pathways that include Ras, extracellular signal-regulated kinase/mitogen-activated protein kinase, and Akt.  Importantly, ΔTrkA altered the apoptotic and growth properties of 32D myeloid progenitor cells, suggesting ΔTrkA may have contributed to the development and/or maintenance of the myeloid leukemia from which it was isolated.  Unlike Bcr-Abl, expression of ΔTrkA did not activate Stat5 in these cells.  The authors have detected expression of ΔTrkA in the original AML sample by reverse transcriptase PCR and by Western blot anal.  While previous TrkA mutations identified from human tumors involved fusion to other proteins, this report is the initial demonstration that deletions within TrkA may play a role in human cancers.  Finally, this report is the first to indicate mutations in TrkA may contribute to leukemogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN8fS7H2J4Y7Vg90H21EOLACvtfcHk0lh-65qT4gNcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFGkurk%253D&md5=38b1eb897615f27b6034468a05cfb913</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.23.8655-8666.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.23.8655-8666.2000%26sid%3Dliteratum%253Aachs%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DLambert%26aufirst%3DQ.%2BT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520an%2520activating%2520TrkA%2520deletion%2520mutation%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D8655%26epage%3D8666%26doi%3D10.1128%2FMCB.20.23.8655-8666.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadnick, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span> <span> </span><span class="NLM_article-title">Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2007.11.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=634-639&author=S.+H.+Kimauthor=J.+S.+Tokarskiauthor=K.+J.+Leavittauthor=B.+E.+Finkauthor=M.+E.+Salvatiauthor=R.+Moquinauthor=M.+T.+Obermeierauthor=G.+L.+Trainorauthor=G.+G.+Viteauthor=L.+K.+Stadnickauthor=J.+S.+Lippyauthor=D.+Youauthor=M.+V.+Lorenziauthor=P.+Chen&title=Identification+of+2-amino-5-%28thioaryl%29thiazoles+as+inhibitors+of+nerve+growth+factor+receptor+TrkA&doi=10.1016%2Fj.bmcl.2007.11.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLeavitt%26aufirst%3DK.%2BJ.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DMoquin%26aufirst%3DR.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DVite%26aufirst%3DG.%2BG.%26aulast%3DStadnick%26aufirst%3DL.%2BK.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DChen%26aufirst%3DP.%26atitle%3DIdentification%2520of%25202-amino-5-%2528thioaryl%2529thiazoles%2520as%2520inhibitors%2520of%2520nerve%2520growth%2520factor%2520receptor%2520TrkA%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D634%26epage%3D639%26doi%3D10.1016%2Fj.bmcl.2007.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, E.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and risk factors: intrahepatic cholangiocarcinoma</span>. <i>Hepatobiliary Surg. Nutr</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.21037/hbsn.2017.01.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.21037%2Fhbsn.2017.01.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28503557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1crnt1WnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=101-104&author=A.+Guptaauthor=E.+Dixon&title=Epidemiology+and+risk+factors%3A+intrahepatic+cholangiocarcinoma&doi=10.21037%2Fhbsn.2017.01.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and risk factors: intrahepatic cholangiocarcinoma</span></div><div class="casAuthors">Gupta Amar; Dixon Elijah</div><div class="citationInfo"><span class="NLM_cas:title">Hepatobiliary surgery and nutrition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-104</span>
        ISSN:<span class="NLM_cas:issn">2304-3881</span>.
    </div><div class="casAbstract">Intrahepatic cholangiocarcinoma (ICC) is a rare entity with a distinct clinical course and epidemiology from hilar and extrahepatic cholangiocarcinoma.  ICC makes up 8-10% of cholangiocarcinomas and 10-20% of all primary liver tumors.  There remains a considerable amount of geographic variation in the incidence of ICC worldwide; however, the overall incidence of this malignancy appears to be rising.  Several risk factors have been identified, such as infectious causes (liver flukes, viral hepatitis), biliary tract disease [primary sclerosing cholangitis (PSC), hepaticolithiasis, biliary cystic diseases], metabolic syndrome, lifestyle choices (alcohol abuse, tobacco use), and cirrhosis.  Despite this, a substantial number of ICC patients do not have any identifiable risk factors, underlining the need for further work into the pathogenesis of this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0S4iCpopdFIqdXsLcGTEUfW6udTcc2ebWAu4c45C3cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crnt1WnsA%253D%253D&md5=eda7445a5640a3a22275da06cc325a8a</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.21037%2Fhbsn.2017.01.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fhbsn.2017.01.02%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DDixon%26aufirst%3DE.%26atitle%3DEpidemiology%2520and%2520risk%2520factors%253A%2520intrahepatic%2520cholangiocarcinoma%26jtitle%3DHepatobiliary%2520Surg.%2520Nutr%26date%3D2017%26volume%3D6%26spage%3D101%26epage%3D104%26doi%3D10.21037%2Fhbsn.2017.01.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selikoff, I. J.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of gastrointestinal cancer</span>. <i>Environ. Health Perspect.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1289/ehp.749299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1289%2Fehp.749299" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1974&pages=299-305&author=I.+J.+Selikoff&title=Epidemiology+of+gastrointestinal+cancer&doi=10.1289%2Fehp.749299"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1289%2Fehp.749299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.749299%26sid%3Dliteratum%253Aachs%26aulast%3DSelikoff%26aufirst%3DI.%2BJ.%26atitle%3DEpidemiology%2520of%2520gastrointestinal%2520cancer%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D1974%26volume%3D9%26spage%3D299%26epage%3D305%26doi%3D10.1289%2Fehp.749299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D. H.</span></span> <span> </span><span class="NLM_article-title">NTRK1 fusion in glioblastoma multiforme</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e91940</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0091940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1371%2Fjournal.pone.0091940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24647444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e91940&author=J.+Kimauthor=Y.+Leeauthor=H.+J.+Choauthor=Y.+E.+Leeauthor=J.+Anauthor=G.+H.+Choauthor=Y.+H.+Koauthor=K.+M.+Jooauthor=D.+H.+Nam&title=NTRK1+fusion+in+glioblastoma+multiforme&doi=10.1371%2Fjournal.pone.0091940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK1 fusion in glioblastoma multiforme</span></div><div class="casAuthors">Kim, Jinkuk; Lee, Yeri; Cho, Hee Jin; Lee, Young-Eun; An, Jaeyeol; Cho, Gye-Hyun; Ko, Young-Hyeh; Joo, Kyeung Min; Nam, Do-Hyun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e91940/1-e91940/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor, yet with no targeted therapy with substantial survival benefit.  Recent studies on solid tumors showed that fusion genes often play driver roles and are promising targets for pharmaceutical intervention.  To survey potential fusion genes in GBMs, we analyzed RNA-Seq data from 162 GBM patients available through The Cancer Genome Atlas (TCGA), and found that 3' exons of neurotrophic tyrosine kinase receptor type 1 (NTRK1, encoding TrkA) are fused to 5' exons of the genes that are highly expressed in neuronal tissues, neurofascin (NFASC) and brevican (BCAN).  The fusions preserved both the transmembrane and kinase domains of NTRK1 in frame.  NTRK1 is a mediator of the pro-survival signaling of nerve growth factor (NGF) and is a known oncogene, found commonly altered in human cancer.  While GBMs largely lacked NTRK1 expression, the fusion-pos. GBMs expressed fusion transcripts in high abundance, and showed elevated NTRK1-pathway activity.  Lentiviral transduction of the NFASC-NTRK1 fusion gene in NIH 3T3 cells increased proliferation in vitro, colony formation in soft agar, and tumor formation in mice, suggesting the possibility that the fusion contributed to the initiation or maintenance of the fusion-pos. GBMs, and therefore may be a rational drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz9tDpBhaQt7Vg90H21EOLACvtfcHk0ljVICxjcvON4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ&md5=c3592983729fa1ad26ee88e9a478d85c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091940%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DY.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DG.%2BH.%26aulast%3DKo%26aufirst%3DY.%2BH.%26aulast%3DJoo%26aufirst%3DK.%2BM.%26aulast%3DNam%26aufirst%3DD.%2BH.%26atitle%3DNTRK1%2520fusion%2520in%2520glioblastoma%2520multiforme%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De91940%26doi%3D10.1371%2Fjournal.pone.0091940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, C.</span></span> <span> </span><span class="NLM_article-title">An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases</span>. <i>J. Cytol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.4103/0970-9371.190455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.4103%2F0970-9371.190455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28028333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FpvVekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=192-198&author=C.+Sharma&title=An+analysis+of+trends+of+incidence+and+cytohistological+correlation+of+papillary+carcinoma+of+the+thyroid+gland+with+evaluation+of+discordant+cases&doi=10.4103%2F0970-9371.190455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases</span></div><div class="casAuthors">Sharma Chetna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cytology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">192-198</span>
        ISSN:<span class="NLM_cas:issn">0970-9371</span>.
    </div><div class="casAbstract">BACKGROUND:  The role of fine-needle aspiration cytology (FNAC) in thyroid nodules has been well-studied but there is a paucity of studies solely involving papillary thyroid carcinoma (PTC).  The diagnostic criteria for PTC are established but still there is a worrisome possibility of false positive and false-negative results, which can have a serious impact on patient care.  This article correlates the cytological and histological diagnosis of PTC with an eventual aim of analyzing the cause of false positive and false negative results in order to prevent misdiagnosis.  An increase in the incidence of PTC in the younger population has been noted.  AIMS:  To analyze the epidemiological trends and cytohistological correlation of PTC and evaluate the discordant cases and pitfalls of FNAC.  MATERIALS AND METHODS:  Seventy-two cases who had undergone both FNAC and histopathological examination (HPE) of the thyroid gland were selected.  Age and sex distribution as well as cytohistological correlation were done for all the cases.  RESULTS:  Cytohistological correlation was 81.94%.  False positives were 5.56% and the false negative rate was 13.2%.  Sensitivity was 86.7% and the positive predictive value was 93.6%.  The peak age was 31-40 years among females and 41-60 years among males.  Seven of our patients were <20 years of age (10%).  CONCLUSION:  FNAC is an indispensible tool for the early diagnosis of PTC.  However, certain conditions of the thyroid gland can cause diagnostic dilemma.  Awareness of pathologists regarding these pitfalls can prevent misdiagnosis and provide better patient care.  Increasing the incidence of PTC with a more striking increase in the younger population makes early diagnosis all the more important owing to better prognosis in this age group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEMeA5etJTeZcXNb62YGmbfW6udTcc2eZYB88KGOc0F7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FpvVekug%253D%253D&md5=b9aed01690c6601bd413b4585bd1fd46</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.4103%2F0970-9371.190455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0970-9371.190455%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DC.%26atitle%3DAn%2520analysis%2520of%2520trends%2520of%2520incidence%2520and%2520cytohistological%2520correlation%2520of%2520papillary%2520carcinoma%2520of%2520the%2520thyroid%2520gland%2520with%2520evaluation%2520of%2520discordant%2520cases%26jtitle%3DJ.%2520Cytol.%26date%3D2016%26volume%3D33%26spage%3D192%26epage%3D198%26doi%3D10.4103%2F0970-9371.190455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grier, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakewich, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)65732-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0002-9440%2810%2965732-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9811336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXns1Ohu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=1998&pages=1451-1458&author=B.+P.+Rubinauthor=C.-J.+Chenauthor=T.+W.+Morganauthor=S.+Xiaoauthor=H.+E.+Grierauthor=H.+P.+Kozakewichauthor=A.+R.+Perez-Ataydeauthor=J.+A.+Fletcher&title=Congenital+mesoblastic+nephroma+t%2812%3B15%29+is+associated+with+ETV6-NTRK3+gene+fusion&doi=10.1016%2FS0002-9440%2810%2965732-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma</span></div><div class="casAuthors">Rubin, Brian P.; Chen, Chang-Jie; Morgan, Thomas W.; Xiao, Sheng; Grier, Holcombe E.; Kozakewich, Harry P.; Perez-Atayde, Antonio R.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1451-1458</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Morphol., cytogenetic, and biol. evidence supports a relation between congenital (infantile) fibrosarcoma (CFS) and congenital mesoblastic nephroma (CMN).  These tumors have a very similar histol. appearance, and they are both assocd. with polysomies for chromosomes 8, 11, 17, and 20.  Recently, CFS was shown to contain a novel t(12; 15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion.  The aims of this study were to det. whether congenital mesoblastic nephroma contains the t(12;15)(p13;q25) translocation and ETV6-NTRK3 gene fusion and whether ETV6-NTRK3 fusions, in CMN and CFS, antedate acquisition of nonrandom chromosome polysomies.  To address these aims, the authors evaluated (1) ETV6-NTRK3 fusion transcripts by reverse transcriptase polymerase chain reaction and sequence anal., (2) genomic ETV6-region chromosomal rearrangement by fluorescence in situ hybridization, and (3) chromosomal polysomies by karyotyping and fluorescence in situ hybridization.  The authors report ETV6-NTRK3 fusion transcripts and/or ETV6-region rearrangement in five of six CMNs and in five of five CFSs.  The ETV6-NTRK3 fusion transcripts and/or ETV-region chromosome rearrangements were demonstrated in two CMNs and one CFS that lacked chromosome polysomies.  These findings demonstrate that t(12;15) translocation, and the assocd. ETV6-NTRK3 fusion, can antedate acquisition of chromosome polysomies in CMN and CFS.  CMN and CFS are pathogenetically related, and it is likely that they represent a single neoplastic entity, arising in either renal or soft tissue locations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4y1vnjx9jLrVg90H21EOLACvtfcHk0ljVICxjcvON4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1Ohu7k%253D&md5=b227a133f1dd93a911628f45ede835fd</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2965732-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252965732-X%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DChen%26aufirst%3DC.-J.%26aulast%3DMorgan%26aufirst%3DT.%2BW.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DGrier%26aufirst%3DH.%2BE.%26aulast%3DKozakewich%26aufirst%3DH.%2BP.%26aulast%3DPerez-Atayde%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCongenital%2520mesoblastic%2520nephroma%2520t%252812%253B15%2529%2520is%2520associated%2520with%2520ETV6-NTRK3%2520gene%2520fusion%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1998%26volume%3D153%26spage%3D1451%26epage%3D1458%26doi%3D10.1016%2FS0002-9440%2810%2965732-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittleman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrom, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruchko, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnholtz-Sloan, J. S.</span></span> <span> </span><span class="NLM_article-title">Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry</span>. <i>Front Public Health</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">151</span>, <span class="refDoi"> DOI: 10.3389/fpubh.2016.00151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3389%2Ffpubh.2016.00151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=27493936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2s3nvVersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=151&author=L.+N.+Chienauthor=H.+Gittlemanauthor=Q.+T.+Ostromauthor=K.+S.+Hungauthor=A.+E.+Sloanauthor=Y.+C.+Hsiehauthor=C.+Kruchkoauthor=L.+R.+Rogersauthor=Y.+F.+Wangauthor=H.+Y.+Chiouauthor=J.+S.+Barnholtz-Sloan&title=Comparative+brain+and+central+nervous+system+tumor+incidence+and+survival+between+the+United+States+and+Taiwan+based+on+population-based+registry&doi=10.3389%2Ffpubh.2016.00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry</span></div><div class="casAuthors">Chien Li-Nien; Gittleman Haley; Ostrom Quinn T; Kruchko Carol; Hung Kuo-Sheng; Sloan Andrew E; Hsieh Yi-Chen; Rogers Lisa R; Wang Ye-Fan Glavin; Chiou Hung-Yi; Barnholtz-Sloan Jill S</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in public health</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151</span>
        ISSN:<span class="NLM_cas:issn">2296-2565</span>.
    </div><div class="casAbstract">PURPOSE:  Reasons for worldwide variability in the burden of primary malignant brain and central nervous system (CNS) tumors remain unclear.  This study compares the incidence and survival of malignant brain and CNS tumors by selected histologic types between the United States (US) and Taiwan.  METHODS:  Data from 2002 to 2010 were selected from two population-based cancer registries for primary malignant brain and CNS tumors: the Central Brain Tumor Registry of the United States and the Taiwan Cancer Registry.  Two registries had similar process of collecting patients with malignant brain tumor, and the quality of two registries was comparative.  The age-adjusted incidence rate (IR), IR ratio, and survival by histological types, age, and gender were used to study regional differences.  RESULTS:  The overall age-adjusted IRs were 5.91 per 100,000 in the US and 2.68 per 100,000 in Taiwan.  The most common histologic type for both countries was glioblastoma (GBM) with a 12.9% higher proportion in the US than in Taiwan.  GBM had the lowest survival rate of any histology in both countries (US 1-year survival rate = 37.5%; Taiwan 1-year survival rate = 50.3%).  The second largest group was astrocytoma, excluding GBM and anaplastic astrocytoma, with the distribution being slightly higher in Taiwan than in the US.  CONCLUSION:  Our findings revealed differences by histological type and grade of primary malignant brain and CNS tumors between two sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-W1hzsSj1oyCEBeYuoi7AfW6udTcc2eaJ08FfPKHU_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3nvVersw%253D%253D&md5=b3ca18e2355a2f51cf3693dfbacf239a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffpubh.2016.00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpubh.2016.00151%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DL.%2BN.%26aulast%3DGittleman%26aufirst%3DH.%26aulast%3DOstrom%26aufirst%3DQ.%2BT.%26aulast%3DHung%26aufirst%3DK.%2BS.%26aulast%3DSloan%26aufirst%3DA.%2BE.%26aulast%3DHsieh%26aufirst%3DY.%2BC.%26aulast%3DKruchko%26aufirst%3DC.%26aulast%3DRogers%26aufirst%3DL.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DChiou%26aufirst%3DH.%2BY.%26aulast%3DBarnholtz-Sloan%26aufirst%3DJ.%2BS.%26atitle%3DComparative%2520brain%2520and%2520central%2520nervous%2520system%2520tumor%2520incidence%2520and%2520survival%2520between%2520the%2520United%2520States%2520and%2520Taiwan%2520based%2520on%2520population-based%2520registry%26jtitle%3DFront%2520Public%2520Health%26date%3D2016%26volume%3D4%26spage%3D151%26doi%3D10.3389%2Ffpubh.2016.00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paugh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahawatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onar-Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becksfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadodaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yergeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boop, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0lgAMfmu6zq-jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mourad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jetmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jategaonkar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moubayed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urken, M. L.</span></span> <span> </span><span class="NLM_article-title">Epidemiological trends of head and neck cancer in the United States: a SEER population study</span>. <i>J. Oral Maxillofac. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">2562</span>– <span class="NLM_lpage">2572</span>, <span class="refDoi"> DOI: 10.1016/j.joms.2017.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.joms.2017.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28618252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1cnos1CisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2017&pages=2562-2572&author=M.+Mouradauthor=T.+Jetmoreauthor=A.+A.+Jategaonkarauthor=S.+Moubayedauthor=E.+Moshierauthor=M.+L.+Urken&title=Epidemiological+trends+of+head+and+neck+cancer+in+the+United+States%3A+a+SEER+population+study&doi=10.1016%2Fj.joms.2017.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study</span></div><div class="casAuthors">Mourad Moustafa; Jetmore Thomas; Jategaonkar Ameya A; Moubayed Sami; Moshier Erin; Urken Mark L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2562-2572</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  This study represents the most recent epidemiologic trends of head and neck cancer (HNC) in the United States.  It provides an important discussion on oropharyngeal cancer and cancers related to the human papillomavirus.  The objective was to identify trends in HNC (2002 to 2012) within the United States.  MATERIALS AND METHODS:  This study is a retrospective analysis of the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) submission.  Using the November 2014 submission of the SEER database and SEER-18 data files, data from 2002 to 2012 were analyzed to determine the most recent epidemiologic trends.  HNCs of all subtypes were analyzed together.  Laryngeal cancers were further analyzed separately.  Oropharyngeal cancers of the base of tongue and tonsil were analyzed independently to attempt to trend HPV-related cancers.  RESULTS:  From 2002 to 2012, there were 149,301 cases of HNC recorded in the SEER database.  The HNC rate decreased by 0.22% per year (P = .0549) and the rate of laryngeal cancer decreased by 1.9% per year (P < .0001).  The rate of oropharyngeal (HPV-related) cancer increased by 2.5% per year (P < .0001).  HNC rates increased significantly in Kentucky and Connecticut and decreased in California (P < .05).  HPV-related cancers increased significantly in all states except Georgia, Hawaii, and Michigan (P < .05).  Laryngeal cancer rates decreased in California, Georgia, New Jersey, and New Mexico (P < .05).  CONCLUSIONS:  The overall incidence of HNC is decreasing in the United States.  There is an increasing incidence of HPV-related cancers of the oropharynx.  Meaningful differences in cancer incidence and rate of change exist between men and women.  Furthermore, younger groups have a greater decrease of overall HNC, with an overall increase in HPV-related cancer in patients older than 50 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaBwyLjBg0t8jl5L8hwNX0fW6udTcc2eaJ08FfPKHU_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnos1CisA%253D%253D&md5=849a0f247d967374ba911aeb06b84b99</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.joms.2017.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joms.2017.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DMourad%26aufirst%3DM.%26aulast%3DJetmore%26aufirst%3DT.%26aulast%3DJategaonkar%26aufirst%3DA.%2BA.%26aulast%3DMoubayed%26aufirst%3DS.%26aulast%3DMoshier%26aufirst%3DE.%26aulast%3DUrken%26aufirst%3DM.%2BL.%26atitle%3DEpidemiological%2520trends%2520of%2520head%2520and%2520neck%2520cancer%2520in%2520the%2520United%2520States%253A%2520a%2520SEER%2520population%2520study%26jtitle%3DJ.%2520Oral%2520Maxillofac.%2520Surg.%26date%3D2017%26volume%3D75%26spage%3D2562%26epage%3D2572%26doi%3D10.1016%2Fj.joms.2017.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, N.</span></span> <span> </span><span class="NLM_article-title">New driver mutations in non-small-cell lung cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(10)70087-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS1470-2045%2810%2970087-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21277552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=175-180&author=W.+Paoauthor=N.+Girard&title=New+driver+mutations+in+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2810%2970087-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">New driver mutations in non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Girard, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Treatment decisions for patients with lung cancer have historically been based on tumor histol.  Some understanding of the mol. compn. of tumors has led to the development of targeted agents, for which initial findings are promising.  Clearer understanding of mutations in relevant genes and their effects on cancer cell proliferation and survival, is, therefore, of substantial interest.  We review current knowledge about mol. subsets in non-small-cell lung cancer that have been identified as potentially having clin. relevance to targeted therapies.  Since mutations in EGFR and KRAS have been extensively reviewed elsewhere, here, we discuss subsets defined by so-called driver mutations in ALK, HER2 (also known as ERBB2), BRAF, PIK3CA, AKT1, MAP2K1, and MET.  The adoption of treatment tailored according to the genetic make-up of individual tumors would involve a paradigm shift, but might lead to substantial therapeutic improvements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplMPwgmZjAT7Vg90H21EOLACvtfcHk0lgiC48RIguK9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D&md5=3d590b884d4a9827e85781d65d17759f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970087-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970087-5%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGirard%26aufirst%3DN.%26atitle%3DNew%2520driver%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D175%26epage%3D180%26doi%3D10.1016%2FS1470-2045%2810%2970087-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damjanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenderi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, S.</span></span> <span> </span><span class="NLM_article-title">Mammary analogue secretory carcinoma (MASC) of the salivary gland: a new tumor entity</span>. <i>Bosnian J. Basic Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.17305/bjbms.2016.1321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.17305%2Fbjbms.2016.1321" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=237-238&author=I.+Damjanovauthor=F.+Skenderiauthor=S.+Vranic&title=Mammary+analogue+secretory+carcinoma+%28MASC%29+of+the+salivary+gland%3A+a+new+tumor+entity&doi=10.17305%2Fbjbms.2016.1321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.17305%2Fbjbms.2016.1321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17305%252Fbjbms.2016.1321%26sid%3Dliteratum%253Aachs%26aulast%3DDamjanov%26aufirst%3DI.%26aulast%3DSkenderi%26aufirst%3DF.%26aulast%3DVranic%26aufirst%3DS.%26atitle%3DMammary%2520analogue%2520secretory%2520carcinoma%2520%2528MASC%2529%2520of%2520the%2520salivary%2520gland%253A%2520a%2520new%2520tumor%2520entity%26jtitle%3DBosnian%2520J.%2520Basic%2520Med.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D237%26epage%3D238%26doi%3D10.17305%2Fbjbms.2016.1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi-Ishimae, M.</span></span> <span> </span><span class="NLM_article-title">Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias</span>. <i>Med. Pediatr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1002/mpo.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fmpo.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11568912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BD3Mrit1eltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=417&author=M.+Eguchiauthor=M.+Eguchi-Ishimae&title=Absence+of+t%2812%3B15%29+associated+ETV6-NTRK3+fusion+transcripts+in+pediatric+acute+leukemias&doi=10.1002%2Fmpo.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias</span></div><div class="casAuthors">Eguchi M; Eguchi-Ishimae M</div><div class="citationInfo"><span class="NLM_cas:title">Medical and pediatric oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">417</span>
        ISSN:<span class="NLM_cas:issn">0098-1532</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzCZP9DwrZeAvupmecNw_lfW6udTcc2ebndog4tzjFi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mrit1eltA%253D%253D&md5=7ef3ad0abc3932135cb256d1d17e5352</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1002%2Fmpo.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmpo.1223%26sid%3Dliteratum%253Aachs%26aulast%3DEguchi%26aufirst%3DM.%26aulast%3DEguchi-Ishimae%26aufirst%3DM.%26atitle%3DAbsence%2520of%2520t%252812%253B15%2529%2520associated%2520ETV6-NTRK3%2520fusion%2520transcripts%2520in%2520pediatric%2520acute%2520leukemias%26jtitle%3DMed.%2520Pediatr.%2520Oncol.%26date%3D2001%26volume%3D37%26spage%3D417%26doi%3D10.1002%2Fmpo.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne-Turner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCastlain, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobucci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiernik, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldoss, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlschmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrozek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornblau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paietta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullighan, C. G.</span></span> <span> </span><span class="NLM_article-title">High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.69.0073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2016.69.0073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=27870571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2snoslCmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=394-401&author=K.%0AG.+Robertsauthor=Z.+Guauthor=D.+Payne-Turnerauthor=K.+McCastlainauthor=R.+C.+Harveyauthor=I.+M.+Chenauthor=D.+Peiauthor=I.+Iacobucciauthor=M.+Valentineauthor=S.+B.+Poundsauthor=L.+Shiauthor=Y.+Liauthor=J.+Zhangauthor=C.+Chengauthor=A.+Rambaldiauthor=M.+Tosiauthor=O.+Spinelliauthor=J.+P.+Radichauthor=M.+D.+Mindenauthor=J.+M.+Roweauthor=S.+Lugerauthor=M.+R.+Litzowauthor=M.+S.+Tallmanauthor=P.+H.+Wiernikauthor=R.+Bhatiaauthor=I.+Aldossauthor=J.+Kohlschmidtauthor=K.+Mrozekauthor=G.+Marcucciauthor=C.+D.+Bloomfieldauthor=W.+Stockauthor=S.+Kornblauauthor=H.+M.+Kantarjianauthor=M.+Konoplevaauthor=E.+Paiettaauthor=C.+L.+Willmanauthor=C.+G.+Mullighan&title=High+frequency+and+poor+outcome+of+philadelphia+chromosome-like+acute+lymphoblastic+leukemia+in+adults&doi=10.1200%2FJCO.2016.69.0073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults</span></div><div class="casAuthors">Roberts Kathryn G; Gu Zhaohui; Payne-Turner Debbie; McCastlain Kelly; Harvey Richard C; Chen I-Ming; Pei Deqing; Iacobucci Ilaria; Valentine Marcus; Pounds Stanley B; Shi Lei; Li Yongjin; Zhang Jinghui; Cheng Cheng; Rambaldi Alessandro; Tosi Manuela; Spinelli Orietta; Radich Jerald P; Minden Mark D; Rowe Jacob M; Luger Selina; Litzow Mark R; Tallman Martin S; Wiernik Peter H; Bhatia Ravi; Aldoss Ibrahim; Kohlschmidt Jessica; Mrozek Krzysztof; Marcucci Guido; Bloomfield Clara D; Stock Wendy; Kornblau Stephen; Kantarjian Hagop M; Konopleva Marina; Paietta Elisabeth; Willman Cheryl L; Mullighan Charles G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">394-401</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors.  We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy.  Patients and Methods The frequency of Ph-like ALL was assessed by gene expression profiling of 798 patients with B-cell ALL age 21 to 86 years.  Event-free survival and overall survival were determined for Ph-like ALL versus non-Ph-like ALL patients.  Detailed genomic analysis was performed on 180 of 194 patients with Ph-like ALL.  Results Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of young adults (age 21 to 39 years), 20.4% of adults (age 40 to 59 years), and 24.0% of older adults (age 60 to 86 years).  Overall, patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3% [95% CI, 42.8% to 56.2%; n = 247], respectively; P < .001).  We identified kinase-activating alterations in 88% of patients with Ph-like ALL, including CRLF2 rearrangements (51%), ABL class fusions (9.8%), JAK2 or EPOR rearrangements (12.4%), other JAK-STAT sequence mutations (7.2%), other kinase alterations (4.1%), and Ras pathway mutations (3.6%).  Eleven new kinase rearrangements were identified, including four involving new kinase or cytokine receptor genes and seven involving new partners for previously identified genes.  Conclusion Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome.  The diverse range of kinase-activating alterations in Ph-like ALL has important therapeutic implications.  Trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to evaluate the clinical utility of these agents in the treatment of Ph-like ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROzMeK0FCHhM25P7XSLhESfW6udTcc2ebndog4tzjFi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snoslCmsQ%253D%253D&md5=a56e0480b6a9bb0ad7bad0c54c7daae8</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.69.0073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.69.0073%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DK.%2BG.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DPayne-Turner%26aufirst%3DD.%26aulast%3DMcCastlain%26aufirst%3DK.%26aulast%3DHarvey%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DI.%2BM.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DValentine%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DRambaldi%26aufirst%3DA.%26aulast%3DTosi%26aufirst%3DM.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26aulast%3DLuger%26aufirst%3DS.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DAldoss%26aufirst%3DI.%26aulast%3DKohlschmidt%26aufirst%3DJ.%26aulast%3DMrozek%26aufirst%3DK.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DKornblau%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DPaietta%26aufirst%3DE.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26atitle%3DHigh%2520frequency%2520and%2520poor%2520outcome%2520of%2520philadelphia%2520chromosome-like%2520acute%2520lymphoblastic%2520leukemia%2520in%2520adults%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D394%26epage%3D401%26doi%3D10.1200%2FJCO.2016.69.0073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fancelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varasi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candiani, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpinelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapwijk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsiglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soncini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storici, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugnoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, P.</span></span> <span> </span><span class="NLM_article-title">1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7247</span>– <span class="NLM_lpage">7251</span>, <span class="refDoi"> DOI: 10.1021/jm060897w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060897w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFCjtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7247-7251&author=D.+Fancelliauthor=J.+Mollauthor=M.+Varasiauthor=R.+Bravoauthor=R.+Articoauthor=D.+Bertaauthor=S.+Bindiauthor=A.+Cameronauthor=I.+Candianiauthor=P.+Cappellaauthor=P.+Carpinelliauthor=W.+Crociauthor=B.+Forteauthor=M.+L.+Giorginiauthor=J.+Klapwijkauthor=A.+Marsiglioauthor=E.+Pesentiauthor=M.+Rocchettiauthor=F.+Rolettoauthor=D.+Severinoauthor=C.+Sonciniauthor=P.+Storiciauthor=R.+Tonaniauthor=P.+Zugnoniauthor=P.+Vianello&title=1%2C4%2C5%2C6-tetrahydropyrrolo%5B3%2C4-c%5Dpyrazoles%3A+identification+of+a+potent+Aurora+kinase+inhibitor+with+a+favorable+antitumor+kinase+inhibition+profile&doi=10.1021%2Fjm060897w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile</span></div><div class="casAuthors">Fancelli, Daniele; Moll, Juergen; Varasi, Mario; Bravo, Rodrigo; Artico, Roberta; Berta, Daniela; Bindi, Simona; Cameron, Alexander; Candiani, Ilaria; Cappella, Paolo; Carpinelli, Patrizia; Croci, Walter; Forte, Barbara; Giorgini, Maria Laura; Klapwijk, Jan; Marsiglio, Aurelio; Pesenti, Enrico; Rocchetti, Maurizio; Roletto, Fulvia; Severino, Dino; Soncini, Chiara; Storici, Paola; Tonani, Roberto; Zugnoni, Paola; Vianello, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7247-7251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization of a series of 5-phenylacetyl 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivs. toward the inhibition of Aurora kinases led to the identification of compd. 9d.(I).  This is a potent inhibitor of Aurora kinases that also shows low nanomolar potency against addnl. anticancer kinase targets.  Based on its high antiproliferative activity on different cancer cell lines, favorable chemico-phys. and pharmacokinetic properties, and high efficacy in in vivo tumor models, compd. 9d was ultimately selected for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0zkyh7ON2-rVg90H21EOLACvtfcHk0lg47Uvi7ZCTVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFCjtb3J&md5=55cd95b6fdef641bdb21c4b5a18f4b28</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm060897w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060897w%26sid%3Dliteratum%253Aachs%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DArtico%26aufirst%3DR.%26aulast%3DBerta%26aufirst%3DD.%26aulast%3DBindi%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCandiani%26aufirst%3DI.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCroci%26aufirst%3DW.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DKlapwijk%26aufirst%3DJ.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DSeverino%26aufirst%3DD.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DTonani%26aufirst%3DR.%26aulast%3DZugnoni%26aufirst%3DP.%26aulast%3DVianello%26aufirst%3DP.%26atitle%3D1%252C4%252C5%252C6-tetrahydropyrrolo%255B3%252C4-c%255Dpyrazoles%253A%2520identification%2520of%2520a%2520potent%2520Aurora%2520kinase%2520inhibitor%2520with%2520a%2520favorable%2520antitumor%2520kinase%2520inhibition%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7247%26epage%3D7251%26doi%3D10.1021%2Fjm060897w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteve-Puig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparatta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerroni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutzner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, B. C.</span></span> <span> </span><span class="NLM_article-title">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3116</span>, <span class="refDoi"> DOI: 10.1038/ncomms4116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fncomms4116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24445538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3116&author=T.+Wiesnerauthor=J.+Heauthor=R.+Yelenskyauthor=R.+Esteve-Puigauthor=T.+Bottonauthor=I.+Yehauthor=D.+Lipsonauthor=G.+Ottoauthor=K.+Brennanauthor=R.+Muraliauthor=M.+Garridoauthor=V.+A.+Millerauthor=J.+S.+Rossauthor=M.+F.+Bergerauthor=A.+Sparattaauthor=G.+Palmedoauthor=L.+Cerroniauthor=K.+J.+Busamauthor=H.+Kutznerauthor=M.+T.+Croninauthor=P.+J.+Stephensauthor=B.+C.+Bastian&title=Kinase+fusions+are+frequent+in+Spitz+tumours+and+spitzoid+melanomas&doi=10.1038%2Fncomms4116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span></div><div class="casAuthors">Wiesner Thomas; Murali Rajmohan; Berger Michael F; Busam Klaus J; Bastian Boris C; Wiesner Thomas; Cerroni Lorenzo; He Jie; Yelensky Roman; Lipson Doron; Otto Geoff; Brennan Kristina; Miller Vincent A; Ross Jeffrey S; Cronin Maureen T; Stephens Philip J; Esteve-Puig Rosaura; Botton Thomas; Yeh Iwei; Garrido Maria; Sparatta Alyssa; Bastian Boris C; Murali Rajmohan; Bastian Boris C; Palmedo Gabriele; Kutzner Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3116</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features.  They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours).  Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent.  Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern.  The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas.  Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro.  In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd1A4UrEIWolQKX3ooHxWjfW6udTcc2eZqEHPFP05thbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D&md5=c98dfce5cbc4b2c38e3898b9e0c4c4fa</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fncomms4116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4116%26sid%3Dliteratum%253Aachs%26aulast%3DWiesner%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DEsteve-Puig%26aufirst%3DR.%26aulast%3DBotton%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DI.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DK.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DSparatta%26aufirst%3DA.%26aulast%3DPalmedo%26aufirst%3DG.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DKinase%2520fusions%2520are%2520frequent%2520in%2520Spitz%2520tumours%2520and%2520spitzoid%2520melanomas%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3116%26doi%3D10.1038%2Fncomms4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turbeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. M.</span></span> <span> </span><span class="NLM_article-title">Prevalence and incidence of acute myeloid leukemia may be higher than currently accepted estimates among the ≥ 65 year-old population in the United States</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=958&author=S.+Turbevilleauthor=K.+M.+Francisauthor=I.+Behmauthor=G.+R.+Chiuauthor=H.+Sanchezauthor=B.+Morrisonauthor=J.+M.+Rowe&title=Prevalence+and+incidence+of+acute+myeloid+leukemia+may+be+higher+than+currently+accepted+estimates+among+the+%E2%89%A5+65+year-old+population+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurbeville%26aufirst%3DS.%26aulast%3DFrancis%26aufirst%3DK.%2BM.%26aulast%3DBehm%26aufirst%3DI.%26aulast%3DChiu%26aufirst%3DG.%2BR.%26aulast%3DSanchez%26aufirst%3DH.%26aulast%3DMorrison%26aufirst%3DB.%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26atitle%3DPrevalence%2520and%2520incidence%2520of%2520acute%2520myeloid%2520leukemia%2520may%2520be%2520higher%2520than%2520currently%2520accepted%2520estimates%2520among%2520the%2520%25E2%2589%25A5%252065%2520year-old%2520population%2520in%2520the%2520United%2520States%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knezevich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P.</span></span> <span> </span><span class="NLM_article-title">A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1038/ng0298-184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fng0298-184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9462753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXos1emsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=184-187&author=S.+Knezevichauthor=D.+McFaddenauthor=W.+Taoauthor=J.+Limauthor=P.+Sorensen&title=A+novel+ETV6-NTRK3+gene+fusion+in+congenital+fibrosarcoma&doi=10.1038%2Fng0298-184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma</span></div><div class="casAuthors">Knezevich, Stevan R.; McFadden, Deborah E.; Tao, Wen; Lim, Jerian F.; Sorensen, Poul H. B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-187</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Congenital (or infantile) fibrosarcoma (CFS) is a malignant tumor of fibroblasts that occurs in patients aged two years or younger.  CFS is unique among human sarcomas in that it has an excellent prognosis and very low metastatic rate.  CFS is histol. identical to adult-type fibrosarcoma (ATFS); however, ATFS is an aggressive malignancy of adults and older children that has a poor prognosis.  We report a novel recurrent t(12; 15)(p13; q25) rearrangement in CFS that may underlie that distinctive biol. properties of this tumor.  By cloning the chromosome breakpoints, we show that the rearrangements fuses the ETV6 (also known as TEL) gene from 12p13 with the 15q25 NTRK3 neurotrophin-3 receptor gene (also known as TRKC).  Anal. of mRNA revealed the expression of ETV6-NTRK3 chimeric transcripts in all three CFS tumors analyzed.  These were not detected in ATFS or infantile fibromatosis (IFB), a histol. similar but benign fibroblastic proliferation occurring in the same age-group as CFS.  ETV6-NTRK3 fusion transcripts encode the helix-loop-helix (HLH) protein dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3.  Our studies indicate that a chimeric PTK is expressed in CFS and this may contribute to oncogenesis by dysregulation of NTRK3 signal transduction pathways.  Moreover, ETV6-NTRK3 gene fusion provide a potential diagnostic marker for CFS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT0hrvnhkh-7Vg90H21EOLACvtfcHk0lh2XxT2aadxNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXos1emsw%253D%253D&md5=6a83b8790a126a34cc8c4afe5d76c4b0</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fng0298-184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0298-184%26sid%3Dliteratum%253Aachs%26aulast%3DKnezevich%26aufirst%3DS.%26aulast%3DMcFadden%26aufirst%3DD.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DSorensen%26aufirst%3DP.%26atitle%3DA%2520novel%2520ETV6-NTRK3%2520gene%2520fusion%2520in%2520congenital%2520fibrosarcoma%26jtitle%3DNat.%2520Genet.%26date%3D1998%26volume%3D18%26spage%3D184%26epage%3D187%26doi%3D10.1038%2Fng0298-184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, J. W.</span></span> <span> </span><span class="NLM_article-title">Secretory breast carcinoma: A report of three cases and a review of the literature</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.3892/ol.2014.2213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3892%2Fol.2014.2213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25009650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpvFejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=683-686&author=S.+G.+Leeauthor=S.+P.+Jungauthor=H.+Y.+Leeauthor=S.+Kimauthor=H.+Y.+Kimauthor=I.+Kimauthor=J.+W.+Bae&title=Secretory+breast+carcinoma%3A+A+report+of+three+cases+and+a+review+of+the+literature&doi=10.3892%2Fol.2014.2213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Secretory breast carcinoma: A report of three cases and a review of the literature</span></div><div class="casAuthors">Lee Seung Geun; Jung Seung Pil; Lee Hye Yoon; Kim Sinill; Kim Hoon Yub; Bae Jeoung Won; Kim Insun</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">683-686</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Secretory breast carcinoma is a very rare and distinct subtype of breast cancer, characterized by the presence of intracellular and extracellular secretory material.  Secretory breast carcinoma has a good clinical outcome and systemic involvement is rare.  The majority of studies of this tumor have been case reports or separate analyses, and due to the rarity of these tumors, it has been difficult to fully elucidate their characteristics and define optimal treatment strategies.  To add to the current knowledge of secretory breast carcinoma, the present study reports three cases of secretory breast carcinoma in patients of different ages, and with different hormone receptor statuses and treatment methods.  The present study identified that each patient with secretory breast carcinoma may present with different symptoms and clinical characteristics.  Therefore, therapeutic options should be selected based on the overall status of the patient and the characteristics of this rare disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_lpLrbLKORMjl5L8hwNX0fW6udTcc2eZqEHPFP05thbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpvFejug%253D%253D&md5=9ae7f3d512e7f16b2d11fc7467527eb4</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.3892%2Fol.2014.2213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2014.2213%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DJung%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DI.%26aulast%3DBae%26aufirst%3DJ.%2BW.%26atitle%3DSecretory%2520breast%2520carcinoma%253A%2520A%2520report%2520of%2520three%2520cases%2520and%2520a%2520review%2520of%2520the%2520literature%26jtitle%3DOncol.%2520Lett.%26date%3D2014%26volume%3D8%26spage%3D683%26epage%3D686%26doi%3D10.3892%2Fol.2014.2213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunnane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, J. L.</span></span> <span> </span><span class="NLM_article-title">The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5729</span>– <span class="NLM_lpage">5735</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1203922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11126359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslylsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5729-5735&author=J.+P.+Russellauthor=D.+J.+Powellauthor=M.+Cunnaneauthor=A.+Grecoauthor=G.+Portellaauthor=M.+Santoroauthor=A.+Fuscoauthor=J.+L.+Rothstein&title=The+TRK-T1+fusion+protein+induces+neoplastic+transformation+of+thyroid+epithelium&doi=10.1038%2Fsj.onc.1203922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium</span></div><div class="casAuthors">Russell, John P.; Powell, Daniel J.; Cunnane, Mary; Greco, Angela; Portella, Giuseppe; Santoro, Massimo; Fusco, Alfredo; Rothstein, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5729-5735</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic anal. of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal translocations that form oncogenic fusion proteins and promote thyroid tumorigenesis in up to 60% of tumors examd.  Although, the majority of thyroid specific translocations involve the growth factor receptor c-RET, variant rearrangements of the receptor for nerve growth factor, NTRK1 have also been described.  One such translocation, TRK-T1, forms a fusion protein composed of the carboxyl terminal tyrosine kinase domain of NTRK1 and the amino terminal portion of TPR (Translocated Promoter Region).  To det. if TRK-T1 expression can cause thyroid cancer in vivo, the authors developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid.  Immunohistochem. anal. of TRK-T1 transgenic mouse thyroids revealed TRK-T1 staining within the thyroid follicular epithelium.  In contrast to nontransgenic littermates, 54% of transgenic mice developed thyroid abnormalities that included follicular hyperplasia and papillary carcinoma.  Furthermore, all transgenic mice examd. greater than 7 mo of age developed thyroid hyperplasia and/or carcinoma.  These data support the conclusion that TRK-T1 is oncogenic in vivo and contributes to the neoplastic transformation of the thyroid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNu_2azw_DDrVg90H21EOLACvtfcHk0lhC2Q50tRF9cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslylsLk%253D&md5=d49e7b624370223e3b73b45aae1fdad6</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203922%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DJ.%2BP.%26aulast%3DPowell%26aufirst%3DD.%2BJ.%26aulast%3DCunnane%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DPortella%26aufirst%3DG.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRothstein%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520TRK-T1%2520fusion%2520protein%2520induces%2520neoplastic%2520transformation%2520of%2520thyroid%2520epithelium%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5729%26epage%3D5735%26doi%3D10.1038%2Fsj.onc.1203922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondellini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span> <span> </span><span class="NLM_article-title">The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1210/en.2002-221002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1210%2Fen.2002-221002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12586769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslCqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2003&pages=922-928&author=V.+Ranziauthor=S.+O.+Meakinauthor=C.+Mirandaauthor=P.+Mondelliniauthor=M.+A.+Pierottiauthor=A.+Greco&title=The+signaling+adapters+fibroblast+growth+factor+receptor+substrate+2+and+3+are+activated+by+the+thyroid+TRK+oncoproteins&doi=10.1210%2Fen.2002-221002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins</span></div><div class="casAuthors">Ranzi, Valeria; Meakin, Susan O.; Miranda, Claudia; Mondellini, Piera; Pierotti, Marco A.; Greco, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">922-928</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The thyroid TRK oncogenes are generated by chromosomal rearrangements juxtaposing the neurotrophic tyrosine receptor kinase type 1 (NTRK1) tyrosine kinase domain to foreign activating sequences.  TRK oncoproteins display a constitutive tyrosine kinase activity resulting in the capability to transform NIH3T3 cells.  The TRK oncoproteins' signal transduction has been in part elucidated, and it involves several signal transducers activated by the NGF-stimulated NTRK1 receptor.  In this paper, we investigate the role of FRS2 and FRS3, two related adapter proteins activated by fibroblast growth factor and NTRK1 receptors, in the signaling of the thyroid TRK-T1 and TRK-T3 oncogenes.  By a combination of in vitro and in vivo assays, we demonstrate that both fibroblast growth factor receptor substrate (FRS)2 and FRS3 are recruited and activated by TRK-T1 and TRK-T3.  Interaction studies using different TRK-T3 mutants indicate that FRS3 is recruited by the same tyrosine residue interacting with She and FRS2.  Expression studies show different expression patterns of the FRS adapters in normal and tumor thyroid samples: FRS3 is expressed in both normal and thyroid tumor samples, whereas FRS2 is not expressed in normal thyroid but is differentially expressed in some tumors.  Altogether, our data indicate that the FRS2 and FRS3 adapters may have a role in thyroid carcinogenesis triggered by TRK oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQWYj0AmS-ULVg90H21EOLACvtfcHk0lhC2Q50tRF9cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslCqsb0%253D&md5=af83b227bf98257d2651b70b6c54e31e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1210%2Fen.2002-221002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2002-221002%26sid%3Dliteratum%253Aachs%26aulast%3DRanzi%26aufirst%3DV.%26aulast%3DMeakin%26aufirst%3DS.%2BO.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DMondellini%26aufirst%3DP.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DGreco%26aufirst%3DA.%26atitle%3DThe%2520signaling%2520adapters%2520fibroblast%2520growth%2520factor%2520receptor%2520substrate%25202%2520and%25203%2520are%2520activated%2520by%2520the%2520thyroid%2520TRK%2520oncoproteins%26jtitle%3DEndocrinology%26date%3D2003%26volume%3D144%26spage%3D922%26epage%3D928%26doi%3D10.1210%2Fen.2002-221002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Obberghen, E.</span></span> <span> </span><span class="NLM_article-title">IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1002/1097-4652(200101)186:1<35::AID-JCP1003>3.0.CO;2-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11147812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslyqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2001&pages=35-46&author=C.+Mirandaauthor=A.+Grecoauthor=C.+Mieleauthor=M.+A.+Pierottiauthor=E.+Van+Obberghen&title=IRS-1+and+IRS-2+are+recruited+by+TrkA+receptor+and+oncogenic+TRK-T1&doi=10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1</span></div><div class="casAuthors">Miranda, Claudia; Greco, Angela; Miele, Claudia; Pierotti, Marco A.; Van Obberghen, Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-46</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">TRK-T1 oncogene is generated by the rearrangement of the NGF receptor TrkA with TPR.  This gives rise to the constitutive tyrosine autophosphorylation and activation of the kinase.  To study TRK-T1 oncogenic signaling and compare it to that induced by the genuine receptor TrkA, we investigated the involvement of IRS-1, a docking protein implicated in mitogenic signaling induced by several growth factors, in TRK-T1 and TrkA signaling.  Here, we show that IRS-1 and IRS-2 are phosphorylated on tyrosine in presence of both TRK-T1 and the activated TrkA receptor.  These tyrosine phosphorylations lead to IRS-1- and IRS-2-induced recruitment of p85P13K, SHP-2, and Grb2 and increase in PI 3-kinase activity assocd. with IRS-1.  Furthermore, we found that TRK-T1 is able to activate c-fos serum responsive element in cooperation with IRS-1 and IRS-2.  We obsd. that TRK-T1 stimulates DNA synthesis in wild-type fibroblasts but not in IRS-1-/- mouse embryo fibroblasts.  Yeast two-hybrid system expts. showed the occurrence of direct interaction between TRK and IRS mols., which suggests involvement of different modes of interactions.  On the whole, our results suggest that IRS-1 and IRS-2 could be substrates of TRK-T1 and TrkA, and hence could participate in their signal generation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqUaP0yBErSrVg90H21EOLACvtfcHk0lhC2Q50tRF9cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslyqtrg%253D&md5=dbaf3311a2456a6307c43bf361f62689</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-4652%2528200101%2529186%253A1%253C35%253A%253AAID-JCP1003%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DVan%2BObberghen%26aufirst%3DE.%26atitle%3DIRS-1%2520and%2520IRS-2%2520are%2520recruited%2520by%2520TrkA%2520receptor%2520and%2520oncogenic%2520TRK-T1%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2001%26volume%3D186%26spage%3D35%26epage%3D46%26doi%3D10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roccato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gishizki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span> <span> </span><span class="NLM_article-title">Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.bjc.6600544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12237775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=645-653&author=E.+Roccatoauthor=C.+Mirandaauthor=V.+Ranziauthor=M.+Gishizkiauthor=M.+A.+Pierottiauthor=A.+Greco&title=Biological+activity+of+the+thyroid+TRK-T3+oncogene+requires+signalling+through+Shc&doi=10.1038%2Fsj.bjc.6600544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc</span></div><div class="casAuthors">Roccato, E.; Miranda, C.; Ranzi, V.; Gishizki, M.; Pierotti, M. A.; Greco, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">645-653</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The thyroid TRK-T3 oncogene, produced by a chromosomal translocation, is a chimeric, constitutively activated version of the NTRK1/NGF receptor and it is able to transform NIH3T3 cells and differentiate PC12 cells.  TRK-T3 oncoprotein triggers multiple signal transduction pathways.  Among others, TRK-T3 binds and phosphorylates the Shc and SNT1/FRS2 adaptor proteins both involved in coupling the receptor tyrosine kinase to the mitogen-activated protein kinase pathway by recruiting Grb2/SOS.  We were interested in defining the role of Shc in the oncogenesis by TRK-T3.  The mutation of TRK-T3 Tyr 291, docking site for both Shc and FRS2, abrogates the oncogene biol. activity.  To directly explore the role of Shc the authors used the ShcY317F mutant, which carries the mutation of a Tyr residue involved in Grb2 recruitment.  We demonstrated that the ShcY317F mutant exerts an inhibitory effect on TRK-T3 transforming activity.  Such effect can be modulated by the amt. of ShcY317F protein and affects the viability of cells expressing TRK-T3 by a mechanism involving apoptosis.  These results indicate a definitive role of the adaptor protein Shc in TRK-T3 transforming activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJgC2dxNyjFbVg90H21EOLACvtfcHk0ljOFsCz67dnTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKjs7g%253D&md5=24ec11983b5c459d714cfe7d87138991</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600544%26sid%3Dliteratum%253Aachs%26aulast%3DRoccato%26aufirst%3DE.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DRanzi%26aufirst%3DV.%26aulast%3DGishizki%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DGreco%26aufirst%3DA.%26atitle%3DBiological%2520activity%2520of%2520the%2520thyroid%2520TRK-T3%2520oncogene%2520requires%2520signalling%2520through%2520Shc%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D87%26spage%3D645%26epage%3D653%26doi%3D10.1038%2Fsj.bjc.6600544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H.</span></span> <span> </span><span class="NLM_article-title">ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5684</span>– <span class="NLM_lpage">5695</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1205669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12173038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVait7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=5684-5695&author=K.+B.+Morrisonauthor=C.+E.+Tognonauthor=M.+J.+Garnettauthor=C.+Dealauthor=P.+H.+Sorensen&title=ETV6-NTRK3+transformation+requires+insulin-like+growth+factor+1+receptor+signaling+and+is+associated+with+constitutive+IRS-1+tyrosine+phosphorylation&doi=10.1038%2Fsj.onc.1205669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation</span></div><div class="casAuthors">Morrison, Kevin B.; Tognon, Cristina E.; Garnett, Mathew J.; Deal, Cheri; Sorensen, Poul H. B.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5684-5695</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are pediatric spindle cell malignancies that share two specific cytogenetic abnormalities: trisomy of chromosome 11 and a t(12;15)(p13;q25) translocation.  The t(12;15) rearrangement creates a transcriptionally active fusion gene that encodes a chimeric oncoprotein, ETV6-NTRK3 (EN).  EN transforms NIH3T3 fibroblasts through constitutive activation of both the Ras-mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3'-kinase (PI3K)-Akt pathway.  However, the role of trisomy 11 in CFS and CMN remains unknown.  In this study we demonstrate elevated expression of the chromosome 11p15.5 insulin-like growth factor 2 gene (IGF2) in CFS and CMN tumors.  Moreover, we present evidence that an intact IGF signaling axis is essential for in vitro EN-mediated transformation.  EN only very weakly transformed so-called R-murine fibroblasts derived from mice with a targeted disruption of the IGF1 receptor gene (IGFRI), but transformation activity was fully restored in R- cells engineered to re-express IGFRI (R+ cells).  We also obsd. that the major IGFRI substrate, insulin-receptor substrate-1 (IRS-1), was constitutively tyrosine phosphorylated and could be co-immunopptd. with EN in either R- or R+ cells expressing the EN oncoprotein.  IRS-1 assocn. with Grb2 and PI3K p85, which link IGFRI to the Ras-MAPK and PI3K-Akt pathways, resp., was enhanced in both cell types in the presence of EN.  However, activation of the Ras-MAPK and PI3K-Akt pathways was markedly attenuated in EN-expressing R- cells compared to EN-transformed R+ cells.  This suggests that IRS-1 may be functioning as an adaptor in EN signal transduction, but that a link to EN transformation pathways requires the presence of IGFRI.  Our findings indicate that an intact IGF signaling axis is essential for EN transformation, and are consistent with a role for trisomy 11 in augmenting this pathway in EN expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZXoCEb6cu97Vg90H21EOLACvtfcHk0ljOFsCz67dnTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVait7s%253D&md5=960b27095466f1313423840e626c0757</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205669%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DK.%2BB.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DDeal%26aufirst%3DC.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%26atitle%3DETV6-NTRK3%2520transformation%2520requires%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520signaling%2520and%2520is%2520associated%2520with%2520constitutive%2520IRS-1%2520tyrosine%2520phosphorylation%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D5684%26epage%3D5695%26doi%3D10.1038%2Fsj.onc.1205669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H. B.</span></span> <span> </span><span class="NLM_article-title">The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8909</span>– <span class="NLM_lpage">8916</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8909-8916&author=C.+Tognonauthor=M.+Garnettauthor=E.+Kenwardauthor=R.+Kayauthor=K.+Morrisonauthor=P.+H.+B.+Sorensen&title=The+chimeric+protein+tyrosine+kinase+ETV6-NTRK3+requires+both+Ras-Erk1%2F2+and+PI3-kinase-Akt+signaling+for+fibroblast+transformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTognon%26aufirst%3DC.%26aulast%3DGarnett%26aufirst%3DM.%26aulast%3DKenward%26aufirst%3DE.%26aulast%3DKay%26aufirst%3DR.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%2BB.%26atitle%3DThe%2520chimeric%2520protein%2520tyrosine%2520kinase%2520ETV6-NTRK3%2520requires%2520both%2520Ras-Erk1%252F2%2520and%2520PI3-kinase-Akt%2520signaling%2520for%2520fibroblast%2520transformation%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D8909%26epage%3D8916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shvarts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4959</span>– <span class="NLM_lpage">4965</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1207667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15077169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=4959-4965&author=M.+J.+Edelauthor=A.+Shvartsauthor=J.+P.+Medemaauthor=R.+Bernards&title=An+in+vivo+functional+genetic+screen+reveals+a+role+for+the+TRK-T3+oncogene+in+tumor+progression&doi=10.1038%2Fsj.onc.1207667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression</span></div><div class="casAuthors">Edel, Michael J.; Shvarts, Avi; Medema, Jan Paul; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4959-4965</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Over the past decades, much has been learnt about the genes that contribute to oncogenic transformation of primary cells in vitro.  However, much less is known about the genes that contribute to the later stages of tumor progression, in which cells of ever increasing malignancy arise through clonal selection in vivo.  To search for genes that confer a tumor progression phenotype in vivo, we have used a functional genetic approach.  We used adenovirus-transformed mouse embryo fibroblasts, which are tumorigenic in immunodeficient nude mice, but not in immunocompetent mice, due to strong cytotoxic T-cell-mediated immune rejection.  We infected these cells in vitro with several high-complexity retroviral cDNA expression libraries and selected rare variants that formed tumors in immunocompetent mice.  Using this approach, we identify here the TRK-T3 oncogene as a tumor progression gene.  TRK-T3 does not inhibit T-cell reactivity towards the tumor cells.  Instead, we find that cells expressing TRK-T3 enhances in vivo growth rate, most likely by stimulating anchorage-independent proliferation in growth factor-limiting conditions.  Our data indicate that cDNA expression libraries can be used to identify tumor progression genes in vivo that cannot be readily identified using in vitro cell culture systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaqkXB8lq10bVg90H21EOLACvtfcHk0ljOFsCz67dnTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVOnsr0%253D&md5=283816bc2c14d046b7fe69b84ac4a2da</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207667%26sid%3Dliteratum%253Aachs%26aulast%3DEdel%26aufirst%3DM.%2BJ.%26aulast%3DShvarts%26aufirst%3DA.%26aulast%3DMedema%26aufirst%3DJ.%2BP.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DAn%2520in%2520vivo%2520functional%2520genetic%2520screen%2520reveals%2520a%2520role%2520for%2520the%2520TRK-T3%2520oncogene%2520in%2520tumor%2520progression%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D4959%26epage%3D4965%26doi%3D10.1038%2Fsj.onc.1207667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span> <span> </span><span class="NLM_article-title">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010–2016-Part I</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1297796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1080%2F13543776.2017.1297796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28270010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=733-751&author=J.+J.+Baileyauthor=R.+Schirrmacherauthor=K.+Farrellauthor=V.+Bernard-Gauthier&title=Tropomyosin+receptor+kinase+inhibitors%3A+an+updated+patent+review+for+2010%E2%80%932016-Part+I&doi=10.1080%2F13543776.2017.1297796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I</span></div><div class="casAuthors">Bailey, Justin J.; Schirrmacher, Ralf; Farrell, Kristen; Bernard-Gauthier, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">733-751</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Tropomyosin receptor kinases (TrkA/B/C) play crucial roles in the development and maintenance of the nervous system, and aberrant expression of Trk has been implicated in neurol. disorders as well as neural and non-neural neoplasms.  Patent activity encompassing Trk inhibitors has grown substantially over the last 6 years, recognized by a rise in the no. of pharmaceutical entrants to the field and the escalation of novel inhibitor chemotypes.  In Part I of this two part review, a biol. and structural overview of Trk is provided in the context of Trk as a therapeutic target for cancer and pain, followed by the report of recent patent literature claiming small mol. inhibitors of Trk family kinases or which describe inhibitors developed for other kinase targets but include noteworthy Trk inhibition/application.  The discussion of the patent literature continues in Part II of this review, which includes an in-depth view of the current clin. applications of Trk inhibitors.  Substantial synthetic efforts in Trk inhibitor development has propagated numerous and diverse inhibitor chemotypes, including TrkA-specific inhibitors.  While many novel Trk inhibitors remain the original progeny of Trk-specific development programs, kinase inhibitors initially developed for other kinases have also been successfully repositioned for Trk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIHEog1RqjUrVg90H21EOLACvtfcHk0lhkd71Zj5tqVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtb0%253D&md5=e863493e3065568c43e39c0fe5a73751</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1297796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1297796%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DK.%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26atitle%3DTropomyosin%2520receptor%2520kinase%2520inhibitors%253A%2520an%2520updated%2520patent%2520review%2520for%25202010%25E2%2580%25932016-Part%2520I%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D733%26epage%3D751%26doi%3D10.1080%2F13543776.2017.1297796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span> <span> </span><span class="NLM_article-title">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010–2016-Part II</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1297797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1080%2F13543776.2017.1297797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28270021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=831-849&author=J.+J.+Baileyauthor=R.+Schirrmacherauthor=K.+Farrellauthor=V.+Bernard-Gauthier&title=Tropomyosin+receptor+kinase+inhibitors%3A+an+updated+patent+review+for+2010%E2%80%932016-Part+II&doi=10.1080%2F13543776.2017.1297797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II</span></div><div class="casAuthors">Bailey, Justin J.; Schirrmacher, Ralf; Farrell, Kristen; Bernard-Gauthier, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">831-849</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">TrkA/B/C receptor activation supports growth, survival, and differentiation of discrete neuronal populations during development, adult life, and ageing but also plays numerous roles in human disease onset and progression.  Trk-specific inhibitors have therapeutic applications in cancer and pain and thus constitute a growing area of interest in oncol. and neurol.  There has been substantial growth in the no. of structural classes of Trk inhibitors and the no. of industrial entrants to the Trk inhibitor field over the past six years.  In Part II of this two-part review, the discussion of recent patent literature covering Trk family inhibitors is continued from Part I and clin. research with Trk inhibitors is considered.  Trk has been molecularly targeted for over a decade resulting in the progressive evolution of structurally diversified Trk inhibitors arising from scaffold hopping and HTS efforts.  Correspondingly, there have been a growing no. of clin. investigations utilizing Trk inhibitors in recent years, with a particular focus on the treatment of NTRK-fusion pos. cancers and chronic pain.  The obsd. potential of Trk inhibitors to cause adverse CNS side effects however suggests the need for a more rigorous consideration of BBB permeation capabilities during drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG_4h-yrNplrVg90H21EOLACvtfcHk0lhkd71Zj5tqVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtbw%253D&md5=9c0a05bec29ecf9ccf53cc26dda78709</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1297797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1297797%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DK.%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26atitle%3DTropomyosin%2520receptor%2520kinase%2520inhibitors%253A%2520an%2520updated%2520patent%2520review%2520for%25202010%25E2%2580%25932016-Part%2520II%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D831%26epage%3D849%26doi%3D10.1080%2F13543776.2017.1297797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E.</span></span> <span> </span><span class="NLM_article-title">Tropomyosin receptor kinase inhibitors: a patent update 2009–2013</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.910195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1517%2F13543776.2014.910195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24809946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=731-744&author=C.+McCarthyauthor=E.+Walker&title=Tropomyosin+receptor+kinase+inhibitors%3A+a+patent+update+2009%E2%80%932013&doi=10.1517%2F13543776.2014.910195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013</span></div><div class="casAuthors">McCarthy, Clive; Walker, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">731-744</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family.  The nerve growth factor antibody tanezumab has provided clin. proof of concept for inhibition of the TrkA pathway in pain.  As an alternative modality, small-mol. inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications.  Areas covered: This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biol. targets.  Addnl. patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is obsd. and the chem. matter is particularly noteworthy.  Patents pre-dating this period have been reviewed previously.  Scifinder and Google were used to find relevant patents and clin. information using Trk or Tropomyosin as the search term.  Expert opinion: Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clin. evaluation.  Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted mols. have been identified.  Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biol. of this isoform to be probed.  The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjXwkruGnLXbVg90H21EOLACvtfcHk0lhkd71Zj5tqVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtr7L&md5=b924331cd9d69192bc10f53424997550</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.910195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.910195%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DE.%26atitle%3DTropomyosin%2520receptor%2520kinase%2520inhibitors%253A%2520a%2520patent%2520update%25202009%25E2%2580%25932013%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D731%26epage%3D744%26doi%3D10.1517%2F13543776.2014.910195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.4155/fmc.13.216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.4155%2Ffmc.13.216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24649957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=541-561&author=S.+W.+Cowan-Jacobauthor=W.+Jahnkeauthor=S.+Knapp&title=Novel+approaches+for+targeting+kinases%3A+allosteric+inhibition%2C+allosteric+activation+and+pseudokinases&doi=10.4155%2Ffmc.13.216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Jahnke, Wolfgang; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">541-561</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in many essential cellular processes and their deregulation can lead to a variety of diseases, including cancer.  The pharmaceutical industry has invested heavily in the identification of kinase inhibitors to modulate these disease-promoting pathways, resulting in several successful drugs.  However, the field is challenging as it is difficult to identify novel selective inhibitors with good pharmacokinetic/pharmacodynamic properties.  In addn., resistance to kinase inhibitor treatment frequently arises.  The identification of non-ATP site targeting ('allosteric') inhibitors, the identification of kinase activators and the expansion of kinase target space to include the less studied members of the family, including atypical- and pseudo-kinases, are potential avenues to overcome these challenges.  In this perspective, the opportunities and challenges of following these approaches and others will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQaQbATcjnLVg90H21EOLACvtfcHk0lgGKlyej23ZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D&md5=74a540a959200628a065e287ea6e48d3</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.216%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DNovel%2520approaches%2520for%2520targeting%2520kinases%253A%2520allosteric%2520inhibition%252C%2520allosteric%2520activation%2520and%2520pseudokinases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D541%26epage%3D561%26doi%3D10.4155%2Ffmc.13.216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lgGKlyej23ZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhtiyarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurzy, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowska-Zoladek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saradjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvagnat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A. J.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of nonactive site, TrkA-selective kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">E297</span>– <span class="NLM_lpage">E306</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611577114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.1611577114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28039433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1ag" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E297-E306&author=H.+P.+Suauthor=K.+Rickertauthor=C.+Burleinauthor=K.+Narayanauthor=M.+Bukhtiyarovaauthor=D.+M.+Hurzyauthor=C.+A.+Stumpauthor=X.+Zhangauthor=J.+Reidauthor=A.+Krasowska-Zoladekauthor=S.+Tummalaauthor=J.+M.+Shipmanauthor=M.+Kornienkoauthor=P.+A.+Lemaireauthor=D.+Kroskyauthor=A.+Hellerauthor=A.+Achabauthor=C.+Chamberlinauthor=P.+Saradjianauthor=B.+Sauvagnatauthor=X.+Yangauthor=M.+R.+Ziebellauthor=E.+Nickbargauthor=J.+M.+Sandersauthor=M.+T.+Bilodeauauthor=S.+S.+Carrollauthor=K.+J.+Lumbauthor=S.+M.+Soissonauthor=D.+A.+Henzeauthor=A.+J.+Cooke&title=Structural+characterization+of+nonactive+site%2C+TrkA-selective+kinase+inhibitors&doi=10.1073%2Fpnas.1611577114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Structural characterization of nonactive site, TrkA-selective kinase inhibitors</span></div><div class="casAuthors">Su, Hua-Poo; Rickert, Keith; Burlein, Christine; Narayan, Kartik; Bukhtiyarova, Marina; Hurzy, Danielle M.; Stump, Craig A.; Zhang, Xufang; Reid, John; Krasowska-Zoladek, Alicja; Tummala, Srivanya; Shipman, Jennifer M.; Kornienko, Maria; Lemaire, Peter A.; Krosky, Daniel; Heller, Amanda; Achab, Abdelghani; Chamberlin, Chad; Saradjian, Peter; Sauvagnat, Berengere; Yang, Xianshu; Ziebell, Michael R.; Nickbarg, Elliott; Sanders, John M.; Bilodeau, Mark T.; Carroll, Steven S.; Lumb, Kevin J.; Soisson, Stephen M.; Henze, Darrell A.; Cooke, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">E297-E306</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Current therapies for chronic pain can have insufficient efficacy and lead to side effects, necessitating research of novel targets against pain.  Although originally identified as an oncogene, Tropomyosin-related kinase A (TrkA) is linked to pain and elevated levels of NGF (the ligand for TrkA) are assocd. with chronic pain.  Antibodies that block TrkA interaction with its ligand, NGF, are in clin. trials for pain relief.  Here, we describe the identification of TrkA-specific inhibitors and the structural basis for their selectivity over other Trk family kinases.  The X-ray structures reveal a binding site outside the kinase active site that uses residues from the kinase domain and the juxtamembrane region.  Three modes of binding with the juxtamembrane region are characterized through a series of ligand-bound complexes.  The structures indicate a crit. pharmacophore on the compds. that leads to the distinct binding modes.  The mode of interaction can allow TrkA selectivity over TrkB and TrkC or promiscuous, pan-Trk inhibition.  This finding highlights the difficulty in characterizing the structure-activity relationship of a chem. series in the absence of structural information because of substantial differences in the interacting residues.  These structures illustrate the flexibility of binding to sequences outside of - but adjacent to - the kinase domain of TrkA.  This knowledge allows development of compds. with specificity for TrkA or the family of Trk proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos46MKDwV6orVg90H21EOLACvtfcHk0lgGKlyej23ZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1ag&md5=831df09deff6360df39f71a0c2d3d46a</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611577114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611577114%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DNarayan%26aufirst%3DK.%26aulast%3DBukhtiyarova%26aufirst%3DM.%26aulast%3DHurzy%26aufirst%3DD.%2BM.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DKrasowska-Zoladek%26aufirst%3DA.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLemaire%26aufirst%3DP.%2BA.%26aulast%3DKrosky%26aufirst%3DD.%26aulast%3DHeller%26aufirst%3DA.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DChamberlin%26aufirst%3DC.%26aulast%3DSaradjian%26aufirst%3DP.%26aulast%3DSauvagnat%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZiebell%26aufirst%3DM.%2BR.%26aulast%3DNickbarg%26aufirst%3DE.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DCooke%26aufirst%3DA.%2BJ.%26atitle%3DStructural%2520characterization%2520of%2520nonactive%2520site%252C%2520TrkA-selective%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3DE297%26epage%3DE306%26doi%3D10.1073%2Fpnas.1611577114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4672</span>– <span class="NLM_lpage">4684</span>, <span class="refDoi"> DOI: 10.1021/jm800343j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800343j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4672-4684&author=T.+Wangauthor=M.+L.+Lambauthor=D.+A.+Scottauthor=H.+Wangauthor=M.+H.+Blockauthor=P.+D.+Lyneauthor=J.+W.+Leeauthor=A.+M.+Daviesauthor=H.+J.+Zhangauthor=Y.+Zhuauthor=F.+Guauthor=Y.+Hanauthor=B.+Wangauthor=P.+J.+Mohrauthor=R.+J.+Kausauthor=J.+A.+Joseyauthor=E.+Hoffmannauthor=K.+Thressauthor=T.+Macintyreauthor=H.+Wangauthor=C.+A.+Omerauthor=D.+Yu&title=Identification+of+4-aminopyrazolylpyrimidines+as+potent+inhibitors+of+Trk+kinases&doi=10.1021%2Fjm800343j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases</span></div><div class="casAuthors">Wang, Tao; Lamb, Michelle L.; Scott, David A.; Wang, Haixia; Block, Michael H.; Lyne, Paul D.; Lee, John W.; Davies, Audrey M.; Zhang, Hai-Jun; Zhu, Yanyi; Gu, Fei; Han, Yongxin; Wang, Bin; Mohr, Peter J.; Kaus, Robert J.; Josey, John A.; Hoffmann, Ethan; Thress, Ken; MacIntyre, Terry; Wang, Haiyun; Omer, Charles A.; Yu, Dingwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4672-4684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluation of a series of 4-(pyrazolylamino)pyrimidines I (R1 = H, Me, SMe, cyclopropyl, Me2CHO, n-PrO, Me3C; R2 = H, Br, Cl, F, Me; R3 = H, HOCH2CH2NH, (S)-HOCH2CH(OH)CH2NH, etc.; R4 = Me, CH2OH, CH2CONMe2, CH2CONHMe; R5 = Ph, 2-ClC6H4, 4-FC6H4, 5-fluoro-2-pyridyl, 5-fluoro-2-pyrimidyl) as potent Trk kinase inhibitors is reported.  High-throughput screening identified a promising hit in the 4-(pyrazolylamino)pyrimidine chemotype.  Initial optimization of the series led to more potent Trk inhibitors.  Further optimization using two strategies resulted in significant improvement of phys. properties and led to the discovery of I (R1 = Me2CHO; R2 = Cl; R3 = H; R4 = (S)-Me; R5 = 5-fluoro-2-pyridyl) (AZ-23), a potent, orally bioavailable Trk A/B inhibitor.  The compd. offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ60edpRrhTrVg90H21EOLACvtfcHk0ljPXH8RKDeNYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D&md5=16401146aa3860d13a4bc35bc04d5f83</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm800343j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800343j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DKaus%26aufirst%3DR.%2BJ.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DMacintyre%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DIdentification%2520of%25204-aminopyrazolylpyrimidines%2520as%2520potent%2520inhibitors%2520of%2520Trk%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4672%26epage%3D4684%26doi%3D10.1021%2Fjm800343j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zage, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweidler-McKay, P. A.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1818</span>– <span class="NLM_lpage">1827</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-09-0036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19509272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVymsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1818-1827&author=K.+Thressauthor=T.+Macintyreauthor=H.+Wangauthor=D.+Whitstonauthor=Z.+Y.+Liuauthor=E.+Hoffmannauthor=T.+Wangauthor=J.+L.+Brownauthor=K.+Websterauthor=C.+Omerauthor=P.+E.+Zageauthor=L.+Zengauthor=P.+A.+Zweidler-McKay&title=Identification+and+preclinical+characterization+of+AZ-23%2C+a+novel%2C+selective%2C+and+orally+bioavailable+inhibitor+of+the+Trk+kinase+pathway&doi=10.1158%2F1535-7163.MCT-09-0036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway</span></div><div class="casAuthors">Thress, Kenneth; MacIntyre, Terry; Wang, Haiyun; Whitston, Dave; Liu, Zhong-Ying; Hoffmann, Ethan; Wang, Tao; Brown, Jeffrey L.; Webster, Kevin; Omer, Charles; Zage, Peter E.; Zeng, Lizhi; Zweidler-McKay, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1818-1827</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tropomyosin-related kinases (TrkA, TrkB, and TrkC) are receptor tyrosine kinases that, along with their ligands, the neurotrophins, are involved in neuronal cell growth, development, and survival.  The Trk-neurotrophin pathway may also play a role in tumorigenesis through oncogenic fusions, mutations, and autocrine signaling, prompting the development of novel Trk inhibitors as agents for cancer therapy.  This report describes the identification of AZ-23, a novel, potent, and selective Trk kinase inhibitor.  In vitro studies with AZ-23 showed improved selectivity over previous compds. and inhibition of Trk kinase activity in cells at low nanomolar concns.  AZ-23 showed in vivo TrkA kinase inhibition and efficacy in mice following oral administration in a TrkA-driven allograft model and significant tumor growth inhibition in a Trk-expressing xenograft model of neuroblastoma.  AZ-23 represents a potent and selective Trk kinase inhibitor from a novel series with the potential for use as a treatment for cancer. [Mol Cancer Ther 2009;8(7):1818-27].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG2uvCSID5vbVg90H21EOLACvtfcHk0ljPXH8RKDeNYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVymsro%253D&md5=8501f75147407ee64920fd4f5e733536</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0036%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%26aulast%3DMacintyre%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWhitston%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BL.%26aulast%3DWebster%26aufirst%3DK.%26aulast%3DOmer%26aufirst%3DC.%26aulast%3DZage%26aufirst%3DP.%2BE.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DZweidler-McKay%26aufirst%3DP.%2BA.%26atitle%3DIdentification%2520and%2520preclinical%2520characterization%2520of%2520AZ-23%252C%2520a%2520novel%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520the%2520Trk%2520kinase%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1818%26epage%3D1827%26doi%3D10.1158%2F1535-7163.MCT-09-0036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of disubstituted imidazo 4,5-b pyridines and purines as potent TrkA inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1021/ml300074j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300074j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=705-709&author=T.+Wangauthor=M.+L.+Lambauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=Y.+X.+Hanauthor=E.+Hoffmannauthor=S.+Ioannidisauthor=J.+A.+Joseyauthor=Z.+Y.+Liuauthor=P.+D.+Lyneauthor=T.+MacIntyreauthor=P.+J.+Mohrauthor=C.+A.+Omerauthor=T.+Sjogrenauthor=K.+Thressauthor=B.+Wangauthor=H.+Y.+Wangauthor=D.+W.+Yuauthor=H.+J.+Zhang&title=Discovery+of+disubstituted+imidazo+4%2C5-b+pyridines+and+purines+as+potent+TrkA+inhibitors&doi=10.1021%2Fml300074j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fml300074j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300074j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DSjogren%26aufirst%3DT.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DYu%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26atitle%3DDiscovery%2520of%2520disubstituted%2520imidazo%25204%252C5-b%2520pyridines%2520and%2520purines%2520as%2520potent%2520TrkA%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D705%26epage%3D709%26doi%3D10.1021%2Fml300074j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span> <span> </span><span class="NLM_article-title">The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.2.442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.90.2.442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=442-446&author=A.+C.+Carreraauthor=K.+Alexandrovauthor=T.+M.+Roberts&title=The+conserved+lysine+of+the+catalytic+domain+of+protein+kinases+is+actively+involved+in+the+phosphotransfer+reaction+and+not+required+for+anchoring+ATP&doi=10.1073%2Fpnas.90.2.442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.2.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.2.442%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DA.%2BC.%26aulast%3DAlexandrov%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26atitle%3DThe%2520conserved%2520lysine%2520of%2520the%2520catalytic%2520domain%2520of%2520protein%2520kinases%2520is%2520actively%2520involved%2520in%2520the%2520phosphotransfer%2520reaction%2520and%2520not%2520required%2520for%2520anchoring%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D442%26epage%3D446%26doi%3D10.1073%2Fpnas.90.2.442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pevarello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traquandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.1021/jm9006559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N%2C1%2C4%2C4-tetramethyl-8-%7B%5B4-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+a+potent%2C+orally+available+cyclin+dependent+kinase+inhibitor&doi=10.1021%2Fjm9006559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N%252C1%252C4%252C4-tetramethyl-8-%257B%255B4-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520a%2520potent%252C%2520orally%2520available%2520cyclin%2520dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163%26doi%3D10.1021%2Fjm9006559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albanese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1111/bph.12112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1111%2Fbph.12112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=23347136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFaksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=156-166&author=C.+Albaneseauthor=R.+Alzaniauthor=N.+Amboldiauthor=A.+Degrassiauthor=C.+Festucciaauthor=F.+Fiorentiniauthor=G.+Gravinaauthor=C.+Mercurioauthor=W.+Pastoriauthor=M.+Brascaauthor=E.+Pesentiauthor=A.+Galvaniauthor=M.+Ciomei&title=Anti-tumour+efficacy+on+glioma+models+of+PHA-848125%2C+a+multi-kinase+inhibitor+able+to+cross+the+blood-brain+barrier&doi=10.1111%2Fbph.12112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier</span></div><div class="casAuthors">Albanese, C.; Alzani, R.; Amboldi, N.; Degrassi, A.; Festuccia, C.; Fiorentini, F.; Gravina, G. L.; Mercurio, C.; Pastori, W.; Brasca, M. G.; Pesenti, E.; Galvani, A.; Ciomei, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-166</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Malignant gliomas, the most common primary brain tumors, are highly invasive and neurol. destructive neoplasms with a very bad prognosis due to the difficulty in removing the mass completely by surgery and the limited activity of current therapeutic agents.  PHA-848125 is a multi-kinase inhibitor with broad anti-tumor activity in pre-clin. studies and good tolerability in phase 1 studies, which could affect two main pathways involved in glioma pathogenesis, the G1-S phase progression control pathway through the inhibition of cyclin-dependent kinases and the signalling pathways mediated by tyrosine kinase growth factor receptors, such as tropomyosin receptors.  For this reason, we tested PHA-848125 in glioma models.  Exptl. Approach PHA-848125 was tested on a panel of glioma cell lines in vitro to evaluate inhibition of proliferation and mechanism of action.  In vivo efficacy was evaluated on two glioma models both as single agent and in combination with std. therapy.  Key Results: When tested on a subset of representative glioma cell lines, PHA-848125 blocked cell proliferation, DNA synthesis and inhibited both cell cycle and signal transduction markers.  Relevantly, PHA-848125 was also able to induce cell death through autophagy in all cell lines.  Good anti-tumor efficacy was obsd. by oral route in different glioma models both with s.c. and intracranial implantation.  Indeed, we demonstrate that the drug is able to cross the blood-brain barrier.  Moreover, the combination of PHA-848125 with temozolomide resulted in a synergistic effect, and a clear therapeutic gain was also obsd. with a triple treatment adding PHA-848125 to radiotherapy and temozolomide.  Conclusions and Implications: All the pre-clin. data obtained so far suggest that PHA-848125 may become a useful agent in chemotherapy regimens for glioma patients and support its evaluation in phase 2 trials for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUKdihsNd4rVg90H21EOLACvtfcHk0liyhMcHudpwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFaksr0%253D&md5=695ce9933c916bbde6548090e9a17b6a</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fbph.12112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12112%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanese%26aufirst%3DC.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DFestuccia%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGravina%26aufirst%3DG.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DBrasca%26aufirst%3DM.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DAnti-tumour%2520efficacy%2520on%2520glioma%2520models%2520of%2520PHA-848125%252C%2520a%2520multi-kinase%2520inhibitor%2520able%2520to%2520cross%2520the%2520blood-brain%2520barrier%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26spage%3D156%26epage%3D166%26doi%3D10.1111%2Fbph.12112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albanese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2243</span>– <span class="NLM_lpage">2254</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-10-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=20682657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2243-2254&author=C.+Albaneseauthor=R.+Alzaniauthor=N.+Amboldiauthor=N.+Avanziauthor=D.+Ballinariauthor=M.+G.+Brascaauthor=C.+Festucciaauthor=F.+Fiorentiniauthor=G.+Locatelliauthor=W.+Pastoriauthor=V.+Pattonauthor=F.+Rolettoauthor=F.+Colottaauthor=A.+Galvaniauthor=A.+Isacchiauthor=J.+Mollauthor=E.+Pesentiauthor=C.+Mercurioauthor=M.+Ciomei&title=Dual+targeting+of+CDK+and+tropomyosin+receptor+kinase+families+by+the+oral+inhibitor+PHA-848125%2C+an+agent+with+broad-spectrum+antitumor+efficacy&doi=10.1158%2F1535-7163.MCT-10-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy</span></div><div class="casAuthors">Albanese, Clara; Alzani, Rachele; Amboldi, Nadia; Avanzi, Nilla; Ballinari, Dario; Brasca, Maria Gabriella; Festuccia, Claudio; Fiorentini, Francesco; Locatelli, Giuseppe; Pastori, Wilma; Patton, Veronica; Roletto, Fulvia; Colotta, Francesco; Galvani, Arturo; Isacchi, Antonella; Moll, Jurgen; Pesenti, Enrico; Mercurio, Ciro; Ciomei, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2243-2254</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Altered expression and activity of cyclin-dependent kinase (CDK) and tropomyosin receptor kinase (TRK) families are obsd. in a wide variety of tumors.  In those malignancies with aberrant CDK activation, the retinoblastoma protein (pRb) pathway is deregulated, leading to uncontrolled cell proliferation.  Constitutive activation of TRKs is instead linked to cancer cell survival and dissemination.  Here, we show that the novel small-mol. PHA-848125, a potent dual inhibitor of CDKs and TRKs, possesses significant antitumor activity.  The compd. inhibits cell proliferation of a wide panel of tumoral cell lines with submicromolar IC50.  PHA-848125-treated cells show cell cycle arrest in G1 and reduced DNA synthesis, accompanied by inhibition of pRb phosphorylation and modulation of other CDK-dependent markers.  The compd. addnl. inhibits phosphorylation of TRKA and its substrates in cells, which functionally express this receptor.  Following oral administration, PHA-848125 has significant antitumor activity in various human xenografts and carcinogen-induced tumors as well as in disseminated primary leukemia models, with plasma concns. in rodents in the same range as those found active in inhibiting cancer cell proliferation.  Mechanism of action was also confirmed in vivo as assessed in tumor biopsies from treated mice.  These results show that the dual CDK-TRK inhibitor PHA-848125 has the potential for being a novel and efficacious targeted drug for cancer treatment.  Mol Cancer Ther; 9(8); 2243-54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3AAtyUnt6jLVg90H21EOLACvtfcHk0liyhMcHudpwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjsL8%253D&md5=71c91cde816f8980db821b934d3ff2d4</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0190%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanese%26aufirst%3DC.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DFestuccia%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DLocatelli%26aufirst%3DG.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPatton%26aufirst%3DV.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DDual%2520targeting%2520of%2520CDK%2520and%2520tropomyosin%2520receptor%2520kinase%2520families%2520by%2520the%2520oral%2520inhibitor%2520PHA-848125%252C%2520an%2520agent%2520with%2520broad-spectrum%2520antitumor%2520efficacy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2243%26epage%3D2254%26doi%3D10.1158%2F1535-7163.MCT-10-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verduzco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatenby, R. A.</span></span> <span> </span><span class="NLM_article-title">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1038/nrc3298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrc3298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22695393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=487-493&author=R.+J.+Gilliesauthor=D.+Verduzcoauthor=R.+A.+Gatenby&title=Evolutionary+dynamics+of+carcinogenesis+and+why+targeted+therapy+does+not+work&doi=10.1038%2Fnrc3298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span></div><div class="casAuthors">Gillies, Robert J.; Verduzco, Daniel; Gatenby, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-493</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  All malignant cancers, whether inherited or sporadic, are fundamentally governed by Darwinian dynamics.  The process of carcinogenesis requires genetic instability and highly selective local microenvironments, the combination of which promotes somatic evolution.  These microenvironmental forces, specifically hypoxia, acidosis and reactive oxygen species, are not only highly selective, but are also able to induce genetic instability.  As a result, malignant cancers are dynamically evolving clades of cells living in distinct microhabitats that almost certainly ensure the emergence of therapy-resistant populations.  Cytotoxic cancer therapies also impose intense evolutionary selection pressures on the surviving cells and thus increase the evolutionary rate.  Importantly, the principles of Darwinian dynamics also embody fundamental principles that can illuminate strategies for the successful management of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorCHoXr5jY_rVg90H21EOLACvtfcHk0lj-M2AurJwZeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D&md5=ae041c5a9585d882c6512e386afb26c2</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnrc3298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3298%26sid%3Dliteratum%253Aachs%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DVerduzco%26aufirst%3DD.%26aulast%3DGatenby%26aufirst%3DR.%2BA.%26atitle%3DEvolutionary%2520dynamics%2520of%2520carcinogenesis%2520and%2520why%2520targeted%2520therapy%2520does%2520not%2520work%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D487%26epage%3D493%26doi%3D10.1038%2Fnrc3298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogliatto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6813</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0lj-M2AurJwZeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosine receptor kinases (Pan-TRKs) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3392</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+entrectinib%3A+a+new+3-aminoindazole+as+a+potent+anaplastic+lymphoma+kinase+%28ALK%29%2C+c-ros+oncogene+1+kinase+%28ROS1%29%2C+and+pan-tropomyosine+receptor+kinases+%28Pan-TRKs%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520entrectinib%253A%2520a%2520new%25203-aminoindazole%2520as%2520a%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%252C%2520c-ros%2520oncogene%25201%2520kinase%2520%2528ROS1%2529%252C%2520and%2520pan-tropomyosine%2520receptor%2520kinases%2520%2528Pan-TRKs%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">628</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.+M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+pan-TRK%2C+ROS1%2C+and+ALK+inhibitor+with+activity+in+multiple+molecularly+defined+cancer+indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lhT1dKgcZjt3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520molecularly%2520defined%2520cancer%2520indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer</span>. <i>Ejc Supplements</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/S1359-6349(10)71807-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS1359-6349%2810%2971807-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=39-40&author=E.+Ardiniauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=N.+Amboldiauthor=D.+Ballinariauthor=M.+B.+Saccardoauthor=P.+Magnaghiauthor=E.+Pesentiauthor=A.+Isacchiauthor=A.+Galvani&title=Identification+and+preclinical+characterization+of+NMS-P626%2C+a+potent%2C+selective+and+orally+bioavailable+TrkA+inhibitor+with+anti-tumor+activity+in+a+TrkA-dependent+colorectal+cancer&doi=10.1016%2FS1359-6349%2810%2971807-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2810%2971807-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252810%252971807-3%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520preclinical%2520characterization%2520of%2520NMS-P626%252C%2520a%2520potent%252C%2520selective%2520and%2520orally%2520bioavailable%2520TrkA%2520inhibitor%2520with%2520anti-tumor%2520activity%2520in%2520a%2520TrkA-dependent%2520colorectal%2520cancer%26jtitle%3DEjc%2520Supplements%26date%3D2010%26volume%3D8%26spage%3D39%26epage%3D40%26doi%3D10.1016%2FS1359-6349%2810%2971807-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span>; <span class="NLM_string-name">Yan, S.</span>; <span class="NLM_string-name">Wei, G.</span>; <span class="NLM_string-name">Li, G.</span>; <span class="NLM_string-name">Harris, J.</span>; <span class="NLM_string-name">Vernier, J.-M.</span></span> <span> </span><span class="NLM_article-title">The structure of TRKA kinase domain bound to the inhibitor Entrectinib</span>. <span class="refDoi"> DOI: 10.2210/pdb5KVT/pdb</span> , <a href="https://www.rcsb.org/structure/5KVT" class="extLink">https://www.rcsb.org/structure/5KVT</a>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2210%2Fpdb5KVT%2Fpdb" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jin%2C+L.%3B+Yan%2C+S.%3B+Wei%2C+G.%3B+Li%2C+G.%3B+Harris%2C+J.%3B+Vernier%2C+J.-M.+The+structure+of+TRKA+kinase+domain+bound+to+the+inhibitor+Entrectinib.+10.2210%2Fpdb5KVT%2Fpdb%2C+https%3A%2F%2Fwww.rcsb.org%2Fstructure%2F5KVT."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.2210%2Fpdb5KVT%2Fpdb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26id%3Ddoi%3A10.2210%252Fpdb5KVT%252Fpdb%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DL.%26atitle%3DThe%2520structure%2520of%2520TRKA%2520kinase%2520domain%2520bound%2520to%2520the%2520inhibitor%2520Entrectinib%26doi%3D10.2210%2Fpdb5KVT%2Fpdb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szilvassy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span> <span> </span><span class="NLM_article-title">The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6540</span>, <span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+discovery+and+optimization+of+a+novel+class+of+potent%2C+selective%2C+and+orally+bioavailable+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+potential+utility+for+the+treatment+of+cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0lhT1dKgcZjt3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520a%2520novel%2520class%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520potential%2520utility%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcoxen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span> <span> </span><span class="NLM_article-title">506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">165</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(14)70632-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-8049%2814%2970632-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=165&author=J.+Sachdevauthor=H.+T.+Arkenauauthor=J.+R.+Infanteauthor=M.+M.+Mitaauthor=S.+P.+Anthonyauthor=R.+B.+Nataleauthor=S.+Ejadiauthor=K.+Wilcoxenauthor=V.+Kansraauthor=H.+Lakenauthor=L.+Hughesauthor=R.+Martellauthor=G.+J.+Weiss&title=506+Phase+%28Ph%29+1%2F2a+study+of+TSR-011%2C+a+potent+inhibitor+of+ALK+and+TRK%2C+in+advanced+solid+tumors+including+crizotinib-resistant+ALK+positive+non-small+cell+lung+cancer&doi=10.1016%2FS0959-8049%2814%2970632-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2814%2970632-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252814%252970632-X%26sid%3Dliteratum%253Aachs%26aulast%3DSachdev%26aufirst%3DJ.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DEjadi%26aufirst%3DS.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DKansra%26aufirst%3DV.%26aulast%3DLaken%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DL.%26aulast%3DMartell%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26atitle%3D506%2520Phase%2520%2528Ph%2529%25201%252F2a%2520study%2520of%2520TSR-011%252C%2520a%2520potent%2520inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520in%2520advanced%2520solid%2520tumors%2520including%2520crizotinib-resistant%2520ALK%2520positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2014%26volume%3D50%26spage%3D165%26doi%3D10.1016%2FS0959-8049%2814%2970632-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiaracina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauth, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3444</span>– <span class="NLM_lpage">3448</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2006.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16632359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3444-3448&author=B.+Lippaauthor=J.+Morrisauthor=M.+Corbettauthor=T.+A.+Kwanauthor=M.+C.+Noeauthor=S.+L.+Snowauthor=T.+G.+Gantauthor=M.+Mangiaracinaauthor=H.+A.+Coffeyauthor=B.+Fosterauthor=E.+A.+Knauthauthor=M.+D.+Wessel&title=Discovery+of+novel+isothiazole+inhibitors+of+the+TrkA+kinase%3A+Structure-activity+relationship%2C+computer+modeling%2C+optimization%2C+and+identification+of+highly+potent+antagonists&doi=10.1016%2Fj.bmcl.2006.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists</span></div><div class="casAuthors">Lippa, Blaise; Morris, Joel; Corbett, Matthew; Kwan, Tricia A.; Noe, Mark C.; Snow, Sheri L.; Gant, Thomas G.; Mangiaracina, Melchiorra; Coffey, Heather A.; Foster, Barbara; Knauth, Elisabeth A.; Wessel, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3444-3448</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ureidoisothiazolecarboxamides such as I are prepd. as antagonists of TrkA kinase.  A model based on the docking of isothiazolecarboxamide II to TrkA kinase is proposed.  The title ureidoisothiazolecarboxamides are prepd. by three different routes.  The ureido moiety can be replaced with a heteroarylamino group such as 2-pyridinyl; the presence of benzocycloalkylthio groups such as benzocycloheptyl at the C3-position of the isothiazolecarboxamide provides TrkA inhibitors with high potency in both kinase-based and cell-based assays.  E.g., I inhibits TrkA kinase with an IC50 value of <1 nM in vitro and with an IC50 value of 7 nM in vivo (in PAE cells).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSvzcj4wLOr7Vg90H21EOLACvtfcHk0ljHobMTf_4JSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2ju74%253D&md5=78ea1bfd163945169d0d47e743bee870</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DKwan%26aufirst%3DT.%2BA.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DSnow%26aufirst%3DS.%2BL.%26aulast%3DGant%26aufirst%3DT.%2BG.%26aulast%3DMangiaracina%26aufirst%3DM.%26aulast%3DCoffey%26aufirst%3DH.%2BA.%26aulast%3DFoster%26aufirst%3DB.%26aulast%3DKnauth%26aufirst%3DE.%2BA.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520novel%2520isothiazole%2520inhibitors%2520of%2520the%2520TrkA%2520kinase%253A%2520Structure-activity%2520relationship%252C%2520computer%2520modeling%252C%2520optimization%252C%2520and%2520identification%2520of%2520highly%2520potent%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3444%26epage%3D3448%26doi%3D10.1016%2Fj.bmcl.2006.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albaugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prashad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">(R)-2-Phenylpyrrolidine substituted imidazopyridazines: a new class of potent and selective pan-TRK inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=562-567&author=H.+S.+Choiauthor=P.+V.+Ruckerauthor=Z.+Wangauthor=Y.+Fanauthor=P.+Albaughauthor=G.+Chopiukauthor=F.+Gessierauthor=F.+Sunauthor=F.+Adrianauthor=G.+Liuauthor=T.+Hoodauthor=N.+Liauthor=Y.+Jiaauthor=J.+Cheauthor=S.+McCormackauthor=A.+Liauthor=J.+Liauthor=A.+Steffyauthor=A.+Culazzoauthor=C.+Tompkinsauthor=V.+Phungauthor=A.+Kreuschauthor=M.+Luauthor=B.+Huauthor=A.+Chaudharyauthor=M.+Prashadauthor=T.+Tuntlandauthor=B.+Liuauthor=J.+Harrisauthor=H.+M.+Seidelauthor=J.+Lorenauthor=V.+Molteni&title=%28R%29-2-Phenylpyrrolidine+substituted+imidazopyridazines%3A+a+new+class+of+potent+and+selective+pan-TRK+inhibitors&doi=10.1021%2Facsmedchemlett.5b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors</span></div><div class="casAuthors">Choi, Ha-Soon; Rucker, Paul V.; Wang, Zhicheng; Fan, Yi; Albaugh, Pamela; Chopiuk, Greg; Gessier, Francois; Sun, Fangxian; Adrian, Francisco; Liu, Guoxun; Hood, Tami; Li, Nanxin; Jia, Yong; Che, Jianwei; McCormack, Susan; Li, Allen; Li, Jie; Steffy, Auzon; Culazzo, AnneMarie; Tompkins, Celine; Phung, Van; Kreusch, Andreas; Lu, Min; Hu, Bin; Chaudhary, Apurva; Prashad, Mahavir; Tuntland, Tove; Liu, Bo; Harris, Jennifer; Seidel, H. Martin; Loren, Jon; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">562-567</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be assocd. with tumorigenesis and poor prognosis in a variety of cancer types.  In particular, several chromosomal rearrangements involving TRKA have been reported in colorectal, papillary thyroid, glioblastoma, melanoma, and lung tissue that are believed to be the key oncogenic driver in these tumors.  By screening the Novartis compd. collection, a novel imidazopyridazine TRK inhibitor was identified that served as a launching point for drug optimization.  Structure guided drug design led to the identification of (R)-2-phenylpyrrolidine substituted imidazopyridazines, e.g., I, as a series of potent, selective, orally bioavailable pan-TRK inhibitors achieving tumor regression in rats bearing KM12 xenografts.  From this work the (R)-2-phenylpyrrolidine has emerged as an ideal moiety to incorporate in bicyclic TRK inhibitors by virtue of its shape complementarity to the hydrophobic pocket of TRKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBOGdLZcZ2HbVg90H21EOLACvtfcHk0liV1LjJ_uF9zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D&md5=e2eacf85a3e762e8f2474a568e6d1b39</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00050%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BS.%26aulast%3DRucker%26aufirst%3DP.%2BV.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DAlbaugh%26aufirst%3DP.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DMcCormack%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DCulazzo%26aufirst%3DA.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DPhung%26aufirst%3DV.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DPrashad%26aufirst%3DM.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DLoren%26aufirst%3DJ.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3D%2528R%2529-2-Phenylpyrrolidine%2520substituted%2520imidazopyridazines%253A%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520pan-TRK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D562%26epage%3D567%26doi%3D10.1021%2Facsmedchemlett.5b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsuru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasawa, Y.</span></span> <span> </span><span class="NLM_article-title">Imidazopyridine derivatives as potent and selective polo-like kinase (PLK) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4673</span>– <span class="NLM_lpage">4678</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2009.06.084" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4673-4678&author=Y.+Satoauthor=Y.+Onozakiauthor=T.+Sugimotoauthor=H.+Kuriharaauthor=K.+Kamijoauthor=C.+Kadowakiauthor=T.+Tsujinoauthor=A.+Watanabeauthor=S.+Otsukiauthor=M.+Mitsuyaauthor=M.+Iidaauthor=K.+Hazeauthor=T.+Machidaauthor=Y.+Nakatsuruauthor=H.+Komataniauthor=H.+Kotaniauthor=Y.+Iwasawa&title=Imidazopyridine+derivatives+as+potent+and+selective+polo-like+kinase+%28PLK%29+inhibitors&doi=10.1016%2Fj.bmcl.2009.06.084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.084%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DY.%26aulast%3DOnozaki%26aufirst%3DY.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DKadowaki%26aufirst%3DC.%26aulast%3DTsujino%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DOtsuki%26aufirst%3DS.%26aulast%3DMitsuya%26aufirst%3DM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DHaze%26aufirst%3DK.%26aulast%3DMachida%26aufirst%3DT.%26aulast%3DNakatsuru%26aufirst%3DY.%26aulast%3DKomatani%26aufirst%3DH.%26aulast%3DKotani%26aufirst%3DH.%26aulast%3DIwasawa%26aufirst%3DY.%26atitle%3DImidazopyridine%2520derivatives%2520as%2520potent%2520and%2520selective%2520polo-like%2520kinase%2520%2528PLK%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4673%26epage%3D4678%26doi%3D10.1016%2Fj.bmcl.2009.06.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keysar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. A.</span></span> <span> </span><span class="NLM_article-title">An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-15-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26216294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wqs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1049-1057&author=R.+C.+Doebeleauthor=L.+E.+Davisauthor=A.+Vaishnaviauthor=A.+T.+Leauthor=A.+Estrada-Bernalauthor=S.+Keysarauthor=A.+Jimenoauthor=M.+Varella-Garciaauthor=D.+L.+Aisnerauthor=Y.+Liauthor=P.+J.+Stephensauthor=D.+Morosiniauthor=B.+B.+Tuchauthor=M.+Fernandesauthor=N.+Nandaauthor=J.+A.+Low&title=An+oncogenic+NTRK+fusion+in+a+patient+with+soft-tissue+sarcoma+with+response+to+the+tropomyosin-related+kinase+inhibitor+LOXO-101&doi=10.1158%2F2159-8290.CD-15-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101</span></div><div class="casAuthors">Doebele, Robert C.; Davis, Lara E.; Vaishnavi, Aria; Le, Anh T.; Estrada-Bernal, Adriana; Keysar, Stephen; Jimeno, Antonio; Varella-Garcia, Marileila; Aisner, Dara L.; Li, Yali; Stephens, Philip J.; Morosini, Deborah; Tuch, Brian B.; Fernandes, Michele; Nanda, Nisha; Low, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1049-1057</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Oncogenic TRK fusions induce cancer cell proliferation and engage crit. cancer-related downstream signaling pathways.  These TRK fusions occur rarely, but in a diverse spectrum of tumor histologies.  LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors.  Preclin. models of LOXO-101 using TRK-fusion-bearing human-derived cancer cell lines demonstrate inhibition of the fusion oncoprotein and cellular proliferation in vitro, and tumor growth in vivo.  The tumor of a 41-yr-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion encoding a functional LMNA-TRKA fusion oncoprotein as detd. by an in situ proximity ligation assay.  In a phase I study of LOXO-101 (ClinicalTrials.gov no. NCT02122913), this patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen satn., and plasma tumor markers.  Significance: TRK fusions have been deemed putative oncogenic drivers, but their clin. significance remained unclear.  A patient with a metastatic soft-tissue sarcoma with an LMNA-NTRK1 fusion had rapid and substantial tumor regression with a novel, highly selective TRK inhibitor, LOXO-101, providing the first clin. evidence of benefit from inhibiting TRK fusions.  Cancer Discov; 5(10); 1049-57. ©2015 AACR.  This article is highlighted in the In This Issue feature, p.  1005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOOz1IuW1mjrVg90H21EOLACvtfcHk0liV1LjJ_uF9zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wqs7fF&md5=52fcc72687bcd256dc54e77936d3ebee</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0443%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DDavis%26aufirst%3DL.%2BE.%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DKeysar%26aufirst%3DS.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMorosini%26aufirst%3DD.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DFernandes%26aufirst%3DM.%26aulast%3DNanda%26aufirst%3DN.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26atitle%3DAn%2520oncogenic%2520NTRK%2520fusion%2520in%2520a%2520patient%2520with%2520soft-tissue%2520sarcoma%2520with%2520response%2520to%2520the%2520tropomyosin-related%2520kinase%2520inhibitor%2520LOXO-101%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D1049%26epage%3D1057%26doi%3D10.1158%2F2159-8290.CD-15-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span> <span> </span><span class="NLM_article-title">Fast-TRKing drug development for rare molecular targets</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">934</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-17-0704" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=934-936&author=A.+R.+Parikhauthor=R.+B.+Corcoran&title=Fast-TRKing+drug+development+for+rare+molecular+targets&doi=10.1158%2F2159-8290.CD-17-0704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0704%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DA.%2BR.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26atitle%3DFast-TRKing%2520drug%2520development%2520for%2520rare%2520molecular%2520targets%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D934%26epage%3D936%26doi%3D10.1158%2F2159-8290.CD-17-0704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.+I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+next-generation+TRK+kinase+inhibitor+overcomes+acquired+resistance+to+prior+TRK+kinase+inhibition+in+patients+with+TRK+fusion-positive+solid+tumors&doi=10.1158%2F2159-8290.CD-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. ©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0lgOQ4BFRUSrXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.%2BI.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520next-generation%2520TRK%2520kinase%2520inhibitor%2520overcomes%2520acquired%2520resistance%2520to%2520prior%2520TRK%2520kinase%2520inhibition%2520in%2520patients%2520with%2520TRK%2520fusion-positive%2520solid%2520tumors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.CD-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisafulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rospo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-15-0940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26546295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36-44&author=M.+Russoauthor=S.+Misaleauthor=G.+Weiauthor=G.+Siravegnaauthor=G.+Crisafulliauthor=L.+Lazzariauthor=G.+Cortiauthor=G.+Rospoauthor=L.+Novaraauthor=B.+Mussolinauthor=A.+Bartoliniauthor=N.+Camauthor=R.+Patelauthor=S.+Q.+Yanauthor=R.+Shoemakerauthor=R.+Wildauthor=F.+Di+Nicolantonioauthor=A.+S.+Bianchiauthor=G.+Liauthor=S.+Sienaauthor=A.+Bardelli&title=Acquired+resistance+to+the+TRK+inhibitor+entrectinib+in+colorectal+cancer&doi=10.1158%2F2159-8290.CD-15-0940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span></div><div class="casAuthors">Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Bianchi, Andrea Sartore; Li, Gang; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clin. testing in colorectal cancer and other tumor types.  A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.  To characterize the mol. bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed.  Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C.  Biochem. and pharmacol. anal. in multiple preclin. models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib.  These findings can be immediately exploited to design next-generation TRKA inhibitors.  Significance: We provide proof of principle that analyses of xenopatients (avatar) and liq. biopsies allow the identification of drug resistance mechanisms in parallel with clin. treatment of an individual patient.  We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Unyh1xjaoLVg90H21EOLACvtfcHk0lhZd5kEyDJRJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D&md5=5baa54a784e355b6afa50336b2708052</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0940%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DCrisafulli%26aufirst%3DG.%26aulast%3DLazzari%26aufirst%3DL.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DRospo%26aufirst%3DG.%26aulast%3DNovara%26aufirst%3DL.%26aulast%3DMussolin%26aufirst%3DB.%26aulast%3DBartolini%26aufirst%3DA.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DS.%2BQ.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DAcquired%2520resistance%2520to%2520the%2520TRK%2520inhibitor%2520entrectinib%2520in%2520colorectal%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D36%26epage%3D44%26doi%3D10.1158%2F2159-8290.CD-15-0940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh-Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2130</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-16-0909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28751539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFylsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2130-2143&author=M.+J.+Fuseauthor=K.+Okadaauthor=T.+Oh-Haraauthor=H.+Oguraauthor=N.+Fujitaauthor=R.+Katayama&title=Mechanisms+of+resistance+to+NTRK+inhibitors+and+therapeutic+strategies+in+NTRK1-rearranged+cancers&doi=10.1158%2F1535-7163.MCT-16-0909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers</span></div><div class="casAuthors">Fuse, Miho J.; Okada, Koutaroh; Oh-hara, Tomoko; Ogura, Hayato; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2130-2143</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Neurotrophic receptor tyrosine kinase 1 (NTRK1) gene rearrangement leads to constitutive activation of NTRK1, which induces high-transforming ability.  NTRK-rearranged cancers have been identified in several cancer types, such as glioblastoma, non-small cell lung cancer, and colorectal cancer.  Although there are currently no clin. approved inhibitors that target NTRK1, several tyrosine kinase inhibitors (TKI), such as entrectinib and LOXO-101, are in clin. trials.  The purpose of this study was to identify potential mechanisms of resistance to NTRK inhibitors and find potential therapeutic strategies to overcome the resistance.  We examd. the sensitivity of TPM3-NTRK1-transformed Ba/F3 cells and TPM3-NTRK1-harboring KM12 cells to multiple NTRK inhibitors.  Acquired NTRK inhibitor-resistant mutations were screened by N-ethyl-N-nitrosourea mutagenesis with Ba/F3-TPM3-NTRK1 cells or by the establishment of NTRK-TKI-resistant cells from KM12 cells continuously treated with NTRK-TKIs.  We identified multiple novel NTRK-TKI resistance mutations in the NTRK1 kinase domain, including G595R, and insulin growth factor receptor type 1 (IGF1R) bypass pathway-mediated resistance.  After identifying the resistance mechanisms, we performed drug screening with small-mol. inhibitors to overcome the resistance.  As a result, we found that ponatinib and nintedanib effectively inhibited the survival of TPM3-NTRK1-G667C but not G595R mutants, both of which showed resistance to entrectinib or larotrectinib (LOXO-101).  Furthermore, cabozantinib with an IGF1R inhibitor such as OSI-906 could overcome bypass pathway-mediated resistance.  We developed a comprehensive model of acquired resistance to NTRK inhibitors in cancer with NTRK1 rearrangement and identified cabozantinib as a therapeutic strategy to overcome the resistance.  Mol Cancer Ther; 16(10); 2130-43. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4DKbnrETRxrVg90H21EOLACvtfcHk0lg_Qsbihtl2Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFylsr3J&md5=7f2b8d211e5b1a404d97d1d8ae5ebfa9</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0909%26sid%3Dliteratum%253Aachs%26aulast%3DFuse%26aufirst%3DM.%2BJ.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DOh-Hara%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520NTRK%2520inhibitors%2520and%2520therapeutic%2520strategies%2520in%2520NTRK1-rearranged%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2130%26epage%3D2143%26doi%3D10.1158%2F1535-7163.MCT-16-0909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddinger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneval, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">CT007</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-CT007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2016-CT007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=CT007&author=A.+Drilonauthor=F.+G.+De+Braudauthor=S.+Sienaauthor=S.+I.+Ouauthor=M.+Patelauthor=M.+Ahnauthor=J.+Leeauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=S.+V.+Liuauthor=N.+Reddingerauthor=R.+Patelauthor=D.+Luoauthor=E.+C.+Manevalauthor=P.+S.+Multaniauthor=R.+C.+Doebeleauthor=A.+T.+Shaw&title=Abstract+CT007%3A+Entrectinib%2C+an+oral+pan-Trk%2C+ROS1%2C+and+ALK+inhibitor+in+TKI-na%C3%AFve+patients+with+advanced+solid+tumors+harboring+gene+rearrangements%3A+Updated+phase+I+results&doi=10.1158%2F1538-7445.AM2016-CT007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-CT007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-CT007%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DReddinger%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DManeval%26aufirst%3DE.%2BC.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DAbstract%2520CT007%253A%2520Entrectinib%252C%2520an%2520oral%2520pan-Trk%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520in%2520TKI-na%25C3%25AFve%2520patients%2520with%2520advanced%2520solid%2520tumors%2520harboring%2520gene%2520rearrangements%253A%2520Updated%2520phase%2520I%2520results%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3DCT007%26doi%3D10.1158%2F1538-7445.AM2016-CT007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">C65</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.TARG-15-C65</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.TARG-15-C65" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=C65&author=A.+Estrada-Bernalauthor=A.+T.+Leauthor=B.+Tuchauthor=T.+Kutateladzeauthor=R.+C.+Doebele&title=Abstract+C65%3A+TRK+kinase+domain+mutations+that+induce+resistance+to+a+pan-TRK+inhibitor&doi=10.1158%2F1535-7163.TARG-15-C65"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-15-C65&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-15-C65%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTuch%26aufirst%3DB.%26aulast%3DKutateladze%26aufirst%3DT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DAbstract%2520C65%253A%2520TRK%2520kinase%2520domain%2520mutations%2520that%2520induce%2520resistance%2520to%2520a%2520pan-TRK%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3DC65%26doi%3D10.1158%2F1535-7163.TARG-15-C65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="note"><p class="first last">The molecular docking was carried out using AutoDock4. The TRKA protein crystal structure was downloaded from the protein data bank (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AOJ">4AOJ</a>). Amino acid mutations were carried out using Maestro 2018-2, and the figures were generated by Maestro 2018-2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S32</span>– <span class="NLM_lpage">S32</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)32675-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-8049%2816%2932675-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=S32-S32&author=J.+J.+Cuiauthor=D.+Zhaiauthor=W.+Dengauthor=E.+Rogersauthor=Z.+Huangauthor=J.+Whittenauthor=Y.+Li&title=TPX-0005%2C+a+novel+ALK%2FROS1%2FTRK+inhibitor%2C+effectively+inhibited+a+broad+spectrum+of+mutations+including+solvent+front+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R+mutants&doi=10.1016%2FS0959-8049%2816%2932675-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2932675-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252932675-2%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTPX-0005%252C%2520a%2520novel%2520ALK%252FROS1%252FTRK%2520inhibitor%252C%2520effectively%2520inhibited%2520a%2520broad%2520spectrum%2520of%2520mutations%2520including%2520solvent%2520front%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%2520mutants%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D69%26spage%3DS32%26epage%3DS32%26doi%3D10.1016%2FS0959-8049%2816%2932675-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. S.</span></span> <span> </span><span class="NLM_article-title">Ending the endless acquired tyrosine kinase resistance mutations - Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2133</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2016-2133" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2133&author=J.+J.+Cuiauthor=E.+Rogersauthor=D.+Y.+Zhaiauthor=W.+Dengauthor=Z.+D.+Huangauthor=J.+Whittenauthor=Y.+S.+Li&title=Ending+the+endless+acquired+tyrosine+kinase+resistance+mutations+-+Design+of+TPX-0005%2C+a+multi-target+ALK%2FROS1%2FTRK+inhibitor+with+broad+spectrum+activity+against+wild-type+and+mutants+including+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R&doi=10.1158%2F1538-7445.AM2016-2133"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-2133%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DD.%2BY.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%2BD.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%2BS.%26atitle%3DEnding%2520the%2520endless%2520acquired%2520tyrosine%2520kinase%2520resistance%2520mutations%2520-%2520Design%2520of%2520TPX-0005%252C%2520a%2520multi-target%2520ALK%252FROS1%252FTRK%2520inhibitor%2520with%2520broad%2520spectrum%2520activity%2520against%2520wild-type%2520and%2520mutants%2520including%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2133%26doi%3D10.1158%2F1538-7445.AM2016-2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S32</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)32675-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-8049%2816%2932675-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=S32&author=J.+J.+Cuiauthor=D.+Zhaiauthor=W.+Dengauthor=E.+Rogersauthor=Z.+Huangauthor=J.+Whittenauthor=Y.+Li&title=TPX-0005%2C+a+novel+ALK%2FROS1%2FTRK+inhibitor%2C+effectively+inhibited+a+broad+spectrum+of+mutations+including+solvent+front+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R+mutants&doi=10.1016%2FS0959-8049%2816%2932675-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2932675-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252932675-2%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTPX-0005%252C%2520a%2520novel%2520ALK%252FROS1%252FTRK%2520inhibitor%252C%2520effectively%2520inhibited%2520a%2520broad%2520spectrum%2520of%2520mutations%2520including%2520solvent%2520front%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%2520mutants%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D69%26spage%3DS32%26doi%3D10.1016%2FS0959-8049%2816%2932675-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuyper, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2003.12.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=953-957&author=E.+R.+Woodauthor=L.+Kuyperauthor=K.+G.+Petrovauthor=R.+N.+Hunterauthor=P.+A.+Harrisauthor=K.+Lackey&title=Discovery+and+in+vitro+evaluation+of+potent+TrkA+kinase+inhibitors%3A+oxindole+and+aza-oxindoles&doi=10.1016%2Fj.bmcl.2003.12.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DKuyper%26aufirst%3DL.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520in%2520vitro%2520evaluation%2520of%2520potent%2520TrkA%2520kinase%2520inhibitors%253A%2520oxindole%2520and%2520aza-oxindoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D953%26epage%3D957%26doi%3D10.1016%2Fj.bmcl.2003.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudjemeline, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopewell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Syntheses and evaluation of carbon-11-and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/cn500193f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500193f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=260-276&author=V.+Bernard-Gauthierauthor=A.+Aliagaauthor=A.+Aliagaauthor=M.+Boudjemelineauthor=R.+Hopewellauthor=A.+Kostikovauthor=P.+Rosa-Netoauthor=A.+Thielauthor=R.+Schirrmacher&title=Syntheses+and+evaluation+of+carbon-11-and+fluorine-18-radiolabeled+pan-tropomyosin+receptor+kinase+%28Trk%29+inhibitors%3A+exploration+of+the+4-aza-2-oxindole+scaffold+as+Trk+PET+imaging+agents&doi=10.1021%2Fcn500193f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4-Aza-2-oxindole Scaffold as Trk PET Imaging Agents</span></div><div class="casAuthors">Bernard-Gauthier, Vadim; Aliaga, Arturo; Aliaga, Antonio; Boudjemeline, Mehdi; Hopewell, Robert; Kostikov, Alexey; Rosa-Neto, Pedro; Thiel, Alexander; Schirrmacher, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-276</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tropomyosin receptor kinases (TrkA/B/C) are critically involved in the development of the nervous system, in neurol. disorders as well as in multiple neoplasms of both neural and non-neural origins.  The development of Trk radiopharmaceuticals would offer unique opportunities toward a more complete understanding of this emerging therapeutic target.  To that end, we first developed [11C]GW441756 ([11C]9), a high affinity photoisomerizable pan-Trk inhibitor, as a lead radiotracer for our positron emission tomog. (PET) program.  Efficient carbon-11 radiolabeling afforded [11C]9 in high radiochem. yields (isolated RCY, 25.9% ± 5.7%).  In vitro autoradiog. studies in rat brain and TrkB-expressing human neuroblastoma cryosections confirmed that [11C]9 specifically binds to Trk receptors in vitro.  MicroPET studies revealed that binding of [11C]9 in the rodent brain was mostly nonspecific despite initial high brain uptake (SUVmax = 2.0).  Modeling studies of the 4-aza-2-oxindole scaffold led to the successful identification of a small series of high affinity fluorinated and methoxy derivatized pan-Trk inhibitors based on our lead compd. 9.  Out of this series, the fluorinated compd. 10 was selected for initial evaluation and radiolabeled with fluorine-18 (isolated RCY, 2.5% ± 0.6%).  Compd. [18F]10 demonstrated excellent Trk selectivity in a panel of cancer relevant kinase targets and a promising in vitro profile in tumors and brain sections but high oxidative metabolic susceptibility leading to nonspecific brain distribution in vivo.  The information gained in this study will guide further exploration of the 4-aza-2-oxindole scaffold as a lead for Trk PET ligand development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZ4BFFghVJbVg90H21EOLACvtfcHk0liOxAH18FrLLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7%252FP&md5=a23e2af118d6ed5e430cbd4687ee5b8f</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fcn500193f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500193f%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DBoudjemeline%26aufirst%3DM.%26aulast%3DHopewell%26aufirst%3DR.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DThiel%26aufirst%3DA.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DSyntheses%2520and%2520evaluation%2520of%2520carbon-11-and%2520fluorine-18-radiolabeled%2520pan-tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520inhibitors%253A%2520exploration%2520of%2520the%25204-aza-2-oxindole%2520scaffold%2520as%2520Trk%2520PET%2520imaging%2520agents%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D260%26epage%3D276%26doi%3D10.1021%2Fcn500193f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrrole[3,4-c]pyrazoles as potent tropomyosin receptor kinase A (TrkA) inhibitors</span>. <i>Bull. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1378</span>– <span class="NLM_lpage">1380</span>, <span class="refDoi"> DOI: 10.1002/bkcs.10862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fbkcs.10862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GjurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1378-1380&author=H.+Choeauthor=Y.+H.+Sonauthor=B.+J.+Byunauthor=S.+U.+Choiauthor=K.+Lee&title=Identification+of+pyrrole%5B3%2C4-c%5Dpyrazoles+as+potent+tropomyosin+receptor+kinase+A+%28TrkA%29+inhibitors&doi=10.1002%2Fbkcs.10862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Pyrrole[3,4-c]pyrazoles as Potent Tropomyosin Receptor Kinase A (TrkA) Inhibitors</span></div><div class="casAuthors">Choe, Hyeonjeong; Son, You Hwa; Byun, Byung Jin; Choi, Sang Un; Lee, Kwangho</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1378-1380</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pyrrole[3,4-c]pyrazoles were identified as potent tropomyosin receptor kinase A (TrkA) inhibitors.  Pyrrolo[3,4-c] pyrazole C3 amido derivs. were explored widely followed by designing and introduction of benzyloxycarbonyl (Cbz) for C3-NH derivatization for novelty consideration.  N-Bu urea was adopted for the pyrrolo[3,4-c]pyrazole N5 substitution.  Substituted with cyclopropyl at the pyrrole[3,4-c]pyrazole C6 position, RMK-036 inhibits TrkA with 19 nM of IC50 value.  Various C6 substitution analogs of RMK-036 reveal dramatic structure-activity relationship in TrkA inhibition.  Thus its been concluded that identification and development of TrkA inhibitors would be valuable for various anticancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkkKsqzaATjLVg90H21EOLACvtfcHk0liOxAH18FrLLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GjurbP&md5=f4ce4ff4f3fe86c65862cdfd5c06f56a</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2Fbkcs.10862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbkcs.10862%26sid%3Dliteratum%253Aachs%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DSon%26aufirst%3DY.%2BH.%26aulast%3DByun%26aufirst%3DB.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BU.%26aulast%3DLee%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520pyrrole%255B3%252C4-c%255Dpyrazoles%2520as%2520potent%2520tropomyosin%2520receptor%2520kinase%2520A%2520%2528TrkA%2529%2520inhibitors%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2016%26volume%3D37%26spage%3D1378%26epage%3D1380%26doi%3D10.1002%2Fbkcs.10862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurlburt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillerman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantor, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dell-John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span> <span> </span><span class="NLM_article-title">BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3349</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-09-0499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19996272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3341-3349&author=J.+M.+Carboniauthor=M.+Wittmanauthor=Z.+Yangauthor=F.+Leeauthor=A.+Greerauthor=W.+Hurlburtauthor=S.+Hillermanauthor=C.+Caoauthor=G.+H.+Cantorauthor=J.+Dell-Johnauthor=C.+Chenauthor=L.+Discenzaauthor=K.+Menardauthor=A.+Liauthor=G.+Trainorauthor=D.+Vyasauthor=R.+Kramerauthor=R.+M.+Attarauthor=M.+M.+Gottardis&title=BMS-754807%2C+a+small+molecule+inhibitor+of+insulin-like+growth+factor-1R%2FIR&doi=10.1158%2F1535-7163.MCT-09-0499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR</span></div><div class="casAuthors">Carboni, Joan M.; Wittman, Mark; Yang, Zheng; Lee, Francis; Greer, Ann; Hurlburt, Warren; Hillerman, Stephen; Cao, Carolyn; Cantor, Glenn H.; Dell-John, Janet; Chen, Cliff; Discenza, Lorell; Menard, Krista; Li, Aixin; Trainor, George; Vyas, Dolatrai; Kramer, Robert; Attar, Ricardo M.; Gottardis, Marco M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3341-3349</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L).  It is currently in phase I development for the treatment of a variety of human cancers.  BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5-365 nmol/L); the compd. caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage.  BMS-754807 is active in vivo in multiple (epithelial, mesenchymal, and hematopoietic) xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a min. ED of as low as 6.25 mg/kg dosed orally daily.  Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, <1.0) when combined with cytotoxic, hormonal, and targeted agents.  The combination of cetuximab and BMS-754807 in vivo, at multiple dose levels, resulted in improved clin. outcome over single agent treatment.  These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmviunBiK1hbVg90H21EOLACvtfcHk0lj96zlhwQHDvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitb3F&md5=1f348da6d076373aaf9296ebfcfc5542</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0499%26sid%3Dliteratum%253Aachs%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DHillerman%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DCantor%26aufirst%3DG.%2BH.%26aulast%3DDell-John%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DMenard%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26aulast%3DKramer%26aufirst%3DR.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26atitle%3DBMS-754807%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1R%252FIR%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3341%26epage%3D3349%26doi%3D10.1158%2F1535-7163.MCT-09-0499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4223</span>– <span class="NLM_lpage">4227</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2010.05.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4223-4227&author=S.+Y.+Choauthor=S.+Y.+Hanauthor=J.+D.+Haauthor=J.+W.+Ryuauthor=C.+O.+Leeauthor=H.+Jungauthor=N.+S.+Kangauthor=H.+R.+Kimauthor=J.+S.+Kohauthor=J.+Lee&title=Discovery+of+aminopyridines+substituted+with+benzoxazole+as+orally+active+c-Met+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.05.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.031%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DHan%26aufirst%3DS.%2BY.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DRyu%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DJung%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DN.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKoh%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520aminopyridines%2520substituted%2520with%2520benzoxazole%2520as%2520orally%2520active%2520c-Met%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4223%26epage%3D4227%26doi%3D10.1016%2Fj.bmcl.2010.05.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1007/s10637-010-9584-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2Fs10637-010-9584-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=518-523&author=S.+Y.+Hanauthor=C.+O.+Leeauthor=S.+H.+Ahnauthor=M.+O.+Leeauthor=S.+Y.+Kangauthor=H.+J.+Chaauthor=S.+Y.+Choauthor=J.+D.+Haauthor=J.+W.+Ryuauthor=H.+Jungauthor=H.+R.+Kimauthor=J.+S.+Kohauthor=J.+Lee&title=Evaluation+of+a+multi-kinase+inhibitor+KRC-108+as+an+anti-tumor+agent+in+vitro+and+in+vivo&doi=10.1007%2Fs10637-010-9584-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9584-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9584-2%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DAhn%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DM.%2BO.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DCha%26aufirst%3DH.%2BJ.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DRyu%26aufirst%3DJ.%2BW.%26aulast%3DJung%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKoh%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520a%2520multi-kinase%2520inhibitor%2520KRC-108%2520as%2520an%2520anti-tumor%2520agent%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D518%26epage%3D523%26doi%3D10.1007%2Fs10637-010-9584-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stachel, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brnardic, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowska-Zoladek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span> <span> </span><span class="NLM_article-title">Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5800</span>– <span class="NLM_lpage">5816</span>, <span class="refDoi"> DOI: 10.1021/jm5006429</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006429" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1SrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5800-5816&author=S.+J.+Stachelauthor=J.+M.+Sandersauthor=D.+A.+Henzeauthor=M.+T.+Ruddauthor=H.+P.+Suauthor=Y.+Liauthor=K.+K.+Nandaauthor=M.+S.+Egbertsonauthor=P.+J.+Manleyauthor=K.+L.+Jonesauthor=E.+J.+Brnardicauthor=A.+Greenauthor=J.+A.+Groblerauthor=B.+Hanneyauthor=M.+Leitlauthor=M.+T.+Laiauthor=V.+Munshiauthor=D.+Murphyauthor=K.+Rickertauthor=D.+Rileyauthor=A.+Krasowska-Zoladekauthor=C.+Daleyauthor=P.+Zuckauthor=S.+A.+Kaneauthor=M.+T.+Bilodeau&title=Maximizing+diversity+from+a+kinase+screen%3A+identification+of+novel+and+selective+pan-Trk+inhibitors+for+chronic+pain&doi=10.1021%2Fjm5006429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain</span></div><div class="casAuthors">Stachel, Shawn J.; Sanders, John M.; Henze, Darrell A.; Rudd, Mike T.; Su, Hua-Poo; Li, Yiwei; Nanda, Kausik K.; Egbertson, Melissa S.; Manley, Peter J.; Jones, Kristen L. G.; Brnardic, Edward J.; Green, Ahren; Grobler, Jay A.; Hanney, Barbara; Leitl, Michael; Lai, Ming-Tain; Munshi, Vandna; Murphy, Dennis; Rickert, Keith; Riley, Daniel; Krasowska-Zoladek, Alicja; Daley, Christopher; Zuck, Paul; Kane, Stephanie A.; Bilodeau, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5800-5816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have identified several series of small mol. inhibitors of TrkA with unique binding modes.  The starting leads were chosen to maximize the structural and binding mode diversity derived from a high throughput screen of our internal compd. collection.  These leads were optimized for potency and selectivity employing a structure based drug design approach adhering to the principles of ligand efficiency to maximize binding affinity without overly relying on lipophilic interactions.  This endeavor resulted in the identification of several small mol. pan-Trk inhibitor series that exhibit high selectivity for TrkA/B/C vs. a diverse panel of kinases.  We have also demonstrated efficacy in both inflammatory and neuropathic pain models upon oral dosing.  Herein we describe the identification process, hit-to-lead progression, and binding profiles of these selective pan-Trk kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj0SoN8gB1M7Vg90H21EOLACvtfcHk0lgp3wcVKRvBHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1SrsLs%253D&md5=f8aaef0b21eb49eed8004fc18f04dff5</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Fjm5006429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006429%26sid%3Dliteratum%253Aachs%26aulast%3DStachel%26aufirst%3DS.%2BJ.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNanda%26aufirst%3DK.%2BK.%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26aulast%3DManley%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DBrnardic%26aufirst%3DE.%2BJ.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DGrobler%26aufirst%3DJ.%2BA.%26aulast%3DHanney%26aufirst%3DB.%26aulast%3DLeitl%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DRiley%26aufirst%3DD.%26aulast%3DKrasowska-Zoladek%26aufirst%3DA.%26aulast%3DDaley%26aufirst%3DC.%26aulast%3DZuck%26aufirst%3DP.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26atitle%3DMaximizing%2520diversity%2520from%2520a%2520kinase%2520screen%253A%2520identification%2520of%2520novel%2520and%2520selective%2520pan-Trk%2520inhibitors%2520for%2520chronic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5800%26epage%3D5816%26doi%3D10.1021%2Fjm5006429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohren, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkington, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span> <span> </span><span class="NLM_article-title">Clinical applications of PET in oncology</span>. <i>Radiology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1148/radiol.2312021185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1148%2Fradiol.2312021185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15044750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BD2c3jtVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2004&pages=305-332&author=E.+M.+Rohrenauthor=T.+G.+Turkingtonauthor=R.+E.+Coleman&title=Clinical+applications+of+PET+in+oncology&doi=10.1148%2Fradiol.2312021185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of PET in oncology</span></div><div class="casAuthors">Rohren Eric M; Turkington Timothy G; Coleman R Edward</div><div class="citationInfo"><span class="NLM_cas:title">Radiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-32</span>
        ISSN:<span class="NLM_cas:issn">0033-8419</span>.
    </div><div class="casAbstract">Positron emission tomography (PET) provides metabolic information that has been documented to be useful in patient care.  The properties of positron decay permit accurate imaging of the distribution of positron-emitting radiopharmaceuticals.  The wide array of positron-emitting radiopharmaceuticals has been used to characterize multiple physiologic and pathologic states.  PET is used for characterizing brain disorders such as Alzheimer disease and epilepsy and cardiac disorders such as coronary artery disease and myocardial viability.  The neurologic and cardiac applications of PET are not covered in this review.  The major utilization of PET clinically is in oncology and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG).  FDG, an analogue of glucose, accumulates in most tumors in a greater amount than it does in normal tissue.  FDG PET is being used in diagnosis and follow-up of several malignancies, and the list of articles supporting its use continues to grow.  In this review, the physics and instrumentation aspects of PET are described.  Many of the clinical applications in oncology are mature and readily covered by third-party payers.  Other applications are being used clinically but have not been as carefully evaluated in the literature, and these applications may not be covered by third-party payers.  The developing applications of PET are included in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxr44wmCntJyEJCPKhJPuqfW6udTcc2eZwLSKIKKwS0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3jtVamtQ%253D%253D&md5=1c1ba1d3d29ea79f0ceb6fff0efdef24</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1148%2Fradiol.2312021185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiol.2312021185%26sid%3Dliteratum%253Aachs%26aulast%3DRohren%26aufirst%3DE.%2BM.%26aulast%3DTurkington%26aufirst%3DT.%2BG.%26aulast%3DColeman%26aufirst%3DR.%2BE.%26atitle%3DClinical%2520applications%2520of%2520PET%2520in%2520oncology%26jtitle%3DRadiology%26date%3D2004%26volume%3D231%26spage%3D305%26epage%3D332%26doi%3D10.1148%2Fradiol.2312021185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span> <span> </span><span class="NLM_article-title">Molecular imaging in drug discovery and development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1038/nrd1007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrd1007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12563303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot12muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=123-131&author=M.+Rudinauthor=R.+Weissleder&title=Molecular+imaging+in+drug+discovery+and+development&doi=10.1038%2Fnrd1007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular imaging in drug discovery and development</span></div><div class="casAuthors">Rudin, Markus; Weissleder, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imaging sciences have grown exponentially during the past three decades, and many techniques, such as magnetic resonance imaging, nuclear tomog. imaging and x-ray computed tomog., have become indispensable in clin. use.  Advances in imaging technologies and imaging probes for humans and for small animals are now extending the applications of imaging further into drug discovery and development, and have the potential to considerably accelerate the process.  This review summarizes some of the recent developments in conventional and mol. imaging, and highlights their impact on drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDy3yn7bOSXbVg90H21EOLACvtfcHk0lgp3wcVKRvBHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot12muw%253D%253D&md5=584c5914a8b2808f7c510528d7017349</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnrd1007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1007%26sid%3Dliteratum%253Aachs%26aulast%3DRudin%26aufirst%3DM.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DMolecular%2520imaging%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D123%26epage%3D131%26doi%3D10.1038%2Fnrd1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slobbe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poot, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windhorst, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dongen, G. A.</span></span> <span> </span><span class="NLM_article-title">PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2012.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.drudis.2012.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22766374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1175-1187&author=P.+Slobbeauthor=A.+J.+Pootauthor=A.+D.+Windhorstauthor=G.+A.+van+Dongen&title=PET+imaging+with+small-molecule+tyrosine+kinase+inhibitors%3A+TKI-PET&doi=10.1016%2Fj.drudis.2012.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET</span></div><div class="casAuthors">Slobbe, Paul; Poot, Alex J.; Windhorst, Albert D.; van Dongen, Guus A. M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21-22</span>),
    <span class="NLM_cas:pages">1175-1187</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery and increased understanding of tumor targets has led to the development and approval of 12 small mol. tyrosine kinase inhibitors (TKIs).  Despite tremendous efforts in TKI development, treatment efficacies with these therapeutics are still too low and improvements require a personalized medicine approach.  Positron emission tomog. (PET) with radiolabeled TKIs (TKI-PET) is a tracking, quantification and imaging method, which provides a unique understanding of the behavior of these drugs in vivo and of the interaction with their target(s).  In this article we provide an overview of tracer synthesis and development because each TKI requires a tailor made approach.  Moreover, we describe current preclin. work and the first proof-of-principle clin. studies on the application of TKI-PET, illustrating the potential of this approach for improving therapy efficacy and personalized cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzoQ0SBqROKbVg90H21EOLACvtfcHk0lgp3wcVKRvBHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLjM&md5=a6d15bd0c3eee95e525e1cbca9f3e587</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DSlobbe%26aufirst%3DP.%26aulast%3DPoot%26aufirst%3DA.%2BJ.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3Dvan%2BDongen%26aufirst%3DG.%2BA.%26atitle%3DPET%2520imaging%2520with%2520small-molecule%2520tyrosine%2520kinase%2520inhibitors%253A%2520TKI-PET%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D1175%26epage%3D1187%26doi%3D10.1016%2Fj.drudis.2012.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">22000</span>– <span class="NLM_lpage">22027</span>, <span class="refDoi"> DOI: 10.3390/molecules201219816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3390%2Fmolecules201219816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26690113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKgsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=22000-22027&author=V.+Bernard-Gauthierauthor=J.+J.+Baileyauthor=S.+Berkeauthor=R.+Schirrmacher&title=Recent+advances+in+the+development+and+application+of+radiolabeled+kinase+inhibitors+for+PET+imaging&doi=10.3390%2Fmolecules201219816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging</span></div><div class="casAuthors">Bernard-Gauthier, Vadim; Bailey, Justin J.; Berke, Sheldon; Schirrmacher, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">22000-22027</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Over the last 20 years, intensive investigation and multiple clin. successes targeting protein kinases, mostly for cancer treatment, have identified small mol. kinase inhibitors as a prominent therapeutic class.  In the course of those investigations, radiolabeled kinase inhibitors for positron emission tomog. (PET) imaging have been synthesized and evaluated as diagnostic imaging probes for cancer characterization.  Given that inhibitor coverage of the kinome is continuously expanding, in vivo PET imaging will likely find increasing applications for therapy monitoring and receptor d. studies both in- and outside of oncol. conditions.  Early investigated radiolabeled inhibitors, which are mostly based on clin. approved tyrosine kinase inhibitor (TKI) isotopologues, have now entered clin. trials.  Novel radioligands for cancer and PET neuroimaging originating from novel but relevant target kinases are currently being explored in preclin. studies.  This article reviews the literature involving radiotracer design, radiochem. approaches, biol. tracer evaluation and nuclear imaging results of radiolabeled kinase inhibitors for PET reported between 2010 and mid-2015.  Aspects regarding the usefulness of pursuing selective vs. promiscuous inhibitor scaffolds and the inherent challenges assocd. with intracellular enzyme imaging will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoK7e4uBNDBLVg90H21EOLACvtfcHk0likqLEUBXz7QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKgsL%252FI&md5=be84e68fe296d62fdcfd15857dda05f0</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3390%2Fmolecules201219816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules201219816%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DBerke%26aufirst%3DS.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520and%2520application%2520of%2520radiolabeled%2520kinase%2520inhibitors%2520for%2520PET%2520imaging%26jtitle%3DMolecules%26date%3D2015%26volume%3D20%26spage%3D22000%26epage%3D22027%26doi%3D10.3390%2Fmolecules201219816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuest, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuest, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo 1,2-b pyridazine pan-Trk inhibitors as candidate PET imaging probes</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2193</span>, <span class="refDoi"> DOI: 10.1039/C5MD00388A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1039%2FC5MD00388A" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2184-2193&author=V.+Bernard-Gauthierauthor=J.+J.+Baileyauthor=A.+Aliagaauthor=A.+Kostikovauthor=P.+Rosa-Netoauthor=M.+Wuestauthor=G.+M.+Brodeurauthor=B.+J.+Bedellauthor=F.+Wuestauthor=R.+Schirrmacher&title=Development+of+subnanomolar+radiofluorinated+%282-pyrrolidin-1-yl%29imidazo+1%2C2-b+pyridazine+pan-Trk+inhibitors+as+candidate+PET+imaging+probes&doi=10.1039%2FC5MD00388A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1039%2FC5MD00388A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00388A%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DWuest%26aufirst%3DM.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DBedell%26aufirst%3DB.%2BJ.%26aulast%3DWuest%26aufirst%3DF.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520subnanomolar%2520radiofluorinated%2520%25282-pyrrolidin-1-yl%2529imidazo%25201%252C2-b%2520pyridazine%2520pan-Trk%2520inhibitors%2520as%2520candidate%2520PET%2520imaging%2520probes%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D2184%26epage%3D2193%26doi%3D10.1039%2FC5MD00388A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesnaver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2775</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2017.04.064" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2771-2775&author=V.+Bernard-Gauthierauthor=A.+Mahringerauthor=M.+Vesnaverauthor=G.+Frickerauthor=R.+Schirrmacher&title=Design+and+synthesis+of+a+fluorinated+quinazoline-based+type-II+Trk+inhibitor+as+a+scaffold+for+PET+radiotracer+development&doi=10.1016%2Fj.bmcl.2017.04.064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.064%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DVesnaver%26aufirst%3DM.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520fluorinated%2520quinazoline-based%2520type-II%2520Trk%2520inhibitor%2520as%2520a%2520scaffold%2520for%2520PET%2520radiotracer%2520development%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2771%26epage%3D2775%26doi%3D10.1016%2Fj.bmcl.2017.04.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">5-(4-((4-[(18)F]Fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: a selective dual inhibitor for potential PET imaging of Trk/CSF-1R</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4784</span>– <span class="NLM_lpage">4790</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2014.09.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4784-4790&author=V.+Bernard-Gauthierauthor=R.+Schirrmacher&title=5-%284-%28%284-%5B%2818%29F%5DFluorobenzyl%29oxy%29-3-methoxybenzyl%29pyrimidine-2%2C4-diamine%3A+a+selective+dual+inhibitor+for+potential+PET+imaging+of+Trk%2FCSF-1R&doi=10.1016%2Fj.bmcl.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3D5-%25284-%2528%25284-%255B%252818%2529F%255DFluorobenzyl%2529oxy%2529-3-methoxybenzyl%2529pyrimidine-2%252C4-diamine%253A%2520a%2520selective%2520dual%2520inhibitor%2520for%2520potential%2520PET%2520imaging%2520of%2520Trk%252FCSF-1R%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4784%26epage%3D4790%26doi%3D10.1016%2Fj.bmcl.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mossine, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vomacka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand’Maison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, P. J. H.</span></span> <span> </span><span class="NLM_article-title">A kinome-wide selective radiolabeled TrkB/C inhibitor for in vitro and in vivo neuroimaging: synthesis, preclinical evaluation, and first-in-human</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6897</span>– <span class="NLM_lpage">6910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6897-6910&author=V.+Bernard-Gauthierauthor=J.+J.+Baileyauthor=A.+V.+Mossineauthor=S.+Lindnerauthor=L.+Vomackaauthor=A.+Aliagaauthor=X.+Shaoauthor=C.+A.+Quesadaauthor=P.+Shermanauthor=A.+Mahringerauthor=A.+Kostikovauthor=M.+Grand%E2%80%99Maisonauthor=P.+Rosa-Netoauthor=J.+P.+Soucyauthor=A.+Thielauthor=D.+R.+Kaplanauthor=G.+Frickerauthor=B.+Wanglerauthor=P.+Bartensteinauthor=R.+Schirrmacherauthor=P.+J.+H.+Scott&title=A+kinome-wide+selective+radiolabeled+TrkB%2FC+inhibitor+for+in+vitro+and+in+vivo+neuroimaging%3A+synthesis%2C+preclinical+evaluation%2C+and+first-in-human&doi=10.1021%2Facs.jmedchem.7b00396"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00396%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DMossine%26aufirst%3DA.%2BV.%26aulast%3DLindner%26aufirst%3DS.%26aulast%3DVomacka%26aufirst%3DL.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DQuesada%26aufirst%3DC.%2BA.%26aulast%3DSherman%26aufirst%3DP.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DGrand%25E2%2580%2599Maison%26aufirst%3DM.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DSoucy%26aufirst%3DJ.%2BP.%26aulast%3DThiel%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DWangler%26aufirst%3DB.%26aulast%3DBartenstein%26aufirst%3DP.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DP.%2BJ.%2BH.%26atitle%3DA%2520kinome-wide%2520selective%2520radiolabeled%2520TrkB%252FC%2520inhibitor%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520neuroimaging%253A%2520synthesis%252C%2520preclinical%2520evaluation%252C%2520and%2520first-in-human%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6897%26epage%3D6910%26doi%3D10.1021%2Facs.jmedchem.7b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mossine, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand’Maison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochon, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, P. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Identification of [(18)F]TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1737</span>– <span class="NLM_lpage">1743</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1737-1743&author=V.+Bernard-Gauthierauthor=A.+V.+Mossineauthor=A.+Mahringerauthor=A.+Aliagaauthor=J.+J.+Baileyauthor=X.+Shaoauthor=J.+Stauffauthor=J.+Arteagaauthor=P.+Shermanauthor=M.+Grand%E2%80%99Maisonauthor=P.+L.+Rochonauthor=B.+Wanglerauthor=C.+Wanglerauthor=P.+Bartensteinauthor=A.+Kostikovauthor=D.+R.+Kaplanauthor=G.+Frickerauthor=P.+Rosa-Netoauthor=P.+J.+H.+Scottauthor=R.+Schirrmacher&title=Identification+of+%5B%2818%29F%5DTRACK%2C+a+fluorine-18-labeled+tropomyosin+receptor+kinase+%28Trk%29+inhibitor+for+PET+imaging&doi=10.1021%2Facs.jmedchem.7b01607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01607%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DMossine%26aufirst%3DA.%2BV.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DStauff%26aufirst%3DJ.%26aulast%3DArteaga%26aufirst%3DJ.%26aulast%3DSherman%26aufirst%3DP.%26aulast%3DGrand%25E2%2580%2599Maison%26aufirst%3DM.%26aulast%3DRochon%26aufirst%3DP.%2BL.%26aulast%3DWangler%26aufirst%3DB.%26aulast%3DWangler%26aufirst%3DC.%26aulast%3DBartenstein%26aufirst%3DP.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DScott%26aufirst%3DP.%2BJ.%2BH.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520%255B%252818%2529F%255DTRACK%252C%2520a%2520fluorine-18-labeled%2520tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520inhibitor%2520for%2520PET%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1737%26epage%3D1743%26doi%3D10.1021%2Facs.jmedchem.7b01607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0li2npbis72Swg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0li2npbis72Swg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albaugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1021/ml200261d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200261d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFCm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=140-145&author=P.+Albaughauthor=Y.+Fanauthor=Y.+Miauthor=F.+X.+Sunauthor=F.+Adrianauthor=N.+X.+Liauthor=Y.+Jiaauthor=Y.+Sarkisovaauthor=A.+Kreuschauthor=T.+Hoodauthor=M.+Luauthor=G.+X.+Liuauthor=S.+L.+Huangauthor=Z.+S.+Liuauthor=J.+Lorenauthor=T.+Tuntlandauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=V.+Molteni&title=Discovery+of+GNF-5837%2C+a+selective+TRK+inhibitor+with+efficacy+in+rodent+cancer+tumor+models&doi=10.1021%2Fml200261d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models</span></div><div class="casAuthors">Albaugh, Pam; Fan, Yi; Mi, Yuan; Sun, Fangxian; Adrian, Francisco; Li, Nanxin; Jia, Yong; Sarkisova, Yelena; Kreusch, Andreas; Hood, Tami; Lu, Min; Liu, Guoxun; Huang, Shenlin; Liu, Zuosheng; Loren, Jon; Tuntland, Tove; Karanewsky, Donald S.; Seidel, H. Martin; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-145</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network.  Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin.  By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified.  Optimization led to the identification of GNF-5837 (I), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF.  The properties of I make it a good tool for the elucidation of TRK biol. in cancer and other nononcol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF4DjLhCqRFrVg90H21EOLACvtfcHk0lhvPJqCNjvfeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFCm&md5=d355489fe9f791a8547699fa65ebba51</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fml200261d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200261d%26sid%3Dliteratum%253Aachs%26aulast%3DAlbaugh%26aufirst%3DP.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%2BX.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DN.%2BX.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%2BX.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%2BS.%26aulast%3DLoren%26aufirst%3DJ.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520GNF-5837%252C%2520a%2520selective%2520TRK%2520inhibitor%2520with%2520efficacy%2520in%2520rodent%2520cancer%2520tumor%2520models%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D140%26epage%3D145%26doi%3D10.1021%2Fml200261d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedderman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span> <span> </span><span class="NLM_article-title">The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10099</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10084-10099&author=S.+E.+Skerrattauthor=M.+Andrewsauthor=S.+K.+Bagalauthor=J.+Bilslandauthor=D.+Brownauthor=P.+J.+Bungayauthor=S.+Coleauthor=K.+R.+Gibsonauthor=R.+Jonesauthor=I.+Moraoauthor=A.+Neddermanauthor=K.+Omotoauthor=C.+Robinsonauthor=T.+Ryckmansauthor=K.+Skinnerauthor=P.+Stuppleauthor=G.+Waldron&title=The+discovery+of+a+potent%2C+selective%2C+and+peripherally+restricted+pan-Trk+inhibitor+%28PF-06273340%29+for+the+treatment+of+pain&doi=10.1021%2Facs.jmedchem.6b00850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span></div><div class="casAuthors">Skerratt, Sarah E.; Andrews, Mark; Bagal, Sharan K.; Bilsland, James; Brown, David; Bungay, Peter J.; Cole, Susan; Gibson, Karl R.; Jones, Russell; Morao, Inaki; Nedderman, Angus; Omoto, Kiyoyuki; Robinson, Colin; Ryckmans, Thomas; Skinner, Kimberly; Stupple, Paul; Waldron, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10099</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4), is implicated in the physiol. of chronic pain.  Given the clin. efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small mol. modulators of neurotrophin activity.  Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention.  To deliver the safety profile required for chronic, non-life threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought.  Herein the authors describe how the use of SBDD, 2D QSAR models and Matched Mol. Pair data in compd. design enabled the delivery of the highly potent, kinase-selective and peripherally restricted clin. candidate PF-06273340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67CFmGAkmRrVg90H21EOLACvtfcHk0lhvPJqCNjvfeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL&md5=f8c904a92c1716062c217fefe2374ce6</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBilsland%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMorao%26aufirst%3DI.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DWaldron%26aufirst%3DG.%26atitle%3DThe%2520discovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520peripherally%2520restricted%2520pan-Trk%2520inhibitor%2520%2528PF-06273340%2529%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10084%26epage%3D10099%26doi%3D10.1021%2Facs.jmedchem.6b00850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pryde, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. D.</span></span> <span> </span><span class="NLM_article-title">Aldehyde oxidase: an enzyme of emerging importance in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8441</span>– <span class="NLM_lpage">8460</span>, <span class="refDoi"> DOI: 10.1021/jm100888d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100888d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8441-8460&author=D.+C.+Prydeauthor=D.+Dalvieauthor=Q.+Huauthor=P.+Jonesauthor=R.+S.+Obachauthor=T.+D.+Tran&title=Aldehyde+oxidase%3A+an+enzyme+of+emerging+importance+in+drug+discovery&doi=10.1021%2Fjm100888d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span></div><div class="casAuthors">Pryde, David C.; Dalvie, Deepak; Hu, Qiyue; Jones, Peter; Obach, R. Scott; Tran, Thien-Duc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8441-8460</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Aldehyde oxidase has for many years been recognized as a metabolizing enzyme contained within the cytosolic compartment of many tissues and in many species.  The first literature ref. to AO dates from the 1930s, but literature citations to this enzyme have been steadily growing ever since, esp. in the past decade.  It has been increasingly recognized in this past decade that AO, through its unique structure, distribution, and substrate recognition, has an important role to play in the metab. of drugs.  In this timely Perspective, we present the current knowledge of the enzyme's expression, its structure, and its distribution across species.  We offer an anal. of substrates recognized by AO and highlight clin. examples where metab. by this enzyme has had significant clin. impact or led to the termination of a drug development program.  Finally, through anal. of the structure of known substrates, we present data to suggest the significant impact AO could play on future drug discovery programs along with strategies that could be employed to mitigate this.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALwFS70G6tLVg90H21EOLACvtfcHk0lhvPJqCNjvfeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N&md5=972eb9862a7dc7bff024b530ab40de7f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Fjm100888d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100888d%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTran%26aufirst%3DT.%2BD.%26atitle%3DAldehyde%2520oxidase%253A%2520an%2520enzyme%2520of%2520emerging%2520importance%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8441%26epage%3D8460%26doi%3D10.1021%2Fjm100888d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pryde, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckworth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry approaches to avoid aldehyde oxidase metabolism</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2856</span>– <span class="NLM_lpage">2860</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2012.02.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22429467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFSitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2856-2860&author=D.+C.+Prydeauthor=T.+D.+Tranauthor=P.+Jonesauthor=J.+Duckworthauthor=M.+Howardauthor=I.+Gardnerauthor=R.+Hylandauthor=R.+Websterauthor=T.+Wenhamauthor=S.+Bagalauthor=K.+Omotoauthor=R.+P.+Schneiderauthor=J.+Lin&title=Medicinal+chemistry+approaches+to+avoid+aldehyde+oxidase+metabolism&doi=10.1016%2Fj.bmcl.2012.02.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry approaches to avoid aldehyde oxidase metabolism</span></div><div class="casAuthors">Pryde, David C.; Tran, Thien-Duc; Jones, Peter; Duckworth, Jonathan; Howard, Martin; Gardner, Iain; Hyland, Ruth; Webster, Rob; Wenham, Tracey; Bagal, Sharan; Omoto, Kiyoyuki; Schneider, Richard P.; Lin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2856-2860</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aldehyde oxidase (AO) is a molybdenum-contg. enzyme distributed throughout the animal kingdom and capable of metabolising a wide range of aldehydes and N-heterocyclic compds.  Although metab. by this enzyme in man is recognized to have significant clin. impact where human AO activity was not predicted by screening in preclin. species, there is very little reported literature offering real examples where drug discoverers have successfully designed away from AO oxidn.  This article reports on some strategies adopted in the Pfizer TLR7 agonist program to successfully switch off AO metab. that was seen principally in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZKVEe9ZUzMbVg90H21EOLACvtfcHk0lgK-hWqgvDjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFSitbs%253D&md5=4c4c68b64f1c7013ad978408add0b09a</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.069%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BD.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DDuckworth%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DM.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DWenham%26aufirst%3DT.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DR.%2BP.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DMedicinal%2520chemistry%2520approaches%2520to%2520avoid%2520aldehyde%2520oxidase%2520metabolism%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2856%26epage%3D2860%26doi%3D10.1016%2Fj.bmcl.2012.02.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, A. H.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2298</span>– <span class="NLM_lpage">2308</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth&doi=10.1158%2F1535-7163.MCT-11-0264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lgK-hWqgvDjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308%26doi%3D10.1158%2F1535-7163.MCT-11-0264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4093</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.18632%2Foncotarget.6547" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=4093-4109&author=P.+P.+Patwardhanauthor=K.+S.+Ivyauthor=E.+Musiauthor=E.+de+Stanchinaauthor=G.+K.+Schwartz&title=Significant+blockade+of+multiple+receptor+tyrosine+kinases+by+MGCD516+%28Sitravatinib%29%2C+a+novel+small+molecule+inhibitor%2C+shows+potent+anti-tumor+activity+in+preclinical+models+of+sarcoma&doi=10.18632%2Foncotarget.6547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6547%26sid%3Dliteratum%253Aachs%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DIvy%26aufirst%3DK.%2BS.%26aulast%3DMusi%26aufirst%3DE.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DSignificant%2520blockade%2520of%2520multiple%2520receptor%2520tyrosine%2520kinases%2520by%2520MGCD516%2520%2528Sitravatinib%2529%252C%2520a%2520novel%2520small%2520molecule%2520inhibitor%252C%2520shows%2520potent%2520anti-tumor%2520activity%2520in%2520preclinical%2520models%2520of%2520sarcoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D4093%26epage%3D4109%26doi%3D10.18632%2Foncotarget.6547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensinger, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patt, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patt, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samarakoon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telikepalli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2023</span>– <span class="NLM_lpage">2034</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-14-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26285778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2023-2034&author=B.+D.+Smithauthor=M.+D.+Kaufmanauthor=C.+B.+Learyauthor=B.+A.+Turnerauthor=S.+C.+Wiseauthor=Y.+M.+Ahnauthor=R.+J.+Boothauthor=T.+M.+Caldwellauthor=C.+L.+Ensingerauthor=M.+M.+Hoodauthor=W.+P.+Luauthor=T.+W.+Pattauthor=W.+C.+Pattauthor=T.+J.+Rutkoskiauthor=T.+Samarakoonauthor=H.+Telikepalliauthor=L.+Vogetiauthor=S.+Vogetiauthor=K.+M.+Yatesauthor=L.+Chunauthor=L.+J.+Stewartauthor=M.+Clareauthor=D.+L.+Flynn&title=Altiratinib+inhibits+tumor+growth%2C+invasion%2C+angiogenesis%2C+and+microenvironment-mediated+drug+resistance+via+balanced+inhibition+of+MET%2C+TIE2%2C+and+VEGFR2&doi=10.1158%2F1535-7163.MCT-14-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2</span></div><div class="casAuthors">Smith, Bryan D.; Kaufman, Michael D.; Leary, Cynthia B.; Turner, Benjamin A.; Wise, Scott C.; Ahn, Yu Mi; Booth, R. John; Caldwell, Timothy M.; Ensinger, Carol L.; Hood, Molly M.; Lu, Wei-Ping; Patt, Tristan W.; Patt, William C.; Rutkoski, Thomas J.; Samarakoon, Thiwanka; Telikepalli, Hanumaiah; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen M.; Chun, Lawrence; Stewart, Lance J.; Clare, Michael; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2023-2034</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1).  Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases.  This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations.  Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo.  Through its balanced inhibitory potency vs. MET, TIE2, and VEGFR2, altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis.  Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9E33eWjRqBrVg90H21EOLACvtfcHk0lih7z95oj6NPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE&md5=34170ba7d22a7fbcea68715fd6a2179b</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1105%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLeary%26aufirst%3DC.%2BB.%26aulast%3DTurner%26aufirst%3DB.%2BA.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DEnsinger%26aufirst%3DC.%2BL.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DLu%26aufirst%3DW.%2BP.%26aulast%3DPatt%26aufirst%3DT.%2BW.%26aulast%3DPatt%26aufirst%3DW.%2BC.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSamarakoon%26aufirst%3DT.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DK.%2BM.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DClare%26aufirst%3DM.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DAltiratinib%2520inhibits%2520tumor%2520growth%252C%2520invasion%252C%2520angiogenesis%252C%2520and%2520microenvironment-mediated%2520drug%2520resistance%2520via%2520balanced%2520inhibition%2520of%2520MET%252C%2520TIE2%252C%2520and%2520VEGFR2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2023%26epage%3D2034%26doi%3D10.1158%2F1535-7163.MCT-14-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Zein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hondt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sariban, E.</span></span> <span> </span><span class="NLM_article-title">Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1447</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2010.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.cellsig.2010.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=20566383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=1437-1447&author=N.+El+Zeinauthor=S.+D%E2%80%99Hondtauthor=E.+Sariban&title=Crosstalks+between+the+receptors+tyrosine+kinase+EGFR+and+TrkA+and+the+GPCR%2C+FPR%2C+in+human+monocytes+are+essential+for+receptors-mediated+cell+activation&doi=10.1016%2Fj.cellsig.2010.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation</span></div><div class="casAuthors">El Zein, Nabil; D'Hondt, Stephanie; Sariban, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1437-1447</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The G-protein coupled receptor (GPCR) fMLP receptor (FPR) and the two receptors tyrosine kinase (RTK), the nerve growth factor (NGF) receptor TrkA and the epidermal growth factor (EGF) receptor (EGFR) are involved in reactive oxygen species (ROS), matrix metalloproteinase-9 (MMP-9) prodn. and CD11b membrane integrin upregulation.  We show that in monocytes the three receptors crosstalk each other to modulate these pro-inflammatory mediators.  Tyrphostin AG1478, the EGFR inhibitor, inhibits fMLP and NGF-assocd. ROS prodn., fMLP-assocd. CD11b upregulation and NGF-induced TrkA phosphorylation; K252a, the NGF receptor inhibitor, inhibits fMLP or EGF-assocd. ROS prodn., CD11b expression and EGF-induced EGFR phosphorylation; cyclosporine H, the FPR inhibitor inhibits EGF or NGF-assocd. ROS prodn., EGF-assocd. CD11b upregulation and prevents EGFR and TrkA phosphorylation by their resp. ligand EGF and NGF.  In response to fMLP, TrkA phosphorylation is inhibited by the EGFR inhibitor while EGFR phosphorylation is inhibited by the TrkA inhibitor.  Receptor crosstalks are Src and ERK dependent.  Down-regulation of each receptor by specific siRNA suppresses the ability of the two other receptors to promote ligand-mediated ERK phosphorylation and pro-inflammatory activities including ROS, MMP-9 prodn. and CD11b upregulation.  Thus, in monocytes GPCR ligands' activity involves activation of RTK while RTK-ligands activity engages GPCR-signalling mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdlNj09PDHLVg90H21EOLACvtfcHk0lih7z95oj6NPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kjsbs%253D&md5=d089d337da801c2cbad4ea30aa9213d9</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BZein%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Hondt%26aufirst%3DS.%26aulast%3DSariban%26aufirst%3DE.%26atitle%3DCrosstalks%2520between%2520the%2520receptors%2520tyrosine%2520kinase%2520EGFR%2520and%2520TrkA%2520and%2520the%2520GPCR%252C%2520FPR%252C%2520in%2520human%2520monocytes%2520are%2520essential%2520for%2520receptors-mediated%2520cell%2520activation%26jtitle%3DCell.%2520Signalling%26date%3D2010%26volume%3D22%26spage%3D1437%26epage%3D1447%26doi%3D10.1016%2Fj.cellsig.2010.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcari, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillo, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungerford, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauth, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagreca, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderstrom, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkalcevic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3059</span>– <span class="NLM_lpage">3063</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2013.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3059-3063&author=J.+T.+Arcariauthor=J.+S.+Beebeauthor=M.+A.+Berlinerauthor=V.+Bernardoauthor=M.+Boehmauthor=G.+V.+Borzilloauthor=T.+Clarkauthor=B.+D.+Cohenauthor=R.+D.+Connellauthor=H.+N.+Frostauthor=D.+A.+Gordonauthor=W.+M.+Hungerfordauthor=S.+M.+Kakarauthor=A.+Kanterauthor=N.+F.+Keeneauthor=E.+A.+Knauthauthor=S.+D.+Lagrecaauthor=Y.+Luauthor=L.+Martinez-Alsinaauthor=M.+A.+Marxauthor=J.+Morrisauthor=N.+C.+Patelauthor=D.+Savageauthor=C.+I.+Soderstromauthor=C.+Thompsonauthor=G.+Tkalcevicauthor=N.+J.+Tomauthor=F.+F.+Vajdosauthor=J.+J.+Valentineauthor=P.+W.+Vincentauthor=M.+D.+Wesselauthor=J.+M.+Chen&title=Discovery+and+synthesis+of+novel+4-aminopyrrolopyrimidine+Tie-2+kinase+inhibitors+for+the+treatment+of+solid+tumors&doi=10.1016%2Fj.bmcl.2013.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DArcari%26aufirst%3DJ.%2BT.%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DBerliner%26aufirst%3DM.%2BA.%26aulast%3DBernardo%26aufirst%3DV.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DBorzillo%26aufirst%3DG.%2BV.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DB.%2BD.%26aulast%3DConnell%26aufirst%3DR.%2BD.%26aulast%3DFrost%26aufirst%3DH.%2BN.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DHungerford%26aufirst%3DW.%2BM.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DKanter%26aufirst%3DA.%26aulast%3DKeene%26aufirst%3DN.%2BF.%26aulast%3DKnauth%26aufirst%3DE.%2BA.%26aulast%3DLagreca%26aufirst%3DS.%2BD.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DN.%2BC.%26aulast%3DSavage%26aufirst%3DD.%26aulast%3DSoderstrom%26aufirst%3DC.%2BI.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DTkalcevic%26aufirst%3DG.%26aulast%3DTom%26aufirst%3DN.%2BJ.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DValentine%26aufirst%3DJ.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520novel%25204-aminopyrrolopyrimidine%2520Tie-2%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3059%26epage%3D3063%26doi%3D10.1016%2Fj.bmcl.2013.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span> <span> </span><span class="NLM_article-title">Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7921</span>– <span class="NLM_lpage">7932</span>, <span class="refDoi"> DOI: 10.1021/jm8010299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7921-7932&author=I.+Kufarevaauthor=R.+Abagyan&title=Type-II+kinase+inhibitor+docking%2C+screening%2C+and+profiling+using+modified+structures+of+active+kinase+states&doi=10.1021%2Fjm8010299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span></div><div class="casAuthors">Kufareva, Irina; Abagyan, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7921-7932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site.  These compds. are often more specific than those that target active DFG-in kinase conformations.  Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable.  We present a computational protocol for converting multiple available DFG-in structures of various kinases (∼70% of mammalian structural kinome) into accurate and specific models of their type-II bound state.  The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compd. pose prediction, screening, and in silico activity profiling.  Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp699dzZf5YRLVg90H21EOLACvtfcHk0ljNisW5_MKc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK&md5=64fb7b9f789940dd61c68015341af4a6</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Fjm8010299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010299%26sid%3Dliteratum%253Aachs%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DType-II%2520kinase%2520inhibitor%2520docking%252C%2520screening%252C%2520and%2520profiling%2520using%2520modified%2520structures%2520of%2520active%2520kinase%2520states%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7921%26epage%3D7932%26doi%3D10.1021%2Fjm8010299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1514</span>, <span class="refDoi"> DOI: 10.1039/C4MD00251B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1039%2FC4MD00251B" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1507-1514&author=B.+Frettauthor=N.+McConnellauthor=Y.+Wangauthor=Z.+Xuauthor=A.+Ambroseauthor=H.+Y.+Li&title=Identification+of+pyrazine-based+TrkA+inhibitors%3A+design%2C+synthesis%2C+evaluation%2C+and+computational+modeling+studies&doi=10.1039%2FC4MD00251B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1039%2FC4MD00251B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00251B%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DMcConnell%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DAmbrose%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DIdentification%2520of%2520pyrazine-based%2520TrkA%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520computational%2520modeling%2520studies%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D1507%26epage%3D1514%26doi%3D10.1039%2FC4MD00251B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">16078</span>– <span class="NLM_lpage">16083</span>, <span class="refDoi"> DOI: 10.1073/pnas.0502000102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.0502000102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16249345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=16078-16083&author=J.+G.+Conwayauthor=B.+McDonaldauthor=J.+Parhamauthor=B.+Keithauthor=D.+W.+Rusnakauthor=E.+Shawauthor=M.+Jansenauthor=P.+Linauthor=A.+Payneauthor=R.+M.+Crosbyauthor=J.+H.+Johnsonauthor=L.+Frickauthor=M.+H.+Linauthor=S.+Depeeauthor=S.+Tadepalliauthor=B.+Vottaauthor=I.+Jamesauthor=K.+Fullerauthor=T.+J.+Chambersauthor=F.+C.+Kullauthor=S.+D.+Chamberlainauthor=J.+T.+Hutchins&title=Inhibition+of+colony-stimulating-factor-1+signaling+in+vivo+with+the+orally+bioavailable+cFMS+kinase+inhibitor+GW2580&doi=10.1073%2Fpnas.0502000102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span></div><div class="casAuthors">Conway, James G.; McDonald, Brad; Parham, Janet; Keith, Barry; Rusnak, David W.; Shaw, Eva; Jansen, Marilyn; Lin, Peiyuan; Payne, Alan; Crosby, Renae M.; Johnson, Jennifer H.; Frick, Lloyd; Lin, Min-Hwa Jasmine; Depee, Scott; Tadepalli, Sarva; Votta, Bart; James, Ian; Fuller, Karen; Chambers, Timothy J.; Kull, Frederick C.; Chamberlain, Stanley D.; Hutchins, Jeff T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16078-16083</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases.  To help investigate the role of cFMS kinase in disease, the authors identified GW2580, an orally bioavailable inhibitor of cFMS kinase.  GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases.  GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degrdn. in cultures of human osteoclasts, rat calvaria, and rat fetal long bone.  In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines.  GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 prodn. in freshly isolated human monocytes and mouse macrophages.  After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 prodn. in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.  Unexpectedly, GW2580 inhibited LPS-induced TNF prodn. in mice, in contrast to effects on monocytes and macrophages in vitro.  In conclusion, GW2580's selective inhibition of monocyte growth and bone degrdn. is consistent with cFMS kinase inhibition.  The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5EGN2P59OrVg90H21EOLACvtfcHk0ljNisW5_MKc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM&md5=6a5afc80faa9acec528fdbf766ad05bd</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502000102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502000102%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DMcDonald%26aufirst%3DB.%26aulast%3DParham%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShaw%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPayne%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DFrick%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DFuller%26aufirst%3DK.%26aulast%3DChambers%26aufirst%3DT.%2BJ.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26atitle%3DInhibition%2520of%2520colony-stimulating-factor-1%2520signaling%2520in%2520vivo%2520with%2520the%2520orally%2520bioavailable%2520cFMS%2520kinase%2520inhibitor%2520GW2580%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D16078%26epage%3D16083%26doi%3D10.1073%2Fpnas.0502000102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergquist, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumrine, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selph, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimpson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, T. A.</span></span> <span> </span><span class="NLM_article-title">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.129429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1124%2Fjpet.107.129429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=18434589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=41-50&author=J.+G.+Conwayauthor=H.+Pinkauthor=M.+L.+Bergquistauthor=B.+Hanauthor=S.+Depeeauthor=S.+Tadepalliauthor=P.+Linauthor=R.+C.+Crumrineauthor=J.+Binzauthor=R.+L.+Clarkauthor=J.+L.+Selphauthor=S.+A.+Stimpsonauthor=J.+T.+Hutchinsauthor=S.+D.+Chamberlainauthor=T.+A.+Brodie&title=Effects+of+the+cFMS+kinase+inhibitor+5-%283-methoxy-4-%28%284-methoxybenzyl%29oxy%29benzyl%29pyrimidine-2%2C4-diamine+%28GW2580%29+in+normal+and+arthritic+rats&doi=10.1124%2Fjpet.107.129429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats</span></div><div class="casAuthors">Conway, James G.; Pink, Heather; Bergquist, Mandy L.; Han, Bajin; Depee, Scott; Tadepalli, Sarva; Lin, Peiyuan; Crumrine, R. Christian; Binz, Jane; Clark, Richard L.; Selph, Jeffrey L.; Stimpson, Stephen A.; Hutchins, Jeff T.; Chamberlain, Stanley D.; Brodie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The cFMS (cellular homolog of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) inhibits colony-stimulating factor (CSF)-1-induced monocyte growth and bone degrdn. in vitro and inhibits CSF-1 signaling through cFMS kinase in 4-day models in mice.  In the present study, the kinase selectivity of GW2580 was further characterized, and the effects of chronic treatment were evaluated in normal and arthritic rats.  GW2580 selectively inhibited cFMS kinase compared with 186 other kinases in vitro and completely inhibited CSF-1-induced growth of rat monocytes, with an IC50 value of 0.2 μM.  GW2580 dosed orally at 25 and 75 mg/kg 1 and 5 h before the injection of lipopolysaccharide inhibited tumor necrosis factor-α prodn. by 60 to 85%, indicating a duration of action of at least 5 h.  In a 21-day adjuvant arthritis model, GW2580 dosed twice a day (b.i.d.) from days 0 to 21, 7 to 21, or 14 to 21 inhibited joint connective tissue and bone destruction as assessed by radiol., histol. and bone mineral content measurements.  In contrast, GW2580 did not affect ankle swelling in the adjuvant model nor did it affect ankle swelling in a model where local arthritis is reactivated by peptidoglycan polysaccharide polymers.  GW2580 administered to normal rats for 21 days showed no effects on tissue histol. and only modest changes in serum clin. chem. and blood hematol.  In conclusion, GW2580 was effective in preserving joint integrity in the adjuvant arthritis model while showing minimal effects in normal rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtnXf8t6eWrLVg90H21EOLACvtfcHk0ljNisW5_MKc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D&md5=51bf18b72ebba4c5ea862b088d0c1ad1</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.129429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.129429%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DPink%26aufirst%3DH.%26aulast%3DBergquist%26aufirst%3DM.%2BL.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DCrumrine%26aufirst%3DR.%2BC.%26aulast%3DBinz%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%2BL.%26aulast%3DSelph%26aufirst%3DJ.%2BL.%26aulast%3DStimpson%26aufirst%3DS.%2BA.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DBrodie%26aufirst%3DT.%2BA.%26atitle%3DEffects%2520of%2520the%2520cFMS%2520kinase%2520inhibitor%25205-%25283-methoxy-4-%2528%25284-methoxybenzyl%2529oxy%2529benzyl%2529pyrimidine-2%252C4-diamine%2520%2528GW2580%2529%2520in%2520normal%2520and%2520arthritic%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D41%26epage%3D50%26doi%3D10.1124%2Fjpet.107.129429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5337</span>– <span class="NLM_lpage">5349</span>, <span class="refDoi"> DOI: 10.1021/jm3002982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3002982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5337-5349&author=S.+Hongauthor=J.+Kimauthor=J.+H.+Seoauthor=K.+H.+Jungauthor=S.+S.+Hongauthor=S.+Hong&title=Design%2C+synthesis%2C+and+evaluation+of+3%2C5-disubstituted+7-azaindoles+as+Trk+inhibitors+with+anticancer+and+antiangiogenic+activities&doi=10.1021%2Fjm3002982"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Fjm3002982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002982%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25203%252C5-disubstituted%25207-azaindoles%2520as%2520Trk%2520inhibitors%2520with%2520anticancer%2520and%2520antiangiogenic%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5337%26epage%3D5349%26doi%3D10.1021%2Fjm3002982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geuns-Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bready, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaffee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polverino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1021/jm061112p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061112p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=627-640&author=V.+J.+Ceeauthor=B.+K.+Albrechtauthor=S.+Geuns-Meyerauthor=P.+Hughesauthor=S.+Bellonauthor=J.+Breadyauthor=S.+Caenepeelauthor=S.+C.+Chaffeeauthor=A.+Coxonauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=B.+L.+Hodousauthor=D.+Hoffmanauthor=R.+E.+Johnsonauthor=R.+Kendallauthor=J.+L.+Kimauthor=A.+M.+Longauthor=D.+McGowanauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=D.+Powersauthor=P.+Roseauthor=L.+Wangauthor=H.+Zhao&title=Alkynylpyrimidine+amide+derivatives+as+potent%2C+selective%2C+and+orally+active+inhibitors+of+Tie-2+kinase&doi=10.1021%2Fjm061112p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fjm061112p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061112p%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DAlkynylpyrimidine%2520amide%2520derivatives%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520inhibitors%2520of%2520Tie-2%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D627%26epage%3D640%26doi%3D10.1021%2Fjm061112p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muranaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span> <span> </span><span class="NLM_article-title">The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1233</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2017.01.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28159414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1233-1236&author=N.+Furuyaauthor=T.+Momoseauthor=K.+Katsunoauthor=N.+Fushimiauthor=H.+Muranakaauthor=C.+Handaauthor=T.+Ozawaauthor=T.+Kinoshita&title=The+juxtamembrane+region+of+TrkA+kinase+is+critical+for+inhibitor+selectivity&doi=10.1016%2Fj.bmcl.2017.01.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity</span></div><div class="casAuthors">Furuya, Noritaka; Momose, Takaki; Katsuno, Kenji; Fushimi, Nobuhiko; Muranaka, Hideyuki; Handa, Chiaki; Ozawa, Tomonaga; Kinoshita, Takayoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1233-1236</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although numerous crystal structures for protein kinases have been reported, many include only the kinase domain but not the juxtamembrane (JM) region, a crit. activity-controlling segment of receptor tyrosine kinases (RTKs).  In this study, we detd. the X-ray crystal structure of the tropomyosin receptor kinase (Trk) A selective inhibitor A1 complexed with the TrkA kinase domain and the JM region.  This structure revealed that the unique inhibitor-binding pocket created by a novel JM configuration yields significant potency and high selectivity against TrkB and TrkC.  Moreover, we validated the importance of the JM region for the potency of A1 using in vitro assays.  The introduction of moieties that interact with the JM region will be one of the most effective strategies for producing highly selective RTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm4KGYAJkWn7Vg90H21EOLACvtfcHk0lgjypydQs6Pgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVKisLo%253D&md5=849ac9c3ebb00c39ef78529cd6eabac5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DFuruya%26aufirst%3DN.%26aulast%3DMomose%26aufirst%3DT.%26aulast%3DKatsuno%26aufirst%3DK.%26aulast%3DFushimi%26aufirst%3DN.%26aulast%3DMuranaka%26aufirst%3DH.%26aulast%3DHanda%26aufirst%3DC.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DKinoshita%26aufirst%3DT.%26atitle%3DThe%2520juxtamembrane%2520region%2520of%2520TrkA%2520kinase%2520is%2520critical%2520for%2520inhibitor%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1233%26epage%3D1236%26doi%3D10.1016%2Fj.bmcl.2017.01.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fengas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitching, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmus, J. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+K.+Bagalauthor=K.+Omotoauthor=D.+C.+Blakemoreauthor=P.+J.+Bungayauthor=J.+G.+Bilslandauthor=P.+J.+Clarkeauthor=M.+S.+Corbettauthor=C.+N.+Croninauthor=J.+J.+Cuiauthor=R.+Diasauthor=N.+J.+Flanaganauthor=S.+E.+Greasleyauthor=R.+Grimleyauthor=E.+Johnsonauthor=D.+Fengasauthor=L.+Kitchingauthor=M.+L.+Krausauthor=I.+McAlpineauthor=A.+Nagataauthor=G.+J.+Waldronauthor=J.+S.+Warmus&title=Discovery+of+allosteric%2C+potent%2C+subtype+selective%2C+and+peripherally+restricted+TrkA+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.8b00280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00280%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DBlakemore%26aufirst%3DD.%2BC.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DClarke%26aufirst%3DP.%2BJ.%26aulast%3DCorbett%26aufirst%3DM.%2BS.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDias%26aufirst%3DR.%26aulast%3DFlanagan%26aufirst%3DN.%2BJ.%26aulast%3DGreasley%26aufirst%3DS.%2BE.%26aulast%3DGrimley%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DFengas%26aufirst%3DD.%26aulast%3DKitching%26aufirst%3DL.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%2BJ.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26atitle%3DDiscovery%2520of%2520allosteric%252C%2520potent%252C%2520subtype%2520selective%252C%2520and%2520peripherally%2520restricted%2520TrkA%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26doi%3D10.1021%2Facs.jmedchem.8b00280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, H. W.</span></span> <span> </span><span class="NLM_article-title">Inhibiting TRK proteins in clinical cancer therapy</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.3390/cancers10040105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3390%2Fcancers10040105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2gtL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=105&author=A.+M.+Langeauthor=H.+W.+Lo&title=Inhibiting+TRK+proteins+in+clinical+cancer+therapy&doi=10.3390%2Fcancers10040105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting TRK proteins in clinical cancer therapy</span></div><div class="casAuthors">Lange, Allison M.; Lo, Hui-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">105/1-105/15</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Gene rearrangements resulting in the aberrant activity of tyrosine kinases have been identified as drivers of oncogenesis in a variety of cancers.  The tropomyosin receptor kinase (TRK) family of tyrosine receptor kinases is emerging as an important target for cancer therapeutics.  The TRK family contains three members, TRKA, TRKB, and TRKC, and these proteins are encoded by the genes NTRK1, NTRK2, and NTRK3, resp.  To activate TRK receptors, neurotrophins bind to the extracellular region stimulating dimerization, phosphorylation, and activation of downstream signaling pathways.  Major known downstream pathways include RAS/MAPK/ERK, PLCγ, and PI3K/Akt.  While being rare in most cancers, TRK fusions with other proteins have been well-established as oncogenic events in specific malignancies, including glioblastoma, papillary thyroid carcinoma, and secretory breast carcinomas.  TRK protein amplification as well as alternative splicing events have also been described as contributors to cancer pathogenesis.  For patients harboring alterations in TRK expression or activity, TRK inhibition emerges as an important therapeutic target.  To date, multiple trials testing TRK-inhibiting compds. in various cancers are underway.  In this review, we will summarize the current therapeutic trials for neoplasms involving NTKR gene alterations, as well as the promises and setbacks that are assocd. with targeting gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvepDLt-_JaLVg90H21EOLACvtfcHk0lh6DaoF0w1JDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2gtL%252FI&md5=f421f06adf15f9357d88b80bf44479e8</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.3390%2Fcancers10040105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10040105%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DA.%2BM.%26aulast%3DLo%26aufirst%3DH.%2BW.%26atitle%3DInhibiting%2520TRK%2520proteins%2520in%2520clinical%2520cancer%2520therapy%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26spage%3D105%26doi%3D10.3390%2Fcancers10040105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span> <span> </span><span class="NLM_article-title">Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4529</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-4529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2015-4529" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4529&author=H.+A.+Burrisauthor=A.+T.+Shawauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=R.+C.+Doebeleauthor=S.+Smithauthor=N.+Nandaauthor=S.+Cruickshankauthor=J.+A.+Lowauthor=M.+S.+Brose&title=Abstract+4529%3A+Pharmacokinetics+%28PK%29+of+LOXO-101+during+the+first-in-human+Phase+I+study+in+patients+with+advanced+solid+tumors%3A+Interim+update&doi=10.1158%2F1538-7445.AM2015-4529"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-4529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-4529%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DNanda%26aufirst%3DN.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26atitle%3DAbstract%25204529%253A%2520Pharmacokinetics%2520%2528PK%2529%2520of%2520LOXO-101%2520during%2520the%2520first-in-human%2520Phase%2520I%2520study%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520Interim%2520update%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4529%26doi%3D10.1158%2F1538-7445.AM2015-4529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span> <span> </span><span class="NLM_article-title">The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">LBA2501</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.18_suppl.LBA2501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2017.35.18_suppl.LBA2501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=LBA2501&author=D.+M.+Hymanauthor=T.+W.+Laetschauthor=S.+Kummarauthor=S.+G.+DuBoisauthor=A.+F.+Faragoauthor=A.+S.+Pappoauthor=G.+D.+Demetriauthor=W.+S.+El-Deiryauthor=U.+N.+Lassenauthor=A.+Dowlatiauthor=M.+S.+Broseauthor=V.+Boniauthor=B.+Turpinauthor=R.+Nagasubramanianauthor=S.+Cruickshankauthor=M.+C.+Coxauthor=N.+C.+Kuauthor=D.+S.+Hawkinsauthor=D.+S.+Hongauthor=A.+E.+Drilon&title=The+efficacy+of+larotrectinib+%28LOXO-101%29%2C+a+selective+tropomyosin+receptor+kinase+%28TRK%29+inhibitor%2C+in+adult+and+pediatric+TRK+fusion+cancers&doi=10.1200%2FJCO.2017.35.18_suppl.LBA2501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.18_suppl.LBA2501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.18_suppl.LBA2501%26sid%3Dliteratum%253Aachs%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DLassen%26aufirst%3DU.%2BN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DKu%26aufirst%3DN.%2BC.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26atitle%3DThe%2520efficacy%2520of%2520larotrectinib%2520%2528LOXO-101%2529%252C%2520a%2520selective%2520tropomyosin%2520receptor%2520kinase%2520%2528TRK%2529%2520inhibitor%252C%2520in%2520adult%2520and%2520pediatric%2520TRK%2520fusion%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3DLBA2501%26doi%3D10.1200%2FJCO.2017.35.18_suppl.LBA2501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span> <span> </span><span class="NLM_article-title">A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">10510</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.10510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2017.35.15_suppl.10510" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=10510&author=T.+W.+Laetschauthor=S.+G.+DuBoisauthor=R.+Nagasubramanianauthor=B.+Turpinauthor=L.+Mascarenhasauthor=N.+Federmanauthor=M.+Reynoldsauthor=S.+Smithauthor=S.+Cruickshankauthor=M.+C.+Coxauthor=A.+S.+Pappoauthor=D.+S.+Hawkins&title=A+pediatric+phase+I+study+of+larotrectinib%2C+a+highly+selective+inhibitor+of+the+tropomyosin+receptor+kinase+%28TRK%29+family&doi=10.1200%2FJCO.2017.35.15_suppl.10510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.10510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.10510%26sid%3Dliteratum%253Aachs%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26atitle%3DA%2520pediatric%2520phase%2520I%2520study%2520of%2520larotrectinib%252C%2520a%2520highly%2520selective%2520inhibitor%2520of%2520the%2520tropomyosin%2520receptor%2520kinase%2520%2528TRK%2529%2520family%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D10510%26doi%3D10.1200%2FJCO.2017.35.15_suppl.10510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feraco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30119-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS1470-2045%2818%2930119-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=29606586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmvFalsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=705-714&author=T.+W.+Laetschauthor=S.+G.+DuBoisauthor=L.+Mascarenhasauthor=B.+Turpinauthor=N.+Federmanauthor=C.+M.+Albertauthor=R.+Nagasubramanianauthor=J.+L.+Davisauthor=E.+Rudzinskiauthor=A.+M.+Feracoauthor=B.+B.+Tuchauthor=K.+T.+Ebataauthor=M.+Reynoldsauthor=S.+Smithauthor=S.+Cruickshankauthor=M.+C.+Coxauthor=A.+S.+Pappoauthor=D.+S.+Hawkins&title=Larotrectinib+for+paediatric+solid+tumours+harbouring+NTRK+gene+fusions%3A+phase+1+results+from+a+multicentre%2C+open-label%2C+phase+1%2F2+study&doi=10.1016%2FS1470-2045%2818%2930119-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study</span></div><div class="casAuthors">Laetsch, Theodore W.; DuBois, Steven G.; Mascarenhas, Leo; Turpin, Brian; Federman, Noah; Albert, Catherine M.; Nagasubramanian, Ramamoorthy; Davis, Jessica L.; Rudzinski, Erin; Feraco, Angela M.; Tuch, Brian B.; Ebata, Kevin T.; Reynolds, Mark; Smith, Steven; Cruickshank, Scott; Cox, Michael C.; Pappo, Alberto S.; Hawkins, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">705-714</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies.  Larotrectinib, a highly selective small-mol. inhibitor of the TRK kinases, had shown activity in preclin. models and in adults with tumors harbouring TRK fusions.  This study aimed to assess the safety of larotrectinib in paediatric patients.  This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 mo to 21 years with locally advanced or metastatic solid tumors or CNS tumors that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy.  Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible.  Patients were enrolled to three dose cohorts according to a rolling six design.  Larotrectinib was administered orally (capsule or liq. formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight.  The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity.  All patients who received at least one dose of larotrectinib were included in the safety analyses.  Reported here are results of the phase 1 dose escalation cohort.  Phase 1 follow-up and phase 2 are ongoing.  This trial is registered with ClinicalTrials.gov, no. NCT02637687.  Between Dec 21, 2015, and Apr. 13, 2017, 24 patients (n=17 with tumors harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3-13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modeling to achieve an area under the curve equiv. to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (max. 100 g per dose), regardless of age, equating to a max. of 173% of the recommended adult phase 2 dose.  Among enrolled patients harbouring TRK fusion-pos. cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer.  Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24).  Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease.  No grade 4 or 5 treatment-related adverse events were obsd.  Two larotrectinib-related serious adverse events were obsd.: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines.  The max. tolerated dose was not reached, and 100 mg/m2 (max. of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-pos. cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumor regression that did not meet the criteria for objective response.  None of the seven patients with TRK fusion-neg. cancers had an objective response.  The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumor activity in all patients with TRK fusion-pos. tumors.  The recommended phase 2 dose was defined as 100mg/m2 (max. 100 mg per dose) for infants, children, and adolescents, regardless of age.Loxo Oncol. Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN4iUwI-8yy7Vg90H21EOLACvtfcHk0li3oFTZdHkukQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmvFalsLg%253D&md5=327df3730acb6d1ac983d4d636533adb</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930119-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930119-0%26sid%3Dliteratum%253Aachs%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DAlbert%26aufirst%3DC.%2BM.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DJ.%2BL.%26aulast%3DRudzinski%26aufirst%3DE.%26aulast%3DFeraco%26aufirst%3DA.%2BM.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%2BT.%26aulast%3DReynolds%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26atitle%3DLarotrectinib%2520for%2520paediatric%2520solid%2520tumours%2520harbouring%2520NTRK%2520gene%2520fusions%253A%2520phase%25201%2520results%2520from%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25201%252F2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D705%26epage%3D714%26doi%3D10.1016%2FS1470-2045%2818%2930119-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidaway, P.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2018.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrclinonc.2018.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1MnivFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=264&author=P.+Sidaway&title=Targeted+therapy%3A+Larotrectinib+effective+against+TRK-fusion-positive+cancers&doi=10.1038%2Fnrclinonc.2018.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer: Changes in clonal dynamics predict response to palbociclib</span></div><div class="casAuthors">Sidaway Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">264-265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGaccJ0yL8kkQ0lWbKiCflfW6udTcc2eZw27yYluVjsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnivFeltw%253D%253D&md5=2031e32ca2099247f28d1386fcf4765e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2018.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2018.40%26sid%3Dliteratum%253Aachs%26aulast%3DSidaway%26aufirst%3DP.%26atitle%3DTargeted%2520therapy%253A%2520Larotrectinib%2520effective%2520against%2520TRK-fusion-positive%2520cancers%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D264%26doi%3D10.1038%2Fnrclinonc.2018.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirru, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencardino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanzulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span> <span> </span><span class="NLM_article-title">Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372–001 and STARTRK-1)</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-16-1237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28183697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=400-409&author=A.+Drilonauthor=S.+Sienaauthor=S.+I.+Ouauthor=M.+Patelauthor=M.+J.+Ahnauthor=J.+Leeauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=J.+J.+Whelerauthor=S.+V.+Liuauthor=R.+Doebeleauthor=L.+Giannettaauthor=G.+Cereaauthor=G.+Marrapeseauthor=M.+Schirruauthor=A.+Amatuauthor=K.+Bencardinoauthor=L.+Palmeriauthor=A.+Sartore-Bianchiauthor=A.+Vanzulliauthor=S.+Crestaauthor=S.+Damianauthor=M.+Ducaauthor=E.+Ardiniauthor=G.+Liauthor=J.+Christiansenauthor=K.+Kowalskiauthor=A.+D.+Johnsonauthor=R.+Patelauthor=D.+Luoauthor=E.+Chow-Manevalauthor=Z.+Hornbyauthor=P.+S.+Multaniauthor=A.+T.+Shawauthor=F.+G.+De+Braud&title=Safety+and+antitumor+activity+of+the+multitargeted+pan-TRK%2C+ROS1%2C+and+ALK+inhibitor+entrectinib%3A+combined+results+from+two+phase+I+trials+%28ALKA-372%E2%80%93001+and+STARTRK-1%29&doi=10.1158%2F2159-8290.CD-16-1237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)</span></div><div class="casAuthors">Drilon, Alexander; Siena, Salvatore; Ou, Sai-Hong Ignatius; Patel, Manish; Ahn, Myung Ju; Lee, Jeeyun; Bauer, Todd M.; Farago, Anna F.; Wheler, Jennifer J.; Liu, Stephen V.; Doebele, Robert; Giannetta, Laura; Cerea, Giulio; Marrapese, Giovanna; Schirru, Michele; Amatu, Alessio; Bencardino, Katia; Palmeri, Laura; Sartore-Bianchi, Andrea; Vanzulli, Angelo; Cresta, Sara; Damian, Silvia; Duca, Matteo; Ardini, Elena; Li, Gang; Christiansen, Jason; Kowalski, Karey; Johnson, Ann D.; Patel, Rupal; Luo, David; Chow-Maneval, Edna; Hornby, Zachary; Multani, Pratik S.; Shaw, Alice T.; De Braud, Filippo G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-409</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease.  Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naive to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the recommended phase II dose.  Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification.  Responses were obsd. in non-small cell lung cancer, colorectal cancer, mammary analog secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 wk after starting treatment and lasting as long as >2 years.  Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.  Significance: Gene fusions of NTRK1/2/3, ROS1, and ALK (encoding TRKA/B/C, ROS1, and ALK, resp.) lead to constitutive activation of oncogenic pathways.  Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-3oFgf_s-LVg90H21EOLACvtfcHk0li3oFTZdHkukQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D&md5=2065abe157ef40489942215ec33482d0</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1237%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DWheler%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DDoebele%26aufirst%3DR.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DSchirru%26aufirst%3DM.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DBencardino%26aufirst%3DK.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DCresta%26aufirst%3DS.%26aulast%3DDamian%26aufirst%3DS.%26aulast%3DDuca%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DA.%2BD.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520the%2520multitargeted%2520pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520entrectinib%253A%2520combined%2520results%2520from%2520two%2520phase%2520I%2520trials%2520%2528ALKA-372%25E2%2580%2593001%2520and%2520STARTRK-1%2529%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D400%26epage%3D409%26doi%3D10.1158%2F2159-8290.CD-16-1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pishvaian, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneval, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Laguna, I.</span></span> <span> </span><span class="NLM_article-title">Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">521</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.4_suppl.521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2018.36.4_suppl.521" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=521&author=M.+J.+Pishvaianauthor=C.+D.+Rolfoauthor=S.+V.+Liuauthor=P.+S.+Multaniauthor=E.+C.+Manevalauthor=I.+Garrido-Laguna&title=Clinical+benefit+of+entrectinib+for+patients+with+metastatic+pancreatic+cancer+who+harbor+NTRK+and+ROS1+fusions&doi=10.1200%2FJCO.2018.36.4_suppl.521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.4_suppl.521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.4_suppl.521%26sid%3Dliteratum%253Aachs%26aulast%3DPishvaian%26aufirst%3DM.%2BJ.%26aulast%3DRolfo%26aufirst%3DC.%2BD.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DManeval%26aufirst%3DE.%2BC.%26aulast%3DGarrido-Laguna%26aufirst%3DI.%26atitle%3DClinical%2520benefit%2520of%2520entrectinib%2520for%2520patients%2520with%2520metastatic%2520pancreatic%2520cancer%2520who%2520harbor%2520NTRK%2520and%2520ROS1%2520fusions%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D521%26doi%3D10.1200%2FJCO.2018.36.4_suppl.521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuteboom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potvin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltaos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levisetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span> <span> </span><span class="NLM_article-title">P2.06-001 A study of MGCD516, a receptor tyrosine kinase (RTK) inhibitor, in molecularly selected patients with NSCLC or other advanced solid tumors</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S1068</span>– <span class="NLM_lpage">S1069</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.1494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.jtho.2016.11.1494" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S1068-S1069&author=T.+Wernerauthor=R.+Heistauthor=R.+Carvajalauthor=D.+Adkinsauthor=A.+Alvaauthor=S.+Goelauthor=D.+Hongauthor=L.+Bazhenovaauthor=M.+Salehauthor=R.+Siegelauthor=C.+Kyriakopoulosauthor=C.+Blakelyauthor=K.+Eatonauthor=R.+Lauerauthor=D.+Wangauthor=G.+Schwartzauthor=S.+Neuteboomauthor=D.+Potvinauthor=D.+Faltaosauthor=I.+Chenauthor=J.+Christensenauthor=M.+Levisettiauthor=R.+Chaoauthor=T.+Bauer&title=P2.06-001+A+study+of+MGCD516%2C+a+receptor+tyrosine+kinase+%28RTK%29+inhibitor%2C+in+molecularly+selected+patients+with+NSCLC+or+other+advanced+solid+tumors&doi=10.1016%2Fj.jtho.2016.11.1494"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.1494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.1494%26sid%3Dliteratum%253Aachs%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DHeist%26aufirst%3DR.%26aulast%3DCarvajal%26aufirst%3DR.%26aulast%3DAdkins%26aufirst%3DD.%26aulast%3DAlva%26aufirst%3DA.%26aulast%3DGoel%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DKyriakopoulos%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DLauer%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSchwartz%26aufirst%3DG.%26aulast%3DNeuteboom%26aufirst%3DS.%26aulast%3DPotvin%26aufirst%3DD.%26aulast%3DFaltaos%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DLevisetti%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DT.%26atitle%3DP2.06-001%2520A%2520study%2520of%2520MGCD516%252C%2520a%2520receptor%2520tyrosine%2520kinase%2520%2528RTK%2529%2520inhibitor%252C%2520in%2520molecularly%2520selected%2520patients%2520with%2520NSCLC%2520or%2520other%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3DS1068%26epage%3DS1069%26doi%3D10.1016%2Fj.jtho.2016.11.1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyozawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span> <span> </span><span class="NLM_article-title">1362PSafety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene</span>. <i>Annals Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>, <span class="NLM_elocation-id">mdx380.063</span> <span class="refDoi"> DOI: 10.1093/annonc/mdx380.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1093%2Fannonc%2Fmdx380.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&author=M.+Takedaauthor=T.+Setoauthor=Y.+Fujiwaraauthor=N.+Yamamotoauthor=K.+Nosakiauthor=R.+Toyozawaauthor=C.+Abeauthor=R.+Shigaauthor=K.+Nakamaruauthor=K.+Nakagawa&title=1362PSafety+and+clinical+activity+of+DS-6051b%2C+a+ROS1%2FNTRK+inhibitor%2C+in+Japanese+patients+with+NSCLC+harboring+ROS1+fusion+gene&doi=10.1093%2Fannonc%2Fmdx380.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx380.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx380.063%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DNosaki%26aufirst%3DK.%26aulast%3DToyozawa%26aufirst%3DR.%26aulast%3DAbe%26aufirst%3DC.%26aulast%3DShiga%26aufirst%3DR.%26aulast%3DNakamaru%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3D1362PSafety%2520and%2520clinical%2520activity%2520of%2520DS-6051b%252C%2520a%2520ROS1%252FNTRK%2520inhibitor%252C%2520in%2520Japanese%2520patients%2520with%2520NSCLC%2520harboring%2520ROS1%2520fusion%2520gene%26jtitle%3DAnnals%2520Oncol.%26date%3D2017%26volume%3D28%26doi%3D10.1093%2Fannonc%2Fmdx380.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borazanci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senaldi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H.</span></span> <span> </span><span class="NLM_article-title">Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">CT024</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-CT024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2016-CT024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=CT024&author=K.+P.+Papadopoulosauthor=E.+Borazanciauthor=D.+Von+Hoffauthor=L.+Gandhiauthor=A.+Patnaikauthor=M.+Tachibanaauthor=H.+Zahirauthor=R.+Gajeeauthor=T.+Goldbergauthor=G.+Senaldiauthor=S.-H.+Ou&title=Abstract+CT024%3A+First-in-human+phase+1+dose-escalation+study+of+DS-6051b%2C+an+oral+ROS1+and+NTRK+inhibitor%2C+in+subjects+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.AM2016-CT024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-CT024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-CT024%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBorazanci%26aufirst%3DE.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DZahir%26aufirst%3DH.%26aulast%3DGajee%26aufirst%3DR.%26aulast%3DGoldberg%26aufirst%3DT.%26aulast%3DSenaldi%26aufirst%3DG.%26aulast%3DOu%26aufirst%3DS.-H.%26atitle%3DAbstract%2520CT024%253A%2520First-in-human%2520phase%25201%2520dose-escalation%2520study%2520of%2520DS-6051b%252C%2520an%2520oral%2520ROS1%2520and%2520NTRK%2520inhibitor%252C%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3DCT024%26doi%3D10.1158%2F1538-7445.AM2016-CT024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D. M.</span></span> <span> </span><span class="NLM_article-title">VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4758</span>– <span class="NLM_lpage">4768</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F0008-5472.CAN-10-2527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4758-4768&author=W.+K.+Youauthor=B.+Senninoauthor=C.+W.+Williamsonauthor=B.+Falconauthor=H.+Hashizumeauthor=L.+C.+Yaoauthor=D.+T.+Aftabauthor=D.+M.+McDonald&title=VEGF+and+c-Met+blockade+amplify+angiogenesis+inhibition+in+pancreatic+islet+cancer&doi=10.1158%2F0008-5472.CAN-10-2527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2527%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DW.%2BK.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BW.%26aulast%3DFalcon%26aufirst%3DB.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DL.%2BC.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DVEGF%2520and%2520c-Met%2520blockade%2520amplify%2520angiogenesis%2520inhibition%2520in%2520pancreatic%2520islet%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4758%26epage%3D4768%26doi%3D10.1158%2F0008-5472.CAN-10-2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pezet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, S. B.</span></span> <span> </span><span class="NLM_article-title">Neurotrophins: mediators and modulators of pain</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.29.051605.112929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.neuro.29.051605.112929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16776595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVeit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=507-538&author=S.+Pezetauthor=S.+B.+McMahon&title=Neurotrophins%3A+mediators+and+modulators+of+pain&doi=10.1146%2Fannurev.neuro.29.051605.112929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotrophins: mediators and modulators of pain</span></div><div class="casAuthors">Pezet, Sophie; McMahon, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">507-538</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The neurotrophin family of neurotrophic factors are well-known for their effects on neuronal survival and growth.  Over the past decade, considerable evidence has accumulated from both humans and animals that one neurotrophin, nerve growth factor (NGF), is a peripheral pain mediator, particularly in inflammatory pain states.  NGF is upregulated in a wide variety of inflammatory conditions, and NGF-neutralizing mols. are effective analgesic agents in many models of persistent pain.  Such mols. are now being evaluated in clin. trials.  NGF regulates the expression of a 2nd neurotrophin, brain-derived neurotrophic factor (BDNF), in nociceptors.  BDNF is released when nociceptors are activated, and it acts as a central modulator of pain.  The chapter reviews the evidence for these roles (and briefly the effects of other neurotrophins), the range of conditions under which they act, and their mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWZk1aBEFejLVg90H21EOLACvtfcHk0lhZoWdL91jtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVeit7w%253D&md5=8c9d57612ae9466e9c73776be0b8a104</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.29.051605.112929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.29.051605.112929%26sid%3Dliteratum%253Aachs%26aulast%3DPezet%26aufirst%3DS.%26aulast%3DMcMahon%26aufirst%3DS.%2BB.%26atitle%3DNeurotrophins%253A%2520mediators%2520and%2520modulators%2520of%2520pain%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2006%26volume%3D29%26spage%3D507%26epage%3D538%26doi%3D10.1146%2Fannurev.neuro.29.051605.112929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':[],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liqun Chen, Yanke Chen, Chunyan Zhang, Bingyang Jiao, Sheng Liang, Qiong Tan, Hongyu Chai, Weihua Yu, Yongzheng Qian, Hui Yang, Wuyi Yao, Jianguo Yu, Ying Luo, Michael Plewe, Jialiang Wang, Xiao-Ran Han, <span class="NLM_string-name hlFld-ContribAuthor">Jing Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14562-14575. <a href="https://doi.org/10.1021/acs.jmedchem.0c01342" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01342</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01342%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BFirst-In-Class%252BPotent%252Band%252BSelective%252BTropomyosin%252BReceptor%252BKinase%252BDegraders%26aulast%3DChen%26aufirst%3DLiqun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07082020%26date%3D15102020%26volume%3D63%26issue%3D23%26spage%3D14562%26epage%3D14575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marialuisa Moccia, Brendan Frett, Lingtian Zhang, Naga Rajiv Lakkaniga, David C. Briggs, Rakhee Chauhan, Annalisa Brescia, Giorgia Federico, Wei Yan, Massimo Santoro, Neil Q. McDonald, Hong-yu Li, <span class="NLM_string-name hlFld-ContribAuthor">Francesca Carlomagno</span>. </span><span class="cited-content_cbyCitation_article-title">Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4506-4516. <a href="https://doi.org/10.1021/acs.jmedchem.9b01336" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01336%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBioisosteric%252BDiscovery%252Bof%252BNPA101.3%25252C%252Ba%252BSecond-Generation%252BRET%25252FVEGFR2%252BInhibitor%252BOptimized%252Bfor%252BSingle-Agent%252BPolypharmacology%26aulast%3DMoccia%26aufirst%3DMarialuisa%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14082019%26date%3D28042020%26date%3D16042020%26volume%3D63%26issue%3D9%26spage%3D4506%26epage%3D4516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Govindan Subramanian, Paul D. Johnson, Theresa Zachary, Nicole Roush, Yaqi Zhu, Scott J. Bowen, Ann Janssen, Brian A. Duclos, Tracey Williams, Christopher Javens, Nancy Dekki Shalaly, Daniel Martinez Molina, Arthur J. Wittwer, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Hirsch</span>. </span><span class="cited-content_cbyCitation_article-title">Deciphering the Allosteric Binding Mechanism of the Human Tropomyosin Receptor Kinase A (hTrkA) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (6)
                                     , 1205-1216. <a href="https://doi.org/10.1021/acschembio.9b00126" title="DOI URL">https://doi.org/10.1021/acschembio.9b00126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00126%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDeciphering%252Bthe%252BAllosteric%252BBinding%252BMechanism%252Bof%252Bthe%252BHuman%252BTropomyosin%252BReceptor%252BKinase%252BA%252B%252528hTrkA%252529%252BInhibitors%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15022019%26date%3D06052019%26date%3D14052019%26date%3D06052019%26volume%3D14%26issue%3D6%26spage%3D1205%26epage%3D1216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mu-Chun  Li</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Pei-Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Chieh  Su</span>, <span class="hlFld-ContribAuthor ">Pei-Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Chu-Min  Fan</span>, <span class="hlFld-ContribAuthor ">Ching-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Chen-Lung  Huang</span>, <span class="hlFld-ContribAuthor ">Chun-Hsien  Chiu</span>, <span class="hlFld-ContribAuthor ">Ling  Chang</span>, <span class="hlFld-ContribAuthor ">Chiung-Tong  Chen</span>, <span class="hlFld-ContribAuthor ">Teng-Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel orally selective and type II Pan-TRK inhibitors to overcome mutations by property-driven optimization. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>169 </em>, 113673. <a href="https://doi.org/10.1016/j.ejmech.2021.113673" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113673</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113673%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Borally%252Bselective%252Band%252Btype%252BII%252BPan-TRK%252Binhibitors%252Bto%252Bovercome%252Bmutations%252Bby%252Bproperty-driven%252Boptimization%26aulast%3DLi%26aufirst%3DMu-Chun%26date%3D2021%26volume%3D169%26spage%3D113673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengping  Lv</span>, <span class="hlFld-ContribAuthor ">Marialuisa  Moccia</span>, <span class="hlFld-ContribAuthor ">Francesca  Carlomagno</span>, <span class="hlFld-ContribAuthor ">Christophe  Landry</span>, <span class="hlFld-ContribAuthor ">Massimo  Santoro</span>, <span class="hlFld-ContribAuthor ">Fabien  Gosselet</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113265. <a href="https://doi.org/10.1016/j.ejmech.2021.113265" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113265%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrazolo-thieno%25255B3%25252C2-d%25255Dpyrimidinylamino-phenyl%252Bacetamides%252Bas%252Btype-II%252Bpan-tropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2021%26volume%3D216%26spage%3D113265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meenakshisundaram  Balasubramaniam</span>, <span class="hlFld-ContribAuthor ">Naga Rajiv  Lakkaniga</span>, <span class="hlFld-ContribAuthor ">Ayed A  Dera</span>, <span class="hlFld-ContribAuthor ">Majed Al  Fayi</span>, <span class="hlFld-ContribAuthor ">Mohammed  Abohashrh</span>, <span class="hlFld-ContribAuthor ">Irfan  Ahmad</span>, <span class="hlFld-ContribAuthor ">Harish C.  Chandramoorthy</span>, <span class="hlFld-ContribAuthor ">Ganesan  Nalini</span>, <span class="hlFld-ContribAuthor ">Prasanna  Rajagopalan</span>. </span><span class="cited-content_cbyCitation_article-title">FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second‐generation arylidene indanone scaffold. </span><span class="cited-content_cbyCitation_journal-name">Biotechnology and Applied Biochemistry</span><span> <strong>2021,</strong> <em>68 </em>
                                    (1)
                                     , 82-91. <a href="https://doi.org/10.1002/bab.1896" title="DOI URL">https://doi.org/10.1002/bab.1896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bab.1896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbab.1896%26sid%3Dliteratum%253Aachs%26jtitle%3DBiotechnology%2520and%2520Applied%2520Biochemistry%26atitle%3DFCX%2525E2%252580%252590146%25252C%252Ba%252Bpotent%252Ballosteric%252Binhibitor%252Bof%252BAkt%252Bkinase%252Bin%252Bcancer%252Bcells%25253A%252BLead%252Boptimization%252Bof%252Bthe%252Bsecond%2525E2%252580%252590generation%252Barylidene%252Bindanone%252Bscaffold%26aulast%3DBalasubramaniam%26aufirst%3DMeenakshisundaram%26date%3D2021%26date%3D2020%26volume%3D68%26issue%3D1%26spage%3D82%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Qinlan  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>39 </em>
                                    (1)
                                     , 202-208. <a href="https://doi.org/10.1080/07391102.2019.1708798" title="DOI URL">https://doi.org/10.1080/07391102.2019.1708798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1708798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1708798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculation%252Bstudies%252Bof%252Bthe%252Bbinding%252Bmechanism%252Bof%252Ballosteric%252Binhibitors%252Bwith%252BTrkA%252Bkinase%26aulast%3DWu%26aufirst%3DXiaoyun%26date%3D2021%26date%3D2019%26volume%3D39%26issue%3D1%26spage%3D202%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>, <span class="hlFld-ContribAuthor ">Carolin  Jaworski</span>, <span class="hlFld-ContribAuthor ">Carmen  Wängler</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>, <span class="hlFld-ContribAuthor ">Justin  Bailey</span>. </span><span class="cited-content_cbyCitation_article-title">Toward Imaging Tropomyosin Receptor Kinase (Trk) with Positron Emission Tomography. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1041-1059. <a href="https://doi.org/10.1007/978-3-030-53176-8_31" title="DOI URL">https://doi.org/10.1007/978-3-030-53176-8_31</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-53176-8_31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-53176-8_31%26sid%3Dliteratum%253Aachs%26atitle%3DToward%252BImaging%252BTropomyosin%252BReceptor%252BKinase%252B%252528Trk%252529%252Bwith%252BPositron%252BEmission%252BTomography%26aulast%3DSchirrmacher%26aufirst%3DRalf%26date%3D2021%26date%3D2020%26spage%3D1041%26epage%3D1059%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DPET%252Band%252BSPECT%252Bof%252BNeurobiological%252BSystems%26aulast%3DDierckx%26aufirst%3DRudi%2BA.J.O.%26date%3D2021%26volume%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjie  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Ying  Zhou</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianfu  Han</span>, <span class="hlFld-ContribAuthor ">Chunlei  Tang</span>, <span class="hlFld-ContribAuthor ">Weizheng  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127712. <a href="https://doi.org/10.1016/j.bmcl.2020.127712" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127712%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252Bbased%252BTrk%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bactivity%252Bevaluation%26aulast%3DZhang%26aufirst%3DYongjie%26date%3D2021%26volume%3D31%26spage%3D127712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minghao  Sun</span>, <span class="hlFld-ContribAuthor ">Shi  Cai</span>, <span class="hlFld-ContribAuthor ">Pei  Li</span>, <span class="hlFld-ContribAuthor ">Fangqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Huibin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (23)
                                     , 115811. <a href="https://doi.org/10.1016/j.bmc.2020.115811" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivity%252Bof%252Bbicyclic%252Bcarboxamide%252Bderivatives%252Bas%252BTRK%252Binhibitors%26aulast%3DSun%26aufirst%3DMinghao%26date%3D2020%26volume%3D28%26issue%3D23%26spage%3D115811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damoder Reddy  Motati</span>, <span class="hlFld-ContribAuthor ">Radhika  Amaradhi</span>, <span class="hlFld-ContribAuthor ">Thota  Ganesh</span>. </span><span class="cited-content_cbyCitation_article-title">Azaindole therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (24)
                                     , 115830. <a href="https://doi.org/10.1016/j.bmc.2020.115830" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115830%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAzaindole%252Btherapeutic%252Bagents%26aulast%3DMotati%26aufirst%3DDamoder%2BReddy%26date%3D2020%26volume%3D28%26issue%3D24%26spage%3D115830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112744. <a href="https://doi.org/10.1016/j.ejmech.2020.112744" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112744%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528E%252529-N-%2525284-methyl-5-%2525283-%2525282-%252528pyridin-2-yl%252529vinyl%252529-1H-indazol-6-yl%252529thiazol-2-yl%252529-2-%2525284-methylpiperazin-1-yl%252529acetamide%252B%252528IHMT-TRK-284%252529%252Bas%252Ba%252Bnovel%252Borally%252Bavailable%252Btype%252BII%252BTRK%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bresistant%252Bmutants%26aulast%3DWang%26aufirst%3DBeilei%26date%3D2020%26volume%3D207%26spage%3D112744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Allosterische Kinaseinhibitoren – Erwartungen und Chancen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (33)
                                     , 13868-13881. <a href="https://doi.org/10.1002/ange.201914525" title="DOI URL">https://doi.org/10.1002/ange.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAllosterische%252BKinaseinhibitoren%252B%2525E2%252580%252593%252BErwartungen%252Bund%252BChancen%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D33%26spage%3D13868%26epage%3D13881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">New Promise and Opportunities for Allosteric Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (33)
                                     , 13764-13776. <a href="https://doi.org/10.1002/anie.201914525" title="DOI URL">https://doi.org/10.1002/anie.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DNew%252BPromise%252Band%252BOpportunities%252Bfor%252BAllosteric%252BKinase%252BInhibitors%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D33%26spage%3D13764%26epage%3D13776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tamara  Fraser</span>, <span class="hlFld-ContribAuthor ">Anubhav  Mittal</span>, <span class="hlFld-ContribAuthor ">Jaswinder  Samra</span>, <span class="hlFld-ContribAuthor ">Angela  Chou</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Gill</span>. </span><span class="cited-content_cbyCitation_article-title">Routine NTRK immunohistochemistry is not a useful screening strategy in unselected pancreatic carcinomas. </span><span class="cited-content_cbyCitation_journal-name">Pathology</span><span> <strong>2020,</strong> <em>52 </em>
                                    (3)
                                     , 398-400. <a href="https://doi.org/10.1016/j.pathol.2020.01.680" title="DOI URL">https://doi.org/10.1016/j.pathol.2020.01.680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pathol.2020.01.680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pathol.2020.01.680%26sid%3Dliteratum%253Aachs%26jtitle%3DPathology%26atitle%3DRoutine%252BNTRK%252Bimmunohistochemistry%252Bis%252Bnot%252Ba%252Buseful%252Bscreening%252Bstrategy%252Bin%252Bunselected%252Bpancreatic%252Bcarcinomas%26aulast%3DFraser%26aufirst%3DTamara%26date%3D2020%26volume%3D52%26issue%3D3%26spage%3D398%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Rajendran  Vairagoundar</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic inhibitor leads of human tropomyosin receptor kinase A (
              h
              TrkA). </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 370-377. <a href="https://doi.org/10.1039/C9MD00554D" title="DOI URL">https://doi.org/10.1039/C9MD00554D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00554D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00554D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252Binhibitor%252Bleads%252Bof%252Bhuman%252Btropomyosin%252Breceptor%252Bkinase%252BA%252B%252528%252Bh%252BTrkA%252529%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D3%26spage%3D370%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han  Cao</span>, <span class="hlFld-ContribAuthor ">Xue-Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Fu-sheng  Bie</span>, <span class="hlFld-ContribAuthor ">Peng  Yan</span>, <span class="hlFld-ContribAuthor ">Jie  Ma</span>, <span class="hlFld-ContribAuthor ">Yi-jun  Shi</span>, <span class="hlFld-ContribAuthor ">Ying  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis of 2-Functionalized Benzoxazoles Catalyzed by Copper Iodide. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2020,</strong> <em>100 </em>
                                    (8)
                                     , 1218. <a href="https://doi.org/10.3987/COM-20-14276" title="DOI URL">https://doi.org/10.3987/COM-20-14276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-20-14276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-20-14276%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DEfficient%252BSynthesis%252Bof%252B2-Functionalized%252BBenzoxazoles%252BCatalyzed%252Bby%252BCopper%252BIodide%26aulast%3DCao%26aufirst%3DHan%26date%3D2020%26volume%3D100%26issue%3D8%26spage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Yaqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Julie A.  White</span>, <span class="hlFld-ContribAuthor ">Dennis  Huczek</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Lead identification and characterization of hTrkA type 2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (22)
                                     , 126680. <a href="https://doi.org/10.1016/j.bmcl.2019.126680" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126680%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bidentification%252Band%252Bcharacterization%252Bof%252BhTrkA%252Btype%252B2%252Binhibitors%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26volume%3D29%26issue%3D22%26spage%3D126680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Yaqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (19)
                                     , 126624. <a href="https://doi.org/10.1016/j.bmcl.2019.126624" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126624%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DType%252B2%252Binhibitor%252Bleads%252Bof%252Bhuman%252Btropomyosin%252Breceptor%252Bkinase%252B%252528hTrkA%252529%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26volume%3D29%26issue%3D19%26spage%3D126624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Miao</span>, <span class="hlFld-ContribAuthor ">Kun  Ma</span>, <span class="hlFld-ContribAuthor ">Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoxing  Wu</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting tropomyosin receptor kinase for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>175 </em>, 129-148. <a href="https://doi.org/10.1016/j.ejmech.2019.04.053" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.053%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Btropomyosin%252Breceptor%252Bkinase%252Bfor%252Bcancer%252Btherapy%26aulast%3DMiao%26aufirst%3DQi%26date%3D2019%26volume%3D175%26spage%3D129%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Justin J.  Bailey</span>, <span class="hlFld-ContribAuthor ">Andrew V.  Mossine</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Lena  Kaiser</span>, <span class="hlFld-ContribAuthor ">Peter  Bartenstein</span>, <span class="hlFld-ContribAuthor ">Simon  Lindner</span>, <span class="hlFld-ContribAuthor ">David R.  Kaplan</span>, <span class="hlFld-ContribAuthor ">Alexey  Kostikov</span>, <span class="hlFld-ContribAuthor ">Gert  Fricker</span>, <span class="hlFld-ContribAuthor ">Anne  Mahringer</span>, <span class="hlFld-ContribAuthor ">Pedro  Rosa-Neto</span>, <span class="hlFld-ContribAuthor ">Esther  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Carmen  Wängler</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>, <span class="hlFld-ContribAuthor ">Alexander  Thiel</span>, <span class="hlFld-ContribAuthor ">Jean-Paul  Soucy</span>, <span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>. </span><span class="cited-content_cbyCitation_article-title">Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2019,</strong> <em>12 </em>
                                    (1)
                                     , 7. <a href="https://doi.org/10.3390/ph12010007" title="DOI URL">https://doi.org/10.3390/ph12010007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph12010007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph12010007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DRadioligands%252Bfor%252BTropomyosin%252BReceptor%252BKinase%252B%252528Trk%252529%252BPositron%252BEmission%252BTomography%252BImaging%26aulast%3DSchirrmacher%26aufirst%3DRalf%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0031.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic view of TRK receptor tyrosine kinases and major signal transduction pathways involved in cell differentiation, proliferation, and survival. TRKA is activated by nerve growth factor (NGF), TRKB is activated by brain-derived neurotrophic factor (BDNF), and TRKC is activated by neurotrophin-3 (NT3). RAS, rat sarcoma oncogene; RAF, rapidly accelerated fibrosarcoma oncogene; MEK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase; GRB2, growth factor receptor-bound protein 2; SHC, SRC homology 2 domain containing; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT, v-AKT murine thymoma viral oncogene homologue; PLCγ, phospholipase C-γ; DAG, diacyl-glycerol; PKC, protein kinase C; IP3, inositol trisphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ligand-independent signaling leading to constitutive TRK activation can occur through three distinct mechanisms: a genomic rearrangement event, extracellular point mutations, or truncations of the extracellular domain. (1) In a genomic rearrangement event, the kinase domain of TRK is fused to an unrelated protein, typically called the fusion partner. In this example, a cytoplasmic chimeric TRK fusion is shown without the transmembrane (TM) domain. Of note, TRK fusions can occur with or without the TM domain.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> (2) Point mutations can occur in the extracellular domain of TRK, generating a TRK oncogene with transforming abilities. Point mutations that are transformative under laboratory conditions have been identified at P203A and C345S.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> (3) Through in-frame deletions and alternative splicing events, the TRK kinase can present with a truncated extracellular domain. These aberrant gene products have been identified in AML and neuroblastoma.<a onclick="showRef(event, 'ref105 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref105 ref106 ref107">(105−107)</a> FP, fusion partner; KD, kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Estimated contribution of TRKA/B/C mutations to all TRK-driven malignancies. Data is based on estimated incidence of cancers at major sites and contribution of TRK mutations at each site. It is estimated that a total of 19 552 cancers are diagnosed each year that have a TRK oncogene. Of the new cases, 55.8% (10 917) are TRKA, 42.6% are TRKC (8325), and 1.6% (310) are TRKB. Because of the limited sequencing data, the actual amount of TRK-driven tumors could be significantly greater or lower depending on robustness of sample size, sample selection, and data analysis. Also, tumors with a TRK mutation could be dependent on a separate pathway. (B) Estimated number of cancers positive for TRKA. Lung (lung adenocarcinoma), IC (intrahepatic cholangiocarcinoma), PTC (papillary thyroid cancer), and Glio (glioblastoma).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Identification of compounds <b>1-3</b>, <b>1-4</b>, and <b>1-5</b> and (B) cocrystal structure of compound <b>1-3</b> in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AOJ">4AOJ</a>, 2.75 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Identification of <b>2-1</b> and (B) cocrystal structure of compound <b>2-1</b> in CDK-2/cyclin A (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WIH">2WIH</a>, 2.5 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Identification of compound <b>3-1b</b>; (B) cocrystal structure of compound <b>3-1b</b> with ALK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA">2XBA</a>, 1.95 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structural optimization from compound <b>4</b> to <b>4-3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cocrystal structure of compound <b>4-3</b> with (A) ALK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a>, 2.22 Å) and (B) TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KVT">5KVT</a>, 2.45 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structural optimization from compound <b>5</b> to <b>5-3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Co-crystal structure of (A) compound <b>5</b> in ALK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOC">4FOC</a>, 1.7 Å) and (B) compound <b>5-3</b> in ALK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOD">4FOD</a>, 2 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structural optimization from compound <b>6</b> to <b>6-3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Co-crystal structure of compound <b>6-3</b> in TRKB (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AT3">4AT3</a>, 1.77 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; sulfur, yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structural optimization from compound <b>7</b> to <b>7-3b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Co-crystal structure of (A) compound <b>7</b> in TRKC (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YMJ">4YMJ</a>, 2 Å) and (B) compound <b>7-3a</b> in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE">4YNE</a>, 2.02 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of compound <b>8</b> and second generation TRK inhibitors <b>9</b> and <b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Proposed binding and steric interactions of <b>8</b> with the TRKA double mutant G595R and G667C and (B) proposed binding of <b>9</b> to the TRKA double mutant for which steric interactions are not predicted between G595R and G667C. The kinase is depicted in yellow ribbons.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of other type I TRK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of representative radiolabeled type I TRK Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structural optimization from compound <b>21</b> to <b>21-3b</b> (GNF-5837).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Co-crystal structure of compound <b>21-3a</b> in TRKC (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V5Q">3V5Q</a>, 2.2 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. (A) Structural optimization from compound <b>22</b> to <b>22-3</b> and (B) cocrystal structure of compound <b>22-3</b> with TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JFX">5JFX</a>, 1.63 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; chlorine, green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. (A) Chemical structures of representative dicarboxamide TRKA inhibitors and (B) cocrystal structure of compound <b>26</b> in c-MET (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DG5">5DG5</a>, 2.6 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structures of other Type II TRK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (A) Identification of compound <b>37-1</b> and (B) cocrystal structure of compound <b>37</b> and its binding mode in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMP">4PMP</a>, 1.8 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan; sulfur, yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. (A) Identification of compound <b>38-1</b> and (B) cocrystal structure of compound <b>38</b> and its binding mode in TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMS">4PMS</a>, 2.8 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (A) Chemical structure of compound <b>39</b>, (B) cocrystal structure of compound <b>39</b> in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMI">5KMI</a>, 1.87 Å), and (C) interactions of compound <b>39</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. (A) Chemical structure of compound <b>40</b>, (B) cocrystal structure of compound <b>40</b> in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMK">5KMK</a>, 2.24 Å), and (C) interactions of compound <b>40</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. (A) Chemical structure of compound <b>41</b>, (B) cocrystal structure of <b>41</b> bound in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5H3Q">5H3Q</a>, 2.1 Å), and (C) interactions of compound <b>41</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; fluorine, cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. (A) Chemical structures of compounds <b>42</b>, <b>43</b>, and <b>44</b>, (B) cocrystal structure of compound <b>44</b> bound to the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20">6D20</a>, 1.94 Å), and (C) interactions of compound <b>44</b> with surrounding residues. The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red; chlorine, green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/medium/jm-2018-01092d_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. (A) Chemical structures of compounds <b>45</b> and <b>46</b>, (B) cocrystal structure of compound <b>45</b> binding in the allosteric pocket of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMM">5KMM</a>, 2.1 Å), (C) interactions of compound <b>45</b> with surrounding residues, and (D) cocrystal structure of compound <b>46</b> in the active site of TRKA (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMO">5KMO</a>, 2.7 Å). The kinase is depicted in yellow ribbons and the hydrogen bonds are illustrated with blue dashed lines. Compound atoms are colored as follows: carbon, orange; nitrogen, blue; oxygen, red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01092/20190221/images/large/jm-2018-01092d_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01092&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 215 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.22-04-01316.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.22-04-01316.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11850459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFeksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=1316-1327&author=A.+R.+Carterauthor=C.+Chenauthor=P.+M.+Schwartzauthor=R.+A.+Segal&title=Brain-derived+neurotrophic+factor+modulates+cerebellar+plasticity+and+synaptic+ultrastructure&doi=10.1523%2FJNEUROSCI.22-04-01316.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure</span></div><div class="casAuthors">Carter, Alexandre R.; Chen, Chinfei; Schwartz, Phillip M.; Segal, Rosalind A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1316-1327</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The effect of brain-derived neurotrophic factor (BDNF) deficiency at the parallel fiber to Purkinje cell (PF/PC) synapses in the cerebellum was studied using a mouse with a targeted deletion of BDNF.  It was shown that TrkB, the receptor for BDNF, was located at parallel fiber to PF/PC synapses of the cerebellum.  Although Purkinje cell dendrites were abnormal in BDNF -/- mice, PF/PC synapses were still able to form.  Immunohistochem. anal. of mutant animals showed the formation of several PF/PC synapses with the appropriate apposition of presynaptic and postsynaptic proteins.  These synapses were functional, and no differences were detected in the waveform of evoked EPSCs, the amplitude of spontaneous mini-EPSCs, or the response to prolonged 10 Hz stimulus trains.  However, paired-pulse facilitation, a form of short-term plasticity, was considerably reduced in BDNF -/- mice.  Detailed ultrastructural anal. of the presynaptic terminals showed that this change in synaptic function was accompanied by an increase in the total no. of synaptic vesicles in mutant mice and a decrease in the proportion of vesicles that are docked.  These data indicated that BDNF regulates both the mechanisms that underlie short-term synaptic plasticity and the steady-state relationship between different vesicle pools within the terminal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-tCNU8Ekjd7Vg90H21EOLACvtfcHk0ljcezFa9j4ICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFeksbY%253D&md5=89624d26614a23cf85ba6c54a2f5707e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.22-04-01316.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.22-04-01316.2002%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DA.%2BR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DP.%2BM.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DBrain-derived%2520neurotrophic%2520factor%2520modulates%2520cerebellar%2520plasticity%2520and%2520synaptic%2520ultrastructure%26jtitle%3DJ.%2520Neurosci.%26date%3D2002%26volume%3D22%26spage%3D1316%26epage%3D1327%26doi%3D10.1523%2FJNEUROSCI.22-04-01316.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palko, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N. Y.</span></span> <span> </span><span class="NLM_article-title">TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1506</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1038/nn.3237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnn.3237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=23064382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=1506-1515&author=K.+O.+Laiauthor=A.+S.+Wongauthor=M.+C.+Cheungauthor=P.+Xuauthor=Z.+Liangauthor=K.+C.+Lokauthor=H.+Xieauthor=M.+E.+Palkoauthor=W.+H.+Yungauthor=L.+Tessarolloauthor=Z.+H.+Cheungauthor=N.+Y.+Ip&title=TrkB+phosphorylation+by+Cdk5+is+required+for+activity-dependent+structural+plasticity+and+spatial+memory&doi=10.1038%2Fnn.3237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory</span></div><div class="casAuthors">Lai, Kwok-On; Wong, Alan S. L.; Cheung, Man-Chun; Xu, Pei; Liang, Zhuoyi; Lok, Ka-Chun; Xie, Hui; Palko, Mary E.; Yung, Wing-Ho; Tessarollo, Lino; Cheung, Zelda H.; Ip, Nancy Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1506-1515</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The neurotrophin brain-derived neurotrophic factor (BDNF) and its receptor TrkB participate in diverse neuronal functions, including activity-dependent synaptic plasticity that is crucial for learning and memory.  On binding to BDNF, TrkB is not only autophosphorylated at tyrosine residues but also undergoes serine phosphorylation at S478 by the serine/threonine kinase cyclin-dependent kinase 5 (Cdk5).  However, the in vivo function of this serine phosphorylation remains unknown.  We generated knock-in mice lacking this serine phosphorylation (TrkbS478A/S478A mice) and found that the TrkB phosphorylation-deficient mice displayed impaired spatial memory and compromised hippocampal long-term potentiation (LTP).  S478 phosphorylation of TrkB regulates its interaction with the Rac1-specific guanine nucleotide exchange factor TIAM1, leading to activation of Rac1 and phosphorylation of S6 ribosomal protein during activity-dependent dendritic spine remodeling.  These findings reveal the importance of Cdk5-mediated S478 phosphorylation of TrkB in activity-dependent structural plasticity, which is crucial for LTP and spatial memory formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk9Ot31Ld6FLVg90H21EOLACvtfcHk0ljcezFa9j4ICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsbbO&md5=3028d87d6d76fd70470936f4e8370a15</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnn.3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.3237%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DK.%2BO.%26aulast%3DWong%26aufirst%3DA.%2BS.%26aulast%3DCheung%26aufirst%3DM.%2BC.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DLok%26aufirst%3DK.%2BC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DPalko%26aufirst%3DM.%2BE.%26aulast%3DYung%26aufirst%3DW.%2BH.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DZ.%2BH.%26aulast%3DIp%26aufirst%3DN.%2BY.%26atitle%3DTrkB%2520phosphorylation%2520by%2520Cdk5%2520is%2520required%2520for%2520activity-dependent%2520structural%2520plasticity%2520and%2520spatial%2520memory%26jtitle%3DNat.%2520Neurosci.%26date%3D2012%26volume%3D15%26spage%3D1506%26epage%3D1515%26doi%3D10.1038%2Fnn.3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubner, R.</span></span> <span> </span><span class="NLM_article-title">Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: role of BDNF-TrkB signaling and NMDA receptors</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1007/s12035-007-0028-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2Fs12035-007-0028-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=17917111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1aisbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=224-235&author=K.+Renauthor=R.+Dubner&title=Pain+facilitation+and+activity-dependent+plasticity+in+pain+modulatory+circuitry%3A+role+of+BDNF-TrkB+signaling+and+NMDA+receptors&doi=10.1007%2Fs12035-007-0028-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: role of BDNF-TrkB signaling and NMDA receptors</span></div><div class="casAuthors">Ren, Ke; Dubner, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-235</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Pain modulatory circuitry in the brainstem exhibits considerable synaptic plasticity.  The increased peripheral neuronal barrage after injury activates spinal projection neurons that then activate multiple chem. mediators including glutamatergic neurons at the brainstem level, leading to an increased synaptic strength and facilitatory output.  It is not surprising that a well-established regulator of synaptic plasticity, brain-derived neurotrophic factor (BDNF), contributes to the mechanisms of descending pain facilitation.  After tissue injury, BDNF and TrkB signaling in the brainstem circuitry is rapidly activated.  Through the intracellular signaling cascade that involves phospholipase C, inositol trisphosphate, protein kinase C, and nonreceptor protein tyrosine kinases; NMDA receptors are phosphorylated, descending facilitatory drive is initiated, and behavioral hyperalgesia follows.  The synaptic plasticity obsd. in the pain pathways shares much similarity with more extensively studied forms of synaptic plasticity such as long-term potentiation (LTP) and long-term depression (LTD), which typically express NMDA receptor dependency and regulation by trophic factors.  However, LTP and LTD are exptl. phenomena whose relationship to functional states of learning and memory has been difficult to prove.  Although mechanisms of synaptic plasticity in pain pathways have typically not been related to LTP and LTD, pain pathways have an advantage as a model system for synaptic modifications as there are many well-established models of persistent pain with clear measures of the behavioral phenotype.  Further studies will elucidate cellular and mol. mechanisms of pain sensitization and further our understanding of principles of central nervous system plasticity and responsiveness to environmental challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjbE4QewGSQrVg90H21EOLACvtfcHk0ljcezFa9j4ICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1aisbvM&md5=8ead666a6776789ec641cd802cc639c1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12035-007-0028-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-007-0028-8%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DK.%26aulast%3DDubner%26aufirst%3DR.%26atitle%3DPain%2520facilitation%2520and%2520activity-dependent%2520plasticity%2520in%2520pain%2520modulatory%2520circuitry%253A%2520role%2520of%2520BDNF-TrkB%2520signaling%2520and%2520NMDA%2520receptors%26jtitle%3DMol.%2520Neurobiol.%26date%3D2007%26volume%3D35%26spage%3D224%26epage%3D235%26doi%3D10.1007%2Fs12035-007-0028-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuman, E. M.</span></span> <span> </span><span class="NLM_article-title">Neurotrophin regulation of synaptic transmission</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/S0959-4388(99)80013-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-4388%2899%2980013-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=105-109&author=E.+M.+Schuman&title=Neurotrophin+regulation+of+synaptic+transmission&doi=10.1016%2FS0959-4388%2899%2980013-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2899%2980013-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252899%252980013-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchuman%26aufirst%3DE.%2BM.%26atitle%3DNeurotrophin%2520regulation%2520of%2520synaptic%2520transmission%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1999%26volume%3D9%26spage%3D105%26epage%3D109%26doi%3D10.1016%2FS0959-4388%2899%2980013-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuman, E. M.</span></span> <span> </span><span class="NLM_article-title">Determinants of BDNF-induced hippocampal synaptic plasticity: role of the Trk B receptor and the kinetics of neurotrophin delivery</span>. <i>Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1101/lm.3.2-3.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1101%2Flm.3.2-3.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10456089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADyaK1MzosFSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1996&pages=188-196&author=H.+Kangauthor=L.+Z.+Jiaauthor=K.+Y.+Suhauthor=L.+Tangauthor=E.+M.+Schuman&title=Determinants+of+BDNF-induced+hippocampal+synaptic+plasticity%3A+role+of+the+Trk+B+receptor+and+the+kinetics+of+neurotrophin+delivery&doi=10.1101%2Flm.3.2-3.188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of BDNF-induced hippocampal synaptic plasticity: role of the Trk B receptor and the kinetics of neurotrophin delivery</span></div><div class="casAuthors">Kang H; Jia L Z; Suh K Y; Tang L; Schuman E M</div><div class="citationInfo"><span class="NLM_cas:title">Learning & memory (Cold Spring Harbor, N.Y.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">188-96</span>
        ISSN:<span class="NLM_cas:issn">1072-0502</span>.
    </div><div class="casAbstract">The neurotrophins are a class of signaling molecules known for their growth and survival-promoting activities during neuronal development.  Recent studies suggest that the neurotrophins, including brain-derived neurotrophic factor (BDNF), can also dramatically influence synaptic transmission in the adult hippocampus.  The experiments described in this paper indicate that ability of BDNF to potentiate synaptic transmission in the hippocampus relies on functional Trk B receptors.  Moreover, the rate at which BDNF is applied to hippocampal synapses is also a potent determinant of whether synaptic potentiation will result.  Hippocampal slices perfused with BDNF at a very slow flow rate (e.g., < or = 25 ml/hr) did not show synaptic potentiation.  Increasing the rate of BDNF application resulted in synaptic potentiation in which the magnitude and onset kinetics of the potentiation were determined by the rate of BDNF delivery.  Immunocytochemical analysis of BDNF detected with confocal microscopy confirmed these electrophysiological observations, indicating that the penetration of BDNF into hippocampal slices is influenced dramatically by the perfusion rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6RwrXwXIsY6x48Rj5GnGofW6udTcc2eabL2HxU5OhO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MzosFSgsw%253D%253D&md5=1a5f796a1559289d5c82ceba1797dcda</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1101%2Flm.3.2-3.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Flm.3.2-3.188%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%2BZ.%26aulast%3DSuh%26aufirst%3DK.%2BY.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DSchuman%26aufirst%3DE.%2BM.%26atitle%3DDeterminants%2520of%2520BDNF-induced%2520hippocampal%2520synaptic%2520plasticity%253A%2520role%2520of%2520the%2520Trk%2520B%2520receptor%2520and%2520the%2520kinetics%2520of%2520neurotrophin%2520delivery%26jtitle%3DLearn.%2520Mem.%26date%3D1996%26volume%3D3%26spage%3D188%26epage%3D196%26doi%3D10.1101%2Flm.3.2-3.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, D. C.</span></span> <span> </span><span class="NLM_article-title">Neurotrophins and synaptic plasticity</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.22.1.295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.neuro.22.1.295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10202541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=295-318&author=A.+K.+McAllisterauthor=L.+C.+Katzauthor=D.+C.+Lo&title=Neurotrophins+and+synaptic+plasticity&doi=10.1146%2Fannurev.neuro.22.1.295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotrophins and synaptic plasticity</span></div><div class="casAuthors">McAllister, A. Kimberley; Katz, Lawrence C.; Lo, Donald C.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295-318</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with ∼220 refs.  Despite considerable evidence that neuronal activity influences the organization and function of circuits in the developing and adult brain, the mol. signals that translate activity into structural and functional changes in connections remain largely obscure.  This review discusses the evidence implicating neurotrophins as mol. mediators of synaptic and morphol. plasticity.  Neurotrophins are attractive candidates for these roles because they and their receptors are expressed in areas of the brain that undergo plasticity, activity can regulate their levels and secretion, and they regulate both synaptic transmission and neuronal growth.  Although numerous expts. show demonstrable effects of neurotrophins on synaptic plasticity, the rules and mechanisms by which they exert their effects remain intriguingly elusive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvlEInDNTlWrVg90H21EOLACvtfcHk0lhavcpAcPjNNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFems78%253D&md5=89366179460c0f90c5a6b50983440ae3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.22.1.295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.22.1.295%26sid%3Dliteratum%253Aachs%26aulast%3DMcAllister%26aufirst%3DA.%2BK.%26aulast%3DKatz%26aufirst%3DL.%2BC.%26aulast%3DLo%26aufirst%3DD.%2BC.%26atitle%3DNeurotrophins%2520and%2520synaptic%2520plasticity%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D1999%26volume%3D22%26spage%3D295%26epage%3D318%26doi%3D10.1146%2Fannurev.neuro.22.1.295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schinder, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poo, M.</span></span> <span> </span><span class="NLM_article-title">The neurotrophin hypothesis for synaptic plasticity</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1016/S0166-2236(00)01672-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0166-2236%2800%2901672-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=639-645&author=A.+F.+Schinderauthor=M.+Poo&title=The+neurotrophin+hypothesis+for+synaptic+plasticity&doi=10.1016%2FS0166-2236%2800%2901672-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0166-2236%2800%2901672-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-2236%252800%252901672-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchinder%26aufirst%3DA.%2BF.%26aulast%3DPoo%26aufirst%3DM.%26atitle%3DThe%2520neurotrophin%2520hypothesis%2520for%2520synaptic%2520plasticity%26jtitle%3DTrends%2520Neurosci.%26date%3D2000%26volume%3D23%26spage%3D639%26epage%3D645%26doi%3D10.1016%2FS0166-2236%2800%2901672-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span> <span> </span><span class="NLM_article-title">Trk receptors: roles in neuronal signal transduction</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.72.121801.161629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.biochem.72.121801.161629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12676795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=609-642&author=E.+J.+Huangauthor=L.+F.+Reichardt&title=Trk+receptors%3A+roles+in+neuronal+signal+transduction&doi=10.1146%2Fannurev.biochem.72.121801.161629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptors: roles in neuronal signal transduction</span></div><div class="casAuthors">Huang, Eric J.; Reichardt, Louis F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">609-642</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Trk receptors are a family of 3 receptor tyrosine kinases, each of which can be activated by ≥1 of 4 neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).  Neurotrophin signaling through these receptors regulates cell survival, proliferation, the fate of neural precursors, axon and dendrite growth and patterning, and the expression and activity of functionally important proteins, such as ion channels and neurotransmitter receptors.  In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity.  The cytoplasmic domains of Trk receptors contain several sites of tyrosine phosphorylation that recruit intermediates in intracellular signaling cascades.  As a result, Trk receptor signaling activates several small G proteins, including Ras, Rap-1, and the Cdc-42-Rac-Rho family, as well as pathways regulated by MAP kinase, PI 3-kinase and phospholipase-C-γ (PLC-γ).  Trk receptor activation has different consequences in different cells, and the specificity of downstream Trk receptor-mediated signaling is controlled through expression of intermediates in these signaling pathways and membrane trafficking that regulates localization of different signaling constituents.  Perhaps the most fascinating aspect of Trk receptor-mediated signaling is its interplay with signaling promoted by the pan-neurotrophin receptor p75NTR.  P75NTR activates a distinct set of signaling pathways within cells that are in some instances synergistic and in other instances antagonistic to those activated by Trk receptors.  Several of these are proapoptotic but are suppressed by Trk receptor-initiated signaling.  P75NTR also influences the conformations of Trk receptors; this modifies ligand-binding specificity and affinity with important developmental consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH3Pdvfi72LVg90H21EOLACvtfcHk0lib2IWBIQiz_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D&md5=939bf60802da0a203c2e0d8585e28dd9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.72.121801.161629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.72.121801.161629%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DE.%2BJ.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26atitle%3DTrk%2520receptors%253A%2520roles%2520in%2520neuronal%2520signal%2520transduction%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2003%26volume%3D72%26spage%3D609%26epage%3D642%26doi%3D10.1146%2Fannurev.biochem.72.121801.161629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, F. D.</span></span> <span> </span><span class="NLM_article-title">Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development</span>. <i>Development</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">4369</span>– <span class="NLM_lpage">4380</span>, <span class="refDoi"> DOI: 10.1242/dev.008227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1242%2Fdev.008227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=18003743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFSktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2007&pages=4369-4380&author=K.+Bartkowskaauthor=A.+Paquinauthor=A.+S.+Gauthierauthor=D.+R.+Kaplanauthor=F.+D.+Miller&title=Trk+signaling+regulates+neural+precursor+cell+proliferation+and+differentiation+during+cortical+development&doi=10.1242%2Fdev.008227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development</span></div><div class="casAuthors">Bartkowska, Katarzyna; Paquin, Annie; Gauthier, Andree S.; Kaplan, David R.; Miller, Freda D.</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4369-4380</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Increasing evidence indicates that development of embryonic central nervous system precursors is tightly regulated by extrinsic cues located in the local environment.  Here, we asked whether neurotrophin-mediated signaling through Trk tyrosine kinase receptors is important for embryonic cortical precursor cell development.  These studies demonstrate that inhibition of TrkB (Ntrk2) and/or TrkC (Ntrk3) signaling using dominant-neg. Trk receptors, or genetic knockdown of TrkB using shRNA, caused a decrease in embryonic precursor cell proliferation both in culture and in vivo.  Inhibition of TrkB/C also caused a delay in the generation of neurons, but not astrocytes, and ultimately perturbed the postnatal localization of cortical neurons in vivo.  Conversely, overexpression of BDNF in cortical precursors in vivo promoted proliferation and enhanced neurogenesis.  Together, these results indicate that neurotrophin-mediated Trk signaling plays an essential, cell-autonomous role in regulating the proliferation and differentiation of embryonic cortical precursors and thus controls cortical development at earlier stages than previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeFolN0ielRrVg90H21EOLACvtfcHk0lib2IWBIQiz_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFSktg%253D%253D&md5=c5c0983e47b863c644a777af76c42eb3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1242%2Fdev.008227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.008227%26sid%3Dliteratum%253Aachs%26aulast%3DBartkowska%26aufirst%3DK.%26aulast%3DPaquin%26aufirst%3DA.%26aulast%3DGauthier%26aufirst%3DA.%2BS.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DF.%2BD.%26atitle%3DTrk%2520signaling%2520regulates%2520neural%2520precursor%2520cell%2520proliferation%2520and%2520differentiation%2520during%2520cortical%2520development%26jtitle%3DDevelopment%26date%3D2007%26volume%3D134%26spage%3D4369%26epage%3D4380%26doi%3D10.1242%2Fdev.008227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Islam, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heese, K.</span></span> <span> </span><span class="NLM_article-title">Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways</span>. <i>Curr. Neurovascular Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.2174/156720209787466028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2174%2F156720209787466028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19355925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislyjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=42-53&author=O.+Islamauthor=T.+X.+Looauthor=K.+Heese&title=Brain-derived+neurotrophic+factor+%28BDNF%29+has+proliferative+effects+on+neural+stem+cells+through+the+truncated+TRK-B+receptor%2C+MAP+kinase%2C+AKT%2C+and+STAT-3+signaling+pathways&doi=10.2174%2F156720209787466028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways</span></div><div class="casAuthors">Islam, Omedul; Loo, Tze X.; Heese, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Current Neurovascular Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-53</span>CODEN:
                <span class="NLM_cas:coden">CNRUAM</span>;
        ISSN:<span class="NLM_cas:issn">1875-5739</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Neurospheres can be generated from the mouse fetal forebrain by exposing multipotent neural stem cells (NSCs) to epidermal growth factor (EGF).  In the presence of EGF, NSCs can proliferate continuously while retaining the potential to differentiate into neurons, astrocytes and oligodendrocytes.  We examd. the expression pattern of the neurotrophin (NT) receptors tropomyosin-related kinase (TRK)-A, TRK-B, TRK-C and p75 neurotrophin receptor (p75NTR) in NSCs and the corresponding lineage cells.  Furthermore, we analyzed the action of the NT Brain-Derived Neurotrophic Factor (BDNF) on NSCs' behavior.  The effects of BDNF on NSC proliferation and differentiation were examd. together with the signaling pathways by which BDNF receptors transduce signaling effects.  We found that all the known NT receptors, including the truncated isoforms of TRK-B (t-TRK-B) and TRK-C (t-TRK-C), were expressed by Nestin-pos. cells within the neurosphere.  Proliferation was enhanced in Nestin-pos. and BrdU-pos. cells in the presence of BDNF.  In particular, we show that t-TRK-B was abundantly expressed in NSCs and the corresponding differentiated glia cells while full length TRK-B (fl-TRK-B) was expressed in fully differentiated post-mitotic neurons such as the neuronal cells of the newborn mouse cortex, suggesting that BDNF may exert its proliferative effects on NSCs through the t-TRK-B receptor.  Finally, we analyzed the cell fates of NSCs differentiated with BDNF in the absence of EGF and we demonstrate that BDNF stimulated the formation of differentiated cell types in different proportions through the MAP kinase, AKT and STAT-3 signaling pathways.  Thus, the in-vivo regulation of neurogenesis may be mediated by the summation of signals from the BDNF receptors, in particular the t-TRK-B receptor, regulating physiol. fates as diverse as normal neural replacement, excessive neural loss, or tumor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvh-yjUGScLVg90H21EOLACvtfcHk0lib2IWBIQiz_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislyjtr0%253D&md5=4486c380d58707ce1f2c639d2f29e6af</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F156720209787466028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720209787466028%26sid%3Dliteratum%253Aachs%26aulast%3DIslam%26aufirst%3DO.%26aulast%3DLoo%26aufirst%3DT.%2BX.%26aulast%3DHeese%26aufirst%3DK.%26atitle%3DBrain-derived%2520neurotrophic%2520factor%2520%2528BDNF%2529%2520has%2520proliferative%2520effects%2520on%2520neural%2520stem%2520cells%2520through%2520the%2520truncated%2520TRK-B%2520receptor%252C%2520MAP%2520kinase%252C%2520AKT%252C%2520and%2520STAT-3%2520signaling%2520pathways%26jtitle%3DCurr.%2520Neurovascular%2520Res.%26date%3D2009%26volume%3D6%26spage%3D42%26epage%3D53%26doi%3D10.2174%2F156720209787466028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdi, J. M.</span></span> <span> </span><span class="NLM_article-title">The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">9861</span>– <span class="NLM_lpage">9870</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.14.9861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.274.14.9861" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=9861-9870&author=S.+O.+Meakinauthor=J.+I.+MacDonaldauthor=E.+A.+Gryzauthor=C.+J.+Kubuauthor=J.+M.+Verdi&title=The+signaling+adapter+FRS-2+competes+with+Shc+for+binding+to+the+nerve+growth+factor+receptor+TrkA.+A+model+for+discriminating+proliferation+and+differentiation&doi=10.1074%2Fjbc.274.14.9861"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.14.9861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.14.9861%26sid%3Dliteratum%253Aachs%26aulast%3DMeakin%26aufirst%3DS.%2BO.%26aulast%3DMacDonald%26aufirst%3DJ.%2BI.%26aulast%3DGryz%26aufirst%3DE.%2BA.%26aulast%3DKubu%26aufirst%3DC.%2BJ.%26aulast%3DVerdi%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520signaling%2520adapter%2520FRS-2%2520competes%2520with%2520Shc%2520for%2520binding%2520to%2520the%2520nerve%2520growth%2520factor%2520receptor%2520TrkA.%2520A%2520model%2520for%2520discriminating%2520proliferation%2520and%2520differentiation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D9861%26epage%3D9870%26doi%3D10.1074%2Fjbc.274.14.9861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vellis, J.</span></span> <span> </span><span class="NLM_article-title">NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-4547(19981215)54:6<754::AID-JNR3>3.0.CO;2-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9856859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFajtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=754-765&author=S.+Kumarauthor=M.+A.+Kahnauthor=L.+Dinhauthor=J.+de+Vellis&title=NT-3-mediated+TrkC+receptor+activation+promotes+proliferation+and+cell+survival+of+rodent+progenitor+oligodendrocyte+cells+in+vitro+and+in+vivo&doi=10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo</span></div><div class="casAuthors">Kumar, Shalini; Kahn, Michelle A.; Dinh, Lan; De Vellis, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">754-765</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We have previously described the expression of a functional full-length TrkC transcript for neurotrophin-3 (NT-3) receptor in oligodendroglia (OL) cells (S. Kumar and J. de Vellis, 1996).  To date, the role of NT-3 and its signal transduction cascade in OL remains poorly defined.  We report that the NT-3 responsive population of cells in the OL lineage are the progenitor cells and that the addn. of NT-3 results in the autophosphorylation of p145TrkC.  Furthermore, NT-3-mediated activation of p21ras and mitogen-activated protein kinase (MAPK), extracellular signal-regulated protein kinase2 (ERK2), were also obsd. in the progenitor OL cells.  These protein tyrosine kinase (PTK)-induced responses were sensitive to the presence of K252a, an inhibitor for tyrosine kinase.  We have detd. that NT-3 promotes progenitor OL cell commitment to enter into S-phase of cell cycle to initiate DNA synthesis, in a manner similar to platelet-derived growth factor-AA (PDGF-AA).  NT-3 thus plays a role in cell proliferation when present alone, while augmenting the proliferation capacity of PDGF-AA as indicated by the nuclear binding activity of the transcription factor, E2F-1.  Both the initiation and progression of mitotic events were confirmed by the expression of c-myc and cdc2 in the presence of NT-3, PDGF-AA or NT-3 plus PDGF-AA.  A cell survival assay examg. interleukin 1β-converting enzyme (ICE)-like protease-mediated cleavage of poly (ADP-ribose) polymerase (PARP) revealed an increase in OL progenitor cell death in the absence of NT-3 or PDGF-AA.  In corroboration with our in vitro studies, in vivo results show an increased expression of the progenitor OL cell marker, glycerol phosphate dehydrogenase (GPDH) within 48 h following an intracranial injection of NT-3, PDGF-AA, or NT-3 plus PDGF-AA in PN4-5 rats.  These novel findings suggest that PDGF-AA potentiates the OL progenitor cell's ability to enter into the S-phase of the cell cycle and that NT-3 can augment this activity.  Furthermore, PDGF-AA and NT-3 can block ICE-like protease-mediated PARP fragmentation in progenitor OL cells.  These results provide important information which further delineates the signal transduction cascades and the role of NT-3 and PDGF-AA on OL progenitor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8DITf886ZbbVg90H21EOLACvtfcHk0ljjtvP6gBlT0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFajtLo%253D&md5=43ff80a18e3010a043e0abd0e8ffa522</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4547%252819981215%252954%253A6%253C754%253A%253AAID-JNR3%253E3.0.CO%253B2-K%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DKahn%26aufirst%3DM.%2BA.%26aulast%3DDinh%26aufirst%3DL.%26aulast%3Dde%2BVellis%26aufirst%3DJ.%26atitle%3DNT-3-mediated%2520TrkC%2520receptor%2520activation%2520promotes%2520proliferation%2520and%2520cell%2520survival%2520of%2520rodent%2520progenitor%2520oligodendrocyte%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D1998%26volume%3D54%26spage%3D754%26epage%3D765%26doi%3D10.1002%2F%28SICI%291097-4547%2819981215%2954%3A6%3C754%3A%3AAID-JNR3%3E3.0.CO%3B2-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashiro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, C. J.</span></span> <span> </span><span class="NLM_article-title">Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1806</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=1798-1806&author=K.+Matsumotoauthor=R.+K.+Wadaauthor=J.+M.+Yamashiroauthor=D.+R.+Kaplanauthor=C.+J.+Thiele&title=Expression+of+brain-derived+neurotrophic+factor+and+p145TrkB+affects+survival%2C+differentiation%2C+and+invasiveness+of+human+neuroblastoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DR.%2BK.%26aulast%3DYamashiro%26aufirst%3DJ.%2BM.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DThiele%26aufirst%3DC.%2BJ.%26atitle%3DExpression%2520of%2520brain-derived%2520neurotrophic%2520factor%2520and%2520p145TrkB%2520affects%2520survival%252C%2520differentiation%252C%2520and%2520invasiveness%2520of%2520human%2520neuroblastoma%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D1798%26epage%3D1806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moheban, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5671</span>– <span class="NLM_lpage">5678</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.20-15-05671.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.20-15-05671.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10908605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=5671-5678&author=Y.+Z.+Zhangauthor=D.+B.+Mohebanauthor=B.+R.+Conwayauthor=A.+Bhattacharyyaauthor=R.+A.+Segal&title=Cell+surface+Trk+receptors+mediate+NGF-induced+survival+while+internalized+receptors+regulate+NGF-induced+differentiation&doi=10.1523%2FJNEUROSCI.20-15-05671.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation</span></div><div class="casAuthors">Zhang, Yan-Zhen; Moheban, Daniel B.; Conway, Bevil R.; Bhattacharyya, Anita; Segal, Rosalind A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5671-5678</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Internalization and transport of a ligand-receptor complex are required to initiate cell body responses to target-derived neurotrophin.  However, it is not known whether internalized receptors and cell surface receptors initiate the same signaling pathways and biol. responses.  Here the authors use a temp.-sensitive mutant of dynamin (G273D) to control the subcellular localization of activated NGF receptors (Trks).  The authors show that dynamin function is required for ligand-dependent endocytosis of Trk receptors.  In PC12 cells, nerve growth factor (NGF) stimulation promotes both survival and neuronal differentiation.  These distinct biol. responses to NGF are controlled by receptors signaling from different locations within the cell.  Neuronal differentiation is promoted by catalytically active Trks within endosomes in the cell interior.  In contrast, survival responses are initiated by activated receptors at the cell surface where they orchestrate prolonged activation of the kinase Akt.  Thus, interactions between Trk receptor tyrosine kinases and intracellular signaling mols. are dictated both by phosphotyrosine motifs within the receptors and by the intracellular location of phosphorylated receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXnkF0vu4BU7Vg90H21EOLACvtfcHk0ljjtvP6gBlT0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbw%253D&md5=0e3daad42223adfe91d8927b32c8d64d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.20-15-05671.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.20-15-05671.2000%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DMoheban%26aufirst%3DD.%2BB.%26aulast%3DConway%26aufirst%3DB.%2BR.%26aulast%3DBhattacharyya%26aufirst%3DA.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DCell%2520surface%2520Trk%2520receptors%2520mediate%2520NGF-induced%2520survival%2520while%2520internalized%2520receptors%2520regulate%2520NGF-induced%2520differentiation%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26spage%3D5671%26epage%3D5678%26doi%3D10.1523%2FJNEUROSCI.20-15-05671.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnabe-Heider, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, F. D.</span></span> <span> </span><span class="NLM_article-title">Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5149</span>– <span class="NLM_lpage">5160</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.23-12-05149.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.23-12-05149.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12832539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltlentLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=5149-5160&author=F.+Barnabe-Heiderauthor=F.+D.+Miller&title=Endogenously+produced+neurotrophins+regulate+survival+and+differentiation+of+cortical+progenitors+via+distinct+signaling+pathways&doi=10.1523%2FJNEUROSCI.23-12-05149.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways</span></div><div class="casAuthors">Barnabe-Heider, Fanie; Miller, Freda D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5149-5160</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Cultured embryonic cortical progenitor cells will mimic the temporal differentiation pattern obsd. in vivo, producing neurons first and then glia.  Here, we investigated the role of two endogenously produced growth factors, the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 (NT-3), in the early progenitor-to-neuron transition.  Cultured cortical progenitors express BDNF and NT-3, as well as their receptors TrkB (tyrosine kinase receptor B) and TrkC.  Inhibition of these endogenously expressed neurotrophins using function-blocking antibodies resulted in a marked decrease in the survival of cortical progenitors, accompanied by decreased proliferation and inhibition of neurogenesis.  Inhibition of neurotrophin function also suppressed the downstream Trk receptor signaling pathways, PI3-kinase (phosphatidyl inositol-3-kinase) and MEK-ERK (MAP kinase kinase-extracellular signal-regulated kinase), indicating the presence of autocrine-paracrine neurotrophin:Trk receptor signaling in these cells.  Moreover, specific inhibition of these two Trk signaling pathways led to distinct biol. effects; inhibition of PI3-kinase decreased progenitor cell survival, whereas inhibition of MEK selectively blocked the generation of neurons, with no effects on survival or proliferation.  Thus, neurotrophins made by cortical progenitor cells themselves signal through the TrkB and TrkC receptors to mediate cortical progenitor cell survival and neurogenesis via two distinct downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMFVyGXurVMbVg90H21EOLACvtfcHk0ljr2YDo6aPk_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltlentLw%253D&md5=328361111454b5d369dcfcf3443ab6f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.23-12-05149.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.23-12-05149.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBarnabe-Heider%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DF.%2BD.%26atitle%3DEndogenously%2520produced%2520neurotrophins%2520regulate%2520survival%2520and%2520differentiation%2520of%2520cortical%2520progenitors%2520via%2520distinct%2520signaling%2520pathways%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26spage%3D5149%26epage%3D5160%26doi%3D10.1523%2FJNEUROSCI.23-12-05149.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eggert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikegaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span> <span> </span><span class="NLM_article-title">Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2043</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1203518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10803465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtF2jsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2043-2051&author=A.+Eggertauthor=N.+Ikegakiauthor=X.+Liuauthor=T.+T.+Chouauthor=V.+M.+Leeauthor=J.+Q.+Trojanowskiauthor=G.+M.+Brodeur&title=Molecular+dissection+of+TrkA+signal+transduction+pathways+mediating+differentiation+in+human+neuroblastoma+cells&doi=10.1038%2Fsj.onc.1203518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells</span></div><div class="casAuthors">Eggert, Angelika; Ikegaki, Naohiko; Liu, Xing-Ge; Chou, Thomas T.; Lee, Virginia M.; Trojanowski, John Q.; Brodeur, Garrett M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2043-2051</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the neurotrophin receptor TrkA by its ligand nerve growth factor (NGF) initiates a cascade of signaling events leading to neuronal differentiation in vitro and might play an important role in the differentiation of favorable neuroblastomas (NB) in vivo.  To study TrkA signal transduction pathways and their effects on differentiation in NB, we stably expressed wild-type TrkA and five different TrkA mutants in the NGF unresponsive human NB cell line SH-SY5Y.  Resulting clones were characterized by TrkA mRNA and protein expression, and by autophosphorylation of the receptor.  Introduction of wild-type TrkA restored NGF responsiveness of SH-SY5Y cells, as demonstrated by morphol. differentiation, activation of mitogen-activated protein kinases (MAPK) and induction of immediate-early genes.  Expression of TrkA in the absence of NGF resulted in growth inhibition of transfectants compared to parental cells, whereas NGF-treatment increased their proliferation rate.  Anal. of downstream signal transduction pathways indicated that NGF-induced differentiation was dependent on TrkA kinase activity.  Our data suggest that several redundant pathways are present further downstream, but activation of the RAS/MAPK signaling pathway seems to be of major importance for NGF mediated differentiation of NB cells.  Our results also show that the signaling effector SH2-B is a substrate of NGF-mediated Trk signaling in NB, whereas it is not activated by NGF in rat pheochromocytoma PC12 cells.  This might explain the differences we obsd. in TrkA signaling between neuroblastoma and PC12 cells.  Further insight into TrkA signaling may suggest new options for the treatment of NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMcffQwGzqfrVg90H21EOLACvtfcHk0ljr2YDo6aPk_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtF2jsbk%253D&md5=11c2bc9243954f97c9a8dab11d9103fd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203518%26sid%3Dliteratum%253Aachs%26aulast%3DEggert%26aufirst%3DA.%26aulast%3DIkegaki%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChou%26aufirst%3DT.%2BT.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26atitle%3DMolecular%2520dissection%2520of%2520TrkA%2520signal%2520transduction%2520pathways%2520mediating%2520differentiation%2520in%2520human%2520neuroblastoma%2520cells%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2043%26epage%3D2051%26doi%3D10.1038%2Fsj.onc.1203518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiCicco-Bloom, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, I. B.</span></span> <span> </span><span class="NLM_article-title">NT-3 stimulates sympathetic neuroblast proliferation by promoting precursor survival</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(93)90223-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0896-6273%2893%2990223-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7903858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1993&pages=1101-1011&author=E.+DiCicco-Bloomauthor=W.+J.+Friedmanauthor=I.+B.+Black&title=NT-3+stimulates+sympathetic+neuroblast+proliferation+by+promoting+precursor+survival&doi=10.1016%2F0896-6273%2893%2990223-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">NT-3 stimulates sympathetic neuroblast proliferation by promoting precursor survival</span></div><div class="casAuthors">DiCicco-Bloom, Emanuel; Friedman, Wilma J.; Black, Ira B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1101-11</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">Although proliferation is fundamental to the generation of neuronal populations, little is known about the function of trophic mechanisms during neurogenesis.  The authors now describe a novel role for neurotrophin-3 (NT-3): the neurotrophin stimulates proliferation of sympathetic neuroblasts through trophic mechanisms.  NT-3 promotes survival of the dividing precursors, but does not directly stimulate mitosis.  NT-3 trophic effects differ markedly from those of the sympathetic mitogen, insulin.  Furthermore, whereas NT-3 exhibits trophic activity for dividing neuroblasts, NGF characteristically promotes survival of postnatal sympathetic neurons.  The stage-specific activity of NT-3 and NGF in culture parallels the sequence of trkC and trkA receptor gene expression detected in vivo.  Thus, neurotrophins apparently serve as trophic factors during ontogeny, acting sequentially during establishment of individual populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz0VvHzDYw0rVg90H21EOLACvtfcHk0ljr2YDo6aPk_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFCnsbs%253D&md5=ac26a42025cd5874fbd32042b524ab06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2893%2990223-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252893%252990223-E%26sid%3Dliteratum%253Aachs%26aulast%3DDiCicco-Bloom%26aufirst%3DE.%26aulast%3DFriedman%26aufirst%3DW.%2BJ.%26aulast%3DBlack%26aufirst%3DI.%2BB.%26atitle%3DNT-3%2520stimulates%2520sympathetic%2520neuroblast%2520proliferation%2520by%2520promoting%2520precursor%2520survival%26jtitle%3DNeuron%26date%3D1993%26volume%3D11%26spage%3D1101%26epage%3D1011%26doi%3D10.1016%2F0896-6273%2893%2990223-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glass, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nye, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantzopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squinto, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">Trkl3 mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90629-D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990629-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1649703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXltVOjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1991&pages=405-413&author=D.+J.+Glassauthor=S.+H.+Nyeauthor=P.+Hantzopoulosauthor=M.+J.+Macchiauthor=S.+P.+Squintoauthor=M.+Goldfarbauthor=G.+D.+Yancopoulos&title=Trkl3+mediates+BDNF%2FNT-3-dependent+survival+and+proliferation+in+fibroblasts+lacking+the+low+affinity+NGF+receptor&doi=10.1016%2F0092-8674%2891%2990629-D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor</span></div><div class="casAuthors">Glass, David J.; Nye, Steven H.; Hantzopoulos, Petros; Macchi, Mary J.; Squinto, Stephen P.; Goldfarb, Mitchell; Yancopoulos, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The neurotrophins nerve growth factor (NGF), brain-derived neurotropic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) have been defined by their ability to support neuronal survival.  These factors utilize the trk family of receptor tyrosine kinases, perhaps in conjunction with a second component known as the low-affinity NGF receptor (LNGFR).  The trkB mediateds survival and proliferation in response to both BDNF and NT-3 when expressed in a particular strain of NIH 3T3 fibroblasts, with BDNF being the more potent ligand.  The BDNF dose-dependency displayed by these trkB-expressing fibroblasts is similar to that required to support the survival of primary neurons.  The LNGFR is not expressed in this fibroblast system, implying that this receptor is not essential for responses to physiol. concns. of the neurotrophins.  The data are discussed in the context of neurotrophin signaling pathways and mechanisms of neuronal cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC8ylYZ45m57Vg90H21EOLACvtfcHk0lhiZGFP4ddExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXltVOjtLY%253D&md5=c34a721159f4a54521e99505a5db90d0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990629-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990629-D%26sid%3Dliteratum%253Aachs%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DNye%26aufirst%3DS.%2BH.%26aulast%3DHantzopoulos%26aufirst%3DP.%26aulast%3DMacchi%26aufirst%3DM.%2BJ.%26aulast%3DSquinto%26aufirst%3DS.%2BP.%26aulast%3DGoldfarb%26aufirst%3DM.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DTrkl3%2520mediates%2520BDNF%252FNT-3-dependent%2520survival%2520and%2520proliferation%2520in%2520fibroblasts%2520lacking%2520the%2520low%2520affinity%2520NGF%2520receptor%26jtitle%3DCell%26date%3D1991%26volume%3D66%26spage%3D405%26epage%3D413%26doi%3D10.1016%2F0092-8674%2891%2990629-D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehler, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, J. A.</span></span> <span> </span><span class="NLM_article-title">Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6433</span>– <span class="NLM_lpage">6442</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.16-20-06433.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.16-20-06433.1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8815922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1Orurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=6433-6442&author=R.+I.+Cohenauthor=R.+Marmurauthor=W.+T.+Nortonauthor=M.+F.+Mehlerauthor=J.+A.+Kessler&title=Nerve+growth+factor+and+neurotrophin-3+differentially+regulate+the+proliferation+and+survival+of+developing+rat+brain+oligodendrocytes&doi=10.1523%2FJNEUROSCI.16-20-06433.1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes</span></div><div class="casAuthors">Cohen, Rick I.; Marmur, Ronen; Norton, William T.; Mehler, Mark F.; Kessler, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6433-6442</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">There is increasing evidence that the neurotrophins, particularly nerve growth factor (NGF) and neurotrophin-3 (NT-3), play a role in the regulation of glial development in the CNS.  Recent studies have shown that the proliferation of optic nerve-derived O2A progenitors (OLPs) is potentiated by NT-3 in combination with platelet-derived growth factor, whereas NT-3 alone supports the survival of their differentiated progeny (Barres et al., 1994).  In this study, we have examd. the expression of the high-affinity neurotrophin receptors (trks) and the low-affinity nerve growth factor receptor p75 in developing oligodendrocytes (OLs).  In addn., we have examd. the effects of NGF and NT-3 on proliferation and survival of OLPs and OLs, resp.  TrkC, the high-affinity NT-3 receptor, and trkA, the high-affinity NGF receptor, are both expressed from the early OLP through the mature OL stage.  The truncated form of trkB, lacking the tyrosine kinase domain, and the low-affinity neurotrophin receptor p75 are expressed at low levels in OLPs and are upregulated in mature OLs.  NGF and NT-3 both induced the phosphorylation of mitogen-activated protein kinase (MAPK) in OLPs and in OLs.  In both OLPs and OLs, NT-3 sustained the activation of MAPK more than NGF.  NT-3 enhanced the proliferation of OLPs and supported the survival of OLs.  By contrast, unless coadministered with FGF-2, NGF did not exhibit mitogenic effects on OLPs but did enhance the survival or differentiated OLs.  Our data demonstrate the presence of functional trkA and trkC in developing OLs and indicate that both NGF and NT-3 have a broad spectrum of developmental actions on cells of the OL lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOnumLvXiccLVg90H21EOLACvtfcHk0lhiZGFP4ddExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1Orurw%253D&md5=1d2424f7bd37bcb9d8e6cf2049157b69</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.16-20-06433.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.16-20-06433.1996%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BI.%26aulast%3DMarmur%26aufirst%3DR.%26aulast%3DNorton%26aufirst%3DW.%2BT.%26aulast%3DMehler%26aufirst%3DM.%2BF.%26aulast%3DKessler%26aufirst%3DJ.%2BA.%26atitle%3DNerve%2520growth%2520factor%2520and%2520neurotrophin-3%2520differentially%2520regulate%2520the%2520proliferation%2520and%2520survival%2520of%2520developing%2520rat%2520brain%2520oligodendrocytes%26jtitle%3DJ.%2520Neurosci.%26date%3D1996%26volume%3D16%26spage%3D6433%26epage%3D6442%26doi%3D10.1523%2FJNEUROSCI.16-20-06433.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebendal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbany, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, H.</span></span> <span> </span><span class="NLM_article-title">Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(92)90413-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2892%2990413-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1314703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK38XisVyltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1992&pages=329-341&author=C.+F.+Ibanezauthor=T.+Ebendalauthor=G.+Barbanyauthor=J.+Murray-Rustauthor=T.+L.+Blundellauthor=H.+Persson&title=Disruption+of+the+low+affinity+receptor-binding+site+in+NGF+allows+neuronal+survival+and+differentiation+by+binding+to+the+trk+gene+product&doi=10.1016%2F0092-8674%2892%2990413-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product</span></div><div class="casAuthors">Ibanez, Carlos F.; Ebendal, Ted; Barbany, Gisela; Murray-Rust, Judith; Blundell, Tom L.; Persson, Haakan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-41</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Nerve growth factor (NGF), like many other growth factors and hormones, binds to two different receptor mols. on responsive cells.  The product of the proto-oncogene trk, p140trk, is a tyrosine kinase receptor that has been identified as a single-transducing receptor for NGF, while the role of the low affinity NGF receptor, p75NGFR, in signal transduction is less clear.  The crystal structure NGF has recently been detd., although structures involved in receptor binding and biol. activity are unknown.  Here it is shown that Lys-32, Lys-34, and Lys-95 form a pos. charged interface involved in binding to p75NGFR.  Simultaneous modification of Lys-32 with either of the two other lysines resulted in loss of binding to p75NGFR.  Despite the lack of binding to p75NGFR, these mutants retained binding to p140trk and biol. activity, demonstrating a functional dissocn. between the two NGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwSfq0fFSwybVg90H21EOLACvtfcHk0lhiZGFP4ddExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVyltbc%253D&md5=f93630f51f55697033df8f5f94772884</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2892%2990413-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252892%252990413-7%26sid%3Dliteratum%253Aachs%26aulast%3DIbanez%26aufirst%3DC.%2BF.%26aulast%3DEbendal%26aufirst%3DT.%26aulast%3DBarbany%26aufirst%3DG.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DPersson%26aufirst%3DH.%26atitle%3DDisruption%2520of%2520the%2520low%2520affinity%2520receptor-binding%2520site%2520in%2520NGF%2520allows%2520neuronal%2520survival%2520and%2520differentiation%2520by%2520binding%2520to%2520the%2520trk%2520gene%2520product%26jtitle%3DCell%26date%3D1992%26volume%3D69%26spage%3D329%26epage%3D341%26doi%3D10.1016%2F0092-8674%2892%2990413-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavenius, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gestblom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahlman, S.</span></span> <span> </span><span class="NLM_article-title">Transfection of Trk-a into human neuroblastoma-cells restores their ability to differentiate in response to nerve growth-factor</span>. <i>Cell Growth Differ.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7669728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1amsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1995&pages=727-736&author=E.+Laveniusauthor=C.+Gestblomauthor=I.+Johanssonauthor=E.+Nanbergauthor=S.+Pahlman&title=Transfection+of+Trk-a+into+human+neuroblastoma-cells+restores+their+ability+to+differentiate+in+response+to+nerve+growth-factor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor</span></div><div class="casAuthors">Lavenius, Erik; Gestblom, Carolina; Johansson, Irja; Naanberg, Eewa; Paahlman, Sven</div><div class="citationInfo"><span class="NLM_cas:title">Cell Growth & Differentiation</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-36</span>CODEN:
                <span class="NLM_cas:coden">CGDIE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-9523</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Human neuroblastoma cell lines frequently express the TRK-A proto-oncogene and bind nerve growth factor (NGF) but do not differentiate when exposed to NGF.  Transient transfection of an exogenous TRK-A gene into SH-SY5Y and LA-N-5 neuroblastoma cells restored the ability of these tumor cells to differentiate with NGF.  Stable TRK-A-transfected SH-SY5Y cell clones were isolated, and they responded to NGF by autophosphorylation of p140trk-A, c-fos induction, morphol. differentiation, and increased expression of two neuronal marker genes, neuropeptide tyrosine and GAP-43.  In phorbol ester-induced differentiated wild-type cells, TRK-A expression was increased with no change in NGF responsiveness.  Thus, the restoration of the NGF-induced differentiation pathway by exogenous TRK-A presents a system of NGF-responsive human cultured cells and focuses attention on the trk-A protein and its function or malfunction in neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp88QfC8g6tO7Vg90H21EOLACvtfcHk0lhiZGFP4ddExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1amsrY%253D&md5=86376b5d0d2690ca256d2a937653c3b8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLavenius%26aufirst%3DE.%26aulast%3DGestblom%26aufirst%3DC.%26aulast%3DJohansson%26aufirst%3DI.%26aulast%3DNanberg%26aufirst%3DE.%26aulast%3DPahlman%26aufirst%3DS.%26atitle%3DTransfection%2520of%2520Trk-a%2520into%2520human%2520neuroblastoma-cells%2520restores%2520their%2520ability%2520to%2520differentiate%2520in%2520response%2520to%2520nerve%2520growth-factor%26jtitle%3DCell%2520Growth%2520Differ.%26date%3D1995%26volume%3D6%26spage%3D727%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. V.</span></span> <span> </span><span class="NLM_article-title">Neurotrophins and their receptors: a convergence point for many signalling pathways</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1038/nrn1078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrn1078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12671646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFWqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=299-309&author=M.+V.+Chao&title=Neurotrophins+and+their+receptors%3A+a+convergence+point+for+many+signalling+pathways&doi=10.1038%2Fnrn1078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotrophins and their receptors: A convergence point for many signalling pathways</span></div><div class="casAuthors">Chao, Moses V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The neurotrophins are a family of proteins that are essential for the development of the vertebrate nervous system.  Each neurotrophin can signal through two different types of cell surface receptor - the Trk receptor tyrosine kinases and the p75 neurotrophin receptor.  Given the wide range of activities that are now assocd. with neurotrophins, it is probable that addnl. regulatory events and signaling systems are involved.  Here, the author reviews recent findings that neurotrophins, in addn. to promoting survival and differentiation, exert various effects through surprising interactions with other receptors and ion channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzyi5WZRP_drVg90H21EOLACvtfcHk0ljhXrE1QaHD2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFWqtLw%253D&md5=8aefc951eb990e6923ac657dba2e725d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrn1078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1078%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DM.%2BV.%26atitle%3DNeurotrophins%2520and%2520their%2520receptors%253A%2520a%2520convergence%2520point%2520for%2520many%2520signalling%2520pathways%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D4%26spage%3D299%26epage%3D309%26doi%3D10.1038%2Fnrn1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bapat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostetter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span> <span> </span><span class="NLM_article-title">Perineural invasion and associated pain in pancreatic cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1038/nrc3131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrc3131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21941281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=695-707&author=A.+A.+Bapatauthor=G.+Hostetterauthor=D.+D.+Von+Hoffauthor=H.+Han&title=Perineural+invasion+and+associated+pain+in+pancreatic+cancer&doi=10.1038%2Fnrc3131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Perineural invasion and associated pain in pancreatic cancer</span></div><div class="casAuthors">Bapat, Aditi A.; Hostetter, Galen; Von Hoff, Daniel D.; Han, Hai-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">695-707</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Perineural invasion (PNI) is a prominent characteristic of pancreatic cancer.  PNI is a process whereby cancer cells invade the surrounding nerves, thus providing an alternative route for metastatic spread and pain generation.  PNI is thought to be an indicator of aggressive tumor behavior and has been shown to correlate with poor prognosis of patients with pancreatic cancer.  Recent studies demonstrated that some signalling mols. and pathways that are involved in PNI are also involved in pain generation.  Targeting these signalling pathways has shown some promise in alleviating pain and reducing PNI, which could potentially improve treatment outcomes for patients with pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfmb_ZatxfE7Vg90H21EOLACvtfcHk0ljhXrE1QaHD2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajurjM&md5=b66fe422a5c7a543bbc14524f5d35a89</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc3131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3131%26sid%3Dliteratum%253Aachs%26aulast%3DBapat%26aufirst%3DA.%2BA.%26aulast%3DHostetter%26aufirst%3DG.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DHan%26aufirst%3DH.%26atitle%3DPerineural%2520invasion%2520and%2520associated%2520pain%2520in%2520pancreatic%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D695%26epage%3D707%26doi%3D10.1038%2Fnrc3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miknyoczki, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchkovich, K.</span></span> <span> </span><span class="NLM_article-title">The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1924</span>– <span class="NLM_lpage">1931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12060637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Crurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1924-1931&author=S.+J.+Miknyoczkiauthor=W.+Wanauthor=H.+Changauthor=P.+Dobrzanskiauthor=B.+A.+Ruggeriauthor=C.+A.+Dionneauthor=K.+Buchkovich&title=The+neurotrophin-trk+receptor+axes+are+critical+for+the+growth+and+progression+of+human+prostatic+carcinoma+and+pancreatic+ductal+adenocarcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophin-Trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice</span></div><div class="casAuthors">Miknyoczki, Sheila J.; Wan, Weihua; Chang, Hong; Dobrazanski, Pawel; Ruggeri, Bruce A.; Dionne, Craig A.; Buchkovich, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1924-1931</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant expression of trk receptor kinases and enhanced expression of various neurotrophins (NTs) have been implicated in the development and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma.  We examd. the antitumor efficacy of administration of NT neutralizing antibodies on the growth of established human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.  In initial studies, tumor-bearing nude mice were treated with a mixt. of NT antibodies [100 μg each of anti-nerve growth factor (NGF), anti-brain-derived neurotrophic factor, anti-NT-3, and anti-NT-4/5] or normal rabbit IgG (400 μg) intratumorally and peritumorally three times/wk over a 15-day dosing period.  In subsequent studies, tumor-bearing nude mice were treated with individual NT antibodies (100 μg), affinity-purified antiNGF (0.1, 1.0, or 10.0 μg), or normal rabbit IgG (100 μg) using the same dosing schedule.  Treatment with the antibody mixt. inhibited significantly the growth of TSU-Pr1 and AsPC-1 xenografts as compared with IgG-treated controls (maximal inhibition of 53 and 53%, resp.), whereas this treatment caused significant regression in PC-3 xenografts.  Treatment of TSU-Pr1 xenografts with either anti-NGF or anti-NT-3 resulted in maximal tumor growth inhibition of 67 and 64%, resp., whereas anti-brain-derived neurotrophic factor and anti-NT-4/5 did not inhibit tumor growth in this tumor model.  Administration of various concns. (0.1, 1.0, or 10.0 μg) of affinity-purified anti-NGF resulted in maximal TSU-Pr1 tumor growth inhibition of 49, 62, and 66%, resp.  These data add further support for the therapeutic potential of disrupting trk-signaling; events in select types of nonneuronal human cancers, specifically prostatic and pancreatic carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-AePr6eQAhrVg90H21EOLACvtfcHk0ljhXrE1QaHD2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Crurk%253D&md5=3032fa3c58ef1986ecbd548b165a5111</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DBuchkovich%26aufirst%3DK.%26atitle%3DThe%2520neurotrophin-trk%2520receptor%2520axes%2520are%2520critical%2520for%2520the%2520growth%2520and%2520progression%2520of%2520human%2520prostatic%2520carcinoma%2520and%2520pancreatic%2520ductal%2520adenocarcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D1924%26epage%3D1931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeper, D. S.</span></span> <span> </span><span class="NLM_article-title">The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1007/s00018-005-5490-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2Fs00018-005-5490-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16568244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFWisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=755-759&author=C.+J.+Desmetauthor=D.+S.+Peeper&title=The+neurotrophic+receptor+TrkB%3A+a+drug+target+in+anti-cancer+therapy%3F&doi=10.1007%2Fs00018-005-5490-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?</span></div><div class="casAuthors">Desmet, C. J.; Peeper, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">755-759</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Increasing evidence implies altered signaling through the neurotrophic receptor tyrosine kinase TrkB in promoting tumor formation and metastasis.  TrkB, sometimes in conjunction with its primary ligand BDNF, is often overexpressed in a variety of human cancers, ranging from neuroblastomas to pancreatic ductal adenocarcinomas, in which it may allow tumor expansion and contribute to resistance to anti-tumor agents.  In vitro, TrkB acts as a potent suppressor of anoikis (detachment-induced apoptosis), which is assocd. with the acquisition of an aggressive tumorigenic and metastatic phenotype in vivo.  In view of its predicted contribution to tumorigenicity and metastasis in humans, TrkB corresponds to a potential drug target, and preclin. models have already been established.  The encouraging results of pharmacol. Trk inhibitors in tumor xenograft models suggest that TrkB inhibition may represent a promising novel anti-tumor therapeutic strategy.  This hypothesis is currently being evaluated in clin. trials.  Here, we will discuss the latest developments on TrkB in these contexts as well as highlight some crit. questions that remain to be addressed for evaluating TrkB as a therapeutic target in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjYylyi1Y6rVg90H21EOLACvtfcHk0lgLoH2gsVry2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFWisLc%253D&md5=02d9f1889ee960621d97eb6f35ddac97</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00018-005-5490-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-005-5490-8%26sid%3Dliteratum%253Aachs%26aulast%3DDesmet%26aufirst%3DC.%2BJ.%26aulast%3DPeeper%26aufirst%3DD.%2BS.%26atitle%3DThe%2520neurotrophic%2520receptor%2520TrkB%253A%2520a%2520drug%2520target%2520in%2520anti-cancer%2520therapy%253F%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2006%26volume%3D63%26spage%3D755%26epage%3D759%26doi%3D10.1007%2Fs00018-005-5490-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Growth, survival and migration: the Trk to cancer</span>. <i>Cancer Treat Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1007/0-306-48158-8_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2F0-306-48158-8_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2004&pages=1-18&author=J.+B.+Rubinauthor=R.+A.+Segal&title=Growth%2C+survival+and+migration%3A+the+Trk+to+cancer&doi=10.1007%2F0-306-48158-8_1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F0-306-48158-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-306-48158-8_1%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DJ.%2BB.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DGrowth%252C%2520survival%2520and%2520migration%253A%2520the%2520Trk%2520to%2520cancer%26jtitle%3DCancer%2520Treat%2520Res.%26date%3D2004%26volume%3D115%26spage%3D1%26epage%3D18%26doi%3D10.1007%2F0-306-48158-8_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minturn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A. E.</span></span> <span> </span><span class="NLM_article-title">Trk receptor expression and inhibition in neuroblastomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-1815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1078-0432.CCR-08-1815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19417027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3244-3250&author=G.+M.+Brodeurauthor=J.+E.+Minturnauthor=R.+Hoauthor=A.+M.+Simpsonauthor=R.+Iyerauthor=C.+R.+Varelaauthor=J.+E.+Lightauthor=V.+Kollaauthor=A.+E.+Evans&title=Trk+receptor+expression+and+inhibition+in+neuroblastomas&doi=10.1158%2F1078-0432.CCR-08-1815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Trk Receptor Expression and Inhibition in Neuroblastomas</span></div><div class="casAuthors">Brodeur, Garrett M.; Minturn, Jane E.; Ho, Ruth; Simpson, Anisha M.; Iyer, Radhika; Varela, Carly R.; Light, Jennifer E.; Kolla, Venkatadri; Evans, Audrey E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3244-3250</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Neuroblastoma, the most common and deadly solid tumor in children, exhibits heterogeneous clin. behavior, from spontaneous regression to relentless progression.  Current evidence suggests that the TRK family of neurotrophin receptors plays a crit. role in these diverse behaviors.  Neuroblastomas expressing TrkA are biol. favorable and prone to spontaneous regression or differentiation, depending on the absence or presence of its ligand (NGF) in the microenvironment.  In contrast, TrkB-expressing tumors frequently have MYCN amplification and are very aggressive and often fatal tumors.  These tumors also express the TrkB ligand (BDNF), resulting in an autocrine or paracrine survival pathway.  Exposure to BDNF promotes survival, drug resistance, and angiogenesis of TrkB-expressing tumors.  Here we review the role of Trks in normal development, the different functions of Trk isoforms, and the major Trk signaling pathways.  We also review the roles these receptors play in the heterogeneous biol. and clin. behavior of neuroblastomas, and the activation of Trk receptors in other cancers.  Finally we address the progress that has been made in developing targeted therapy with Trk-selective inhibitors to treat neuroblastomas and other tumors with activated Trk expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XUqj0KJ-GLVg90H21EOLACvtfcHk0lgLoH2gsVry2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D&md5=cb21a6625f5d8464325522fb5b87c710</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1815%26sid%3Dliteratum%253Aachs%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DMinturn%26aufirst%3DJ.%2BE.%26aulast%3DHo%26aufirst%3DR.%26aulast%3DSimpson%26aufirst%3DA.%2BM.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DVarela%26aufirst%3DC.%2BR.%26aulast%3DLight%26aufirst%3DJ.%2BE.%26aulast%3DKolla%26aufirst%3DV.%26aulast%3DEvans%26aufirst%3DA.%2BE.%26atitle%3DTrk%2520receptor%2520expression%2520and%2520inhibition%2520in%2520neuroblastomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3244%26epage%3D3250%26doi%3D10.1158%2F1078-0432.CCR-08-1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Trk kinase inhibitors as new treatments for cancer and pain</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1517/13543770902721261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1517%2F13543770902721261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19441906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=305-319&author=T.+Wangauthor=D.+Yuauthor=M.+L.+Lamb&title=Trk+kinase+inhibitors+as+new+treatments+for+cancer+and+pain&doi=10.1517%2F13543770902721261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Trk kinase inhibitors as new treatments for cancer and pain</span></div><div class="casAuthors">Wang, Tao; Yu, Dingwei; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-319</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins.  Trks play important roles in pain sensation as well as tumor cell growth and survival signaling.  Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.  Objective: This paper reviews those patent applications since 2002 claiming small-mol. inhibitors of Trk receptor kinases.  Methods: Primary literature and patents were searched with SciFinder and Google Scholar.  Patents were selected based on their relevance to Trks and were evaluated and representative compds. were listed as examples.  Results/conclusion: Several series of Trk inhibitors with excellent in vitro potencies have been reported and a no. of compds. have gone into the clinic.  It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvknvXUUz2DbVg90H21EOLACvtfcHk0limR31ZvubXCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D&md5=ffc2d3e33102631cac7b89dce7f96a5a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F13543770902721261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770902721261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTrk%2520kinase%2520inhibitors%2520as%2520new%2520treatments%2520for%2520cancer%2520and%2520pain%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D305%26epage%3D319%26doi%3D10.1517%2F13543770902721261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weeraratna, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miknyoczki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span> <span> </span><span class="NLM_article-title">Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11489797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsVOmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2237-2245&author=A.+T.+Weeraratnaauthor=S.+L.+Dalrympleauthor=J.+C.+Lambauthor=S.+R.+Denmeadeauthor=S.+Miknyoczkiauthor=C.+A.+Dionneauthor=J.+T.+Isaacs&title=Pan-trk+inhibition+decreases+metastasis+and+enhances+host+survival+in+experimental+models+as+a+result+of+its+selective+induction+of+apoptosis+of+prostate+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells</span></div><div class="casAuthors">Weeraratna, Ashani T.; Dalrymple, Susan L.; Lamb, John C.; Denmeade, Samuel R.; Miknyoczki, Sheila; Dionne, Craig A.; Isaacs, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2237-2245</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">During the progression of prostate cancer, mol. changes occur resulting in the autocrine prodn. of a series of neurotrophins by the malignant cells.  This is coupled with expression of high-affinity cognate receptors for these ligands, termed trk receptors, by these cancer cells.  The binding of the neurotrophins to their trk receptors activates the receptor latent tyrosine kinase activity inducing a series of signal transduction pathways within these prostate cancer cells.  These mol. changes result in the acquisition by prostate cancer cells of a restricted requirement for these trk signaling pathways for optimal survival.  CEP-701 is an indolocarbazole compd. specifically designed as a potent inhibitor (IC50, 4 nM) of the tyrosine kinase activity of the trk receptors required for initiation of these survival pathways.  In the present studies, the consequences of CEP-701 inhibition of these trk signaling survival pathways were tested in vivo using both rat (R3327 AT 6.3 and H) and human (TSU-pr1 and CWR-22Rv1) prostatic cancer models.  These in vivo studies demonstrated that treatment with CEP-701 inhibits the growth of both rodent and human prostate cancers, without being toxic to the normal tissue including the host prostate.  Because of this selective effect, CEP-701 inhibits metastasis and growth of both primary and metastatic sites of prostate cancer.  Based upon this profile, long-term survival studies were performed using the slow-growing Dunning H rat prostate cancer model.  For these latter studies, the dosing regimen was 10 mg CEP-701/kg/dose twice a day via gavage 5 days a week.  This regimen maintains CEP-701 tumor tissue concns. of 25-50 nM.  Such chronic dosing increased (P < 0.001) the median survival of rats bearing the slow growing H prostate cancers from 408 days (395-432 days, 95% confidence interval) for the vehicle group (n = 18) to 566 days (497-598 days, 95% confidence interval) for the CEP-701-treated group (n = 24).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0P697XWQs_bVg90H21EOLACvtfcHk0limR31ZvubXCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsVOmtrw%253D&md5=4458b949ee63142d57c0c72632915a7d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeeraratna%26aufirst%3DA.%2BT.%26aulast%3DDalrymple%26aufirst%3DS.%2BL.%26aulast%3DLamb%26aufirst%3DJ.%2BC.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26atitle%3DPan-trk%2520inhibition%2520decreases%2520metastasis%2520and%2520enhances%2520host%2520survival%2520in%2520experimental%2520models%2520as%2520a%2520result%2520of%2520its%2520selective%2520induction%2520of%2520apoptosis%2520of%2520prostate%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2237%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weeraratna, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span> <span> </span><span class="NLM_article-title">Rational basis for Trk inhibition therapy for prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11027413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsFGisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2000&pages=140-148&author=A.+T.+Weeraratnaauthor=J.+T.+Arnoldauthor=D.+J.+Georgeauthor=A.+DeMarzoauthor=J.+T.+Isaacs&title=Rational+basis+for+Trk+inhibition+therapy+for+prostate+cancer&doi=10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rational basis for trk inhibition therapy for prostate cancer</span></div><div class="casAuthors">Weeraratna, Ashani T.; Arnold, Julia T.; George, Dan J.; DeMarzo, Angelo; Isaacs, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-148</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Prostatic cancer cells are lethal because they acquire the ability to activate survival pathways that do not require androgenic stimulation.  As a rational approach to developing effective therapy for these devastating cells, specific signal transduction pathways uniquely required for the survival of these nonandrogen-dependent prostate cancer cells must be identified.  Previous studies suggested that the neurotrophin/trk signal transduction axis may regulate such unique survival pathways.  In the present study, the changes in expression of the neurotrophins (NGF, BDNF, and NT-3) and their cognate receptors (i.e., trk and p75NTR) during the progression of normal prostatic epithelial cells to malignancy were documented.  Addnl., the consequences of inhibiting these trk signaling pathways on the in vitro survival of prostate cancer cells was tested.  Immunocytochem., RT-PCR, and ELISA assays were used to characterize the changes in the neurotrophin ligands (i.e., NGF, BDNF, and NT-3) and their cognate high-affinity (i.e., trk A, B, and C) and low-affinity neurotrophin (i.e., p75 NTR) receptors in normal vs. malignant human prostatic tissues.  CEP-751 is an indolocarbazole compd. specifically designed to inhibit the initiation of these neurotrophin/trk signal transductions.  The consequence of CEP-751 inhibition of trk signaling for in vitro clonogenic survival of a series of human prostatic cancer lines was also tested.  These studies demonstrated that normal prostatic tissue from patients without prostate cancer contains substantial levels of nerve growth factor (NGF), which is produced in a paracrine manner by stromal cells.  These stromal cells lack both trk and p75NTR receptors.  In contrast, normal prostatic epithelial cells from patients without prostate cancer do not secrete detectable levels of neurotrophins, but do express trk A and p75 NTR.  While the NGF/trkA/p75 NTR axis is present in the normal prostate, normal prostatic epithelial cells do not depend on this axis for their survival.  In contrast, malignant prostate epithelial cells directly secrete a series of neurotrophins (i.e., NGF, BDNF, and/or NT-3) and express at least one if not more of the trk receptor proteins (i.e., trk A, B, and/or C), while no longer expressing the p75NTR receptors.  In addn., inhibition of autocrine trk signaling via CEP-751 treatment induces the apoptotic death of these malignant cells.  Prostate carcinogenesis involves mol. changes leading to the paracrine and/or autocrine prodn. of a series of neurotrophins.  This is coupled to the ectopic expression of trk B and trk C, as well as to the continued expression of trk A, and the loss of expression of p75NTR receptors.  These changes result in the acquisition by malignant prostate cells of a unique requirement for trk signaling pathways for survival.  Based on these findings, trk inhibition is a novel, rational approach for prostate cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UOauVsgym7Vg90H21EOLACvtfcHk0ljfzXqHyCrSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsFGisrk%253D&md5=8d63f443c04004fb615dce89f1c3d91a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0045%252820001001%252945%253A2%253C140%253A%253AAID-PROS8%253E3.0.CO%253B2-%2523%26sid%3Dliteratum%253Aachs%26aulast%3DWeeraratna%26aufirst%3DA.%2BT.%26aulast%3DArnold%26aufirst%3DJ.%2BT.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26aulast%3DDeMarzo%26aufirst%3DA.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26atitle%3DRational%2520basis%2520for%2520Trk%2520inhibition%2520therapy%2520for%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2000%26volume%3D45%26spage%3D140%26epage%3D148%26doi%3D10.1002%2F1097-0045%2820001001%2945%3A2%3C140%3A%3AAID-PROS8%3E3.0.CO%3B2-%23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, A. E.</span></span> <span> </span><span class="NLM_article-title">On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5962</span>– <span class="NLM_lpage">5967</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1078-0432.CCR-08-0651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19755385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5962-5967&author=C.+J.+Thieleauthor=Z.+Liauthor=A.+E.+McKee&title=On+Trk%2D%2Dthe+TrkB+signal+transduction+pathway+is+an+increasingly+important+target+in+cancer+biology&doi=10.1158%2F1078-0432.CCR-08-0651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">On Trk-The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology</span></div><div class="casAuthors">Thiele, Carol J.; Li, Zhijie; McKee, Amy E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5962-5967</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  In the beginning, Trk was an oncogene.  Yet Neurotrophin-Trk signaling came to preeminence in the field of neurobiol.  Now it is appreciated that Trks regulate important processes in nonneuronal cells and, in addn. to their impact on tumors of neural origin, may contribute to the pathogenesis of carcinomas, myelomas, and prostate and lymphoid tumors.  Although mutations and rearrangements of Trk are seen only sporadically in human cancers, such as medullary thyroid carcinoma, a no. of recent studies indicate that expression of TrkB contributes to tumor pathol.  In neuroblastoma, TrkA expression marks good prognosis which TrkB and Brain-derived neurotrophic factor (BDNF) expression marks poor prognosis.  Activation of the BDNF/TrkB signal transduction pathway also stimulates tumor cell survival and angiogenesis and contributes to resistance to cytotoxic drugs and anoikis, enabling cells to acquire many of the characteristic features required for tumorigenesis.  Small mol. inhibitors, such as Cephalon's CEP-701, are in phase 1 and 2 clin. trials, and a series of AstraZeneca Trk inhibitors are poised to enter the clinic.  As monotherapy, inhibitors may be effective only in tumors with activating Trk mutations.  Important clin. follow-up will be the assessment of Trk inhibitors in combination with std. chemo- or radiotherapy or other signal transduction pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8u_7H2PK8S7Vg90H21EOLACvtfcHk0ljfzXqHyCrSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltbnI&md5=7e3f0c917b803215734a3231ee5271a9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0651%26sid%3Dliteratum%253Aachs%26aulast%3DThiele%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMcKee%26aufirst%3DA.%2BE.%26atitle%3DOn%2520Trk--the%2520TrkB%2520signal%2520transduction%2520pathway%2520is%2520an%2520increasingly%2520important%2520target%2520in%2520cancer%2520biology%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5962%26epage%3D5967%26doi%3D10.1158%2F1078-0432.CCR-08-0651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petrocellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span> <span> </span><span class="NLM_article-title">Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1210/endo.141.1.7239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1210%2Fendo.141.1.7239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10614630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslCj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2000&pages=118-126&author=D.+Melckauthor=L.+De+Petrocellisauthor=P.+Orlandoauthor=T.+Bisognoauthor=C.+Laezzaauthor=M.+Bifulcoauthor=V.+Di+Marzo&title=Suppression+of+nerve+growth+factor+Trk+receptors+and+prolactin+receptors+by+endocannabinoids+leads+to+inhibition+of+human+breast+and+prostate+cancer+cell+proliferation&doi=10.1210%2Fendo.141.1.7239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation</span></div><div class="casAuthors">Melck, Dominique; De Petrocellis, Luciano; Orlando, Pierangelo; Bisogno, Tiziana; Laezza, Chiara; Bifulco, Maurizio; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-126</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr).  Here the authors report that (1) anandamide and 2-AG inhibit the nerve growth factor (NGF)-induced proliferation of HBCCs through suppression of the levels of NGF Trk receptors; (2) inhibition of PRLr levels results in inhibition of the proliferation of other PRL-responsive cells, the prostate cancer DU-145 cell line; and (3) CB1-like cannabinoid receptors are expressed in HBCCs and DU-145 cells and mediate the inhibition of cell proliferation and Trk/PRLr expression.  β-NGF-induced HBCC proliferation was potently inhibited (IC50 = 50-600 nM) by the synthetic cannabinoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but not by the anandamide congener, palmitoylethanolamide, or the selective agonist of CB2 cannabinoid receptors, BML-190.  The effect of anandamide was blocked by the CB1 receptor antagonist, SR141716A, but not by the CB2 receptor antagonist, SR144528.  Anandamide and HU-210 exerted a strong inhibition of the levels of NGF Trk receptors as detected by Western immunoblotting; this effect was reversed by SR141716A.  When induced by exogenous PRL, the proliferation of prostate DU-145 cells was potently inhibited (IC50 = 100-300 nM) by anandamide, 2-AG, and HU-210.  Anandamide also down-regulated the levels of PRLr in DU-145 cells.  SR141716A attenuated these two effects of anandamide.  HBCCs and DU-145 cells were shown to contain (1) transcripts for CB1 and, to a lesser extent, CB2 cannabinoid receptors, (2) specific binding sites for [3H]SR141716A that could be displaced by anandamide, and (3) a CB1 receptor-immunoreactive protein.  These findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential neg. effectors of PRL- and NGF-induced biol. responses, at least in some cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNwzwH2Pc55bVg90H21EOLACvtfcHk0ljfzXqHyCrSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslCj&md5=14d3446530519dbddaee9e1071b7a76f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1210%2Fendo.141.1.7239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.141.1.7239%26sid%3Dliteratum%253Aachs%26aulast%3DMelck%26aufirst%3DD.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26aulast%3DOrlando%26aufirst%3DP.%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DSuppression%2520of%2520nerve%2520growth%2520factor%2520Trk%2520receptors%2520and%2520prolactin%2520receptors%2520by%2520endocannabinoids%2520leads%2520to%2520inhibition%2520of%2520human%2520breast%2520and%2520prostate%2520cancer%2520cell%2520proliferation%26jtitle%3DEndocrinology%26date%3D2000%26volume%3D141%26spage%3D118%26epage%3D126%26doi%3D10.1210%2Fendo.141.1.7239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawara, A.</span></span> <span> </span><span class="NLM_article-title">Trk receptor tyrosine kinases: A bridge between cancer and neural development</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/S0304-3835(01)00530-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0304-3835%2801%2900530-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11431098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Onu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2001&pages=107-114&author=A.+Nakagawara&title=Trk+receptor+tyrosine+kinases%3A+A+bridge+between+cancer+and+neural+development&doi=10.1016%2FS0304-3835%2801%2900530-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptor tyrosine kinases: A bridge between cancer and neural development</span></div><div class="casAuthors">Nakagawara, A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 40 refs.  The proto-oncogene Trks encode the high-affinity receptor tyrosine kinases for neurotrophins of a nerve growth factor (NGF) family.  The Trk signals spatiotemporally regulate neural development and maintenance of neural network.  However, Trk was originally cloned as an oncogene fused with the tropomyosin gene in the extracellular domain.  Accumulating evidence has demonstrated that the rearranged Trk oncogene is often obsd. in non-neuronal neoplasms such as colon and papillary thyroid cancers, while the signals through the receptors encoded by the proto-oncogene Trks regulate growth, differentiation and apoptosis of the tumors with neuronal origin such as neuroblastoma and medulloblastoma.  The intracellular Trk signaling pathway is also different depending on the Trk family receptors, cell types and the grade of transformation.  Furthermore, developmentally programmed cell death of neuron, which is largely regulated by neurotrophin signaling, is at least in part controlled by tumor suppressors p53 and p73 as well as their antagonist ΔNp73.  Thus, the Trks and their downstream signaling function in both ontogenesis and oncogenesis.  In this short review, the dynamic role of the Trk family receptors signaling in neural development, neurogenic tumors and other cancers will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHWRClrjDaErVg90H21EOLACvtfcHk0ljfzXqHyCrSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Onu7Y%253D&md5=c02ab60eb9ff9c18d0708ee5b064d45e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0304-3835%2801%2900530-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3835%252801%252900530-4%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawara%26aufirst%3DA.%26atitle%3DTrk%2520receptor%2520tyrosine%2520kinases%253A%2520A%2520bridge%2520between%2520cancer%2520and%2520neural%2520development%26jtitle%3DCancer%2520Lett.%26date%3D2001%26volume%3D169%26spage%3D107%26epage%3D114%26doi%3D10.1016%2FS0304-3835%2801%2900530-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edakuni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasatomi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, K.</span></span> <span> </span><span class="NLM_article-title">Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.3892/or.8.3.477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3892%2For.8.3.477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11295066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=477-484&author=Y.+Sakamotoauthor=Y.+Kitajimaauthor=G.+Edakuniauthor=E.+Sasatomiauthor=M.+Moriauthor=K.+Kitaharaauthor=K.+Miyazaki&title=Expression+of+Trk+tyrosine+kinase+receptor+is+a+biologic+marker+for+cell+proliferation+and+perineural+invasion+of+human+pancreatic+ductal+adenocarcinoma&doi=10.3892%2For.8.3.477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Sakamoto, Yuichiro; Kitajima, Yoshihiko; Edakuni, Genichiro; Sasatomi, Eizaburo; Mori, Michito; Kitahara, Kenji; Miyazaki, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-484</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is a widely known severe malignancy with a poor prognosis.  Perineural invasion extending to the extra-pancreatic nerve plexus, a significant concern in the treatment is frequently present in this cancer.  We analyzed immunohistochem. expression of neurotrophins (NGF, BDNF, NT-3) and the cognate receptors, Trk tyrosine kinase receptor family (TrkA, B, C) and p75NGFR in 28 surgically resected PDAC specimens.  A comparative study between several clinico-pathol. factors and Trk receptors revealed a significant correlation between increased expression of TrkA and cancer proliferation, as well as TrkC and cancer invasion, including venous and perineural invasion.  The present findings revealed a novel mechanism in PDAC progression that is mediated via a NTs-Trk interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbjgctwxB0yrVg90H21EOLACvtfcHk0lhMguh0j0wIbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVSitrs%253D&md5=6c76c1e851cc29c1ad50c7c89ade6955</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3892%2For.8.3.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.8.3.477%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DY.%26aulast%3DKitajima%26aufirst%3DY.%26aulast%3DEdakuni%26aufirst%3DG.%26aulast%3DSasatomi%26aufirst%3DE.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKitahara%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DK.%26atitle%3DExpression%2520of%2520Trk%2520tyrosine%2520kinase%2520receptor%2520is%2520a%2520biologic%2520marker%2520for%2520cell%2520proliferation%2520and%2520perineural%2520invasion%2520of%2520human%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2001%26volume%3D8%26spage%3D477%26epage%3D484%26doi%3D10.3892%2For.8.3.477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Standop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friess, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andren-Sandberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pour, P. M.</span></span> <span> </span><span class="NLM_article-title">Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1210</span>, <span class="refDoi"> DOI: 10.1177/002215540104901002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1177%2F002215540104901002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11561004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFSqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=1205-1210&author=M.+B.+Schneiderauthor=J.+Standopauthor=A.+Ulrichauthor=U.+Wittelauthor=H.+Friessauthor=A.+Andren-Sandbergauthor=P.+M.+Pour&title=Expression+of+nerve+growth+factors+in+pancreatic+neural+tissue+and+pancreatic+cancer&doi=10.1177%2F002215540104901002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer</span></div><div class="casAuthors">Schneider, Matthias B.; Standop, Jens; Ulrich, Alexis; Wittel, Uwe; Friess, Helmut; Andren-Sandberg, Ake; Pour, Parviz M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1205-1210</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">One of the characteristics of pancreatic cancer is its tendency to invade neural tissue.  We hypothesized that the affinity of cancer cells for nerve tissue is related to the presence of growth factors in neural tissue and their receptors in cancer cells.  Sections of pancreatic cancer and normal pancreatic tissue were examd. by immunohistochem. for the expression of the neurotrophins NGF, BDNF, NT-3, NT-4, and their receptors TrkA, TrkB, and TrkC, as well as the low-affinity receptor, p75NTR.  TrkA expression was found in duct, islet, and cancer cells; TrkB was found in the α-cells of the islet only.  The anti-pan-Trk antibody (TrkB3), which is presumed to recognize all three receptors, immunoreacted with duct and acinar cells in normal tissue and with cancer cells.  The staining with TrkC was similar to that of TrkA.  The low-affinity receptor p75NTR was expressed in the neural tissue and in scattered duct cells of the normal tissue only.  Duct and acinar cells, as well as neural tissue and cancer cells, showed weak to strong immunoreactivity with NGF.  NT-3 expression was noted in capillary endothelia and erythrocytes.  NT-4 showed specific staining for ductule cells.  The expression and distribution of neurotrophins and their receptors suggest their role in the potential of pancreatic cancer cells for neural invasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPSyuQpq0sW7Vg90H21EOLACvtfcHk0lhMguh0j0wIbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFSqtrk%253D&md5=5f600dbef4456c54ccdfe021fdc129af</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1177%2F002215540104901002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F002215540104901002%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DM.%2BB.%26aulast%3DStandop%26aufirst%3DJ.%26aulast%3DUlrich%26aufirst%3DA.%26aulast%3DWittel%26aufirst%3DU.%26aulast%3DFriess%26aufirst%3DH.%26aulast%3DAndren-Sandberg%26aufirst%3DA.%26aulast%3DPour%26aufirst%3DP.%2BM.%26atitle%3DExpression%2520of%2520nerve%2520growth%2520factors%2520in%2520pancreatic%2520neural%2520tissue%2520and%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2001%26volume%3D49%26spage%3D1205%26epage%3D1210%26doi%3D10.1177%2F002215540104901002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCune, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romans, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkin, B. D.</span></span> <span> </span><span class="NLM_article-title">Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4545</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.8.4540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.96.8.4540" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=4540-4545&author=L.+M.+McGregorauthor=B.+K.+McCuneauthor=J.+R.+Graffauthor=P.+R.+McDowellauthor=K.+E.+Romansauthor=G.+D.+Yancopoulosauthor=D.+W.+Ballauthor=S.+B.+Baylinauthor=B.+D.+Nelkin&title=Roles+of+trk+family+neurotrophin+receptors+in+medullary+thyroid+carcinoma+development+and+progression&doi=10.1073%2Fpnas.96.8.4540"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.8.4540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.8.4540%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DMcCune%26aufirst%3DB.%2BK.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DMcDowell%26aufirst%3DP.%2BR.%26aulast%3DRomans%26aufirst%3DK.%2BE.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DBall%26aufirst%3DD.%2BW.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DNelkin%26aufirst%3DB.%2BD.%26atitle%3DRoles%2520of%2520trk%2520family%2520neurotrophin%2520receptors%2520in%2520medullary%2520thyroid%2520carcinoma%2520development%2520and%2520progression%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D4540%26epage%3D4545%26doi%3D10.1073%2Fpnas.96.8.4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sclabas, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, P. J.</span></span> <span> </span><span class="NLM_article-title">Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15701826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=440-449&author=G.+M.+Sclabasauthor=S.+Fujiokaauthor=C.+Schmidtauthor=Z.+Liauthor=W.+A.+Frederickauthor=W.+Yangauthor=K.+Yokoiauthor=D.+B.+Evansauthor=J.+L.+Abbruzzeseauthor=K.+R.+Hessauthor=W.+Zhangauthor=I.+J.+Fidlerauthor=P.+J.+Chiao&title=Overexpression+of+tropomysin-related+kinase+B+in+metastatic+human+pancreatic+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells</span></div><div class="casAuthors">Sclabas, Guido M.; Fujioka, Shuichi; Schmidt, Christian; Li, Zhongkui; Frederick, Wayne A. I.; Yang, Wentao; Yokoi, Kenji; Evans, Douglas B.; Abbruzzese, James L.; Hess, Kenneth R.; Zhang, Wei; Fidler, Isaiah J.; Chiao, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">440-449</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pancreatic adenocarcinoma is currently the fourth leading cause of cancer death in the United States, and most pancreatic cancers develop locally advanced disease or metastasis at the time of diagnosis.  The mechanisms by which it invades and metastasizes are not known.  To identify the genes involved in pancreatic cancer metastasis, we analyzed the gene expression profiles between highly metastatic Colo357L3.6pl and parental Colo357FG pancreatic cancer cell lines using cDNA microarrays and confirmed differential gene expression by reverse transcription-PCR, Western blotting, and immunol. anal. of 54 samples from pancreatic cancer patients.  The correlation with clin. outcome was also examd.  The possible signaling pathways involved with tropomyosin-related kinase B (TrkB) were analyzed.  Our findings showed that TrkB was overexpressed in the highly metastatic Colo357L3.6pl cells, which correlated with perineural invasion (P = 0.026), pos. retroperitoneal margin (P = 0.0005), and shorter latency to development of liver metastasis (Cox proportional hazard ratio, 0.3; 95% confidence interval, 0.1-0.8; P = 0.01) in patient samples.  Extracellular signal-regulated kinases 1 and 2 were activated and Elk-1 and AP-1 DNA binding activity was induced in Colo357L3.6pl cells.  Furthermore, interleukin 8 and vascular endothelial growth factor were more strongly expressed in Colo357L3.6pl than Colo357FG cells, and these findings were confirmed in Colo357L3.6pl and Colo357FG orthotopic tumors.  These results suggest that overexpression of TrkB and activation of mitogen-activated protein kinase and AP-1, which may in turn induce the expression of vascular endothelial growth factor and interleukin 8, may mediate the cardinal clin. features of locally aggressive growth and metastasis of pancreatic cancer.  Our results also imply that TrkB receptor may be a novel therapeutic target for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw13VKIBfliLVg90H21EOLACvtfcHk0lj5pegJQT5z4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWgtrg%253D&md5=5412f2a642835410bee82aecf302ba21</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSclabas%26aufirst%3DG.%2BM.%26aulast%3DFujioka%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFrederick%26aufirst%3DW.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DEvans%26aufirst%3DD.%2BB.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHess%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26aulast%3DChiao%26aufirst%3DP.%2BJ.%26atitle%3DOverexpression%2520of%2520tropomysin-related%2520kinase%2520B%2520in%2520metastatic%2520human%2520pancreatic%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D440%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, S.</span></span> <span> </span><span class="NLM_article-title">Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2001.tb01077.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1111%2Fj.1349-7006.2001.tb01077.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11223544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis1KgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2001&pages=152-160&author=T.+Sugimotoauthor=H.+Kurodaauthor=Y.+Horiiauthor=H.+Moritakeauthor=T.+Tanakaauthor=S.+Hattori&title=Signal+transduction+pathways+through+TRK-A+and+TRK-B+receptors+in+human+neuroblastoma+cells&doi=10.1111%2Fj.1349-7006.2001.tb01077.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells</span></div><div class="casAuthors">Sugimoto, Tohru; Kuroda, Hiroshi; Horii, Yoshihiro; Moritake, Hiroshi; Tanaka, Takeo; Hattori, Seisuke</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-160</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Little is known about the signal transduction pathways of TRK family receptors in neuroblastoma (NB) cells.  In this study, an NB cell line, designated MP-N-TS, was established from an adrenal tumor taken from a 2-yr-old boy.  This cell line expressed both TRK-A and TRK-B receptors, which is rare in a single NB cell line.  Therefore, the MP-N-TS cell line was used to det. whether the signal transduction through these constitutive receptors is functional.  Three neurotrophins, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), induced tyrosine phosphorylation of panTRK, and BDNF and NT-4/5 induced tyrosine phosphorylation of TRK-B.  Tyrosine phosphorylation of pan TRK and/or TRK-B by the neurotrophins was inhibited in the presence of a tyrosine kinase inhibitor K252a.  Tyrosine phosphorylation of Src homologous and collagen (Shc), extracellular signal-regulated kinase (ERK)-1 and ERK-2, and phospholipase C-γ1 (PLC-γ1) was increased by the three neurotrophins and the increase was inhibited in the presence of K252a.  Activation of Ras, detected as the GTP-bound form of Ras, was induced by the three neurotrophins.  The neurotrophins did not modulate the expressions of TRK-A or TRK-B mRNA, but they did induce the expression of c-fos mRNA.  Exogenous NGF induced weak neurite outgrowth, whereas exogenous BDNF and NT-4/5 induced distinct neurite outgrowth.  Exogenous BDNF and NT-4/5 increased the no. of viable cells, while NGF did not.  Our results demonstrate that the signal transduction pathways through TRK-A and TRK-B in MP-N-TS cells are functional and similar, and the main downstream signaling pathways from the three neurotrophins are mitogen-activated protein kinase (MAPK) cascades through Shc, activated Ras, ERK-1 and ERK-2, and the transduction pathway through PLC-γ1.  Further, BDNF and NT-4/5 increased cell viability.  The MP-N-TS cell line should be useful for clarifying the TRK-A and TRK-B signaling pathways responsible for the different prognoses in patients with NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAYVFkXAMrWLVg90H21EOLACvtfcHk0lj5pegJQT5z4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis1KgtLw%253D&md5=f01b9d02f6f598fe55ef304b5069be8d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2001.tb01077.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2001.tb01077.x%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DH.%26aulast%3DHorii%26aufirst%3DY.%26aulast%3DMoritake%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DS.%26atitle%3DSignal%2520transduction%2520pathways%2520through%2520TRK-A%2520and%2520TRK-B%2520receptors%2520in%2520human%2520neuroblastoma%2520cells%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D2001%26volume%3D92%26spage%3D152%26epage%3D160%26doi%3D10.1111%2Fj.1349-7006.2001.tb01077.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borrello, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongarzone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plerotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luksch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pllotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rlzzetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondellini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bernardi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Martino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garaventa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisigotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span> <span> </span><span class="NLM_article-title">Trk and ret proto-oncogene expression in human neuroblastoma specimens: High frequency oftrk expression in non-advanced stages</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1002/ijc.2910540404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fijc.2910540404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8514446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXmt1ejsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1993&pages=540-545&author=M.+G.+Borrelloauthor=I.+Bongarzoneauthor=M.+A.+Plerottiauthor=R.+Lukschauthor=M.+Gaspariniauthor=P.+Colliniauthor=S.+Pllottiauthor=M.+G.+Rlzzettiauthor=P.+Mondelliniauthor=B.+De+Bernardiauthor=D.+Di+Martinoauthor=A.+Garaventaauthor=M.+Brisigottiauthor=G.+P.+Tonini&title=Trk+and+ret+proto-oncogene+expression+in+human+neuroblastoma+specimens%3A+High+frequency+oftrk+expression+in+non-advanced+stages&doi=10.1002%2Fijc.2910540404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages</span></div><div class="casAuthors">Borrello, M. G.; Bongarzone, I.; Pierotti, M. A.; Luksch, R.; Gasparini, M.; Collini, P.; Pilotti, S.; Rizzetti, M. G.; Mondellini, P.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">540-5</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Forty-three fresh tumor specimens of human neuroblastoma belonging to different clin. stages were analyzed for the expression of 2 proto-oncogenes: trk, which encodes a tyrosine-kinase receptor for nerve growth factor (NGF) and ret, another receptor-type tyrosine kinase whose ligand is unknown.  The cases, with increased frequency in I, II and IVs Evans' stages and in patients with favorable prognosis according to the Shimada classification.  Moreover, trk expression inversely correlated with Nmyc-gene amplification.  Ret mRNA was found in 36.8% of cases and equally distributed in the different stages.  In addn., ngfR (low-affinity NGF receptor)-gene expression was present in 9 out of 25 cases.  The simultaneous presence of mRNA related to both forms of the NGF receptor, while not proving the presence of a functional receptor, indicates the existence of a sub-set of neuroblastoma cells potentially responsive to NGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh8NpsOzKBJbVg90H21EOLACvtfcHk0lgRotWRDJS1nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmt1ejsLY%253D&md5=3df319674e53149df74c242ffb379b0b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910540404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910540404%26sid%3Dliteratum%253Aachs%26aulast%3DBorrello%26aufirst%3DM.%2BG.%26aulast%3DBongarzone%26aufirst%3DI.%26aulast%3DPlerotti%26aufirst%3DM.%2BA.%26aulast%3DLuksch%26aufirst%3DR.%26aulast%3DGasparini%26aufirst%3DM.%26aulast%3DCollini%26aufirst%3DP.%26aulast%3DPllotti%26aufirst%3DS.%26aulast%3DRlzzetti%26aufirst%3DM.%2BG.%26aulast%3DMondellini%26aufirst%3DP.%26aulast%3DDe%2BBernardi%26aufirst%3DB.%26aulast%3DDi%2BMartino%26aufirst%3DD.%26aulast%3DGaraventa%26aufirst%3DA.%26aulast%3DBrisigotti%26aufirst%3DM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26atitle%3DTrk%2520and%2520ret%2520proto-oncogene%2520expression%2520in%2520human%2520neuroblastoma%2520specimens%253A%2520High%2520frequency%2520oftrk%2520expression%2520in%2520non-advanced%2520stages%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1993%26volume%3D54%26spage%3D540%26epage%3D545%26doi%3D10.1002%2Fijc.2910540404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eibl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reber, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, O. J.</span></span> <span> </span><span class="NLM_article-title">Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells</span>. <i>Clin. Exp. Metastasis</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1023/B:CLIN.0000046131.24625.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1023%2FB%3ACLIN.0000046131.24625.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15554384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFOgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=285-292&author=Y.+Okadaauthor=G.+Eiblauthor=S.+Guhaauthor=J.+P.+Duffyauthor=H.+A.+Reberauthor=O.+J.+Hines&title=Nerve+growth+factor+stimulates+MMP-2+expression+and+activity+and+increases+invasion+by+human+pancreatic+cancer+cells&doi=10.1023%2FB%3ACLIN.0000046131.24625.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells</span></div><div class="casAuthors">Okada, Yuji; Eibl, Guido; Guha, Sushovan; Duffy, John P.; Reber, Howard A.; Hines, Oscar J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Metastasis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-292</span>CODEN:
                <span class="NLM_cas:coden">CEXMD2</span>;
        ISSN:<span class="NLM_cas:issn">0262-0898</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Pancreatic cancer frequently invades and migrates along neural tissue.  Although the exact mechanisms are unknown, perineural invasion neg. impacts prognosis for pancreatic cancer patients.  Matrix metalloproteinases (MMPs) are overexpressed in pancreatic cancer and are assocd. with poor prognosis.  We hypothesized that nerve growth factor (NGF) released from neural tissue increases the invasive properties of pancreatic cancer cells.  In the present study we investigated the effect of NGF on the expression and activity of MMP-2 in human pancreatic cancer cells.  NGF dose dependently increased MMP-2 protein in the culture medium and stimulated MMP-2 gelatinolytic activity.  This effect was mediated by specific binding of NGF to its receptor trk A, which was detected on all pancreatic cancer cells, with subsequent activation of the p44/42 MAPK signaling pathway.  The NGF-induced increase in MMP-2 expression and activity lead to an enhanced invasion in vitro.  These findings support the hypothesis that neurotrophic factors, e.g., NGF, are critically involved in mediating perineural invasion of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNTV-xLbJq7Vg90H21EOLACvtfcHk0lgRotWRDJS1nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFOgsbs%253D&md5=5096ebb4253a5c9c0dcebbfc10fca5c3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1023%2FB%3ACLIN.0000046131.24625.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ACLIN.0000046131.24625.54%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DEibl%26aufirst%3DG.%26aulast%3DGuha%26aufirst%3DS.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DReber%26aufirst%3DH.%2BA.%26aulast%3DHines%26aufirst%3DO.%2BJ.%26atitle%3DNerve%2520growth%2520factor%2520stimulates%2520MMP-2%2520expression%2520and%2520activity%2520and%2520increases%2520invasion%2520by%2520human%2520pancreatic%2520cancer%2520cells%26jtitle%3DClin.%2520Exp.%2520Metastasis%26date%3D2004%26volume%3D21%26spage%3D285%26epage%3D292%26doi%3D10.1023%2FB%3ACLIN.0000046131.24625.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sapio, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raggioli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deandrea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limone, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caleo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, M.</span></span> <span> </span><span class="NLM_article-title">Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings</span>. <i>Clin. Endocrinol. (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2265.2007.02800.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1111%2Fj.1365-2265.2007.02800.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=17381488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvFKlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2007&pages=678-683&author=M.+R.+Sapioauthor=D.+Poscaauthor=A.+Raggioliauthor=A.+Guerraauthor=V.+Marottaauthor=M.+Deandreaauthor=M.+Mottaauthor=P.+P.+Limoneauthor=G.+Tronconeauthor=A.+Caleoauthor=G.+Rossiauthor=G.+Fenziauthor=M.+Vitale&title=Detection+of+RET%2FPTC%2C+TRK+and+BRAF+mutations+in+preoperative+diagnosis+of+thyroid+nodules+with+indeterminate+cytological+findings&doi=10.1111%2Fj.1365-2265.2007.02800.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings</span></div><div class="casAuthors">Sapio, Maria Rosaria; Posca, Daniela; Raggioli, Angelo; Guerra, Anna; Marotta, Vincenzo; Deandreat, Maurilio; Motta, Manuela; Limonet, Paolo Piero; Troncone, Giancarlo; Caleo, Alessia; Rossi, Guido; Fenzi, Gianfranco; Vitale, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Endocrinology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">678-683</span>CODEN:
                <span class="NLM_cas:coden">CLECAP</span>;
        ISSN:<span class="NLM_cas:issn">0300-0664</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Fine-needle aspiration biopsy (FNAB) is the primary means to distinguish benign from malignant nodules and select patients for surgery.  However, adjunctive diagnostic tests are needed because in 20-40% of cases the FNAB result is uncertain.  We investigated whether a search for the oncogenes RET/PTC, TRK,and BRAFV600E in thyroid aspirates could refine an uncertain diagnosis.  A total of 132 thyroid aspirates, including colloid nodules, inadequate samplings, indeterminate and suspicious for malignancy were analyzed by reverse transcription polymerase chain reaction (RT-PCR) and mutant allele-specific amplification techniques for the presence of oncogenes.  No oncogenes were detected in 48 colloid nodules, 46 inadequate and 19 indeterminate FNABs, then confirmed to be benign at histol.  No oncogenes were detected in one follicular thyroid cancer (FTC) with indeterminate cytol.  Five out of six papillary thyroid cancers (83%) with FNAB suspicious for malignancy were correctly diagnosed by the presence of oncogenes.  Among these, four (67%) contained the BRAF mutation and one (17%) contained RET/PTC-3.  On final anal., no false-pos. results were reported in 131 samples and five out of seven carcinomas (71%) were correctly diagnosed.  The finding of oncogenes in FNAB specimens suspicious for malignancy guided the extent of surgical resection, changing the surgery from diagnostic to therapeutic in five cases.  Detection of RET/PTC, TRK and BRAFV600E in FNAB specimens is proposed as a diagnostic adjunctive tool in the evaluation of thyroid nodules with suspicious cytol. findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYfEq1ByeMabVg90H21EOLACvtfcHk0ljkewZNlU0Ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvFKlu78%253D&md5=1d3d7c671e9964057261c2f5e3fb0ccd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2265.2007.02800.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2265.2007.02800.x%26sid%3Dliteratum%253Aachs%26aulast%3DSapio%26aufirst%3DM.%2BR.%26aulast%3DPosca%26aufirst%3DD.%26aulast%3DRaggioli%26aufirst%3DA.%26aulast%3DGuerra%26aufirst%3DA.%26aulast%3DMarotta%26aufirst%3DV.%26aulast%3DDeandrea%26aufirst%3DM.%26aulast%3DMotta%26aufirst%3DM.%26aulast%3DLimone%26aufirst%3DP.%2BP.%26aulast%3DTroncone%26aufirst%3DG.%26aulast%3DCaleo%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DG.%26aulast%3DFenzi%26aufirst%3DG.%26aulast%3DVitale%26aufirst%3DM.%26atitle%3DDetection%2520of%2520RET%252FPTC%252C%2520TRK%2520and%2520BRAF%2520mutations%2520in%2520preoperative%2520diagnosis%2520of%2520thyroid%2520nodules%2520with%2520indeterminate%2520cytological%2520findings%26jtitle%3DClin.%2520Endocrinol.%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2007%26volume%3D66%26spage%3D678%26epage%3D683%26doi%3D10.1111%2Fj.1365-2265.2007.02800.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span> <span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nm0596-561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells&doi=10.1038%2Fnm0596-561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0ljkewZNlU0Ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnm0596-561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">TRKing down an old oncogene in a new era of targeted therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-14-0765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25527197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=25-34&author=A.+Vaishnaviauthor=A.+T.+Leauthor=R.+C.+Doebele&title=TRKing+down+an+old+oncogene+in+a+new+era+of+targeted+therapy&doi=10.1158%2F2159-8290.CD-14-0765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span></div><div class="casAuthors">Vaishnavi, Aria; Le, Anh T.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date.  These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago.  However, no drug has yet been approved by the FDA for cancers harboring this oncogene.  This review will discuss the biol. of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.  Significance: Precision oncol. approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples.  Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types.  The scientific rationale for the targeting of the TRK oncogene family will be discussed here.  Cancer Discov; 5(1); 25-34. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUH4ooHY0TbVg90H21EOLACvtfcHk0ljkewZNlU0Ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D&md5=02103d46d85b6dc948dba58d32ffba9f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0765%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTRKing%2520down%2520an%2520old%2520oncogene%2520in%2520a%2520new%2520era%2520of%2520targeted%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D25%26epage%3D34%26doi%3D10.1158%2F2159-8290.CD-14-0765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span> <span> </span><span class="NLM_article-title">NTRK gene fusions as novel targets of cancer therapy across multiple tumour types</span>. <i>ESMO Open</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e000023</span>, <span class="refDoi"> DOI: 10.1136/esmoopen-2015-000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1136%2Fesmoopen-2015-000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=27843590" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e000023&author=A.+Amatuauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=NTRK+gene+fusions+as+novel+targets+of+cancer+therapy+across+multiple+tumour+types&doi=10.1136%2Fesmoopen-2015-000023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fesmoopen-2015-000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fesmoopen-2015-000023%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNTRK%2520gene%2520fusions%2520as%2520novel%2520targets%2520of%2520cancer%2520therapy%2520across%2520multiple%2520tumour%2520types%26jtitle%3DESMO%2520Open%26date%3D2016%26volume%3D1%26spage%3De000023%26doi%3D10.1136%2Fesmoopen-2015-000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span> <span> </span><span class="NLM_article-title">The landscape of kinase fusions in cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">4846</span>, <span class="refDoi"> DOI: 10.1038/ncomms5846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fncomms5846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25204415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVShsbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4846&author=N.+Stranskyauthor=E.+Ceramiauthor=S.+Schalmauthor=J.+L.+Kimauthor=C.+Lengauer&title=The+landscape+of+kinase+fusions+in+cancer&doi=10.1038%2Fncomms5846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The landscape of kinase fusions in cancer</span></div><div class="casAuthors">Stransky, Nicolas; Cerami, Ethan; Schalm, Stefanie; Kim, Joseph L.; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4846</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genomes harbor a variety of alterations leading to the deregulation of key pathways in tumor cells.  The genomic characterization of tumors has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as extensively.  Here we develop heuristics for reliably detecting gene fusion events in RNA-seq data and apply them to nearly 7,000 samples from The Cancer Genome Atlas.  We thereby are able to discover several novel and recurrent fusions involving kinases.  These findings have immediate clin. implications and expand the therapeutic options for cancer patients, as approved or exploratory drugs exist for many of these kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtVLhAUa2IjLVg90H21EOLACvtfcHk0lj5Z0fKzXNmrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVShsbvP&md5=f71bed662172018e65e53ec086e113e3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fncomms5846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5846%26sid%3Dliteratum%253Aachs%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DCerami%26aufirst%3DE.%26aulast%3DSchalm%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DThe%2520landscape%2520of%2520kinase%2520fusions%2520in%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4846%26doi%3D10.1038%2Fncomms5846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dela
Cruz, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanoue, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthay, R. A.</span></span> <span> </span><span class="NLM_article-title">Lung cancer: epidemiology, etiology, and prevention</span>. <i>Clin. Chest Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/j.ccm.2011.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.ccm.2011.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22054876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC3MbmvVOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=605-644&author=C.+S.+Dela%0ACruzauthor=L.+T.+Tanoueauthor=R.+A.+Matthay&title=Lung+cancer%3A+epidemiology%2C+etiology%2C+and+prevention&doi=10.1016%2Fj.ccm.2011.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Lung cancer: epidemiology, etiology, and prevention</span></div><div class="casAuthors">Dela Cruz Charles S; Tanoue Lynn T; Matthay Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer death in the United States and around the world.  A vast majority of lung cancer deaths are attributable to cigarette smoking, and curbing the rates of cigarette smoking is imperative.  Understanding the epidemiology and causal factors of lung cancer can provide additional foundation for disease prevention.  This article focuses on modifiable risk factors, including tobacco smoking, occupational carcinogens, diet, and ionizing radiation.  It also discusses briefly the molecular and genetic aspects of lung carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvaMTw8VxvNHRxY89Cm6SyfW6udTcc2ebQHaxns8Puirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbmvVOgsg%253D%253D&md5=e5901b74d858bf24d8ed740c1ed4d929</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ccm.2011.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccm.2011.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DDela%2BCruz%26aufirst%3DC.%2BS.%26aulast%3DTanoue%26aufirst%3DL.%2BT.%26aulast%3DMatthay%26aufirst%3DR.%2BA.%26atitle%3DLung%2520cancer%253A%2520epidemiology%252C%2520etiology%252C%2520and%2520prevention%26jtitle%3DClin.%2520Chest%2520Med.%26date%3D2011%26volume%3D32%26spage%3D605%26epage%3D644%26doi%3D10.1016%2Fj.ccm.2011.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneval, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katabi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A. L.</span></span> <span> </span><span class="NLM_article-title">What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1093%2Fannonc%2Fmdw042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26884591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC28jhsVWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=920-926&author=A.+Drilonauthor=G.+Liauthor=S.+Doganauthor=M.+Gounderauthor=R.+Shenauthor=M.+Arcilaauthor=L.+Wangauthor=D.+M.+Hymanauthor=J.+Hechtmanauthor=G.+Weiauthor=N.+R.+Camauthor=J.+Christiansenauthor=D.+Luoauthor=E.+C.+Manevalauthor=T.+Bauerauthor=M.+Patelauthor=S.+V.+Liuauthor=S.+H.+Ouauthor=A.+Faragoauthor=A.+Shawauthor=R.+F.+Shoemakerauthor=J.+Limauthor=Z.+Hornbyauthor=P.+Multaniauthor=M.+Ladanyiauthor=M.+Bergerauthor=N.+Katabiauthor=R.+Ghosseinauthor=A.+L.+Ho&title=What+hides+behind+the+MASC%3A+clinical+response+and+acquired+resistance+to+entrectinib+after+ETV6-NTRK3+identification+in+a+mammary+analogue+secretory+carcinoma+%28MASC%29&doi=10.1093%2Fannonc%2Fmdw042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)</span></div><div class="casAuthors">Drilon A; Gounder M; Hyman D M; Ho A L; Li G; Wei G; Cam N R; Christiansen J; Luo D; Maneval E C; Shoemaker R F; Lim J; Hornby Z; Multani P; Dogan S; Arcila M; Wang L; Hechtman J; Ladanyi M; Berger M; Katabi N; Ghossein R; Shen R; Bauer T; Patel M; Liu S V; Ou S H I; Farago A; Shaw A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">920-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity.  We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion.  PATIENTS AND METHODS:  This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro activity against cell lines containing various NTRK1/2/3 fusions.  RESULTS:  A dramatic and durable response was achieved with entrectinib in this patient, followed by acquired resistance that correlated with the appearance of a novel NTRK3 G623R mutation.  Structural modeling predicts that this alteration sterically interferes with drug binding, correlating to decreased sensitivity to drug inhibition observed in cell-based assays.  CONCLUSIONS:  This first report of clinical activity with TrkC inhibition and the development of acquired resistance in an NTRK3-rearranged cancer emphasize the utility of comprehensive molecular profiling and targeted therapy for rare malignancies (NCT02097810).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9gxQ1W-lQaLt7lRqEFUJVfW6udTcc2ebQHaxns8Puirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhsVWhsQ%253D%253D&md5=2fb8579504f22f5fbfc90f086dd0c743</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw042%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDogan%26aufirst%3DS.%26aulast%3DGounder%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DHechtman%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DCam%26aufirst%3DN.%2BR.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DManeval%26aufirst%3DE.%2BC.%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DFarago%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DShoemaker%26aufirst%3DR.%2BF.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DKatabi%26aufirst%3DN.%26aulast%3DGhossein%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DA.%2BL.%26atitle%3DWhat%2520hides%2520behind%2520the%2520MASC%253A%2520clinical%2520response%2520and%2520acquired%2520resistance%2520to%2520entrectinib%2520after%2520ETV6-NTRK3%2520identification%2520in%2520a%2520mammary%2520analogue%2520secretory%2520carcinoma%2520%2528MASC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D920%26epage%3D926%26doi%3D10.1093%2Fannonc%2Fmdw042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khotskaya, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills Shaw, K. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span> <span> </span><span class="NLM_article-title">Targeting TRK family proteins in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.pharmthera.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28174090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=58-66&author=Y.+B.+Khotskayaauthor=V.+R.+Hollaauthor=A.+F.+Faragoauthor=K.+R.+M.+Mills+Shawauthor=F.+Meric-Bernstamauthor=D.+S.+Hong&title=Targeting+TRK+family+proteins+in+cancer&doi=10.1016%2Fj.pharmthera.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting TRK family proteins in cancer</span></div><div class="casAuthors">Khotskaya, Yekaterina B.; Holla, Vijaykumar R.; Farago, Anna F.; Mills Shaw, Kenna R.; Meric-Bernstam, Funda; Hong, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3 genes, resp.  Binding of neurotrophins to TRK proteins induces receptor dimerization, phosphorylation, and activation of the downstream signaling cascades via PI3K, RAS/MAPK/ERK, and PLC-gamma.  TRK pathway aberrations, including gene fusions, protein overexpression, and single nucleotide alterations, have been implicated in the pathogenesis of many cancer types, with NTRK gene fusions being the most well validated oncogenic events to date.  Although the NTRK gene fusions are infrequent in most cancer types, certain rare tumor types are predominately driven by these events.  Conversely, in more common histologies, such as lung and colorectal cancers, prevalence of the NTRK fusions is well below 5%.  Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations.  Currently, several TRK-targeting compds. are in clin. development.  The ongoing Phase 2 trials with entrectinib and LOXO-101, two of the leading TRK inhibitors, are designed as 'basket trials', inclusive of patients whose tumors harbor NTRK gene fusions, independent of histol.  Addnl. Phase 1 studies of other TRK inhibitors, including MGCD516, PLX7486, DS-6051b, and TSR-011, are underway.  Interim data examg. NTRK-rearranged tumors treated with entrectinib or LOXO-101 demonstrate encouraging activity, with patients achieving rapid and durable responses.  Consequently, both drugs have achieved orphan designation from regulatory agencies, and efforts are underway to further expedite their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozoy77YmUc_LVg90H21EOLACvtfcHk0lh-tGgo__wHFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D&md5=f18f232e6d3c4c9a5d2e398fe60ae7e4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKhotskaya%26aufirst%3DY.%2BB.%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DMills%2BShaw%26aufirst%3DK.%2BR.%2BM.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DD.%2BS.%26atitle%3DTargeting%2520TRK%2520family%2520proteins%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.pharmthera.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kako, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1472</span>, <span class="refDoi"> DOI: 10.1038/nm.3352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnm.3352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24162815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1469-1472&author=A.+Vaishnaviauthor=M.+Capellettiauthor=A.+T.+Leauthor=S.+Kakoauthor=M.+Butaneyauthor=D.+Ercanauthor=S.+Mahaleauthor=K.+D.+Daviesauthor=D.+L.+Aisnerauthor=A.+B.+Pillingauthor=E.+M.+Bergeauthor=J.+Kimauthor=H.+Sasakiauthor=S.+Parkauthor=G.+Kryukovauthor=L.+A.+Garrawayauthor=P.+S.+Hammermanauthor=J.+Haasauthor=S.+W.+Andrewsauthor=D.+Lipsonauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=M.+Varella-Garciaauthor=P.+A.+Janneauthor=R.+C.+Doebele&title=Oncogenic+and+drug-sensitive+NTRK1+rearrangements+in+lung+cancer&doi=10.1038%2Fnm.3352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span></div><div class="casAuthors">Vaishnavi, Aria; Capelletti, Marzia; Le, Anh T.; Kako, Severine; Butaney, Mohit; Ercan, Dalia; Mahale, Sakshi; Davies, Kurtis D.; Aisner, Dara L.; Pilling, Amanda B.; Berge, Eamon M.; Kim, Jhingook; Sasaki, Hidefumi; Park, Seung-il; Kryukov, Gregory; Garraway, Levi A.; Hammerman, Peter S.; Haas, Julia; Andrews, Steven W.; Lipson, Doron; Stephens, Philip J.; Miller, Vince A.; Varella-Garcia, Marileila; Jaenne, Pasi A.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1472</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein).  Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic.  Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth.  Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHNoZGMQLMrVg90H21EOLACvtfcHk0lh-tGgo__wHFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI&md5=23b413826ea700bd831eadbfde270615</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnm.3352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3352%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DKako%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMahale%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKryukov%26aufirst%3DG.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DOncogenic%2520and%2520drug-sensitive%2520NTRK1%2520rearrangements%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1469%26epage%3D1472%26doi%3D10.1038%2Fnm.3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1038/319743a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2F319743a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=2869410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaL28XhvVSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=1986&pages=743-748&author=D.+Martin-Zancaauthor=S.+H.+Hughesauthor=M.+Barbacid&title=A+human+oncogene+formed+by+the+fusion+of+truncated+tropomyosin+and+protein+tyrosine+kinase+sequences&doi=10.1038%2F319743a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences</span></div><div class="casAuthors">Martin-Zanca, Dionisio; Hughes, Stephen H.; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">6056</span>),
    <span class="NLM_cas:pages">743-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A biol. active cDNA clone of a transforming gene present in a human colon carcinoma contains gene sequences of both tropomyosin and a previously unknown tyrosine kinase  [80449-02-1].  The predicted protein (641 amino acids) encoded by this oncogene seems to have been formed by a somatic rearrangement that replaced the extracellular domain of a putative transmembrane receptor by the 1st 221 amino acids of a non-muscle tropomyosin mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0AjUZGDew7Vg90H21EOLACvtfcHk0lh_FZkrSl20Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhvVSqt7g%253D&md5=da5002349ed602cac199727be7149d40</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2F319743a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F319743a0%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DA%2520human%2520oncogene%2520formed%2520by%2520the%2520fusion%2520of%2520truncated%2520tropomyosin%2520and%2520protein%2520tyrosine%2520kinase%2520sequences%26jtitle%3DNature%26date%3D1986%26volume%3D319%26spage%3D743%26epage%3D748%26doi%3D10.1038%2F319743a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaschini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raddrizzani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span> <span> </span><span class="NLM_article-title">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.molonc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24962792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1495-1507&author=E.+Ardiniauthor=R.+Bosottiauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=A.+Somaschiniauthor=R.+Cammarotaauthor=N.+Amboldiauthor=L.+Raddrizzaniauthor=A.+Milaniauthor=P.+Magnaghiauthor=D.+Ballinariauthor=D.+Caseroauthor=F.+Gasparriauthor=P.+Banfiauthor=N.+Avanziauthor=M.+B.+Saccardoauthor=R.+Alzaniauthor=T.+Bandieraauthor=E.+Felderauthor=D.+Donatiauthor=E.+Pesentiauthor=A.+Sartore-Bianchiauthor=M.+Gambacortaauthor=M.+A.+Pierottiauthor=S.+Sienaauthor=S.+Veroneseauthor=A.+Galvaniauthor=A.+Isacchi&title=The+TPM3-NTRK1+rearrangement+is+a+recurring+event+in+colorectal+carcinoma+and+is+associated+with+tumor+sensitivity+to+TRKA+kinase+inhibition&doi=10.1016%2Fj.molonc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span></div><div class="casAuthors">Ardini, Elena; Bosotti, Roberta; Borgia, Andrea Lombardi; De Ponti, Cristina; Somaschini, Alessio; Cammarota, Rosaria; Amboldi, Nadia; Raddrizzani, Laura; Milani, Andrea; Magnaghi, Paola; Ballinari, Dario; Casero, Daniele; Gasparri, Fabio; Banfi, Patrizia; Avanzi, Nilla; Saccardo, Maria B.; Alzani, Rachele; Bandiera, Tiziano; Felder, Eduard; Donati, Daniele; Pesenti, Enrico; Sartore-Bianchi, Andrea; Gambacorta, Marcello; Pierotti, Marco A.; Siena, Salvatore; Veronese, Silvio; Galvani, Arturo; Isacchi, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NTRK1 gene encodes Tropomyosin-related kinase A (TRKA), the high-affinity Nerve Growth Factor Receptor.  NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3-NTRK1) resulting in expression of the oncogenic chimeric protein TPM3-TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC.  The KM12 human CRC cell line expresses the chimeric TPM3-TRKA protein and is hypersensitive to TRKA kinase inhibition.  We report the detailed characterization of the TPM3-NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS-P626, a novel highly potent and selective TRKA inhibitor.  NMS-P626 suppressed TPM3-TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors.  Finally, using quant. reverse transcriptase PCR and immunohistochem. (IHC) we identified the TPM3-NTRK1 rearrangement in a CRC clin. sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-EhukkQ24OrVg90H21EOLACvtfcHk0lh_FZkrSl20Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI&md5=2a9de2410f69e2eb8ff84c9516828984</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DMilani%26aufirst%3DA.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26atitle%3DThe%2520TPM3-NTRK1%2520rearrangement%2520is%2520a%2520recurring%2520event%2520in%2520colorectal%2520carcinoma%2520and%2520is%2520associated%2520with%2520tumor%2520sensitivity%2520to%2520TRKA%2520kinase%2520inhibition%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1495%26epage%3D1507%26doi%3D10.1016%2Fj.molonc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappabianca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A. R.</span></span> <span> </span><span class="NLM_article-title">Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.2217/14796694.1.5.689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2217%2F14796694.1.5.689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16556046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyiu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=689-698&author=A.+Tacconelliauthor=A.+R.+Farinaauthor=L.+Cappabiancaauthor=A.+Gulinoauthor=A.+R.+Mackay&title=Alternative+TrkAIII+splicing%3A+a+potential+regulated+tumor-promoting+switch+and+therapeutic+target+in+neuroblastoma&doi=10.2217%2F14796694.1.5.689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma</span></div><div class="casAuthors">Tacconelli, Antonella; Farina, Antonietta R.; Cappabianca, Lucia; Gulino, Alberto; Mackay, Andrew R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  An assocn. between elevated tyrosine kinase receptor (Trk)-A expression and better prognosis; the absence of mutation-activated TrkA oncogenes; the induction of apoptosis, growth arrest, morphol. differentiation and inhibition of xenograft growth; and angiogenesis by TrkA gene transduction, provide the basis for the current concept of an exclusively tumor-suppressor role for TrkA in the aggressive pediatric tumor, neuroblastoma.  This concept, however, has recently been challenged by the discovery of a novel hypoxia-regulated alternative TrkAIII splice variant, initial data for which suggest predominant expression in advanced-stage neuroblastoma.  TrkAIII exhibits neuroblastoma xenograft tumor-promoting activity assocd. with the induction of a more angiogenic and stress-resistant neuroblastoma phenotype and antagonizes nerve growth factor/TrkAI antioncogenic signaling.  In this short review, the authors integrate this novel information into a modified concept that places alternative TrkA splicing as a potential pivotal regulator of neuroblastoma behavior and identifies the TrkAIII alternative splice variant as a potential biomarker of patient prognosis and novel therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH2ePUWUJFSbVg90H21EOLACvtfcHk0lh_FZkrSl20Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyiu7fO&md5=54842fe723412f666aec829930979c76</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2217%2F14796694.1.5.689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14796694.1.5.689%26sid%3Dliteratum%253Aachs%26aulast%3DTacconelli%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DA.%2BR.%26aulast%3DCappabianca%26aufirst%3DL.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DMackay%26aufirst%3DA.%2BR.%26atitle%3DAlternative%2520TrkAIII%2520splicing%253A%2520a%2520potential%2520regulated%2520tumor-promoting%2520switch%2520and%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DFuture%2520Oncol.%26date%3D2005%26volume%3D1%26spage%3D689%26epage%3D698%26doi%3D10.2217%2F14796694.1.5.689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.mce.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19883730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2010&pages=44-49&author=A.+Grecoauthor=C.+Mirandaauthor=M.+A.+Pierotti&title=Rearrangements+of+NTRK1+gene+in+papillary+thyroid+carcinoma&doi=10.1016%2Fj.mce.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span></div><div class="casAuthors">Greco, A.; Miranda, C.; Pierotti, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  TRK oncogenes are obsd. in a consistent fraction of papillary thyroid carcinoma (PTC); they arise from the fusion of the 3' terminal sequences of the NTRK1/NGF receptor gene with 5' terminal sequences of various activating genes, such as TPM3, TPR and TFG.  TRK oncoproteins display constitutive tyrosine-kinase activity, leading to in vitro and in vivo transformation.  In this review studies performed during the last 20 years will be summarized.  The following topics will be illustrated: (a) frequency of TRK oncogenes and correlation with radiation and tumor histopathol. features; (b) mol. mechanisms underlying NTRK1 oncogenic rearrangements; (c) mol. and biochem. characterization of TRK oncoproteins, and their mechanism of action; (d) role of activating sequences in the activation of TRK oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGkkW9wYpTLVg90H21EOLACvtfcHk0lin-l7ovF-sBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D&md5=ea9abddd4191599672958ac3875bf9ae</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRearrangements%2520of%2520NTRK1%2520gene%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2010%26volume%3D321%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.mce.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kralik, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranewitter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesmueller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschurtschenthaler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpold, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webersinke, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia</span>. <i>Diagn. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/1746-1596-6-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1186%2F1746-1596-6-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21401966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=19&author=J.+M.+Kralikauthor=W.+Kranewitterauthor=H.+Boesmuellerauthor=R.+Marschonauthor=G.+Tschurtschenthalerauthor=H.+Rumpoldauthor=K.+Wiesingerauthor=M.+Erdelauthor=A.+L.+Petzerauthor=G.+Webersinke&title=Characterization+of+a+newly+identified+ETV6-NTRK3+fusion+transcript+in+acute+myeloid+leukemia&doi=10.1186%2F1746-1596-6-19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia</span></div><div class="casAuthors">Kralik, Johanna M.; Kranewitter, Wolfgang; Boesmueller, Hans; Marschon, Renate; Tschurtschenthaler, Gertraud; Rumpold, Holger; Wiesinger, Kurt; Erdel, Martin; Petzer, Andreas L.; Webersinke, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>CODEN:
                <span class="NLM_cas:coden">DPIAAA</span>;
        ISSN:<span class="NLM_cas:issn">1746-1596</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Characterization of novel fusion genes in acute leukemia is important for gaining information about leukemia genesis.  We describe the characterization of a new ETV6 fusion gene in acute myeloid leukemia (AML) FAB M0 as a result of an uncommon translocation involving chromosomes 12 and 15.  Methods: The ETV6 locus at 12p13 was shown to be translocated and to constitute the 5' end of the fusion product by ETV6 break apart fluorescence in situ hybridization (FISH).  To identify a fusion partner 3' rapid amplification of cDNA-ends with polymerase chain reaction (RACE PCR) was performed followed by cloning and sequencing.  Results: The NTRK3 gene on chromosome 15 was found to constitute the 3' end of the fusion gene and the underlying ETV6-NTRK3 rearrangement was verified by reverse transcriptase PCR.  No RNA of the reciprocal NTRK3-ETV6 fusion gene could be detected.  Conclusion: We have characterized a novel ETV6-NTRK3 fusion transcript which has not been previously described in AML FAB M0 by FISH and RACE PCR.  ETV6-NTRK3 rearrangements have been described in secretory breast carcinoma and congenital fibrosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5P9PTYZD7rVg90H21EOLACvtfcHk0lin-l7ovF-sBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCjt7s%253D&md5=4e65d970d478898268f34cfb7a4cc5ac</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1746-1596-6-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1746-1596-6-19%26sid%3Dliteratum%253Aachs%26aulast%3DKralik%26aufirst%3DJ.%2BM.%26aulast%3DKranewitter%26aufirst%3DW.%26aulast%3DBoesmueller%26aufirst%3DH.%26aulast%3DMarschon%26aufirst%3DR.%26aulast%3DTschurtschenthaler%26aufirst%3DG.%26aulast%3DRumpold%26aufirst%3DH.%26aulast%3DWiesinger%26aufirst%3DK.%26aulast%3DErdel%26aufirst%3DM.%26aulast%3DPetzer%26aufirst%3DA.%2BL.%26aulast%3DWebersinke%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520a%2520newly%2520identified%2520ETV6-NTRK3%2520fusion%2520transcript%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DDiagn.%2520Pathol.%26date%3D2011%26volume%3D6%26spage%3D19%26doi%3D10.1186%2F1746-1596-6-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifonov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoppoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danussi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgalev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porrati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegatta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heguy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisapia, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canoll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldape, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finocchiaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prive, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasorella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabadan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, A.</span></span> <span> </span><span class="NLM_article-title">The integrated landscape of driver genomic alterations in glioblastoma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1038/ng.2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fng.2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=23917401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wrt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1141-1149&author=V.+Frattiniauthor=V.+Trifonovauthor=J.+M.+Chanauthor=A.+Castanoauthor=M.+Liaauthor=F.+Abateauthor=S.+T.+Keirauthor=A.+X.+Jiauthor=P.+Zoppoliauthor=F.+Niolaauthor=C.+Danussiauthor=I.+Dolgalevauthor=P.+Porratiauthor=S.+Pellegattaauthor=A.+Heguyauthor=G.+Guptaauthor=D.+J.+Pisapiaauthor=P.+Canollauthor=J.+N.+Bruceauthor=R.+E.+McLendonauthor=H.+Yanauthor=K.+Aldapeauthor=G.+Finocchiaroauthor=T.+Mikkelsenauthor=G.+G.+Priveauthor=D.+D.+Bignerauthor=A.+Lasorellaauthor=R.+Rabadanauthor=A.+Iavarone&title=The+integrated+landscape+of+driver+genomic+alterations+in+glioblastoma&doi=10.1038%2Fng.2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The integrated landscape of driver genomic alterations in glioblastoma</span></div><div class="casAuthors">Frattini, Veronique; Trifonov, Vladimir; Chan, Joseph Minhow; Castano, Angelica; Lia, Marie; Abate, Francesco; Keir, Stephen T.; Ji, Alan X.; Zoppoli, Pietro; Niola, Francesco; Danussi, Carla; Dolgalev, Igor; Porrati, Paola; Pellegatta, Serena; Heguy, Adriana; Gupta, Gaurav; Pisapia, David J.; Canoll, Peter; Bruce, Jeffrey N.; McLendon, Roger E.; Yan, Hai; Aldape, Ken; Finocchiaro, Gaetano; Mikkelsen, Tom; Prive, Gilbert G.; Bigner, Darell D.; Lasorella, Anna; Rabadan, Raul; Iavarone, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1141-1149</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma is one of the most challenging forms of cancer to treat.  Here we describe a computational platform that integrates the anal. of copy no. variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma.  We found mutations with loss of heterozygosity in LZTR1, encoding an adaptor of CUL3-contg. E3 ligase complexes.  Mutations and deletions disrupt LZTR1 function, which restrains the self renewal and growth of glioma spheres that retain stem cell features.  Loss-of-function mutations in CTNND2 target a neural-specific gene and are assocd. with the transformation of glioma cells along the very aggressive mesenchymal phenotype.  We also report recurrent translocations that fuse the coding sequence of EGFR to several partners, with EGFR-SEPT14 being the most frequent functional gene fusion in human glioblastoma.  EGFR-SEPT14 fusions activate STAT3 signaling and confer mitogen independence and sensitivity to EGFR inhibition.  These results provide insights into the pathogenesis of glioblastoma and highlight new targets for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjNGcPWRhHtLVg90H21EOLACvtfcHk0lin-l7ovF-sBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wrt7zF&md5=bd2514caccf8b5fd46ef070fe951f7b0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fng.2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2734%26sid%3Dliteratum%253Aachs%26aulast%3DFrattini%26aufirst%3DV.%26aulast%3DTrifonov%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DCastano%26aufirst%3DA.%26aulast%3DLia%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DF.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DJi%26aufirst%3DA.%2BX.%26aulast%3DZoppoli%26aufirst%3DP.%26aulast%3DNiola%26aufirst%3DF.%26aulast%3DDanussi%26aufirst%3DC.%26aulast%3DDolgalev%26aufirst%3DI.%26aulast%3DPorrati%26aufirst%3DP.%26aulast%3DPellegatta%26aufirst%3DS.%26aulast%3DHeguy%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DG.%26aulast%3DPisapia%26aufirst%3DD.%2BJ.%26aulast%3DCanoll%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DJ.%2BN.%26aulast%3DMcLendon%26aufirst%3DR.%2BE.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DAldape%26aufirst%3DK.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DMikkelsen%26aufirst%3DT.%26aulast%3DPrive%26aufirst%3DG.%2BG.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DLasorella%26aufirst%3DA.%26aulast%3DRabadan%26aufirst%3DR.%26aulast%3DIavarone%26aufirst%3DA.%26atitle%3DThe%2520integrated%2520landscape%2520of%2520driver%2520genomic%2520alterations%2520in%2520glioblastoma%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26spage%3D1141%26epage%3D1149%26doi%3D10.1038%2Fng.2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricarte-Filho, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Rendueles, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero-Conde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heguy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">4935</span>– <span class="NLM_lpage">4944</span>, <span class="refDoi"> DOI: 10.1172/JCI69766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1172%2FJCI69766" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=4935-4944&author=J.+C.+Ricarte-Filhoauthor=S.+Liauthor=M.+E.+Garcia-Renduelesauthor=C.+Montero-Condeauthor=F.+Vozaauthor=J.+A.+Knaufauthor=A.+Heguyauthor=A.+Vialeauthor=T.+Bogdanovaauthor=G.+A.+Thomasauthor=C.+E.+Masonauthor=J.+A.+Fagin&title=Identification+of+kinase+fusion+oncogenes+in+post-Chernobyl+radiation-induced+thyroid+cancers&doi=10.1172%2FJCI69766"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1172%2FJCI69766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69766%26sid%3Dliteratum%253Aachs%26aulast%3DRicarte-Filho%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGarcia-Rendueles%26aufirst%3DM.%2BE.%26aulast%3DMontero-Conde%26aufirst%3DC.%26aulast%3DVoza%26aufirst%3DF.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DHeguy%26aufirst%3DA.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DBogdanova%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DG.%2BA.%26aulast%3DMason%26aufirst%3DC.%2BE.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520kinase%2520fusion%2520oncogenes%2520in%2520post-Chernobyl%2520radiation-induced%2520thyroid%2520cancers%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D4935%26epage%3D4944%26doi%3D10.1172%2FJCI69766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeman-Neill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanova, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdokimova, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurnadzy, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tronko, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforov, Y. E.</span></span> <span> </span><span class="NLM_article-title">ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1002/cncr.28484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fcncr.28484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24327398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=799-807&author=R.+J.+Leeman-Neillauthor=L.+M.+Kellyauthor=P.+Liuauthor=A.+V.+Brennerauthor=M.+P.+Littleauthor=T.+I.+Bogdanovaauthor=V.+N.+Evdokimovaauthor=M.+Hatchauthor=L.+Y.+Zurnadzyauthor=M.+N.+Nikiforovaauthor=N.+J.+Yueauthor=M.+Zhangauthor=K.+Mabuchiauthor=M.+D.+Tronkoauthor=Y.+E.+Nikiforov&title=ETV6-NTRK3+is+a+common+chromosomal+rearrangement+in+radiation-associated+thyroid+cancer&doi=10.1002%2Fcncr.28484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer</span></div><div class="casAuthors">Leeman-Neill, Rebecca J.; Kelly, Lindsey M.; Liu, Pengyuan; Brenner, Alina V.; Little, Mark P.; Bogdanova, Tetiana I.; Evdokimova, Viktoria N.; Hatch, Maureen; Zurnadzy, Liudmyla Y.; Nikiforova, Marina N.; Yue, Ning J.; Zhang, Miao; Mabuchi, Kiyohiko; Tronko, Mykola D.; Nikiforov, Yuri E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">799-807</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: In their previous anal. of papillary thyroid carcinomas (PTCs) from an Ukrainian-American cohort that was exposed to iodine-131 (131I) from the Chernobyl accident, the authors identified RET/PTC rearrangements and other driver mutations in 60% of tumors.  Methods: In this study, the remaining mutation-neg. tumors from that cohort were analyzed using RNA sequencing (RNA-Seq) and reverse transcriptase-polymerase chain reaction to identify novel chromosomal rearrangements and to characterize their relation with radiation dose.  Results: The ETS variant gene 6 (ETV6)-neurotrophin receptor 3 (NTRK3) rearrangement (ETV6-NTRK3) was identified by RNA-Seq in a tumor from a patient who received a high 131I dose.  Overall, the rearrangement was detected in 9 of 62 (14.5%) post-Chernobyl PTCs and in 3 of 151 (2%) sporadic PTCs (P = .019).  The most common fusion type was between exon 4 of ETV6 and exon 14 of NTRK3.  The prevalence of ETV6-NTRK3 rearrangement in post-Chernobyl PTCs was assocd. with increasing 131I dose, albeit at borderline significance (P = .126).  The group of rearrangement-pos. PTCs (ETV6-NTRK3, RET/PTC, PAX8-PPARγ) was assocd. with significantly higher dose response compared with the group of PTCs with point mutations (BRAF, RAS; P < .001).  In vitro exposure of human thyroid cells to 1 Gy of 131I and γ-radiation resulted in the formation of ETV6-NTRK3 rearrangement at a rate of 7.9 × 10-6 cells and 3.0 × 10-6 cells, resp.  Conclusions: The authors report the occurrence of ETV6-NTRK3 rearrangements in thyroid cancer and demonstrate that this rearrangement is significantly more common in tumors assocd. with exposure to 131I and has a borderline significant dose response.  Moreover, ETV6-NTRK3 rearrangement can be directly induced in thyroid cells by ionizing radiation in vitro and, thus, may represent a novel mechanism of radiation-induced carcinogenesis.  Cancer 2014;120:799-807. © 2013 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWJqPd2X_b1LVg90H21EOLACvtfcHk0lhqmA80Y6VYXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVymtbY%253D&md5=848873fbbaa919533fee2208bfad31f7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28484%26sid%3Dliteratum%253Aachs%26aulast%3DLeeman-Neill%26aufirst%3DR.%2BJ.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBrenner%26aufirst%3DA.%2BV.%26aulast%3DLittle%26aufirst%3DM.%2BP.%26aulast%3DBogdanova%26aufirst%3DT.%2BI.%26aulast%3DEvdokimova%26aufirst%3DV.%2BN.%26aulast%3DHatch%26aufirst%3DM.%26aulast%3DZurnadzy%26aufirst%3DL.%2BY.%26aulast%3DNikiforova%26aufirst%3DM.%2BN.%26aulast%3DYue%26aufirst%3DN.%2BJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DMabuchi%26aufirst%3DK.%26aulast%3DTronko%26aufirst%3DM.%2BD.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26atitle%3DETV6-NTRK3%2520is%2520a%2520common%2520chromosomal%2520rearrangement%2520in%2520radiation-associated%2520thyroid%2520cancer%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26spage%3D799%26epage%3D807%26doi%3D10.1002%2Fcncr.28484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span> <span> </span><span class="NLM_article-title">Selectivity in neurotrophin signaling: theme and variations</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.26.041002.131421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.neuro.26.041002.131421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12598680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=299-330&author=R.+A.+Segal&title=Selectivity+in+neurotrophin+signaling%3A+theme+and+variations&doi=10.1146%2Fannurev.neuro.26.041002.131421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity in neurotrophin signaling: theme and variations</span></div><div class="casAuthors">Segal, Rosalind A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">299-330</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Neurotrophins are a family of growth factors crit. for the development and functioning of the nervous system.  Although originally identified as neuronal survival factors, neurotrophins elicit many biol. effects, ranging from proliferation to synaptic modulation to axonal pathfinding.  Recent data indicate that the nature of the signaling cascades activated by neurotrophins, and the biol. responses that ensue, are specified not only by the ligand itself but also by the temporal pattern and spatial location of stimulation.  Studies on neurotrophin signaling have revealed variations in the Ras/MAP kinase, phosphatidylinositol 3-kinase, and phospholipase C pathways, which transmit spatial and temporal information.  The anatomy of neurons makes them particularly appropriate for studying how the location and tempo of stimulation det. the signal cascades that are activated by receptor tyrosine kinases such as the Trk receptors.  These signaling variations may represent a general mechanism eliciting specificity in growth factor responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZGcPFtywOLVg90H21EOLACvtfcHk0lhqmA80Y6VYXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSisLo%253D&md5=f585bf86e97bbcf7467d21533b62cda2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.26.041002.131421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.26.041002.131421%26sid%3Dliteratum%253Aachs%26aulast%3DSegal%26aufirst%3DR.%2BA.%26atitle%3DSelectivity%2520in%2520neurotrophin%2520signaling%253A%2520theme%2520and%2520variations%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D26%26spage%3D299%26epage%3D330%26doi%3D10.1146%2Fannurev.neuro.26.041002.131421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliardini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">The DNA rearrangement that generates the Trk-T3 oncogene involves a nnovel gene on chromosome-3 whose product has a potential coiled-coil domain</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6118</span>– <span class="NLM_lpage">6127</span>, <span class="refDoi"> DOI: 10.1128/MCB.15.11.6118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.15.11.6118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7565764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXovVylu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=6118-6127&author=A.+Grecoauthor=C.+Marianiauthor=C.+Mirandaauthor=A.+Lupasauthor=S.+Pagliardiniauthor=M.+Pomatiauthor=M.+A.+Pierotti&title=The+DNA+rearrangement+that+generates+the+Trk-T3+oncogene+involves+a+nnovel+gene+on+chromosome-3+whose+product+has+a+potential+coiled-coil+domain&doi=10.1128%2FMCB.15.11.6118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain</span></div><div class="casAuthors">Greco, Angela; Mariani, Cristina; Miranda, Claudia; Lupas, Andrei; Pagliardini, Sonia; Pomati, Mauro; Pierotti, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6118-27</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Oncogenic rearrangements of the NTRK1 gene (also designated TRKA), encoding one of the receptors for nerve growth factor, are frequently detected in thyroid carcinomas.  Such rearrangements fuse the NTRK1 tyrosine kinase domain to 5'-end sequences belonging to different genes.  In previously reported studies the authors have demonstrated that NTRK1 oncogenic activation involves two genes, TPM3 and TPR, both localized similarly to the receptor tyrosine kinase, on the q arm of chromosome 1.  Here the authors report the characterization of a novel NTRK1-derived thyroid oncogene, named TRK-T3.  A cDNA clone, capable of transforming activity, was isolated from a transformant cell line.  Sequence anal. revealed that TRK-T3 contains 1412 nucleotides of NTRK1 preceded by 598 nucleotides belonging to a novel gene that the authors have named TFG (TRK-fused gene).  The TRK-T3 amino acid sequence displays, within the TFG region, a coiled-coil motif that could endow the oncoprotein with the capability to form complexes.  The TRK-T3 oncogene encodes a 68-kDa cytoplasmic protein reacting with NTRK1-specific antibodies.  By sedimentation gradient expts. the TRK-T3 oncoprotein was shown to form, in vivo, multimeric complexes, most likely trimers or tetramers.  The TFG gene is ubiquitously expressed and is located on chromosome 3.  The breakpoint producing the TRK-T3 oncogene occurs within exons of both the TFG gene and the NTRK1 gene and produces a chimeric exon that undergoes alternative splicing.  Mol. anal. of the NTRK1 rearranged fragments indicated that the chromosomal rearrangement is reciprocal and balanced and involves loss of a few nucleotides of germ line sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpcwCHCIAp7Vg90H21EOLACvtfcHk0liJ7VfjhnxOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVylu7s%253D&md5=e2a680bfd17f90e40faf4ed23baf4c98</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.11.6118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.11.6118%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DC.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DLupas%26aufirst%3DA.%26aulast%3DPagliardini%26aufirst%3DS.%26aulast%3DPomati%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DThe%2520DNA%2520rearrangement%2520that%2520generates%2520the%2520Trk-T3%2520oncogene%2520involves%2520a%2520nnovel%2520gene%2520on%2520chromosome-3%2520whose%2520product%2520has%2520a%2520potential%2520coiled-coil%2520domain%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26spage%3D6118%26epage%3D6127%26doi%3D10.1128%2FMCB.15.11.6118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Identification and biochemical characterization of p70TRK, product of the human TRK oncogene</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">6707</span>– <span class="NLM_lpage">6711</span>, <span class="refDoi"> DOI: 10.1073/pnas.84.19.6707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.84.19.6707" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=6707-6711&author=G.+Mitraauthor=D.+Martin-Zancaauthor=M.+Barbacid&title=Identification+and+biochemical+characterization+of+p70TRK%2C+product+of+the+human+TRK+oncogene&doi=10.1073%2Fpnas.84.19.6707"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.84.19.6707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.84.19.6707%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DG.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DIdentification%2520and%2520biochemical%2520characterization%2520of%2520p70TRK%252C%2520product%2520of%2520the%2520human%2520TRK%2520oncogene%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1987%26volume%3D84%26spage%3D6707%26epage%3D6711%26doi%3D10.1073%2Fpnas.84.19.6707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliardini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1201596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9488046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlGgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=809-816&author=A.+Grecoauthor=L.+Fusettiauthor=C.+Mirandaauthor=R.+Villaauthor=S.+Zanottiauthor=S.+Pagliardiniauthor=M.+A.+Pierotti&title=Role+of+the+TFG+N-terminus+and+coiled-coil+domain+in+the+transforming+activity+of+the+thyroid+TRK-T3+oncogene&doi=10.1038%2Fsj.onc.1201596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene</span></div><div class="casAuthors">Greco, Angela; Fusetti, Lisa; Miranda, Claudia; Villa, Riccardo; Zanotti, Simona; Pagliardini, Sonia; Pierotti, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-816</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The thyroid TRK-T3 oncogene results from the fusion of the tyrosine kinase (TK) domain of NTRK1 (one of the receptors for the Nerve Growth Factor) on chromosome 1 to sequences of a novel gene, TFG, on chromosome 3.  The 68 kDa TRK-T3 fusion oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform mouse NIH3T3 cells.  The TFG portion of TRK-T3 contains a coiled-coil domain most likely responsible for the constitutive, ligand-independent activation of the receptor tyrosine kinase activity.  It has been previously shown that TRK-T3 oncoprotein forms, in vivo, complexes of three or four mols.  By mean of different exptl. approaches, it is shown here that TRK-T3 activity depends on oligomers formation.  In addn., the anal. of different TRK-T3 mutants indicates that the TFG coiled-coil domain and its N-terminal region are both required for the activation and the fully transforming activity of the TRK-T3 oncoprotein, although, most likely, they play a role in different steps of the transforming process.  The deletion of the coiled-coil domain abrogates the oligomers formation leading to a constitutive activation; the deletion of the N-terminal region, although not affecting phosphorylation and complexes formation, abrogates transformation, thus suggesting a role in cellular localization and/or interaction with substrata.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVVcHfyYqbtbVg90H21EOLACvtfcHk0liJ7VfjhnxOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlGgtL4%253D&md5=916a02812313984aa591f5b164fd67a5</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201596%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DFusetti%26aufirst%3DL.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DVilla%26aufirst%3DR.%26aulast%3DZanotti%26aufirst%3DS.%26aulast%3DPagliardini%26aufirst%3DS.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520the%2520TFG%2520N-terminus%2520and%2520coiled-coil%2520domain%2520in%2520the%2520transforming%2520activity%2520of%2520the%2520thyroid%2520TRK-T3%2520oncogene%26jtitle%3DOncogene%26date%3D1998%26volume%3D16%26spage%3D809%26epage%3D816%26doi%3D10.1038%2Fsj.onc.1201596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gysin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies for targeting ras proteins</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1177/1947601911412376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1177%2F1947601911412376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21779505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=359-372&author=S.+Gysinauthor=M.+Saltauthor=A.+Youngauthor=F.+McCormick&title=Therapeutic+strategies+for+targeting+ras+proteins&doi=10.1177%2F1947601911412376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies for targeting Ras proteins</span></div><div class="casAuthors">Gysin, Stephan; Salt, Megan; Young, Amy; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-372</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ras genes are frequently activated in cancer.  Attempts to develop drugs that target mutant Ras proteins have, so far, been unsuccessful.  Tumors bearing these mutations, therefore, remain among the most difficult to treat.  Most efforts to block activated Ras have focused on pathways downstream.  Drugs that inhibit Raf kinase have shown clin. benefit in the treatment of malignant melanoma.  However, these drugs have failed to show clin. benefit in Ras mutant tumors.  It remains unclear to what extent Ras depends on Raf kinase for transforming activity, even though Raf proteins bind directly to Ras and are certainly major effectors of Ras action in normal cells and in development.  Furthermore, Raf kinase inhibitors can lead to paradoxical activation of the MAPK pathway.  MEK inhibitors block the Ras-MAPK pathway, but often activate the PI3'-kinase, and have shown little clin. benefit as single agents.  This activation is mediated by EGF-R and other receptor tyrosine kinases through relief of a neg. feedback loop from ERK.  Drug combinations that target multiple points within the Ras signaling network are likely to be necessary to achieve substantial clin. benefit.  Other effectors may also contribute to Ras signaling and provide a source of targets.  In addn., unbiased screens for genes necessary for Ras transformation have revealed new potential targets and have added to our understanding of Ras cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTnzEvjaufXrVg90H21EOLACvtfcHk0lgMJhSJBmigSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D&md5=f680dda525256c8388e417d45ebe4299</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1177%2F1947601911412376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601911412376%26sid%3Dliteratum%253Aachs%26aulast%3DGysin%26aufirst%3DS.%26aulast%3DSalt%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DTherapeutic%2520strategies%2520for%2520targeting%2520ras%2520proteins%26jtitle%3DGenes%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D359%26epage%3D372%26doi%3D10.1177%2F1947601911412376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oskam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Molecular and biochemical characterization of the human trk proto-oncogene</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1128/MCB.9.1.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.9.1.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=2927393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaL1MXmtV2ru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1989&pages=24-33&author=D.+Martin-Zancaauthor=R.+Oskamauthor=G.+Mitraauthor=T.+Copelandauthor=M.+Barbacid&title=Molecular+and+biochemical+characterization+of+the+human+trk+proto-oncogene&doi=10.1128%2FMCB.9.1.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and biochemical characterization of the human trk proto-oncogene</span></div><div class="casAuthors">Martin-Zanca, Dionisio; Oskam, Ralph; Mitra, Gopa; Copeland, Terry; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">Mol. anal. of the human trk oncogene, a transforming gene isolated from a colon biopsy, revealed the existence of a novel member of the tyrosine kinase gene family.  This locus codes for a protein of 790 amino acid residues that has several features characteristic of cell surface receptors.  They include (i) a 32-amino-acid-long putative signal peptide, (ii) an amino-terminal moiety (residues 33 to 407) rich in consensus sites for N-glycosylation, (iii) a transmembrane domain, (iv) a kinase catalytic region highly related to that of other tyrosine kinases, and (v) a very short (15 residue) carboxy-terminal tail.  Residues 1 to 392 were absent in the trk oncogene, as they were replaced by tropomyosin sequences.  However, no other differences were found between the transforming and nontransforming trk alleles (residues 392 to 790), suggesting that no addnl. mutations are required to activate the transforming potential of this gene.  The human trk proto-oncogene codes for a 140,000-dalton glycoprotein, designated gp140proto-trk.  However, its primary translational product is a 110,000-dalton glycoprotein which becomes immediately glycosylated, presumably during its translocation into the endoplasmic reticulum.  This mol., designated gp110proto-trk, is further glycosylated to yield the mature form, gp140proto-trk.  Both gp110proto-trk and gp140proto-trk proteins possess in vitro kinase activity specific for tyrosine residues.  Finally, iodination of intact NIH 3T3 cells expressing trk proto-oncogene products indicated that only the mature form, gp140proto-trk, cross the plasma membrane, becoming exposed to the outside of the cell.  These results indicate that the product of the human trk locus is a novel tyrosine kinase cell surface receptor for an as yet unknown ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru0x_s3mmlXrVg90H21EOLACvtfcHk0lgMJhSJBmigSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtV2ru78%253D&md5=6b98f810db97ba934de4c5e6a848abd9</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FMCB.9.1.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.9.1.24%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DOskam%26aufirst%3DR.%26aulast%3DMitra%26aufirst%3DG.%26aulast%3DCopeland%26aufirst%3DT.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMolecular%2520and%2520biochemical%2520characterization%2520of%2520the%2520human%2520trk%2520proto-oncogene%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1989%26volume%3D9%26spage%3D24%26epage%3D33%26doi%3D10.1128%2FMCB.9.1.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1999.2816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1006%2Fjmbi.1999.2816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1999&pages=149-159&author=M.+H.+Ultschauthor=C.+Wiesmannauthor=L.+C.+Simmonsauthor=J.+Henrichauthor=M.+Yangauthor=D.+Reillyauthor=S.+H.+Bassauthor=A.+M.+de+Vos&title=Crystal+structures+of+the+neurotrophin-binding+domain+of+TrkA%2C+TrkB+and+TrkC&doi=10.1006%2Fjmbi.1999.2816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.2816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.2816%26sid%3Dliteratum%253Aachs%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DSimmons%26aufirst%3DL.%2BC.%26aulast%3DHenrich%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DReilly%26aufirst%3DD.%26aulast%3DBass%26aufirst%3DS.%2BH.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structures%2520of%2520the%2520neurotrophin-binding%2520domain%2520of%2520TrkA%252C%2520TrkB%2520and%2520TrkC%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D290%26spage%3D149%26epage%3D159%26doi%3D10.1006%2Fjmbi.1999.2816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>401</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/43705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2F43705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10490030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=184-188&author=C.+Wiesmannauthor=M.+H.+Ultschauthor=S.+H.+Bassauthor=A.+M.+de+Vos&title=Crystal+structure+of+nerve+growth+factor+in+complex+with+the+ligand-binding+domain+of+the+TrkA+receptor&doi=10.1038%2F43705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor</span></div><div class="casAuthors">Wiesmann, Christian; Ultsch, Mark H.; Bass, Steven H.; De Vos, Abraham M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">184-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Nerve growth factor (NGF) is involved in a variety of processes involving signaling, such as cell differentiation and survival, growth cessation and apoptosis of neurons.  These events are mediated by NGF as a result of binding to its two cell-surface receptors, TrkA and p75.  TrkA is a receptor with tyrosine kinase activity that forms a high-affinity binding site for NGF.  Of the five domains comprising its extracellular portion, the Ig-like domain proximal to the membrane (TrkA-d5 domain) is necessary and sufficient for NGF binding.  Here we present the crystal structure of human NGF in complex with human TrkA-d5 at 2.2 Å resoln.  The ligand-receptor interface consists of two patches of similar size.  One patch involves the central β-sheet that forms the core of the homodimeric NGF mol. and the loops at the carboxy-terminal pole of TrkA-d5.  The second patch comprises the amino-terminal residues of NGF, which adopt a helical conformation upon complex formation, packing against the 'ABED' sheet of TrkA-d5.  The structure is consistent with results from mutagenesis expts. for all neurotrophins, and indicates that the first patch may constitute a conserved binding motif for all family members, whereas the second patch is specific for the interaction between NGF and TrkA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLzeWkHXAgWrVg90H21EOLACvtfcHk0lgMJhSJBmigSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrs%253D&md5=3562e557288cf0c986b7bcb42258b59c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2F43705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43705%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DBass%26aufirst%3DS.%2BH.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520nerve%2520growth%2520factor%2520in%2520complex%2520with%2520the%2520ligand-binding%2520domain%2520of%2520the%2520TrkA%2520receptor%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D184%26epage%3D188%26doi%3D10.1038%2F43705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweiger, M.</span></span> <span> </span><span class="NLM_article-title">A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1811</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1656363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK38XisVKh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=1807-1811&author=R.+Schneiderauthor=M.+Schweiger&title=A+novel+modular+mosaic+of+cell+adhesion+motifs+in+the+extracellular+domains+of+the+neurogenic+trk+and+trkB+tyrosine+kinase+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors</span></div><div class="casAuthors">Schneider, R.; Schweiger, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1807-11</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The extracellular domains of the human trk protooncogene and the closely homologous murine trkB share 2 highly conserved regions as well as several invariant cysteines which are supposed to be important for ligand recognition.  Detailed comparative sequence analyses have now revealed the presence of a novel combination of distinct cell adhesion motifs corresponding precisely with these conserved regions.  The N-terminal part consists of an array of 3 tandem leucine-rich motifs of 24 amino acids which is flanked by 2 distinct cysteine clusters.  Significantly homologous structural features are found in the toll gene product of Drosophila, a transmembrane protein mediating specific cell adhesion events involved in the dorsoventral embryonic pattern formation.  Directly adjacent to these structures two repeats of the Ig-like C2 type were identified, which are significantly similar to repeats found in the neural cell adhesion mols. (N-CAMs) and in the platelet-derived growth factor receptor (PDGFR)-like tyrosine kinase receptor family.  The findings indicate that the trk/trkB protein tyrosine kinase receptors are involved in the transmembrane signalling of growth factor binding as well as of specific cell adhesion events during neuronal development.  Addnl., it is proposed that the specifically expressed truncated forms of the trkB receptor, lacking the tyrosine kinase domain, are functioning as neural cell adhesion mols.  The knowledge of this domain structure will facilitate the elucidation of the mol. reasons why alterations in the extracellular region lead to oncogenic activation of the human trk protooncogene, which is a major cause of papillary thyroid carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKoCn1JzNpG7Vg90H21EOLACvtfcHk0liolnu-ZFDpDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVKh&md5=87ec0daabaccbe4541b69616771bec48</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DSchweiger%26aufirst%3DM.%26atitle%3DA%2520novel%2520modular%2520mosaic%2520of%2520cell%2520adhesion%2520motifs%2520in%2520the%2520extracellular%2520domains%2520of%2520the%2520neurogenic%2520trk%2520and%2520trkB%2520tyrosine%2520kinase%2520receptors%26jtitle%3DOncogene%26date%3D1991%26volume%3D6%26spage%3D1807%26epage%3D1811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geetha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rege, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, J. R.</span></span> <span> </span><span class="NLM_article-title">Nerve growth factor receptor TrkA, a new receptor in insulin signaling pathway in PC12 cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">23807</span>– <span class="NLM_lpage">23813</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.436279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.M112.436279" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=23807-23813&author=T.+Geethaauthor=S.+D.+Regeauthor=S.+E.+Mathewsauthor=S.+O.+Meakinauthor=M.+F.+Whiteauthor=J.+R.+Babu&title=Nerve+growth+factor+receptor+TrkA%2C+a+new+receptor+in+insulin+signaling+pathway+in+PC12+cells&doi=10.1074%2Fjbc.M112.436279"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.436279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.436279%26sid%3Dliteratum%253Aachs%26aulast%3DGeetha%26aufirst%3DT.%26aulast%3DRege%26aufirst%3DS.%2BD.%26aulast%3DMathews%26aufirst%3DS.%2BE.%26aulast%3DMeakin%26aufirst%3DS.%2BO.%26aulast%3DWhite%26aufirst%3DM.%2BF.%26aulast%3DBabu%26aufirst%3DJ.%2BR.%26atitle%3DNerve%2520growth%2520factor%2520receptor%2520TrkA%252C%2520a%2520new%2520receptor%2520in%2520insulin%2520signaling%2520pathway%2520in%2520PC12%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D23807%26epage%3D23813%26doi%3D10.1074%2Fjbc.M112.436279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hempstead, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">The trk proto-oncogene product: a signal transducing receptor for nerve growth factor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>252</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1126/science.1850549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.1850549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1850549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXisVWgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1991&pages=554-558&author=D.+R.+Kaplanauthor=B.+L.+Hempsteadauthor=D.+Martin-Zancaauthor=M.+V.+Chaoauthor=L.+F.+Parada&title=The+trk+proto-oncogene+product%3A+a+signal+transducing+receptor+for+nerve+growth+factor&doi=10.1126%2Fscience.1850549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The trk proto-oncogene product:  a signal transducing receptor for nerve growth factor</span></div><div class="casAuthors">Kaplan, David R.; Hempstead, Barbara L.; Martin-Zanca, Dionisio; Chao, Moses V.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">252</span>
        (<span class="NLM_cas:issue">5005</span>),
    <span class="NLM_cas:pages">554-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The trk proto-oncogene encodes a 140-kilodalton, membrane-spanning protein tyrosine kinase (p140prototrk) that is expressed only in neural tissues.  Nerve growth factor (NGF) stimulates phosphorylation of p140prototrk in neural cell lines and in embσyonic dorsal root ganglia.  Affinity crosslinking and equil. binding expts. with 125I-labeled NGF indicate that p140prototrk binds NGF specifically in cultured cells with a dissocn. const. of 10-9 M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOsZ0C6-OsXrVg90H21EOLACvtfcHk0liolnu-ZFDpDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVWgtrg%253D&md5=5daf16d6938c40bbeb4c44fc58a5df87</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1126%2Fscience.1850549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1850549%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DHempstead%26aufirst%3DB.%2BL.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DChao%26aufirst%3DM.%2BV.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DThe%2520trk%2520proto-oncogene%2520product%253A%2520a%2520signal%2520transducing%2520receptor%2520for%2520nerve%2520growth%2520factor%26jtitle%3DScience%26date%3D1991%26volume%3D252%26spage%3D554%26epage%3D558%26doi%3D10.1126%2Fscience.1850549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Squinto, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stitt, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RadzieJewski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masiakowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furth, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distefano, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">TrkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90395-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990395-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1710174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXks1Gnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=885-893&author=S.+P.+Squintoauthor=T.+N.+Stittauthor=T.+H.+Aldrichauthor=S.+Davisauthor=S.+M.+Blancoauthor=C.+RadzieJewskiauthor=D.+J.+Glassauthor=P.+Masiakowskiauthor=M.+E.+Furthauthor=D.+M.+Valenzuelaauthor=P.+S.+Distefanoauthor=G.+D.+Yancopoulos&title=TrkB+encodes+a+functional+receptor+for+brain-derived+neurotrophic+factor+and+neurotrophin-3+but+not+nerve+growth+factor&doi=10.1016%2F0092-8674%2891%2990395-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB encodes a functional receptor for brain-derived neurotropic factor and neurotrophin-3 but not nerve growth factor</span></div><div class="casAuthors">Squinto, Stephen P.; Stitt, Trevor N.; Aldrich, Thomas H.; Davis, Samuel; Bianco, Stella M.; Radziejewski, Czeslaw; Glass, David J.; Masiakowski, Piotr; Furth, Mark E.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">885-93</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A variety of findings seem to functionally link brain-derived neurotropic factor (BDNF) and neurotrophin-3 (NT-3), while distinguishing both of these factors from the third member of the neurotrophin family, nerve growth factor (NGF).  It is demonstrated that all 3 of these neuronal survival mols. bind similarly to the low affinity NGF receptor, but that BDNF and NT-3, unlike NGF, do not act via the high affinity NGF receptor.  However, both BDNF and NT-3, but not NGF, bind to full-length and truncated forms of a receptor-like tyrosine kinase, trkB, for which no ligand had previously been identified.  In addn. to binding BDNF and NT-3, trkB can mediate functional responses to both of these neurotrophins when it is expressed in PC12 cells, although BDNF appears to be the more effective ligand.  Thus trkB encodes an essential component of a functional receptor for BDNF and NT-3, but not for NGF.  Further evidence predicts the existence of addnl. functional receptors for the neurotrophins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqElX9eizlBwLVg90H21EOLACvtfcHk0liolnu-ZFDpDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXks1Gnur4%253D&md5=f00debdf449455a7105f172e3c088cdd</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990395-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990395-F%26sid%3Dliteratum%253Aachs%26aulast%3DSquinto%26aufirst%3DS.%2BP.%26aulast%3DStitt%26aufirst%3DT.%2BN.%26aulast%3DAldrich%26aufirst%3DT.%2BH.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DBlanco%26aufirst%3DS.%2BM.%26aulast%3DRadzieJewski%26aufirst%3DC.%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DMasiakowski%26aufirst%3DP.%26aulast%3DFurth%26aufirst%3DM.%2BE.%26aulast%3DValenzuela%26aufirst%3DD.%2BM.%26aulast%3DDistefano%26aufirst%3DP.%2BS.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DTrkB%2520encodes%2520a%2520functional%2520receptor%2520for%2520brain-derived%2520neurotrophic%2520factor%2520and%2520neurotrophin-3%2520but%2520not%2520nerve%2520growth%2520factor%26jtitle%3DCell%26date%3D1991%26volume%3D65%26spage%3D885%26epage%3D893%26doi%3D10.1016%2F0092-8674%2891%2990395-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanduri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">The trk proto-oncogene encodes a receptor for nerve growth factor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90419-Y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990419-Y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1849459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3MXisVWgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=189-197&author=R.+Kleinauthor=S.+Q.+Jingauthor=V.+Nanduriauthor=E.+O%E2%80%99Rourkeauthor=M.+Barbacid&title=The+trk+proto-oncogene+encodes+a+receptor+for+nerve+growth+factor&doi=10.1016%2F0092-8674%2891%2990419-Y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The trk proto-oncogene encodes a receptor for nerve growth factor</span></div><div class="casAuthors">Klein, Ruediger; Jing, Shuqian; Nanduri, Venkata; O'Rourke, Edward; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-97</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Two classes of receptors with distinct affinities for nerve growth factor (NGF) have been identified.  The low affinity receptor (Kd ≈ 10-9-10-8M) is a cysteine-rich glycoprotein encoded by the previously characterized LNGFR gene.  The structural nature of the high affinity receptor (Kd ≈ 10-10M) has yet to be established.  The product of the human trk proto-oncogene (gp140trk) bound NGF with high affinity.  Moreover, NGF could be chem. cross-linked to the endogenous gp140trk present in rat PC12 pheochromocytoma cells, as well as to gp140trk ectopically expressed in mouse fibroblasts and in insect Sf9 cells.  High affinity binding of NGF to gp140trk could occur in the absence of low affinity LNGFR receptors, at least in nonneural cells.  Addn. of NGF to PC12 cells elicited rapid phosphorylation of gp140trk on tyrosine residues and stimulated its tyrosine kinase activity.  Apparently, gp14-trk is a functional NGF receptor that mediates at least some of the signal transduction processes initiated by this neurotropic factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlUBY2nUNMtLVg90H21EOLACvtfcHk0lj_bm-5jSjpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVWgs7Y%253D&md5=362cd01ed7fdf258cfe7f59169b6b5ee</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990419-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990419-Y%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DS.%2BQ.%26aulast%3DNanduri%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DE.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DThe%2520trk%2520proto-oncogene%2520encodes%2520a%2520receptor%2520for%2520nerve%2520growth%2520factor%26jtitle%3DCell%26date%3D1991%26volume%3D65%26spage%3D189%26epage%3D197%26doi%3D10.1016%2F0092-8674%2891%2990419-Y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamballe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90442-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2891%2990442-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1653651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK38Xmt12jsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1991&pages=967-979&author=F.+Lamballeauthor=R.+Kleinauthor=M.+Barbacid&title=TrkC%2C+a+new+member+of+the+trk+family+of+tyrosine+protein+kinases%2C+is+a+receptor+for+neurotrophin-3&doi=10.1016%2F0092-8674%2891%2990442-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3</span></div><div class="casAuthors">Lamballe, Fabienne; Klein, Rudiger; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">967-79</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The isolation and mol. characterization of trkC, a new member of the trk family of tyrosine protein kinase genes is reported.  Gene trkC is preferentially expressed in the brain.  In situ hybridization studies revealed trkC transcripts in the hippocampus, cerebral cortex, and the granular cell layer of the cerebellum.  The product of the trkC gene was identified as a glycoprotein of 145,000 daltons, gp145trkC, which is equally related to the previously characterized gp140trk and gp145trkB tyrosine kinases.  Glycoprotein gp145trkC is a functional receptor for neurotrophin-3 (NT-3).  However, gp145trkC does not bind the highly related neurotrophic factors, NGF or BDNF.  In proliferating cells, the interaction between gp145trkC and NT-3 elicits a more efficient biol. response than when NT-3 binds to its other receptors, gp140trk and gp145trkB.  These results indicate that gp145trkC may play an important role in mediating the neurotrophic effects of NT-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp1C6bvPklNLVg90H21EOLACvtfcHk0lj_bm-5jSjpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xmt12jsro%253D&md5=8aa49b5b94d3f1f337ae097d246e8e9e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990442-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990442-2%26sid%3Dliteratum%253Aachs%26aulast%3DLamballe%26aufirst%3DF.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DTrkC%252C%2520a%2520new%2520member%2520of%2520the%2520trk%2520family%2520of%2520tyrosine%2520protein%2520kinases%252C%2520is%2520a%2520receptor%2520for%2520neurotrophin-3%26jtitle%3DCell%26date%3D1991%26volume%3D66%26spage%3D967%26epage%3D979%26doi%3D10.1016%2F0092-8674%2891%2990442-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobley, W. C.</span></span> <span> </span><span class="NLM_article-title">Early BDNF, NT-3, and NT-4 signaling events</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1006/exnr.1999.7148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1006%2Fexnr.1999.7148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10486198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVWqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=1999&pages=297-308&author=E.+C.+Yuenauthor=W.+C.+Mobley&title=Early+BDNF%2C+NT-3%2C+and+NT-4+signaling+events&doi=10.1006%2Fexnr.1999.7148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Early BDNF, NT-3, and NT-4 Signaling Events</span></div><div class="casAuthors">Yuen, Eric C.; Mobley, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Much more is known about nerve growth factor (NGF) signaling than that initiated by brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), or NT-4.  The authors sought to study early BDNF, NT-3, and NT-4 signaling events.  Using TrkB-expressing cells, the authors found that BDNF and NT-4 individually induced tyrosine phosphorylation of TrkB in a dose-dependent fashion.  At maximally effective concns., BDNF or NT-4 induced robust TrkB tyrosine phosphorylation at 5 min; this progressively declined at 15, 30, and 60 min.  Using immunopptn., PI3-kinase and tyrosine phosphorylated PLC-γ1 and SHC were shown to be assocd. with tyrosine phosphorylated TrkB in response to both BDNF and NT-4.  BDNF and NT-4 induced similar intensities of phosphorylation of TrkB and signaling intermediates at equiv. doses.  NT-3 treatment of TrkC-expressing cells induced very similar patterns for induction of TrkC tyrosine phosphorylation and recruitment of signaling intermediates.  BDNF, NT-3, and NT-4 caused rapid tyrosine phosphorylation of ERK and SNT.  These data suggest that the earliest signaling events for BDNF, NT-3, and NT-4 are very similar to those for NGF.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHikLwhhyc7Vg90H21EOLACvtfcHk0lj_bm-5jSjpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVWqsL4%253D&md5=f48a52261fc456fa4572a57fcfb524f2</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1006%2Fexnr.1999.7148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.1999.7148%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DE.%2BC.%26aulast%3DMobley%26aufirst%3DW.%2BC.%26atitle%3DEarly%2520BDNF%252C%2520NT-3%252C%2520and%2520NT-4%2520signaling%2520events%26jtitle%3DExp.%2520Neurol.%26date%3D1999%26volume%3D159%26spage%3D297%26epage%3D308%26doi%3D10.1006%2Fexnr.1999.7148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crenne, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span> <span> </span><span class="NLM_article-title">The crystal structures of trkA and trkB suggest key regions for achieving selective inhibition</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2012.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.jmb.2012.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22902478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=439-453&author=T.+Bertrandauthor=M.+Kotheauthor=J.+Liuauthor=A.+Dupuyauthor=A.+Rakauthor=P.+F.+Berneauthor=S.+Davisauthor=T.+Gladyshevaauthor=C.+Valtreauthor=J.+Y.+Crenneauthor=M.+Mathieu&title=The+crystal+structures+of+trkA+and+trkB+suggest+key+regions+for+achieving+selective+inhibition&doi=10.1016%2Fj.jmb.2012.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition</span></div><div class="casAuthors">Bertrand, T.; Kothe, M.; Liu, J.; Dupuy, A.; Rak, A.; Berne, P. F.; Davis, S.; Gladysheva, T.; Valtre, C.; Crenne, J. Y.; Mathieu, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-453</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Trk family of neurotrophin receptors, which includes the three highly homologous proteins TrkA, TrkB and TrkC, is strongly assocd. with central and peripheral nervous system processes.  Trk proteins are also of interest in oncol., since Trk activation has been obsd. in several cancer types.  While Trk kinases are attractive oncol. targets, selectivity might be more of an issue than for other kinases due to potential CNS side effects if several Trk kinases are simultaneously targeted.  In order to address this issue, we present here the first structures of human TrkA and TrkB kinase domains and three complexes between TrkB and Trk inhibitors.  These structures reveal different conformations of the kinase domain and suggest new regions of selectivity among the Trk family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryh_7mc93WjLVg90H21EOLACvtfcHk0lhMwQ3fWsMomw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN&md5=39409144c4655d93164a881cc28a6115</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDupuy%26aufirst%3DA.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DBerne%26aufirst%3DP.%2BF.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DGladysheva%26aufirst%3DT.%26aulast%3DValtre%26aufirst%3DC.%26aulast%3DCrenne%26aufirst%3DJ.%2BY.%26aulast%3DMathieu%26aufirst%3DM.%26atitle%3DThe%2520crystal%2520structures%2520of%2520trkA%2520and%2520trkB%2520suggest%2520key%2520regions%2520for%2520achieving%2520selective%2520inhibition%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D423%26spage%3D439%26epage%3D453%26doi%3D10.1016%2Fj.jmb.2012.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. H.</span></span> <span> </span><span class="NLM_article-title">Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.2174/0929867043455792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2174%2F0929867043455792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15032722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFWgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=663-673&author=M.+Cherryauthor=D.+H.+Williams&title=Recent+kinase+and+kinase+inhibitor+X-ray+structures%3A+mechanisms+of+inhibition+and+selectivity+insights&doi=10.2174%2F0929867043455792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Recent kinase and kinase inhibitor x-ray structures: mechanisms of inhibition and selectivity insights</span></div><div class="casAuthors">Cherry, M.; Williams, D. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">663-673</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent years have seen an explosion in the no. of publicly available x-ray crystal structures of protein kinases.  These structures have provided a wealth of information on the regulatory mechanisms, conformational plasticity and drugability of this important family of enzymes.  Drawing upon structural information, new insights into the development of protein kinase inhibitors are discussed including de-novo design, mol. templates for ATP competitive inhibitors and alternative mechanisms of inhibition.  The highly conserved nature of the ATP binding site is of central concern to drug development and the concept of a selectivity profile has arisen with structure-based design emerging as a key tool for addressing the challenges of specificity.  In addn., protein-ligand complexes, where the enzyme is in an inactive conformation, signify an alternate approach to protein kinase inhibition.  The belief that an inactive kinase presents a less conserved target is reviewed using observations on the structural changes occurring during protein kinase regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB19ovXBL1mrVg90H21EOLACvtfcHk0lhMwQ3fWsMomw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFWgs7w%253D&md5=63c621c012a6e1cc9f795565580d7492</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2174%2F0929867043455792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043455792%26sid%3Dliteratum%253Aachs%26aulast%3DCherry%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26atitle%3DRecent%2520kinase%2520and%2520kinase%2520inhibitor%2520X-ray%2520structures%253A%2520mechanisms%2520of%2520inhibition%2520and%2520selectivity%2520insights%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D663%26epage%3D673%26doi%3D10.2174%2F0929867043455792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Nerve growth-factor mediates signal transduction through Trk homodimer receptors</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1079</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(92)90066-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0896-6273%2892%2990066-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1281417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVCht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1992&pages=1067-1079&author=S.+Q.+Jingauthor=P.+Tapleyauthor=M.+Barbacid&title=Nerve+growth-factor+mediates+signal+transduction+through+Trk+homodimer+receptors&doi=10.1016%2F0896-6273%2892%2990066-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Nerve growth factor mediates signal transduction through trk homodimer receptors</span></div><div class="casAuthors">Jing, Shuqian; Tapley, Peter; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1067-79</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">The mol. nature of the high affinity nerve growth factor (NGF) receptors was investigated by using cell lines expressing gp75LNGFR and gp140trk.  Gp75LNGFR and gp140trk. interact with NGF independently and that only gp140trk mediates NGF signaling.  NGF binds to gp140trk with picomolar affinity and induces its phosphorylation on tyrosine residues regardless of the presence of gp75LNGFR.  NGF-gp140trk complexes display the slow dissocn. rate and rapid internalization characteristics of high affinity NGF receptors.  Crosslinking studies reveal the existence of gp75LNGFR and gp140trk homodimers.  However, gp75LNGFR-pg 140trk heterodimers were not detected.  Coexpression in COS cells of wild-type and kinase deficient mutants reveals that gp140trk receptors can undergo intermol. phosphorylation, indicating the formation of functional homodimers.  Moreover, these kinase deficient mutants inhibit NGF-induced signaling through wild-type gp140trk receptors.  These results indicate that the functional high affinity NGF receptors consist of gp140trk homodimeric (or oligomeric) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSQLmINGdcU7Vg90H21EOLACvtfcHk0lhMwQ3fWsMomw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVCht7g%253D&md5=f861b0c299299b4f409ae8fe37a4d72d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2892%2990066-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252892%252990066-M%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DS.%2BQ.%26aulast%3DTapley%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DNerve%2520growth-factor%2520mediates%2520signal%2520transduction%2520through%2520Trk%2520homodimer%2520receptors%26jtitle%3DNeuron%26date%3D1992%26volume%3D9%26spage%3D1067%26epage%3D1079%26doi%3D10.1016%2F0896-6273%2892%2990066-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span> <span> </span><span class="NLM_article-title">Autophosphorylation of activation loop tyrosines regulates signaling by the TRK nerve growth factor receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">10957</span>– <span class="NLM_lpage">10967</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.16.10957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.272.16.10957" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=10957-10967&author=M.+E.+Cunninghamauthor=R.+M.+Stephensauthor=D.+R.+Kaplanauthor=L.+A.+Greene&title=Autophosphorylation+of+activation+loop+tyrosines+regulates+signaling+by+the+TRK+nerve+growth+factor+receptor&doi=10.1074%2Fjbc.272.16.10957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.16.10957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.16.10957%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DM.%2BE.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26atitle%3DAutophosphorylation%2520of%2520activation%2520loop%2520tyrosines%2520regulates%2520signaling%2520by%2520the%2520TRK%2520nerve%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D10957%26epage%3D10967%26doi%3D10.1074%2Fjbc.272.16.10957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span> <span> </span><span class="NLM_article-title">A function-structure model for NGF-activated TRK</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7282</span>– <span class="NLM_lpage">7293</span>, <span class="refDoi"> DOI: 10.1093/emboj/17.24.7282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1093%2Femboj%2F17.24.7282" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=7282-7293&author=M.+E.+Cunninghamauthor=L.+A.+Greene&title=A+function-structure+model+for+NGF-activated+TRK&doi=10.1093%2Femboj%2F17.24.7282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.24.7282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.24.7282%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DM.%2BE.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26atitle%3DA%2520function-structure%2520model%2520for%2520NGF-activated%2520TRK%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D7282%26epage%3D7293%26doi%3D10.1093%2Femboj%2F17.24.7282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Middlemas, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenhelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">Identification of Trkb autophosphorylation sites and evidence that phospholipase C-gamma-1 is a substrate of the Trkb receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">5458</span>– <span class="NLM_lpage">5466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=5458-5466&author=D.+S.+Middlemasauthor=J.+Meisenhelderauthor=T.+Hunter&title=Identification+of+Trkb+autophosphorylation+sites+and+evidence+that+phospholipase+C-gamma-1+is+a+substrate+of+the+Trkb+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiddlemas%26aufirst%3DD.%2BS.%26aulast%3DMeisenhelder%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DIdentification%2520of%2520Trkb%2520autophosphorylation%2520sites%2520and%2520evidence%2520that%2520phospholipase%2520C-gamma-1%2520is%2520a%2520substrate%2520of%2520the%2520Trkb%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D5458%26epage%3D5466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span> <span> </span><span class="NLM_article-title">A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">8901</span>– <span class="NLM_lpage">8910</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=8901-8910&author=D.+M.+Loebauthor=R.+M.+Stephensauthor=T.+Copelandauthor=D.+R.+Kaplanauthor=L.+A.+Greene&title=A+Trk+nerve+growth+factor+%28NGF%29+receptor+point+mutation+affecting+interaction+with+phospholipase+C-gamma+1+abolishes+NGF-promoted+peripherin+induction+but+not+neurite+outgrowth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoeb%26aufirst%3DD.%2BM.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DCopeland%26aufirst%3DT.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26atitle%3DA%2520Trk%2520nerve%2520growth%2520factor%2520%2528NGF%2529%2520receptor%2520point%2520mutation%2520affecting%2520interaction%2520with%2520phospholipase%2520C-gamma%25201%2520abolishes%2520NGF-promoted%2520peripherin%2520induction%2520but%2520not%2520neurite%2520outgrowth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D8901%26epage%3D8910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmuller, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Identification of Trk binding sites for SHC and phosphatidylinositol 3′-kinase and formation of a multimeric signaling complex</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">22963</span>– <span class="NLM_lpage">22966</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=22963-22966&author=A.+Obermeierauthor=R.+Lammersauthor=K.+H.+Wiesmullerauthor=G.+Jungauthor=J.+Schlessingerauthor=A.+Ullrich&title=Identification+of+Trk+binding+sites+for+SHC+and+phosphatidylinositol+3%E2%80%B2-kinase+and+formation+of+a+multimeric+signaling+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObermeier%26aufirst%3DA.%26aulast%3DLammers%26aufirst%3DR.%26aulast%3DWiesmuller%26aufirst%3DK.%2BH.%26aulast%3DJung%26aufirst%3DG.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520Trk%2520binding%2520sites%2520for%2520SHC%2520and%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%2520and%2520formation%2520of%2520a%2520multimeric%2520signaling%2520complex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D22963%26epage%3D22966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedorf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1585</span>– <span class="NLM_lpage">1590</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1994.tb06421.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fj.1460-2075.1994.tb06421.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1994&pages=1585-1590&author=A.+Obermeierauthor=R.+A.+Bradshawauthor=K.+Seedorfauthor=A.+Choidasauthor=J.+Schlessingerauthor=A.+Ullrich&title=Neuronal+differentiation+signals+are+controlled+by+nerve+growth+factor+receptor%2FTrk+binding+sites+for+SHC+and+PLC+gamma&doi=10.1002%2Fj.1460-2075.1994.tb06421.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1994.tb06421.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1994.tb06421.x%26sid%3Dliteratum%253Aachs%26aulast%3DObermeier%26aufirst%3DA.%26aulast%3DBradshaw%26aufirst%3DR.%2BA.%26aulast%3DSeedorf%26aufirst%3DK.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DNeuronal%2520differentiation%2520signals%2520are%2520controlled%2520by%2520nerve%2520growth%2520factor%2520receptor%252FTrk%2520binding%2520sites%2520for%2520SHC%2520and%2520PLC%2520gamma%26jtitle%3DEMBO%2520J.%26date%3D1994%26volume%3D13%26spage%3D1585%26epage%3D1590%26doi%3D10.1002%2Fj.1460-2075.1994.tb06421.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span> <span> </span><span class="NLM_article-title">Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(94)90223-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0896-6273%2894%2990223-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=8155326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2cXitlKqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=691-705&author=R.+M.+Stephensauthor=D.+M.+Loebauthor=T.+D.+Copelandauthor=T.+Pawsonauthor=L.+A.+Greeneauthor=D.+R.+Kaplan&title=Trk+receptors+use+redundant+signal+transduction+pathways+involving+SHC+and+PLC-%CE%B31+to+mediate+NGF+responses&doi=10.1016%2F0896-6273%2894%2990223-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses</span></div><div class="casAuthors">Stephens, Robert M.; Loeb, David M.; Copeland, Terry D.; Pawson, Tony; Greene, Lloyd A.; Kaplan, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">ISS/REP#/MLT:  3</span>),
    <span class="NLM_cas:pages">691-705</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">In response to NGF, the Trk receptor tyrosine kinase forms a complex with SHC, a protein that couples receptor tyrosine kinases to p21ras.  Complex formation between Trk and SHC, SHC tyrosine phosphorylation, and assocn. of SHC with Grb2 were mediated by autophosphorylation at Y490 in trk (NPQYFSD).  To det. the role of SHC and other Trk substrates in NGF signaling, Trk receptors with mutations in Y490 and Y785 (the PLC-γ1 assocn. site) were introduced into PC12nnr5 cells.  NGF treatment of PC12nnr5 cells expressing Trk with mutations in either substrate-binding site resulted in normal neurite outgrowth and Erk1 activity and tyrosine phosphorylation.  However, PC12nnr5 cells expressing Trk with mutations at both sites failed to stably extend neurites and efficiently induce Erk1 activity and tyrosine phosphorylation in response to NGF.  The authors postulate that Trk receptors can activate Erk1 by either SHC- or PLC-γ1-dependent signaling pathways.  These results suggest a model whereby Trk receptors utilize at least partially redundant signal transduction pathways to mediate NGF responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlp14Enz7B17Vg90H21EOLACvtfcHk0ljqb28xBP3Ofg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlKqur0%253D&md5=f23ea0ae13424a0ebc5cb237d7b181e4</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2894%2990223-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252894%252990223-2%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DLoeb%26aufirst%3DD.%2BM.%26aulast%3DCopeland%26aufirst%3DT.%2BD.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DGreene%26aufirst%3DL.%2BA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26atitle%3DTrk%2520receptors%2520use%2520redundant%2520signal%2520transduction%2520pathways%2520involving%2520SHC%2520and%2520PLC-%25CE%25B31%2520to%2520mediate%2520NGF%2520responses%26jtitle%3DNeuron%26date%3D1994%26volume%3D12%26spage%3D691%26epage%3D705%26doi%3D10.1016%2F0896-6273%2894%2990223-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patapoutian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span> <span> </span><span class="NLM_article-title">Trk receptors: mediators of neurotrophin action</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1016/S0959-4388(00)00208-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-4388%2800%2900208-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=272-280&author=A.+Patapoutianauthor=L.+F.+Reichardt&title=Trk+receptors%3A+mediators+of+neurotrophin+action&doi=10.1016%2FS0959-4388%2800%2900208-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2800%2900208-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252800%252900208-7%26sid%3Dliteratum%253Aachs%26aulast%3DPatapoutian%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26atitle%3DTrk%2520receptors%253A%2520mediators%2520of%2520neurotrophin%2520action%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D2001%26volume%3D11%26spage%3D272%26epage%3D280%26doi%3D10.1016%2FS0959-4388%2800%2900208-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">14863</span>– <span class="NLM_lpage">14866</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.25.14863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.270.25.14863" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=14863-14866&author=Z.+Songyangauthor=B.+Margolisauthor=M.+Chaudhuriauthor=S.+E.+Shoelsonauthor=L.+C.+Cantley&title=The+phosphotyrosine+interaction+domain+of+SHC+recognizes+tyrosine-phosphorylated+NPXY+motif&doi=10.1074%2Fjbc.270.25.14863"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.25.14863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.25.14863%26sid%3Dliteratum%253Aachs%26aulast%3DSongyang%26aufirst%3DZ.%26aulast%3DMargolis%26aufirst%3DB.%26aulast%3DChaudhuri%26aufirst%3DM.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520phosphotyrosine%2520interaction%2520domain%2520of%2520SHC%2520recognizes%2520tyrosine-phosphorylated%2520NPXY%2520motif%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D14863%26epage%3D14866%26doi%3D10.1074%2Fjbc.270.25.14863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batzer, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(92)90167-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0092-8674%2892%2990167-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1322798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXkt1ajtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1992&pages=431-442&author=E.+J.+Lowensteinauthor=R.+J.+Dalyauthor=A.+G.+Batzerauthor=W.+Liauthor=B.+Margolisauthor=R.+Lammersauthor=A.+Ullrichauthor=E.+Y.+Skolnikauthor=D.+Bar-Sagiauthor=J.+Schlessinger&title=The+SH2+and+SH3+domain-containing+protein+GRB2+links+receptor+tyrosine+kinases+to+ras+signaling&doi=10.1016%2F0092-8674%2892%2990167-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling</span></div><div class="casAuthors">Lowenstein, E. J.; Daly, R. J.; Batzer, A. G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E. Y.; Bar-Sagi, D.; Schlessinger, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-42</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) contg. one src homol. 2 (SH2) domain and two SH3 domains was isolated.  Immunoblotting expts. indicate that GRB2 assocs. with tyrosine-phosphorylated epidermal growth factor receptors (EGFRs) and platelet-derived growth factor receptors (PDGFRs) via its SH2 domain.  Interestingly, GRB2 exhibits striking structural and functional homol. to the Caenorhabditis elegans protein sem-5.  To examine whether GRB2 is also a component of ras signaling in mammalian cells, microinjection studies were performed.  While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.  These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo0LYdxA1IuLVg90H21EOLACvtfcHk0lhMLFo32V8GDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkt1ajtbg%253D&md5=86885e1cbee3f637ae9470aa9f8c264e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2892%2990167-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252892%252990167-B%26sid%3Dliteratum%253Aachs%26aulast%3DLowenstein%26aufirst%3DE.%2BJ.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DBatzer%26aufirst%3DA.%2BG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMargolis%26aufirst%3DB.%26aulast%3DLammers%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSkolnik%26aufirst%3DE.%2BY.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DThe%2520SH2%2520and%2520SH3%2520domain-containing%2520protein%2520GRB2%2520links%2520receptor%2520tyrosine%2520kinases%2520to%2520ras%2520signaling%26jtitle%3DCell%26date%3D1992%26volume%3D70%26spage%3D431%26epage%3D442%26doi%3D10.1016%2F0092-8674%2892%2990167-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonfini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, U.</span></span> <span> </span><span class="NLM_article-title">The Son of sevenless gene product: a putative activator of Ras</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1126/science.1736363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.1736363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1736363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3sXisVyks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1992&pages=603-606&author=L.+Bonfiniauthor=C.+A.+Karlovichauthor=C.+Dasguptaauthor=U.+Banerjee&title=The+Son+of+sevenless+gene+product%3A+a+putative+activator+of+Ras&doi=10.1126%2Fscience.1736363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The Son of sevenless gene product:  a putative activator of Ras</span></div><div class="casAuthors">Bonfini, Laura; Karlovich, Chris A.; Dasgupta, Chiranjib; Banerjee, Utpal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">5044</span>),
    <span class="NLM_cas:pages">603-6</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The Son of sevenless (Sos) gene functions in signaling pathways initiated by the sevenless and epidermal growth factor receptor tyrosine kinases.  The Sos gene has now been isolated and sequenced.  Its product is a 1595-amino acid protein similar to the CDC25 protein in Saccharomyces cerevisiae, a guanine nucleotide exchange factor that activates Ras.  These results imply a role for the ras pathway in Drosophila melanogaster neuronal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_g7EQIixe0bVg90H21EOLACvtfcHk0lhMLFo32V8GDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVyks74%253D&md5=e36b8121233e5a78da0f5786c579b514</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1126%2Fscience.1736363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1736363%26sid%3Dliteratum%253Aachs%26aulast%3DBonfini%26aufirst%3DL.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DDasgupta%26aufirst%3DC.%26aulast%3DBanerjee%26aufirst%3DU.%26atitle%3DThe%2520Son%2520of%2520sevenless%2520gene%2520product%253A%2520a%2520putative%2520activator%2520of%2520Ras%26jtitle%3DScience%26date%3D1992%26volume%3D255%26spage%3D603%26epage%3D606%26doi%3D10.1126%2Fscience.1736363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, Y.</span></span> <span> </span><span class="NLM_article-title">The map kinase sascade is essential for diverse signal transduction pathways</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/0968-0004(93)90019-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2F0968-0004%2893%2990019-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1993&pages=128-131&author=E.+Nishidaauthor=Y.+Gotoh&title=The+map+kinase+sascade+is+essential+for+diverse+signal+transduction+pathways&doi=10.1016%2F0968-0004%2893%2990019-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0968-0004%2893%2990019-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0968-0004%252893%252990019-J%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DE.%26aulast%3DGotoh%26aufirst%3DY.%26atitle%3DThe%2520map%2520kinase%2520sascade%2520is%2520essential%2520for%2520diverse%2520signal%2520transduction%2520pathways%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1993%26volume%3D18%26spage%3D128%26epage%3D131%26doi%3D10.1016%2F0968-0004%2893%2990019-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span> <span> </span><span class="NLM_article-title">The TrkB-Shc site signals neuronal survival and local axon growth via MEK and PI3-kinase</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(00)00035-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0896-6273%2800%2900035-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10985347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVWmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=265-277&author=J.+K.+Atwalauthor=B.+Massieauthor=F.+D.+Millerauthor=D.+R.+Kaplan&title=The+TrkB-Shc+site+signals+neuronal+survival+and+local+axon+growth+via+MEK+and+PI3-kinase&doi=10.1016%2FS0896-6273%2800%2900035-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The TrkB-Shc site signals neuronal survival and local axon growth via MEK and PI3-kinase</span></div><div class="casAuthors">Atwal, Jasvinder K.; Massie, Bernard; Miller, Freda D.; Kaplan, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-277</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To det. how signals emanating from Trk transmit neurotrophin actions in primary neurons, the authors tested the ability of TrkB mutated at defined effector binding sites to promote sympathetic neuron survival or local axon growth.  TrkB stimulated signaling proteins and induced survival and growth in a manner similar to TrkA.  TrkB mutated at the Shc binding site supported survival and growth poorly relative to wild-type TrkB, whereas TrkB mutated at the PLC-γ1 binding site supported growth and survival well.  TrkB-mediated neuronal survival was dependent on PI3-kinase and to a lesser extent MEK activity, while growth depended upon both MEK and PI3-kinase activities.  These results indicate that the TrkB-Shc site mediates both neuronal survival and axonal outgrowth by activating the PI3-kinase and MEK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhOunf-Qm0DbVg90H21EOLACvtfcHk0lhMLFo32V8GDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVWmt7w%253D&md5=6203e8a8f3d7945c949b83e111ae0e97</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2800%2900035-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252800%252900035-0%26sid%3Dliteratum%253Aachs%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DMassie%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DF.%2BD.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26atitle%3DThe%2520TrkB-Shc%2520site%2520signals%2520neuronal%2520survival%2520and%2520local%2520axon%2520growth%2520via%2520MEK%2520and%2520PI3-kinase%26jtitle%3DNeuron%26date%3D2000%26volume%3D27%26spage%3D265%26epage%3D277%26doi%3D10.1016%2FS0896-6273%2800%2900035-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazeski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godement, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. A.</span></span> <span> </span><span class="NLM_article-title">Optical microscopy. 3. Tracking fluorescently labeled neurons in developing brain</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1096/fasebj.9.5.7896001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1096%2Ffasebj.9.5.7896001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=324-334&author=G.+Fishellauthor=R.+Blazeskiauthor=P.+Godementauthor=R.+Rivasauthor=L.+C.+Wangauthor=C.+A.+Mason&title=Optical+microscopy.+3.+Tracking+fluorescently+labeled+neurons+in+developing+brain&doi=10.1096%2Ffasebj.9.5.7896001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1096%2Ffasebj.9.5.7896001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffasebj.9.5.7896001%26sid%3Dliteratum%253Aachs%26aulast%3DFishell%26aufirst%3DG.%26aulast%3DBlazeski%26aufirst%3DR.%26aulast%3DGodement%26aufirst%3DP.%26aulast%3DRivas%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%2BC.%26aulast%3DMason%26aufirst%3DC.%2BA.%26atitle%3DOptical%2520microscopy.%25203.%2520Tracking%2520fluorescently%2520labeled%2520neurons%2520in%2520developing%2520brain%26jtitle%3DFASEB%2520J.%26date%3D1995%26volume%3D9%26spage%3D324%26epage%3D334%26doi%3D10.1096%2Ffasebj.9.5.7896001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellacosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsichlis, P. N.</span></span> <span> </span><span class="NLM_article-title">Akt is a direct target of the phosphatidylinositol 3-kinase - Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">30835</span>– <span class="NLM_lpage">30839</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.48.30835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.271.48.30835" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=30835-30839&author=K.+Dattaauthor=A.+Bellacosaauthor=T.+O.+Chanauthor=P.+N.+Tsichlis&title=Akt+is+a+direct+target+of+the+phosphatidylinositol+3-kinase+-+Activation+by+growth+factors%2C+v-src+and+v-Ha-ras%2C+in+Sf9+and+mammalian+cells&doi=10.1074%2Fjbc.271.48.30835"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.48.30835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.48.30835%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DK.%26aulast%3DBellacosa%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DT.%2BO.%26aulast%3DTsichlis%26aufirst%3DP.%2BN.%26atitle%3DAkt%2520is%2520a%2520direct%2520target%2520of%2520the%2520phosphatidylinositol%25203-kinase%2520-%2520Activation%2520by%2520growth%2520factors%252C%2520v-src%2520and%2520v-Ha-ras%252C%2520in%2520Sf9%2520and%2520mammalian%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D30835%26epage%3D30839%26doi%3D10.1074%2Fjbc.271.48.30835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Update: Signal transduction - PH domains - A universal membrane adapter</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1899</span>– <span class="NLM_lpage">1899</span>, <span class="refDoi"> DOI: 10.1126/science.275.5308.1899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.275.5308.1899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9122692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXit1Sktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=1899-1899&author=B.+A.+Hemmings&title=Update%3A+Signal+transduction+-+PH+domains+-+A+universal+membrane+adapter&doi=10.1126%2Fscience.275.5308.1899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">PH domains-a universal membrane adapter</span></div><div class="casAuthors">Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">5308</span>),
    <span class="NLM_cas:pages">1899</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs. on pleckstrin homol. domain in as signal dependent membrane adapter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_lyNIvJitkrVg90H21EOLACvtfcHk0ljzqQWIFXmqIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1Sktbk%253D&md5=de871d2b24f7e92404f1c461173ad7fc</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscience.275.5308.1899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.275.5308.1899%26sid%3Dliteratum%253Aachs%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DUpdate%253A%2520Signal%2520transduction%2520-%2520PH%2520domains%2520-%2520A%2520universal%2520membrane%2520adapter%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D1899%26epage%3D1899%26doi%3D10.1126%2Fscience.275.5308.1899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffney, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(06)00122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0960-9822%2806%2900122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9094314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=261-269&author=D.+R.+Alessiauthor=S.+R.+Jamesauthor=C.+P.+Downesauthor=A.+B.+Holmesauthor=P.+R.+J.+Gaffneyauthor=C.+B.+Reeseauthor=P.+Cohen&title=Characterization+of+a+3-phosphoinositide-dependent+protein+kinase+which+phosphorylates+and+activates+protein+kinase+B%CE%B1&doi=10.1016%2FS0960-9822%2806%2900122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα</span></div><div class="casAuthors">Alessi, Dario R.; James, Stephen R.; Downes, C. Peter; Holmes, Andrew B.; Gaffney, Piers R. J.; Reese, Colin B.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-269</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Protein kinase B (PKB), also known as c-Akt, is activated rapidly when mammalian cells are stimulated with insulin and growth factors, and much of the current interest in this enzyme stems from the observation that it lies 'downstream' of phosphoinositide 3-kinase on intracellular signaling pathways.  We recently showed that insulin or insulin-like growth factor 1 induce the phosphorylation of PKB at two residues, Thr308 and Ser473.  The phosphorylation of both residues is required for maximal activation of PKB. The kinases that phosphorylate PKB are, however, unknown.  We have purified 500,000-fold from rabbit skeletal muscle exts. a protein kinase which phosphorylates PKBα at Thr308 and increases its activity over 30-fold.  We tested the kinase in the presence of several inositol phospholipids and found that only low micromolar concns. of the D enantiomers of either phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) or PtdIns(3,4)P2 were effective in potently activating the kinase, which has been named PtdIns(3,4,5)P3-dependent protein kinase-1 (PDK1).  None of the inositol phospholipids tested activated or inhibited PKBα or induced its phosphorylation under the conditions used.  PDK1 activity was not affected by wortmannin, indicating that it is not likely to be a member of the phosphoinositide 3-kinase family.  PDK1 is likely to be one of the protein kinases that mediate the activation of PKB by insulin and growth factors.  PDK1 may, therefore, play a key role in mediating many of the actions of the second messenger(s) PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2sSM5v7MnWrVg90H21EOLACvtfcHk0ljzqQWIFXmqIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D&md5=7f3794216810a4273d091b8d4590aaa9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2806%2900122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252806%252900122-9%26sid%3Dliteratum%253Aachs%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DJames%26aufirst%3DS.%2BR.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BB.%26aulast%3DGaffney%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DReese%26aufirst%3DC.%2BB.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DCharacterization%2520of%2520a%25203-phosphoinositide-dependent%2520protein%2520kinase%2520which%2520phosphorylates%2520and%2520activates%2520protein%2520kinase%2520B%25CE%25B1%26jtitle%3DCurr.%2520Biol.%26date%3D1997%26volume%3D7%26spage%3D261%26epage%3D269%26doi%3D10.1016%2FS0960-9822%2806%2900122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andjelkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frech, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucocq, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Role of translocation in the activation and function of protein kinase B</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">31515</span>– <span class="NLM_lpage">31524</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.50.31515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1074%2Fjbc.272.50.31515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9395488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXotVSktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=31515-31524&author=M.+Andjelkovicauthor=D.+R.+Alessiauthor=R.+Meierauthor=A.+Fernandezauthor=N.+J.+Lambauthor=M.+Frechauthor=P.+Cronauthor=P.+Cohenauthor=J.+M.+Lucocqauthor=B.+A.+Hemmings&title=Role+of+translocation+in+the+activation+and+function+of+protein+kinase+B&doi=10.1074%2Fjbc.272.50.31515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Role of translocation in the activation and function of protein kinase B</span></div><div class="casAuthors">Andjelkovic, Mirjana; Alessi, Dario R.; Meier, Roger; Fernandez, Anne; Lamb, Ned J. C.; Frech, Matthias; Cron, Peter; Cohen, Philip; Lucocq, John M.; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">31515-31524</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The role of subcellular localization in the regulation of protein kinase B (PKB) activation was investigated.  The myristoylation/palmitylation motif from Lck tyrosine kinase was attached to the N-terminus of protein kinase B to alter its subcellular location.  Myristoylated/palmitylated (m/p)-PKBα was assocd. with the plasma membrane of transfected cells, whereas the wild-type kinase was mostly cytosolic.  The activity of m/p-PKBα was 60-fold higher compared with the unstimulated wild-type enzyme, and could not be stimulated further by growth factors or phosphatase inhibitors.  In vivo 32P labeling and mutagenesis demonstrated that m/p-PKBα activity was due to phosphorylation on Thr-308 and Ser-473, that are normally induced on PKB following stimulation of the cells with insulin or insulin-like growth factor-1 (IGF-1).  A dominant neg. form of phosphoinositide 3-kinase (PI3-K) did not affect m/p-PKBα activity.  The pleckstrin homol. (PH) domain of m/p-PKBα was not required for its activation or phosphorylation on Thr-308 and Ser-473, suggesting that this domain may serve as a membrane-targeting module.  Consistent with this view, PKBα was translocated to the plasma membrane within minutes after stimulation with IGF-1.  This translocation required the PH domain and was sensitive to wortmannin.  The results indicate that PI3-K activity is required for translocation of PKB to the plasma membrane, where its activation occurs through phosphorylation of the same sites that are induced by insulin or IGF-1.  Following activation, the kinase detached from the membrane and translocated to the nucleus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_oKYG4NVOQrVg90H21EOLACvtfcHk0lj2yRNzDf-QiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVSktr8%253D&md5=76c4e60f70dc603f066d3fafc67aaa51</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.50.31515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.50.31515%26sid%3Dliteratum%253Aachs%26aulast%3DAndjelkovic%26aufirst%3DM.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DMeier%26aufirst%3DR.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DLamb%26aufirst%3DN.%2BJ.%26aulast%3DFrech%26aufirst%3DM.%26aulast%3DCron%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DLucocq%26aufirst%3DJ.%2BM.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DRole%2520of%2520translocation%2520in%2520the%2520activation%2520and%2520function%2520of%2520protein%2520kinase%2520B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D31515%26epage%3D31524%26doi%3D10.1074%2Fjbc.272.50.31515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgering, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffer, P. J.</span></span> <span> </span><span class="NLM_article-title">Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/376599a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2F376599a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7637810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXns1SjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=599-602&author=B.+M.+Burgeringauthor=P.+J.+Coffer&title=Protein+kinase+B+%28c-Akt%29+in+phosphatidylinositol-3-OH+kinase+signal+transduction&doi=10.1038%2F376599a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction</span></div><div class="casAuthors">Burgering, Boudewijn M. Th.; Coffer, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6541</span>),
    <span class="NLM_cas:pages">599-602</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A serine/threonine kinase, named protein kinase B (PKB) for its sequence homol. to both protein kinase A and C, has previously been isolated.  PKB, which is identical to the kinase Rac, was later the cellular homolog of the transforming v-Akt.  Here, the authors show that PKB is activated by stimuli such as insulin, platelet-derived growth factor (PDGF), EGF and basic FGF (bFGF).  Activation of PKB was inhibited by the phosphatidylinositol-3-OH kinase [PI(3)K] inhibitor wortmannin and by coexpression of a dominant-neg. mutant of PI(3)K.  PDGF receptor mutants that lack detectable assocd. PI(3)K activity also fail to induce PKB activation.  PKB kinase activity is correlated with phosphorylation of PKB on serine.  Finally, the authors show that a constructed Gag-PKB fusion protein, homologous to the v-akt oncogene, displays significantly increased ligand-independent kinase activity.  This activity is sufficient to activate the p70 S6-kinase (p70S6k).  These results suggest a role for PKB in PI(3)K-mediated signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVbJ5pW1rL97Vg90H21EOLACvtfcHk0lj2yRNzDf-QiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXns1SjtLw%253D&md5=487e94d078aad3fcfb4ef6a4810c0332</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2F376599a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376599a0%26sid%3Dliteratum%253Aachs%26aulast%3DBurgering%26aufirst%3DB.%2BM.%26aulast%3DCoffer%26aufirst%3DP.%2BJ.%26atitle%3DProtein%2520kinase%2520B%2520%2528c-Akt%2529%2520in%2520phosphatidylinositol-3-OH%2520kinase%2520signal%2520transduction%26jtitle%3DNature%26date%3D1995%26volume%3D376%26spage%3D599%26epage%3D602%26doi%3D10.1038%2F376599a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, M. E.</span></span> <span> </span><span class="NLM_article-title">Regulation of neuronal survival by the serine-threonine protein kinase Akt</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1126/science.275.5300.661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.275.5300.661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9005851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2sXptV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=661-665&author=H.+Dudekauthor=S.+R.+Dattaauthor=T.+F.+Frankeauthor=M.+J.+Birnbaumauthor=R.+Yaoauthor=G.+M.+Cooperauthor=R.+A.+Segalauthor=D.+R.+Kaplanauthor=M.+E.+Greenberg&title=Regulation+of+neuronal+survival+by+the+serine-threonine+protein+kinase+Akt&doi=10.1126%2Fscience.275.5300.661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of neuronal survival by the serine-threonine protein kinase Akt</span></div><div class="casAuthors">Dudek, Henryk; Datta, Sandeep Robert; Franke, Thomas F.; Birnbaum, Morris J.; Yao, Ryoji; Cooper, Geoffrey M.; Segal, Rosalind A.; Kaplan, David R.; Greenberg, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">5300</span>),
    <span class="NLM_cas:pages">661-665</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A signaling pathway was delineated by which insulin-like growth factor 1 (IGF-1) promotes the survival of cerebellar neurons.  IGF-1 activation of phosphoinositide 3-kinase (P13-K) triggered the activation of two protein kinases, the serine-threonine kinase Akt and the p70 ribosomal protein S6 kinase (p70s6k).  Expts. with pharmacol. inhibitors, as well as expression of wild-type and dominant-inhibitory forms of Akt, demonstrated that Akt but not p70s6k mediates P13-K-dependent survival.  These findings suggest that in the developing nervous system, Akt is a crit. mediator of growth factor-induced neuronal survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhXSq1is28BbVg90H21EOLACvtfcHk0lj2yRNzDf-QiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXptV2msA%253D%253D&md5=46584bdcfb3f885781ba13d5f60c3266</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1126%2Fscience.275.5300.661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.275.5300.661%26sid%3Dliteratum%253Aachs%26aulast%3DDudek%26aufirst%3DH.%26aulast%3DDatta%26aufirst%3DS.%2BR.%26aulast%3DFranke%26aufirst%3DT.%2BF.%26aulast%3DBirnbaum%26aufirst%3DM.%2BJ.%26aulast%3DYao%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DG.%2BM.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGreenberg%26aufirst%3DM.%2BE.%26atitle%3DRegulation%2520of%2520neuronal%2520survival%2520by%2520the%2520serine-threonine%2520protein%2520kinase%2520Akt%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D661%26epage%3D665%26doi%3D10.1126%2Fscience.275.5300.661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R. S.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2933</span>– <span class="NLM_lpage">2943</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.18-08-02933.1998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1523%2FJNEUROSCI.18-08-02933.1998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9526010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXis1ejtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=2933-2943&author=R.+J.+Crowderauthor=R.+S.+Freeman&title=Phosphatidylinositol+3-kinase+and+Akt+protein+kinase+are+necessary+and+sufficient+for+the+survival+of+nerve+growth+factor-dependent+sympathetic+neurons&doi=10.1523%2FJNEUROSCI.18-08-02933.1998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons</span></div><div class="casAuthors">Crowder, Robert J.; Freeman, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2933-2943</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Recent studies have suggested a role for phosphatidylinositol (PI) 3-kinase in cell survival, including the survival of neurons.  We used rat sympathetic neurons maintained in vitro to characterize the potential survival signals mediated by PI 3-kinase and to test whether the Akt protein kinase, a putative effector of PI 3-kinase, functions during nerve growth factor (NGF)-mediated survival.  Two PI 3-kinase inhibitors, LY294002 and wortmannin, block NGF-mediated survival of sympathetic neurons.  Cell death caused by LY294002 resembles death caused by NGF deprivation in that it is blocked by a caspase inhibitor or a cAMP analog and that it is accompanied by the induction of c-jun, c-fos, and cyclin D1 mRNAs.  Treatment of neurons with NGF activates endogenous Akt protein kinase, and LY294002 or wortmannin blocks this activation.  Expression of constitutively active Akt or PI 3-kinase in neurons efficiently prevents death after NGF withdrawal.  Conversely, expression of dominant neg. forms of PI 3-kinase or Akt induces apoptosis in the presence of NGF.  These results demonstrate that PI 3-kinase and Akt are both necessary and sufficient for the survival of NGF-dependent sympathetic neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocAiecC5-6hbVg90H21EOLACvtfcHk0ljH_LT6zWIImQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1ejtLg%253D&md5=72a9a6bafc78f567d8c1b38934bab7e0</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.18-08-02933.1998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.18-08-02933.1998%26sid%3Dliteratum%253Aachs%26aulast%3DCrowder%26aufirst%3DR.%2BJ.%26aulast%3DFreeman%26aufirst%3DR.%2BS.%26atitle%3DPhosphatidylinositol%25203-kinase%2520and%2520Akt%2520protein%2520kinase%2520are%2520necessary%2520and%2520sufficient%2520for%2520the%2520survival%2520of%2520nerve%2520growth%2520factor-dependent%2520sympathetic%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D1998%26volume%3D18%26spage%3D2933%26epage%3D2943%26doi%3D10.1523%2FJNEUROSCI.18-08-02933.1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, G. M.</span></span> <span> </span><span class="NLM_article-title">Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2006</span>, <span class="refDoi"> DOI: 10.1126/science.7701324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1126%2Fscience.7701324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7701324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXkslOkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1995&pages=2003-2006&author=R.+Yaoauthor=G.+M.+Cooper&title=Requirement+for+phosphatidylinositol-3+kinase+in+the+prevention+of+apoptosis+by+nerve+growth+factor&doi=10.1126%2Fscience.7701324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor</span></div><div class="casAuthors">Yao, Ryoji; Cooper, Geoffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">5206</span>),
    <span class="NLM_cas:pages">2003-6</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nerve growth factor (NGF) induces both differentiation and survival of neurons by binding to the Trk receptor protein tyrosine kinase.  Although Ras is required for differentiation, it was not required for NGF-mediated survival of rat pheochromocytoma PC-12 cells in serum-free medium.  However, the ability of NGF to prevent apoptosis (programmed cell death) was inhibited by wortmannin or LY 294002, two specific inhibitors of phosphatidylinositol (PI)-3 kinase.  Moreover, platelet-derived growth factor (PDGF) prevented apoptosis of PC-12 cells expressing the wild-type PDGF receptor, but not of cells expressing a mutant receptor that failed to activate PI-3 kinase.  Cell survival thus appears to be mediated by a PI-3 kinase signaling pathway distinct from the pathway that mediates differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ITwHLlYZv7Vg90H21EOLACvtfcHk0ljH_LT6zWIImQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkslOkur0%253D&md5=e6e47faef5b39f2bcb851b06e26ca064</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1126%2Fscience.7701324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7701324%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DG.%2BM.%26atitle%3DRequirement%2520for%2520phosphatidylinositol-3%2520kinase%2520in%2520the%2520prevention%2520of%2520apoptosis%2520by%2520nerve%2520growth%2520factor%26jtitle%3DScience%26date%3D1995%26volume%3D267%26spage%3D2003%26epage%3D2006%26doi%3D10.1126%2Fscience.7701324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zirrgiebel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span> <span> </span><span class="NLM_article-title">Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2241</span>– <span class="NLM_lpage">2250</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1995.65052241.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1046%2Fj.1471-4159.1995.65052241.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=7595513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK2MXovFGmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1995&pages=2241-2250&author=U.+Zirrgiebelauthor=Y.+Ohgaauthor=B.+Carterauthor=B.+Berningerauthor=N.+Inagakiauthor=H.+Thoenenauthor=D.+Lindholm&title=Characterization+of+TrkB+receptor-mediated+signaling+pathways+in+rat+cerebellar+granule+neurons%3A+involvement+of+protein+kinase+C+in+neuronal+survival&doi=10.1046%2Fj.1471-4159.1995.65052241.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival</span></div><div class="casAuthors">Zirrgiebel, Ute; Ohga, Yoko; Carter, Bruce; Berninger, Benedikt; Inagaki, Naoyuki; Thoenen, Hans; Lindolm, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2241-50</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">TrkB belongs to the Trk family of tyrosine kinase receptors and mediates the response to brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-45).  Here, the authors report that both truncated and full-length forms of TrkB receptors are expressed in developing cerebellar granule neurons.  BDNF and NZT-4/5 increased the survival of cultured cerebellar granule neurons.  BDNF and NT-4/5 also induced an autophosphorylation of TrkB receptors and subsequently resulted in a phosphorylation and binding of phospholipase C-γ (PLC-γ) and SH2-contg. sequence to the autophosphorylated TrkB receptors.  Both contain src homol. 2 (SH2) regions.  In keeping with a signaling function of PLC-γ, BDNF increased the phosphatidylinositol (PI) turnover and elevated intracellular calcium levels.  To investigate the involvement of protein kinase C (PKC) in the survival of granular neurons, the authors show here activation of PKC after BDNF or TPA treatment and blocking of the obsd. survival-promoting effects of BDNF and TPA with calphostin C, a specific PKC inhibitor.  In addn., BDNF activated c-ras in a concn.-dependent manner.  These results suggest that two different pathways, the c-ras and the PLC-γ pathway, are activated by TrkB receptors in primary neurons and that PKC activation is involved in the survival promoting effect of BDNF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomW6Wv5ZWfybVg90H21EOLACvtfcHk0ljH_LT6zWIImQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovFGmur4%253D&md5=056848ace12631e665b9116ea8dda4d2</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1995.65052241.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1995.65052241.x%26sid%3Dliteratum%253Aachs%26aulast%3DZirrgiebel%26aufirst%3DU.%26aulast%3DOhga%26aufirst%3DY.%26aulast%3DCarter%26aufirst%3DB.%26aulast%3DBerninger%26aufirst%3DB.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DThoenen%26aufirst%3DH.%26aulast%3DLindholm%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520TrkB%2520receptor-mediated%2520signaling%2520pathways%2520in%2520rat%2520cerebellar%2520granule%2520neurons%253A%2520involvement%2520of%2520protein%2520kinase%2520C%2520in%2520neuronal%2520survival%26jtitle%3DJ.%2520Neurochem.%26date%3D1995%26volume%3D65%26spage%3D2241%26epage%3D2250%26doi%3D10.1046%2Fj.1471-4159.1995.65052241.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, D. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1714448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1056%2FNEJMoa1714448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=29466156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=731-739&author=A.+Drilonauthor=T.+W.+Laetschauthor=S.+Kummarauthor=S.+G.+DuBoisauthor=U.+N.+Lassenauthor=G.+D.+Demetriauthor=M.+Nathensonauthor=R.+C.+Doebeleauthor=A.+F.+Faragoauthor=A.+S.+Pappoauthor=B.+Turpinauthor=A.+Dowlatiauthor=M.+S.+Broseauthor=L.+Mascarenhasauthor=N.+Federmanauthor=J.+Berlinauthor=W.+S.+El-Deiryauthor=C.+Baikauthor=J.+Deekenauthor=V.+Boniauthor=R.+Nagasubramanianauthor=M.+Taylorauthor=E.+R.+Rudzinskiauthor=F.+Meric-Bernstamauthor=D.+P.+S.+Sohalauthor=P.+C.+Maauthor=L.+E.+Raezauthor=J.+F.+Hechtmanauthor=R.+Benayedauthor=M.+Ladanyiauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Cruickshankauthor=N.+C.+Kuauthor=M.+C.+Coxauthor=D.+S.+Hawkinsauthor=D.+S.+Hongauthor=D.+M.+Hyman&title=Efficacy+of+larotrectinib+in+TRK+fusion-positive+cancers+in+adults+and+children&doi=10.1056%2FNEJMoa1714448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</span></div><div class="casAuthors">Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; Pappo, A. S.; Turpin, B.; Dowlati, A.; Brose, M. S.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W. S.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; Taylor, M.; Rudzinski, E. R.; Meric-Bernstam, F.; Sohal, D. P. S.; Ma, P. C.; Raez, L. E.; Hechtman, J. F.; Benayed, R.; Ladanyi, M.; Tuch, B. B.; Ebata, K.; Cruickshank, S.; Ku, N. C.; Cox, M. C.; Hawkins, D. S.; Hong, D. S.; Hyman, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">731-739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults.  We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.  METHODS We enrolled patients with consecutively and prospectively identified TRK fusion-pos. cancers, detected by mol. profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults.  The primary end point for the combined anal. was the overall response rate according to independent review.  Secondary end points included duration of response, progressionfree survival, and safety.  RESULTS A total of 55 patients, ranging in age from 4 mo to 76 years, were enrolled and treated.  Patients had 17 unique TRK fusion-pos. tumor types.  The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment.  At 1 yr, 71% of the responses were ongoing and 55% of the patients remained progression-free.  The median duration of response and progression-free survival had not been reached.  At a median follow-up of 9.4 mo, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative.  Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients.  No patient discontinued larotrectinib owing to drug-related adverse events.  CONCLUSIONS Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-pos. cancer, regardless of the age of the patient or of the tumor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwp_pcLYdv5bVg90H21EOLACvtfcHk0lhLyha9rUgNvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D&md5=b636d83c2cd61b4b35c36e36c950196c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1714448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1714448%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DLassen%26aufirst%3DU.%2BN.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DNathenson%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DBaik%26aufirst%3DC.%26aulast%3DDeeken%26aufirst%3DJ.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DRudzinski%26aufirst%3DE.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSohal%26aufirst%3DD.%2BP.%2BS.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DKu%26aufirst%3DN.%2BC.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DEfficacy%2520of%2520larotrectinib%2520in%2520TRK%2520fusion-positive%2520cancers%2520in%2520adults%2520and%2520children%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D731%26epage%3D739%26doi%3D10.1056%2FNEJMoa1714448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span> <span> </span><span class="NLM_article-title">Developing anticancer drugs in orphan molecular entities - a paradigm under construction</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1056/NEJMe1716821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1056%2FNEJMe1716821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=29466154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1MrjvVygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=763-765&author=F.+Andre&title=Developing+anticancer+drugs+in+orphan+molecular+entities+-+a+paradigm+under+construction&doi=10.1056%2FNEJMe1716821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Drugs in Orphan Molecular Entities - A Paradigm under Construction</span></div><div class="casAuthors">Andre Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">763-765</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9RoVGgdaKyTMsgLhIoICsfW6udTcc2eaXbdPWtX_FgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrjvVygug%253D%253D&md5=856d8e03d468f9b64a87f04026f265de</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1716821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1716821%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26atitle%3DDeveloping%2520anticancer%2520drugs%2520in%2520orphan%2520molecular%2520entities%2520-%2520a%2520paradigm%2520under%2520construction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D763%26epage%3D765%26doi%3D10.1056%2FNEJMe1716821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">Role and relevance of TrkB mutations and expression in non-small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1078-0432.CCR-10-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21242122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVGhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2638-2645&author=T.+Haradaauthor=Y.+Yatabeauthor=M.+Takeshitaauthor=T.+Kogaauthor=T.+Yanoauthor=Y.+Wangauthor=G.+Giaccone&title=Role+and+relevance+of+TrkB+mutations+and+expression+in+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-10-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Harada, Taishi; Yatabe, Yasushi; Takeshita, Masafumi; Koga, Takaomi; Yano, Tokujiro; Wang, Yisong; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: TrkB has been involved in poor cancer outcome.  TrkB mutations have been reported in non-small cell lung cancer.  In this study, we aimed at characterizing the role of three potentially sensitizing TrkB mutations previously reported in lung cancer.  Exptl. Design: We characterized three activation loop mutants of TrkB (M713I, R715G, and R734C) in terms of pathway activation/phosphorylation, migration, anchorage-independent growth, and sensitivity to a Trk inhibitor, using NIH3T3 cells and Baf3 cells.  We also sequenced the tyrosine kinase domain of TrkB in a large no. of lung cancer samples of East-Asian origin and cell lines.  RESULTS: None of the mutants were constitutively active in NIH3T3 transformation and migration assays.  M713I and R734C mutants showed low levels of autophosphorylation in comparison with wild-type TrkB.  Although R715G showed similar level of autophosphorylation to wild-type TrkB on brain-derived neurotrophic factor stimulation, the mutant was not as competent as wild-type TrkB in supporting interleukin-3-independent growth of Baf3 cells.  In addn., the Trk inhibitor AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth, whereas the mutants were relatively resistant to the Trk inhibitor compared with wild-type TrkB.  We could not confirm the presence of nonsynonymous mutation in 78 lung cancer samples and 29 cell lines.  CONCLUSIONS: Wild-type, but not mutant, TrkB enhances cell migration and transformation.  Our study suggests that TrkB mutations should not be used for selection of patients with lung cancer treated with Trk inhibitors.  High expression of wild-type TrkB might be beneficial for studies of Trk inhibitors.  Clin Cancer Res; 17(9); 2638-45.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1K7iKVaqCbVg90H21EOLACvtfcHk0lgBvDBJbNJl0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVGhu74%253D&md5=4560249cbf46b90fda1f79c9ba6c6922</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3034%26sid%3Dliteratum%253Aachs%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeshita%26aufirst%3DM.%26aulast%3DKoga%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DRole%2520and%2520relevance%2520of%2520TrkB%2520mutations%2520and%2520expression%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2638%26epage%3D2645%26doi%3D10.1158%2F1078-0432.CCR-10-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1674</span>, <span class="refDoi"> DOI: 10.1097/01.JTO.0000473485.38553.f0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1097%2F01.JTO.0000473485.38553.f0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26565381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1670-1674&author=A.+F.+Faragoauthor=L.+P.+Leauthor=Z.+Zhengauthor=A.+Muzikanskyauthor=A.+Drilonauthor=M.+Patelauthor=T.+M.+Bauerauthor=S.+V.+Liuauthor=S.+H.+Ouauthor=D.+Jackmanauthor=D.+B.+Costaauthor=P.+S.+Multaniauthor=G.+G.+Liauthor=Z.+Hornbyauthor=E.+Chow-Manevalauthor=D.+Luoauthor=J.+E.+Limauthor=A.+J.+Iafrateauthor=A.+T.+Shaw&title=Durable+clinical+response+to+entrectinib+in+NTRK1-rearranged+non-small+cell+lung+cancer&doi=10.1097%2F01.JTO.0000473485.38553.f0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Farago, Anna F.; Le, Long P.; Zheng, Zongli; Muzikansky, Alona; Drilon, Alexander; Patel, Manish; Bauer, Todd M.; Liu, Stephen V.; Ou, Sai-Hong I.; Jackman, David; Costa, Daniel B.; Multani, Pratik S.; Li, Gary G.; Hornby, Zachary; Chow-Maneval, Edna; Luo, David; Lim, Jonathan E.; Iafrate, Anthony J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1670-1674</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor malignancies, leading to expression of an oncogenic TrkA fusion protein.  Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor, including TrkA.  We sought to det. the frequency of NTRK1 rearrangements in NSCLC and to assess the clin. activity of entrectinib.  Methods: We screened 1378 cases of NSCLC using anchored multiplex polymerase chain reaction (AMP).  A patient with an NTRK1 gene rearrangement was enrolled onto a Phase 1 dose escalation study of entrectinib in adult patients with locally advanced or metastatic tumors (NCT02097810).  We assessed safety and response to treatment.  Results: We identified NTRK1 gene rearrangements at a frequency of 0.1% in this cohort.  A patient with stage IV lung adenocrcinoma with an SQSTM1-NTRK1 fusion transcript expression was treated with entrectinib.  Entrectinib was well tolerated, with no grade 3-4 adverse events.  Within three weeks of starting on treatment, the patient reported resoln. of prior dyspnea and pain.  Restaging CT scans demonstrated a RECIST partial response (PR) and complete resoln. of all brain metastases.  This patient has continued on treatment for over 6 mo with an ongoing PR.  Conclusions: Entrectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrangements, including those with central nervous system metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9e_5UdIxTprVg90H21EOLACvtfcHk0lgBvDBJbNJl0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rN&md5=1d0160c35a3bdbdcb2ebd01313cc18ba</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1097%2F01.JTO.0000473485.38553.f0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.JTO.0000473485.38553.f0%26sid%3Dliteratum%253Aachs%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DLe%26aufirst%3DL.%2BP.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DJackman%26aufirst%3DD.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DLi%26aufirst%3DG.%2BG.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DJ.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DDurable%2520clinical%2520response%2520to%2520entrectinib%2520in%2520NTRK1-rearranged%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D1670%26epage%3D1674%26doi%3D10.1097%2F01.JTO.0000473485.38553.f0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coulier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4202</span>– <span class="NLM_lpage">4210</span>, <span class="refDoi"> DOI: 10.1128/MCB.10.8.4202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.10.8.4202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1695324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK3cXltFSgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=4202-4210&author=F.+Coulierauthor=R.+Kumarauthor=M.+Ernstauthor=R.+Kleinauthor=D.+Martin-Zancaauthor=M.+Barbacid&title=Human+trk+oncogenes+activated+by+point+mutation%2C+in-frame+deletion%2C+and+duplication+of+the+tyrosine+kinase+domain&doi=10.1128%2FMCB.10.8.4202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain</span></div><div class="casAuthors">Coulier, Francois; Kumar, Ramesh; Ernst, Mary; Klein, Rudiger; Martin-Zanca, Dionisio; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4202-10</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">Malignant activation of the human trk proto-oncogene, a member of the tyrosine protein kinase receptor family, has been implicated in the development of certain human cancers, including colon and thyroid papillary carcinomas.  trk Oncogenes have also been identified in cultured cells transfected with various DNAs.  Three in vitro-generated trk oncogenes, trk2, trk4, and trk5, were studied in an effort to understand the spectrum of mutational events that can activate the human trk gene.  Nucleotide sequence anal. of cDNA clones of trk2 and trk4 revealed that these oncogenes were generated by a head-to-tail arrangement of two trk tyrosine protein kinase domains connected by a purine-rich region.  These oncogenes code for cytoplasmic mols. of 67,000 (p67trk2) and 69,000 (p69trk4) daltons.  In contrast, the product of the trk5 oncogene, gp95trk5, is a cell surface glycoprotein of 95,000 daltons.  This oncogene was generated by a 153-bp in-frame deletion within sequences coding for the extracellular domain of the trk receptor.  This activating deletion encompasses a triplet coding for one of the nine cysteine residues that the trk receptor shares with the product of the highly related trkB tyrosine protein kinase gene.  Introduction of a single point mutation (TGT → AGT) in this codon resulted in a novel trk oncogene whose product, gp140S345, differs from the nontransforming trk proto-oncogene receptor in a single amino acid residue, Ser-345 instead of Cys-345.  These results illustrate that multipole mol. mechanisms, including point mutation, internal deletion, and kinase domain duplication, can result in the malignant activation of the human trk proto-oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBfzY9l-Be7Vg90H21EOLACvtfcHk0lgBvDBJbNJl0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltFSgtro%253D&md5=5d0bdb195835480233dec86b99e587fc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1128%2FMCB.10.8.4202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.10.8.4202%26sid%3Dliteratum%253Aachs%26aulast%3DCoulier%26aufirst%3DF.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DErnst%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DHuman%2520trk%2520oncogenes%2520activated%2520by%2520point%2520mutation%252C%2520in-frame%2520deletion%252C%2520and%2520duplication%2520of%2520the%2520tyrosine%2520kinase%2520domain%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1990%26volume%3D10%26spage%3D4202%26epage%3D4210%26doi%3D10.1128%2FMCB.10.8.4202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arevalo, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hempstead, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Zanca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, P.</span></span> <span> </span><span class="NLM_article-title">A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1204215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11313867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Oitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=1229-1234&author=J.+C.+Arevaloauthor=B.+Condeauthor=B.+I.+Hempsteadauthor=M.+V.+Chaoauthor=D.+Martin-Zancaauthor=P.+Perez&title=A+novel+mutation+within+the+extracellular+domain+of+TrkA+causes+constitutive+receptor+activation&doi=10.1038%2Fsj.onc.1204215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation</span></div><div class="casAuthors">Arevalo, Juan C.; Conde, Blanca; Hempstead, Barbara I.; Chao, Moses V.; Martin-Zanca, Dionisio; Perez, Pilar</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1229-1234</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The TrkA NGF receptor extracellular region contains three leucine repeats flanked by cysteine clusters and two Ig-like domains that are required for specific ligand binding.  Deletion of the Ig-like domains abolishes NGF binding and causes ligand independent activation of the receptor.  Here the authors report a specific mutation that increases the binding affinity of the TrkA receptor for NGF.  A change of proline 203 to alanine (P203A) in the linker region between the leucine repeats and the first Ig-like domain increased NGF binding by decreasing the ligand rate of dissocn.  This mutated receptor was appropriately expressed on the cell surface and promoted ligand-independent neurite outgrowth in PC12nnr5 cells.  The mutant receptor was capable of spontaneous dimerization and was constitutively phosphorylated in the absence of ligand.  Moreover, expression of TrkA-P203A receptor in fibroblasts induced DNA synthesis and transformation and generated tumors in nude mice.  These data suggest that domains outside of the Ig-like structure contribute to ligand binding and constitutive activation of Trk receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdInzQUFxLlLVg90H21EOLACvtfcHk0lgYWlmDou_R1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Oitb8%253D&md5=ab124796f01721d55a355b5bb501dc5d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204215%26sid%3Dliteratum%253Aachs%26aulast%3DArevalo%26aufirst%3DJ.%2BC.%26aulast%3DConde%26aufirst%3DB.%26aulast%3DHempstead%26aufirst%3DB.%2BI.%26aulast%3DChao%26aufirst%3DM.%2BV.%26aulast%3DMartin-Zanca%26aufirst%3DD.%26aulast%3DPerez%26aufirst%3DP.%26atitle%3DA%2520novel%2520mutation%2520within%2520the%2520extracellular%2520domain%2520of%2520TrkA%2520causes%2520constitutive%2520receptor%2520activation%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D1229%26epage%3D1234%26doi%3D10.1038%2Fsj.onc.1204215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomasson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremont, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westervelt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPersio, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, T. J.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4797</span>– <span class="NLM_lpage">4808</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-09-113027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1182%2Fblood-2007-09-113027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=18270328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVSrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=4797-4808&author=M.+H.+Tomassonauthor=Z.+Xiangauthor=R.+Walgrenauthor=Y.+Zhaoauthor=Y.+Kasaiauthor=T.+Minerauthor=R.+E.+Riesauthor=O.+Lubmanauthor=D.+H.+Fremontauthor=M.+D.+McLellanauthor=J.+E.+Paytonauthor=P.+Westerveltauthor=J.+F.+DiPersioauthor=D.+C.+Linkauthor=M.+J.+Walterauthor=T.+A.+Graubertauthor=M.+Watsonauthor=J.+Batyauthor=S.+Heathauthor=W.+D.+Shannonauthor=R.+Nagarajanauthor=C.+D.+Bloomfieldauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=T.+J.+Ley&title=Somatic+mutations+and+germline+sequence+variants+in+the+expressed+tyrosine+kinase+genes+of+patients+with+de+novo+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-09-113027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia</span></div><div class="casAuthors">Tomasson, Michael H.; Xiang, Zhifu; Walgren, Richard; Zhao, Yu; Kasai, Yumi; Miner, Tracie; Ries, Rhonda E.; Lubman, Olga; Fremont, Daved H.; McLellan, Michael D.; Payton, Jacqueline E.; Westervelt, Peter; DiPersio, John F.; Link, Daniel C.; Walter, Matthew J.; Graubert, Timothy A.; Watson, Mark; Baty, Jack; Heath, Sharon; Shannon, William D.; Nagarajan, Rakesh; Bloomfield, Clara D.; Mardis, Elaine R.; Wilson, Richard K.; Ley, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4797-4808</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in tyrosine kinase (TK) genes (eg, FLT3 and KIT) are found in more than 30% of patients with de novo acute myeloid leukemia (AML); many groups have speculated that mutations in other TK genes may be present in the remaining 70%.  We performed high-throughput resequencing of the kinase domains of 26 TK genes (11 receptor TK; 15 cytoplasmic TK) expressed in most AML patients using genomic DNA from the bone marrow (tumor) and matched skin biopsy samples ("germline") from 94 patients with de novo AML; sequence variants were validated in an addnl. 94 AML tumor samples (14.3 million base pairs of sequence were obtained and analyzed).  We identified known somatic mutations in FLT3, KIT, and JAK2 TK genes at the expected frequencies and found 4 novel somatic mutations, JAK1V623A, JAK1T478S, DDR1A803V, and NTRK1S677N, once each in 4 resp. patients of 188 tested.  We also identified novel germline sequence changes encoding amino acid substitutions (ie, nonsynonymous changes) in 14 TK genes, including TYK2, which had the largest no. of nonsynonymous sequence variants (11 total detected).  Addnl. studies will be required to define the roles that these somatic and germline TK gene variants play in AML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJsCqunCvQLVg90H21EOLACvtfcHk0lgYWlmDou_R1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVSrsb4%253D&md5=b28273dc598f04d1de0633703a68299a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-09-113027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-09-113027%26sid%3Dliteratum%253Aachs%26aulast%3DTomasson%26aufirst%3DM.%2BH.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DWalgren%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKasai%26aufirst%3DY.%26aulast%3DMiner%26aufirst%3DT.%26aulast%3DRies%26aufirst%3DR.%2BE.%26aulast%3DLubman%26aufirst%3DO.%26aulast%3DFremont%26aufirst%3DD.%2BH.%26aulast%3DMcLellan%26aufirst%3DM.%2BD.%26aulast%3DPayton%26aufirst%3DJ.%2BE.%26aulast%3DWestervelt%26aufirst%3DP.%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26aulast%3DLink%26aufirst%3DD.%2BC.%26aulast%3DWalter%26aufirst%3DM.%2BJ.%26aulast%3DGraubert%26aufirst%3DT.%2BA.%26aulast%3DWatson%26aufirst%3DM.%26aulast%3DBaty%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DW.%2BD.%26aulast%3DNagarajan%26aufirst%3DR.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DLey%26aufirst%3DT.%2BJ.%26atitle%3DSomatic%2520mutations%2520and%2520germline%2520sequence%2520variants%2520in%2520the%2520expressed%2520tyrosine%2520kinase%2520genes%2520of%2520patients%2520with%2520de%2520novo%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D4797%26epage%3D4808%26doi%3D10.1182%2Fblood-2007-09-113027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappabianca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessitore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetuschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argenti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Screpanti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A. R.</span></span> <span> </span><span class="NLM_article-title">TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.ccr.2004.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15488758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsF2rt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=347-360&author=A.+Tacconelliauthor=A.+R.+Farinaauthor=L.+Cappabiancaauthor=G.+Desantisauthor=A.+Tessitoreauthor=A.+Vetuschiauthor=R.+Sferraauthor=N.+Rucciauthor=B.+Argentiauthor=I.+Screpantiauthor=A.+Gulinoauthor=A.+R.+Mackay&title=TrkA+alternative+splicing%3A+a+regulated+tumor-promoting+switch+in+human+neuroblastoma&doi=10.1016%2Fj.ccr.2004.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma</span></div><div class="casAuthors">Tacconelli, Antonella; Farina, Antonietta R.; Cappabianca, Lucia; DeSantis, Giuseppina; Tessitore, Alessandra; Vetuschi, Antonella; Sferra, Roberta; Rucci, Nadia; Argenti, Beatrice; Screpanti, Isabella; Gulino, Alberto; Mackay, Andrew R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-360</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We identify a novel alternative TrkA splice variant, TrkAIII, with deletion of exons 6, 7, and 9 and functional extracellular IG-C1 and N-glycosylation domains, that exhibits expression restricted to undifferentiated early neural progenitors, human neuroblastomas (NBs), and a subset of other neural crest-derived tumors.  This NGF-unresponsive isoform is oncogenic in NIH3T3 cells and promotes tumorigenic NB cell behavior in vitro and in vivo (cell survival, xenograft growth, angiogenesis) resulting from spontaneous tyrosine kinase activity and IP3K/Akt/NF-κB but not Ras/MAPK signaling.  TrkAIII antagonizes NGF/TrkAI signaling, which is responsible for NB growth arrest and differentiation through Ras/MAPK, and its expression is promoted by hypoxia at the expense of NGF-responsive receptors, providing a mechanism for converting NGF/TrkA/Ras/MAPK antioncogenic signals to TrkAIII/IP3K/Akt/NF-κB tumor-promoting signals during tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5rPRmGuddPbVg90H21EOLACvtfcHk0lh_lz_K4mkdVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsF2rt7c%253D&md5=ced7070be1a53d286839a908d65d03aa</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DTacconelli%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DA.%2BR.%26aulast%3DCappabianca%26aufirst%3DL.%26aulast%3DDesantis%26aufirst%3DG.%26aulast%3DTessitore%26aufirst%3DA.%26aulast%3DVetuschi%26aufirst%3DA.%26aulast%3DSferra%26aufirst%3DR.%26aulast%3DRucci%26aufirst%3DN.%26aulast%3DArgenti%26aufirst%3DB.%26aulast%3DScrepanti%26aufirst%3DI.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DMackay%26aufirst%3DA.%2BR.%26atitle%3DTrkA%2520alternative%2520splicing%253A%2520a%2520regulated%2520tumor-promoting%2520switch%2520in%2520human%2520neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D347%26epage%3D360%26doi%3D10.1016%2Fj.ccr.2004.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">8655</span>– <span class="NLM_lpage">8666</span>, <span class="refDoi"> DOI: 10.1128/MCB.20.23.8655-8666.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1128%2FMCB.20.23.8655-8666.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11073967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFGkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=8655-8666&author=G.+W.+Reutherauthor=Q.+T.+Lambertauthor=M.+A.+Caligiuriauthor=C.+J.+Der&title=Identification+and+characterization+of+an+activating+TrkA+deletion+mutation+in+acute+myeloid+leukemia&doi=10.1128%2FMCB.20.23.8655-8666.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia</span></div><div class="casAuthors">Reuther, Gary W.; Lambert, Que T.; Caligiuri, Michael A.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8655-8666</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, the authors utilized retroviral transfer of cDNA libraries to identify oncogenes that are expressed in acute myeloid leukemia (AML).  From screens using two different cell types as targets for cellular transformation, a single cDNA encoding a variant of the TrkA protooncogene was isolated.  The protein product of this protooncogene, TrkA, is a receptor tyrosine kinase for nerve growth factor.  The isolated transforming cDNA encoded a TrkA protein that contains a 75-amino-acid deletion in the extracellular domain of the receptor and was named ΔTrkA.  ΔTrkA readily transformed fibroblast and epithelial cell lines.  The deletion resulted in activation of the tyrosine kinase domain leading to constitutive tyrosine phosphorylation of the protein.  Expression of ΔTrkA in cells led to the constitutive activation of intracellular signaling pathways that include Ras, extracellular signal-regulated kinase/mitogen-activated protein kinase, and Akt.  Importantly, ΔTrkA altered the apoptotic and growth properties of 32D myeloid progenitor cells, suggesting ΔTrkA may have contributed to the development and/or maintenance of the myeloid leukemia from which it was isolated.  Unlike Bcr-Abl, expression of ΔTrkA did not activate Stat5 in these cells.  The authors have detected expression of ΔTrkA in the original AML sample by reverse transcriptase PCR and by Western blot anal.  While previous TrkA mutations identified from human tumors involved fusion to other proteins, this report is the initial demonstration that deletions within TrkA may play a role in human cancers.  Finally, this report is the first to indicate mutations in TrkA may contribute to leukemogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN8fS7H2J4Y7Vg90H21EOLACvtfcHk0lh_lz_K4mkdVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFGkurk%253D&md5=38b1eb897615f27b6034468a05cfb913</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.23.8655-8666.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.23.8655-8666.2000%26sid%3Dliteratum%253Aachs%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DLambert%26aufirst%3DQ.%2BT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520an%2520activating%2520TrkA%2520deletion%2520mutation%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D8655%26epage%3D8666%26doi%3D10.1128%2FMCB.20.23.8655-8666.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadnick, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span> <span> </span><span class="NLM_article-title">Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2007.11.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=634-639&author=S.+H.+Kimauthor=J.+S.+Tokarskiauthor=K.+J.+Leavittauthor=B.+E.+Finkauthor=M.+E.+Salvatiauthor=R.+Moquinauthor=M.+T.+Obermeierauthor=G.+L.+Trainorauthor=G.+G.+Viteauthor=L.+K.+Stadnickauthor=J.+S.+Lippyauthor=D.+Youauthor=M.+V.+Lorenziauthor=P.+Chen&title=Identification+of+2-amino-5-%28thioaryl%29thiazoles+as+inhibitors+of+nerve+growth+factor+receptor+TrkA&doi=10.1016%2Fj.bmcl.2007.11.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLeavitt%26aufirst%3DK.%2BJ.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DMoquin%26aufirst%3DR.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DVite%26aufirst%3DG.%2BG.%26aulast%3DStadnick%26aufirst%3DL.%2BK.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DChen%26aufirst%3DP.%26atitle%3DIdentification%2520of%25202-amino-5-%2528thioaryl%2529thiazoles%2520as%2520inhibitors%2520of%2520nerve%2520growth%2520factor%2520receptor%2520TrkA%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D634%26epage%3D639%26doi%3D10.1016%2Fj.bmcl.2007.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, E.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and risk factors: intrahepatic cholangiocarcinoma</span>. <i>Hepatobiliary Surg. Nutr</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.21037/hbsn.2017.01.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.21037%2Fhbsn.2017.01.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28503557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1crnt1WnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=101-104&author=A.+Guptaauthor=E.+Dixon&title=Epidemiology+and+risk+factors%3A+intrahepatic+cholangiocarcinoma&doi=10.21037%2Fhbsn.2017.01.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and risk factors: intrahepatic cholangiocarcinoma</span></div><div class="casAuthors">Gupta Amar; Dixon Elijah</div><div class="citationInfo"><span class="NLM_cas:title">Hepatobiliary surgery and nutrition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-104</span>
        ISSN:<span class="NLM_cas:issn">2304-3881</span>.
    </div><div class="casAbstract">Intrahepatic cholangiocarcinoma (ICC) is a rare entity with a distinct clinical course and epidemiology from hilar and extrahepatic cholangiocarcinoma.  ICC makes up 8-10% of cholangiocarcinomas and 10-20% of all primary liver tumors.  There remains a considerable amount of geographic variation in the incidence of ICC worldwide; however, the overall incidence of this malignancy appears to be rising.  Several risk factors have been identified, such as infectious causes (liver flukes, viral hepatitis), biliary tract disease [primary sclerosing cholangitis (PSC), hepaticolithiasis, biliary cystic diseases], metabolic syndrome, lifestyle choices (alcohol abuse, tobacco use), and cirrhosis.  Despite this, a substantial number of ICC patients do not have any identifiable risk factors, underlining the need for further work into the pathogenesis of this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0S4iCpopdFIqdXsLcGTEUfW6udTcc2eaagFuLUn4hmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crnt1WnsA%253D%253D&md5=eda7445a5640a3a22275da06cc325a8a</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.21037%2Fhbsn.2017.01.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fhbsn.2017.01.02%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DDixon%26aufirst%3DE.%26atitle%3DEpidemiology%2520and%2520risk%2520factors%253A%2520intrahepatic%2520cholangiocarcinoma%26jtitle%3DHepatobiliary%2520Surg.%2520Nutr%26date%3D2017%26volume%3D6%26spage%3D101%26epage%3D104%26doi%3D10.21037%2Fhbsn.2017.01.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selikoff, I. J.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of gastrointestinal cancer</span>. <i>Environ. Health Perspect.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1289/ehp.749299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1289%2Fehp.749299" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1974&pages=299-305&author=I.+J.+Selikoff&title=Epidemiology+of+gastrointestinal+cancer&doi=10.1289%2Fehp.749299"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1289%2Fehp.749299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.749299%26sid%3Dliteratum%253Aachs%26aulast%3DSelikoff%26aufirst%3DI.%2BJ.%26atitle%3DEpidemiology%2520of%2520gastrointestinal%2520cancer%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D1974%26volume%3D9%26spage%3D299%26epage%3D305%26doi%3D10.1289%2Fehp.749299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D. H.</span></span> <span> </span><span class="NLM_article-title">NTRK1 fusion in glioblastoma multiforme</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e91940</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0091940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1371%2Fjournal.pone.0091940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24647444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e91940&author=J.+Kimauthor=Y.+Leeauthor=H.+J.+Choauthor=Y.+E.+Leeauthor=J.+Anauthor=G.+H.+Choauthor=Y.+H.+Koauthor=K.+M.+Jooauthor=D.+H.+Nam&title=NTRK1+fusion+in+glioblastoma+multiforme&doi=10.1371%2Fjournal.pone.0091940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK1 fusion in glioblastoma multiforme</span></div><div class="casAuthors">Kim, Jinkuk; Lee, Yeri; Cho, Hee Jin; Lee, Young-Eun; An, Jaeyeol; Cho, Gye-Hyun; Ko, Young-Hyeh; Joo, Kyeung Min; Nam, Do-Hyun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e91940/1-e91940/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor, yet with no targeted therapy with substantial survival benefit.  Recent studies on solid tumors showed that fusion genes often play driver roles and are promising targets for pharmaceutical intervention.  To survey potential fusion genes in GBMs, we analyzed RNA-Seq data from 162 GBM patients available through The Cancer Genome Atlas (TCGA), and found that 3' exons of neurotrophic tyrosine kinase receptor type 1 (NTRK1, encoding TrkA) are fused to 5' exons of the genes that are highly expressed in neuronal tissues, neurofascin (NFASC) and brevican (BCAN).  The fusions preserved both the transmembrane and kinase domains of NTRK1 in frame.  NTRK1 is a mediator of the pro-survival signaling of nerve growth factor (NGF) and is a known oncogene, found commonly altered in human cancer.  While GBMs largely lacked NTRK1 expression, the fusion-pos. GBMs expressed fusion transcripts in high abundance, and showed elevated NTRK1-pathway activity.  Lentiviral transduction of the NFASC-NTRK1 fusion gene in NIH 3T3 cells increased proliferation in vitro, colony formation in soft agar, and tumor formation in mice, suggesting the possibility that the fusion contributed to the initiation or maintenance of the fusion-pos. GBMs, and therefore may be a rational drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz9tDpBhaQt7Vg90H21EOLACvtfcHk0ljLBqA8N3AIJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ&md5=c3592983729fa1ad26ee88e9a478d85c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091940%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DY.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DG.%2BH.%26aulast%3DKo%26aufirst%3DY.%2BH.%26aulast%3DJoo%26aufirst%3DK.%2BM.%26aulast%3DNam%26aufirst%3DD.%2BH.%26atitle%3DNTRK1%2520fusion%2520in%2520glioblastoma%2520multiforme%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De91940%26doi%3D10.1371%2Fjournal.pone.0091940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, C.</span></span> <span> </span><span class="NLM_article-title">An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases</span>. <i>J. Cytol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.4103/0970-9371.190455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.4103%2F0970-9371.190455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28028333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FpvVekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=192-198&author=C.+Sharma&title=An+analysis+of+trends+of+incidence+and+cytohistological+correlation+of+papillary+carcinoma+of+the+thyroid+gland+with+evaluation+of+discordant+cases&doi=10.4103%2F0970-9371.190455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases</span></div><div class="casAuthors">Sharma Chetna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cytology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">192-198</span>
        ISSN:<span class="NLM_cas:issn">0970-9371</span>.
    </div><div class="casAbstract">BACKGROUND:  The role of fine-needle aspiration cytology (FNAC) in thyroid nodules has been well-studied but there is a paucity of studies solely involving papillary thyroid carcinoma (PTC).  The diagnostic criteria for PTC are established but still there is a worrisome possibility of false positive and false-negative results, which can have a serious impact on patient care.  This article correlates the cytological and histological diagnosis of PTC with an eventual aim of analyzing the cause of false positive and false negative results in order to prevent misdiagnosis.  An increase in the incidence of PTC in the younger population has been noted.  AIMS:  To analyze the epidemiological trends and cytohistological correlation of PTC and evaluate the discordant cases and pitfalls of FNAC.  MATERIALS AND METHODS:  Seventy-two cases who had undergone both FNAC and histopathological examination (HPE) of the thyroid gland were selected.  Age and sex distribution as well as cytohistological correlation were done for all the cases.  RESULTS:  Cytohistological correlation was 81.94%.  False positives were 5.56% and the false negative rate was 13.2%.  Sensitivity was 86.7% and the positive predictive value was 93.6%.  The peak age was 31-40 years among females and 41-60 years among males.  Seven of our patients were <20 years of age (10%).  CONCLUSION:  FNAC is an indispensible tool for the early diagnosis of PTC.  However, certain conditions of the thyroid gland can cause diagnostic dilemma.  Awareness of pathologists regarding these pitfalls can prevent misdiagnosis and provide better patient care.  Increasing the incidence of PTC with a more striking increase in the younger population makes early diagnosis all the more important owing to better prognosis in this age group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEMeA5etJTeZcXNb62YGmbfW6udTcc2eaagFuLUn4hmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FpvVekug%253D%253D&md5=b9aed01690c6601bd413b4585bd1fd46</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.4103%2F0970-9371.190455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0970-9371.190455%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DC.%26atitle%3DAn%2520analysis%2520of%2520trends%2520of%2520incidence%2520and%2520cytohistological%2520correlation%2520of%2520papillary%2520carcinoma%2520of%2520the%2520thyroid%2520gland%2520with%2520evaluation%2520of%2520discordant%2520cases%26jtitle%3DJ.%2520Cytol.%26date%3D2016%26volume%3D33%26spage%3D192%26epage%3D198%26doi%3D10.4103%2F0970-9371.190455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grier, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakewich, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)65732-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0002-9440%2810%2965732-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9811336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXns1Ohu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=1998&pages=1451-1458&author=B.+P.+Rubinauthor=C.-J.+Chenauthor=T.+W.+Morganauthor=S.+Xiaoauthor=H.+E.+Grierauthor=H.+P.+Kozakewichauthor=A.+R.+Perez-Ataydeauthor=J.+A.+Fletcher&title=Congenital+mesoblastic+nephroma+t%2812%3B15%29+is+associated+with+ETV6-NTRK3+gene+fusion&doi=10.1016%2FS0002-9440%2810%2965732-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma</span></div><div class="casAuthors">Rubin, Brian P.; Chen, Chang-Jie; Morgan, Thomas W.; Xiao, Sheng; Grier, Holcombe E.; Kozakewich, Harry P.; Perez-Atayde, Antonio R.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1451-1458</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Morphol., cytogenetic, and biol. evidence supports a relation between congenital (infantile) fibrosarcoma (CFS) and congenital mesoblastic nephroma (CMN).  These tumors have a very similar histol. appearance, and they are both assocd. with polysomies for chromosomes 8, 11, 17, and 20.  Recently, CFS was shown to contain a novel t(12; 15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion.  The aims of this study were to det. whether congenital mesoblastic nephroma contains the t(12;15)(p13;q25) translocation and ETV6-NTRK3 gene fusion and whether ETV6-NTRK3 fusions, in CMN and CFS, antedate acquisition of nonrandom chromosome polysomies.  To address these aims, the authors evaluated (1) ETV6-NTRK3 fusion transcripts by reverse transcriptase polymerase chain reaction and sequence anal., (2) genomic ETV6-region chromosomal rearrangement by fluorescence in situ hybridization, and (3) chromosomal polysomies by karyotyping and fluorescence in situ hybridization.  The authors report ETV6-NTRK3 fusion transcripts and/or ETV6-region rearrangement in five of six CMNs and in five of five CFSs.  The ETV6-NTRK3 fusion transcripts and/or ETV-region chromosome rearrangements were demonstrated in two CMNs and one CFS that lacked chromosome polysomies.  These findings demonstrate that t(12;15) translocation, and the assocd. ETV6-NTRK3 fusion, can antedate acquisition of chromosome polysomies in CMN and CFS.  CMN and CFS are pathogenetically related, and it is likely that they represent a single neoplastic entity, arising in either renal or soft tissue locations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4y1vnjx9jLrVg90H21EOLACvtfcHk0lh84Z6J5cyT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1Ohu7k%253D&md5=b227a133f1dd93a911628f45ede835fd</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2965732-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252965732-X%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DChen%26aufirst%3DC.-J.%26aulast%3DMorgan%26aufirst%3DT.%2BW.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DGrier%26aufirst%3DH.%2BE.%26aulast%3DKozakewich%26aufirst%3DH.%2BP.%26aulast%3DPerez-Atayde%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCongenital%2520mesoblastic%2520nephroma%2520t%252812%253B15%2529%2520is%2520associated%2520with%2520ETV6-NTRK3%2520gene%2520fusion%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1998%26volume%3D153%26spage%3D1451%26epage%3D1458%26doi%3D10.1016%2FS0002-9440%2810%2965732-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittleman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrom, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruchko, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnholtz-Sloan, J. S.</span></span> <span> </span><span class="NLM_article-title">Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry</span>. <i>Front Public Health</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">151</span>, <span class="refDoi"> DOI: 10.3389/fpubh.2016.00151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3389%2Ffpubh.2016.00151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=27493936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2s3nvVersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=151&author=L.+N.+Chienauthor=H.+Gittlemanauthor=Q.+T.+Ostromauthor=K.+S.+Hungauthor=A.+E.+Sloanauthor=Y.+C.+Hsiehauthor=C.+Kruchkoauthor=L.+R.+Rogersauthor=Y.+F.+Wangauthor=H.+Y.+Chiouauthor=J.+S.+Barnholtz-Sloan&title=Comparative+brain+and+central+nervous+system+tumor+incidence+and+survival+between+the+United+States+and+Taiwan+based+on+population-based+registry&doi=10.3389%2Ffpubh.2016.00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry</span></div><div class="casAuthors">Chien Li-Nien; Gittleman Haley; Ostrom Quinn T; Kruchko Carol; Hung Kuo-Sheng; Sloan Andrew E; Hsieh Yi-Chen; Rogers Lisa R; Wang Ye-Fan Glavin; Chiou Hung-Yi; Barnholtz-Sloan Jill S</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in public health</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151</span>
        ISSN:<span class="NLM_cas:issn">2296-2565</span>.
    </div><div class="casAbstract">PURPOSE:  Reasons for worldwide variability in the burden of primary malignant brain and central nervous system (CNS) tumors remain unclear.  This study compares the incidence and survival of malignant brain and CNS tumors by selected histologic types between the United States (US) and Taiwan.  METHODS:  Data from 2002 to 2010 were selected from two population-based cancer registries for primary malignant brain and CNS tumors: the Central Brain Tumor Registry of the United States and the Taiwan Cancer Registry.  Two registries had similar process of collecting patients with malignant brain tumor, and the quality of two registries was comparative.  The age-adjusted incidence rate (IR), IR ratio, and survival by histological types, age, and gender were used to study regional differences.  RESULTS:  The overall age-adjusted IRs were 5.91 per 100,000 in the US and 2.68 per 100,000 in Taiwan.  The most common histologic type for both countries was glioblastoma (GBM) with a 12.9% higher proportion in the US than in Taiwan.  GBM had the lowest survival rate of any histology in both countries (US 1-year survival rate = 37.5%; Taiwan 1-year survival rate = 50.3%).  The second largest group was astrocytoma, excluding GBM and anaplastic astrocytoma, with the distribution being slightly higher in Taiwan than in the US.  CONCLUSION:  Our findings revealed differences by histological type and grade of primary malignant brain and CNS tumors between two sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-W1hzsSj1oyCEBeYuoi7AfW6udTcc2eayYj8AjSObbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3nvVersw%253D%253D&md5=b3ca18e2355a2f51cf3693dfbacf239a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffpubh.2016.00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpubh.2016.00151%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DL.%2BN.%26aulast%3DGittleman%26aufirst%3DH.%26aulast%3DOstrom%26aufirst%3DQ.%2BT.%26aulast%3DHung%26aufirst%3DK.%2BS.%26aulast%3DSloan%26aufirst%3DA.%2BE.%26aulast%3DHsieh%26aufirst%3DY.%2BC.%26aulast%3DKruchko%26aufirst%3DC.%26aulast%3DRogers%26aufirst%3DL.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DChiou%26aufirst%3DH.%2BY.%26aulast%3DBarnholtz-Sloan%26aufirst%3DJ.%2BS.%26atitle%3DComparative%2520brain%2520and%2520central%2520nervous%2520system%2520tumor%2520incidence%2520and%2520survival%2520between%2520the%2520United%2520States%2520and%2520Taiwan%2520based%2520on%2520population-based%2520registry%26jtitle%3DFront%2520Public%2520Health%26date%3D2016%26volume%3D4%26spage%3D151%26doi%3D10.3389%2Ffpubh.2016.00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paugh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahawatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onar-Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becksfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadodaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yergeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boop, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0lh84Z6J5cyT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mourad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jetmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jategaonkar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moubayed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urken, M. L.</span></span> <span> </span><span class="NLM_article-title">Epidemiological trends of head and neck cancer in the United States: a SEER population study</span>. <i>J. Oral Maxillofac. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">2562</span>– <span class="NLM_lpage">2572</span>, <span class="refDoi"> DOI: 10.1016/j.joms.2017.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.joms.2017.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28618252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1cnos1CisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2017&pages=2562-2572&author=M.+Mouradauthor=T.+Jetmoreauthor=A.+A.+Jategaonkarauthor=S.+Moubayedauthor=E.+Moshierauthor=M.+L.+Urken&title=Epidemiological+trends+of+head+and+neck+cancer+in+the+United+States%3A+a+SEER+population+study&doi=10.1016%2Fj.joms.2017.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study</span></div><div class="casAuthors">Mourad Moustafa; Jetmore Thomas; Jategaonkar Ameya A; Moubayed Sami; Moshier Erin; Urken Mark L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2562-2572</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  This study represents the most recent epidemiologic trends of head and neck cancer (HNC) in the United States.  It provides an important discussion on oropharyngeal cancer and cancers related to the human papillomavirus.  The objective was to identify trends in HNC (2002 to 2012) within the United States.  MATERIALS AND METHODS:  This study is a retrospective analysis of the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) submission.  Using the November 2014 submission of the SEER database and SEER-18 data files, data from 2002 to 2012 were analyzed to determine the most recent epidemiologic trends.  HNCs of all subtypes were analyzed together.  Laryngeal cancers were further analyzed separately.  Oropharyngeal cancers of the base of tongue and tonsil were analyzed independently to attempt to trend HPV-related cancers.  RESULTS:  From 2002 to 2012, there were 149,301 cases of HNC recorded in the SEER database.  The HNC rate decreased by 0.22% per year (P = .0549) and the rate of laryngeal cancer decreased by 1.9% per year (P < .0001).  The rate of oropharyngeal (HPV-related) cancer increased by 2.5% per year (P < .0001).  HNC rates increased significantly in Kentucky and Connecticut and decreased in California (P < .05).  HPV-related cancers increased significantly in all states except Georgia, Hawaii, and Michigan (P < .05).  Laryngeal cancer rates decreased in California, Georgia, New Jersey, and New Mexico (P < .05).  CONCLUSIONS:  The overall incidence of HNC is decreasing in the United States.  There is an increasing incidence of HPV-related cancers of the oropharynx.  Meaningful differences in cancer incidence and rate of change exist between men and women.  Furthermore, younger groups have a greater decrease of overall HNC, with an overall increase in HPV-related cancer in patients older than 50 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaBwyLjBg0t8jl5L8hwNX0fW6udTcc2ea9Gedef0u9cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnos1CisA%253D%253D&md5=849a0f247d967374ba911aeb06b84b99</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.joms.2017.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joms.2017.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DMourad%26aufirst%3DM.%26aulast%3DJetmore%26aufirst%3DT.%26aulast%3DJategaonkar%26aufirst%3DA.%2BA.%26aulast%3DMoubayed%26aufirst%3DS.%26aulast%3DMoshier%26aufirst%3DE.%26aulast%3DUrken%26aufirst%3DM.%2BL.%26atitle%3DEpidemiological%2520trends%2520of%2520head%2520and%2520neck%2520cancer%2520in%2520the%2520United%2520States%253A%2520a%2520SEER%2520population%2520study%26jtitle%3DJ.%2520Oral%2520Maxillofac.%2520Surg.%26date%3D2017%26volume%3D75%26spage%3D2562%26epage%3D2572%26doi%3D10.1016%2Fj.joms.2017.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, N.</span></span> <span> </span><span class="NLM_article-title">New driver mutations in non-small-cell lung cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(10)70087-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS1470-2045%2810%2970087-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21277552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=175-180&author=W.+Paoauthor=N.+Girard&title=New+driver+mutations+in+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2810%2970087-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">New driver mutations in non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Girard, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Treatment decisions for patients with lung cancer have historically been based on tumor histol.  Some understanding of the mol. compn. of tumors has led to the development of targeted agents, for which initial findings are promising.  Clearer understanding of mutations in relevant genes and their effects on cancer cell proliferation and survival, is, therefore, of substantial interest.  We review current knowledge about mol. subsets in non-small-cell lung cancer that have been identified as potentially having clin. relevance to targeted therapies.  Since mutations in EGFR and KRAS have been extensively reviewed elsewhere, here, we discuss subsets defined by so-called driver mutations in ALK, HER2 (also known as ERBB2), BRAF, PIK3CA, AKT1, MAP2K1, and MET.  The adoption of treatment tailored according to the genetic make-up of individual tumors would involve a paradigm shift, but might lead to substantial therapeutic improvements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplMPwgmZjAT7Vg90H21EOLACvtfcHk0lh4kufnVJU26g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D&md5=3d590b884d4a9827e85781d65d17759f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970087-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970087-5%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGirard%26aufirst%3DN.%26atitle%3DNew%2520driver%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D175%26epage%3D180%26doi%3D10.1016%2FS1470-2045%2810%2970087-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damjanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenderi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, S.</span></span> <span> </span><span class="NLM_article-title">Mammary analogue secretory carcinoma (MASC) of the salivary gland: a new tumor entity</span>. <i>Bosnian J. Basic Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.17305/bjbms.2016.1321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.17305%2Fbjbms.2016.1321" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=237-238&author=I.+Damjanovauthor=F.+Skenderiauthor=S.+Vranic&title=Mammary+analogue+secretory+carcinoma+%28MASC%29+of+the+salivary+gland%3A+a+new+tumor+entity&doi=10.17305%2Fbjbms.2016.1321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.17305%2Fbjbms.2016.1321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17305%252Fbjbms.2016.1321%26sid%3Dliteratum%253Aachs%26aulast%3DDamjanov%26aufirst%3DI.%26aulast%3DSkenderi%26aufirst%3DF.%26aulast%3DVranic%26aufirst%3DS.%26atitle%3DMammary%2520analogue%2520secretory%2520carcinoma%2520%2528MASC%2529%2520of%2520the%2520salivary%2520gland%253A%2520a%2520new%2520tumor%2520entity%26jtitle%3DBosnian%2520J.%2520Basic%2520Med.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D237%26epage%3D238%26doi%3D10.17305%2Fbjbms.2016.1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi-Ishimae, M.</span></span> <span> </span><span class="NLM_article-title">Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias</span>. <i>Med. Pediatr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1002/mpo.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fmpo.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11568912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BD3Mrit1eltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=417&author=M.+Eguchiauthor=M.+Eguchi-Ishimae&title=Absence+of+t%2812%3B15%29+associated+ETV6-NTRK3+fusion+transcripts+in+pediatric+acute+leukemias&doi=10.1002%2Fmpo.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias</span></div><div class="casAuthors">Eguchi M; Eguchi-Ishimae M</div><div class="citationInfo"><span class="NLM_cas:title">Medical and pediatric oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">417</span>
        ISSN:<span class="NLM_cas:issn">0098-1532</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzCZP9DwrZeAvupmecNw_lfW6udTcc2ea9Gedef0u9cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mrit1eltA%253D%253D&md5=7ef3ad0abc3932135cb256d1d17e5352</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1002%2Fmpo.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmpo.1223%26sid%3Dliteratum%253Aachs%26aulast%3DEguchi%26aufirst%3DM.%26aulast%3DEguchi-Ishimae%26aufirst%3DM.%26atitle%3DAbsence%2520of%2520t%252812%253B15%2529%2520associated%2520ETV6-NTRK3%2520fusion%2520transcripts%2520in%2520pediatric%2520acute%2520leukemias%26jtitle%3DMed.%2520Pediatr.%2520Oncol.%26date%3D2001%26volume%3D37%26spage%3D417%26doi%3D10.1002%2Fmpo.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne-Turner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCastlain, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobucci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiernik, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldoss, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlschmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrozek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornblau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paietta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullighan, C. G.</span></span> <span> </span><span class="NLM_article-title">High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.69.0073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2016.69.0073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=27870571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2snoslCmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=394-401&author=K.%0AG.+Robertsauthor=Z.+Guauthor=D.+Payne-Turnerauthor=K.+McCastlainauthor=R.+C.+Harveyauthor=I.+M.+Chenauthor=D.+Peiauthor=I.+Iacobucciauthor=M.+Valentineauthor=S.+B.+Poundsauthor=L.+Shiauthor=Y.+Liauthor=J.+Zhangauthor=C.+Chengauthor=A.+Rambaldiauthor=M.+Tosiauthor=O.+Spinelliauthor=J.+P.+Radichauthor=M.+D.+Mindenauthor=J.+M.+Roweauthor=S.+Lugerauthor=M.+R.+Litzowauthor=M.+S.+Tallmanauthor=P.+H.+Wiernikauthor=R.+Bhatiaauthor=I.+Aldossauthor=J.+Kohlschmidtauthor=K.+Mrozekauthor=G.+Marcucciauthor=C.+D.+Bloomfieldauthor=W.+Stockauthor=S.+Kornblauauthor=H.+M.+Kantarjianauthor=M.+Konoplevaauthor=E.+Paiettaauthor=C.+L.+Willmanauthor=C.+G.+Mullighan&title=High+frequency+and+poor+outcome+of+philadelphia+chromosome-like+acute+lymphoblastic+leukemia+in+adults&doi=10.1200%2FJCO.2016.69.0073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults</span></div><div class="casAuthors">Roberts Kathryn G; Gu Zhaohui; Payne-Turner Debbie; McCastlain Kelly; Harvey Richard C; Chen I-Ming; Pei Deqing; Iacobucci Ilaria; Valentine Marcus; Pounds Stanley B; Shi Lei; Li Yongjin; Zhang Jinghui; Cheng Cheng; Rambaldi Alessandro; Tosi Manuela; Spinelli Orietta; Radich Jerald P; Minden Mark D; Rowe Jacob M; Luger Selina; Litzow Mark R; Tallman Martin S; Wiernik Peter H; Bhatia Ravi; Aldoss Ibrahim; Kohlschmidt Jessica; Mrozek Krzysztof; Marcucci Guido; Bloomfield Clara D; Stock Wendy; Kornblau Stephen; Kantarjian Hagop M; Konopleva Marina; Paietta Elisabeth; Willman Cheryl L; Mullighan Charles G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">394-401</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors.  We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy.  Patients and Methods The frequency of Ph-like ALL was assessed by gene expression profiling of 798 patients with B-cell ALL age 21 to 86 years.  Event-free survival and overall survival were determined for Ph-like ALL versus non-Ph-like ALL patients.  Detailed genomic analysis was performed on 180 of 194 patients with Ph-like ALL.  Results Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of young adults (age 21 to 39 years), 20.4% of adults (age 40 to 59 years), and 24.0% of older adults (age 60 to 86 years).  Overall, patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3% [95% CI, 42.8% to 56.2%; n = 247], respectively; P < .001).  We identified kinase-activating alterations in 88% of patients with Ph-like ALL, including CRLF2 rearrangements (51%), ABL class fusions (9.8%), JAK2 or EPOR rearrangements (12.4%), other JAK-STAT sequence mutations (7.2%), other kinase alterations (4.1%), and Ras pathway mutations (3.6%).  Eleven new kinase rearrangements were identified, including four involving new kinase or cytokine receptor genes and seven involving new partners for previously identified genes.  Conclusion Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome.  The diverse range of kinase-activating alterations in Ph-like ALL has important therapeutic implications.  Trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to evaluate the clinical utility of these agents in the treatment of Ph-like ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROzMeK0FCHhM25P7XSLhESfW6udTcc2eZtTww9xukaS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snoslCmsQ%253D%253D&md5=a56e0480b6a9bb0ad7bad0c54c7daae8</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.69.0073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.69.0073%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DK.%2BG.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DPayne-Turner%26aufirst%3DD.%26aulast%3DMcCastlain%26aufirst%3DK.%26aulast%3DHarvey%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DI.%2BM.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DValentine%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DRambaldi%26aufirst%3DA.%26aulast%3DTosi%26aufirst%3DM.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26aulast%3DLuger%26aufirst%3DS.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DAldoss%26aufirst%3DI.%26aulast%3DKohlschmidt%26aufirst%3DJ.%26aulast%3DMrozek%26aufirst%3DK.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DKornblau%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DPaietta%26aufirst%3DE.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26atitle%3DHigh%2520frequency%2520and%2520poor%2520outcome%2520of%2520philadelphia%2520chromosome-like%2520acute%2520lymphoblastic%2520leukemia%2520in%2520adults%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D394%26epage%3D401%26doi%3D10.1200%2FJCO.2016.69.0073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fancelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varasi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candiani, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpinelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapwijk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsiglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soncini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storici, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugnoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, P.</span></span> <span> </span><span class="NLM_article-title">1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7247</span>– <span class="NLM_lpage">7251</span>, <span class="refDoi"> DOI: 10.1021/jm060897w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060897w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFCjtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7247-7251&author=D.+Fancelliauthor=J.+Mollauthor=M.+Varasiauthor=R.+Bravoauthor=R.+Articoauthor=D.+Bertaauthor=S.+Bindiauthor=A.+Cameronauthor=I.+Candianiauthor=P.+Cappellaauthor=P.+Carpinelliauthor=W.+Crociauthor=B.+Forteauthor=M.+L.+Giorginiauthor=J.+Klapwijkauthor=A.+Marsiglioauthor=E.+Pesentiauthor=M.+Rocchettiauthor=F.+Rolettoauthor=D.+Severinoauthor=C.+Sonciniauthor=P.+Storiciauthor=R.+Tonaniauthor=P.+Zugnoniauthor=P.+Vianello&title=1%2C4%2C5%2C6-tetrahydropyrrolo%5B3%2C4-c%5Dpyrazoles%3A+identification+of+a+potent+Aurora+kinase+inhibitor+with+a+favorable+antitumor+kinase+inhibition+profile&doi=10.1021%2Fjm060897w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile</span></div><div class="casAuthors">Fancelli, Daniele; Moll, Juergen; Varasi, Mario; Bravo, Rodrigo; Artico, Roberta; Berta, Daniela; Bindi, Simona; Cameron, Alexander; Candiani, Ilaria; Cappella, Paolo; Carpinelli, Patrizia; Croci, Walter; Forte, Barbara; Giorgini, Maria Laura; Klapwijk, Jan; Marsiglio, Aurelio; Pesenti, Enrico; Rocchetti, Maurizio; Roletto, Fulvia; Severino, Dino; Soncini, Chiara; Storici, Paola; Tonani, Roberto; Zugnoni, Paola; Vianello, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7247-7251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization of a series of 5-phenylacetyl 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivs. toward the inhibition of Aurora kinases led to the identification of compd. 9d.(I).  This is a potent inhibitor of Aurora kinases that also shows low nanomolar potency against addnl. anticancer kinase targets.  Based on its high antiproliferative activity on different cancer cell lines, favorable chemico-phys. and pharmacokinetic properties, and high efficacy in in vivo tumor models, compd. 9d was ultimately selected for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0zkyh7ON2-rVg90H21EOLACvtfcHk0liLDAporhR6WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFCjtb3J&md5=55cd95b6fdef641bdb21c4b5a18f4b28</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm060897w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060897w%26sid%3Dliteratum%253Aachs%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DArtico%26aufirst%3DR.%26aulast%3DBerta%26aufirst%3DD.%26aulast%3DBindi%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCandiani%26aufirst%3DI.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCroci%26aufirst%3DW.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DKlapwijk%26aufirst%3DJ.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DSeverino%26aufirst%3DD.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DTonani%26aufirst%3DR.%26aulast%3DZugnoni%26aufirst%3DP.%26aulast%3DVianello%26aufirst%3DP.%26atitle%3D1%252C4%252C5%252C6-tetrahydropyrrolo%255B3%252C4-c%255Dpyrazoles%253A%2520identification%2520of%2520a%2520potent%2520Aurora%2520kinase%2520inhibitor%2520with%2520a%2520favorable%2520antitumor%2520kinase%2520inhibition%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7247%26epage%3D7251%26doi%3D10.1021%2Fjm060897w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteve-Puig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparatta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerroni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutzner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, B. C.</span></span> <span> </span><span class="NLM_article-title">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3116</span>, <span class="refDoi"> DOI: 10.1038/ncomms4116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fncomms4116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24445538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3116&author=T.+Wiesnerauthor=J.+Heauthor=R.+Yelenskyauthor=R.+Esteve-Puigauthor=T.+Bottonauthor=I.+Yehauthor=D.+Lipsonauthor=G.+Ottoauthor=K.+Brennanauthor=R.+Muraliauthor=M.+Garridoauthor=V.+A.+Millerauthor=J.+S.+Rossauthor=M.+F.+Bergerauthor=A.+Sparattaauthor=G.+Palmedoauthor=L.+Cerroniauthor=K.+J.+Busamauthor=H.+Kutznerauthor=M.+T.+Croninauthor=P.+J.+Stephensauthor=B.+C.+Bastian&title=Kinase+fusions+are+frequent+in+Spitz+tumours+and+spitzoid+melanomas&doi=10.1038%2Fncomms4116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span></div><div class="casAuthors">Wiesner Thomas; Murali Rajmohan; Berger Michael F; Busam Klaus J; Bastian Boris C; Wiesner Thomas; Cerroni Lorenzo; He Jie; Yelensky Roman; Lipson Doron; Otto Geoff; Brennan Kristina; Miller Vincent A; Ross Jeffrey S; Cronin Maureen T; Stephens Philip J; Esteve-Puig Rosaura; Botton Thomas; Yeh Iwei; Garrido Maria; Sparatta Alyssa; Bastian Boris C; Murali Rajmohan; Bastian Boris C; Palmedo Gabriele; Kutzner Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3116</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features.  They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours).  Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent.  Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern.  The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas.  Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro.  In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd1A4UrEIWolQKX3ooHxWjfW6udTcc2eY6DLjkHrWXNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D&md5=c98dfce5cbc4b2c38e3898b9e0c4c4fa</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fncomms4116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4116%26sid%3Dliteratum%253Aachs%26aulast%3DWiesner%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DEsteve-Puig%26aufirst%3DR.%26aulast%3DBotton%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DI.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DK.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DSparatta%26aufirst%3DA.%26aulast%3DPalmedo%26aufirst%3DG.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DKinase%2520fusions%2520are%2520frequent%2520in%2520Spitz%2520tumours%2520and%2520spitzoid%2520melanomas%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3116%26doi%3D10.1038%2Fncomms4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turbeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. M.</span></span> <span> </span><span class="NLM_article-title">Prevalence and incidence of acute myeloid leukemia may be higher than currently accepted estimates among the ≥ 65 year-old population in the United States</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=958&author=S.+Turbevilleauthor=K.+M.+Francisauthor=I.+Behmauthor=G.+R.+Chiuauthor=H.+Sanchezauthor=B.+Morrisonauthor=J.+M.+Rowe&title=Prevalence+and+incidence+of+acute+myeloid+leukemia+may+be+higher+than+currently+accepted+estimates+among+the+%E2%89%A5+65+year-old+population+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurbeville%26aufirst%3DS.%26aulast%3DFrancis%26aufirst%3DK.%2BM.%26aulast%3DBehm%26aufirst%3DI.%26aulast%3DChiu%26aufirst%3DG.%2BR.%26aulast%3DSanchez%26aufirst%3DH.%26aulast%3DMorrison%26aufirst%3DB.%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26atitle%3DPrevalence%2520and%2520incidence%2520of%2520acute%2520myeloid%2520leukemia%2520may%2520be%2520higher%2520than%2520currently%2520accepted%2520estimates%2520among%2520the%2520%25E2%2589%25A5%252065%2520year-old%2520population%2520in%2520the%2520United%2520States%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knezevich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P.</span></span> <span> </span><span class="NLM_article-title">A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1038/ng0298-184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fng0298-184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=9462753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADyaK1cXos1emsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=184-187&author=S.+Knezevichauthor=D.+McFaddenauthor=W.+Taoauthor=J.+Limauthor=P.+Sorensen&title=A+novel+ETV6-NTRK3+gene+fusion+in+congenital+fibrosarcoma&doi=10.1038%2Fng0298-184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma</span></div><div class="casAuthors">Knezevich, Stevan R.; McFadden, Deborah E.; Tao, Wen; Lim, Jerian F.; Sorensen, Poul H. B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-187</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Congenital (or infantile) fibrosarcoma (CFS) is a malignant tumor of fibroblasts that occurs in patients aged two years or younger.  CFS is unique among human sarcomas in that it has an excellent prognosis and very low metastatic rate.  CFS is histol. identical to adult-type fibrosarcoma (ATFS); however, ATFS is an aggressive malignancy of adults and older children that has a poor prognosis.  We report a novel recurrent t(12; 15)(p13; q25) rearrangement in CFS that may underlie that distinctive biol. properties of this tumor.  By cloning the chromosome breakpoints, we show that the rearrangements fuses the ETV6 (also known as TEL) gene from 12p13 with the 15q25 NTRK3 neurotrophin-3 receptor gene (also known as TRKC).  Anal. of mRNA revealed the expression of ETV6-NTRK3 chimeric transcripts in all three CFS tumors analyzed.  These were not detected in ATFS or infantile fibromatosis (IFB), a histol. similar but benign fibroblastic proliferation occurring in the same age-group as CFS.  ETV6-NTRK3 fusion transcripts encode the helix-loop-helix (HLH) protein dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3.  Our studies indicate that a chimeric PTK is expressed in CFS and this may contribute to oncogenesis by dysregulation of NTRK3 signal transduction pathways.  Moreover, ETV6-NTRK3 gene fusion provide a potential diagnostic marker for CFS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT0hrvnhkh-7Vg90H21EOLACvtfcHk0lgnkoRROZ5xgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXos1emsw%253D%253D&md5=6a83b8790a126a34cc8c4afe5d76c4b0</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fng0298-184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0298-184%26sid%3Dliteratum%253Aachs%26aulast%3DKnezevich%26aufirst%3DS.%26aulast%3DMcFadden%26aufirst%3DD.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DSorensen%26aufirst%3DP.%26atitle%3DA%2520novel%2520ETV6-NTRK3%2520gene%2520fusion%2520in%2520congenital%2520fibrosarcoma%26jtitle%3DNat.%2520Genet.%26date%3D1998%26volume%3D18%26spage%3D184%26epage%3D187%26doi%3D10.1038%2Fng0298-184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, J. W.</span></span> <span> </span><span class="NLM_article-title">Secretory breast carcinoma: A report of three cases and a review of the literature</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.3892/ol.2014.2213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3892%2Fol.2014.2213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25009650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpvFejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=683-686&author=S.+G.+Leeauthor=S.+P.+Jungauthor=H.+Y.+Leeauthor=S.+Kimauthor=H.+Y.+Kimauthor=I.+Kimauthor=J.+W.+Bae&title=Secretory+breast+carcinoma%3A+A+report+of+three+cases+and+a+review+of+the+literature&doi=10.3892%2Fol.2014.2213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Secretory breast carcinoma: A report of three cases and a review of the literature</span></div><div class="casAuthors">Lee Seung Geun; Jung Seung Pil; Lee Hye Yoon; Kim Sinill; Kim Hoon Yub; Bae Jeoung Won; Kim Insun</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">683-686</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Secretory breast carcinoma is a very rare and distinct subtype of breast cancer, characterized by the presence of intracellular and extracellular secretory material.  Secretory breast carcinoma has a good clinical outcome and systemic involvement is rare.  The majority of studies of this tumor have been case reports or separate analyses, and due to the rarity of these tumors, it has been difficult to fully elucidate their characteristics and define optimal treatment strategies.  To add to the current knowledge of secretory breast carcinoma, the present study reports three cases of secretory breast carcinoma in patients of different ages, and with different hormone receptor statuses and treatment methods.  The present study identified that each patient with secretory breast carcinoma may present with different symptoms and clinical characteristics.  Therefore, therapeutic options should be selected based on the overall status of the patient and the characteristics of this rare disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_lpLrbLKORMjl5L8hwNX0fW6udTcc2eaDzvTniCIwJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpvFejug%253D%253D&md5=9ae7f3d512e7f16b2d11fc7467527eb4</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.3892%2Fol.2014.2213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2014.2213%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DJung%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DI.%26aulast%3DBae%26aufirst%3DJ.%2BW.%26atitle%3DSecretory%2520breast%2520carcinoma%253A%2520A%2520report%2520of%2520three%2520cases%2520and%2520a%2520review%2520of%2520the%2520literature%26jtitle%3DOncol.%2520Lett.%26date%3D2014%26volume%3D8%26spage%3D683%26epage%3D686%26doi%3D10.3892%2Fol.2014.2213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunnane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, J. L.</span></span> <span> </span><span class="NLM_article-title">The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5729</span>– <span class="NLM_lpage">5735</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1203922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11126359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslylsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5729-5735&author=J.+P.+Russellauthor=D.+J.+Powellauthor=M.+Cunnaneauthor=A.+Grecoauthor=G.+Portellaauthor=M.+Santoroauthor=A.+Fuscoauthor=J.+L.+Rothstein&title=The+TRK-T1+fusion+protein+induces+neoplastic+transformation+of+thyroid+epithelium&doi=10.1038%2Fsj.onc.1203922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium</span></div><div class="casAuthors">Russell, John P.; Powell, Daniel J.; Cunnane, Mary; Greco, Angela; Portella, Giuseppe; Santoro, Massimo; Fusco, Alfredo; Rothstein, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5729-5735</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic anal. of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal translocations that form oncogenic fusion proteins and promote thyroid tumorigenesis in up to 60% of tumors examd.  Although, the majority of thyroid specific translocations involve the growth factor receptor c-RET, variant rearrangements of the receptor for nerve growth factor, NTRK1 have also been described.  One such translocation, TRK-T1, forms a fusion protein composed of the carboxyl terminal tyrosine kinase domain of NTRK1 and the amino terminal portion of TPR (Translocated Promoter Region).  To det. if TRK-T1 expression can cause thyroid cancer in vivo, the authors developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid.  Immunohistochem. anal. of TRK-T1 transgenic mouse thyroids revealed TRK-T1 staining within the thyroid follicular epithelium.  In contrast to nontransgenic littermates, 54% of transgenic mice developed thyroid abnormalities that included follicular hyperplasia and papillary carcinoma.  Furthermore, all transgenic mice examd. greater than 7 mo of age developed thyroid hyperplasia and/or carcinoma.  These data support the conclusion that TRK-T1 is oncogenic in vivo and contributes to the neoplastic transformation of the thyroid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNu_2azw_DDrVg90H21EOLACvtfcHk0ljp1aqZc9FKxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslylsLk%253D&md5=d49e7b624370223e3b73b45aae1fdad6</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203922%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DJ.%2BP.%26aulast%3DPowell%26aufirst%3DD.%2BJ.%26aulast%3DCunnane%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DPortella%26aufirst%3DG.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRothstein%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520TRK-T1%2520fusion%2520protein%2520induces%2520neoplastic%2520transformation%2520of%2520thyroid%2520epithelium%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5729%26epage%3D5735%26doi%3D10.1038%2Fsj.onc.1203922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondellini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span> <span> </span><span class="NLM_article-title">The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1210/en.2002-221002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1210%2Fen.2002-221002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12586769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslCqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2003&pages=922-928&author=V.+Ranziauthor=S.+O.+Meakinauthor=C.+Mirandaauthor=P.+Mondelliniauthor=M.+A.+Pierottiauthor=A.+Greco&title=The+signaling+adapters+fibroblast+growth+factor+receptor+substrate+2+and+3+are+activated+by+the+thyroid+TRK+oncoproteins&doi=10.1210%2Fen.2002-221002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins</span></div><div class="casAuthors">Ranzi, Valeria; Meakin, Susan O.; Miranda, Claudia; Mondellini, Piera; Pierotti, Marco A.; Greco, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">922-928</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The thyroid TRK oncogenes are generated by chromosomal rearrangements juxtaposing the neurotrophic tyrosine receptor kinase type 1 (NTRK1) tyrosine kinase domain to foreign activating sequences.  TRK oncoproteins display a constitutive tyrosine kinase activity resulting in the capability to transform NIH3T3 cells.  The TRK oncoproteins' signal transduction has been in part elucidated, and it involves several signal transducers activated by the NGF-stimulated NTRK1 receptor.  In this paper, we investigate the role of FRS2 and FRS3, two related adapter proteins activated by fibroblast growth factor and NTRK1 receptors, in the signaling of the thyroid TRK-T1 and TRK-T3 oncogenes.  By a combination of in vitro and in vivo assays, we demonstrate that both fibroblast growth factor receptor substrate (FRS)2 and FRS3 are recruited and activated by TRK-T1 and TRK-T3.  Interaction studies using different TRK-T3 mutants indicate that FRS3 is recruited by the same tyrosine residue interacting with She and FRS2.  Expression studies show different expression patterns of the FRS adapters in normal and tumor thyroid samples: FRS3 is expressed in both normal and thyroid tumor samples, whereas FRS2 is not expressed in normal thyroid but is differentially expressed in some tumors.  Altogether, our data indicate that the FRS2 and FRS3 adapters may have a role in thyroid carcinogenesis triggered by TRK oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQWYj0AmS-ULVg90H21EOLACvtfcHk0ljp1aqZc9FKxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslCqsb0%253D&md5=af83b227bf98257d2651b70b6c54e31e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1210%2Fen.2002-221002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2002-221002%26sid%3Dliteratum%253Aachs%26aulast%3DRanzi%26aufirst%3DV.%26aulast%3DMeakin%26aufirst%3DS.%2BO.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DMondellini%26aufirst%3DP.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DGreco%26aufirst%3DA.%26atitle%3DThe%2520signaling%2520adapters%2520fibroblast%2520growth%2520factor%2520receptor%2520substrate%25202%2520and%25203%2520are%2520activated%2520by%2520the%2520thyroid%2520TRK%2520oncoproteins%26jtitle%3DEndocrinology%26date%3D2003%26volume%3D144%26spage%3D922%26epage%3D928%26doi%3D10.1210%2Fen.2002-221002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Obberghen, E.</span></span> <span> </span><span class="NLM_article-title">IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1002/1097-4652(200101)186:1<35::AID-JCP1003>3.0.CO;2-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11147812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslyqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2001&pages=35-46&author=C.+Mirandaauthor=A.+Grecoauthor=C.+Mieleauthor=M.+A.+Pierottiauthor=E.+Van+Obberghen&title=IRS-1+and+IRS-2+are+recruited+by+TrkA+receptor+and+oncogenic+TRK-T1&doi=10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1</span></div><div class="casAuthors">Miranda, Claudia; Greco, Angela; Miele, Claudia; Pierotti, Marco A.; Van Obberghen, Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-46</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">TRK-T1 oncogene is generated by the rearrangement of the NGF receptor TrkA with TPR.  This gives rise to the constitutive tyrosine autophosphorylation and activation of the kinase.  To study TRK-T1 oncogenic signaling and compare it to that induced by the genuine receptor TrkA, we investigated the involvement of IRS-1, a docking protein implicated in mitogenic signaling induced by several growth factors, in TRK-T1 and TrkA signaling.  Here, we show that IRS-1 and IRS-2 are phosphorylated on tyrosine in presence of both TRK-T1 and the activated TrkA receptor.  These tyrosine phosphorylations lead to IRS-1- and IRS-2-induced recruitment of p85P13K, SHP-2, and Grb2 and increase in PI 3-kinase activity assocd. with IRS-1.  Furthermore, we found that TRK-T1 is able to activate c-fos serum responsive element in cooperation with IRS-1 and IRS-2.  We obsd. that TRK-T1 stimulates DNA synthesis in wild-type fibroblasts but not in IRS-1-/- mouse embryo fibroblasts.  Yeast two-hybrid system expts. showed the occurrence of direct interaction between TRK and IRS mols., which suggests involvement of different modes of interactions.  On the whole, our results suggest that IRS-1 and IRS-2 could be substrates of TRK-T1 and TrkA, and hence could participate in their signal generation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqUaP0yBErSrVg90H21EOLACvtfcHk0lj9SPSAJkNQQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslyqtrg%253D&md5=dbaf3311a2456a6307c43bf361f62689</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-4652%2528200101%2529186%253A1%253C35%253A%253AAID-JCP1003%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DVan%2BObberghen%26aufirst%3DE.%26atitle%3DIRS-1%2520and%2520IRS-2%2520are%2520recruited%2520by%2520TrkA%2520receptor%2520and%2520oncogenic%2520TRK-T1%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2001%26volume%3D186%26spage%3D35%26epage%3D46%26doi%3D10.1002%2F1097-4652%28200101%29186%3A1%3C35%3A%3AAID-JCP1003%3E3.0.CO%3B2-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roccato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gishizki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span> <span> </span><span class="NLM_article-title">Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.bjc.6600544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12237775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=645-653&author=E.+Roccatoauthor=C.+Mirandaauthor=V.+Ranziauthor=M.+Gishizkiauthor=M.+A.+Pierottiauthor=A.+Greco&title=Biological+activity+of+the+thyroid+TRK-T3+oncogene+requires+signalling+through+Shc&doi=10.1038%2Fsj.bjc.6600544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc</span></div><div class="casAuthors">Roccato, E.; Miranda, C.; Ranzi, V.; Gishizki, M.; Pierotti, M. A.; Greco, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">645-653</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The thyroid TRK-T3 oncogene, produced by a chromosomal translocation, is a chimeric, constitutively activated version of the NTRK1/NGF receptor and it is able to transform NIH3T3 cells and differentiate PC12 cells.  TRK-T3 oncoprotein triggers multiple signal transduction pathways.  Among others, TRK-T3 binds and phosphorylates the Shc and SNT1/FRS2 adaptor proteins both involved in coupling the receptor tyrosine kinase to the mitogen-activated protein kinase pathway by recruiting Grb2/SOS.  We were interested in defining the role of Shc in the oncogenesis by TRK-T3.  The mutation of TRK-T3 Tyr 291, docking site for both Shc and FRS2, abrogates the oncogene biol. activity.  To directly explore the role of Shc the authors used the ShcY317F mutant, which carries the mutation of a Tyr residue involved in Grb2 recruitment.  We demonstrated that the ShcY317F mutant exerts an inhibitory effect on TRK-T3 transforming activity.  Such effect can be modulated by the amt. of ShcY317F protein and affects the viability of cells expressing TRK-T3 by a mechanism involving apoptosis.  These results indicate a definitive role of the adaptor protein Shc in TRK-T3 transforming activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJgC2dxNyjFbVg90H21EOLACvtfcHk0lj9SPSAJkNQQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKjs7g%253D&md5=24ec11983b5c459d714cfe7d87138991</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600544%26sid%3Dliteratum%253Aachs%26aulast%3DRoccato%26aufirst%3DE.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DRanzi%26aufirst%3DV.%26aulast%3DGishizki%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DGreco%26aufirst%3DA.%26atitle%3DBiological%2520activity%2520of%2520the%2520thyroid%2520TRK-T3%2520oncogene%2520requires%2520signalling%2520through%2520Shc%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D87%26spage%3D645%26epage%3D653%26doi%3D10.1038%2Fsj.bjc.6600544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H.</span></span> <span> </span><span class="NLM_article-title">ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5684</span>– <span class="NLM_lpage">5695</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1205669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12173038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVait7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=5684-5695&author=K.+B.+Morrisonauthor=C.+E.+Tognonauthor=M.+J.+Garnettauthor=C.+Dealauthor=P.+H.+Sorensen&title=ETV6-NTRK3+transformation+requires+insulin-like+growth+factor+1+receptor+signaling+and+is+associated+with+constitutive+IRS-1+tyrosine+phosphorylation&doi=10.1038%2Fsj.onc.1205669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation</span></div><div class="casAuthors">Morrison, Kevin B.; Tognon, Cristina E.; Garnett, Mathew J.; Deal, Cheri; Sorensen, Poul H. B.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5684-5695</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are pediatric spindle cell malignancies that share two specific cytogenetic abnormalities: trisomy of chromosome 11 and a t(12;15)(p13;q25) translocation.  The t(12;15) rearrangement creates a transcriptionally active fusion gene that encodes a chimeric oncoprotein, ETV6-NTRK3 (EN).  EN transforms NIH3T3 fibroblasts through constitutive activation of both the Ras-mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3'-kinase (PI3K)-Akt pathway.  However, the role of trisomy 11 in CFS and CMN remains unknown.  In this study we demonstrate elevated expression of the chromosome 11p15.5 insulin-like growth factor 2 gene (IGF2) in CFS and CMN tumors.  Moreover, we present evidence that an intact IGF signaling axis is essential for in vitro EN-mediated transformation.  EN only very weakly transformed so-called R-murine fibroblasts derived from mice with a targeted disruption of the IGF1 receptor gene (IGFRI), but transformation activity was fully restored in R- cells engineered to re-express IGFRI (R+ cells).  We also obsd. that the major IGFRI substrate, insulin-receptor substrate-1 (IRS-1), was constitutively tyrosine phosphorylated and could be co-immunopptd. with EN in either R- or R+ cells expressing the EN oncoprotein.  IRS-1 assocn. with Grb2 and PI3K p85, which link IGFRI to the Ras-MAPK and PI3K-Akt pathways, resp., was enhanced in both cell types in the presence of EN.  However, activation of the Ras-MAPK and PI3K-Akt pathways was markedly attenuated in EN-expressing R- cells compared to EN-transformed R+ cells.  This suggests that IRS-1 may be functioning as an adaptor in EN signal transduction, but that a link to EN transformation pathways requires the presence of IGFRI.  Our findings indicate that an intact IGF signaling axis is essential for EN transformation, and are consistent with a role for trisomy 11 in augmenting this pathway in EN expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZXoCEb6cu97Vg90H21EOLACvtfcHk0lj9SPSAJkNQQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVait7s%253D&md5=960b27095466f1313423840e626c0757</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205669%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DK.%2BB.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DDeal%26aufirst%3DC.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%26atitle%3DETV6-NTRK3%2520transformation%2520requires%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520signaling%2520and%2520is%2520associated%2520with%2520constitutive%2520IRS-1%2520tyrosine%2520phosphorylation%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D5684%26epage%3D5695%26doi%3D10.1038%2Fsj.onc.1205669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H. B.</span></span> <span> </span><span class="NLM_article-title">The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8909</span>– <span class="NLM_lpage">8916</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8909-8916&author=C.+Tognonauthor=M.+Garnettauthor=E.+Kenwardauthor=R.+Kayauthor=K.+Morrisonauthor=P.+H.+B.+Sorensen&title=The+chimeric+protein+tyrosine+kinase+ETV6-NTRK3+requires+both+Ras-Erk1%2F2+and+PI3-kinase-Akt+signaling+for+fibroblast+transformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTognon%26aufirst%3DC.%26aulast%3DGarnett%26aufirst%3DM.%26aulast%3DKenward%26aufirst%3DE.%26aulast%3DKay%26aufirst%3DR.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%2BB.%26atitle%3DThe%2520chimeric%2520protein%2520tyrosine%2520kinase%2520ETV6-NTRK3%2520requires%2520both%2520Ras-Erk1%252F2%2520and%2520PI3-kinase-Akt%2520signaling%2520for%2520fibroblast%2520transformation%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D8909%26epage%3D8916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shvarts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4959</span>– <span class="NLM_lpage">4965</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fsj.onc.1207667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15077169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=4959-4965&author=M.+J.+Edelauthor=A.+Shvartsauthor=J.+P.+Medemaauthor=R.+Bernards&title=An+in+vivo+functional+genetic+screen+reveals+a+role+for+the+TRK-T3+oncogene+in+tumor+progression&doi=10.1038%2Fsj.onc.1207667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression</span></div><div class="casAuthors">Edel, Michael J.; Shvarts, Avi; Medema, Jan Paul; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4959-4965</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Over the past decades, much has been learnt about the genes that contribute to oncogenic transformation of primary cells in vitro.  However, much less is known about the genes that contribute to the later stages of tumor progression, in which cells of ever increasing malignancy arise through clonal selection in vivo.  To search for genes that confer a tumor progression phenotype in vivo, we have used a functional genetic approach.  We used adenovirus-transformed mouse embryo fibroblasts, which are tumorigenic in immunodeficient nude mice, but not in immunocompetent mice, due to strong cytotoxic T-cell-mediated immune rejection.  We infected these cells in vitro with several high-complexity retroviral cDNA expression libraries and selected rare variants that formed tumors in immunocompetent mice.  Using this approach, we identify here the TRK-T3 oncogene as a tumor progression gene.  TRK-T3 does not inhibit T-cell reactivity towards the tumor cells.  Instead, we find that cells expressing TRK-T3 enhances in vivo growth rate, most likely by stimulating anchorage-independent proliferation in growth factor-limiting conditions.  Our data indicate that cDNA expression libraries can be used to identify tumor progression genes in vivo that cannot be readily identified using in vitro cell culture systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaqkXB8lq10bVg90H21EOLACvtfcHk0lhkmxQ8DS5saA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVOnsr0%253D&md5=283816bc2c14d046b7fe69b84ac4a2da</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207667%26sid%3Dliteratum%253Aachs%26aulast%3DEdel%26aufirst%3DM.%2BJ.%26aulast%3DShvarts%26aufirst%3DA.%26aulast%3DMedema%26aufirst%3DJ.%2BP.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DAn%2520in%2520vivo%2520functional%2520genetic%2520screen%2520reveals%2520a%2520role%2520for%2520the%2520TRK-T3%2520oncogene%2520in%2520tumor%2520progression%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D4959%26epage%3D4965%26doi%3D10.1038%2Fsj.onc.1207667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span> <span> </span><span class="NLM_article-title">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010–2016-Part I</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1297796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1080%2F13543776.2017.1297796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28270010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=733-751&author=J.+J.+Baileyauthor=R.+Schirrmacherauthor=K.+Farrellauthor=V.+Bernard-Gauthier&title=Tropomyosin+receptor+kinase+inhibitors%3A+an+updated+patent+review+for+2010%E2%80%932016-Part+I&doi=10.1080%2F13543776.2017.1297796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I</span></div><div class="casAuthors">Bailey, Justin J.; Schirrmacher, Ralf; Farrell, Kristen; Bernard-Gauthier, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">733-751</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Tropomyosin receptor kinases (TrkA/B/C) play crucial roles in the development and maintenance of the nervous system, and aberrant expression of Trk has been implicated in neurol. disorders as well as neural and non-neural neoplasms.  Patent activity encompassing Trk inhibitors has grown substantially over the last 6 years, recognized by a rise in the no. of pharmaceutical entrants to the field and the escalation of novel inhibitor chemotypes.  In Part I of this two part review, a biol. and structural overview of Trk is provided in the context of Trk as a therapeutic target for cancer and pain, followed by the report of recent patent literature claiming small mol. inhibitors of Trk family kinases or which describe inhibitors developed for other kinase targets but include noteworthy Trk inhibition/application.  The discussion of the patent literature continues in Part II of this review, which includes an in-depth view of the current clin. applications of Trk inhibitors.  Substantial synthetic efforts in Trk inhibitor development has propagated numerous and diverse inhibitor chemotypes, including TrkA-specific inhibitors.  While many novel Trk inhibitors remain the original progeny of Trk-specific development programs, kinase inhibitors initially developed for other kinases have also been successfully repositioned for Trk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIHEog1RqjUrVg90H21EOLACvtfcHk0lhkmxQ8DS5saA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtb0%253D&md5=e863493e3065568c43e39c0fe5a73751</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1297796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1297796%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DK.%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26atitle%3DTropomyosin%2520receptor%2520kinase%2520inhibitors%253A%2520an%2520updated%2520patent%2520review%2520for%25202010%25E2%2580%25932016-Part%2520I%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D733%26epage%3D751%26doi%3D10.1080%2F13543776.2017.1297796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span> <span> </span><span class="NLM_article-title">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010–2016-Part II</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1297797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1080%2F13543776.2017.1297797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28270021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=831-849&author=J.+J.+Baileyauthor=R.+Schirrmacherauthor=K.+Farrellauthor=V.+Bernard-Gauthier&title=Tropomyosin+receptor+kinase+inhibitors%3A+an+updated+patent+review+for+2010%E2%80%932016-Part+II&doi=10.1080%2F13543776.2017.1297797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II</span></div><div class="casAuthors">Bailey, Justin J.; Schirrmacher, Ralf; Farrell, Kristen; Bernard-Gauthier, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">831-849</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">TrkA/B/C receptor activation supports growth, survival, and differentiation of discrete neuronal populations during development, adult life, and ageing but also plays numerous roles in human disease onset and progression.  Trk-specific inhibitors have therapeutic applications in cancer and pain and thus constitute a growing area of interest in oncol. and neurol.  There has been substantial growth in the no. of structural classes of Trk inhibitors and the no. of industrial entrants to the Trk inhibitor field over the past six years.  In Part II of this two-part review, the discussion of recent patent literature covering Trk family inhibitors is continued from Part I and clin. research with Trk inhibitors is considered.  Trk has been molecularly targeted for over a decade resulting in the progressive evolution of structurally diversified Trk inhibitors arising from scaffold hopping and HTS efforts.  Correspondingly, there have been a growing no. of clin. investigations utilizing Trk inhibitors in recent years, with a particular focus on the treatment of NTRK-fusion pos. cancers and chronic pain.  The obsd. potential of Trk inhibitors to cause adverse CNS side effects however suggests the need for a more rigorous consideration of BBB permeation capabilities during drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG_4h-yrNplrVg90H21EOLACvtfcHk0lhkmxQ8DS5saA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvFyjtbw%253D&md5=9c0a05bec29ecf9ccf53cc26dda78709</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1297797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1297797%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DK.%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26atitle%3DTropomyosin%2520receptor%2520kinase%2520inhibitors%253A%2520an%2520updated%2520patent%2520review%2520for%25202010%25E2%2580%25932016-Part%2520II%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D831%26epage%3D849%26doi%3D10.1080%2F13543776.2017.1297797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E.</span></span> <span> </span><span class="NLM_article-title">Tropomyosin receptor kinase inhibitors: a patent update 2009–2013</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.910195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1517%2F13543776.2014.910195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24809946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=731-744&author=C.+McCarthyauthor=E.+Walker&title=Tropomyosin+receptor+kinase+inhibitors%3A+a+patent+update+2009%E2%80%932013&doi=10.1517%2F13543776.2014.910195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013</span></div><div class="casAuthors">McCarthy, Clive; Walker, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">731-744</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family.  The nerve growth factor antibody tanezumab has provided clin. proof of concept for inhibition of the TrkA pathway in pain.  As an alternative modality, small-mol. inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications.  Areas covered: This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biol. targets.  Addnl. patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is obsd. and the chem. matter is particularly noteworthy.  Patents pre-dating this period have been reviewed previously.  Scifinder and Google were used to find relevant patents and clin. information using Trk or Tropomyosin as the search term.  Expert opinion: Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clin. evaluation.  Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted mols. have been identified.  Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biol. of this isoform to be probed.  The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjXwkruGnLXbVg90H21EOLACvtfcHk0lh-bYicQJq-rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtr7L&md5=b924331cd9d69192bc10f53424997550</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.910195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.910195%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DE.%26atitle%3DTropomyosin%2520receptor%2520kinase%2520inhibitors%253A%2520a%2520patent%2520update%25202009%25E2%2580%25932013%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D731%26epage%3D744%26doi%3D10.1517%2F13543776.2014.910195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.4155/fmc.13.216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.4155%2Ffmc.13.216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=24649957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=541-561&author=S.+W.+Cowan-Jacobauthor=W.+Jahnkeauthor=S.+Knapp&title=Novel+approaches+for+targeting+kinases%3A+allosteric+inhibition%2C+allosteric+activation+and+pseudokinases&doi=10.4155%2Ffmc.13.216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Jahnke, Wolfgang; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">541-561</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in many essential cellular processes and their deregulation can lead to a variety of diseases, including cancer.  The pharmaceutical industry has invested heavily in the identification of kinase inhibitors to modulate these disease-promoting pathways, resulting in several successful drugs.  However, the field is challenging as it is difficult to identify novel selective inhibitors with good pharmacokinetic/pharmacodynamic properties.  In addn., resistance to kinase inhibitor treatment frequently arises.  The identification of non-ATP site targeting ('allosteric') inhibitors, the identification of kinase activators and the expansion of kinase target space to include the less studied members of the family, including atypical- and pseudo-kinases, are potential avenues to overcome these challenges.  In this perspective, the opportunities and challenges of following these approaches and others will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQaQbATcjnLVg90H21EOLACvtfcHk0ljyE3j5cjMKaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D&md5=74a540a959200628a065e287ea6e48d3</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.216%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DNovel%2520approaches%2520for%2520targeting%2520kinases%253A%2520allosteric%2520inhibition%252C%2520allosteric%2520activation%2520and%2520pseudokinases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D541%26epage%3D561%26doi%3D10.4155%2Ffmc.13.216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0ljyE3j5cjMKaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhtiyarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurzy, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowska-Zoladek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saradjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvagnat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A. J.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of nonactive site, TrkA-selective kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">E297</span>– <span class="NLM_lpage">E306</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611577114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.1611577114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28039433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1ag" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E297-E306&author=H.+P.+Suauthor=K.+Rickertauthor=C.+Burleinauthor=K.+Narayanauthor=M.+Bukhtiyarovaauthor=D.+M.+Hurzyauthor=C.+A.+Stumpauthor=X.+Zhangauthor=J.+Reidauthor=A.+Krasowska-Zoladekauthor=S.+Tummalaauthor=J.+M.+Shipmanauthor=M.+Kornienkoauthor=P.+A.+Lemaireauthor=D.+Kroskyauthor=A.+Hellerauthor=A.+Achabauthor=C.+Chamberlinauthor=P.+Saradjianauthor=B.+Sauvagnatauthor=X.+Yangauthor=M.+R.+Ziebellauthor=E.+Nickbargauthor=J.+M.+Sandersauthor=M.+T.+Bilodeauauthor=S.+S.+Carrollauthor=K.+J.+Lumbauthor=S.+M.+Soissonauthor=D.+A.+Henzeauthor=A.+J.+Cooke&title=Structural+characterization+of+nonactive+site%2C+TrkA-selective+kinase+inhibitors&doi=10.1073%2Fpnas.1611577114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Structural characterization of nonactive site, TrkA-selective kinase inhibitors</span></div><div class="casAuthors">Su, Hua-Poo; Rickert, Keith; Burlein, Christine; Narayan, Kartik; Bukhtiyarova, Marina; Hurzy, Danielle M.; Stump, Craig A.; Zhang, Xufang; Reid, John; Krasowska-Zoladek, Alicja; Tummala, Srivanya; Shipman, Jennifer M.; Kornienko, Maria; Lemaire, Peter A.; Krosky, Daniel; Heller, Amanda; Achab, Abdelghani; Chamberlin, Chad; Saradjian, Peter; Sauvagnat, Berengere; Yang, Xianshu; Ziebell, Michael R.; Nickbarg, Elliott; Sanders, John M.; Bilodeau, Mark T.; Carroll, Steven S.; Lumb, Kevin J.; Soisson, Stephen M.; Henze, Darrell A.; Cooke, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">E297-E306</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Current therapies for chronic pain can have insufficient efficacy and lead to side effects, necessitating research of novel targets against pain.  Although originally identified as an oncogene, Tropomyosin-related kinase A (TrkA) is linked to pain and elevated levels of NGF (the ligand for TrkA) are assocd. with chronic pain.  Antibodies that block TrkA interaction with its ligand, NGF, are in clin. trials for pain relief.  Here, we describe the identification of TrkA-specific inhibitors and the structural basis for their selectivity over other Trk family kinases.  The X-ray structures reveal a binding site outside the kinase active site that uses residues from the kinase domain and the juxtamembrane region.  Three modes of binding with the juxtamembrane region are characterized through a series of ligand-bound complexes.  The structures indicate a crit. pharmacophore on the compds. that leads to the distinct binding modes.  The mode of interaction can allow TrkA selectivity over TrkB and TrkC or promiscuous, pan-Trk inhibition.  This finding highlights the difficulty in characterizing the structure-activity relationship of a chem. series in the absence of structural information because of substantial differences in the interacting residues.  These structures illustrate the flexibility of binding to sequences outside of - but adjacent to - the kinase domain of TrkA.  This knowledge allows development of compds. with specificity for TrkA or the family of Trk proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos46MKDwV6orVg90H21EOLACvtfcHk0lj48YXO2ucn5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1ag&md5=831df09deff6360df39f71a0c2d3d46a</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611577114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611577114%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DNarayan%26aufirst%3DK.%26aulast%3DBukhtiyarova%26aufirst%3DM.%26aulast%3DHurzy%26aufirst%3DD.%2BM.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DKrasowska-Zoladek%26aufirst%3DA.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLemaire%26aufirst%3DP.%2BA.%26aulast%3DKrosky%26aufirst%3DD.%26aulast%3DHeller%26aufirst%3DA.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DChamberlin%26aufirst%3DC.%26aulast%3DSaradjian%26aufirst%3DP.%26aulast%3DSauvagnat%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZiebell%26aufirst%3DM.%2BR.%26aulast%3DNickbarg%26aufirst%3DE.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DCooke%26aufirst%3DA.%2BJ.%26atitle%3DStructural%2520characterization%2520of%2520nonactive%2520site%252C%2520TrkA-selective%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3DE297%26epage%3DE306%26doi%3D10.1073%2Fpnas.1611577114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4672</span>– <span class="NLM_lpage">4684</span>, <span class="refDoi"> DOI: 10.1021/jm800343j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800343j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4672-4684&author=T.+Wangauthor=M.+L.+Lambauthor=D.+A.+Scottauthor=H.+Wangauthor=M.+H.+Blockauthor=P.+D.+Lyneauthor=J.+W.+Leeauthor=A.+M.+Daviesauthor=H.+J.+Zhangauthor=Y.+Zhuauthor=F.+Guauthor=Y.+Hanauthor=B.+Wangauthor=P.+J.+Mohrauthor=R.+J.+Kausauthor=J.+A.+Joseyauthor=E.+Hoffmannauthor=K.+Thressauthor=T.+Macintyreauthor=H.+Wangauthor=C.+A.+Omerauthor=D.+Yu&title=Identification+of+4-aminopyrazolylpyrimidines+as+potent+inhibitors+of+Trk+kinases&doi=10.1021%2Fjm800343j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases</span></div><div class="casAuthors">Wang, Tao; Lamb, Michelle L.; Scott, David A.; Wang, Haixia; Block, Michael H.; Lyne, Paul D.; Lee, John W.; Davies, Audrey M.; Zhang, Hai-Jun; Zhu, Yanyi; Gu, Fei; Han, Yongxin; Wang, Bin; Mohr, Peter J.; Kaus, Robert J.; Josey, John A.; Hoffmann, Ethan; Thress, Ken; MacIntyre, Terry; Wang, Haiyun; Omer, Charles A.; Yu, Dingwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4672-4684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluation of a series of 4-(pyrazolylamino)pyrimidines I (R1 = H, Me, SMe, cyclopropyl, Me2CHO, n-PrO, Me3C; R2 = H, Br, Cl, F, Me; R3 = H, HOCH2CH2NH, (S)-HOCH2CH(OH)CH2NH, etc.; R4 = Me, CH2OH, CH2CONMe2, CH2CONHMe; R5 = Ph, 2-ClC6H4, 4-FC6H4, 5-fluoro-2-pyridyl, 5-fluoro-2-pyrimidyl) as potent Trk kinase inhibitors is reported.  High-throughput screening identified a promising hit in the 4-(pyrazolylamino)pyrimidine chemotype.  Initial optimization of the series led to more potent Trk inhibitors.  Further optimization using two strategies resulted in significant improvement of phys. properties and led to the discovery of I (R1 = Me2CHO; R2 = Cl; R3 = H; R4 = (S)-Me; R5 = 5-fluoro-2-pyridyl) (AZ-23), a potent, orally bioavailable Trk A/B inhibitor.  The compd. offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ60edpRrhTrVg90H21EOLACvtfcHk0lj48YXO2ucn5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D&md5=16401146aa3860d13a4bc35bc04d5f83</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm800343j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800343j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DKaus%26aufirst%3DR.%2BJ.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DMacintyre%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DIdentification%2520of%25204-aminopyrazolylpyrimidines%2520as%2520potent%2520inhibitors%2520of%2520Trk%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4672%26epage%3D4684%26doi%3D10.1021%2Fjm800343j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zage, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweidler-McKay, P. A.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1818</span>– <span class="NLM_lpage">1827</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-09-0036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19509272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVymsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1818-1827&author=K.+Thressauthor=T.+Macintyreauthor=H.+Wangauthor=D.+Whitstonauthor=Z.+Y.+Liuauthor=E.+Hoffmannauthor=T.+Wangauthor=J.+L.+Brownauthor=K.+Websterauthor=C.+Omerauthor=P.+E.+Zageauthor=L.+Zengauthor=P.+A.+Zweidler-McKay&title=Identification+and+preclinical+characterization+of+AZ-23%2C+a+novel%2C+selective%2C+and+orally+bioavailable+inhibitor+of+the+Trk+kinase+pathway&doi=10.1158%2F1535-7163.MCT-09-0036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway</span></div><div class="casAuthors">Thress, Kenneth; MacIntyre, Terry; Wang, Haiyun; Whitston, Dave; Liu, Zhong-Ying; Hoffmann, Ethan; Wang, Tao; Brown, Jeffrey L.; Webster, Kevin; Omer, Charles; Zage, Peter E.; Zeng, Lizhi; Zweidler-McKay, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1818-1827</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tropomyosin-related kinases (TrkA, TrkB, and TrkC) are receptor tyrosine kinases that, along with their ligands, the neurotrophins, are involved in neuronal cell growth, development, and survival.  The Trk-neurotrophin pathway may also play a role in tumorigenesis through oncogenic fusions, mutations, and autocrine signaling, prompting the development of novel Trk inhibitors as agents for cancer therapy.  This report describes the identification of AZ-23, a novel, potent, and selective Trk kinase inhibitor.  In vitro studies with AZ-23 showed improved selectivity over previous compds. and inhibition of Trk kinase activity in cells at low nanomolar concns.  AZ-23 showed in vivo TrkA kinase inhibition and efficacy in mice following oral administration in a TrkA-driven allograft model and significant tumor growth inhibition in a Trk-expressing xenograft model of neuroblastoma.  AZ-23 represents a potent and selective Trk kinase inhibitor from a novel series with the potential for use as a treatment for cancer. [Mol Cancer Ther 2009;8(7):1818-27].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG2uvCSID5vbVg90H21EOLACvtfcHk0lj48YXO2ucn5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVymsro%253D&md5=8501f75147407ee64920fd4f5e733536</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0036%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%26aulast%3DMacintyre%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWhitston%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BL.%26aulast%3DWebster%26aufirst%3DK.%26aulast%3DOmer%26aufirst%3DC.%26aulast%3DZage%26aufirst%3DP.%2BE.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DZweidler-McKay%26aufirst%3DP.%2BA.%26atitle%3DIdentification%2520and%2520preclinical%2520characterization%2520of%2520AZ-23%252C%2520a%2520novel%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520the%2520Trk%2520kinase%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1818%26epage%3D1827%26doi%3D10.1158%2F1535-7163.MCT-09-0036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of disubstituted imidazo 4,5-b pyridines and purines as potent TrkA inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1021/ml300074j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300074j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=705-709&author=T.+Wangauthor=M.+L.+Lambauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=Y.+X.+Hanauthor=E.+Hoffmannauthor=S.+Ioannidisauthor=J.+A.+Joseyauthor=Z.+Y.+Liuauthor=P.+D.+Lyneauthor=T.+MacIntyreauthor=P.+J.+Mohrauthor=C.+A.+Omerauthor=T.+Sjogrenauthor=K.+Thressauthor=B.+Wangauthor=H.+Y.+Wangauthor=D.+W.+Yuauthor=H.+J.+Zhang&title=Discovery+of+disubstituted+imidazo+4%2C5-b+pyridines+and+purines+as+potent+TrkA+inhibitors&doi=10.1021%2Fml300074j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fml300074j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300074j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DSjogren%26aufirst%3DT.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DYu%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26atitle%3DDiscovery%2520of%2520disubstituted%2520imidazo%25204%252C5-b%2520pyridines%2520and%2520purines%2520as%2520potent%2520TrkA%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D705%26epage%3D709%26doi%3D10.1021%2Fml300074j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span> <span> </span><span class="NLM_article-title">The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.2.442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.90.2.442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=442-446&author=A.+C.+Carreraauthor=K.+Alexandrovauthor=T.+M.+Roberts&title=The+conserved+lysine+of+the+catalytic+domain+of+protein+kinases+is+actively+involved+in+the+phosphotransfer+reaction+and+not+required+for+anchoring+ATP&doi=10.1073%2Fpnas.90.2.442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.2.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.2.442%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DA.%2BC.%26aulast%3DAlexandrov%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26atitle%3DThe%2520conserved%2520lysine%2520of%2520the%2520catalytic%2520domain%2520of%2520protein%2520kinases%2520is%2520actively%2520involved%2520in%2520the%2520phosphotransfer%2520reaction%2520and%2520not%2520required%2520for%2520anchoring%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D442%26epage%3D446%26doi%3D10.1073%2Fpnas.90.2.442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pevarello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traquandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.1021/jm9006559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N%2C1%2C4%2C4-tetramethyl-8-%7B%5B4-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+a+potent%2C+orally+available+cyclin+dependent+kinase+inhibitor&doi=10.1021%2Fjm9006559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N%252C1%252C4%252C4-tetramethyl-8-%257B%255B4-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520a%2520potent%252C%2520orally%2520available%2520cyclin%2520dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163%26doi%3D10.1021%2Fjm9006559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albanese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1111/bph.12112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1111%2Fbph.12112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=23347136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFaksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=156-166&author=C.+Albaneseauthor=R.+Alzaniauthor=N.+Amboldiauthor=A.+Degrassiauthor=C.+Festucciaauthor=F.+Fiorentiniauthor=G.+Gravinaauthor=C.+Mercurioauthor=W.+Pastoriauthor=M.+Brascaauthor=E.+Pesentiauthor=A.+Galvaniauthor=M.+Ciomei&title=Anti-tumour+efficacy+on+glioma+models+of+PHA-848125%2C+a+multi-kinase+inhibitor+able+to+cross+the+blood-brain+barrier&doi=10.1111%2Fbph.12112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier</span></div><div class="casAuthors">Albanese, C.; Alzani, R.; Amboldi, N.; Degrassi, A.; Festuccia, C.; Fiorentini, F.; Gravina, G. L.; Mercurio, C.; Pastori, W.; Brasca, M. G.; Pesenti, E.; Galvani, A.; Ciomei, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-166</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Malignant gliomas, the most common primary brain tumors, are highly invasive and neurol. destructive neoplasms with a very bad prognosis due to the difficulty in removing the mass completely by surgery and the limited activity of current therapeutic agents.  PHA-848125 is a multi-kinase inhibitor with broad anti-tumor activity in pre-clin. studies and good tolerability in phase 1 studies, which could affect two main pathways involved in glioma pathogenesis, the G1-S phase progression control pathway through the inhibition of cyclin-dependent kinases and the signalling pathways mediated by tyrosine kinase growth factor receptors, such as tropomyosin receptors.  For this reason, we tested PHA-848125 in glioma models.  Exptl. Approach PHA-848125 was tested on a panel of glioma cell lines in vitro to evaluate inhibition of proliferation and mechanism of action.  In vivo efficacy was evaluated on two glioma models both as single agent and in combination with std. therapy.  Key Results: When tested on a subset of representative glioma cell lines, PHA-848125 blocked cell proliferation, DNA synthesis and inhibited both cell cycle and signal transduction markers.  Relevantly, PHA-848125 was also able to induce cell death through autophagy in all cell lines.  Good anti-tumor efficacy was obsd. by oral route in different glioma models both with s.c. and intracranial implantation.  Indeed, we demonstrate that the drug is able to cross the blood-brain barrier.  Moreover, the combination of PHA-848125 with temozolomide resulted in a synergistic effect, and a clear therapeutic gain was also obsd. with a triple treatment adding PHA-848125 to radiotherapy and temozolomide.  Conclusions and Implications: All the pre-clin. data obtained so far suggest that PHA-848125 may become a useful agent in chemotherapy regimens for glioma patients and support its evaluation in phase 2 trials for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUKdihsNd4rVg90H21EOLACvtfcHk0ljs6NLMiSLkXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFaksr0%253D&md5=695ce9933c916bbde6548090e9a17b6a</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fbph.12112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12112%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanese%26aufirst%3DC.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DFestuccia%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGravina%26aufirst%3DG.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DBrasca%26aufirst%3DM.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DAnti-tumour%2520efficacy%2520on%2520glioma%2520models%2520of%2520PHA-848125%252C%2520a%2520multi-kinase%2520inhibitor%2520able%2520to%2520cross%2520the%2520blood-brain%2520barrier%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26spage%3D156%26epage%3D166%26doi%3D10.1111%2Fbph.12112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albanese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2243</span>– <span class="NLM_lpage">2254</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-10-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=20682657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2243-2254&author=C.+Albaneseauthor=R.+Alzaniauthor=N.+Amboldiauthor=N.+Avanziauthor=D.+Ballinariauthor=M.+G.+Brascaauthor=C.+Festucciaauthor=F.+Fiorentiniauthor=G.+Locatelliauthor=W.+Pastoriauthor=V.+Pattonauthor=F.+Rolettoauthor=F.+Colottaauthor=A.+Galvaniauthor=A.+Isacchiauthor=J.+Mollauthor=E.+Pesentiauthor=C.+Mercurioauthor=M.+Ciomei&title=Dual+targeting+of+CDK+and+tropomyosin+receptor+kinase+families+by+the+oral+inhibitor+PHA-848125%2C+an+agent+with+broad-spectrum+antitumor+efficacy&doi=10.1158%2F1535-7163.MCT-10-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy</span></div><div class="casAuthors">Albanese, Clara; Alzani, Rachele; Amboldi, Nadia; Avanzi, Nilla; Ballinari, Dario; Brasca, Maria Gabriella; Festuccia, Claudio; Fiorentini, Francesco; Locatelli, Giuseppe; Pastori, Wilma; Patton, Veronica; Roletto, Fulvia; Colotta, Francesco; Galvani, Arturo; Isacchi, Antonella; Moll, Jurgen; Pesenti, Enrico; Mercurio, Ciro; Ciomei, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2243-2254</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Altered expression and activity of cyclin-dependent kinase (CDK) and tropomyosin receptor kinase (TRK) families are obsd. in a wide variety of tumors.  In those malignancies with aberrant CDK activation, the retinoblastoma protein (pRb) pathway is deregulated, leading to uncontrolled cell proliferation.  Constitutive activation of TRKs is instead linked to cancer cell survival and dissemination.  Here, we show that the novel small-mol. PHA-848125, a potent dual inhibitor of CDKs and TRKs, possesses significant antitumor activity.  The compd. inhibits cell proliferation of a wide panel of tumoral cell lines with submicromolar IC50.  PHA-848125-treated cells show cell cycle arrest in G1 and reduced DNA synthesis, accompanied by inhibition of pRb phosphorylation and modulation of other CDK-dependent markers.  The compd. addnl. inhibits phosphorylation of TRKA and its substrates in cells, which functionally express this receptor.  Following oral administration, PHA-848125 has significant antitumor activity in various human xenografts and carcinogen-induced tumors as well as in disseminated primary leukemia models, with plasma concns. in rodents in the same range as those found active in inhibiting cancer cell proliferation.  Mechanism of action was also confirmed in vivo as assessed in tumor biopsies from treated mice.  These results show that the dual CDK-TRK inhibitor PHA-848125 has the potential for being a novel and efficacious targeted drug for cancer treatment.  Mol Cancer Ther; 9(8); 2243-54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3AAtyUnt6jLVg90H21EOLACvtfcHk0liXdKSxvuTQOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjsL8%253D&md5=71c91cde816f8980db821b934d3ff2d4</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0190%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanese%26aufirst%3DC.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DFestuccia%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DLocatelli%26aufirst%3DG.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPatton%26aufirst%3DV.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DDual%2520targeting%2520of%2520CDK%2520and%2520tropomyosin%2520receptor%2520kinase%2520families%2520by%2520the%2520oral%2520inhibitor%2520PHA-848125%252C%2520an%2520agent%2520with%2520broad-spectrum%2520antitumor%2520efficacy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2243%26epage%3D2254%26doi%3D10.1158%2F1535-7163.MCT-10-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verduzco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatenby, R. A.</span></span> <span> </span><span class="NLM_article-title">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1038/nrc3298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrc3298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22695393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=487-493&author=R.+J.+Gilliesauthor=D.+Verduzcoauthor=R.+A.+Gatenby&title=Evolutionary+dynamics+of+carcinogenesis+and+why+targeted+therapy+does+not+work&doi=10.1038%2Fnrc3298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span></div><div class="casAuthors">Gillies, Robert J.; Verduzco, Daniel; Gatenby, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-493</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  All malignant cancers, whether inherited or sporadic, are fundamentally governed by Darwinian dynamics.  The process of carcinogenesis requires genetic instability and highly selective local microenvironments, the combination of which promotes somatic evolution.  These microenvironmental forces, specifically hypoxia, acidosis and reactive oxygen species, are not only highly selective, but are also able to induce genetic instability.  As a result, malignant cancers are dynamically evolving clades of cells living in distinct microhabitats that almost certainly ensure the emergence of therapy-resistant populations.  Cytotoxic cancer therapies also impose intense evolutionary selection pressures on the surviving cells and thus increase the evolutionary rate.  Importantly, the principles of Darwinian dynamics also embody fundamental principles that can illuminate strategies for the successful management of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorCHoXr5jY_rVg90H21EOLACvtfcHk0liXdKSxvuTQOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D&md5=ae041c5a9585d882c6512e386afb26c2</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnrc3298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3298%26sid%3Dliteratum%253Aachs%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DVerduzco%26aufirst%3DD.%26aulast%3DGatenby%26aufirst%3DR.%2BA.%26atitle%3DEvolutionary%2520dynamics%2520of%2520carcinogenesis%2520and%2520why%2520targeted%2520therapy%2520does%2520not%2520work%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D487%26epage%3D493%26doi%3D10.1038%2Fnrc3298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogliatto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6813</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0liXdKSxvuTQOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosine receptor kinases (Pan-TRKs) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3392</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+entrectinib%3A+a+new+3-aminoindazole+as+a+potent+anaplastic+lymphoma+kinase+%28ALK%29%2C+c-ros+oncogene+1+kinase+%28ROS1%29%2C+and+pan-tropomyosine+receptor+kinases+%28Pan-TRKs%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520entrectinib%253A%2520a%2520new%25203-aminoindazole%2520as%2520a%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%252C%2520c-ros%2520oncogene%25201%2520kinase%2520%2528ROS1%2529%252C%2520and%2520pan-tropomyosine%2520receptor%2520kinases%2520%2528Pan-TRKs%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">628</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.+M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+pan-TRK%2C+ROS1%2C+and+ALK+inhibitor+with+activity+in+multiple+molecularly+defined+cancer+indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0ljgyfE6LPz1vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520molecularly%2520defined%2520cancer%2520indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer</span>. <i>Ejc Supplements</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/S1359-6349(10)71807-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS1359-6349%2810%2971807-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=39-40&author=E.+Ardiniauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=N.+Amboldiauthor=D.+Ballinariauthor=M.+B.+Saccardoauthor=P.+Magnaghiauthor=E.+Pesentiauthor=A.+Isacchiauthor=A.+Galvani&title=Identification+and+preclinical+characterization+of+NMS-P626%2C+a+potent%2C+selective+and+orally+bioavailable+TrkA+inhibitor+with+anti-tumor+activity+in+a+TrkA-dependent+colorectal+cancer&doi=10.1016%2FS1359-6349%2810%2971807-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2810%2971807-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252810%252971807-3%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520preclinical%2520characterization%2520of%2520NMS-P626%252C%2520a%2520potent%252C%2520selective%2520and%2520orally%2520bioavailable%2520TrkA%2520inhibitor%2520with%2520anti-tumor%2520activity%2520in%2520a%2520TrkA-dependent%2520colorectal%2520cancer%26jtitle%3DEjc%2520Supplements%26date%3D2010%26volume%3D8%26spage%3D39%26epage%3D40%26doi%3D10.1016%2FS1359-6349%2810%2971807-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span>; <span class="NLM_string-name">Yan, S.</span>; <span class="NLM_string-name">Wei, G.</span>; <span class="NLM_string-name">Li, G.</span>; <span class="NLM_string-name">Harris, J.</span>; <span class="NLM_string-name">Vernier, J.-M.</span></span> <span> </span><span class="NLM_article-title">The structure of TRKA kinase domain bound to the inhibitor Entrectinib</span>. <span class="refDoi"> DOI: 10.2210/pdb5KVT/pdb</span> , <a href="https://www.rcsb.org/structure/5KVT" class="extLink">https://www.rcsb.org/structure/5KVT</a>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.2210%2Fpdb5KVT%2Fpdb" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jin%2C+L.%3B+Yan%2C+S.%3B+Wei%2C+G.%3B+Li%2C+G.%3B+Harris%2C+J.%3B+Vernier%2C+J.-M.+The+structure+of+TRKA+kinase+domain+bound+to+the+inhibitor+Entrectinib.+10.2210%2Fpdb5KVT%2Fpdb%2C+https%3A%2F%2Fwww.rcsb.org%2Fstructure%2F5KVT."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.2210%2Fpdb5KVT%2Fpdb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26id%3Ddoi%3A10.2210%252Fpdb5KVT%252Fpdb%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DL.%26atitle%3DThe%2520structure%2520of%2520TRKA%2520kinase%2520domain%2520bound%2520to%2520the%2520inhibitor%2520Entrectinib%26doi%3D10.2210%2Fpdb5KVT%2Fpdb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szilvassy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span> <span> </span><span class="NLM_article-title">The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6540</span>, <span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+discovery+and+optimization+of+a+novel+class+of+potent%2C+selective%2C+and+orally+bioavailable+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+potential+utility+for+the+treatment+of+cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0lhb2rfwTeJ_7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520a%2520novel%2520class%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520potential%2520utility%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcoxen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span> <span> </span><span class="NLM_article-title">506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">165</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(14)70632-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-8049%2814%2970632-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=165&author=J.+Sachdevauthor=H.+T.+Arkenauauthor=J.+R.+Infanteauthor=M.+M.+Mitaauthor=S.+P.+Anthonyauthor=R.+B.+Nataleauthor=S.+Ejadiauthor=K.+Wilcoxenauthor=V.+Kansraauthor=H.+Lakenauthor=L.+Hughesauthor=R.+Martellauthor=G.+J.+Weiss&title=506+Phase+%28Ph%29+1%2F2a+study+of+TSR-011%2C+a+potent+inhibitor+of+ALK+and+TRK%2C+in+advanced+solid+tumors+including+crizotinib-resistant+ALK+positive+non-small+cell+lung+cancer&doi=10.1016%2FS0959-8049%2814%2970632-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2814%2970632-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252814%252970632-X%26sid%3Dliteratum%253Aachs%26aulast%3DSachdev%26aufirst%3DJ.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DEjadi%26aufirst%3DS.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DKansra%26aufirst%3DV.%26aulast%3DLaken%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DL.%26aulast%3DMartell%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26atitle%3D506%2520Phase%2520%2528Ph%2529%25201%252F2a%2520study%2520of%2520TSR-011%252C%2520a%2520potent%2520inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520in%2520advanced%2520solid%2520tumors%2520including%2520crizotinib-resistant%2520ALK%2520positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2014%26volume%3D50%26spage%3D165%26doi%3D10.1016%2FS0959-8049%2814%2970632-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiaracina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauth, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3444</span>– <span class="NLM_lpage">3448</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2006.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16632359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3444-3448&author=B.+Lippaauthor=J.+Morrisauthor=M.+Corbettauthor=T.+A.+Kwanauthor=M.+C.+Noeauthor=S.+L.+Snowauthor=T.+G.+Gantauthor=M.+Mangiaracinaauthor=H.+A.+Coffeyauthor=B.+Fosterauthor=E.+A.+Knauthauthor=M.+D.+Wessel&title=Discovery+of+novel+isothiazole+inhibitors+of+the+TrkA+kinase%3A+Structure-activity+relationship%2C+computer+modeling%2C+optimization%2C+and+identification+of+highly+potent+antagonists&doi=10.1016%2Fj.bmcl.2006.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists</span></div><div class="casAuthors">Lippa, Blaise; Morris, Joel; Corbett, Matthew; Kwan, Tricia A.; Noe, Mark C.; Snow, Sheri L.; Gant, Thomas G.; Mangiaracina, Melchiorra; Coffey, Heather A.; Foster, Barbara; Knauth, Elisabeth A.; Wessel, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3444-3448</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ureidoisothiazolecarboxamides such as I are prepd. as antagonists of TrkA kinase.  A model based on the docking of isothiazolecarboxamide II to TrkA kinase is proposed.  The title ureidoisothiazolecarboxamides are prepd. by three different routes.  The ureido moiety can be replaced with a heteroarylamino group such as 2-pyridinyl; the presence of benzocycloalkylthio groups such as benzocycloheptyl at the C3-position of the isothiazolecarboxamide provides TrkA inhibitors with high potency in both kinase-based and cell-based assays.  E.g., I inhibits TrkA kinase with an IC50 value of <1 nM in vitro and with an IC50 value of 7 nM in vivo (in PAE cells).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSvzcj4wLOr7Vg90H21EOLACvtfcHk0ljFuyRpZARIhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2ju74%253D&md5=78ea1bfd163945169d0d47e743bee870</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DKwan%26aufirst%3DT.%2BA.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DSnow%26aufirst%3DS.%2BL.%26aulast%3DGant%26aufirst%3DT.%2BG.%26aulast%3DMangiaracina%26aufirst%3DM.%26aulast%3DCoffey%26aufirst%3DH.%2BA.%26aulast%3DFoster%26aufirst%3DB.%26aulast%3DKnauth%26aufirst%3DE.%2BA.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520novel%2520isothiazole%2520inhibitors%2520of%2520the%2520TrkA%2520kinase%253A%2520Structure-activity%2520relationship%252C%2520computer%2520modeling%252C%2520optimization%252C%2520and%2520identification%2520of%2520highly%2520potent%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3444%26epage%3D3448%26doi%3D10.1016%2Fj.bmcl.2006.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albaugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prashad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">(R)-2-Phenylpyrrolidine substituted imidazopyridazines: a new class of potent and selective pan-TRK inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=562-567&author=H.+S.+Choiauthor=P.+V.+Ruckerauthor=Z.+Wangauthor=Y.+Fanauthor=P.+Albaughauthor=G.+Chopiukauthor=F.+Gessierauthor=F.+Sunauthor=F.+Adrianauthor=G.+Liuauthor=T.+Hoodauthor=N.+Liauthor=Y.+Jiaauthor=J.+Cheauthor=S.+McCormackauthor=A.+Liauthor=J.+Liauthor=A.+Steffyauthor=A.+Culazzoauthor=C.+Tompkinsauthor=V.+Phungauthor=A.+Kreuschauthor=M.+Luauthor=B.+Huauthor=A.+Chaudharyauthor=M.+Prashadauthor=T.+Tuntlandauthor=B.+Liuauthor=J.+Harrisauthor=H.+M.+Seidelauthor=J.+Lorenauthor=V.+Molteni&title=%28R%29-2-Phenylpyrrolidine+substituted+imidazopyridazines%3A+a+new+class+of+potent+and+selective+pan-TRK+inhibitors&doi=10.1021%2Facsmedchemlett.5b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors</span></div><div class="casAuthors">Choi, Ha-Soon; Rucker, Paul V.; Wang, Zhicheng; Fan, Yi; Albaugh, Pamela; Chopiuk, Greg; Gessier, Francois; Sun, Fangxian; Adrian, Francisco; Liu, Guoxun; Hood, Tami; Li, Nanxin; Jia, Yong; Che, Jianwei; McCormack, Susan; Li, Allen; Li, Jie; Steffy, Auzon; Culazzo, AnneMarie; Tompkins, Celine; Phung, Van; Kreusch, Andreas; Lu, Min; Hu, Bin; Chaudhary, Apurva; Prashad, Mahavir; Tuntland, Tove; Liu, Bo; Harris, Jennifer; Seidel, H. Martin; Loren, Jon; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">562-567</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be assocd. with tumorigenesis and poor prognosis in a variety of cancer types.  In particular, several chromosomal rearrangements involving TRKA have been reported in colorectal, papillary thyroid, glioblastoma, melanoma, and lung tissue that are believed to be the key oncogenic driver in these tumors.  By screening the Novartis compd. collection, a novel imidazopyridazine TRK inhibitor was identified that served as a launching point for drug optimization.  Structure guided drug design led to the identification of (R)-2-phenylpyrrolidine substituted imidazopyridazines, e.g., I, as a series of potent, selective, orally bioavailable pan-TRK inhibitors achieving tumor regression in rats bearing KM12 xenografts.  From this work the (R)-2-phenylpyrrolidine has emerged as an ideal moiety to incorporate in bicyclic TRK inhibitors by virtue of its shape complementarity to the hydrophobic pocket of TRKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBOGdLZcZ2HbVg90H21EOLACvtfcHk0ljFuyRpZARIhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D&md5=e2eacf85a3e762e8f2474a568e6d1b39</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00050%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BS.%26aulast%3DRucker%26aufirst%3DP.%2BV.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DAlbaugh%26aufirst%3DP.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DMcCormack%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DCulazzo%26aufirst%3DA.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DPhung%26aufirst%3DV.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DPrashad%26aufirst%3DM.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DLoren%26aufirst%3DJ.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3D%2528R%2529-2-Phenylpyrrolidine%2520substituted%2520imidazopyridazines%253A%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520pan-TRK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D562%26epage%3D567%26doi%3D10.1021%2Facsmedchemlett.5b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsuru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasawa, Y.</span></span> <span> </span><span class="NLM_article-title">Imidazopyridine derivatives as potent and selective polo-like kinase (PLK) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4673</span>– <span class="NLM_lpage">4678</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2009.06.084" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4673-4678&author=Y.+Satoauthor=Y.+Onozakiauthor=T.+Sugimotoauthor=H.+Kuriharaauthor=K.+Kamijoauthor=C.+Kadowakiauthor=T.+Tsujinoauthor=A.+Watanabeauthor=S.+Otsukiauthor=M.+Mitsuyaauthor=M.+Iidaauthor=K.+Hazeauthor=T.+Machidaauthor=Y.+Nakatsuruauthor=H.+Komataniauthor=H.+Kotaniauthor=Y.+Iwasawa&title=Imidazopyridine+derivatives+as+potent+and+selective+polo-like+kinase+%28PLK%29+inhibitors&doi=10.1016%2Fj.bmcl.2009.06.084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.084%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DY.%26aulast%3DOnozaki%26aufirst%3DY.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DKadowaki%26aufirst%3DC.%26aulast%3DTsujino%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DOtsuki%26aufirst%3DS.%26aulast%3DMitsuya%26aufirst%3DM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DHaze%26aufirst%3DK.%26aulast%3DMachida%26aufirst%3DT.%26aulast%3DNakatsuru%26aufirst%3DY.%26aulast%3DKomatani%26aufirst%3DH.%26aulast%3DKotani%26aufirst%3DH.%26aulast%3DIwasawa%26aufirst%3DY.%26atitle%3DImidazopyridine%2520derivatives%2520as%2520potent%2520and%2520selective%2520polo-like%2520kinase%2520%2528PLK%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4673%26epage%3D4678%26doi%3D10.1016%2Fj.bmcl.2009.06.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keysar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. A.</span></span> <span> </span><span class="NLM_article-title">An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-15-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26216294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wqs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1049-1057&author=R.+C.+Doebeleauthor=L.+E.+Davisauthor=A.+Vaishnaviauthor=A.+T.+Leauthor=A.+Estrada-Bernalauthor=S.+Keysarauthor=A.+Jimenoauthor=M.+Varella-Garciaauthor=D.+L.+Aisnerauthor=Y.+Liauthor=P.+J.+Stephensauthor=D.+Morosiniauthor=B.+B.+Tuchauthor=M.+Fernandesauthor=N.+Nandaauthor=J.+A.+Low&title=An+oncogenic+NTRK+fusion+in+a+patient+with+soft-tissue+sarcoma+with+response+to+the+tropomyosin-related+kinase+inhibitor+LOXO-101&doi=10.1158%2F2159-8290.CD-15-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101</span></div><div class="casAuthors">Doebele, Robert C.; Davis, Lara E.; Vaishnavi, Aria; Le, Anh T.; Estrada-Bernal, Adriana; Keysar, Stephen; Jimeno, Antonio; Varella-Garcia, Marileila; Aisner, Dara L.; Li, Yali; Stephens, Philip J.; Morosini, Deborah; Tuch, Brian B.; Fernandes, Michele; Nanda, Nisha; Low, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1049-1057</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Oncogenic TRK fusions induce cancer cell proliferation and engage crit. cancer-related downstream signaling pathways.  These TRK fusions occur rarely, but in a diverse spectrum of tumor histologies.  LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors.  Preclin. models of LOXO-101 using TRK-fusion-bearing human-derived cancer cell lines demonstrate inhibition of the fusion oncoprotein and cellular proliferation in vitro, and tumor growth in vivo.  The tumor of a 41-yr-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion encoding a functional LMNA-TRKA fusion oncoprotein as detd. by an in situ proximity ligation assay.  In a phase I study of LOXO-101 (ClinicalTrials.gov no. NCT02122913), this patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen satn., and plasma tumor markers.  Significance: TRK fusions have been deemed putative oncogenic drivers, but their clin. significance remained unclear.  A patient with a metastatic soft-tissue sarcoma with an LMNA-NTRK1 fusion had rapid and substantial tumor regression with a novel, highly selective TRK inhibitor, LOXO-101, providing the first clin. evidence of benefit from inhibiting TRK fusions.  Cancer Discov; 5(10); 1049-57. ©2015 AACR.  This article is highlighted in the In This Issue feature, p.  1005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOOz1IuW1mjrVg90H21EOLACvtfcHk0liBNtuAFXDBJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wqs7fF&md5=52fcc72687bcd256dc54e77936d3ebee</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0443%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DDavis%26aufirst%3DL.%2BE.%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DKeysar%26aufirst%3DS.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMorosini%26aufirst%3DD.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DFernandes%26aufirst%3DM.%26aulast%3DNanda%26aufirst%3DN.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26atitle%3DAn%2520oncogenic%2520NTRK%2520fusion%2520in%2520a%2520patient%2520with%2520soft-tissue%2520sarcoma%2520with%2520response%2520to%2520the%2520tropomyosin-related%2520kinase%2520inhibitor%2520LOXO-101%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D1049%26epage%3D1057%26doi%3D10.1158%2F2159-8290.CD-15-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span> <span> </span><span class="NLM_article-title">Fast-TRKing drug development for rare molecular targets</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">934</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-17-0704" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=934-936&author=A.+R.+Parikhauthor=R.+B.+Corcoran&title=Fast-TRKing+drug+development+for+rare+molecular+targets&doi=10.1158%2F2159-8290.CD-17-0704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0704%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DA.%2BR.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26atitle%3DFast-TRKing%2520drug%2520development%2520for%2520rare%2520molecular%2520targets%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D934%26epage%3D936%26doi%3D10.1158%2F2159-8290.CD-17-0704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.+I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+next-generation+TRK+kinase+inhibitor+overcomes+acquired+resistance+to+prior+TRK+kinase+inhibition+in+patients+with+TRK+fusion-positive+solid+tumors&doi=10.1158%2F2159-8290.CD-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. ©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0liBNtuAFXDBJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.%2BI.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520next-generation%2520TRK%2520kinase%2520inhibitor%2520overcomes%2520acquired%2520resistance%2520to%2520prior%2520TRK%2520kinase%2520inhibition%2520in%2520patients%2520with%2520TRK%2520fusion-positive%2520solid%2520tumors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.CD-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisafulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rospo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-15-0940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26546295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36-44&author=M.+Russoauthor=S.+Misaleauthor=G.+Weiauthor=G.+Siravegnaauthor=G.+Crisafulliauthor=L.+Lazzariauthor=G.+Cortiauthor=G.+Rospoauthor=L.+Novaraauthor=B.+Mussolinauthor=A.+Bartoliniauthor=N.+Camauthor=R.+Patelauthor=S.+Q.+Yanauthor=R.+Shoemakerauthor=R.+Wildauthor=F.+Di+Nicolantonioauthor=A.+S.+Bianchiauthor=G.+Liauthor=S.+Sienaauthor=A.+Bardelli&title=Acquired+resistance+to+the+TRK+inhibitor+entrectinib+in+colorectal+cancer&doi=10.1158%2F2159-8290.CD-15-0940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span></div><div class="casAuthors">Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Bianchi, Andrea Sartore; Li, Gang; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clin. testing in colorectal cancer and other tumor types.  A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.  To characterize the mol. bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed.  Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C.  Biochem. and pharmacol. anal. in multiple preclin. models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib.  These findings can be immediately exploited to design next-generation TRKA inhibitors.  Significance: We provide proof of principle that analyses of xenopatients (avatar) and liq. biopsies allow the identification of drug resistance mechanisms in parallel with clin. treatment of an individual patient.  We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Unyh1xjaoLVg90H21EOLACvtfcHk0lgNfZ5RF2BtPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D&md5=5baa54a784e355b6afa50336b2708052</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0940%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DCrisafulli%26aufirst%3DG.%26aulast%3DLazzari%26aufirst%3DL.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DRospo%26aufirst%3DG.%26aulast%3DNovara%26aufirst%3DL.%26aulast%3DMussolin%26aufirst%3DB.%26aulast%3DBartolini%26aufirst%3DA.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DS.%2BQ.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DAcquired%2520resistance%2520to%2520the%2520TRK%2520inhibitor%2520entrectinib%2520in%2520colorectal%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D36%26epage%3D44%26doi%3D10.1158%2F2159-8290.CD-15-0940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh-Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2130</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-16-0909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28751539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFylsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2130-2143&author=M.+J.+Fuseauthor=K.+Okadaauthor=T.+Oh-Haraauthor=H.+Oguraauthor=N.+Fujitaauthor=R.+Katayama&title=Mechanisms+of+resistance+to+NTRK+inhibitors+and+therapeutic+strategies+in+NTRK1-rearranged+cancers&doi=10.1158%2F1535-7163.MCT-16-0909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers</span></div><div class="casAuthors">Fuse, Miho J.; Okada, Koutaroh; Oh-hara, Tomoko; Ogura, Hayato; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2130-2143</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Neurotrophic receptor tyrosine kinase 1 (NTRK1) gene rearrangement leads to constitutive activation of NTRK1, which induces high-transforming ability.  NTRK-rearranged cancers have been identified in several cancer types, such as glioblastoma, non-small cell lung cancer, and colorectal cancer.  Although there are currently no clin. approved inhibitors that target NTRK1, several tyrosine kinase inhibitors (TKI), such as entrectinib and LOXO-101, are in clin. trials.  The purpose of this study was to identify potential mechanisms of resistance to NTRK inhibitors and find potential therapeutic strategies to overcome the resistance.  We examd. the sensitivity of TPM3-NTRK1-transformed Ba/F3 cells and TPM3-NTRK1-harboring KM12 cells to multiple NTRK inhibitors.  Acquired NTRK inhibitor-resistant mutations were screened by N-ethyl-N-nitrosourea mutagenesis with Ba/F3-TPM3-NTRK1 cells or by the establishment of NTRK-TKI-resistant cells from KM12 cells continuously treated with NTRK-TKIs.  We identified multiple novel NTRK-TKI resistance mutations in the NTRK1 kinase domain, including G595R, and insulin growth factor receptor type 1 (IGF1R) bypass pathway-mediated resistance.  After identifying the resistance mechanisms, we performed drug screening with small-mol. inhibitors to overcome the resistance.  As a result, we found that ponatinib and nintedanib effectively inhibited the survival of TPM3-NTRK1-G667C but not G595R mutants, both of which showed resistance to entrectinib or larotrectinib (LOXO-101).  Furthermore, cabozantinib with an IGF1R inhibitor such as OSI-906 could overcome bypass pathway-mediated resistance.  We developed a comprehensive model of acquired resistance to NTRK inhibitors in cancer with NTRK1 rearrangement and identified cabozantinib as a therapeutic strategy to overcome the resistance.  Mol Cancer Ther; 16(10); 2130-43. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4DKbnrETRxrVg90H21EOLACvtfcHk0lgNfZ5RF2BtPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFylsr3J&md5=7f2b8d211e5b1a404d97d1d8ae5ebfa9</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0909%26sid%3Dliteratum%253Aachs%26aulast%3DFuse%26aufirst%3DM.%2BJ.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DOh-Hara%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520NTRK%2520inhibitors%2520and%2520therapeutic%2520strategies%2520in%2520NTRK1-rearranged%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2130%26epage%3D2143%26doi%3D10.1158%2F1535-7163.MCT-16-0909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddinger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneval, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">CT007</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-CT007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2016-CT007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=CT007&author=A.+Drilonauthor=F.+G.+De+Braudauthor=S.+Sienaauthor=S.+I.+Ouauthor=M.+Patelauthor=M.+Ahnauthor=J.+Leeauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=S.+V.+Liuauthor=N.+Reddingerauthor=R.+Patelauthor=D.+Luoauthor=E.+C.+Manevalauthor=P.+S.+Multaniauthor=R.+C.+Doebeleauthor=A.+T.+Shaw&title=Abstract+CT007%3A+Entrectinib%2C+an+oral+pan-Trk%2C+ROS1%2C+and+ALK+inhibitor+in+TKI-na%C3%AFve+patients+with+advanced+solid+tumors+harboring+gene+rearrangements%3A+Updated+phase+I+results&doi=10.1158%2F1538-7445.AM2016-CT007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-CT007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-CT007%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DReddinger%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DManeval%26aufirst%3DE.%2BC.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DAbstract%2520CT007%253A%2520Entrectinib%252C%2520an%2520oral%2520pan-Trk%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520in%2520TKI-na%25C3%25AFve%2520patients%2520with%2520advanced%2520solid%2520tumors%2520harboring%2520gene%2520rearrangements%253A%2520Updated%2520phase%2520I%2520results%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3DCT007%26doi%3D10.1158%2F1538-7445.AM2016-CT007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">C65</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.TARG-15-C65</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.TARG-15-C65" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=C65&author=A.+Estrada-Bernalauthor=A.+T.+Leauthor=B.+Tuchauthor=T.+Kutateladzeauthor=R.+C.+Doebele&title=Abstract+C65%3A+TRK+kinase+domain+mutations+that+induce+resistance+to+a+pan-TRK+inhibitor&doi=10.1158%2F1535-7163.TARG-15-C65"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-15-C65&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-15-C65%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTuch%26aufirst%3DB.%26aulast%3DKutateladze%26aufirst%3DT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DAbstract%2520C65%253A%2520TRK%2520kinase%2520domain%2520mutations%2520that%2520induce%2520resistance%2520to%2520a%2520pan-TRK%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3DC65%26doi%3D10.1158%2F1535-7163.TARG-15-C65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="note"><p class="first last">The molecular docking was carried out using AutoDock4. The TRKA protein crystal structure was downloaded from the protein data bank (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AOJ">4AOJ</a>). Amino acid mutations were carried out using Maestro 2018-2, and the figures were generated by Maestro 2018-2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S32</span>– <span class="NLM_lpage">S32</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)32675-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-8049%2816%2932675-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=S32-S32&author=J.+J.+Cuiauthor=D.+Zhaiauthor=W.+Dengauthor=E.+Rogersauthor=Z.+Huangauthor=J.+Whittenauthor=Y.+Li&title=TPX-0005%2C+a+novel+ALK%2FROS1%2FTRK+inhibitor%2C+effectively+inhibited+a+broad+spectrum+of+mutations+including+solvent+front+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R+mutants&doi=10.1016%2FS0959-8049%2816%2932675-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2932675-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252932675-2%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTPX-0005%252C%2520a%2520novel%2520ALK%252FROS1%252FTRK%2520inhibitor%252C%2520effectively%2520inhibited%2520a%2520broad%2520spectrum%2520of%2520mutations%2520including%2520solvent%2520front%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%2520mutants%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D69%26spage%3DS32%26epage%3DS32%26doi%3D10.1016%2FS0959-8049%2816%2932675-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. S.</span></span> <span> </span><span class="NLM_article-title">Ending the endless acquired tyrosine kinase resistance mutations - Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2133</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2016-2133" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2133&author=J.+J.+Cuiauthor=E.+Rogersauthor=D.+Y.+Zhaiauthor=W.+Dengauthor=Z.+D.+Huangauthor=J.+Whittenauthor=Y.+S.+Li&title=Ending+the+endless+acquired+tyrosine+kinase+resistance+mutations+-+Design+of+TPX-0005%2C+a+multi-target+ALK%2FROS1%2FTRK+inhibitor+with+broad+spectrum+activity+against+wild-type+and+mutants+including+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R&doi=10.1158%2F1538-7445.AM2016-2133"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-2133%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DD.%2BY.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%2BD.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%2BS.%26atitle%3DEnding%2520the%2520endless%2520acquired%2520tyrosine%2520kinase%2520resistance%2520mutations%2520-%2520Design%2520of%2520TPX-0005%252C%2520a%2520multi-target%2520ALK%252FROS1%252FTRK%2520inhibitor%2520with%2520broad%2520spectrum%2520activity%2520against%2520wild-type%2520and%2520mutants%2520including%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2133%26doi%3D10.1158%2F1538-7445.AM2016-2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S32</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)32675-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS0959-8049%2816%2932675-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=S32&author=J.+J.+Cuiauthor=D.+Zhaiauthor=W.+Dengauthor=E.+Rogersauthor=Z.+Huangauthor=J.+Whittenauthor=Y.+Li&title=TPX-0005%2C+a+novel+ALK%2FROS1%2FTRK+inhibitor%2C+effectively+inhibited+a+broad+spectrum+of+mutations+including+solvent+front+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R+mutants&doi=10.1016%2FS0959-8049%2816%2932675-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2932675-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252932675-2%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTPX-0005%252C%2520a%2520novel%2520ALK%252FROS1%252FTRK%2520inhibitor%252C%2520effectively%2520inhibited%2520a%2520broad%2520spectrum%2520of%2520mutations%2520including%2520solvent%2520front%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%2520mutants%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D69%26spage%3DS32%26doi%3D10.1016%2FS0959-8049%2816%2932675-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuyper, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2003.12.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=953-957&author=E.+R.+Woodauthor=L.+Kuyperauthor=K.+G.+Petrovauthor=R.+N.+Hunterauthor=P.+A.+Harrisauthor=K.+Lackey&title=Discovery+and+in+vitro+evaluation+of+potent+TrkA+kinase+inhibitors%3A+oxindole+and+aza-oxindoles&doi=10.1016%2Fj.bmcl.2003.12.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DKuyper%26aufirst%3DL.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520in%2520vitro%2520evaluation%2520of%2520potent%2520TrkA%2520kinase%2520inhibitors%253A%2520oxindole%2520and%2520aza-oxindoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D953%26epage%3D957%26doi%3D10.1016%2Fj.bmcl.2003.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudjemeline, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopewell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Syntheses and evaluation of carbon-11-and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/cn500193f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500193f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=260-276&author=V.+Bernard-Gauthierauthor=A.+Aliagaauthor=A.+Aliagaauthor=M.+Boudjemelineauthor=R.+Hopewellauthor=A.+Kostikovauthor=P.+Rosa-Netoauthor=A.+Thielauthor=R.+Schirrmacher&title=Syntheses+and+evaluation+of+carbon-11-and+fluorine-18-radiolabeled+pan-tropomyosin+receptor+kinase+%28Trk%29+inhibitors%3A+exploration+of+the+4-aza-2-oxindole+scaffold+as+Trk+PET+imaging+agents&doi=10.1021%2Fcn500193f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4-Aza-2-oxindole Scaffold as Trk PET Imaging Agents</span></div><div class="casAuthors">Bernard-Gauthier, Vadim; Aliaga, Arturo; Aliaga, Antonio; Boudjemeline, Mehdi; Hopewell, Robert; Kostikov, Alexey; Rosa-Neto, Pedro; Thiel, Alexander; Schirrmacher, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-276</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tropomyosin receptor kinases (TrkA/B/C) are critically involved in the development of the nervous system, in neurol. disorders as well as in multiple neoplasms of both neural and non-neural origins.  The development of Trk radiopharmaceuticals would offer unique opportunities toward a more complete understanding of this emerging therapeutic target.  To that end, we first developed [11C]GW441756 ([11C]9), a high affinity photoisomerizable pan-Trk inhibitor, as a lead radiotracer for our positron emission tomog. (PET) program.  Efficient carbon-11 radiolabeling afforded [11C]9 in high radiochem. yields (isolated RCY, 25.9% ± 5.7%).  In vitro autoradiog. studies in rat brain and TrkB-expressing human neuroblastoma cryosections confirmed that [11C]9 specifically binds to Trk receptors in vitro.  MicroPET studies revealed that binding of [11C]9 in the rodent brain was mostly nonspecific despite initial high brain uptake (SUVmax = 2.0).  Modeling studies of the 4-aza-2-oxindole scaffold led to the successful identification of a small series of high affinity fluorinated and methoxy derivatized pan-Trk inhibitors based on our lead compd. 9.  Out of this series, the fluorinated compd. 10 was selected for initial evaluation and radiolabeled with fluorine-18 (isolated RCY, 2.5% ± 0.6%).  Compd. [18F]10 demonstrated excellent Trk selectivity in a panel of cancer relevant kinase targets and a promising in vitro profile in tumors and brain sections but high oxidative metabolic susceptibility leading to nonspecific brain distribution in vivo.  The information gained in this study will guide further exploration of the 4-aza-2-oxindole scaffold as a lead for Trk PET ligand development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZ4BFFghVJbVg90H21EOLACvtfcHk0lgF2AsbKyVFVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7%252FP&md5=a23e2af118d6ed5e430cbd4687ee5b8f</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fcn500193f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500193f%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DBoudjemeline%26aufirst%3DM.%26aulast%3DHopewell%26aufirst%3DR.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DThiel%26aufirst%3DA.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DSyntheses%2520and%2520evaluation%2520of%2520carbon-11-and%2520fluorine-18-radiolabeled%2520pan-tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520inhibitors%253A%2520exploration%2520of%2520the%25204-aza-2-oxindole%2520scaffold%2520as%2520Trk%2520PET%2520imaging%2520agents%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D260%26epage%3D276%26doi%3D10.1021%2Fcn500193f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrrole[3,4-c]pyrazoles as potent tropomyosin receptor kinase A (TrkA) inhibitors</span>. <i>Bull. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1378</span>– <span class="NLM_lpage">1380</span>, <span class="refDoi"> DOI: 10.1002/bkcs.10862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1002%2Fbkcs.10862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GjurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1378-1380&author=H.+Choeauthor=Y.+H.+Sonauthor=B.+J.+Byunauthor=S.+U.+Choiauthor=K.+Lee&title=Identification+of+pyrrole%5B3%2C4-c%5Dpyrazoles+as+potent+tropomyosin+receptor+kinase+A+%28TrkA%29+inhibitors&doi=10.1002%2Fbkcs.10862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Pyrrole[3,4-c]pyrazoles as Potent Tropomyosin Receptor Kinase A (TrkA) Inhibitors</span></div><div class="casAuthors">Choe, Hyeonjeong; Son, You Hwa; Byun, Byung Jin; Choi, Sang Un; Lee, Kwangho</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1378-1380</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pyrrole[3,4-c]pyrazoles were identified as potent tropomyosin receptor kinase A (TrkA) inhibitors.  Pyrrolo[3,4-c] pyrazole C3 amido derivs. were explored widely followed by designing and introduction of benzyloxycarbonyl (Cbz) for C3-NH derivatization for novelty consideration.  N-Bu urea was adopted for the pyrrolo[3,4-c]pyrazole N5 substitution.  Substituted with cyclopropyl at the pyrrole[3,4-c]pyrazole C6 position, RMK-036 inhibits TrkA with 19 nM of IC50 value.  Various C6 substitution analogs of RMK-036 reveal dramatic structure-activity relationship in TrkA inhibition.  Thus its been concluded that identification and development of TrkA inhibitors would be valuable for various anticancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkkKsqzaATjLVg90H21EOLACvtfcHk0ljeTvrAErIH0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GjurbP&md5=f4ce4ff4f3fe86c65862cdfd5c06f56a</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2Fbkcs.10862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbkcs.10862%26sid%3Dliteratum%253Aachs%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DSon%26aufirst%3DY.%2BH.%26aulast%3DByun%26aufirst%3DB.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BU.%26aulast%3DLee%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520pyrrole%255B3%252C4-c%255Dpyrazoles%2520as%2520potent%2520tropomyosin%2520receptor%2520kinase%2520A%2520%2528TrkA%2529%2520inhibitors%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2016%26volume%3D37%26spage%3D1378%26epage%3D1380%26doi%3D10.1002%2Fbkcs.10862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurlburt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillerman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantor, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dell-John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span> <span> </span><span class="NLM_article-title">BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3349</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-09-0499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=19996272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3341-3349&author=J.+M.+Carboniauthor=M.+Wittmanauthor=Z.+Yangauthor=F.+Leeauthor=A.+Greerauthor=W.+Hurlburtauthor=S.+Hillermanauthor=C.+Caoauthor=G.+H.+Cantorauthor=J.+Dell-Johnauthor=C.+Chenauthor=L.+Discenzaauthor=K.+Menardauthor=A.+Liauthor=G.+Trainorauthor=D.+Vyasauthor=R.+Kramerauthor=R.+M.+Attarauthor=M.+M.+Gottardis&title=BMS-754807%2C+a+small+molecule+inhibitor+of+insulin-like+growth+factor-1R%2FIR&doi=10.1158%2F1535-7163.MCT-09-0499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR</span></div><div class="casAuthors">Carboni, Joan M.; Wittman, Mark; Yang, Zheng; Lee, Francis; Greer, Ann; Hurlburt, Warren; Hillerman, Stephen; Cao, Carolyn; Cantor, Glenn H.; Dell-John, Janet; Chen, Cliff; Discenza, Lorell; Menard, Krista; Li, Aixin; Trainor, George; Vyas, Dolatrai; Kramer, Robert; Attar, Ricardo M.; Gottardis, Marco M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3341-3349</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L).  It is currently in phase I development for the treatment of a variety of human cancers.  BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5-365 nmol/L); the compd. caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage.  BMS-754807 is active in vivo in multiple (epithelial, mesenchymal, and hematopoietic) xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a min. ED of as low as 6.25 mg/kg dosed orally daily.  Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, <1.0) when combined with cytotoxic, hormonal, and targeted agents.  The combination of cetuximab and BMS-754807 in vivo, at multiple dose levels, resulted in improved clin. outcome over single agent treatment.  These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmviunBiK1hbVg90H21EOLACvtfcHk0ljeTvrAErIH0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitb3F&md5=1f348da6d076373aaf9296ebfcfc5542</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0499%26sid%3Dliteratum%253Aachs%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DHillerman%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DCantor%26aufirst%3DG.%2BH.%26aulast%3DDell-John%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DMenard%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26aulast%3DKramer%26aufirst%3DR.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26atitle%3DBMS-754807%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1R%252FIR%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3341%26epage%3D3349%26doi%3D10.1158%2F1535-7163.MCT-09-0499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4223</span>– <span class="NLM_lpage">4227</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2010.05.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4223-4227&author=S.+Y.+Choauthor=S.+Y.+Hanauthor=J.+D.+Haauthor=J.+W.+Ryuauthor=C.+O.+Leeauthor=H.+Jungauthor=N.+S.+Kangauthor=H.+R.+Kimauthor=J.+S.+Kohauthor=J.+Lee&title=Discovery+of+aminopyridines+substituted+with+benzoxazole+as+orally+active+c-Met+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.05.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.031%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DHan%26aufirst%3DS.%2BY.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DRyu%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DJung%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DN.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKoh%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520aminopyridines%2520substituted%2520with%2520benzoxazole%2520as%2520orally%2520active%2520c-Met%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4223%26epage%3D4227%26doi%3D10.1016%2Fj.bmcl.2010.05.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1007/s10637-010-9584-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1007%2Fs10637-010-9584-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=518-523&author=S.+Y.+Hanauthor=C.+O.+Leeauthor=S.+H.+Ahnauthor=M.+O.+Leeauthor=S.+Y.+Kangauthor=H.+J.+Chaauthor=S.+Y.+Choauthor=J.+D.+Haauthor=J.+W.+Ryuauthor=H.+Jungauthor=H.+R.+Kimauthor=J.+S.+Kohauthor=J.+Lee&title=Evaluation+of+a+multi-kinase+inhibitor+KRC-108+as+an+anti-tumor+agent+in+vitro+and+in+vivo&doi=10.1007%2Fs10637-010-9584-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9584-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9584-2%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DAhn%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DM.%2BO.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DCha%26aufirst%3DH.%2BJ.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DRyu%26aufirst%3DJ.%2BW.%26aulast%3DJung%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKoh%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520a%2520multi-kinase%2520inhibitor%2520KRC-108%2520as%2520an%2520anti-tumor%2520agent%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D518%26epage%3D523%26doi%3D10.1007%2Fs10637-010-9584-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stachel, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brnardic, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowska-Zoladek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span> <span> </span><span class="NLM_article-title">Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5800</span>– <span class="NLM_lpage">5816</span>, <span class="refDoi"> DOI: 10.1021/jm5006429</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006429" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1SrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5800-5816&author=S.+J.+Stachelauthor=J.+M.+Sandersauthor=D.+A.+Henzeauthor=M.+T.+Ruddauthor=H.+P.+Suauthor=Y.+Liauthor=K.+K.+Nandaauthor=M.+S.+Egbertsonauthor=P.+J.+Manleyauthor=K.+L.+Jonesauthor=E.+J.+Brnardicauthor=A.+Greenauthor=J.+A.+Groblerauthor=B.+Hanneyauthor=M.+Leitlauthor=M.+T.+Laiauthor=V.+Munshiauthor=D.+Murphyauthor=K.+Rickertauthor=D.+Rileyauthor=A.+Krasowska-Zoladekauthor=C.+Daleyauthor=P.+Zuckauthor=S.+A.+Kaneauthor=M.+T.+Bilodeau&title=Maximizing+diversity+from+a+kinase+screen%3A+identification+of+novel+and+selective+pan-Trk+inhibitors+for+chronic+pain&doi=10.1021%2Fjm5006429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain</span></div><div class="casAuthors">Stachel, Shawn J.; Sanders, John M.; Henze, Darrell A.; Rudd, Mike T.; Su, Hua-Poo; Li, Yiwei; Nanda, Kausik K.; Egbertson, Melissa S.; Manley, Peter J.; Jones, Kristen L. G.; Brnardic, Edward J.; Green, Ahren; Grobler, Jay A.; Hanney, Barbara; Leitl, Michael; Lai, Ming-Tain; Munshi, Vandna; Murphy, Dennis; Rickert, Keith; Riley, Daniel; Krasowska-Zoladek, Alicja; Daley, Christopher; Zuck, Paul; Kane, Stephanie A.; Bilodeau, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5800-5816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have identified several series of small mol. inhibitors of TrkA with unique binding modes.  The starting leads were chosen to maximize the structural and binding mode diversity derived from a high throughput screen of our internal compd. collection.  These leads were optimized for potency and selectivity employing a structure based drug design approach adhering to the principles of ligand efficiency to maximize binding affinity without overly relying on lipophilic interactions.  This endeavor resulted in the identification of several small mol. pan-Trk inhibitor series that exhibit high selectivity for TrkA/B/C vs. a diverse panel of kinases.  We have also demonstrated efficacy in both inflammatory and neuropathic pain models upon oral dosing.  Herein we describe the identification process, hit-to-lead progression, and binding profiles of these selective pan-Trk kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj0SoN8gB1M7Vg90H21EOLACvtfcHk0likfiKp_Ti1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1SrsLs%253D&md5=f8aaef0b21eb49eed8004fc18f04dff5</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Fjm5006429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006429%26sid%3Dliteratum%253Aachs%26aulast%3DStachel%26aufirst%3DS.%2BJ.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNanda%26aufirst%3DK.%2BK.%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26aulast%3DManley%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DBrnardic%26aufirst%3DE.%2BJ.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DGrobler%26aufirst%3DJ.%2BA.%26aulast%3DHanney%26aufirst%3DB.%26aulast%3DLeitl%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DRiley%26aufirst%3DD.%26aulast%3DKrasowska-Zoladek%26aufirst%3DA.%26aulast%3DDaley%26aufirst%3DC.%26aulast%3DZuck%26aufirst%3DP.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26atitle%3DMaximizing%2520diversity%2520from%2520a%2520kinase%2520screen%253A%2520identification%2520of%2520novel%2520and%2520selective%2520pan-Trk%2520inhibitors%2520for%2520chronic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5800%26epage%3D5816%26doi%3D10.1021%2Fjm5006429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohren, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkington, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span> <span> </span><span class="NLM_article-title">Clinical applications of PET in oncology</span>. <i>Radiology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1148/radiol.2312021185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1148%2Fradiol.2312021185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=15044750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BD2c3jtVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2004&pages=305-332&author=E.+M.+Rohrenauthor=T.+G.+Turkingtonauthor=R.+E.+Coleman&title=Clinical+applications+of+PET+in+oncology&doi=10.1148%2Fradiol.2312021185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of PET in oncology</span></div><div class="casAuthors">Rohren Eric M; Turkington Timothy G; Coleman R Edward</div><div class="citationInfo"><span class="NLM_cas:title">Radiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-32</span>
        ISSN:<span class="NLM_cas:issn">0033-8419</span>.
    </div><div class="casAbstract">Positron emission tomography (PET) provides metabolic information that has been documented to be useful in patient care.  The properties of positron decay permit accurate imaging of the distribution of positron-emitting radiopharmaceuticals.  The wide array of positron-emitting radiopharmaceuticals has been used to characterize multiple physiologic and pathologic states.  PET is used for characterizing brain disorders such as Alzheimer disease and epilepsy and cardiac disorders such as coronary artery disease and myocardial viability.  The neurologic and cardiac applications of PET are not covered in this review.  The major utilization of PET clinically is in oncology and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG).  FDG, an analogue of glucose, accumulates in most tumors in a greater amount than it does in normal tissue.  FDG PET is being used in diagnosis and follow-up of several malignancies, and the list of articles supporting its use continues to grow.  In this review, the physics and instrumentation aspects of PET are described.  Many of the clinical applications in oncology are mature and readily covered by third-party payers.  Other applications are being used clinically but have not been as carefully evaluated in the literature, and these applications may not be covered by third-party payers.  The developing applications of PET are included in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxr44wmCntJyEJCPKhJPuqfW6udTcc2eaf8o6mgXjN8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3jtVamtQ%253D%253D&md5=1c1ba1d3d29ea79f0ceb6fff0efdef24</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1148%2Fradiol.2312021185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiol.2312021185%26sid%3Dliteratum%253Aachs%26aulast%3DRohren%26aufirst%3DE.%2BM.%26aulast%3DTurkington%26aufirst%3DT.%2BG.%26aulast%3DColeman%26aufirst%3DR.%2BE.%26atitle%3DClinical%2520applications%2520of%2520PET%2520in%2520oncology%26jtitle%3DRadiology%26date%3D2004%26volume%3D231%26spage%3D305%26epage%3D332%26doi%3D10.1148%2Fradiol.2312021185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span> <span> </span><span class="NLM_article-title">Molecular imaging in drug discovery and development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1038/nrd1007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrd1007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=12563303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot12muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=123-131&author=M.+Rudinauthor=R.+Weissleder&title=Molecular+imaging+in+drug+discovery+and+development&doi=10.1038%2Fnrd1007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular imaging in drug discovery and development</span></div><div class="casAuthors">Rudin, Markus; Weissleder, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imaging sciences have grown exponentially during the past three decades, and many techniques, such as magnetic resonance imaging, nuclear tomog. imaging and x-ray computed tomog., have become indispensable in clin. use.  Advances in imaging technologies and imaging probes for humans and for small animals are now extending the applications of imaging further into drug discovery and development, and have the potential to considerably accelerate the process.  This review summarizes some of the recent developments in conventional and mol. imaging, and highlights their impact on drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDy3yn7bOSXbVg90H21EOLACvtfcHk0likfiKp_Ti1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot12muw%253D%253D&md5=584c5914a8b2808f7c510528d7017349</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnrd1007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1007%26sid%3Dliteratum%253Aachs%26aulast%3DRudin%26aufirst%3DM.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DMolecular%2520imaging%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D123%26epage%3D131%26doi%3D10.1038%2Fnrd1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slobbe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poot, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windhorst, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dongen, G. A.</span></span> <span> </span><span class="NLM_article-title">PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2012.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.drudis.2012.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22766374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1175-1187&author=P.+Slobbeauthor=A.+J.+Pootauthor=A.+D.+Windhorstauthor=G.+A.+van+Dongen&title=PET+imaging+with+small-molecule+tyrosine+kinase+inhibitors%3A+TKI-PET&doi=10.1016%2Fj.drudis.2012.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET</span></div><div class="casAuthors">Slobbe, Paul; Poot, Alex J.; Windhorst, Albert D.; van Dongen, Guus A. M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21-22</span>),
    <span class="NLM_cas:pages">1175-1187</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery and increased understanding of tumor targets has led to the development and approval of 12 small mol. tyrosine kinase inhibitors (TKIs).  Despite tremendous efforts in TKI development, treatment efficacies with these therapeutics are still too low and improvements require a personalized medicine approach.  Positron emission tomog. (PET) with radiolabeled TKIs (TKI-PET) is a tracking, quantification and imaging method, which provides a unique understanding of the behavior of these drugs in vivo and of the interaction with their target(s).  In this article we provide an overview of tracer synthesis and development because each TKI requires a tailor made approach.  Moreover, we describe current preclin. work and the first proof-of-principle clin. studies on the application of TKI-PET, illustrating the potential of this approach for improving therapy efficacy and personalized cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzoQ0SBqROKbVg90H21EOLACvtfcHk0ljaaqfmQI2-Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLjM&md5=a6d15bd0c3eee95e525e1cbca9f3e587</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DSlobbe%26aufirst%3DP.%26aulast%3DPoot%26aufirst%3DA.%2BJ.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3Dvan%2BDongen%26aufirst%3DG.%2BA.%26atitle%3DPET%2520imaging%2520with%2520small-molecule%2520tyrosine%2520kinase%2520inhibitors%253A%2520TKI-PET%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D1175%26epage%3D1187%26doi%3D10.1016%2Fj.drudis.2012.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">22000</span>– <span class="NLM_lpage">22027</span>, <span class="refDoi"> DOI: 10.3390/molecules201219816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3390%2Fmolecules201219816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26690113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKgsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=22000-22027&author=V.+Bernard-Gauthierauthor=J.+J.+Baileyauthor=S.+Berkeauthor=R.+Schirrmacher&title=Recent+advances+in+the+development+and+application+of+radiolabeled+kinase+inhibitors+for+PET+imaging&doi=10.3390%2Fmolecules201219816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging</span></div><div class="casAuthors">Bernard-Gauthier, Vadim; Bailey, Justin J.; Berke, Sheldon; Schirrmacher, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">22000-22027</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Over the last 20 years, intensive investigation and multiple clin. successes targeting protein kinases, mostly for cancer treatment, have identified small mol. kinase inhibitors as a prominent therapeutic class.  In the course of those investigations, radiolabeled kinase inhibitors for positron emission tomog. (PET) imaging have been synthesized and evaluated as diagnostic imaging probes for cancer characterization.  Given that inhibitor coverage of the kinome is continuously expanding, in vivo PET imaging will likely find increasing applications for therapy monitoring and receptor d. studies both in- and outside of oncol. conditions.  Early investigated radiolabeled inhibitors, which are mostly based on clin. approved tyrosine kinase inhibitor (TKI) isotopologues, have now entered clin. trials.  Novel radioligands for cancer and PET neuroimaging originating from novel but relevant target kinases are currently being explored in preclin. studies.  This article reviews the literature involving radiotracer design, radiochem. approaches, biol. tracer evaluation and nuclear imaging results of radiolabeled kinase inhibitors for PET reported between 2010 and mid-2015.  Aspects regarding the usefulness of pursuing selective vs. promiscuous inhibitor scaffolds and the inherent challenges assocd. with intracellular enzyme imaging will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoK7e4uBNDBLVg90H21EOLACvtfcHk0ljaaqfmQI2-Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKgsL%252FI&md5=be84e68fe296d62fdcfd15857dda05f0</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3390%2Fmolecules201219816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules201219816%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DBerke%26aufirst%3DS.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520and%2520application%2520of%2520radiolabeled%2520kinase%2520inhibitors%2520for%2520PET%2520imaging%26jtitle%3DMolecules%26date%3D2015%26volume%3D20%26spage%3D22000%26epage%3D22027%26doi%3D10.3390%2Fmolecules201219816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuest, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuest, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo 1,2-b pyridazine pan-Trk inhibitors as candidate PET imaging probes</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2193</span>, <span class="refDoi"> DOI: 10.1039/C5MD00388A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1039%2FC5MD00388A" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2184-2193&author=V.+Bernard-Gauthierauthor=J.+J.+Baileyauthor=A.+Aliagaauthor=A.+Kostikovauthor=P.+Rosa-Netoauthor=M.+Wuestauthor=G.+M.+Brodeurauthor=B.+J.+Bedellauthor=F.+Wuestauthor=R.+Schirrmacher&title=Development+of+subnanomolar+radiofluorinated+%282-pyrrolidin-1-yl%29imidazo+1%2C2-b+pyridazine+pan-Trk+inhibitors+as+candidate+PET+imaging+probes&doi=10.1039%2FC5MD00388A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1039%2FC5MD00388A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00388A%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DWuest%26aufirst%3DM.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DBedell%26aufirst%3DB.%2BJ.%26aulast%3DWuest%26aufirst%3DF.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520subnanomolar%2520radiofluorinated%2520%25282-pyrrolidin-1-yl%2529imidazo%25201%252C2-b%2520pyridazine%2520pan-Trk%2520inhibitors%2520as%2520candidate%2520PET%2520imaging%2520probes%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D2184%26epage%3D2193%26doi%3D10.1039%2FC5MD00388A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesnaver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2775</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2017.04.064" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2771-2775&author=V.+Bernard-Gauthierauthor=A.+Mahringerauthor=M.+Vesnaverauthor=G.+Frickerauthor=R.+Schirrmacher&title=Design+and+synthesis+of+a+fluorinated+quinazoline-based+type-II+Trk+inhibitor+as+a+scaffold+for+PET+radiotracer+development&doi=10.1016%2Fj.bmcl.2017.04.064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.064%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DVesnaver%26aufirst%3DM.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520fluorinated%2520quinazoline-based%2520type-II%2520Trk%2520inhibitor%2520as%2520a%2520scaffold%2520for%2520PET%2520radiotracer%2520development%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2771%26epage%3D2775%26doi%3D10.1016%2Fj.bmcl.2017.04.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">5-(4-((4-[(18)F]Fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: a selective dual inhibitor for potential PET imaging of Trk/CSF-1R</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4784</span>– <span class="NLM_lpage">4790</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2014.09.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4784-4790&author=V.+Bernard-Gauthierauthor=R.+Schirrmacher&title=5-%284-%28%284-%5B%2818%29F%5DFluorobenzyl%29oxy%29-3-methoxybenzyl%29pyrimidine-2%2C4-diamine%3A+a+selective+dual+inhibitor+for+potential+PET+imaging+of+Trk%2FCSF-1R&doi=10.1016%2Fj.bmcl.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3D5-%25284-%2528%25284-%255B%252818%2529F%255DFluorobenzyl%2529oxy%2529-3-methoxybenzyl%2529pyrimidine-2%252C4-diamine%253A%2520a%2520selective%2520dual%2520inhibitor%2520for%2520potential%2520PET%2520imaging%2520of%2520Trk%252FCSF-1R%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4784%26epage%3D4790%26doi%3D10.1016%2Fj.bmcl.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mossine, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vomacka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand’Maison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, P. J. H.</span></span> <span> </span><span class="NLM_article-title">A kinome-wide selective radiolabeled TrkB/C inhibitor for in vitro and in vivo neuroimaging: synthesis, preclinical evaluation, and first-in-human</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6897</span>– <span class="NLM_lpage">6910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6897-6910&author=V.+Bernard-Gauthierauthor=J.+J.+Baileyauthor=A.+V.+Mossineauthor=S.+Lindnerauthor=L.+Vomackaauthor=A.+Aliagaauthor=X.+Shaoauthor=C.+A.+Quesadaauthor=P.+Shermanauthor=A.+Mahringerauthor=A.+Kostikovauthor=M.+Grand%E2%80%99Maisonauthor=P.+Rosa-Netoauthor=J.+P.+Soucyauthor=A.+Thielauthor=D.+R.+Kaplanauthor=G.+Frickerauthor=B.+Wanglerauthor=P.+Bartensteinauthor=R.+Schirrmacherauthor=P.+J.+H.+Scott&title=A+kinome-wide+selective+radiolabeled+TrkB%2FC+inhibitor+for+in+vitro+and+in+vivo+neuroimaging%3A+synthesis%2C+preclinical+evaluation%2C+and+first-in-human&doi=10.1021%2Facs.jmedchem.7b00396"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00396%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DMossine%26aufirst%3DA.%2BV.%26aulast%3DLindner%26aufirst%3DS.%26aulast%3DVomacka%26aufirst%3DL.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DQuesada%26aufirst%3DC.%2BA.%26aulast%3DSherman%26aufirst%3DP.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DGrand%25E2%2580%2599Maison%26aufirst%3DM.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DSoucy%26aufirst%3DJ.%2BP.%26aulast%3DThiel%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DWangler%26aufirst%3DB.%26aulast%3DBartenstein%26aufirst%3DP.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DP.%2BJ.%2BH.%26atitle%3DA%2520kinome-wide%2520selective%2520radiolabeled%2520TrkB%252FC%2520inhibitor%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520neuroimaging%253A%2520synthesis%252C%2520preclinical%2520evaluation%252C%2520and%2520first-in-human%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6897%26epage%3D6910%26doi%3D10.1021%2Facs.jmedchem.7b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mossine, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand’Maison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochon, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa-Neto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, P. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span> <span> </span><span class="NLM_article-title">Identification of [(18)F]TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1737</span>– <span class="NLM_lpage">1743</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1737-1743&author=V.+Bernard-Gauthierauthor=A.+V.+Mossineauthor=A.+Mahringerauthor=A.+Aliagaauthor=J.+J.+Baileyauthor=X.+Shaoauthor=J.+Stauffauthor=J.+Arteagaauthor=P.+Shermanauthor=M.+Grand%E2%80%99Maisonauthor=P.+L.+Rochonauthor=B.+Wanglerauthor=C.+Wanglerauthor=P.+Bartensteinauthor=A.+Kostikovauthor=D.+R.+Kaplanauthor=G.+Frickerauthor=P.+Rosa-Netoauthor=P.+J.+H.+Scottauthor=R.+Schirrmacher&title=Identification+of+%5B%2818%29F%5DTRACK%2C+a+fluorine-18-labeled+tropomyosin+receptor+kinase+%28Trk%29+inhibitor+for+PET+imaging&doi=10.1021%2Facs.jmedchem.7b01607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01607%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DMossine%26aufirst%3DA.%2BV.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DAliaga%26aufirst%3DA.%26aulast%3DBailey%26aufirst%3DJ.%2BJ.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DStauff%26aufirst%3DJ.%26aulast%3DArteaga%26aufirst%3DJ.%26aulast%3DSherman%26aufirst%3DP.%26aulast%3DGrand%25E2%2580%2599Maison%26aufirst%3DM.%26aulast%3DRochon%26aufirst%3DP.%2BL.%26aulast%3DWangler%26aufirst%3DB.%26aulast%3DWangler%26aufirst%3DC.%26aulast%3DBartenstein%26aufirst%3DP.%26aulast%3DKostikov%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DRosa-Neto%26aufirst%3DP.%26aulast%3DScott%26aufirst%3DP.%2BJ.%2BH.%26aulast%3DSchirrmacher%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520%255B%252818%2529F%255DTRACK%252C%2520a%2520fluorine-18-labeled%2520tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520inhibitor%2520for%2520PET%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1737%26epage%3D1743%26doi%3D10.1021%2Facs.jmedchem.7b01607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lgOSLmntxqLMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lgOSLmntxqLMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albaugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1021/ml200261d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200261d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFCm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=140-145&author=P.+Albaughauthor=Y.+Fanauthor=Y.+Miauthor=F.+X.+Sunauthor=F.+Adrianauthor=N.+X.+Liauthor=Y.+Jiaauthor=Y.+Sarkisovaauthor=A.+Kreuschauthor=T.+Hoodauthor=M.+Luauthor=G.+X.+Liuauthor=S.+L.+Huangauthor=Z.+S.+Liuauthor=J.+Lorenauthor=T.+Tuntlandauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=V.+Molteni&title=Discovery+of+GNF-5837%2C+a+selective+TRK+inhibitor+with+efficacy+in+rodent+cancer+tumor+models&doi=10.1021%2Fml200261d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models</span></div><div class="casAuthors">Albaugh, Pam; Fan, Yi; Mi, Yuan; Sun, Fangxian; Adrian, Francisco; Li, Nanxin; Jia, Yong; Sarkisova, Yelena; Kreusch, Andreas; Hood, Tami; Lu, Min; Liu, Guoxun; Huang, Shenlin; Liu, Zuosheng; Loren, Jon; Tuntland, Tove; Karanewsky, Donald S.; Seidel, H. Martin; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-145</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network.  Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin.  By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified.  Optimization led to the identification of GNF-5837 (I), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF.  The properties of I make it a good tool for the elucidation of TRK biol. in cancer and other nononcol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF4DjLhCqRFrVg90H21EOLACvtfcHk0lhI-RHndQrn1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFCm&md5=d355489fe9f791a8547699fa65ebba51</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fml200261d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200261d%26sid%3Dliteratum%253Aachs%26aulast%3DAlbaugh%26aufirst%3DP.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%2BX.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DN.%2BX.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%2BX.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%2BS.%26aulast%3DLoren%26aufirst%3DJ.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520GNF-5837%252C%2520a%2520selective%2520TRK%2520inhibitor%2520with%2520efficacy%2520in%2520rodent%2520cancer%2520tumor%2520models%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D140%26epage%3D145%26doi%3D10.1021%2Fml200261d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedderman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span> <span> </span><span class="NLM_article-title">The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10099</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10084-10099&author=S.+E.+Skerrattauthor=M.+Andrewsauthor=S.+K.+Bagalauthor=J.+Bilslandauthor=D.+Brownauthor=P.+J.+Bungayauthor=S.+Coleauthor=K.+R.+Gibsonauthor=R.+Jonesauthor=I.+Moraoauthor=A.+Neddermanauthor=K.+Omotoauthor=C.+Robinsonauthor=T.+Ryckmansauthor=K.+Skinnerauthor=P.+Stuppleauthor=G.+Waldron&title=The+discovery+of+a+potent%2C+selective%2C+and+peripherally+restricted+pan-Trk+inhibitor+%28PF-06273340%29+for+the+treatment+of+pain&doi=10.1021%2Facs.jmedchem.6b00850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span></div><div class="casAuthors">Skerratt, Sarah E.; Andrews, Mark; Bagal, Sharan K.; Bilsland, James; Brown, David; Bungay, Peter J.; Cole, Susan; Gibson, Karl R.; Jones, Russell; Morao, Inaki; Nedderman, Angus; Omoto, Kiyoyuki; Robinson, Colin; Ryckmans, Thomas; Skinner, Kimberly; Stupple, Paul; Waldron, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10099</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4), is implicated in the physiol. of chronic pain.  Given the clin. efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small mol. modulators of neurotrophin activity.  Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention.  To deliver the safety profile required for chronic, non-life threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought.  Herein the authors describe how the use of SBDD, 2D QSAR models and Matched Mol. Pair data in compd. design enabled the delivery of the highly potent, kinase-selective and peripherally restricted clin. candidate PF-06273340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67CFmGAkmRrVg90H21EOLACvtfcHk0lhI-RHndQrn1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL&md5=f8c904a92c1716062c217fefe2374ce6</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBilsland%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMorao%26aufirst%3DI.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DWaldron%26aufirst%3DG.%26atitle%3DThe%2520discovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520peripherally%2520restricted%2520pan-Trk%2520inhibitor%2520%2528PF-06273340%2529%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10084%26epage%3D10099%26doi%3D10.1021%2Facs.jmedchem.6b00850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pryde, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. D.</span></span> <span> </span><span class="NLM_article-title">Aldehyde oxidase: an enzyme of emerging importance in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8441</span>– <span class="NLM_lpage">8460</span>, <span class="refDoi"> DOI: 10.1021/jm100888d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100888d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8441-8460&author=D.+C.+Prydeauthor=D.+Dalvieauthor=Q.+Huauthor=P.+Jonesauthor=R.+S.+Obachauthor=T.+D.+Tran&title=Aldehyde+oxidase%3A+an+enzyme+of+emerging+importance+in+drug+discovery&doi=10.1021%2Fjm100888d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span></div><div class="casAuthors">Pryde, David C.; Dalvie, Deepak; Hu, Qiyue; Jones, Peter; Obach, R. Scott; Tran, Thien-Duc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8441-8460</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Aldehyde oxidase has for many years been recognized as a metabolizing enzyme contained within the cytosolic compartment of many tissues and in many species.  The first literature ref. to AO dates from the 1930s, but literature citations to this enzyme have been steadily growing ever since, esp. in the past decade.  It has been increasingly recognized in this past decade that AO, through its unique structure, distribution, and substrate recognition, has an important role to play in the metab. of drugs.  In this timely Perspective, we present the current knowledge of the enzyme's expression, its structure, and its distribution across species.  We offer an anal. of substrates recognized by AO and highlight clin. examples where metab. by this enzyme has had significant clin. impact or led to the termination of a drug development program.  Finally, through anal. of the structure of known substrates, we present data to suggest the significant impact AO could play on future drug discovery programs along with strategies that could be employed to mitigate this.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALwFS70G6tLVg90H21EOLACvtfcHk0lhI-RHndQrn1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N&md5=972eb9862a7dc7bff024b530ab40de7f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Fjm100888d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100888d%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTran%26aufirst%3DT.%2BD.%26atitle%3DAldehyde%2520oxidase%253A%2520an%2520enzyme%2520of%2520emerging%2520importance%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8441%26epage%3D8460%26doi%3D10.1021%2Fjm100888d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pryde, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckworth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry approaches to avoid aldehyde oxidase metabolism</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2856</span>– <span class="NLM_lpage">2860</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2012.02.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=22429467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFSitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2856-2860&author=D.+C.+Prydeauthor=T.+D.+Tranauthor=P.+Jonesauthor=J.+Duckworthauthor=M.+Howardauthor=I.+Gardnerauthor=R.+Hylandauthor=R.+Websterauthor=T.+Wenhamauthor=S.+Bagalauthor=K.+Omotoauthor=R.+P.+Schneiderauthor=J.+Lin&title=Medicinal+chemistry+approaches+to+avoid+aldehyde+oxidase+metabolism&doi=10.1016%2Fj.bmcl.2012.02.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry approaches to avoid aldehyde oxidase metabolism</span></div><div class="casAuthors">Pryde, David C.; Tran, Thien-Duc; Jones, Peter; Duckworth, Jonathan; Howard, Martin; Gardner, Iain; Hyland, Ruth; Webster, Rob; Wenham, Tracey; Bagal, Sharan; Omoto, Kiyoyuki; Schneider, Richard P.; Lin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2856-2860</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aldehyde oxidase (AO) is a molybdenum-contg. enzyme distributed throughout the animal kingdom and capable of metabolising a wide range of aldehydes and N-heterocyclic compds.  Although metab. by this enzyme in man is recognized to have significant clin. impact where human AO activity was not predicted by screening in preclin. species, there is very little reported literature offering real examples where drug discoverers have successfully designed away from AO oxidn.  This article reports on some strategies adopted in the Pfizer TLR7 agonist program to successfully switch off AO metab. that was seen principally in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZKVEe9ZUzMbVg90H21EOLACvtfcHk0li4GLb4oWOIPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFSitbs%253D&md5=4c4c68b64f1c7013ad978408add0b09a</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.069%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BD.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DDuckworth%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DM.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DWenham%26aufirst%3DT.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DR.%2BP.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DMedicinal%2520chemistry%2520approaches%2520to%2520avoid%2520aldehyde%2520oxidase%2520metabolism%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2856%26epage%3D2860%26doi%3D10.1016%2Fj.bmcl.2012.02.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, A. H.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2298</span>– <span class="NLM_lpage">2308</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth&doi=10.1158%2F1535-7163.MCT-11-0264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0li4GLb4oWOIPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308%26doi%3D10.1158%2F1535-7163.MCT-11-0264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4093</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.18632%2Foncotarget.6547" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=4093-4109&author=P.+P.+Patwardhanauthor=K.+S.+Ivyauthor=E.+Musiauthor=E.+de+Stanchinaauthor=G.+K.+Schwartz&title=Significant+blockade+of+multiple+receptor+tyrosine+kinases+by+MGCD516+%28Sitravatinib%29%2C+a+novel+small+molecule+inhibitor%2C+shows+potent+anti-tumor+activity+in+preclinical+models+of+sarcoma&doi=10.18632%2Foncotarget.6547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6547%26sid%3Dliteratum%253Aachs%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DIvy%26aufirst%3DK.%2BS.%26aulast%3DMusi%26aufirst%3DE.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DSignificant%2520blockade%2520of%2520multiple%2520receptor%2520tyrosine%2520kinases%2520by%2520MGCD516%2520%2528Sitravatinib%2529%252C%2520a%2520novel%2520small%2520molecule%2520inhibitor%252C%2520shows%2520potent%2520anti-tumor%2520activity%2520in%2520preclinical%2520models%2520of%2520sarcoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D4093%26epage%3D4109%26doi%3D10.18632%2Foncotarget.6547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensinger, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patt, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patt, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samarakoon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telikepalli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2023</span>– <span class="NLM_lpage">2034</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1535-7163.MCT-14-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=26285778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2023-2034&author=B.+D.+Smithauthor=M.+D.+Kaufmanauthor=C.+B.+Learyauthor=B.+A.+Turnerauthor=S.+C.+Wiseauthor=Y.+M.+Ahnauthor=R.+J.+Boothauthor=T.+M.+Caldwellauthor=C.+L.+Ensingerauthor=M.+M.+Hoodauthor=W.+P.+Luauthor=T.+W.+Pattauthor=W.+C.+Pattauthor=T.+J.+Rutkoskiauthor=T.+Samarakoonauthor=H.+Telikepalliauthor=L.+Vogetiauthor=S.+Vogetiauthor=K.+M.+Yatesauthor=L.+Chunauthor=L.+J.+Stewartauthor=M.+Clareauthor=D.+L.+Flynn&title=Altiratinib+inhibits+tumor+growth%2C+invasion%2C+angiogenesis%2C+and+microenvironment-mediated+drug+resistance+via+balanced+inhibition+of+MET%2C+TIE2%2C+and+VEGFR2&doi=10.1158%2F1535-7163.MCT-14-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2</span></div><div class="casAuthors">Smith, Bryan D.; Kaufman, Michael D.; Leary, Cynthia B.; Turner, Benjamin A.; Wise, Scott C.; Ahn, Yu Mi; Booth, R. John; Caldwell, Timothy M.; Ensinger, Carol L.; Hood, Molly M.; Lu, Wei-Ping; Patt, Tristan W.; Patt, William C.; Rutkoski, Thomas J.; Samarakoon, Thiwanka; Telikepalli, Hanumaiah; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen M.; Chun, Lawrence; Stewart, Lance J.; Clare, Michael; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2023-2034</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1).  Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases.  This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations.  Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo.  Through its balanced inhibitory potency vs. MET, TIE2, and VEGFR2, altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis.  Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9E33eWjRqBrVg90H21EOLACvtfcHk0lhWnQjlMiI0cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE&md5=34170ba7d22a7fbcea68715fd6a2179b</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1105%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLeary%26aufirst%3DC.%2BB.%26aulast%3DTurner%26aufirst%3DB.%2BA.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DEnsinger%26aufirst%3DC.%2BL.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DLu%26aufirst%3DW.%2BP.%26aulast%3DPatt%26aufirst%3DT.%2BW.%26aulast%3DPatt%26aufirst%3DW.%2BC.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSamarakoon%26aufirst%3DT.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DK.%2BM.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DClare%26aufirst%3DM.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DAltiratinib%2520inhibits%2520tumor%2520growth%252C%2520invasion%252C%2520angiogenesis%252C%2520and%2520microenvironment-mediated%2520drug%2520resistance%2520via%2520balanced%2520inhibition%2520of%2520MET%252C%2520TIE2%252C%2520and%2520VEGFR2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2023%26epage%3D2034%26doi%3D10.1158%2F1535-7163.MCT-14-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Zein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hondt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sariban, E.</span></span> <span> </span><span class="NLM_article-title">Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1447</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2010.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.cellsig.2010.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=20566383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=1437-1447&author=N.+El+Zeinauthor=S.+D%E2%80%99Hondtauthor=E.+Sariban&title=Crosstalks+between+the+receptors+tyrosine+kinase+EGFR+and+TrkA+and+the+GPCR%2C+FPR%2C+in+human+monocytes+are+essential+for+receptors-mediated+cell+activation&doi=10.1016%2Fj.cellsig.2010.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation</span></div><div class="casAuthors">El Zein, Nabil; D'Hondt, Stephanie; Sariban, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1437-1447</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The G-protein coupled receptor (GPCR) fMLP receptor (FPR) and the two receptors tyrosine kinase (RTK), the nerve growth factor (NGF) receptor TrkA and the epidermal growth factor (EGF) receptor (EGFR) are involved in reactive oxygen species (ROS), matrix metalloproteinase-9 (MMP-9) prodn. and CD11b membrane integrin upregulation.  We show that in monocytes the three receptors crosstalk each other to modulate these pro-inflammatory mediators.  Tyrphostin AG1478, the EGFR inhibitor, inhibits fMLP and NGF-assocd. ROS prodn., fMLP-assocd. CD11b upregulation and NGF-induced TrkA phosphorylation; K252a, the NGF receptor inhibitor, inhibits fMLP or EGF-assocd. ROS prodn., CD11b expression and EGF-induced EGFR phosphorylation; cyclosporine H, the FPR inhibitor inhibits EGF or NGF-assocd. ROS prodn., EGF-assocd. CD11b upregulation and prevents EGFR and TrkA phosphorylation by their resp. ligand EGF and NGF.  In response to fMLP, TrkA phosphorylation is inhibited by the EGFR inhibitor while EGFR phosphorylation is inhibited by the TrkA inhibitor.  Receptor crosstalks are Src and ERK dependent.  Down-regulation of each receptor by specific siRNA suppresses the ability of the two other receptors to promote ligand-mediated ERK phosphorylation and pro-inflammatory activities including ROS, MMP-9 prodn. and CD11b upregulation.  Thus, in monocytes GPCR ligands' activity involves activation of RTK while RTK-ligands activity engages GPCR-signalling mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdlNj09PDHLVg90H21EOLACvtfcHk0lhWnQjlMiI0cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kjsbs%253D&md5=d089d337da801c2cbad4ea30aa9213d9</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BZein%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Hondt%26aufirst%3DS.%26aulast%3DSariban%26aufirst%3DE.%26atitle%3DCrosstalks%2520between%2520the%2520receptors%2520tyrosine%2520kinase%2520EGFR%2520and%2520TrkA%2520and%2520the%2520GPCR%252C%2520FPR%252C%2520in%2520human%2520monocytes%2520are%2520essential%2520for%2520receptors-mediated%2520cell%2520activation%26jtitle%3DCell.%2520Signalling%26date%3D2010%26volume%3D22%26spage%3D1437%26epage%3D1447%26doi%3D10.1016%2Fj.cellsig.2010.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcari, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillo, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungerford, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauth, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagreca, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderstrom, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkalcevic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3059</span>– <span class="NLM_lpage">3063</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2013.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3059-3063&author=J.+T.+Arcariauthor=J.+S.+Beebeauthor=M.+A.+Berlinerauthor=V.+Bernardoauthor=M.+Boehmauthor=G.+V.+Borzilloauthor=T.+Clarkauthor=B.+D.+Cohenauthor=R.+D.+Connellauthor=H.+N.+Frostauthor=D.+A.+Gordonauthor=W.+M.+Hungerfordauthor=S.+M.+Kakarauthor=A.+Kanterauthor=N.+F.+Keeneauthor=E.+A.+Knauthauthor=S.+D.+Lagrecaauthor=Y.+Luauthor=L.+Martinez-Alsinaauthor=M.+A.+Marxauthor=J.+Morrisauthor=N.+C.+Patelauthor=D.+Savageauthor=C.+I.+Soderstromauthor=C.+Thompsonauthor=G.+Tkalcevicauthor=N.+J.+Tomauthor=F.+F.+Vajdosauthor=J.+J.+Valentineauthor=P.+W.+Vincentauthor=M.+D.+Wesselauthor=J.+M.+Chen&title=Discovery+and+synthesis+of+novel+4-aminopyrrolopyrimidine+Tie-2+kinase+inhibitors+for+the+treatment+of+solid+tumors&doi=10.1016%2Fj.bmcl.2013.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DArcari%26aufirst%3DJ.%2BT.%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DBerliner%26aufirst%3DM.%2BA.%26aulast%3DBernardo%26aufirst%3DV.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DBorzillo%26aufirst%3DG.%2BV.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DB.%2BD.%26aulast%3DConnell%26aufirst%3DR.%2BD.%26aulast%3DFrost%26aufirst%3DH.%2BN.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DHungerford%26aufirst%3DW.%2BM.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DKanter%26aufirst%3DA.%26aulast%3DKeene%26aufirst%3DN.%2BF.%26aulast%3DKnauth%26aufirst%3DE.%2BA.%26aulast%3DLagreca%26aufirst%3DS.%2BD.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DN.%2BC.%26aulast%3DSavage%26aufirst%3DD.%26aulast%3DSoderstrom%26aufirst%3DC.%2BI.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DTkalcevic%26aufirst%3DG.%26aulast%3DTom%26aufirst%3DN.%2BJ.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DValentine%26aufirst%3DJ.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520novel%25204-aminopyrrolopyrimidine%2520Tie-2%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3059%26epage%3D3063%26doi%3D10.1016%2Fj.bmcl.2013.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span> <span> </span><span class="NLM_article-title">Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7921</span>– <span class="NLM_lpage">7932</span>, <span class="refDoi"> DOI: 10.1021/jm8010299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7921-7932&author=I.+Kufarevaauthor=R.+Abagyan&title=Type-II+kinase+inhibitor+docking%2C+screening%2C+and+profiling+using+modified+structures+of+active+kinase+states&doi=10.1021%2Fjm8010299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span></div><div class="casAuthors">Kufareva, Irina; Abagyan, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7921-7932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site.  These compds. are often more specific than those that target active DFG-in kinase conformations.  Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable.  We present a computational protocol for converting multiple available DFG-in structures of various kinases (∼70% of mammalian structural kinome) into accurate and specific models of their type-II bound state.  The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compd. pose prediction, screening, and in silico activity profiling.  Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp699dzZf5YRLVg90H21EOLACvtfcHk0liERY-lSH6ogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK&md5=64fb7b9f789940dd61c68015341af4a6</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Fjm8010299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010299%26sid%3Dliteratum%253Aachs%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DType-II%2520kinase%2520inhibitor%2520docking%252C%2520screening%252C%2520and%2520profiling%2520using%2520modified%2520structures%2520of%2520active%2520kinase%2520states%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7921%26epage%3D7932%26doi%3D10.1021%2Fjm8010299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1514</span>, <span class="refDoi"> DOI: 10.1039/C4MD00251B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1039%2FC4MD00251B" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1507-1514&author=B.+Frettauthor=N.+McConnellauthor=Y.+Wangauthor=Z.+Xuauthor=A.+Ambroseauthor=H.+Y.+Li&title=Identification+of+pyrazine-based+TrkA+inhibitors%3A+design%2C+synthesis%2C+evaluation%2C+and+computational+modeling+studies&doi=10.1039%2FC4MD00251B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1039%2FC4MD00251B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00251B%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DMcConnell%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DAmbrose%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DIdentification%2520of%2520pyrazine-based%2520TrkA%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520computational%2520modeling%2520studies%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D1507%26epage%3D1514%26doi%3D10.1039%2FC4MD00251B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">16078</span>– <span class="NLM_lpage">16083</span>, <span class="refDoi"> DOI: 10.1073/pnas.0502000102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1073%2Fpnas.0502000102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16249345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=16078-16083&author=J.+G.+Conwayauthor=B.+McDonaldauthor=J.+Parhamauthor=B.+Keithauthor=D.+W.+Rusnakauthor=E.+Shawauthor=M.+Jansenauthor=P.+Linauthor=A.+Payneauthor=R.+M.+Crosbyauthor=J.+H.+Johnsonauthor=L.+Frickauthor=M.+H.+Linauthor=S.+Depeeauthor=S.+Tadepalliauthor=B.+Vottaauthor=I.+Jamesauthor=K.+Fullerauthor=T.+J.+Chambersauthor=F.+C.+Kullauthor=S.+D.+Chamberlainauthor=J.+T.+Hutchins&title=Inhibition+of+colony-stimulating-factor-1+signaling+in+vivo+with+the+orally+bioavailable+cFMS+kinase+inhibitor+GW2580&doi=10.1073%2Fpnas.0502000102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span></div><div class="casAuthors">Conway, James G.; McDonald, Brad; Parham, Janet; Keith, Barry; Rusnak, David W.; Shaw, Eva; Jansen, Marilyn; Lin, Peiyuan; Payne, Alan; Crosby, Renae M.; Johnson, Jennifer H.; Frick, Lloyd; Lin, Min-Hwa Jasmine; Depee, Scott; Tadepalli, Sarva; Votta, Bart; James, Ian; Fuller, Karen; Chambers, Timothy J.; Kull, Frederick C.; Chamberlain, Stanley D.; Hutchins, Jeff T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16078-16083</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases.  To help investigate the role of cFMS kinase in disease, the authors identified GW2580, an orally bioavailable inhibitor of cFMS kinase.  GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases.  GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degrdn. in cultures of human osteoclasts, rat calvaria, and rat fetal long bone.  In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines.  GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 prodn. in freshly isolated human monocytes and mouse macrophages.  After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 prodn. in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.  Unexpectedly, GW2580 inhibited LPS-induced TNF prodn. in mice, in contrast to effects on monocytes and macrophages in vitro.  In conclusion, GW2580's selective inhibition of monocyte growth and bone degrdn. is consistent with cFMS kinase inhibition.  The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5EGN2P59OrVg90H21EOLACvtfcHk0liERY-lSH6ogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM&md5=6a5afc80faa9acec528fdbf766ad05bd</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502000102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502000102%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DMcDonald%26aufirst%3DB.%26aulast%3DParham%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShaw%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPayne%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DFrick%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DFuller%26aufirst%3DK.%26aulast%3DChambers%26aufirst%3DT.%2BJ.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26atitle%3DInhibition%2520of%2520colony-stimulating-factor-1%2520signaling%2520in%2520vivo%2520with%2520the%2520orally%2520bioavailable%2520cFMS%2520kinase%2520inhibitor%2520GW2580%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D16078%26epage%3D16083%26doi%3D10.1073%2Fpnas.0502000102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergquist, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumrine, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selph, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimpson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, T. A.</span></span> <span> </span><span class="NLM_article-title">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.129429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1124%2Fjpet.107.129429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=18434589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=41-50&author=J.+G.+Conwayauthor=H.+Pinkauthor=M.+L.+Bergquistauthor=B.+Hanauthor=S.+Depeeauthor=S.+Tadepalliauthor=P.+Linauthor=R.+C.+Crumrineauthor=J.+Binzauthor=R.+L.+Clarkauthor=J.+L.+Selphauthor=S.+A.+Stimpsonauthor=J.+T.+Hutchinsauthor=S.+D.+Chamberlainauthor=T.+A.+Brodie&title=Effects+of+the+cFMS+kinase+inhibitor+5-%283-methoxy-4-%28%284-methoxybenzyl%29oxy%29benzyl%29pyrimidine-2%2C4-diamine+%28GW2580%29+in+normal+and+arthritic+rats&doi=10.1124%2Fjpet.107.129429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats</span></div><div class="casAuthors">Conway, James G.; Pink, Heather; Bergquist, Mandy L.; Han, Bajin; Depee, Scott; Tadepalli, Sarva; Lin, Peiyuan; Crumrine, R. Christian; Binz, Jane; Clark, Richard L.; Selph, Jeffrey L.; Stimpson, Stephen A.; Hutchins, Jeff T.; Chamberlain, Stanley D.; Brodie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The cFMS (cellular homolog of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) inhibits colony-stimulating factor (CSF)-1-induced monocyte growth and bone degrdn. in vitro and inhibits CSF-1 signaling through cFMS kinase in 4-day models in mice.  In the present study, the kinase selectivity of GW2580 was further characterized, and the effects of chronic treatment were evaluated in normal and arthritic rats.  GW2580 selectively inhibited cFMS kinase compared with 186 other kinases in vitro and completely inhibited CSF-1-induced growth of rat monocytes, with an IC50 value of 0.2 μM.  GW2580 dosed orally at 25 and 75 mg/kg 1 and 5 h before the injection of lipopolysaccharide inhibited tumor necrosis factor-α prodn. by 60 to 85%, indicating a duration of action of at least 5 h.  In a 21-day adjuvant arthritis model, GW2580 dosed twice a day (b.i.d.) from days 0 to 21, 7 to 21, or 14 to 21 inhibited joint connective tissue and bone destruction as assessed by radiol., histol. and bone mineral content measurements.  In contrast, GW2580 did not affect ankle swelling in the adjuvant model nor did it affect ankle swelling in a model where local arthritis is reactivated by peptidoglycan polysaccharide polymers.  GW2580 administered to normal rats for 21 days showed no effects on tissue histol. and only modest changes in serum clin. chem. and blood hematol.  In conclusion, GW2580 was effective in preserving joint integrity in the adjuvant arthritis model while showing minimal effects in normal rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtnXf8t6eWrLVg90H21EOLACvtfcHk0ljZ0u2HOFo1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D&md5=51bf18b72ebba4c5ea862b088d0c1ad1</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.129429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.129429%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DPink%26aufirst%3DH.%26aulast%3DBergquist%26aufirst%3DM.%2BL.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DCrumrine%26aufirst%3DR.%2BC.%26aulast%3DBinz%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%2BL.%26aulast%3DSelph%26aufirst%3DJ.%2BL.%26aulast%3DStimpson%26aufirst%3DS.%2BA.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DBrodie%26aufirst%3DT.%2BA.%26atitle%3DEffects%2520of%2520the%2520cFMS%2520kinase%2520inhibitor%25205-%25283-methoxy-4-%2528%25284-methoxybenzyl%2529oxy%2529benzyl%2529pyrimidine-2%252C4-diamine%2520%2528GW2580%2529%2520in%2520normal%2520and%2520arthritic%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D41%26epage%3D50%26doi%3D10.1124%2Fjpet.107.129429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5337</span>– <span class="NLM_lpage">5349</span>, <span class="refDoi"> DOI: 10.1021/jm3002982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3002982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5337-5349&author=S.+Hongauthor=J.+Kimauthor=J.+H.+Seoauthor=K.+H.+Jungauthor=S.+S.+Hongauthor=S.+Hong&title=Design%2C+synthesis%2C+and+evaluation+of+3%2C5-disubstituted+7-azaindoles+as+Trk+inhibitors+with+anticancer+and+antiangiogenic+activities&doi=10.1021%2Fjm3002982"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Fjm3002982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002982%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25203%252C5-disubstituted%25207-azaindoles%2520as%2520Trk%2520inhibitors%2520with%2520anticancer%2520and%2520antiangiogenic%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5337%26epage%3D5349%26doi%3D10.1021%2Fjm3002982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geuns-Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bready, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaffee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polverino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1021/jm061112p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061112p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=627-640&author=V.+J.+Ceeauthor=B.+K.+Albrechtauthor=S.+Geuns-Meyerauthor=P.+Hughesauthor=S.+Bellonauthor=J.+Breadyauthor=S.+Caenepeelauthor=S.+C.+Chaffeeauthor=A.+Coxonauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=B.+L.+Hodousauthor=D.+Hoffmanauthor=R.+E.+Johnsonauthor=R.+Kendallauthor=J.+L.+Kimauthor=A.+M.+Longauthor=D.+McGowanauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=D.+Powersauthor=P.+Roseauthor=L.+Wangauthor=H.+Zhao&title=Alkynylpyrimidine+amide+derivatives+as+potent%2C+selective%2C+and+orally+active+inhibitors+of+Tie-2+kinase&doi=10.1021%2Fjm061112p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fjm061112p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061112p%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DAlkynylpyrimidine%2520amide%2520derivatives%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520inhibitors%2520of%2520Tie-2%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D627%26epage%3D640%26doi%3D10.1021%2Fjm061112p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muranaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span> <span> </span><span class="NLM_article-title">The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1233</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.bmcl.2017.01.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28159414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1233-1236&author=N.+Furuyaauthor=T.+Momoseauthor=K.+Katsunoauthor=N.+Fushimiauthor=H.+Muranakaauthor=C.+Handaauthor=T.+Ozawaauthor=T.+Kinoshita&title=The+juxtamembrane+region+of+TrkA+kinase+is+critical+for+inhibitor+selectivity&doi=10.1016%2Fj.bmcl.2017.01.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity</span></div><div class="casAuthors">Furuya, Noritaka; Momose, Takaki; Katsuno, Kenji; Fushimi, Nobuhiko; Muranaka, Hideyuki; Handa, Chiaki; Ozawa, Tomonaga; Kinoshita, Takayoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1233-1236</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although numerous crystal structures for protein kinases have been reported, many include only the kinase domain but not the juxtamembrane (JM) region, a crit. activity-controlling segment of receptor tyrosine kinases (RTKs).  In this study, we detd. the X-ray crystal structure of the tropomyosin receptor kinase (Trk) A selective inhibitor A1 complexed with the TrkA kinase domain and the JM region.  This structure revealed that the unique inhibitor-binding pocket created by a novel JM configuration yields significant potency and high selectivity against TrkB and TrkC.  Moreover, we validated the importance of the JM region for the potency of A1 using in vitro assays.  The introduction of moieties that interact with the JM region will be one of the most effective strategies for producing highly selective RTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm4KGYAJkWn7Vg90H21EOLACvtfcHk0ljoOj38IZnazw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVKisLo%253D&md5=849ac9c3ebb00c39ef78529cd6eabac5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DFuruya%26aufirst%3DN.%26aulast%3DMomose%26aufirst%3DT.%26aulast%3DKatsuno%26aufirst%3DK.%26aulast%3DFushimi%26aufirst%3DN.%26aulast%3DMuranaka%26aufirst%3DH.%26aulast%3DHanda%26aufirst%3DC.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DKinoshita%26aufirst%3DT.%26atitle%3DThe%2520juxtamembrane%2520region%2520of%2520TrkA%2520kinase%2520is%2520critical%2520for%2520inhibitor%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1233%26epage%3D1236%26doi%3D10.1016%2Fj.bmcl.2017.01.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fengas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitching, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmus, J. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+K.+Bagalauthor=K.+Omotoauthor=D.+C.+Blakemoreauthor=P.+J.+Bungayauthor=J.+G.+Bilslandauthor=P.+J.+Clarkeauthor=M.+S.+Corbettauthor=C.+N.+Croninauthor=J.+J.+Cuiauthor=R.+Diasauthor=N.+J.+Flanaganauthor=S.+E.+Greasleyauthor=R.+Grimleyauthor=E.+Johnsonauthor=D.+Fengasauthor=L.+Kitchingauthor=M.+L.+Krausauthor=I.+McAlpineauthor=A.+Nagataauthor=G.+J.+Waldronauthor=J.+S.+Warmus&title=Discovery+of+allosteric%2C+potent%2C+subtype+selective%2C+and+peripherally+restricted+TrkA+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.8b00280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00280%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DBlakemore%26aufirst%3DD.%2BC.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DClarke%26aufirst%3DP.%2BJ.%26aulast%3DCorbett%26aufirst%3DM.%2BS.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDias%26aufirst%3DR.%26aulast%3DFlanagan%26aufirst%3DN.%2BJ.%26aulast%3DGreasley%26aufirst%3DS.%2BE.%26aulast%3DGrimley%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DFengas%26aufirst%3DD.%26aulast%3DKitching%26aufirst%3DL.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%2BJ.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26atitle%3DDiscovery%2520of%2520allosteric%252C%2520potent%252C%2520subtype%2520selective%252C%2520and%2520peripherally%2520restricted%2520TrkA%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26doi%3D10.1021%2Facs.jmedchem.8b00280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, H. W.</span></span> <span> </span><span class="NLM_article-title">Inhibiting TRK proteins in clinical cancer therapy</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.3390/cancers10040105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.3390%2Fcancers10040105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2gtL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=105&author=A.+M.+Langeauthor=H.+W.+Lo&title=Inhibiting+TRK+proteins+in+clinical+cancer+therapy&doi=10.3390%2Fcancers10040105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting TRK proteins in clinical cancer therapy</span></div><div class="casAuthors">Lange, Allison M.; Lo, Hui-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">105/1-105/15</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Gene rearrangements resulting in the aberrant activity of tyrosine kinases have been identified as drivers of oncogenesis in a variety of cancers.  The tropomyosin receptor kinase (TRK) family of tyrosine receptor kinases is emerging as an important target for cancer therapeutics.  The TRK family contains three members, TRKA, TRKB, and TRKC, and these proteins are encoded by the genes NTRK1, NTRK2, and NTRK3, resp.  To activate TRK receptors, neurotrophins bind to the extracellular region stimulating dimerization, phosphorylation, and activation of downstream signaling pathways.  Major known downstream pathways include RAS/MAPK/ERK, PLCγ, and PI3K/Akt.  While being rare in most cancers, TRK fusions with other proteins have been well-established as oncogenic events in specific malignancies, including glioblastoma, papillary thyroid carcinoma, and secretory breast carcinomas.  TRK protein amplification as well as alternative splicing events have also been described as contributors to cancer pathogenesis.  For patients harboring alterations in TRK expression or activity, TRK inhibition emerges as an important therapeutic target.  To date, multiple trials testing TRK-inhibiting compds. in various cancers are underway.  In this review, we will summarize the current therapeutic trials for neoplasms involving NTKR gene alterations, as well as the promises and setbacks that are assocd. with targeting gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvepDLt-_JaLVg90H21EOLACvtfcHk0ljoOj38IZnazw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2gtL%252FI&md5=f421f06adf15f9357d88b80bf44479e8</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.3390%2Fcancers10040105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10040105%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DA.%2BM.%26aulast%3DLo%26aufirst%3DH.%2BW.%26atitle%3DInhibiting%2520TRK%2520proteins%2520in%2520clinical%2520cancer%2520therapy%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26spage%3D105%26doi%3D10.3390%2Fcancers10040105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span> <span> </span><span class="NLM_article-title">Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4529</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-4529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2015-4529" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4529&author=H.+A.+Burrisauthor=A.+T.+Shawauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=R.+C.+Doebeleauthor=S.+Smithauthor=N.+Nandaauthor=S.+Cruickshankauthor=J.+A.+Lowauthor=M.+S.+Brose&title=Abstract+4529%3A+Pharmacokinetics+%28PK%29+of+LOXO-101+during+the+first-in-human+Phase+I+study+in+patients+with+advanced+solid+tumors%3A+Interim+update&doi=10.1158%2F1538-7445.AM2015-4529"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-4529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-4529%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DNanda%26aufirst%3DN.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26atitle%3DAbstract%25204529%253A%2520Pharmacokinetics%2520%2528PK%2529%2520of%2520LOXO-101%2520during%2520the%2520first-in-human%2520Phase%2520I%2520study%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520Interim%2520update%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4529%26doi%3D10.1158%2F1538-7445.AM2015-4529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span> <span> </span><span class="NLM_article-title">The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">LBA2501</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.18_suppl.LBA2501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2017.35.18_suppl.LBA2501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=LBA2501&author=D.+M.+Hymanauthor=T.+W.+Laetschauthor=S.+Kummarauthor=S.+G.+DuBoisauthor=A.+F.+Faragoauthor=A.+S.+Pappoauthor=G.+D.+Demetriauthor=W.+S.+El-Deiryauthor=U.+N.+Lassenauthor=A.+Dowlatiauthor=M.+S.+Broseauthor=V.+Boniauthor=B.+Turpinauthor=R.+Nagasubramanianauthor=S.+Cruickshankauthor=M.+C.+Coxauthor=N.+C.+Kuauthor=D.+S.+Hawkinsauthor=D.+S.+Hongauthor=A.+E.+Drilon&title=The+efficacy+of+larotrectinib+%28LOXO-101%29%2C+a+selective+tropomyosin+receptor+kinase+%28TRK%29+inhibitor%2C+in+adult+and+pediatric+TRK+fusion+cancers&doi=10.1200%2FJCO.2017.35.18_suppl.LBA2501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.18_suppl.LBA2501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.18_suppl.LBA2501%26sid%3Dliteratum%253Aachs%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DLassen%26aufirst%3DU.%2BN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DKu%26aufirst%3DN.%2BC.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26atitle%3DThe%2520efficacy%2520of%2520larotrectinib%2520%2528LOXO-101%2529%252C%2520a%2520selective%2520tropomyosin%2520receptor%2520kinase%2520%2528TRK%2529%2520inhibitor%252C%2520in%2520adult%2520and%2520pediatric%2520TRK%2520fusion%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3DLBA2501%26doi%3D10.1200%2FJCO.2017.35.18_suppl.LBA2501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span> <span> </span><span class="NLM_article-title">A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">10510</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.10510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2017.35.15_suppl.10510" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=10510&author=T.+W.+Laetschauthor=S.+G.+DuBoisauthor=R.+Nagasubramanianauthor=B.+Turpinauthor=L.+Mascarenhasauthor=N.+Federmanauthor=M.+Reynoldsauthor=S.+Smithauthor=S.+Cruickshankauthor=M.+C.+Coxauthor=A.+S.+Pappoauthor=D.+S.+Hawkins&title=A+pediatric+phase+I+study+of+larotrectinib%2C+a+highly+selective+inhibitor+of+the+tropomyosin+receptor+kinase+%28TRK%29+family&doi=10.1200%2FJCO.2017.35.15_suppl.10510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.10510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.10510%26sid%3Dliteratum%253Aachs%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26atitle%3DA%2520pediatric%2520phase%2520I%2520study%2520of%2520larotrectinib%252C%2520a%2520highly%2520selective%2520inhibitor%2520of%2520the%2520tropomyosin%2520receptor%2520kinase%2520%2528TRK%2529%2520family%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D10510%26doi%3D10.1200%2FJCO.2017.35.15_suppl.10510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feraco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30119-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2FS1470-2045%2818%2930119-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=29606586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmvFalsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=705-714&author=T.+W.+Laetschauthor=S.+G.+DuBoisauthor=L.+Mascarenhasauthor=B.+Turpinauthor=N.+Federmanauthor=C.+M.+Albertauthor=R.+Nagasubramanianauthor=J.+L.+Davisauthor=E.+Rudzinskiauthor=A.+M.+Feracoauthor=B.+B.+Tuchauthor=K.+T.+Ebataauthor=M.+Reynoldsauthor=S.+Smithauthor=S.+Cruickshankauthor=M.+C.+Coxauthor=A.+S.+Pappoauthor=D.+S.+Hawkins&title=Larotrectinib+for+paediatric+solid+tumours+harbouring+NTRK+gene+fusions%3A+phase+1+results+from+a+multicentre%2C+open-label%2C+phase+1%2F2+study&doi=10.1016%2FS1470-2045%2818%2930119-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study</span></div><div class="casAuthors">Laetsch, Theodore W.; DuBois, Steven G.; Mascarenhas, Leo; Turpin, Brian; Federman, Noah; Albert, Catherine M.; Nagasubramanian, Ramamoorthy; Davis, Jessica L.; Rudzinski, Erin; Feraco, Angela M.; Tuch, Brian B.; Ebata, Kevin T.; Reynolds, Mark; Smith, Steven; Cruickshank, Scott; Cox, Michael C.; Pappo, Alberto S.; Hawkins, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">705-714</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies.  Larotrectinib, a highly selective small-mol. inhibitor of the TRK kinases, had shown activity in preclin. models and in adults with tumors harbouring TRK fusions.  This study aimed to assess the safety of larotrectinib in paediatric patients.  This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 mo to 21 years with locally advanced or metastatic solid tumors or CNS tumors that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy.  Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible.  Patients were enrolled to three dose cohorts according to a rolling six design.  Larotrectinib was administered orally (capsule or liq. formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight.  The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity.  All patients who received at least one dose of larotrectinib were included in the safety analyses.  Reported here are results of the phase 1 dose escalation cohort.  Phase 1 follow-up and phase 2 are ongoing.  This trial is registered with ClinicalTrials.gov, no. NCT02637687.  Between Dec 21, 2015, and Apr. 13, 2017, 24 patients (n=17 with tumors harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3-13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modeling to achieve an area under the curve equiv. to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (max. 100 g per dose), regardless of age, equating to a max. of 173% of the recommended adult phase 2 dose.  Among enrolled patients harbouring TRK fusion-pos. cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer.  Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24).  Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease.  No grade 4 or 5 treatment-related adverse events were obsd.  Two larotrectinib-related serious adverse events were obsd.: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines.  The max. tolerated dose was not reached, and 100 mg/m2 (max. of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-pos. cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumor regression that did not meet the criteria for objective response.  None of the seven patients with TRK fusion-neg. cancers had an objective response.  The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumor activity in all patients with TRK fusion-pos. tumors.  The recommended phase 2 dose was defined as 100mg/m2 (max. 100 mg per dose) for infants, children, and adolescents, regardless of age.Loxo Oncol. Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN4iUwI-8yy7Vg90H21EOLACvtfcHk0lgKdTQHDjeILA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmvFalsLg%253D&md5=327df3730acb6d1ac983d4d636533adb</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930119-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930119-0%26sid%3Dliteratum%253Aachs%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DAlbert%26aufirst%3DC.%2BM.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DJ.%2BL.%26aulast%3DRudzinski%26aufirst%3DE.%26aulast%3DFeraco%26aufirst%3DA.%2BM.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%2BT.%26aulast%3DReynolds%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26atitle%3DLarotrectinib%2520for%2520paediatric%2520solid%2520tumours%2520harbouring%2520NTRK%2520gene%2520fusions%253A%2520phase%25201%2520results%2520from%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25201%252F2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D705%26epage%3D714%26doi%3D10.1016%2FS1470-2045%2818%2930119-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidaway, P.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2018.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1038%2Fnrclinonc.2018.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A280%3ADC%252BC1MnivFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=264&author=P.+Sidaway&title=Targeted+therapy%3A+Larotrectinib+effective+against+TRK-fusion-positive+cancers&doi=10.1038%2Fnrclinonc.2018.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer: Changes in clonal dynamics predict response to palbociclib</span></div><div class="casAuthors">Sidaway Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">264-265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGaccJ0yL8kkQ0lWbKiCflfW6udTcc2eZHAJ9hgvTxGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnivFeltw%253D%253D&md5=2031e32ca2099247f28d1386fcf4765e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2018.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2018.40%26sid%3Dliteratum%253Aachs%26aulast%3DSidaway%26aufirst%3DP.%26atitle%3DTargeted%2520therapy%253A%2520Larotrectinib%2520effective%2520against%2520TRK-fusion-positive%2520cancers%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D264%26doi%3D10.1038%2Fnrclinonc.2018.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirru, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencardino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanzulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span> <span> </span><span class="NLM_article-title">Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372–001 and STARTRK-1)</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F2159-8290.CD-16-1237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=28183697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=400-409&author=A.+Drilonauthor=S.+Sienaauthor=S.+I.+Ouauthor=M.+Patelauthor=M.+J.+Ahnauthor=J.+Leeauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=J.+J.+Whelerauthor=S.+V.+Liuauthor=R.+Doebeleauthor=L.+Giannettaauthor=G.+Cereaauthor=G.+Marrapeseauthor=M.+Schirruauthor=A.+Amatuauthor=K.+Bencardinoauthor=L.+Palmeriauthor=A.+Sartore-Bianchiauthor=A.+Vanzulliauthor=S.+Crestaauthor=S.+Damianauthor=M.+Ducaauthor=E.+Ardiniauthor=G.+Liauthor=J.+Christiansenauthor=K.+Kowalskiauthor=A.+D.+Johnsonauthor=R.+Patelauthor=D.+Luoauthor=E.+Chow-Manevalauthor=Z.+Hornbyauthor=P.+S.+Multaniauthor=A.+T.+Shawauthor=F.+G.+De+Braud&title=Safety+and+antitumor+activity+of+the+multitargeted+pan-TRK%2C+ROS1%2C+and+ALK+inhibitor+entrectinib%3A+combined+results+from+two+phase+I+trials+%28ALKA-372%E2%80%93001+and+STARTRK-1%29&doi=10.1158%2F2159-8290.CD-16-1237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)</span></div><div class="casAuthors">Drilon, Alexander; Siena, Salvatore; Ou, Sai-Hong Ignatius; Patel, Manish; Ahn, Myung Ju; Lee, Jeeyun; Bauer, Todd M.; Farago, Anna F.; Wheler, Jennifer J.; Liu, Stephen V.; Doebele, Robert; Giannetta, Laura; Cerea, Giulio; Marrapese, Giovanna; Schirru, Michele; Amatu, Alessio; Bencardino, Katia; Palmeri, Laura; Sartore-Bianchi, Andrea; Vanzulli, Angelo; Cresta, Sara; Damian, Silvia; Duca, Matteo; Ardini, Elena; Li, Gang; Christiansen, Jason; Kowalski, Karey; Johnson, Ann D.; Patel, Rupal; Luo, David; Chow-Maneval, Edna; Hornby, Zachary; Multani, Pratik S.; Shaw, Alice T.; De Braud, Filippo G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-409</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease.  Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naive to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the recommended phase II dose.  Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification.  Responses were obsd. in non-small cell lung cancer, colorectal cancer, mammary analog secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 wk after starting treatment and lasting as long as >2 years.  Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.  Significance: Gene fusions of NTRK1/2/3, ROS1, and ALK (encoding TRKA/B/C, ROS1, and ALK, resp.) lead to constitutive activation of oncogenic pathways.  Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-3oFgf_s-LVg90H21EOLACvtfcHk0lgoNwmVrMlctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D&md5=2065abe157ef40489942215ec33482d0</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1237%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DWheler%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DDoebele%26aufirst%3DR.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DSchirru%26aufirst%3DM.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DBencardino%26aufirst%3DK.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DCresta%26aufirst%3DS.%26aulast%3DDamian%26aufirst%3DS.%26aulast%3DDuca%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DA.%2BD.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520the%2520multitargeted%2520pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520entrectinib%253A%2520combined%2520results%2520from%2520two%2520phase%2520I%2520trials%2520%2528ALKA-372%25E2%2580%2593001%2520and%2520STARTRK-1%2529%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D400%26epage%3D409%26doi%3D10.1158%2F2159-8290.CD-16-1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pishvaian, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneval, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Laguna, I.</span></span> <span> </span><span class="NLM_article-title">Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">521</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.4_suppl.521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1200%2FJCO.2018.36.4_suppl.521" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=521&author=M.+J.+Pishvaianauthor=C.+D.+Rolfoauthor=S.+V.+Liuauthor=P.+S.+Multaniauthor=E.+C.+Manevalauthor=I.+Garrido-Laguna&title=Clinical+benefit+of+entrectinib+for+patients+with+metastatic+pancreatic+cancer+who+harbor+NTRK+and+ROS1+fusions&doi=10.1200%2FJCO.2018.36.4_suppl.521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.4_suppl.521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.4_suppl.521%26sid%3Dliteratum%253Aachs%26aulast%3DPishvaian%26aufirst%3DM.%2BJ.%26aulast%3DRolfo%26aufirst%3DC.%2BD.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DManeval%26aufirst%3DE.%2BC.%26aulast%3DGarrido-Laguna%26aufirst%3DI.%26atitle%3DClinical%2520benefit%2520of%2520entrectinib%2520for%2520patients%2520with%2520metastatic%2520pancreatic%2520cancer%2520who%2520harbor%2520NTRK%2520and%2520ROS1%2520fusions%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D521%26doi%3D10.1200%2FJCO.2018.36.4_suppl.521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuteboom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potvin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltaos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levisetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span> <span> </span><span class="NLM_article-title">P2.06-001 A study of MGCD516, a receptor tyrosine kinase (RTK) inhibitor, in molecularly selected patients with NSCLC or other advanced solid tumors</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S1068</span>– <span class="NLM_lpage">S1069</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.1494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1016%2Fj.jtho.2016.11.1494" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S1068-S1069&author=T.+Wernerauthor=R.+Heistauthor=R.+Carvajalauthor=D.+Adkinsauthor=A.+Alvaauthor=S.+Goelauthor=D.+Hongauthor=L.+Bazhenovaauthor=M.+Salehauthor=R.+Siegelauthor=C.+Kyriakopoulosauthor=C.+Blakelyauthor=K.+Eatonauthor=R.+Lauerauthor=D.+Wangauthor=G.+Schwartzauthor=S.+Neuteboomauthor=D.+Potvinauthor=D.+Faltaosauthor=I.+Chenauthor=J.+Christensenauthor=M.+Levisettiauthor=R.+Chaoauthor=T.+Bauer&title=P2.06-001+A+study+of+MGCD516%2C+a+receptor+tyrosine+kinase+%28RTK%29+inhibitor%2C+in+molecularly+selected+patients+with+NSCLC+or+other+advanced+solid+tumors&doi=10.1016%2Fj.jtho.2016.11.1494"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.1494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.1494%26sid%3Dliteratum%253Aachs%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DHeist%26aufirst%3DR.%26aulast%3DCarvajal%26aufirst%3DR.%26aulast%3DAdkins%26aufirst%3DD.%26aulast%3DAlva%26aufirst%3DA.%26aulast%3DGoel%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DKyriakopoulos%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DLauer%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSchwartz%26aufirst%3DG.%26aulast%3DNeuteboom%26aufirst%3DS.%26aulast%3DPotvin%26aufirst%3DD.%26aulast%3DFaltaos%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DLevisetti%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DT.%26atitle%3DP2.06-001%2520A%2520study%2520of%2520MGCD516%252C%2520a%2520receptor%2520tyrosine%2520kinase%2520%2528RTK%2529%2520inhibitor%252C%2520in%2520molecularly%2520selected%2520patients%2520with%2520NSCLC%2520or%2520other%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3DS1068%26epage%3DS1069%26doi%3D10.1016%2Fj.jtho.2016.11.1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyozawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span> <span> </span><span class="NLM_article-title">1362PSafety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene</span>. <i>Annals Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>, <span class="NLM_elocation-id">mdx380.063</span> <span class="refDoi"> DOI: 10.1093/annonc/mdx380.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1093%2Fannonc%2Fmdx380.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&author=M.+Takedaauthor=T.+Setoauthor=Y.+Fujiwaraauthor=N.+Yamamotoauthor=K.+Nosakiauthor=R.+Toyozawaauthor=C.+Abeauthor=R.+Shigaauthor=K.+Nakamaruauthor=K.+Nakagawa&title=1362PSafety+and+clinical+activity+of+DS-6051b%2C+a+ROS1%2FNTRK+inhibitor%2C+in+Japanese+patients+with+NSCLC+harboring+ROS1+fusion+gene&doi=10.1093%2Fannonc%2Fmdx380.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx380.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx380.063%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DNosaki%26aufirst%3DK.%26aulast%3DToyozawa%26aufirst%3DR.%26aulast%3DAbe%26aufirst%3DC.%26aulast%3DShiga%26aufirst%3DR.%26aulast%3DNakamaru%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3D1362PSafety%2520and%2520clinical%2520activity%2520of%2520DS-6051b%252C%2520a%2520ROS1%252FNTRK%2520inhibitor%252C%2520in%2520Japanese%2520patients%2520with%2520NSCLC%2520harboring%2520ROS1%2520fusion%2520gene%26jtitle%3DAnnals%2520Oncol.%26date%3D2017%26volume%3D28%26doi%3D10.1093%2Fannonc%2Fmdx380.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borazanci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senaldi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H.</span></span> <span> </span><span class="NLM_article-title">Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">CT024</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-CT024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F1538-7445.AM2016-CT024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=CT024&author=K.+P.+Papadopoulosauthor=E.+Borazanciauthor=D.+Von+Hoffauthor=L.+Gandhiauthor=A.+Patnaikauthor=M.+Tachibanaauthor=H.+Zahirauthor=R.+Gajeeauthor=T.+Goldbergauthor=G.+Senaldiauthor=S.-H.+Ou&title=Abstract+CT024%3A+First-in-human+phase+1+dose-escalation+study+of+DS-6051b%2C+an+oral+ROS1+and+NTRK+inhibitor%2C+in+subjects+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.AM2016-CT024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-CT024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-CT024%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBorazanci%26aufirst%3DE.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DZahir%26aufirst%3DH.%26aulast%3DGajee%26aufirst%3DR.%26aulast%3DGoldberg%26aufirst%3DT.%26aulast%3DSenaldi%26aufirst%3DG.%26aulast%3DOu%26aufirst%3DS.-H.%26atitle%3DAbstract%2520CT024%253A%2520First-in-human%2520phase%25201%2520dose-escalation%2520study%2520of%2520DS-6051b%252C%2520an%2520oral%2520ROS1%2520and%2520NTRK%2520inhibitor%252C%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3DCT024%26doi%3D10.1158%2F1538-7445.AM2016-CT024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D. M.</span></span> <span> </span><span class="NLM_article-title">VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4758</span>– <span class="NLM_lpage">4768</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1158%2F0008-5472.CAN-10-2527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4758-4768&author=W.+K.+Youauthor=B.+Senninoauthor=C.+W.+Williamsonauthor=B.+Falconauthor=H.+Hashizumeauthor=L.+C.+Yaoauthor=D.+T.+Aftabauthor=D.+M.+McDonald&title=VEGF+and+c-Met+blockade+amplify+angiogenesis+inhibition+in+pancreatic+islet+cancer&doi=10.1158%2F0008-5472.CAN-10-2527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2527%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DW.%2BK.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BW.%26aulast%3DFalcon%26aufirst%3DB.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DL.%2BC.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DVEGF%2520and%2520c-Met%2520blockade%2520amplify%2520angiogenesis%2520inhibition%2520in%2520pancreatic%2520islet%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4758%26epage%3D4768%26doi%3D10.1158%2F0008-5472.CAN-10-2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pezet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, S. B.</span></span> <span> </span><span class="NLM_article-title">Neurotrophins: mediators and modulators of pain</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.29.051605.112929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=10.1146%2Fannurev.neuro.29.051605.112929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=16776595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVeit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=507-538&author=S.+Pezetauthor=S.+B.+McMahon&title=Neurotrophins%3A+mediators+and+modulators+of+pain&doi=10.1146%2Fannurev.neuro.29.051605.112929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotrophins: mediators and modulators of pain</span></div><div class="casAuthors">Pezet, Sophie; McMahon, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">507-538</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The neurotrophin family of neurotrophic factors are well-known for their effects on neuronal survival and growth.  Over the past decade, considerable evidence has accumulated from both humans and animals that one neurotrophin, nerve growth factor (NGF), is a peripheral pain mediator, particularly in inflammatory pain states.  NGF is upregulated in a wide variety of inflammatory conditions, and NGF-neutralizing mols. are effective analgesic agents in many models of persistent pain.  Such mols. are now being evaluated in clin. trials.  NGF regulates the expression of a 2nd neurotrophin, brain-derived neurotrophic factor (BDNF), in nociceptors.  BDNF is released when nociceptors are activated, and it acts as a central modulator of pain.  The chapter reviews the evidence for these roles (and briefly the effects of other neurotrophins), the range of conditions under which they act, and their mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWZk1aBEFejLVg90H21EOLACvtfcHk0ljD2zKWOM8i5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVeit7w%253D&md5=8c9d57612ae9466e9c73776be0b8a104</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.29.051605.112929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.29.051605.112929%26sid%3Dliteratum%253Aachs%26aulast%3DPezet%26aufirst%3DS.%26aulast%3DMcMahon%26aufirst%3DS.%2BB.%26atitle%3DNeurotrophins%253A%2520mediators%2520and%2520modulators%2520of%2520pain%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2006%26volume%3D29%26spage%3D507%26epage%3D538%26doi%3D10.1146%2Fannurev.neuro.29.051605.112929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AOJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AOJ','PDB','4AOJ'); return false;">PDB: 4AOJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WIH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WIH','PDB','2WIH'); return false;">PDB: 2WIH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA','PDB','2XBA'); return false;">PDB: 2XBA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO','PDB','5FTO'); return false;">PDB: 5FTO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KVT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KVT','PDB','5KVT'); return false;">PDB: 5KVT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOC','PDB','4FOC'); return false;">PDB: 4FOC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FOD','PDB','4FOD'); return false;">PDB: 4FOD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AT3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AT3','PDB','4AT3'); return false;">PDB: 4AT3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YMJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YMJ','PDB','4YMJ'); return false;">PDB: 4YMJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE','PDB','4YNE'); return false;">PDB: 4YNE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V5Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V5Q','PDB','3V5Q'); return false;">PDB: 3V5Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JFX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JFX','PDB','5JFX'); return false;">PDB: 5JFX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DG5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DG5','PDB','5DG5'); return false;">PDB: 5DG5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMP','PDB','4PMP'); return false;">PDB: 4PMP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PMS','PDB','4PMS'); return false;">PDB: 4PMS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMI','PDB','5KMI'); return false;">PDB: 5KMI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMK','PDB','5KMK'); return false;">PDB: 5KMK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5H3Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5H3Q','PDB','5H3Q'); return false;">PDB: 5H3Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20','PDB','6D20'); return false;">PDB: 6D20</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMM','PDB','5KMM'); return false;">PDB: 5KMM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KMO','PDB','5KMO'); return false;">PDB: 5KMO</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01092%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01092" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e10a516ccb195f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
